{"original_filename": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb.pdf", "predictions": {"document_type": "prospectus"}, "blobs": [{"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-0-0", "text": "OCTOPLUS N.V.\n", "page_number": 0, "bounding_box": {"top_left_x": 0.4337568058076225, "top_left_y": 0.13821138211382114, "lower_right_x": 0.5680580762250453, "lower_right_y": 0.1540436456996149, "height": 0.01583226358579376, "width": 0.13430127041742285}, "blob_type": "headline", "predictions": {}, "annotations": {"issuer_name": ["OCTOPLUS N.V."]}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-0-1", "text": "(a limited liability company incorporated under the laws of the Netherlands,\n                       with its corporate seat in Leiden)\n", "page_number": 0, "bounding_box": {"top_left_x": 0.25105868118572294, "top_left_y": 0.1810012836970475, "lower_right_x": 0.7501512401693889, "lower_right_y": 0.2079589216944801, "height": 0.026957637997432615, "width": 0.499092558983666}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-0-2", "text": "Offering of up to \u20ac25 million in newly issued ordinary shares with a nominal value of \u20ac0.12 per Share.\n", "page_number": 0, "bounding_box": {"top_left_x": 0.14458560193587416, "top_left_y": 0.21951219512195122, "lower_right_x": 0.8548094373865699, "lower_right_y": 0.23577235772357724, "height": 0.01626016260162602, "width": 0.7102238354506958}, "blob_type": "headline", "predictions": {}, "annotations": {"initial_price_range": ["\u20ac0.12 "]}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-0-3", "text": "   We are offering up to \u20ac25 million in newly issued ordinary shares (the \u201cOffer Shares\u201d). The offer consists of a\npublic offering in the Netherlands and an international offering to institutional investors in certain other jurisdictions\n(the \u201cOffer\u201d).\n", "page_number": 0, "bounding_box": {"top_left_x": 0.11433756805807622, "top_left_y": 0.2631578947368421, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.30124090714591356, "height": 0.03808301240907147, "width": 0.7664851784633998}, "blob_type": "paragraph", "predictions": {}, "annotations": {"transaction": ["public offering"]}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-0-4", "text": "   In this Prospectus, the \u201cCompany\u201d, \u201cOctoPlus\u201d, \u201cwe\u201d, \u201cour\u201d, \u201cus\u201d and similar terms refer to OctoPlus N.V. and,\nwhere appropriate, its subsidiaries. Any reference to \u201cShares\u201d shall refer to ordinary shares of the Company,\nincluding the Offer Shares, outstanding from time to time.\n", "page_number": 0, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.31450577663671375, "lower_right_x": 0.8711433756805808, "lower_right_y": 0.3560119811724433, "height": 0.04150620453572956, "width": 0.7555958862673926}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-0-5", "text": "  Our business and any investments in our Shares involve significant risks. These risks are described under\n\u201cRisk Factors\u201d beginning on page 9 of this Prospectus.\n", "page_number": 0, "bounding_box": {"top_left_x": 0.1191772534785239, "top_left_y": 0.36927685066324345, "lower_right_x": 0.8705384150030248, "lower_right_y": 0.3970902866923406, "height": 0.02781343602909714, "width": 0.7513611615245008}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-0-6", "text": "   The Shares which are currently outstanding are listed and traded on Eurolist by Euronext Amsterdam (\u201cEuronext\nAmsterdam\u201d) under the symbol \u201cOCTO\u201d and ISIN Code NL0000345718. On 8 November 2007, the closing price of\nour Shares on Euronext Amsterdam was \u20ac3.95 per Share. We shall apply for admission of the Offer Shares to listing\nand trading on Euronext Amsterdam. We expect that trading in our Offer Shares offered in the Offer on Euronext\nAmsterdam will commence on or about 3 December 2007 (the \u201cListing Date\u201d), subject to acceleration or extension\nof the timetable of the Offer.\n", "page_number": 0, "bounding_box": {"top_left_x": 0.11433756805807622, "top_left_y": 0.40864356011981173, "lower_right_x": 0.8850574712643678, "lower_right_y": 0.48823277706461277, "height": 0.07958921694480103, "width": 0.7707199032062916}, "blob_type": "paragraph", "predictions": {}, "annotations": {"isin": ["NL0000345718"], "listing_venue": ["EuronextAmsterdam"]}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-0-7", "text": "   Subject to acceleration or extension of the timetable of the Offer, the closing of the Offer is expected to occur on\nor about 3 December 2007 (the \u201cSettlement Date\u201d). If closing of the Offer does not take place on the Settlement\nDate or at all, the Offer will be withdrawn, all subscriptions for the Offer Shares will be disregarded, any allotments\nmade will be deemed not to have been made, any subscription payments made will be returned without interest or\nother compensation and all transactions in our Offer Shares on Euronext Amsterdam will be cancelled. All dealings\nin the Offer Shares prior to settlement and delivery are at the sole risk of the parties concerned.\n", "page_number": 0, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.5027813436029097, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.5845100556268721, "height": 0.08172871202396237, "width": 0.7604355716878403}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-0-8", "text": "   The Offer Shares have not been and will not be registered under the United States Securities Act of 1933,\nas amended (the \u201cSecurities Act\u201d). The Offer Shares are being offered and sold in the United States in\nreliance on Rule 144A under the Securities Act (\u201cRule 144A\u201d). Prospective purchasers that are \u201cqualified\ninstitutional buyers\u201d (\u201cQIBs\u201d) are hereby notified that sellers of the Offer Shares may be relying on the\nexemption from the provisions of Section 5 of the Securities Act provided by Rule 144A. The Offer Shares are\nbeing offered and sold outside the United States in reliance on Regulation S under the Securities Act\n(\u201cRegulation S\u201d). For a description of restrictions on offers, sales and transfers of the Shares and the\ndistribution of this Prospectus in other jurisdictions, see \u201cSelling Restrictions\u201d and \u201cTransfer Restrictions\u201d.\n\n  We have granted to Cowen International Limited (\u201cCowen\u201d), Kempen & Co N.V. (\u201cKempen & Co\u201d) and SNS\nSecurities N.V. (\u201cSNS Securities\u201d, and together with Cowen and Kempen & Co, the \u201cUnderwriters\u201d) an option (the\nOverallotment Option) exercisable within 30 calendar days after the Listing Date pursuant to which the\nUnderwriters may require us to issue additional Offer Shares at the Offer Price for an amount up to 15% of the\namount of the Offer.\n", "page_number": 0, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.5849379546427044, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.7839109970047069, "height": 0.19897304236200253, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {"rule_144a_applies": ["Rule 144A\u201d)."]}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-0-9", "text": "   Delivery of the Offer Shares is expected to take place on or about 3 December 2007 through the book-entry\nfacilities of Nederlands Centraal Instituut voor Giraal Effectenverkeer B.V. (\u201cEuroclear Netherlands\u201d) only, in\naccordance with its normal settlement procedures applicable to equity securities and against payment for the Offer\nShares in immediately available funds, subject to acceleration or extension of the timetable of the Offer.\n", "page_number": 0, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.7971758664955071, "lower_right_x": 0.8663036902601331, "lower_right_y": 0.8519469405220368, "height": 0.0547710740265297, "width": 0.7507562008469449}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-1-0", "text": "   The offer price for the Offer Shares offered in the Offer (the \u201cOffer Price\u201d) will be determined on the basis of the\nquoted share price of the Shares and certain other factors described under \u201cThe Offer\u201d, and will, together with the\nactual number of Offer Shares offered in the Offer and the Offer proceeds, be incorporated in a pricing statement\nwhich will be deposited with the Dutch Authority for the Financial Markets (Autoriteit Financi\u00eble Markten) (the\n\u201cAFM\u201d) on or about 28 November 2007 and published in the Daily Official List of Euronext Amsterdam (Offici\u00eble\nPrijscourant) (the \u201cDaily Official List\u201d) and in a national newspaper distributed daily in the Netherlands, subject to\nacceleration or extension of the timetable of the Offer. The pricing statement will also be placed on our website at\nwww.octoplus.nl and you should access this information as soon as it is available. The contents of our website are\nexpressly not incorporated by reference into this Prospectus.\n", "page_number": 1, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.12623020967051776, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.24604193410355157, "height": 0.11981172443303381, "width": 0.7604355716878403}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-1-1", "text": "   Any acceleration or extension of the timetable for the Offer will be announced in a press release, in the event of\nan accelerated timetable for the Offer, at least three hours before the proposed expiration of the accelerated timetable\nfor the Offer or, in the event of an extended timetable for the Offer, at least three hours before the expiration of the\nthen-current timetable for the Offer. Any extension of the timetable for the Offer will be for a minimum of one full\ntrading day.\n", "page_number": 1, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.259734702610184, "lower_right_x": 0.8850574712643678, "lower_right_y": 0.3252032520325203, "height": 0.06546854942233632, "width": 0.7695099818511797}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-1-2", "text": "  This Prospectus constitutes a prospectus for the purposes of Article 3 of the Directive 2003/71/EC (the\n\u201cProspectus Directive\u201d) and has been prepared pursuant to Article 5:2 of the Financial Markets Supervision Act\n(Wet op het financieel toezicht (the \u201cFinancial Supervision Act\u201d)) and the rules promulgated thereunder. This\nProspectus has been approved by and filed with the AFM.\n", "page_number": 1, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.3384681215233205, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.3936670945656825, "height": 0.05519897304236199, "width": 0.736237144585602}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-1-3", "text": "Joint Global Coordinators and Joint Bookrunners\n", "page_number": 1, "bounding_box": {"top_left_x": 0.34361766485178463, "top_left_y": 0.43431750106974754, "lower_right_x": 0.677555958862674, "lower_right_y": 0.4450149764655541, "height": 0.010697475395806566, "width": 0.3339382940108893}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-1-4", "text": "Cowen International Limited\n", "page_number": 1, "bounding_box": {"top_left_x": 0.24016938898971568, "top_left_y": 0.4587077449721866, "lower_right_x": 0.4954627949183303, "lower_right_y": 0.47753530166880614, "height": 0.018827556696619563, "width": 0.2552934059286146}, "blob_type": "headline", "predictions": {}, "annotations": {"investment_bank": ["Cowen International Limited"]}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-1-5", "text": "Kempen & Co\n", "page_number": 1, "bounding_box": {"top_left_x": 0.6140350877192983, "top_left_y": 0.4587077449721866, "lower_right_x": 0.7447065940713854, "lower_right_y": 0.4792468977321352, "height": 0.02053915275994861, "width": 0.13067150635208713}, "blob_type": "headline", "predictions": {}, "annotations": {"investment_bank": ["Kempen & Co"]}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-1-6", "text": "Co-Manager\n", "page_number": 1, "bounding_box": {"top_left_x": 0.4591651542649728, "top_left_y": 0.4925117672229354, "lower_right_x": 0.5468844525105868, "lower_right_y": 0.5040650406504065, "height": 0.011553273427471089, "width": 0.08771929824561403}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-1-7", "text": "SNS Securities\n", "page_number": 1, "bounding_box": {"top_left_x": 0.4398064125831821, "top_left_y": 0.5198973042362003, "lower_right_x": 0.5607985480943739, "lower_right_y": 0.5323063756953359, "height": 0.012409071459135612, "width": 0.12099213551119181}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-1-8", "text": "Prospectus dated 9 November 2007\n", "page_number": 1, "bounding_box": {"top_left_x": 0.38173018753781, "top_left_y": 0.5464270432178006, "lower_right_x": 0.6212946158499697, "lower_right_y": 0.5618314077877621, "height": 0.015404364569961526, "width": 0.23956442831215968}, "blob_type": "paragraph", "predictions": {}, "annotations": {"filing_date": ["9 November 2007"]}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-2-0", "text": "Table of Contents\n", "page_number": 2, "bounding_box": {"top_left_x": 0.4107683000604961, "top_left_y": 0.14035087719298245, "lower_right_x": 0.5898366606170599, "lower_right_y": 0.15575524176294395, "height": 0.015404364569961498, "width": 0.17906836055656378}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-2-1", "text": "Table of Contents................................................................................................................................................ 3\nSummary ............................................................................................................................................................. 1\nSummary of Terms of the Offer ......................................................................................................................... 4\nSummary Consolidated Financial Information .................................................................................................. 7\nRisk Factors......................................................................................................................................................... 9\nImportant Information........................................................................................................................................ 27\nForward-Looking Statements........................................................................................................................... 30\nDividend Policy.................................................................................................................................................. 31\nUse of Proceeds................................................................................................................................................ 32\nCapitalization and Indebtedness...................................................................................................................... 33\nSelected Financial Information......................................................................................................................... 35\nOperating and Financial Review ...................................................................................................................... 37\nBusiness ............................................................................................................................................................ 48\nManagement and Employees .......................................................................................................................... 82\nMajor Shareholders........................................................................................................................................... 92\nRelated Party Transactions.............................................................................................................................. 94\nDescription of Share Capital and Corporate Governance.............................................................................. 95\nMarket Information .......................................................................................................................................... 106\nTaxation ........................................................................................................................................................... 107\nThe Offer.......................................................................................................................................................... 117\nUnderwriting .................................................................................................................................................... 120\nSelling Restrictions ......................................................................................................................................... 124\nTransfer Restrictions....................................................................................................................................... 127\nGeneral Information ........................................................................................................................................ 128\nSummary of Significant Differences between IFRS and US GAAP ............................................................ 130\nGlossary of Selected Terms........................................................................................................................... 136\nIndex to Financial Statements..........................................................................................................................F1\n", "page_number": 2, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.19127086007702182, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.6247325631151048, "height": 0.433461703038083, "width": 0.7701149425287356}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-3-0", "text": "Summary\n", "page_number": 3, "bounding_box": {"top_left_x": 0.4494857834240774, "top_left_y": 0.10269576379974327, "lower_right_x": 0.5511191772534785, "lower_right_y": 0.11938382541720154, "height": 0.01668806161745827, "width": 0.10163339382940106}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-3-1", "text": "   This summary provides an overview of selected information contained elsewhere in this Prospectus and\nshould be read as an introduction to this Prospectus. Any decision to invest in our Shares should be based on\nconsideration of this Prospectus as a whole by you. You should carefully read the Prospectus in its entirety\nbefore investing in our Shares, including the information discussed under \u201cRisk Factors\u201d beginning on page 9\nand our consolidated financial statements and the notes thereto that appear elsewhere in this Prospectus.\nUnless otherwise stated, all the information in this Prospectus assumes that the Underwriters will not exercise\nthe Overallotment Option.\n", "page_number": 3, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.1364997860504921, "lower_right_x": 0.8663036902601331, "lower_right_y": 0.23234916559691912, "height": 0.09584937954642703, "width": 0.7459165154264973}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-3-2", "text": "   Under laws in effect in the states within the European Economic Area, no civil liability will attach to us in\nrespect of this Summary, including the Summary of Terms of the Offer and the Summary Consolidated Financial\nInformation included herein, or any translation thereof, unless it is misleading, inaccurate or inconsistent when\nread together with the other parts of this Prospectus. Where a claim relating to information contained in this\nProspectus is brought before a court in a state within the European Economic Area, the plaintiff investor may,\nunder the national legislation of the state where the claim is brought, be required to bear the costs of translating\nthis Prospectus before the legal proceedings are initiated.\n", "page_number": 3, "bounding_box": {"top_left_x": 0.11796733212341198, "top_left_y": 0.24604193410355157, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.3423192126658109, "height": 0.09627727856225932, "width": 0.7628554143980641}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-3-3", "text": "Summary of our Business\n", "page_number": 3, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.355584082156611, "lower_right_x": 0.30490018148820325, "lower_right_y": 0.36970474967907574, "height": 0.014120667522464714, "width": 0.18451300665456744}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-3-4", "text": "    We are a product-oriented biopharmaceutical company committed to the development of improved\npharmaceutical products based on our proprietary drug delivery technologies that have fewer side effects,\nincreased patient convenience and better efficacy than existing products. We currently have five product\ncandidates in development, of which two are in Phase II clinical trials. Our lead product candidate, Locteron\u2122,\nis a novel interferon alfa combined with our proprietary PolyActive\u2122 drug delivery technology for the\ntreatment of chronic hepatitis C infection. Locteron is designed to require less frequent administration and cause\nfewer side effects than marketed forms of interferon alfa which currently represent the standard of care for this\nillness. We have completed patient treatment in a Phase IIa study of Locteron and intend to commence a Phase\nIIb clinical trial in the middle of 2008. We also intend to commence a separate study in the United States in a\ndifficult-to-treat patient population later this year or in the first quarter of 2008. Our second clinical-stage\nproduct candidate is OP-145 CSOM, a novel proprietary peptide therapeutic for the treatment of chronic otitis\nmedia, also known as chronic middle ear infection, that is currently in Phase II clinical trials. In addition, we\nhave three product candidates in pre-clinical development. OP-286 CR is a controlled-release formulation of a\nglucagon-like peptide-1 (\u201cGLP-1\u201d) analogue for the treatment of type II diabetes. We are also developing single\nshot vaccines based on our proprietary OctoVAX\u2122 platform, HBV-OctoVAX for hepatitis B vaccination and\nJEV-OctoVAX for Japanese encephalitis vaccination.\n", "page_number": 3, "bounding_box": {"top_left_x": 0.1161524500907441, "top_left_y": 0.3821138211382114, "lower_right_x": 0.8802177858439202, "lower_right_y": 0.6011981172443304, "height": 0.21908429610611896, "width": 0.7640653357531761}, "blob_type": "paragraph", "predictions": {}, "annotations": {"description_of_the_business": ["We are a product-oriented biopharmaceutical company committed to the development of improvedpharmaceutical products based on our proprietary drug delivery technologies that have fewer side effects,increased patient convenience and better efficacy than existing products. We currently have five productcandidates in development, of which two are in Phase II clinical trials. Our lead product candidate, Locteron\u2122,is a novel interferon alfa combined with our proprietary PolyActive\u2122 drug delivery technology for thetreatment of chronic hepatitis C infection. Locteron is designed to require less frequent administration and causefewer side effects than marketed forms of interferon alfa which currently represent the standard of care for thisillness. We have completed patient treatment in a Phase IIa study of Locteron and intend to commence a PhaseIIb clinical trial in the middle of 2008. We also intend to commence a separate study in the United States in adifficult-to-treat patient population later this year or in the first quarter of 2008. Our second clinical-stageproduct candidate is OP-145 CSOM, a novel proprietary peptide therapeutic for the treatment of chronic otitismedia, also known as chronic middle ear infection, that is currently in Phase II clinical trials. In addition, wehave three product candidates in pre-clinical development. OP-286 CR is a controlled-release formulation of aglucagon-like peptide-1 (\u201cGLP-1\u201d) analogue for the treatment of type II diabetes. We are also developing singleshot vaccines based on our proprietary OctoVAX\u2122 platform, HBV-OctoVAX for hepatitis B vaccination andJEV-OctoVAX for Japanese encephalitis vaccination."]}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-3-5", "text": "Our Clinical Product Candidates\n", "page_number": 3, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.6191698759092854, "lower_right_x": 0.352692075015124, "lower_right_y": 0.6294394522892597, "height": 0.010269576379974277, "width": 0.2323049001814882}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-3-6", "text": "   Locteron for Chronic HCV Infection. Locteron is a proprietary controlled release formulation of interferon\nalfa. The primary indication for Locteron is the treatment of chronic infection by the hepatitis C virus (\u201cHCV\u201d),\na virus that affects over 180 million people worldwide. Locteron combines interferon alfa produced by our co-\ndevelopment partner, Biolex Therapeutics, Inc. (\u201cBiolex\u201d), with our proprietary PolyActive microspheres.\nLocteron is designed to gradually release interferon alfa over a 14-day period after a single injection. Currently\nmarketed pegylated interferons are dosed once-every-week. By releasing interferon alfa in the body in a gradual\nmanner, Locteron avoids the high initial blood levels of interferon alfa which we believe cause many of the\nacute flu-like symptoms commonly associated with the current standard of care. We believe that the severity of\nthese flu-like symptoms leads many patients to suspend or avoid treatment, despite the often serious nature of\nHCV infection.\n", "page_number": 3, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.6465554129225503, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.7804878048780488, "height": 0.13393239195549855, "width": 0.7555958862673926}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-3-7", "text": "   We have completed patient treatment in a European Phase IIa clinical trial in 32 treatment-na\u00efve patients with\ngenotype I chronic HCV. This trial was designed to test the safety and tolerability of Locteron and to evaluate\nthe preliminary efficacy of Locteron over a course of multiple injections. The results of the study showed that 12\nweeks of treatment with Locteron in combination with ribavirin was effective in reducing hepatitis C virus\nlevels and that Locteron was generally safe and well tolerated.\n", "page_number": 3, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.7971758664955071, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.8647839109970047, "height": 0.0676080445014976, "width": 0.7604355716878403}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-3-8", "text": "   The viral responses of patients in the study at 12 weeks compared favorably to results reported in prior\nclinical trials for other interferons. In particular, the average viral reduction after 12 weeks of treatment for\n", "page_number": 3, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.8793324775353016, "lower_right_x": 0.8396854204476709, "lower_right_y": 0.9062901155327343, "height": 0.02695763799743267, "width": 0.7192982456140351}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-3-9", "text": "1\n", "page_number": 3, "bounding_box": {"top_left_x": 0.8705384150030248, "top_left_y": 0.9477963200684638, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9559264013692769, "height": 0.008130081300813052, "width": 0.010284331518451317}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-4-0", "text": "patients in the three highest dose cohorts, 320\u00b5g, 480\u00b5g and 640\u00b5g, was 4.48, 4.22 and 4.72 logs, respectively,\nwhich we believe indicates that Locteron has the potential to provide efficacy equal to or better than currently\nmarketed hepatitis C treatments.\n", "page_number": 4, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.08515190415062045, "lower_right_x": 0.8663036902601331, "lower_right_y": 0.12623020967051776, "height": 0.041078305519897315, "width": 0.7459165154264973}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-4-1", "text": "   Furthermore, in all four cohorts of the study, the majority of the adverse events was classified as mild and all\nadverse events were limited to flu-like symptoms and other side effects that are typically associated with\ninterferon treatment in this patient population. We believe the safety and tolerability results position Locteron\nfavorably compared to other treatments because patients receiving Locteron experienced side effects that were\nless frequent and less severe than those reported in the results of previous clinical trials for the currently\nmarketed pegylated interferons and Albuferon, a long-acting formulation of interferon alfa being developed by\nHuman Genome Sciences and Novartis.\n", "page_number": 4, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.1399229781771502, "lower_right_x": 0.8711433756805808, "lower_right_y": 0.23534445870774498, "height": 0.0954214805305948, "width": 0.7507562008469449}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-4-2", "text": "   We intend to commence a Phase IIb study to test the efficacy of Locteron in direct comparison with one of\nthe currently marketed pegylated interferons in the middle of 2008. We also intend to commence a separate\nstudy in the United States in a difficult-to-treat patient population later this year or in the first quarter of 2008.\n", "page_number": 4, "bounding_box": {"top_left_x": 0.12099213551119177, "top_left_y": 0.24946512623020967, "lower_right_x": 0.8602540834845736, "lower_right_y": 0.29097133076593923, "height": 0.04150620453572956, "width": 0.7392619479733817}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-4-3", "text": "   OP-145 CSOM for Chronic Middle Ear Infection. OP-145 CSOM is our novel, proprietary peptide\ntherapeutic for the treatment of chronic middle ear infection, administered locally through an eardrop\nformulation. It is currently in Phase II clinical development. Chronic middle ear infection is a very common\ndisease, affecting approximately 15% of all children as well as many adults. It is the most frequently recorded\ndiagnosis for children in the United States and is the most common reason for a child being prescribed oral\nantibiotics. Acute middle ear infections are caused by a range of microbes. However, when toxic microbial\ndegradation products linger in the mucus of the middle ear a chronic infection may develop. Antibiotics are not\neffective in treating many chronic cases. Surgery is only effective in a minority of chronic patients.\n", "page_number": 4, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.3042362002567394, "lower_right_x": 0.8705384150030248, "lower_right_y": 0.41420624732563116, "height": 0.10997004706889174, "width": 0.7501512401693889}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-4-4", "text": "   OP-145 CSOM has been designed to neutralize toxic degradation products at the site of chronic infection,\nthereby restoring the body\u2019s natural clearance mechanism. OP-145 CSOM also has anti-microbial effects as it\ndestabilizes the cell membrane of bacteria. We have demonstrated these two characteristics of OP-145 CSOM in\npre-clinical studies. In 2006, we completed a Phase I/IIa study in 16 therapy-resistant patients who had an\naverage disease duration of 17 years. Patients in this study received OP-145 CSOM for two weeks. This study\ndemonstrated that OP-145 CSOM was safe and well tolerated. Furthermore, at a 12-week follow-up\nexamination, nine out of the 16 patients showed either full recovery or a meaningful improvement.\n", "page_number": 4, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.4274711168164313, "lower_right_x": 0.8802177858439202, "lower_right_y": 0.5254599914420197, "height": 0.09798887462558842, "width": 0.7598306110102844}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-4-5", "text": "   We are currently conducting a placebo controlled Phase II study in 52 patients to evaluate the safety and\nefficacy of OP-145 CSOM. We expect to complete patient treatment in this trial by the end of 2007 and intend\nto announce the trial results in the first half of 2008.\n", "page_number": 4, "bounding_box": {"top_left_x": 0.12159709618874773, "top_left_y": 0.540436456996149, "lower_right_x": 0.8663036902601331, "lower_right_y": 0.5785194694052204, "height": 0.038083012409071415, "width": 0.7447065940713854}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-4-6", "text": "Our Pre-Clinical Product Candidates\n", "page_number": 4, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.5952075310226786, "lower_right_x": 0.382335148215366, "lower_right_y": 0.6059050064184852, "height": 0.010697475395806566, "width": 0.2619479733817302}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-4-7", "text": "   OP-286 CR for Type II Diabetes. OP-286 CR is a controlled-release formulation of a GLP-1 analogue for the\ntreatment of type II diabetes. We intend to combine this GLP-1 analogue with one of our drug delivery\ntechnologies to enable once-every-two-weeks or less frequent administration. We anticipate that OP-286 CR\nwill initially be targeted at type II diabetes patients for whom oral anti-diabetic treatments alone are not\nsufficient, but who do not yet require insulin injections. We anticipate that less frequent administration will\nrepresent a significant convenience advantage for patients as compared to the currently marketed GLP-1\nanalogue, which requires two injections per day. We have initiated formulation studies of OP-286 CR and\nexpect to commence a pre-clinical proof-of-concept study in the second quarter of 2008.\n", "page_number": 4, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.6225930680359435, "lower_right_x": 0.8753781004234725, "lower_right_y": 0.7325631151048353, "height": 0.1099700470688918, "width": 0.7549909255898367}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-4-8", "text": "   HBV-OctoVAX for Hepatitis B Vaccination. HBV-OctoVAX is our single-shot vaccine for hepatitis B. We\nhave an ongoing pre-clinical program to test several different hepatitis B vaccines in combination with\nOctoVAX. We have a non-exclusive collaboration with SciGen, Ltd. to test Sci-B-Vac, the hepatitis B vaccine\nmarketed by SciGen. Upon completion of our pre-clinical development program, we and SciGen intend to\nexecute another agreement and intend to commence Phase I clinical trials in the first quarter of 2009, subject to\nreaching a final agreement relating to this development.\n", "page_number": 4, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.7458279845956355, "lower_right_x": 0.8705384150030248, "lower_right_y": 0.8284124946512623, "height": 0.08258451005562684, "width": 0.7501512401693889}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-4-9", "text": "   JEV-OctoVAX for Japanese Encephalitis Vaccination. JEV-OctoVAX is our single-shot vaccine for Japanese\nencephalitis vaccination. We have entered into an exclusive co-development agreement with SingVax Pte. Ltd.\nfor the development of JEV-OctoVAX, whereby we and SingVax will jointly carry out pre-clinical, clinical and\nregulatory activities. We are currently performing pre-clinical experiments with SingVax to select the most\n", "page_number": 4, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.8416773641420625, "lower_right_x": 0.8753781004234725, "lower_right_y": 0.8968763371844245, "height": 0.05519897304236199, "width": 0.7549909255898367}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-4-10", "text": "", "page_number": 4, "bounding_box": {"top_left_x": 0.8705384150030248, "top_left_y": 0.9477963200684638, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9546427043217801, "height": 0.0068463842533162955, "width": 0.010284331518451317}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-5-0", "text": "promising formulation for further development. We anticipate that Phase I clinical trials of JEV-OctoVAX will\ncommence in the first half of 2009.\n", "page_number": 5, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.08515190415062045, "lower_right_x": 0.868723532970357, "lower_right_y": 0.10954214805305948, "height": 0.024390243902439032, "width": 0.7483363581367212}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-5-1", "text": "Our Proprietary Drug Delivery Technologies\n", "page_number": 5, "bounding_box": {"top_left_x": 0.12099213551119177, "top_left_y": 0.12623020967051776, "lower_right_x": 0.4343617664851785, "lower_right_y": 0.14035087719298245, "height": 0.014120667522464686, "width": 0.31336963097398673}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-5-2", "text": "   We use our proprietary drug delivery systems, including OctoDEX\u2122 and PolyActive, to develop products\nthat provide controlled and prolonged release of a drug, so as to enable reduced dosing frequency and reduced\nside effects with comparable or better efficacy relative to immediate release drugs. Rather than seeking to\ndiscover novel drug candidates through early stage research activities, we focus on the development of long-\nacting, controlled-release versions of known protein therapeutics and other drugs. In contrast to certain other\napproaches to improve the clinical benefit of protein therapeutics, such as chemical modification (including\npegylation and polymer conjugates) or protein engineering (including changes in primary structure and fusion),\nour technologies are designed to have the advantage of efficiently and gradually delivering a drug in its native\nform. We believe that products based on our OctoDEX and PolyActive technologies can be applied in many\ntherapeutic areas. However, our current product focus is primarily directed at improving the treatment or\nprevention of viral and bacterial infections as well as treatment of metabolic disorders.\n", "page_number": 5, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.15361574668378264, "lower_right_x": 0.8711433756805808, "lower_right_y": 0.30466409927257165, "height": 0.15104835258878901, "width": 0.7507562008469449}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-5-3", "text": "Our Contract Development Business\n", "page_number": 5, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.32135216089002994, "lower_right_x": 0.37749546279491836, "lower_right_y": 0.3337612323491656, "height": 0.012409071459135668, "width": 0.25710828796128254}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-5-4", "text": "   We are a leading European provider of advanced drug formulation and clinical scale manufacturing services\nto the pharmaceutical and biotechnology industries, with a focus on difficult to formulate active pharmaceutical\ningredients in non-oral formulations. We have provided our services to more than 100 clients that have\nprogressed more than 40 products into clinical studies and six products on to the market. Currently,\napproximately 70% of our revenues from this business originate in Europe, while the remainder is sourced from\nclients in North America, the Far East and Australia. Our cGMP pilot plant allows us to offer our customers a\nfull range of sterile pharmaceutical production options, including freeze drying. The expertise that we derive\nfrom rendering formulation and manufacturing services helps to support us in our own drug development\nprograms.\n", "page_number": 5, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.34873769790329484, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.47068891741548996, "height": 0.12195121951219512, "width": 0.7555958862673926}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-5-5", "text": "Our Strategy\n", "page_number": 5, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.4856653829696192, "lower_right_x": 0.21294615849969753, "lower_right_y": 0.49893025246041933, "height": 0.013264869490800135, "width": 0.09255898366606172}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-5-6", "text": "  We aim to leverage our broad expertise in pharmaceutical development and drug delivery in order to develop\npharmaceutical products that improve existing approaches to the treatment of serious illnesses. Key elements of\nour corporate strategy include:\n", "page_number": 5, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.513050919982884, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.5541292255027813, "height": 0.04107830551989733, "width": 0.7555958862673926}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-5-7", "text": "Advance the development of our lead product candidates;\n\nContinue to expand our product candidate portfolio by combining our drug delivery technologies with\nknown biopharmaceutical drugs or other therapeutics in need of clinical improvement;\n\nCapture value by entering into partnerships with large pharmaceutical or biotechnology companies for\nour product candidates; and\n\nFurther expand the potential applications of our drug delivery platforms.\n", "page_number": 5, "bounding_box": {"top_left_x": 0.16696914700544466, "top_left_y": 0.5656824989302525, "lower_right_x": 0.8632788868723533, "lower_right_y": 0.6927685066324347, "height": 0.12708600770218226, "width": 0.6963097398669087}, "blob_type": "paragraph", "predictions": {}, "annotations": {"key_element_strategy": ["Advance the development of our lead product candidates;", "Continue to expand our product candidate portfolio by combining our drug delivery technologies withknown biopharmaceutical drugs or other therapeutics in need of clinical improvement;", "Capture value by entering into partnerships with large pharmaceutical or biotechnology companies forour product candidates;", "Further expand the potential applications of our drug delivery platforms."]}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-5-8", "text": "Risks Associated with Our Business\n", "page_number": 5, "bounding_box": {"top_left_x": 0.11796733212341198, "top_left_y": 0.7081728712023962, "lower_right_x": 0.3720508166969147, "lower_right_y": 0.7188703465982028, "height": 0.010697475395806566, "width": 0.2540834845735027}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-5-9", "text": "  Our business is subject to numerous risks, such as risks related to our business and strategy, our dependence\non third parties, our intellectual property, our employees and growth, regulatory approval and other government\nregulations, and our financial condition. These risks are more fully described in the section entitled \u201cRisk\nFactors\u201d immediately following this Prospectus summary.\n", "page_number": 5, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.7355584082156611, "lower_right_x": 0.8753781004234725, "lower_right_y": 0.7907573812580231, "height": 0.05519897304236199, "width": 0.7549909255898367}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-5-10", "text": "Corporate Information\n", "page_number": 5, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.8040222507488233, "lower_right_x": 0.2807017543859649, "lower_right_y": 0.8177150192554558, "height": 0.01369276850663248, "width": 0.16031457955232908}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-5-11", "text": "   We are a public company with limited liability incorporated under the laws of the Netherlands and are\nregistered with the Trade Register of the Chamber of Commerce of Rijnland under number 28075073 and we\nhave our corporate seat in Leiden, the Netherlands. Our business address is Zernikedreef 12, 2333 CL Leiden,\nthe Netherlands and our website is www.octoplus.nl.\n", "page_number": 5, "bounding_box": {"top_left_x": 0.12159709618874773, "top_left_y": 0.8314077877620881, "lower_right_x": 0.8614640048396854, "lower_right_y": 0.8866067608044501, "height": 0.05519897304236199, "width": 0.7398669086509377}, "blob_type": "paragraph", "predictions": {}, "annotations": {"country_of_origin/headquarters": ["Netherlands"], "country_of_registration/incorporation": ["Netherlands"]}}, {"blob_number_in_page": 12, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-5-12", "text": "3\n", "page_number": 5, "bounding_box": {"top_left_x": 0.8705384150030248, "top_left_y": 0.9477963200684638, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9554985023534446, "height": 0.007702182284980763, "width": 0.010284331518451317}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-6-0", "text": "Summary of Terms of the Offer\n", "page_number": 6, "bounding_box": {"top_left_x": 0.33817301875378103, "top_left_y": 0.10226786478391099, "lower_right_x": 0.663036902601331, "lower_right_y": 0.11895592640136927, "height": 0.016688061617458283, "width": 0.32486388384754994}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-6-1", "text": "OctoPlus N.V., a public company with limited liability\nincorporated under the laws of the Netherlands, with its corporate\nseat in Leiden, the Netherlands.\n", "page_number": 6, "bounding_box": {"top_left_x": 0.4531155474894132, "top_left_y": 0.13436029097133076, "lower_right_x": 0.9001814882032668, "lower_right_y": 0.17800599058622166, "height": 0.0436456996148909, "width": 0.44706594071385364}, "blob_type": "headline", "predictions": {}, "annotations": {"issuer_name": ["OctoPlus N.V."], "country_of_registration/incorporation": ["Netherlands,"], "country_of_origin/headquarters": ["Netherlands."]}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-6-2", "text": "Issuer\n", "page_number": 6, "bounding_box": {"top_left_x": 0.12099213551119177, "top_left_y": 0.1364997860504921, "lower_right_x": 0.1645493042952208, "lower_right_y": 0.1467693624304664, "height": 0.010269576379974305, "width": 0.04355716878402903}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-6-3", "text": "We are offering Offer Shares for an amount of up to \u20ac25 million,\nsubject to any change by reference to the factors set forth on page\n118, assuming no exercise of the Overallotment Option. The\nactual number of Offer Shares offered in the Offer will be\npublished in a pricing statement and placed on our website on or\nabout 28 November 2007, subject to acceleration or extension of\nthe timetable for the Offer. The rights of holders of the Offer\nShares and our existing Shares will rank pari passu with each\nother.\n", "page_number": 6, "bounding_box": {"top_left_x": 0.4543254688445251, "top_left_y": 0.19127086007702182, "lower_right_x": 0.8995765275257108, "lower_right_y": 0.3115104835258879, "height": 0.12023962344886607, "width": 0.4452510586811857}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-6-4", "text": "Offer Shares\n", "page_number": 6, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.19169875909285408, "lower_right_x": 0.20810647307924984, "lower_right_y": 0.20367993153615746, "height": 0.011981172443303378, "width": 0.08771929824561403}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-6-5", "text": "Immediately prior to the Offer, we will have 16,207,076 Shares\noutstanding, see \u201cDescription of Share Capital and Corporate\nGovernance \u2013 Share Capital \u2013 Authorized and Issued Share\nCapital\u201d.\n", "page_number": 6, "bounding_box": {"top_left_x": 0.4543254688445251, "top_left_y": 0.3281985451433462, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.38339751818570816, "height": 0.05519897304236199, "width": 0.4313369630973986}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-6-6", "text": "Shares Outstanding\n", "page_number": 6, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.3290543431750107, "lower_right_x": 0.2516636418632789, "lower_right_y": 0.3423192126658109, "height": 0.01326486949080019, "width": 0.13127646702964307}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-6-7", "text": "Immediately after the Offer, we expect to have 22,536,190 Shares\noutstanding, assuming we raise \u20ac25 million in the Offer, no\nexercise of the Overallotment Option and an Offer Price of \u20ac3.95,\nthe closing price of our Shares on Euronext Amsterdam on 8\nNovember 2007.\n", "page_number": 6, "bounding_box": {"top_left_x": 0.4543254688445251, "top_left_y": 0.39666238767650835, "lower_right_x": 0.9026013309134906, "lower_right_y": 0.46512623020967053, "height": 0.06846384253316218, "width": 0.44827586206896547}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-6-8", "text": "Immediately after the Offer, assuming we raise \u20ac25 million in the\nOffer, no exercise of the Overallotment Option and an Offer Price\nof \u20ac3.95, the closing price of our Shares on Euronext Amsterdam\non 8 November 2007, we expect approximately 52.3% of our\noutstanding share capital will be owned by our CEO (partly\nthrough his personal holding company Sodoro B.V.), Innoven\nPartenaires S.A., S.R. One, Limited, Life Sciences Partners III\nB.V. / C.V., SurModics, Inc., and Fagus N.V. (the \u201cMajor\nShareholders\u201d), excluding any Offer Shares which may be\nacquired by any of the Major Shareholders pursuant to the Offer\n(see under \u201cMajor Shareholders\u201d).\n", "page_number": 6, "bounding_box": {"top_left_x": 0.4543254688445251, "top_left_y": 0.48224219084296105, "lower_right_x": 0.9050211736237145, "lower_right_y": 0.6328626444159179, "height": 0.15062045357295684, "width": 0.45069570477918935}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-6-9", "text": "Share Ownership\n", "page_number": 6, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.48224219084296105, "lower_right_x": 0.23714458560193588, "lower_right_y": 0.49550706033376124, "height": 0.01326486949080019, "width": 0.11675741076830007}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-6-10", "text": "The Offer consists of a public offering in the Netherlands and an\ninternational offering to institutional investors in certain other\njurisdictions. The Offer includes an offer of Offer Shares in the\nUnited States in reliance on Rule 144A. The Offer Shares are\nbeing sold outside the United States in reliance on Regulation S.\n", "page_number": 6, "bounding_box": {"top_left_x": 0.4543254688445251, "top_left_y": 0.6465554129225503, "lower_right_x": 0.8935269207501513, "lower_right_y": 0.7150192554557124, "height": 0.06846384253316218, "width": 0.43920145190562615}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-6-11", "text": "Offer\n", "page_number": 6, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.6465554129225503, "lower_right_x": 0.15789473684210525, "lower_right_y": 0.6568249893025246, "height": 0.010269576379974388, "width": 0.03750756200846944}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-6-12", "text": "The Offer Price, which applies to the Offer Shares offered in the\nOffer, will be determined by reference to the factors set forth on\npage 118 and will be published in a pricing statement and placed\non our website on or about 28 November 2007, subject to\nacceleration or extension of the timetable for the Offer.\n", "page_number": 6, "bounding_box": {"top_left_x": 0.4543254688445251, "top_left_y": 0.7287120239623449, "lower_right_x": 0.8953418027828192, "lower_right_y": 0.7976037655113393, "height": 0.06889174154899436, "width": 0.44101633393829404}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-6-13", "text": "Offer Price\n", "page_number": 6, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.7295678219940094, "lower_right_x": 0.1984271022383545, "lower_right_y": 0.7424047924689773, "height": 0.012836970474967901, "width": 0.07803992740471868}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-6-14", "text": "Expected to be on or about 27 November 2007, subject to\nacceleration or extension of the timetable for the Offer.\n", "page_number": 6, "bounding_box": {"top_left_x": 0.4543254688445251, "top_left_y": 0.8142918271287976, "lower_right_x": 0.8469449485783425, "lower_right_y": 0.8386820710312366, "height": 0.024390243902439046, "width": 0.39261947973381733}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-6-15", "text": "Pricing Date\n", "page_number": 6, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.8142918271287976, "lower_right_x": 0.20629159104658198, "lower_right_y": 0.8275566966195977, "height": 0.01326486949080019, "width": 0.08590441621294617}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 16, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-6-16", "text": "Expected to be on or about 27 November 2007, before the start of\ntrading of the Shares on Euronext Amsterdam, subject to\nacceleration or extension of the timetable for the Offer.\n", "page_number": 6, "bounding_box": {"top_left_x": 0.4543254688445251, "top_left_y": 0.8553701326486949, "lower_right_x": 0.9050211736237145, "lower_right_y": 0.8934531450577664, "height": 0.038083012409071526, "width": 0.45069570477918935}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 17, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-6-17", "text": "Allotment Date\n", "page_number": 6, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.8553701326486949, "lower_right_x": 0.22686025408348456, "lower_right_y": 0.8660676080445014, "height": 0.010697475395806566, "width": 0.10647307924984875}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 18, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-6-18", "text": "4\n", "page_number": 6, "bounding_box": {"top_left_x": 0.8705384150030248, "top_left_y": 0.9477963200684638, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9554985023534446, "height": 0.007702182284980763, "width": 0.010284331518451317}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-7-0", "text": "Expected to be on or about 3 December 2007, subject to\nacceleration or extension of the timetable for the Offer.\n", "page_number": 7, "bounding_box": {"top_left_x": 0.4543254688445251, "top_left_y": 0.09884467265725289, "lower_right_x": 0.837265577737447, "lower_right_y": 0.12494651262302096, "height": 0.02610183996576808, "width": 0.3829401088929219}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-7-1", "text": "Listing Date\n", "page_number": 7, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.09927257167308515, "lower_right_x": 0.20387174833635813, "lower_right_y": 0.11210954214805306, "height": 0.012836970474967915, "width": 0.08348457350272231}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-7-2", "text": "Expected to be on or about 3 December 2007, subject to\nacceleration or extension of the timetable for the Offer.\n", "page_number": 7, "bounding_box": {"top_left_x": 0.4543254688445251, "top_left_y": 0.1399229781771502, "lower_right_x": 0.8360556563823351, "lower_right_y": 0.16773641420624733, "height": 0.02781343602909714, "width": 0.38173018753781}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-7-3", "text": "Settlement Date\n", "page_number": 7, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.14120667522464697, "lower_right_x": 0.2323049001814882, "lower_right_y": 0.15361574668378264, "height": 0.012409071459135668, "width": 0.11191772534785238}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-7-4", "text": "Joint Global Coordinators and Joint\n", "page_number": 7, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.18271287976037656, "lower_right_x": 0.3629764065335753, "lower_right_y": 0.1951219512195122, "height": 0.01240907145913564, "width": 0.2425892316999395}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-7-5", "text": "Cowen and Kempen & Co.\n", "page_number": 7, "bounding_box": {"top_left_x": 0.4543254688445251, "top_left_y": 0.1844244758237056, "lower_right_x": 0.6388384754990926, "lower_right_y": 0.1972614462986735, "height": 0.012836970474967901, "width": 0.18451300665456744}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-7-6", "text": "Bookrunners\n", "page_number": 7, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.196405648267009, "lower_right_x": 0.2075015124016939, "lower_right_y": 0.20881471972614463, "height": 0.01240907145913564, "width": 0.08711433756805809}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-7-7", "text": "Co-Manager\n", "page_number": 7, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.2255027813436029, "lower_right_x": 0.20810647307924984, "lower_right_y": 0.23876765083440307, "height": 0.013264869490800163, "width": 0.08771929824561403}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-7-8", "text": "SNS Securities.\n", "page_number": 7, "bounding_box": {"top_left_x": 0.4543254688445251, "top_left_y": 0.2255027813436029, "lower_right_x": 0.5656382335148216, "lower_right_y": 0.2362002567394095, "height": 0.010697475395806594, "width": 0.11131276467029644}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-7-9", "text": "We have granted to the Underwriters an option, exercisable within\n30 calendar days after the Listing Date, pursuant to which the\nUnderwriters may require us to issue additional Offer Shares at\nthe Offer Price for an amount up to 15% of the amount of the\nOffer. The Underwriters may exercise this option at their\ndiscretion for any purpose in accordance with applicable law,\nincluding covering short positions created in the initial allotment\nof Offer Shares or in subsequent transactions.\n", "page_number": 7, "bounding_box": {"top_left_x": 0.4543254688445251, "top_left_y": 0.25288831835686776, "lower_right_x": 0.9038112522686026, "lower_right_y": 0.362002567394095, "height": 0.10911424903722722, "width": 0.44948578342407747}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-7-10", "text": "Overallotment Option\n", "page_number": 7, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.25288831835686776, "lower_right_x": 0.2710223835450696, "lower_right_y": 0.26658108686350024, "height": 0.01369276850663248, "width": 0.15063520871143377}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-7-11", "text": "We intend to raise up to \u20ac25 million of gross proceeds from the\nissue of Offer Shares in the Offer. We intend to use the net\nproceeds we receive from the Offer, after deduction of the\nunderwriting fees and commissions and our expenses related to\nthe Offer, for the development of our product candidates, in-\nlicensing or acquiring of additional product candidates or\ntechnologies, other general corporate purposes, including capital\nexpenditures and working capital, and for acquisitions if and when\nthey present themselves, see \u201cUse of Proceeds\u201d.\n", "page_number": 7, "bounding_box": {"top_left_x": 0.4543254688445251, "top_left_y": 0.3761232349165597, "lower_right_x": 0.9068360556563824, "lower_right_y": 0.4993581514762516, "height": 0.12323491655969193, "width": 0.45251058681185724}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-7-12", "text": "Use of Proceeds\n", "page_number": 7, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.3761232349165597, "lower_right_x": 0.2323049001814882, "lower_right_y": 0.38682071031236626, "height": 0.010697475395806566, "width": 0.11191772534785238}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-7-13", "text": "We and the members of our Executive Board and our Senior\nManagement have entered into \u201clock-up\u201d agreements for a\nminimum period of 180 days from the date of the underwriting\nagreement, pursuant to which we and they have agreed, subject to\ncertain exceptions, not to dispose in any way of any Shares and\nsecurities convertible into or exchangeable or exercisable for or\nrepayable with Shares, unless Cowen has given its prior written\nconsent thereto, see \u201cUnderwriting \u2013 Lock-Up Arrangements\u201d.\nWe have also entered into a \u201crestricted sales\u201d agreement with our\nMajor Shareholders (excluding our CEO and Sodoro B.V., the\npersonal holding company of our CEO), FormFarm Holding B.V.,\nNPM Capital B.V. and 7X Life Sciences B.V., pursuant to which\nthese shareholders have agreed, subject to certain exceptions, not\nto dispose in any way of any Shares currently held by them during\na period of 60 days following the Listing Date, unless Cowen has\ngiven its prior written consent thereto, and to restrict such\ntransactions during a subsequent period of 120 days, see \u201cMajor\nShareholders \u2013 Restricted Sales Agreement\u201d.\n", "page_number": 7, "bounding_box": {"top_left_x": 0.4543254688445251, "top_left_y": 0.513050919982884, "lower_right_x": 0.9050211736237145, "lower_right_y": 0.7595207531022679, "height": 0.24646983311938386, "width": 0.45069570477918935}, "blob_type": "paragraph", "predictions": {}, "annotations": {"lock-up_period": ["180 days"]}}, {"blob_number_in_page": 14, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-7-14", "text": "Lock-Up Arrangements\n", "page_number": 7, "bounding_box": {"top_left_x": 0.12099213551119177, "top_left_y": 0.513050919982884, "lower_right_x": 0.28009679370840895, "lower_right_y": 0.5267436884895165, "height": 0.01369276850663248, "width": 0.1591046581972172}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-7-15", "text": "If closing of the Offer does not take place on the Settlement Date\nor at all, the Offer will be withdrawn, all subscriptions for the\nOffer Shares will be disregarded, any allotments made will be\ndeemed not to have been made, any subscription payments made\nwill be returned without interest or other compensation and all\ntransactions in the Offer Shares on Euronext Amsterdam will be\ncancelled. All dealings in the Offer Shares on Euronext\nAmsterdam prior to settlement and delivery are at the sole risk of\nthe parties concerned.\n", "page_number": 7, "bounding_box": {"top_left_x": 0.4543254688445251, "top_left_y": 0.7732135216089003, "lower_right_x": 0.9001814882032668, "lower_right_y": 0.8968763371844245, "height": 0.12366281557552417, "width": 0.4458560193587417}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 16, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-7-16", "text": "Withdrawal of the Offer\n", "page_number": 7, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.7732135216089003, "lower_right_x": 0.2837265577737447, "lower_right_y": 0.7839109970047069, "height": 0.010697475395806566, "width": 0.1633393829401089}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 17, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-7-17", "text": "5\n", "page_number": 7, "bounding_box": {"top_left_x": 0.8705384150030248, "top_left_y": 0.9490800171159607, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9550706033376123, "height": 0.005990586221651606, "width": 0.010284331518451317}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-8-0", "text": "We do not anticipate paying any dividends for the foreseeable\nfuture. See \u201cDividend Policy\u201d.\n", "page_number": 8, "bounding_box": {"top_left_x": 0.4543254688445251, "top_left_y": 0.09884467265725289, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.12665810868635002, "height": 0.02781343602909714, "width": 0.4216575922565033}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-8-1", "text": "Dividends\n", "page_number": 8, "bounding_box": {"top_left_x": 0.12099213551119177, "top_left_y": 0.09927257167308515, "lower_right_x": 0.19298245614035087, "lower_right_y": 0.11125374411638853, "height": 0.011981172443303378, "width": 0.0719903206291591}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-8-2", "text": "Holders of the Shares will be entitled to one vote per Share at\nGeneral Meetings of Shareholders. See \u201cDescription of Share\nCapital and Corporate Governance \u2013 General Meetings of\nShareholders and Voting Rights\u201d.\n", "page_number": 8, "bounding_box": {"top_left_x": 0.45493042952208107, "top_left_y": 0.1399229781771502, "lower_right_x": 0.8711433756805808, "lower_right_y": 0.1951219512195122, "height": 0.055198973042362015, "width": 0.4162129461584997}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-8-3", "text": "Voting Rights\n", "page_number": 8, "bounding_box": {"top_left_x": 0.12159709618874773, "top_left_y": 0.14120667522464697, "lower_right_x": 0.21536600120992136, "lower_right_y": 0.1540436456996149, "height": 0.01283697047496793, "width": 0.09376890502117363}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-8-4", "text": "Payment for the Offer Shares, including any Offer Shares issued\nupon exercise of the Overallotment Option prior to the Settlement\nDate, will take place on the Settlement Date. Delivery of the Offer\nShares is expected to take place on or about 3 December 2007\nthrough the book-entry facilities of Euroclear Netherlands only, in\naccordance with its normal settlement procedures applicable to\nequity securities and against payment for the Offer Shares in\nimmediately available funds.\n", "page_number": 8, "bounding_box": {"top_left_x": 0.4543254688445251, "top_left_y": 0.20838682071031236, "lower_right_x": 0.9044162129461585, "lower_right_y": 0.31835686777920413, "height": 0.10997004706889177, "width": 0.45009074410163336}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-8-5", "text": "Payment, Delivery, Clearing and Settlement\n", "page_number": 8, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.20838682071031236, "lower_right_x": 0.42105263157894735, "lower_right_y": 0.22250748823277705, "height": 0.014120667522464686, "width": 0.30066545674531153}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-8-6", "text": "Share Trading Information   ISIN Code: NL0000345718\n\n                            Common Code: 026668441\n\n                            Amsterdam Security Code: 34571\n\n                            Euronext Amsterdam Symbol: OCTO\n\nListing Agent               Kempen & Co N.V.\n\nPaying Agent                Fortis Bank (Nederland) N.V.\n", "page_number": 8, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.33162173727000427, "lower_right_x": 0.7168784029038112, "lower_right_y": 0.48609328198545143, "height": 0.15447154471544716, "width": 0.5964912280701754}, "blob_type": "headline", "predictions": {}, "annotations": {"isin": ["NL0000345718"], "ticker": ["OCTO"]}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-8-7", "text": "", "page_number": 8, "bounding_box": {"top_left_x": 0.8723532970356926, "top_left_y": 0.9477963200684638, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9546427043217801, "height": 0.0068463842533162955, "width": 0.008469449485783431}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-9-0", "text": "Summary Consolidated Financial Information\n", "page_number": 9, "bounding_box": {"top_left_x": 0.2655777374470659, "top_left_y": 0.10226786478391099, "lower_right_x": 0.735632183908046, "lower_right_y": 0.11895592640136927, "height": 0.016688061617458283, "width": 0.47005444646098005}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-9-1", "text": "   The summary consolidated financial information set forth below should be read in conjunction with\n\u201cOperating and Financial Review\u201d, \u201cSelected Financial Information\u201d and our consolidated financial\nstatements and unaudited condensed consolidated interim financial statements and their related notes that\nappear elsewhere in this Prospectus. The year-end consolidated financial information has been extracted from\nour consolidated financial statements that have been audited by Deloitte Accountants B.V., independent\nauditors. Our six month consolidated financial information has been extracted from our unaudited condensed\nconsolidated interim financial statements as of and for the six month periods ended 30 June 2006 and 30 June\n2007. The unaudited condensed consolidated interim financial statements for the sixth month periods ended\n30 June 2006 and 30 June 2007 have been reviewed by Deloitte Accountants B.V. See \u201cIndex to Financial\nStatements \u2013 Condensed Consolidated Interim Financial Statements 30 June 2007 and 2006 \u2013 Review Report\u201d.\n", "page_number": 9, "bounding_box": {"top_left_x": 0.1161524500907441, "top_left_y": 0.1364997860504921, "lower_right_x": 0.8699334543254689, "lower_right_y": 0.2734274711168164, "height": 0.13692768506632433, "width": 0.7537810042347248}, "blob_type": "paragraph", "predictions": {}, "annotations": {"unaudited_interim_financial_statements": ["unaudited condensedconsolidated interim financial statements as of and for the six month periods ended 30 June 2006 and 30 June2007."], "periods_of_unaudited_interim_fs": [" 30 June 2006 and 30 June2007"]}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-9-2", "text": "   Our results for the six month period ended 30 June 2007 are not necessarily indicative of our results for the\nfull year. Our consolidated financial statements, from which the summary consolidated financial information set\nforth below has been derived, were prepared in accordance with IFRS, which may differ from US GAAP in\ncertain significant respects. For a discussion of the most significant differences between IFRS and US GAAP as\nthey relate to us, in particular regarding finance leases, intellectual property rights and business combinations,\nsee \u201cSummary of Significant Differences between IFRS and US GAAP\u201d. The summary consolidated financial\ninformation set forth below may not contain all of the information that is important to you.\n", "page_number": 9, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.28712023962344885, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.38339751818570816, "height": 0.09627727856225932, "width": 0.7652752571082879}, "blob_type": "paragraph", "predictions": {}, "annotations": {"accounting_standards": ["IFRS,"]}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-9-3", "text": "Consolidated Income Statement Information\n", "page_number": 9, "bounding_box": {"top_left_x": 0.12159709618874773, "top_left_y": 0.39666238767650835, "lower_right_x": 0.44162129461585, "lower_right_y": 0.4103551561831408, "height": 0.013692768506632425, "width": 0.3200241984271023}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-9-4", "text": "                                                    Year ended 31 December            Six months ended 30 June\n (in thousands)                              2004            2005          2006         2006            2007\n                                                                                     UNAUDITED     UNAUDITED\nService revenues                              \u20ac4,924         \u20ac6,563        \u20ac5,587       \u20ac3,157          \u20ac2,543\nRoyalty and license revenues                      60             60           332           30             213\nIncome from subsidies                            708            394           132           92             118\nOther income                                      26              -             -            -               -\nTotal (consolidated) revenues                  5,718          7,017         6,051        3,279           2,874\nRaw materials and auxiliaries                     70            237           180          100             191\nCost of contracted work and other external\ncharges                                           307         1,390          1,928        1,147          1,403\nEmployee benefits                               3,597         4,758          6,140        2,920          3,993\nDepreciation and amortization                     860           863          1,060          512            541\nOther costs                                     2,667         4,213          5,263        2,597          2,930\nTotal operating costs                           7,501       11,461         14,571         7,276          9,058\nOperating loss                                (1,783)       (4,444)        (8,520)      (3,997)        (6,184)\nInterest                                        (394)         (118)          (145)        (104)             63\nResult before corporate income taxes         \u20ac(2,177)      \u20ac(4,562)       \u20ac(8,665)     \u20ac(4,101)       \u20ac(6,121)\n", "page_number": 9, "bounding_box": {"top_left_x": 0.11070780399274047, "top_left_y": 0.4240479246897732, "lower_right_x": 0.9147005444646098, "lower_right_y": 0.6807873341891314, "height": 0.2567394094993582, "width": 0.8039927404718693}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-9-5", "text": "Segmented Income Statement Information\n", "page_number": 9, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.6944801026957638, "lower_right_x": 0.4246823956442831, "lower_right_y": 0.7086007702182285, "height": 0.01412066752246477, "width": 0.3042952208106473}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-9-6", "text": "                                             Year ended 31 December            Six months ended 30 June\n (in thousands)                       2004            2005          2006         2006           2007\n                                                                              UNAUDITED     UNAUDITED\nContract Development gross revenues   \u20ac5,444          \u20ac6,804        \u20ac8,504       \u20ac4,112          \u20ac4,533\nOperating costs                        4,631           6,086         7,869        3,854           4,257\nOperating profit                         813             718           635          258             276\n\nInter-segment (internal) revenues        772             366         2,927           955          2,084\n\nProducts & Drug Delivery revenues       1,046             579           474          122            425\nOperating costs                         3,642           5,776         9,287        4,339          6,770\nOperating loss                        (2,596)         (5,197)       (8,813)      (4,217)        (6,345)\n", "page_number": 9, "bounding_box": {"top_left_x": 0.11070780399274047, "top_left_y": 0.7210098416773641, "lower_right_x": 0.9104658197217181, "lower_right_y": 0.9071459135643988, "height": 0.18613607188703463, "width": 0.7997580157289776}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-9-7", "text": "", "page_number": 9, "bounding_box": {"top_left_x": 0.8723532970356926, "top_left_y": 0.9477963200684638, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9542148053059478, "height": 0.006418485237484006, "width": 0.008469449485783431}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-10-0", "text": "Unallocated costs                    -        35      (342)        (38)     (115)\n\nConsolidated operating loss   \u20ac(1,783)   \u20ac(4,444)   \u20ac(8,520)   \u20ac(3,997)   \u20ac(6,184)\n", "page_number": 10, "bounding_box": {"top_left_x": 0.11070780399274047, "top_left_y": 0.08172871202396234, "lower_right_x": 0.9147005444646098, "lower_right_y": 0.13008130081300814, "height": 0.0483525887890458, "width": 0.8039927404718693}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-10-1", "text": "Consolidated Balance Sheet Information\n", "page_number": 10, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.1433461703038083, "lower_right_x": 0.4107683000604961, "lower_right_y": 0.1540436456996149, "height": 0.010697475395806594, "width": 0.29038112522686027}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-10-2", "text": "                                      Year ended 31 December           Six months ended 30 June\n (in thousands)                2004            2005          2006        2006            2007\n                                                                      UNAUDITED     UNAUDITED\nIntangible fixed assets        \u20ac1,421          \u20ac1,705        \u20ac1,766      \u20ac1,725          \u20ac3,018\nOther fixed assets              6,054           6,289         7,366       6,363           6,638\nCurrent assets                  1,879          12,506        23,134       8,762          15,609\nTotal assets                    9,354          20,500        32,266      16,850          25,265\n\nEquity (deficit)               (1,356)         11,751        21,142       8,456         15,317\nNon-current liabilities          4,345          3,738         3,618       3,711          3,583\nCurrent liabilities              6,365          5,011         7,506       4,683          6,365\nTotal equity and liabilities   \u20ac9,354         \u20ac20,500       \u20ac32,266     \u20ac16,850        \u20ac25,265\n", "page_number": 10, "bounding_box": {"top_left_x": 0.11070780399274047, "top_left_y": 0.16730851519041506, "lower_right_x": 0.911070780399274, "lower_right_y": 0.33975181857081727, "height": 0.1724433033804022, "width": 0.8003629764065335}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-10-3", "text": "Consolidated Cash Flow Statement Information\n", "page_number": 10, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.35216089002995293, "lower_right_x": 0.46400483968542044, "lower_right_y": 0.36499786050492083, "height": 0.012836970474967901, "width": 0.34361766485178463}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-10-4", "text": "                                              Year ended 31 December            Six months ended 30 June\n (in thousands)                        2004            2005          2006         2006            2007\n                                                                               UNAUDITED     UNAUDITED\nResult before corporate income taxes   \u20ac(2,177)      \u20ac(4,562)       \u20ac(8,665)     \u20ac(4,101)       \u20ac(6,121)\nDepreciation and amortization               860           863          1,060          512            541\nChanges in working capital                2,265       (1,037)          1,195      (1,090)          (555)\nCash flow from operating activities         948       (4,736)        (6,410)      (4,679)        (6,135)\nCash flow from investing activities       (944)       (1,218)       (13,588)        (606)          3,938\nCash flow from financing activities       (923)       16,860          17,821           29             62\nNet cash flow                             (919)       10,906         (2,177)      (5,256)        (2,135)\n\nCash at beginning of period               (757)        (1,676)         9,230        9,230          7,053\nCash at end of period                   (1,676)          9,230         7,053        3,974          4,918\nNet cash flow                            \u20ac(919)       \u20ac10,906       \u20ac(2,177)     \u20ac(5,256)       \u20ac(2,135)\n", "page_number": 10, "bounding_box": {"top_left_x": 0.11070780399274047, "top_left_y": 0.37997432605905007, "lower_right_x": 0.9086509376890503, "lower_right_y": 0.5789473684210527, "height": 0.19897304236200258, "width": 0.7979431336963098}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-10-5", "text": "", "page_number": 10, "bounding_box": {"top_left_x": 0.8705384150030248, "top_left_y": 0.9482242190842961, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9546427043217801, "height": 0.006418485237484006, "width": 0.010284331518451317}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-11-0", "text": "Risk Factors\n", "page_number": 11, "bounding_box": {"top_left_x": 0.4355716878402904, "top_left_y": 0.10226786478391099, "lower_right_x": 0.5656382335148216, "lower_right_y": 0.11596063329054343, "height": 0.013692768506632438, "width": 0.1300665456745312}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-11-1", "text": "   Investing in the Shares involves a high degree of risk. You should carefully consider the risks described below\nand all of the other information set forth in this Prospectus before deciding to invest in any of our Shares. If any\nof the events or developments described below occurs, our business, financial condition or results of operations\ncould be negatively affected. In that case, the trading price of the Shares could decline, and you could lose all or\npart of your investment in the Shares.\n", "page_number": 11, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.1364997860504921, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.20496362858365424, "height": 0.06846384253316215, "width": 0.7652752571082879}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-11-2", "text": "   Although we believe that the risks and uncertainties described below are our most material risks and\nuncertainties, they are not the only ones we face. Additional risks and uncertainties not presently known to us or\nthat we currently deem immaterial may also have a material adverse effect on our business, results of\noperations or financial condition and could negatively affect the price of the Shares.\n", "page_number": 11, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.2186563970902867, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.2738553701326487, "height": 0.055198973042362015, "width": 0.7604355716878403}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-11-3", "text": "Risks Related to Our Business and Strategy\n", "page_number": 11, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.28712023962344885, "lower_right_x": 0.4355716878402904, "lower_right_y": 0.30124090714591356, "height": 0.014120667522464714, "width": 0.31518451300665457}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-11-4", "text": "  Our success depends substantially on our most advanced product candidates, which are still under\ndevelopment. If we are unable to bring any or all of these product candidates to market successfully or to\ndevelop additional product candidates, or if we experience significant delays in doing so, our ability to\ngenerate product revenue and our likelihood of success will be harmed.\n", "page_number": 11, "bounding_box": {"top_left_x": 0.1161524500907441, "top_left_y": 0.31407787762088146, "lower_right_x": 0.8499697519661222, "lower_right_y": 0.37098844672657255, "height": 0.05691056910569109, "width": 0.7338173018753782}, "blob_type": "paragraph", "predictions": {}, "annotations": {"risk_factor": ["Our success depends substantially on our most advanced product candidates, which are still underdevelopment. If we are unable to bring any or all of these product candidates to market successfully or todevelop additional product candidates, or if we experience significant delays in doing so, our ability togenerate product revenue and our likelihood of success will be harmed."]}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-11-5", "text": "   Our two most advanced product candidates are in Phase II clinical trials. We have completed patient\ntreatment in a Phase IIa trial for Locteron and are currently evaluating OP-145 CSOM in a Phase II trial. Our\nability to generate product revenue in the future will depend on the successful development and\ncommercialization of these product candidates. Our other product candidates are in pre-clinical development.\nAny of our product candidates could be unsuccessful if:\n", "page_number": 11, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.38296961916987593, "lower_right_x": 0.8560193587416818, "lower_right_y": 0.4535729567821994, "height": 0.07060333761232346, "width": 0.735632183908046}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-11-6", "text": "\u00b7   it does not demonstrate acceptable safety and efficacy in pre-clinical or clinical trials or otherwise does\n    not meet applicable regulatory standards for approval;\n\n\u00b7   it does not offer therapeutic or other improvements over existing or future drugs used to treat the same\n    conditions;\n\n\u00b7   it is not capable of being produced in commercial quantities at acceptable costs;\n\n\u00b7   it is not accepted in the medical community or by third-party payors; or\n\n\u00b7   we are unable to manufacture such product candidate in sufficient quantities to conduct clinical testing,\n    because our facilities and operations fail to meet the complex requirements of the European Medicines\n    Evaluation Agency (the \u201cEMEA\u201d), the US Food and Drug Administration (the \u201cFDA\u201d) and other\n    regulatory agencies.\n", "page_number": 11, "bounding_box": {"top_left_x": 0.14216575922565033, "top_left_y": 0.4685494223363286, "lower_right_x": 0.8663036902601331, "lower_right_y": 0.660676080445015, "height": 0.1921266581086864, "width": 0.7241379310344828}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-11-7", "text": "", "page_number": 11, "bounding_box": {"top_left_x": 0.1355111917725348, "top_left_y": 0.4719726144629867, "lower_right_x": 0.14156079854809436, "lower_right_y": 0.47753530166880614, "height": 0.005562687205819428, "width": 0.006049606775559574}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-11-8", "text": "\u00b7\n", "page_number": 11, "bounding_box": {"top_left_x": 0.1355111917725348, "top_left_y": 0.513050919982884, "lower_right_x": 0.14156079854809436, "lower_right_y": 0.5198973042362003, "height": 0.0068463842533162955, "width": 0.006049606775559574}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-11-9", "text": "\u00b7\n", "page_number": 11, "bounding_box": {"top_left_x": 0.1367211131276467, "top_left_y": 0.5545571245186136, "lower_right_x": 0.14156079854809436, "lower_right_y": 0.5609756097560976, "height": 0.006418485237484006, "width": 0.004839685420447659}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-11-10", "text": "\u00b7\n", "page_number": 11, "bounding_box": {"top_left_x": 0.1355111917725348, "top_left_y": 0.5823705605477107, "lower_right_x": 0.14156079854809436, "lower_right_y": 0.5887890457851946, "height": 0.006418485237483895, "width": 0.006049606775559574}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-11-11", "text": "\u00b7\n", "page_number": 11, "bounding_box": {"top_left_x": 0.1355111917725348, "top_left_y": 0.6101839965768079, "lower_right_x": 0.14156079854809436, "lower_right_y": 0.6161745827984596, "height": 0.005990586221651717, "width": 0.006049606775559574}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-11-12", "text": "  We will need to continue to identify and develop additional product candidates, particularly if we are not\nsuccessful in developing our existing product candidates.\n", "page_number": 11, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.6739409499358151, "lower_right_x": 0.8469449485783425, "lower_right_y": 0.7017543859649122, "height": 0.02781343602909714, "width": 0.7265577737447066}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-11-13", "text": "   Our lead product candidate, Locteron, uses interferon alfa produced through a plant-based expression system.\nThis method of production is different from that used for other interferon alfa products currently on the market,\nwhich are produced through mammalian or bacterial cultures. We cannot assure you that the EMEA, the FDA or\nother regulatory authorities will approve this interferon alfa product, known as BLX-883, or its method of\nproduction. For Phase III trials, we intend to use a different strain of the expressing plant, which we believe\nproduces a more consistent interferon alfa than the strain we used for our Phase I and Phase IIa trials and intend\nto use for our Phase IIb trials. We cannot assure you that this interferon alfa will not be inferior to the interferon\nalfa that we have already tested.\n", "page_number": 11, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.7184424475823705, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.8267008985879333, "height": 0.10825845100556275, "width": 0.7604355716878403}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-11-14", "text": "   We do not expect any of our current product candidates to be commercially available until 2012 at the\nearliest, if at all. If we are unable to make our product candidates commercially available, we will not generate\nproduct revenues and we will not be successful. The results of our clinical trials to date do not provide assurance\nthat acceptable efficacy or safety will be shown upon completion of Phase III clinical trials.\n", "page_number": 11, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.8416773641420625, "lower_right_x": 0.8790078644888082, "lower_right_y": 0.8955926401369276, "height": 0.05391527599486512, "width": 0.7586206896551724}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-11-15", "text": "9\n", "page_number": 11, "bounding_box": {"top_left_x": 0.8711433756805808, "top_left_y": 0.9482242190842961, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9554985023534446, "height": 0.007274283269148474, "width": 0.009679370840895318}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-12-0", "text": "  Any failure or delay in commencing or completing clinical trials for our product candidates could severely\nharm our business.\n", "page_number": 12, "bounding_box": {"top_left_x": 0.1161524500907441, "top_left_y": 0.08301240907145914, "lower_right_x": 0.8753781004234725, "lower_right_y": 0.11125374411638853, "height": 0.028241335044929386, "width": 0.7592256503327284}, "blob_type": "headline", "predictions": {}, "annotations": {"risk_factor": ["Any failure or delay in commencing or completing clinical trials for our product candidates could severelyharm our business."]}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-12-1", "text": "   To obtain the requisite regulatory approvals to market and sell any of our product candidates, we must\ndemonstrate, through extensive pre-clinical and clinical trials, that the product candidate is safe and effective in\nhumans. Pre-clinical and clinical trials are expensive, can take many years and have an uncertain outcome. A\nfailure of one or more of our clinical trials could occur at any stage of testing.\n", "page_number": 12, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.12623020967051776, "lower_right_x": 0.8711433756805808, "lower_right_y": 0.18142918271287975, "height": 0.05519897304236199, "width": 0.7507562008469449}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-12-2", "text": "   Positive or timely results from pre-clinical and early clinical trials do not ensure positive or timely results in\nlate stage clinical trials or product approval by the EMEA, the FDA or any other regulatory authority. Product\ncandidates that show positive pre-clinical or early clinical results often fail in later stage clinical trials.\n", "page_number": 12, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.19469405220367994, "lower_right_x": 0.8663036902601331, "lower_right_y": 0.2362002567394095, "height": 0.04150620453572956, "width": 0.7459165154264973}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-12-3", "text": "  We have limited experience in conducting the clinical trials required to obtain regulatory approval. We may\nnot be able to conduct clinical trials at preferred sites, enlist clinical investigators, enroll sufficient numbers of\npatients, or begin or successfully complete clinical trials in a timely fashion, if at all.\n", "page_number": 12, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.24946512623020967, "lower_right_x": 0.8663036902601331, "lower_right_y": 0.29097133076593923, "height": 0.04150620453572956, "width": 0.7459165154264973}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-12-4", "text": "   To date, we have not completed all clinical trials required for the approval of any product candidate. The\ncommencement and completion of clinical trials for our product candidates may be delayed, suspended or\nterminated as a result of many factors, including:\n", "page_number": 12, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.3076593923833975, "lower_right_x": 0.8421052631578947, "lower_right_y": 0.3461703038083012, "height": 0.038510911424903704, "width": 0.7217180883242589}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-12-5", "text": "erminated as a result of many factors, including:\n\n \u00b7    our inability or the inability of our collaborators or licensees to manufacture or obtain from third parties\n      materials sufficient for use in pre-clinical and clinical trials;\n\n \u00b7    the delay or refusal of regulators or institutional review boards to authorize us to commence a clinical\n      trial at a prospective trial site;\n\n \u00b7    delays in patient enrollment and variability in the number and types of patients available for clinical\n      trials;\n\n \u00b7    lower than anticipated retention rates of patients and volunteers in clinical trials;\n\n \u00b7    difficulty in maintaining contact with patients after treatment, resulting in incomplete data;\n\n \u00b7    negative or inconclusive results, which may require us to conduct additional pre-clinical or clinical trials\n      or to abandon projects that we expect to be promising;\n\n \u00b7    poor efficacy of product candidates during clinical trials;\n\n \u00b7    unforeseen safety issues or side effects;\n\n \u00b7    unfavorable governmental or regulatory inspection and review of a clinical trial site or records of any\n      clinical or pre-clinical trial; and\n\n \u00b7    governmental or regulatory delays and changes in regulatory requirements, policies and guidelines.\n", "page_number": 12, "bounding_box": {"top_left_x": 0.13490623109497882, "top_left_y": 0.3465982028241335, "lower_right_x": 0.8753781004234725, "lower_right_y": 0.6949080017115961, "height": 0.34830979888746255, "width": 0.7404718693284937}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-12-6", "text": "   Any delay in commencing or completing clinical trials for our product candidates could delay\ncommercialization of our product candidates and may severely harm our business and financial condition. It is\nalso possible that none of our product candidates will complete clinical trials in any of the markets in which we\nor our collaborators intend to sell those product candidates. Accordingly, neither we, nor our collaborators,\nwould receive the regulatory approvals needed to market our product candidates, which would severely harm\nour business and financial condition.\n", "page_number": 12, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.7086007702182285, "lower_right_x": 0.8711433756805808, "lower_right_y": 0.7894736842105263, "height": 0.08087291399229779, "width": 0.7507562008469449}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-12-7", "text": "   Completion of our Phase II trial for OP-145 CSOM has been delayed by at least a calendar quarter due to\nslower than anticipated patient enrollment.\n", "page_number": 12, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.8040222507488233, "lower_right_x": 0.8469449485783425, "lower_right_y": 0.8318356867779204, "height": 0.02781343602909714, "width": 0.7265577737447066}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-12-8", "text": "   The EMEA, the FDA and other regulatory agencies may require additional pre-clinical and clinical data\nfor our product candidates.\n", "page_number": 12, "bounding_box": {"top_left_x": 0.12280701754385964, "top_left_y": 0.8451005562687206, "lower_right_x": 0.8620689655172413, "lower_right_y": 0.8741976893453145, "height": 0.029097133076593895, "width": 0.7392619479733817}, "blob_type": "paragraph", "predictions": {}, "annotations": {"risk_factor": ["The EMEA, the FDA and other regulatory agencies may require additional pre-clinical and clinical datafor our product candidates."]}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-12-9", "text": "10\n", "page_number": 12, "bounding_box": {"top_left_x": 0.8608590441621294, "top_left_y": 0.9477963200684638, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9572100984167736, "height": 0.00941377834830981, "width": 0.019963702359346636}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-13-0", "text": "   Many of our product candidates involve the combination of a marketed drug or similar compound with\nPolyActive, OctoDEX or OctoVAX. As a result, we anticipate that we will not need to conduct some early stage\ntests concerning the safety and toxicology of the active pharmaceutical ingredient contained in some of our\nproduct candidates. We cannot assure you, however, that the EMEA, the FDA or other regulatory authorities\nwill not require such tests. If we are required to conduct further pre-clinical or clinical trials, our costs will\nincrease and we will not be able to progress our product candidates towards commercialization as rapidly as we\nexpect.\n", "page_number": 13, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.08515190415062045, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.1797175866495507, "height": 0.09456568249893026, "width": 0.7604355716878403}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-13-1", "text": "   We may fail to identify, select or capitalize on the most scientifically, clinically or commercially promising\nor profitable product candidates. We may terminate development programs.\n", "page_number": 13, "bounding_box": {"top_left_x": 0.1161524500907441, "top_left_y": 0.19298245614035087, "lower_right_x": 0.8705384150030248, "lower_right_y": 0.21822849807445444, "height": 0.02524604193410357, "width": 0.7543859649122806}, "blob_type": "paragraph", "predictions": {}, "annotations": {"risk_factor": ["We may fail to identify, select or capitalize on the most scientifically, clinically or commercially promisingor profitable product candidates. We may terminate development programs."]}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-13-2", "text": "   We intend to commence one new development program per year and thus need to continuously identify new\nproduct candidates. We may fail to identify promising new product candidates. We have limited technical,\nmanagerial and financial resources to determine which of our product candidates should proceed to initial\nclinical trials, later stage clinical development and potential commercialization. We may make incorrect\ndeterminations in this regard. Our decisions to allocate our research, management and financial resources\ntowards particular product candidates or therapeutic areas may not lead to the development of viable\ncommercial products and may divert resources from better opportunities. Similarly, our decisions to delay or\nterminate drug development programs may also be incorrect and could cause us to miss valuable opportunities.\nIn August 2007, we decided to discontinue development of our product candidate for controlled release of\nhuman growth hormone, hGH-OctoDEX, which had been in Phase I clinical trials, in order to re-allocate our\nresources to our other product candidates, which we believe will have greater commercial potential in light of\nthe increasingly competitive market for human growth hormone.\n", "page_number": 13, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.23577235772357724, "lower_right_x": 0.8705384150030248, "lower_right_y": 0.40051347881899874, "height": 0.1647411210954215, "width": 0.7501512401693889}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-13-3", "text": "We face intense competition.\n", "page_number": 13, "bounding_box": {"top_left_x": 0.13430127041742287, "top_left_y": 0.41292255027813435, "lower_right_x": 0.34180278281911675, "lower_right_y": 0.4291827128797604, "height": 0.01626016260162605, "width": 0.20750151240169387}, "blob_type": "headline", "predictions": {}, "annotations": {"risk_factor": ["We face intense competition."]}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-13-4", "text": "   The pharmaceutical and biotechnology industries are highly competitive. Any product candidates that we\nsuccessfully develop will compete with existing and future therapies. There are many organizations, including\npharmaceutical companies, biotechnology companies, academic laboratories, research institutions,\ngovernmental agencies and public and private universities, which are actively engaged in developing products\nthat target the same markets as our product candidates.\n", "page_number": 13, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.4411638853230638, "lower_right_x": 0.8614640048396854, "lower_right_y": 0.5117672229353872, "height": 0.07060333761232346, "width": 0.7410768300060496}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-13-5", "text": "   Many of these competitors have substantially greater financial, technological, manufacturing, marketing,\nmanagerial and research and development resources and experience than we do. Many of these organizations\nalso have much more experience than we do in pre-clinical and clinical trials of new drugs and in obtaining\nregulatory approvals. Accordingly, our competitors may succeed in developing competing technologies and\nproducts more rapidly than we do.\n", "page_number": 13, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.5267436884895165, "lower_right_x": 0.8566243194192378, "lower_right_y": 0.5943517329910141, "height": 0.0676080445014976, "width": 0.736237144585602}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-13-6", "text": "   Our product candidates, if successfully developed and approved for commercial sale, will compete with a\nnumber of drugs and therapies currently manufactured and marketed by major pharmaceutical and\nbiotechnology companies. Our product candidates may also compete with new products currently under\ndevelopment by others. These new products may turn out to be safer or may work better, or be as effective but\ncheaper, than our products. If our competitors develop and market product candidates that are safer, more\neffective or cheaper, or develop, obtain regulatory approval and market such product candidates earlier than we\ndo, our commercial opportunity will be reduced or eliminated.\n", "page_number": 13, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.6089002995293111, "lower_right_x": 0.8711433756805808, "lower_right_y": 0.7043217800599059, "height": 0.09542148053059474, "width": 0.7507562008469449}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-13-7", "text": "We face rapid technological change.\n", "page_number": 13, "bounding_box": {"top_left_x": 0.13430127041742287, "top_left_y": 0.7163029525032092, "lower_right_x": 0.3956442831215971, "lower_right_y": 0.7325631151048353, "height": 0.016260162601626105, "width": 0.26134301270417426}, "blob_type": "headline", "predictions": {}, "annotations": {"risk_factor": ["We face rapid technological change."]}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-13-8", "text": "   Our success depends, in part, on maintaining a competitive position in the development of products and\ntechnologies in a rapidly evolving field. Within the pharmaceutical and biotechnology industries, major\ntechnological changes can happen quickly. The rapid technological change, or the development by competitors\nof technologically improved or different drug delivery systems or products, could render our platform\ntechnologies or product candidates obsolete or non-competitive. For example, the current standard of care for\nHCV infection consists of a combination therapy using interferon alfa and ribavirin. Our lead product candidate,\nLocteron, is designed to be an improved interferon alfa component of this therapy. In the event that a new\nstandard of care emerges that does not use interferon alfa, Locteron could become obsolete.\n", "page_number": 13, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.7458279845956355, "lower_right_x": 0.8753781004234725, "lower_right_y": 0.8557980316645272, "height": 0.10997004706889169, "width": 0.7549909255898367}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-13-9", "text": "Our product candidates may not gain market acceptance.\n", "page_number": 13, "bounding_box": {"top_left_x": 0.13430127041742287, "top_left_y": 0.8677792041078306, "lower_right_x": 0.5390199637023594, "lower_right_y": 0.8840393667094566, "height": 0.016260162601625994, "width": 0.4047186932849365}, "blob_type": "headline", "predictions": {}, "annotations": {"risk_factor": ["Our product candidates may not gain market acceptance."]}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-13-10", "text": "11\n", "page_number": 13, "bounding_box": {"top_left_x": 0.8608590441621294, "top_left_y": 0.9477963200684638, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9572100984167736, "height": 0.00941377834830981, "width": 0.019963702359346636}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-14-0", "text": "  Even if our product candidates are ultimately approved, they may not gain market acceptance among\nphysicians, patients and others in the medical community.\n", "page_number": 14, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.08515190415062045, "lower_right_x": 0.8179068360556564, "lower_right_y": 0.11296534017971759, "height": 0.02781343602909714, "width": 0.6975196612220206}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-14-1", "text": "  Sales of medical products depend on physicians\u2019 willingness to prescribe the treatment, which is likely to be\nbased on a determination by these physicians that the products are safe and effective from a therapeutic and cost\nperspective relative to competing treatments. We cannot predict whether physicians will make this\ndetermination as it relates to our product candidates.\n", "page_number": 14, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.12623020967051776, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.18142918271287975, "height": 0.05519897304236199, "width": 0.7555958862673926}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-14-2", "text": "   Physicians may elect not to recommend, and patients may elect not to use, our products for a variety of\nreasons, including:\n", "page_number": 14, "bounding_box": {"top_left_x": 0.12099213551119177, "top_left_y": 0.19469405220367994, "lower_right_x": 0.8366606170598911, "lower_right_y": 0.22250748823277705, "height": 0.02781343602909711, "width": 0.7156684815486993}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-14-3", "text": "\u00b7   lower demonstrated clinical safety and efficacy compared to other products;\n\n\u00b7   prevalence and severity of side effects;\n\n\u00b7   advantages of alternative treatment methods;\n\n\u00b7   ineffective marketing and distribution support;\n\n\u00b7   lack of availability of reimbursement from managed care plans and other third-party payors;\n\n\u00b7   lack of cost-effectiveness; and\n\n\u00b7   timing of market introduction of competitive products.\n", "page_number": 14, "bounding_box": {"top_left_x": 0.13490623109497882, "top_left_y": 0.23577235772357724, "lower_right_x": 0.793708408953418, "lower_right_y": 0.41762943945228925, "height": 0.181857081728712, "width": 0.6588021778584392}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-14-4", "text": "   If any of our product candidates fails to achieve market acceptance, we may not be able to generate\nsignificant revenue, if any.\n", "page_number": 14, "bounding_box": {"top_left_x": 0.12099213551119177, "top_left_y": 0.43431750106974754, "lower_right_x": 0.8082274652147611, "lower_right_y": 0.46084724005134786, "height": 0.026529738981600326, "width": 0.6872353297035693}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-14-5", "text": "We have significant product liability exposure, which may harm our business and our reputation.\n", "page_number": 14, "bounding_box": {"top_left_x": 0.13430127041742287, "top_left_y": 0.472400513478819, "lower_right_x": 0.8166969147005445, "lower_right_y": 0.48694908001711595, "height": 0.014548566538296948, "width": 0.6823956442831216}, "blob_type": "headline", "predictions": {}, "annotations": {"risk_factor": ["We have significant product liability exposure, which may harm our business and our reputation."]}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-14-6", "text": "   We face an inherent risk of product liability lawsuits related to the testing of our product candidates, and will\nface an even greater risk if our product candidates are introduced commercially. An individual may bring a\nliability claim against us if one of our product candidates causes, or merely appears to have caused, an injury. If\nwe cannot successfully defend ourselves against the product liability claim, we may incur substantial liabilities.\nRegardless of merit or eventual outcome, liability claims may result in:\n", "page_number": 14, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.5027813436029097, "lower_right_x": 0.8753781004234725, "lower_right_y": 0.5712451861360719, "height": 0.06846384253316218, "width": 0.7549909255898367}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-14-7", "text": "decreased demand for our product candidates;\n\ninjury to our reputation;\n\nwithdrawal of clinical trial participants;\n\nsignificant litigation costs;\n\nsubstantial monetary awards to, or costly settlements with, patients;\n\nproduct recalls;\n\nloss of revenue;\n\nthe inability to commercialize our product candidates; and\n\nthe diversion of management\u2019s attention from managing our business.\n", "page_number": 14, "bounding_box": {"top_left_x": 0.16878402903811252, "top_left_y": 0.5849379546427044, "lower_right_x": 0.6394434361766486, "lower_right_y": 0.8215661103979461, "height": 0.23662815575524176, "width": 0.47065940713853605}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-14-8", "text": "\u00b7\n", "page_number": 14, "bounding_box": {"top_left_x": 0.1367211131276467, "top_left_y": 0.5887890457851946, "lower_right_x": 0.14519056261343014, "lower_right_y": 0.5952075310226786, "height": 0.006418485237484006, "width": 0.008469449485783431}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-14-9", "text": "\u00b7\n", "page_number": 14, "bounding_box": {"top_left_x": 0.1355111917725348, "top_left_y": 0.6166024818142918, "lower_right_x": 0.14519056261343014, "lower_right_y": 0.6230209670517758, "height": 0.006418485237484006, "width": 0.009679370840895346}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-14-10", "text": "\u00b7\n", "page_number": 14, "bounding_box": {"top_left_x": 0.1367211131276467, "top_left_y": 0.6469833119383825, "lower_right_x": 0.14277071990320628, "lower_right_y": 0.6499786050492083, "height": 0.002995293110825803, "width": 0.006049606775559574}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-14-11", "text": "\u00b7\n", "page_number": 14, "bounding_box": {"top_left_x": 0.1355111917725348, "top_left_y": 0.6739409499358151, "lower_right_x": 0.14519056261343014, "lower_right_y": 0.6795036371416345, "height": 0.005562687205819428, "width": 0.009679370840895346}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-14-12", "text": "\u00b7\n", "page_number": 14, "bounding_box": {"top_left_x": 0.1355111917725348, "top_left_y": 0.7013264869490801, "lower_right_x": 0.14519056261343014, "lower_right_y": 0.707744972186564, "height": 0.006418485237483895, "width": 0.009679370840895346}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-14-13", "text": "\u00b7\n", "page_number": 14, "bounding_box": {"top_left_x": 0.1355111917725348, "top_left_y": 0.7287120239623449, "lower_right_x": 0.14519056261343014, "lower_right_y": 0.7355584082156611, "height": 0.0068463842533161845, "width": 0.009679370840895346}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-14-14", "text": "\u00b7\n", "page_number": 14, "bounding_box": {"top_left_x": 0.1355111917725348, "top_left_y": 0.7560975609756098, "lower_right_x": 0.14519056261343014, "lower_right_y": 0.762943945228926, "height": 0.0068463842533161845, "width": 0.009679370840895346}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-14-15", "text": "\u00b7\n", "page_number": 14, "bounding_box": {"top_left_x": 0.1355111917725348, "top_left_y": 0.7843388960205392, "lower_right_x": 0.14519056261343014, "lower_right_y": 0.7907573812580231, "height": 0.006418485237483895, "width": 0.009679370840895346}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 16, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-14-16", "text": "\u00b7\n", "page_number": 14, "bounding_box": {"top_left_x": 0.1355111917725348, "top_left_y": 0.8121523320496363, "lower_right_x": 0.14458560193587416, "lower_right_y": 0.8181429182712879, "height": 0.005990586221651606, "width": 0.009074410163339375}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 17, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-14-17", "text": "   We are highly dependent upon market perceptions of us, our brands and the safety and quality of our\nproducts. We could be adversely affected if we or our brands are subject to negative publicity. We could also be\nadversely affected if any of our products or any similar products distributed by other companies prove to be, or\nare asserted to be, harmful to consumers. Also, because of our dependence upon market perceptions, any\nadverse publicity associated with illness or other adverse effects resulting from consumers\u2019 use or misuse of our\n", "page_number": 14, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.8348309798887462, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.9037227214377407, "height": 0.06889174154899447, "width": 0.7555958862673926}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 18, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-14-18", "text": "12\n", "page_number": 14, "bounding_box": {"top_left_x": 0.8608590441621294, "top_left_y": 0.9477963200684638, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9572100984167736, "height": 0.00941377834830981, "width": 0.019963702359346636}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-15-0", "text": "products or any similar products distributed by other companies could have a material adverse impact on our\nresults of operations.\n", "page_number": 15, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.08515190415062045, "lower_right_x": 0.8511796733212341, "lower_right_y": 0.11296534017971759, "height": 0.02781343602909714, "width": 0.7307924984875983}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-15-1", "text": "  We are also exposed to similar liability risks due to the provision of pharmaceutical development and\nmanufacturing services by our Contract Development Business.\n", "page_number": 15, "bounding_box": {"top_left_x": 0.12159709618874773, "top_left_y": 0.12623020967051776, "lower_right_x": 0.822746521476104, "lower_right_y": 0.1540436456996149, "height": 0.02781343602909714, "width": 0.7011494252873564}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-15-2", "text": "   Some of our collaboration and customer supply agreements contain liability and/or indemnification\nprovisions under which we may claim damages from our counterparties and under which our counterparties may\nclaim damages from us, including damages caused by product defects. In the event we need to claim damages\nfrom a counterparty, we may not receive payments covering in full our damages, either because the applicable\nprovision limits the payment to a certain amount, is unenforceable for any reason or because the counterparty is\nunable to pay (due to insolvency or otherwise). Although in many cases we try to limit our liability, such\nlimitations may not be effective in the event that we need to pay damages and we nevertheless could become\nliable to make substantial payments.\n", "page_number": 15, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.16730851519041506, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.2772785622593068, "height": 0.10997004706889174, "width": 0.7604355716878403}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-15-3", "text": "   We have clinical trial and other liability insurance, which we currently believe is adequate to cover liabilities\nwe may incur. However, our current or future insurance coverage may prove insufficient to cover any liability\nclaims brought against us. We intend to expand our insurance coverage to include the sale of commercial\nproducts if marketing approval is obtained for our product candidates. Because of the increasing costs of\ninsurance coverage, we may not be able to maintain insurance coverage at a reasonable cost or obtain insurance\ncoverage that will be adequate to satisfy any liability that may arise.\n", "page_number": 15, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.290543431750107, "lower_right_x": 0.8711433756805808, "lower_right_y": 0.37312794180573383, "height": 0.08258451005562684, "width": 0.7507562008469449}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-15-4", "text": "  Unanticipated side effects during clinical development of Locteron may result in an interruption, delay o\nhalt in clinical trials and could result in the denial of regulatory approval by the EMEA, FDA or other\nregulatory authorities.\n", "page_number": 15, "bounding_box": {"top_left_x": 0.11675741076830005, "top_left_y": 0.38596491228070173, "lower_right_x": 0.8578342407743497, "lower_right_y": 0.4278990158322636, "height": 0.04193410355156185, "width": 0.7410768300060496}, "blob_type": "paragraph", "predictions": {}, "annotations": {"risk_factor": ["Unanticipated side effects during clinical development of Locteron may result in an interruption, delay orhalt in clinical trials and could result in the denial of regulatory approval by the EMEA, FDA or otherregulatory authorities."]}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-15-5", "text": "   The active agent in Locteron is interferon alfa, variants of which are currently marketed in Europe, the United\nStates and elsewhere for treatment of chronic hepatitis C. Treatment of patients with interferon alfa has\nhistorically been associated with significant adverse side effects, including severe flu-like symptoms,\ndepression, suicidal thoughts and attempts, fatigue, alopecia, bone marrow toxicity, endocrine disorders,\nhepatotoxicity, cardiovascular and pulmonary disorders, pancreatitis, worsening of auto-immune disorders,\nsleep disorders, arthralgia, myalgia and ophthalmologic disorders. A number of participants in our Phase IIa\nclinical trial for Locteron have experienced adverse events adjudicated or determined by trial investigators to be\npotentially attributable to Locteron, although most of these adverse events have been rated as mild and only two\nof such adverse events were rated as severe or serious. Future clinical trials may demonstrate that the gradual\nrelease of interferon alfa does not reduce the frequency, duration or severity of side effects commonly\nexperienced by patients treated with currently marketed pegylated interferons or alternatives currently under\ndevelopment, such as Albuferon.\n", "page_number": 15, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.44458707744972187, "lower_right_x": 0.8790078644888082, "lower_right_y": 0.6084724005134788, "height": 0.16388532306375697, "width": 0.7586206896551724}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-15-6", "text": "   Because Locteron has only been tested in a limited number of patients over a short duration, we cannot\nassure you that Locteron\u2019s efficacy or safety and tolerability profile suggested to date will be replicated in the\nfuture.\n", "page_number": 15, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.62002567394095, "lower_right_x": 0.8747731397459165, "lower_right_y": 0.6640992725716731, "height": 0.04407359863072313, "width": 0.7592256503327284}, "blob_type": "paragraph", "predictions": {}, "annotations": {"risk_factor": ["Because Locteron has only been tested in a limited number of patients over a short duration, we cannotassure you that Locteron\u2019s efficacy or safety and tolerability profile suggested to date will be replicated in thefuture."]}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-15-7", "text": "   To date, Locteron has only been tested in a very limited number of patients. Furthermore, most of the adverse\nside effects observed in our Phase IIa trial were based on symptoms that are measured subjectively, as they are\nsubject to both varying perceptions by the patients and varying interpretations by our clinical investigators,\nincluding by virtue of their characterization as mild, moderate, severe or serious and their varying effect on\ndiverse patient populations. Accordingly, and because observed significant adverse effects have been associated\nwith currently marketed variants of interferon alfa, we cannot assure you that the favorable safety and\ntolerability profile suggested by Locteron in our completed early-stage clinical trials will be replicated in larger,\nlater-stage trials. In addition, a definitive comparison of Locteron with currently marketed drugs or other drugs\nin clinical development requires a controlled, head-to-head clinical trial. To date, the longest a patient has been\ndosed with Locteron has been for 12 weeks. The anticipated dosing period for Locteron, if approved, is expected\nto be 48 weeks in the most prevalent genotype of hepatitis C patients. Accordingly, we cannot assure you that\nthe results indicated by Locteron in early trials will be replicated in longer trials that will be required prior to\nany regulatory approval.\n", "page_number": 15, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.6773641420624733, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.8557980316645272, "height": 0.17843388960205386, "width": 0.7604355716878403}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-15-8", "text": "  The success of Locteron depends heavily on our collaboration with Biolex, which involves a complex\nsharing of decisions, responsibilities, costs and benefits. A loss of Biolex as a partner, or any adverse\ndevelopments in the collaboration, would materially harm our business.\n", "page_number": 15, "bounding_box": {"top_left_x": 0.1161524500907441, "top_left_y": 0.866923406076166, "lower_right_x": 0.8402903811252269, "lower_right_y": 0.9105691056910569, "height": 0.04364569961489084, "width": 0.7241379310344829}, "blob_type": "paragraph", "predictions": {}, "annotations": {"risk_factor": ["The success of Locteron depends heavily on our collaboration with Biolex, which involves a complexsharing of decisions, responsibilities, costs and benefits. A loss of Biolex as a partner, or any adversedevelopments in the collaboration, would materially harm our business."]}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-15-9", "text": "13\n", "page_number": 15, "bounding_box": {"top_left_x": 0.8608590441621294, "top_left_y": 0.9477963200684638, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9572100984167736, "height": 0.00941377834830981, "width": 0.019963702359346636}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-16-0", "text": "   In February 2005, we entered into a collaboration agreement with Biolex to develop and commercialize\nLocteron. Locteron combines our PolyActive drug delivery technology and Biolex\u2019s proprietary BLX-883\ninterferon alfa.\n", "page_number": 16, "bounding_box": {"top_left_x": 0.12099213551119177, "top_left_y": 0.08515190415062045, "lower_right_x": 0.837265577737447, "lower_right_y": 0.12280701754385964, "height": 0.037655113393239195, "width": 0.7162734422262552}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-16-1", "text": "  We are subject to a number of additional risks associated with our dependence on our collaboration with\nBiolex, including:\n\n  \u00b7    We and Biolex could disagree as to development plans, including clinical trials or regulatory approval\n       strategy, or as to which additional indications for Locteron should be pursued. Disputes regarding the\n       collaboration agreement that delay or terminate the development, receipt of regulatory approvals or\n       commercialization of Locteron would harm our business and could result in significant litigation or\n       arbitration.\n\n  \u00b7    Biolex could fail to devote sufficient resources towards the development and approval of Locteron. After\n       the time periods stated in the collaboration agreement, Biolex could shift its research and development\n       resources to other product opportunities.\n\n  \u00b7    Biolex may not be able to provide us with sufficient quantities of BLX-883 for incorporation into\n       Locteron for commercial sale in a cost effective and timely manner.\n\n   Furthermore, Biolex may terminate our collaboration agreement at will upon due notice, subject to the\nsurvival of certain obligations, or upon our material breach of the collaboration agreement.\n", "page_number": 16, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.1399229781771502, "lower_right_x": 0.8771929824561403, "lower_right_y": 0.3902439024390244, "height": 0.25032092426187424, "width": 0.7568058076225045}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-16-2", "text": "  We do not currently have the resources necessary to develop Locteron on our own. If either we or Biolex do\nnot perform our respective obligations under, or devote sufficient resources to, our collaboration, or if we and\nBiolex do not work effectively together, Locteron may not be successfully developed and commercialized. If\nour collaboration were to be terminated, we would need to establish an alternative arrangement and may not be\nable to do so on acceptable terms or at all.\n", "page_number": 16, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.40350877192982454, "lower_right_x": 0.8711433756805808, "lower_right_y": 0.4719726144629867, "height": 0.06846384253316218, "width": 0.7507562008469449}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-16-3", "text": "No product manufactured using Biolex\u2019s novel plant-based expression technology has yet been approved.\n", "page_number": 16, "bounding_box": {"top_left_x": 0.13430127041742287, "top_left_y": 0.48352588789045786, "lower_right_x": 0.8717483363581368, "lower_right_y": 0.4985023534445871, "height": 0.014976465554129237, "width": 0.7374470659407139}, "blob_type": "headline", "predictions": {}, "annotations": {"risk_factor": ["No product manufactured using Biolex\u2019s novel plant-based expression technology has yet been approved."]}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-16-4", "text": "  Biolex produces BLX-883, the active pharmaceutical ingredient in Locteron, in genetically engineered\nLemna, a clonal higher order plant species. To date, none of Biolex\u2019s Lemna-based compounds have been\napproved for sale in the European Union, the United States or any other jurisdiction. Moreover, to our\nknowledge, no product produced in any plant-based expression system has been submitted to the EMEA, the\nFDA or any other regulatory agency for final regulatory approval.\n", "page_number": 16, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.513050919982884, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.5819426615318785, "height": 0.06889174154899447, "width": 0.736237144585602}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-16-5", "text": "   If unforeseen technological, regulatory or other challenges associated with Biolex\u2019s plant-based expression\nsystem materialize, we will not be able to use BLX-883 and we would have great difficulty in sourcing\ninterferon alfa for use in Locteron, and our ability to develop and commercialize this product will be severely\ndisrupted.\n", "page_number": 16, "bounding_box": {"top_left_x": 0.12099213551119177, "top_left_y": 0.5952075310226786, "lower_right_x": 0.8614640048396854, "lower_right_y": 0.6504065040650406, "height": 0.05519897304236199, "width": 0.7404718693284936}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-16-6", "text": "  We have not yet developed OP-286 CR, our controlled-release GLP-1 analogue product candidate, which\ncombines OP-286, a GLP-1 analogue, with one of our drug delivery technologies.\n", "page_number": 16, "bounding_box": {"top_left_x": 0.1161524500907441, "top_left_y": 0.6632434745400085, "lower_right_x": 0.8638838475499092, "lower_right_y": 0.6944801026957638, "height": 0.03123662815575523, "width": 0.7477313974591651}, "blob_type": "paragraph", "predictions": {}, "annotations": {"risk_factor": ["We have not yet developed OP-286 CR, our controlled-release GLP-1 analogue product candidate, whichcombines OP-286, a GLP-1 analogue, with one of our drug delivery technologies."]}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-16-7", "text": "   We have not yet developed OP-286 CR, our controlled-release GLP-1 analogue product candidate. We have\nrecently initiated formulation studies of OP-286 and cannot assure you that we will be able to successfully\ndevelop a controlled-release formulation for further pre-clinical and clinical development. We also cannot\nassure you that further pre-clinical trials with OP-286 and OP-286 CR will be successful or that its benefits will\nbe realized in clinical trials.\n", "page_number": 16, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.7081728712023962, "lower_right_x": 0.8705384150030248, "lower_right_y": 0.7736414206247325, "height": 0.06546854942233626, "width": 0.7501512401693889}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-16-8", "text": "  Our information technology systems could face serious disruptions that could adversely affect our\nbusiness.\n", "page_number": 16, "bounding_box": {"top_left_x": 0.1161524500907441, "top_left_y": 0.787334189131365, "lower_right_x": 0.8203266787658802, "lower_right_y": 0.8172871202396235, "height": 0.029952931108258474, "width": 0.704174228675136}, "blob_type": "headline", "predictions": {}, "annotations": {"risk_factor": ["Our information technology systems could face serious disruptions that could adversely affect ourbusiness."]}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-16-9", "text": "   Our information technology and other internal infrastructure systems, including corporate firewalls, servers,\nleased lines and connection to the Internet, face the risk of systemic failure that could disrupt our operations. A\nsignificant disruption in the availability of our information technology and other internal infrastructure systems\ncould cause interruptions in our service to customers, delays in our research and development work or the loss\nor delay of client relationships.\n", "page_number": 16, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.8314077877620881, "lower_right_x": 0.8693284936479129, "lower_right_y": 0.8998716302952503, "height": 0.06846384253316218, "width": 0.7489413188142771}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-16-10", "text": "14\n", "page_number": 16, "bounding_box": {"top_left_x": 0.8608590441621294, "top_left_y": 0.9477963200684638, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9572100984167736, "height": 0.00941377834830981, "width": 0.019963702359346636}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-17-0", "text": "We do not have large-scale manufacturing experience.\n", "page_number": 17, "bounding_box": {"top_left_x": 0.13430127041742287, "top_left_y": 0.08301240907145914, "lower_right_x": 0.5214761040532365, "lower_right_y": 0.09970047068891741, "height": 0.01668806161745827, "width": 0.3871748336358136}, "blob_type": "headline", "predictions": {}, "annotations": {"risk_factor": ["We do not have large-scale manufacturing experience."]}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-17-1", "text": "   Although we have manufactured certain product candidates on a small scale for use in clinical trials, we\ncannot assure you that we can successfully manufacture our products under current Good Manufacturing\nPractices (\u201ccGMP\u201d) and applicable laws and regulations in sufficient quantities for clinical trials, or in a timely\nor economical manner. We have not yet produced any biopharmaceutical products on a large scale or in\ncommercial quantities and do not have the facilities and staff required for commercial production of any\nproducts that require large-scale manufacturing. To obtain such resources, we may seek to enter into\ncollaborative arrangements with other parties. There can be no assurance that we will be able to obtain such\ncapabilities through arrangements with others on acceptable terms, if at all.\n", "page_number": 17, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.11253744116388532, "lower_right_x": 0.8699334543254689, "lower_right_y": 0.22250748823277705, "height": 0.10997004706889173, "width": 0.7495462794918331}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-17-2", "text": "  We are vulnerable to natural and other types of disaster, which could cause damage to our facilities and\nequipment and require us to cease or curtail operations.\n", "page_number": 17, "bounding_box": {"top_left_x": 0.1161524500907441, "top_left_y": 0.23491655969191272, "lower_right_x": 0.8620689655172413, "lower_right_y": 0.2644415917843389, "height": 0.029525032092426184, "width": 0.7459165154264973}, "blob_type": "paragraph", "predictions": {}, "annotations": {"risk_factor": ["We are vulnerable to natural and other types of disaster, which could cause damage to our facilities andequipment and require us to cease or curtail operations."]}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-17-3", "text": "   Substantially all of our facilities are located within a single facility in Leiden, the Netherlands. We are\nvulnerable to damage from natural and other types of disasters, including power loss, attacks from extremist\norganizations, fire, floods and similar events. If any disaster were to occur, our ability to operate our business\ncould be seriously impaired. In addition, the nature of our research activities and of much of our equipment\ncould make it difficult for us to recover from this type of disaster. We currently may not have adequate\ninsurance to cover our losses resulting from disasters or other similar significant business interruptions, and we\ndo not plan to purchase additional insurance to cover such losses due to the cost of obtaining such coverage.\nAny significant losses that are not recoverable under our insurance policies could seriously impair our business\nand financial condition.\n", "page_number": 17, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.2768506632434745, "lower_right_x": 0.8711433756805808, "lower_right_y": 0.3996576807873342, "height": 0.1228070175438597, "width": 0.7507562008469449}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-17-4", "text": "Risks Related to Our Dependence on Third Parties\n", "page_number": 17, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.417201540436457, "lower_right_x": 0.4882032667876588, "lower_right_y": 0.4300385109114249, "height": 0.012836970474967901, "width": 0.367816091954023}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-17-5", "text": "   We need to enter into collaborative relationships to further develop our business and if we fail to enter into\nsuch agreements, or if we, or any of our collaborators, terminate or fail to perform any obligations under our\ncollaborative agreements, the development and commercialization of our product candidates could be delayed\nor terminated.\n", "page_number": 17, "bounding_box": {"top_left_x": 0.11857229280096794, "top_left_y": 0.441591784338896, "lower_right_x": 0.882637628554144, "lower_right_y": 0.4980744544287548, "height": 0.0564826700898588, "width": 0.764065335753176}, "blob_type": "paragraph", "predictions": {}, "annotations": {"risk_factor": ["We need to enter into collaborative relationships to further develop our business and if we fail to enter intosuch agreements, or if we, or any of our collaborators, terminate or fail to perform any obligations under ourcollaborative agreements, the development and commercialization of our product candidates could be delayedor terminated."]}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-17-6", "text": "  A material component of our business strategy is to establish and maintain collaborative arrangements with\npharmaceutical and biotechnology companies, research institutions and foundations and private and public\nuniversities and to seek grants from the Dutch government and the European Union, to fund research and\npossible development and commercialization of our product candidates. We also intend to establish\ncollaborative relationships to obtain domestic or international sales, marketing and distribution capabilities if\nany of our product candidates receives regulatory approval.\n", "page_number": 17, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.513050919982884, "lower_right_x": 0.8614640048396854, "lower_right_y": 0.5952075310226786, "height": 0.08215661103979466, "width": 0.7410768300060496}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-17-7", "text": "   The process of establishing collaborative relationships is difficult, time-consuming and involves significant\nuncertainty. Moreover, even if we establish collaborative relationships, it may be difficult to maintain or\nperform under such collaboration arrangements, as funding resources may be limited or our collaborators may\nseek to renegotiate or terminate their relationships with us due to unsatisfactory clinical results, a change in\nbusiness strategy, a change of control or other reasons. If we or any of our collaborators fail to fulfill any\nresponsibilities in a timely manner, or at all, contractual disputes may arise and our research, clinical\ndevelopment or commercialization efforts related to that collaboration could be delayed or terminated.\nAdditionally, it may become necessary for us to assume responsibility for activities that would otherwise have\nbeen the responsibility of our collaborators. Further, if we are unable to establish and maintain collaborative\nrelationships on acceptable terms, we may have to delay or discontinue further development of one or more of\nour product candidates, undertake development and commercialization activities at our own expense or find\nalternative sources of funding.\n", "page_number": 17, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.6089002995293111, "lower_right_x": 0.8663036902601331, "lower_right_y": 0.7732135216089003, "height": 0.1643132220795892, "width": 0.7459165154264973}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-17-8", "text": "   Our ability to predict the success of our collaborations is limited due to the complexity and uncertainty of\nthese arrangements. Our collaborations typically involve a complex allocation of responsibilities, costs and\nbenefits. Collaboration agreements may provide for milestone payments upon the achievement of specified\nclinical and regulatory milestones. They may also provide royalty-based revenue if product candidates are\nsuccessfully commercialized. We will rely on our collaborators to provide resources to develop new product\ncandidates and to potentially achieve these milestones and commercialize any new products. We may not be\nable to achieve any of the milestones provided for in our collaborative agreements or derive any license or\nroyalty revenue with respect to these collaborations.\n", "page_number": 17, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.7869062901155327, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.8968763371844245, "height": 0.1099700470688918, "width": 0.7313974591651543}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-17-9", "text": "15\n", "page_number": 17, "bounding_box": {"top_left_x": 0.8608590441621294, "top_left_y": 0.9477963200684638, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9572100984167736, "height": 0.00941377834830981, "width": 0.019963702359346636}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-18-0", "text": "We depend on third parties for active pharmaceutical ingredients.\n", "page_number": 18, "bounding_box": {"top_left_x": 0.13430127041742287, "top_left_y": 0.08301240907145914, "lower_right_x": 0.5977011494252874, "lower_right_y": 0.09970047068891741, "height": 0.01668806161745827, "width": 0.4633998790078645}, "blob_type": "headline", "predictions": {}, "annotations": {"risk_factor": ["We depend on third parties for active pharmaceutical ingredients."]}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-18-1", "text": "   None of our drug delivery systems can be commercialized as a stand-alone therapeutic product. They must be\ncombined with an active pharmaceutical ingredient. To develop new proprietary product candidates based on\nour drug delivery systems, we must obtain the active pharmaceutical ingredient from another party. This active\npharmaceutical ingredient may not be available to us on acceptable terms, if at all. Our arrangements with\ndevelopers and manufacturers of active pharmaceutical ingredients are critical to our success in developing our\nproduct candidates and bringing our products to the market. For example, we rely on Biolex to provide us with\nBLX-883, their proprietary version of interferon alfa, for use in Locteron. Should Biolex terminate its\narrangements with us, we would have great difficulty in finding another supplier of interferon alfa that would\nenable Locteron to be a commercially viable product.\n", "page_number": 18, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.11253744116388532, "lower_right_x": 0.8784029038112523, "lower_right_y": 0.2362002567394095, "height": 0.12366281557552418, "width": 0.7580157289776165}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-18-2", "text": "   Our current and future suppliers may not be able to supply us with the quantity of active pharmaceutical\ningredients we require, particularly in the quantities required for commercialization of any product.\nManufacturers of active pharmaceutical ingredients typically can terminate their agreements at will, in which\ncase we will be required to identify an alternative manufacturer. Taking into account the limited number of\nmanufacturers for certain active pharmaceutical ingredients, identifying and utilizing additional or replacement\nmanufacturers may not be accomplished quickly, if at all. This could result in significant additional costs or\nlimit our ability to develop and commercialize product candidates.\n", "page_number": 18, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.24946512623020967, "lower_right_x": 0.8705384150030248, "lower_right_y": 0.345742404792469, "height": 0.09627727856225932, "width": 0.7501512401693889}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-18-3", "text": "   We rely on third parties to conduct our pre-clinical and clinical trials. If these third parties do not perform\nas contractually required or expected, we may not be able to obtain regulatory approval for or commercialize\nour product candidates.\n", "page_number": 18, "bounding_box": {"top_left_x": 0.1161524500907441, "top_left_y": 0.3585793752674369, "lower_right_x": 0.8777979431336963, "lower_right_y": 0.4017971758664955, "height": 0.04321780059905861, "width": 0.7616454930429521}, "blob_type": "paragraph", "predictions": {}, "annotations": {"risk_factor": ["We rely on third parties to conduct our pre-clinical and clinical trials. If these third parties do not performas contractually required or expected, we may not be able to obtain regulatory approval for or commercializeour product candidates."]}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-18-4", "text": "   We do not have the ability to independently conduct pre-clinical and clinical trials for our product candidates,\nand we must rely on third parties, such as contract research organizations, medical institutions, clinical\ninvestigators and contract laboratories, to conduct our pre-clinical and clinical trials. We have, in the ordinary\ncourse of business, entered into agreements with these third parties. Nonetheless, we are responsible for\nconfirming that each of our pre-clinical and clinical trials is conducted in accordance with its general\ninvestigational plan and protocol. Moreover, the EMEA, the FDA and other regulatory agencies require us to\ncomply with regulations and standards, commonly referred to as good clinical practices, for conducting,\nrecording and reporting the results of pre-clinical and clinical trials to ensure that data and reported results are\ncredible and accurate and that trial participants are adequately protected. Our reliance on third parties that we do\nnot control does not relieve us of these responsibilities and requirements. If these third parties do not\nsuccessfully carry out their contractual duties or regulatory obligations or meet expected deadlines, if the third\nparties need to be replaced or if the quality or accuracy of the data they obtain is compromised due to the failure\nto adhere to our pre-clinical and clinical protocols or regulatory requirements or for other reasons, our pre-\nclinical or clinical trials may be extended, delayed, suspended or terminated, and we may not be able to obtain\nregulatory approval for, or successfully commercialize, our product candidates.\n", "page_number": 18, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.41377834830979887, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.6195977749251177, "height": 0.20581942661531882, "width": 0.7555958862673926}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-18-5", "text": "   We currently rely on single source suppliers for the provision of essential materials incorporated in certain\nof our product candidates, and we have no arrangements in place for the commercial supply of any of our\nproduct candidates.\n", "page_number": 18, "bounding_box": {"top_left_x": 0.1161524500907441, "top_left_y": 0.6328626444159179, "lower_right_x": 0.8747731397459165, "lower_right_y": 0.6777920410783055, "height": 0.0449293966623876, "width": 0.7586206896551724}, "blob_type": "paragraph", "predictions": {}, "annotations": {"risk_factor": ["We currently rely on single source suppliers for the provision of essential materials incorporated in certainof our product candidates, and we have no arrangements in place for the commercial supply of any of ourproduct candidates."]}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-18-6", "text": "   For many of the essential materials incorporated into our product candidates, we rely on a single supplier.\nAny disruption in the supply of these materials could adversely affect our ability to successfully complete the\nclinical trials and other studies of our product candidates, delay submissions of our regulatory applications or\nadversely affect our ability to commercialize our product candidates in a timely manner, or at all.\n", "page_number": 18, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.6910569105691057, "lower_right_x": 0.8566243194192378, "lower_right_y": 0.7462558836114677, "height": 0.05519897304236199, "width": 0.736237144585602}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-18-7", "text": "   We do not currently have any agreements to manufacture our product candidates on a commercial scale. In\norder to commercialize our product candidates, our existing suppliers will need to scale up their manufacturing\nof essential materials incorporated in our product candidates. We may be required to fund capital improvements\nto support scale-up of manufacturing and related activities. Our existing manufacturers may not be able to\nsuccessfully increase their manufacturing capacity of materials essential for any of our product candidates for\nwhich we obtain marketing approval in a timely or economic manner, or at all. We may need to engage other\nmanufacturers to provide commercial supplies of our product candidates. It may be difficult for us to enter into\ncommercial supply arrangements on a timely basis or on acceptable terms, which could delay or prevent our\nability to commercialize our product candidates. If our existing manufacturers are unable or unwilling to\nincrease their manufacturing capacity or we are unable to establish alternative arrangements, the development\nand commercialization of our product candidates may be delayed or there may be a shortage in supply.\n", "page_number": 18, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.7595207531022679, "lower_right_x": 0.8753781004234725, "lower_right_y": 0.9097133076593924, "height": 0.15019255455712455, "width": 0.7549909255898367}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-18-8", "text": "16\n", "page_number": 18, "bounding_box": {"top_left_x": 0.8608590441621294, "top_left_y": 0.9477963200684638, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9572100984167736, "height": 0.00941377834830981, "width": 0.019963702359346636}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-19-0", "text": "  If we are unable to enter into agreements with third parties to market and sell our product candidates, we\nmay be unable to generate product revenue.\n", "page_number": 19, "bounding_box": {"top_left_x": 0.1161524500907441, "top_left_y": 0.08301240907145914, "lower_right_x": 0.8699334543254689, "lower_right_y": 0.110397946084724, "height": 0.027385537013264863, "width": 0.7537810042347248}, "blob_type": "headline", "predictions": {}, "annotations": {"risk_factor": ["If we are unable to enter into agreements with third parties to market and sell our product candidates, wemay be unable to generate product revenue."]}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-19-1", "text": "  As we have no marketing, sales or distribution capabilities, if our product candidates receive marketing\nauthorization we will have to enter into arrangements with third parties to market, sell and distribute our product\ncandidates. If we are not able to enter into such arrangements, we will have difficulty commercializing our\nproduct candidates, which would adversely affect our business and financial condition.\n", "page_number": 19, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.12623020967051776, "lower_right_x": 0.8802177858439202, "lower_right_y": 0.18142918271287975, "height": 0.05519897304236199, "width": 0.7598306110102844}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-19-2", "text": "Risks Related to Our Intellectual Property\n", "page_number": 19, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.19469405220367994, "lower_right_x": 0.42589231699939506, "lower_right_y": 0.20881471972614463, "height": 0.014120667522464686, "width": 0.30550514216575925}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-19-3", "text": "   Our success is dependent on intellectual property rights held by us, and third parties, and the value of such\nrights is complex and uncertain.\n", "page_number": 19, "bounding_box": {"top_left_x": 0.1161524500907441, "top_left_y": 0.22165169020111253, "lower_right_x": 0.8838475499092558, "lower_right_y": 0.2507488232777065, "height": 0.02909713307659395, "width": 0.7676950998185117}, "blob_type": "paragraph", "predictions": {}, "annotations": {"risk_factor": ["Our success is dependent on intellectual property rights held by us, and third parties, and the value of suchrights is complex and uncertain."]}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-19-4", "text": "   Our success depends, in part, on our ability to obtain, maintain and enforce our intellectual property rights\nrelating to our technologies and product candidates, and to preserve our trade secrets and other proprietary\ninformation. Our success also depends, in part, on the ability of our licensors to obtain, maintain and enforce\ntheir intellectual property rights to the extent that we rely on those rights.\n", "page_number": 19, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.26658108686350024, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.3204963628583654, "height": 0.053915275994865175, "width": 0.7313974591651543}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-19-5", "text": "  Patent positions, in particular those of pharmaceutical and biotechnology companies, including ours, involve\ncomplex legal and factual questions. Validity and enforceability of patents cannot be guaranteed. Patents may be\nchallenged, invalidated, deemed unenforceable, or circumvented. The validity, enforceability and commercial\nvalue of patents are therefore highly uncertain.\n", "page_number": 19, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.33504492939666236, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.3893881044073599, "height": 0.05434317501069752, "width": 0.7604355716878403}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-19-6", "text": "   We intend to apply for patents covering our technologies and product candidates as we deem appropriate. We\nmay fail to apply for patents on important technologies or products in a timely fashion, or at all, and in any\nevent, the patent applications filed by us may not result in issued patents, or their validity may be challenged.\nAny patents obtained by us may not be sufficiently broad to prevent others from using our technologies or from\ndeveloping competing products. Furthermore, others may independently develop similar or alternative\ntechnologies or design around our patented technologies. In addition, if challenged, our patents may be declared\ninvalid. Even if valid, our patents may fail to provide us with any competitive advantages.\n", "page_number": 19, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.40350877192982454, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.4993581514762516, "height": 0.09584937954642708, "width": 0.7555958862673926}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-19-7", "text": "  Any adverse outcome we may experience while attempting to obtain, maintain or enforce our intellectual\nproperty rights may have a material adverse effect on our business and financial condition.\n", "page_number": 19, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.513050919982884, "lower_right_x": 0.8463399879007865, "lower_right_y": 0.5408643560119811, "height": 0.02781343602909714, "width": 0.7259528130671506}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-19-8", "text": "  Litigation or third party claims of intellectual property infringement could require substantial time and\nmoney to resolve. Unfavorable outcomes in these proceedings could limit the value of our intellectual\nproperty rights and our activities.\n", "page_number": 19, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.5528455284552846, "lower_right_x": 0.8554143980641258, "lower_right_y": 0.5964912280701754, "height": 0.04364569961489084, "width": 0.7398669086509376}, "blob_type": "paragraph", "predictions": {}, "annotations": {"risk_factor": ["Litigation or third party claims of intellectual property infringement could require substantial time andmoney to resolve. Unfavorable outcomes in these proceedings could limit the value of our intellectualproperty rights and our activities."]}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-19-9", "text": "   We may need to resort to litigation to enforce or defend our intellectual property rights, including any patents\nissued to us. If a competitor or collaborator files a patent application having a scope covering our technology or\nour product candidates, in order to protect our rights, we may have to participate in expensive and time-\nconsuming opposition proceedings, re-examination proceedings, or nullity proceedings, whichever is applicable,\nbefore the European Patent Office, the US Patent and Trademark Office (\u201cUSPTO\u201d) or patent authorities in\nother jurisdictions. We cannot guarantee that there will be no claims from third parties alleging that our product\ncandidates infringe their intellectual property rights. Third parties may assert that we are employing their\nproprietary technologies without authorization and they may resort to litigation to attempt to enforce their rights.\nThird parties may own or obtain patents relevant to our technology or product candidates and claim that the use\nof our technology or any of our product candidates infringes their patents. We may not be able to develop or\ncommercialize product candidates due to third party patent protection. Our business may be harmed if we cannot\nnegotiate a necessary or desirable license, can obtain such a license only on terms we consider to be unattractive\nor unacceptable, or if we are unable to redesign our product candidates or processes to avoid actual or potential\ninfringement of patents or other intellectual property. Our efforts to obtain, protect and defend our patents and\nother intellectual property rights, whether successfully or not, may be expensive and may require us to incur\nsubstantial costs, including the diversion of management and technical personnel. An unfavorable ruling in\npatent or intellectual property litigation could subject us to significant liabilities to third parties, require us to\ncease developing, manufacturing or selling the affected products or using the affected processes, require us to\nlicense the disputed rights from third parties, or result in awards of substantial damages against us. During the\ncourse of any patent litigation, there may be public announcements of the results of hearings, motions and other\ninterim proceedings or developments in the litigation. If securities analysts or investors regard these\n", "page_number": 19, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.6089002995293111, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.8968763371844245, "height": 0.28797603765511337, "width": 0.7604355716878403}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-19-10", "text": "17\n", "page_number": 19, "bounding_box": {"top_left_x": 0.8608590441621294, "top_left_y": 0.9477963200684638, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9572100984167736, "height": 0.00941377834830981, "width": 0.019963702359346636}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-20-0", "text": "announcements as negative, the market price of our Shares may decline. General proclamations or statements by\nkey public figures may also have a negative impact on the perceived value of our intellectual property.\n", "page_number": 20, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.08515190415062045, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.11296534017971759, "height": 0.02781343602909714, "width": 0.7604355716878403}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-20-1", "text": "  In 2004, we commenced opposition proceedings against a European patent application filed by Schering-\nPlough covering the administration of interferon alfa for the treatment of HCV within a specific dosing range.\nAlthough we believe the dose of Locteron will fall outside the claimed dosing range, we intend to continue our\nopposition proceedings in order to preserve freedom in our further development activities. Schering-Plough\ncurrently holds a corresponding US patent covering subject matter similar to the opposed European patent\napplication. If Locteron is formulated with a dose of interferon alfa that falls within the covered dosing range,\nwe could be precluded from commercializing Locteron in the United States. In such event, we would consider\ncommencing re-examination proceedings before the USPTO or legal proceedings to invalidate the US patent.\n", "page_number": 20, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.12623020967051776, "lower_right_x": 0.8663036902601331, "lower_right_y": 0.2362002567394095, "height": 0.10997004706889174, "width": 0.7459165154264973}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-20-2", "text": "   We cannot assure you that we would prevail in any intellectual property action, including our opposition\nproceedings in respect of the Schering-Plough patent mentioned above, or will be able to obtain a license to any\nthird party intellectual property on commercially reasonable terms, successfully develop non-infringing\nalternatives on a timely basis, or license non-infringing alternatives, if any exist, on commercially reasonable\nterms. Any significant intellectual property impediment to our ability to develop and commercialize our\nproducts could have a material adverse affect on our business and prospects.\n", "page_number": 20, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.24946512623020967, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.33204963628583656, "height": 0.08258451005562689, "width": 0.7555958862673926}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-20-3", "text": "   Confidentiality agreements with employees and others may not adequately prevent disclosure of trade\nsecrets and other proprietary information.\n", "page_number": 20, "bounding_box": {"top_left_x": 0.1161524500907441, "top_left_y": 0.34488660676080446, "lower_right_x": 0.8433151845130067, "lower_right_y": 0.376551133932392, "height": 0.03166452717158752, "width": 0.7271627344222626}, "blob_type": "paragraph", "predictions": {}, "annotations": {"risk_factor": ["Confidentiality agreements with employees and others may not adequately prevent disclosure of tradesecrets and other proprietary information."]}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-20-4", "text": "   We rely substantially upon proprietary materials, information, trade secrets and know-how to conduct our\nresearch and development activities, and to attract and retain collaborators, licensees and customers. We take\nsteps to protect our proprietary rights and information, including the use of confidentiality and other agreements\nwith our employees and consultants and with academic and commercial relationships. However, these steps may\nbe inadequate, agreements may be violated, or there may be no adequate remedy available for a violation of an\nagreement. We cannot assure you that our proprietary information will not be disclosed or that we can\nmeaningfully protect our trade secrets. Our competitors may independently develop substantially equivalent\nproprietary information or may otherwise gain access to our trade secrets, which could adversely affect our\nability to compete in the market.\n", "page_number": 20, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.386392811296534, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.5104835258878905, "height": 0.12409071459135645, "width": 0.7604355716878403}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-20-5", "text": "Risks Related to Our Employees and Growth\n", "page_number": 20, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.5267436884895165, "lower_right_x": 0.4452510586811857, "lower_right_y": 0.5408643560119811, "height": 0.014120667522464658, "width": 0.3248638838475499}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-20-6", "text": "  We rely significantly on the skills and experience of our chief executive officer and other key executives\nand the loss of these individuals could harm our business.\n", "page_number": 20, "bounding_box": {"top_left_x": 0.1161524500907441, "top_left_y": 0.5515618314077878, "lower_right_x": 0.8602540834845736, "lower_right_y": 0.5815147625160462, "height": 0.029952931108258363, "width": 0.7441016333938295}, "blob_type": "paragraph", "predictions": {}, "annotations": {"risk_factor": ["We rely significantly on the skills and experience of our chief executive officer and other key executivesand the loss of these individuals could harm our business."]}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-20-7", "text": "   Our success depends on our ability to attract, retain and motivate highly qualified management and scientific\npersonnel. In particular, we are highly dependent on Joost Holthuis, Ph.D., our Chief Executive Officer, and the\nother principal members of our executive and scientific teams. If we are not able to retain these persons, we may\nnot be able to successfully develop or commercialize our product candidates. We do not maintain \u201ckey person\u201d\ninsurance in relation to any of our employees.\n", "page_number": 20, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.5952075310226786, "lower_right_x": 0.8784029038112523, "lower_right_y": 0.6636713735558408, "height": 0.06846384253316218, "width": 0.7580157289776165}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-20-8", "text": "Our future success depends on our ability to attract, retain and motivate qualified personnel.\n", "page_number": 20, "bounding_box": {"top_left_x": 0.13914095583787053, "top_left_y": 0.6756525459991441, "lower_right_x": 0.7834240774349668, "lower_right_y": 0.6919127086007703, "height": 0.016260162601626105, "width": 0.6442831215970962}, "blob_type": "headline", "predictions": {}, "annotations": {"risk_factor": ["Our future success depends on our ability to attract, retain and motivate qualified personnel."]}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-20-9", "text": "   Recruiting and retaining qualified personnel is critical to our success. We may not be able to attract and retain\nqualified personnel on acceptable terms given the competition among pharmaceutical and biotechnology\ncompanies for similar personnel. We also experience competition for the hiring of scientific personnel from\nuniversities and research institutions. In addition, we rely on consultants and advisors, including scientific and\nclinical advisors, to assist us in formulating our research, clinical development and commercialization strategy.\nOur consultants and advisors may be employed by third parties or may have commitments under consulting or\nadvisory contracts with third parties that may limit their availability to us.\n", "page_number": 20, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.7051775780915703, "lower_right_x": 0.8765880217785844, "lower_right_y": 0.8010269576379975, "height": 0.09584937954642714, "width": 0.7562008469449486}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-20-10", "text": "We may encounter difficulties in managing our growth.\n", "page_number": 20, "bounding_box": {"top_left_x": 0.13430127041742287, "top_left_y": 0.8134360290971331, "lower_right_x": 0.529340592861464, "lower_right_y": 0.8296961916987591, "height": 0.016260162601625994, "width": 0.39503932244404105}, "blob_type": "headline", "predictions": {}, "annotations": {"risk_factor": ["We may encounter difficulties in managing our growth."]}}, {"blob_number_in_page": 11, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-20-11", "text": "  We expect to experience significant growth in the number of our employees and the scope of our operations\nover the next several years. To manage our anticipated future growth, we must continue to implement and\nimprove our managerial, operational and financial systems, and continue to recruit and train additional qualified\npersonnel. Due to our limited resources, we may not be able to effectively manage the expansion of our\noperations or to recruit and train additional qualified personnel. The expansion of our operations may lead to\n", "page_number": 20, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.8416773641420625, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.9122807017543859, "height": 0.0706033376123234, "width": 0.7555958862673926}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-20-12", "text": "18\n", "page_number": 20, "bounding_box": {"top_left_x": 0.8608590441621294, "top_left_y": 0.9477963200684638, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9572100984167736, "height": 0.00941377834830981, "width": 0.019963702359346636}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-21-0", "text": "significant costs and may divert our management and business development resources. Any inability to manage\ngrowth could delay the execution of our business plans, which would adversely affect our results.\n", "page_number": 21, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.08515190415062045, "lower_right_x": 0.8711433756805808, "lower_right_y": 0.11296534017971759, "height": 0.02781343602909714, "width": 0.7507562008469449}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-21-1", "text": "Risks Related to Regulatory Approval and Other Government Regulations\n", "page_number": 21, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.12623020967051776, "lower_right_x": 0.6581972171808832, "lower_right_y": 0.14035087719298245, "height": 0.014120667522464686, "width": 0.5378100423472474}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-21-2", "text": "  The regulatory approval process is costly and lengthy and we may not be able to successfully obtain all\nrequired regulatory approvals.\n", "page_number": 21, "bounding_box": {"top_left_x": 0.12159709618874773, "top_left_y": 0.1527599486521181, "lower_right_x": 0.8463399879007865, "lower_right_y": 0.17843388960205392, "height": 0.02567394094993583, "width": 0.7247428917120388}, "blob_type": "paragraph", "predictions": {}, "annotations": {"risk_factor": ["The regulatory approval process is costly and lengthy and we may not be able to successfully obtain allrequired regulatory approvals."]}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-21-3", "text": "   The pre-clinical development, clinical trials, manufacturing, marketing and labeling of pharmaceuticals and\nmedical devices are all subject to extensive regulation by numerous governmental authorities and agencies in the\nEuropean Union, the United States and other jurisdictions. We or our collaborators must obtain regulatory\napproval for product candidates before marketing or selling any of them. The approval process is typically\nlengthy and expensive, and approval is never certain. It is not possible to predict how long the approval\nprocesses of the EMEA, the FDA or any other applicable regulatory agency will take or whether any such\napprovals ultimately will be granted. The EMEA, the FDA and other regulatory agencies have substantial\ndiscretion in the drug and medical device approval process, and positive results in pre-clinical or early clinical\ntrials provide no assurance of success in later phases of the approval process. Generally, pre-clinical and clinical\ntrials of products and medical devices can take many years and require the expenditure of substantial resources,\nand the data obtained from these trials can be susceptible to varying interpretations that could delay, limit or\nprevent regulatory approval. The risks associated with the approval process include delays or rejections in the\nregulatory approval process based on the failure of clinical or other data to meet expectations, or the failure of\nthe product or medical device to meet a regulatory agency\u2019s requirements for safety and efficacy. In addition,\nregulatory approval, if obtained, may significantly limit the indicated uses for which a product may be marketed.\n", "page_number": 21, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.19469405220367994, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.40051347881899874, "height": 0.2058194266153188, "width": 0.7604355716878403}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-21-4", "text": "   Additional clinical trials may be required if clinical trial results are negative or inconclusive, which will\nrequire us to incur additional costs and significant delays. If we do not receive the necessary regulatory\napprovals, we will not be able to generate product revenues and may not become profitable. We may encounter\nsignificant delays in the regulatory process that could result in excessive costs that may prevent us from\ncontinuing to develop our product candidates. In addition, the failure to comply with applicable regulatory\nrequirements may result in criminal prosecution, civil penalties, product recalls, withdrawal of product approval,\nmandatory restrictions and other actions that could impair our ability to conduct our business.\n", "page_number": 21, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.41377834830979887, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.5117672229353872, "height": 0.09798887462558836, "width": 0.7604355716878403}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-21-5", "text": "  Our product candidates will remain subject to ongoing regulatory review even if they receive marketing\napproval. If we fail to comply with continuing regulations, we could lose these approvals and the sale of our\nproducts could be suspended.\n", "page_number": 21, "bounding_box": {"top_left_x": 0.1161524500907441, "top_left_y": 0.5237483953786907, "lower_right_x": 0.868118572292801, "lower_right_y": 0.5673940949935815, "height": 0.04364569961489084, "width": 0.7519661222020568}, "blob_type": "paragraph", "predictions": {}, "annotations": {"risk_factor": ["Our product candidates will remain subject to ongoing regulatory review even if they receive marketingapproval. If we fail to comply with continuing regulations, we could lose these approvals and the sale of ourproducts could be suspended."]}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-21-6", "text": "   Even if we receive regulatory approval to market a particular product candidate, the approval could be\nconditioned on us conducting additional costly post-approval studies or could limit the indicated uses included\nin the labeling of our products. Moreover, the product may later cause adverse effects that limit or prevent its\nwidespread use, force us to withdraw it from the market or impede or delay our ability to obtain regulatory\napprovals in additional countries. In addition, the manufacturer of the product and its facilities will continue to\nbe subject to regulatory review and periodic inspections to ensure adherence to applicable regulations. After\nreceiving marketing approval, the manufacturing, labeling, packaging, adverse event reporting, storage,\nadvertising, promotion and record keeping related to the product will remain subject to extensive regulatory\nrequirements.\n", "page_number": 21, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.5815147625160462, "lower_right_x": 0.8663036902601331, "lower_right_y": 0.7051775780915703, "height": 0.12366281557552417, "width": 0.7459165154264973}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-21-7", "text": "   If we fail to comply with applicable regulatory requirements, or previously unknown problems with our\nproducts, manufacturers or manufacturing processes are discovered, we could be subject to administrative or\njudicially imposed sanctions, including:\n", "page_number": 21, "bounding_box": {"top_left_x": 0.11857229280096794, "top_left_y": 0.7184424475823705, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.7595207531022679, "height": 0.04107830551989733, "width": 0.7332123411978222}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-21-8", "text": "\u00b7   restrictions on our products, manufacturers or manufacturing processes;\n\n\u00b7   warning letters;\n\n\u00b7   civil or criminal penalties or fines;\n\n\u00b7   injunctions;\n\n\u00b7   product seizures, detentions or import bans;\n", "page_number": 21, "bounding_box": {"top_left_x": 0.1355111917725348, "top_left_y": 0.7732135216089003, "lower_right_x": 0.6533575317604355, "lower_right_y": 0.8998716302952503, "height": 0.12665810868634997, "width": 0.5178463399879008}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-21-9", "text": "19\n", "page_number": 21, "bounding_box": {"top_left_x": 0.8608590441621294, "top_left_y": 0.9477963200684638, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9572100984167736, "height": 0.00941377834830981, "width": 0.019963702359346636}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-22-0", "text": "voluntary or mandatory product recalls and publicity requirements;\n\nsuspension or withdrawal of regulatory approvals;\n\ntotal or partial suspension of production; and\n\nrefusal to approve pending applications for marketing approval of new drugs or supplements to approved\napplications.\n", "page_number": 22, "bounding_box": {"top_left_x": 0.16878402903811252, "top_left_y": 0.08515190415062045, "lower_right_x": 0.8777979431336963, "lower_right_y": 0.196405648267009, "height": 0.11125374411638854, "width": 0.7090139140955838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-22-1", "text": "\u00b7\n", "page_number": 22, "bounding_box": {"top_left_x": 0.1367211131276467, "top_left_y": 0.08900299529311083, "lower_right_x": 0.14519056261343014, "lower_right_y": 0.09542148053059478, "height": 0.006418485237483951, "width": 0.008469449485783431}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-22-2", "text": "\u00b7\n", "page_number": 22, "bounding_box": {"top_left_x": 0.1355111917725348, "top_left_y": 0.11681643132220795, "lower_right_x": 0.14519056261343014, "lower_right_y": 0.12323491655969192, "height": 0.006418485237483965, "width": 0.009679370840895346}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-22-3", "text": "", "page_number": 22, "bounding_box": {"top_left_x": 0.1367211131276467, "top_left_y": 0.14719726144629866, "lower_right_x": 0.14277071990320628, "lower_right_y": 0.15019255455712452, "height": 0.0029952931108258585, "width": 0.006049606775559574}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-22-4", "text": "\u00b7\n", "page_number": 22, "bounding_box": {"top_left_x": 0.1355111917725348, "top_left_y": 0.17415489944373128, "lower_right_x": 0.14519056261343014, "lower_right_y": 0.1797175866495507, "height": 0.005562687205819428, "width": 0.009679370840895346}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-22-5", "text": "Any such sanction could severely harm our business and financial condition.\n", "page_number": 22, "bounding_box": {"top_left_x": 0.13793103448275862, "top_left_y": 0.21181001283697048, "lower_right_x": 0.6527525710828797, "lower_right_y": 0.2246469833119384, "height": 0.012836970474967901, "width": 0.514821536600121}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-22-6", "text": "   Our Contract Development Business involves drug development and manufacture on behalf of third parties.\nBoth of these activities, comprising decision making processes, manufacturing processes, procurement,\nmanufacture, storage, shipping and recordkeeping, must comply with the FDA\u2019s cGMP regulations, among\nother requirements. FDA oversight, including facility inspections, is ongoing, and a failure to comply with\napplicable requirements can result in adverse publicity, warning letters, civil and criminal liability, and\nrestrictions on and/or prohibitions against the performance of these activities, any of which may result in a loss\nof business.\n", "page_number": 22, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.23919554985023533, "lower_right_x": 0.8663036902601331, "lower_right_y": 0.33204963628583656, "height": 0.09285408643560122, "width": 0.7459165154264973}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-22-7", "text": "  Our ability to generate revenue from any products that we may develop will depend on reimbursement and\ndrug pricing policies and regulations.\n", "page_number": 22, "bounding_box": {"top_left_x": 0.1161524500907441, "top_left_y": 0.3465982028241335, "lower_right_x": 0.8771929824561403, "lower_right_y": 0.3722721437740693, "height": 0.025673940949935803, "width": 0.7610405323653961}, "blob_type": "headline", "predictions": {}, "annotations": {"risk_factor": ["Our ability to generate revenue from any products that we may develop will depend on reimbursement anddrug pricing policies and regulations."]}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-22-8", "text": "   Many patients will rely on governmental authorities, private health insurers and other third-party payors to\npay for their medical needs. Our ability to achieve acceptable levels of reimbursement for drug treatments by\ngovernmental authorities, private health insurers and other organizations will have an effect on our ability to\nsuccessfully commercialize, and attract collaborative partners to invest in the development of, our product\ncandidates. We cannot be sure that reimbursement in the European Union, the United States or other\njurisdictions will be available for any products that we may develop, and any reimbursement that may become\navailable may be decreased or eliminated in the future. Third-party payors increasingly are challenging prices\ncharged for pharmaceutical products, and many third-party payors may refuse to provide reimbursement for\nparticular drugs when an equivalent generic or alternative non-generic drug is available. Even if we show\nimproved efficacy or improved convenience of administration with our product candidate, pricing of the existing\ndrug may limit the amount we will be able to charge for our product candidate. If reimbursement is not available\nor is available only at limited levels, we may not be able to successfully commercialize our product candidates,\nand may not be able to obtain a satisfactory financial return on products that we may develop.\n", "page_number": 22, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.3898160034231921, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.5682498930252461, "height": 0.17843388960205397, "width": 0.7652752571082879}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-22-9", "text": "   In addition, in some countries, particularly those in the European Union, prescription drug pricing is subject\nto governmental control. In these countries, pricing negotiations with governmental authorities can take\nconsiderable time after the receipt of marketing approval for a drug candidate. To obtain reimbursement or\npricing approval in some countries, we may be required to conduct a clinical trial that compares the cost-\neffectiveness of our product candidates to other available therapies. If reimbursement of our future products is\nunavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, we may be unable to\nachieve or sustain profitability.\n", "page_number": 22, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.5815147625160462, "lower_right_x": 0.8656987295825771, "lower_right_y": 0.6777920410783055, "height": 0.09627727856225932, "width": 0.7453115547489413}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-22-10", "text": "  In recent years, the pricing of prescription drugs has been a subject of focus in many of the major\npharmaceutical markets. Any future regulatory changes regarding the healthcare industry or third-party coverage\nand reimbursement may affect demand for any products that we may develop and could harm our sales and\nprofitability.\n", "page_number": 22, "bounding_box": {"top_left_x": 0.12099213551119177, "top_left_y": 0.6910569105691057, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.7462558836114677, "height": 0.05519897304236199, "width": 0.7598306110102843}, "blob_type": "paragraph", "predictions": {}, "annotations": {"industry": ["healthcare industry"]}}, {"blob_number_in_page": 11, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-22-11", "text": "Risks Related to Our Financial Condition\n", "page_number": 22, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.762943945228926, "lower_right_x": 0.42105263157894735, "lower_right_y": 0.7736414206247325, "height": 0.010697475395806566, "width": 0.30066545674531153}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-22-12", "text": "   We have incurred losses since 2002 and anticipate that we will continue to incur losses for the foreseea\nfuture. We may not achieve or sustain profitability again.\n", "page_number": 22, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.7869062901155327, "lower_right_x": 0.8499697519661222, "lower_right_y": 0.8181429182712879, "height": 0.03123662815575523, "width": 0.7344222625529341}, "blob_type": "paragraph", "predictions": {}, "annotations": {"risk_factor": ["We have incurred losses since 2002 and anticipate that we will continue to incur losses for the foreseeablefuture. We may not achieve or sustain profitability again."]}}, {"blob_number_in_page": 13, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-22-13", "text": "   We are not profitable and have incurred losses in each year since 2002. We do not currently have any\nproducts that have been approved for marketing, and we continue to incur research and development and general\nand administrative expenses related to our operations. Our net loss for the six months ended 30 June 2007 and\nthe years ended 31 December 2006, 2005 and 2004 was \u20ac6.1 million, \u20ac8.7 million, \u20ac4.6 million and\n\u20ac2.2 million, respectively. As of 30 June 2007, we had an accumulated deficit of \u20ac25.1 million. We expect to\ncontinue to incur losses for the foreseeable future, and we expect these losses to increase as we continue our\n", "page_number": 22, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.8314077877620881, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9127086007702182, "height": 0.08130081300813008, "width": 0.7604355716878403}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-22-14", "text": "20\n", "page_number": 22, "bounding_box": {"top_left_x": 0.8608590441621294, "top_left_y": 0.9477963200684638, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9572100984167736, "height": 0.00941377834830981, "width": 0.019963702359346636}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-23-0", "text": "research activities and conduct development of, and seek regulatory approvals for, our product candidates, and\ncommercialize any approved drugs. Our losses, among other things, have caused and will continue to cause our\nshareholders\u2019 equity and working capital to decrease. To date, we have derived a substantial portion of our\nrevenues from our Contract Development Business. We have also received government subsidies and have\ngenerated nominal licensing revenues through the out-licensing of certain technologies. We do not anticipate\nthat we will generate revenues from the sale of products for the foreseeable future. If our product candidates fail\nin clinical trials or do not gain regulatory approval, or if our product candidates do not achieve market\nacceptance, we may never again achieve profitability. Even if we achieve profitability in the future, we may not\nbe able to sustain profitability in subsequent periods.\n", "page_number": 23, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.08515190415062045, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.20838682071031236, "height": 0.12323491655969192, "width": 0.7555958862673926}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-23-1", "text": "   We will need substantial additional funding in the future, which may not be available to us on acceptable\nterms, or at all, and which could force us to delay, reduce or eliminate our product development programs or\ncommercialization efforts or cause us to discontinue our operations.\n", "page_number": 23, "bounding_box": {"top_left_x": 0.1161524500907441, "top_left_y": 0.22036799315361574, "lower_right_x": 0.8765880217785844, "lower_right_y": 0.2605905006418485, "height": 0.04022250748823278, "width": 0.7604355716878404}, "blob_type": "paragraph", "predictions": {}, "annotations": {"risk_factor": ["We will need substantial additional funding in the future, which may not be available to us on acceptableterms, or at all, and which could force us to delay, reduce or eliminate our product development programs orcommercialization efforts or cause us to discontinue our operations."]}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-23-2", "text": "   We will need to raise substantial additional capital to pursue our business strategy and continue the\ndevelopment of our product candidates. Our future funding requirements will depend on many factors,\nincluding:\n", "page_number": 23, "bounding_box": {"top_left_x": 0.12099213551119177, "top_left_y": 0.2768506632434745, "lower_right_x": 0.8130671506352087, "lower_right_y": 0.31835686777920413, "height": 0.04150620453572962, "width": 0.6920750151240169}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-23-3", "text": "\u00b7   scope, rate of progress, results and cost of our pre-clinical and clinical trials and other research and\n    development activities;\n\n\u00b7   terms and timing of any collaborative, licensing and other arrangements that we may establish;\n\n\u00b7   cost, timing and outcomes of regulatory approvals;\n\n\u00b7   number and characteristics of product candidates that we pursue;\n\n\u00b7   cost and timing of establishing sales, marketing and distribution capabilities;\n\n\u00b7   cost of clinical and commercial supplies of our product candidates and any products that we may\n    develop;\n\n\u00b7   timing, receipt and amount of sales or royalties, if any, from our potential products, or any up-front or\n    milestone payments during their development phase;\n\n\u00b7   the cost of preparing, filing, prosecuting, defending and enforcing any patent claims and other\n    intellectual property rights;\n\n\u00b7   the extent to which we acquire or invest in businesses, products or technologies, although we currently\n    have no commitments or agreements relating to any of these types of transactions; and\n\n\u00b7   our ability to continue to generate revenues from our Contract Development Business.\n", "page_number": 23, "bounding_box": {"top_left_x": 0.13490623109497882, "top_left_y": 0.3324775353016688, "lower_right_x": 0.8614640048396854, "lower_right_y": 0.6675224646983312, "height": 0.3350449293966624, "width": 0.7265577737447066}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-23-4", "text": "  Additional funds may not be available when we need them on terms that are acceptable to us, or at all. If\nadequate funds are not available on a timely basis, we may:\n", "page_number": 23, "bounding_box": {"top_left_x": 0.12099213551119177, "top_left_y": 0.6807873341891314, "lower_right_x": 0.8463399879007865, "lower_right_y": 0.7086007702182285, "height": 0.02781343602909714, "width": 0.7253478523895946}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-23-5", "text": "\u00b7   terminate or delay pre-clinical and clinical trials for one or more of our product candidates;\n\n\u00b7   delay our establishment of sales and marketing capabilities or other activities that may be necessary to\n    commercialize our product candidates; or\n\n\u00b7   curtail development programs.\n", "page_number": 23, "bounding_box": {"top_left_x": 0.1355111917725348, "top_left_y": 0.7218656397090286, "lower_right_x": 0.8614640048396854, "lower_right_y": 0.8044501497646556, "height": 0.08258451005562695, "width": 0.7259528130671506}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-23-6", "text": "   If required, additional funds are not available on a timely basis, we may be required to delay, scale back or\neliminate certain of our activities and commercialization efforts, which would have a material adverse affect on\nour financial condition and ability to develop our product candidates or cause us to discontinue our operations.\n", "page_number": 23, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.8211382113821138, "lower_right_x": 0.8711433756805808, "lower_right_y": 0.8626444159178434, "height": 0.04150620453572951, "width": 0.7507562008469449}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-23-7", "text": "  Raising additional capital by issuing securities or through collaboration and licensing arrangements may\ncause dilution to existing shareholders, restrict our operations or require us to relinquish proprietary rights\n", "page_number": 23, "bounding_box": {"top_left_x": 0.11978221415607986, "top_left_y": 0.87334189131365, "lower_right_x": 0.8590441621294616, "lower_right_y": 0.9024390243902439, "height": 0.029097133076593895, "width": 0.7392619479733817}, "blob_type": "paragraph", "predictions": {}, "annotations": {"risk_factor": ["Raising additional capital by issuing securities or through collaboration and licensing arrangements maycause dilution to existing shareholders, restrict our operations or require us to relinquish proprietary rights."]}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-23-8", "text": "21\n", "page_number": 23, "bounding_box": {"top_left_x": 0.8608590441621294, "top_left_y": 0.9477963200684638, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9572100984167736, "height": 0.00941377834830981, "width": 0.019963702359346636}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-24-0", "text": "   We may seek the additional capital necessary to fund our operations through public or private equity offers,\ndebt financings and collaboration and licensing arrangements. To the extent that we raise additional capital\nthrough the issuance of Shares or convertible debt, your ownership interest will be diluted, and the terms of such\nsecurities may include liquidation or other preferences that adversely affect your rights as a shareholder. Debt\nfinancing, if available, may involve agreements that include covenants limiting or restricting our ability to take\nspecific actions such as incurring additional debt, making capital expenditures or declaring dividends. If we\nraise additional funds through collaboration and licensing arrangements with third parties, we may have to\nrelinquish valuable rights to our technologies or product candidates, or grant licenses on terms that are not\nfavorable to us.\n", "page_number": 24, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.08515190415062045, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.20539152759948653, "height": 0.12023962344886609, "width": 0.7604355716878403}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-24-1", "text": "   We face the potential loss of significant revenue from the loss, modification or delay of large contracts or\nthe inability to secure new contracts.\n", "page_number": 24, "bounding_box": {"top_left_x": 0.11857229280096794, "top_left_y": 0.22036799315361574, "lower_right_x": 0.8584392014519057, "lower_right_y": 0.24732563115104836, "height": 0.026957637997432615, "width": 0.7398669086509377}, "blob_type": "headline", "predictions": {}, "annotations": {"risk_factor": ["We face the potential loss of significant revenue from the loss, modification or delay of large contracts orthe inability to secure new contracts."]}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-24-2", "text": "   To date, our principal sources of revenue have been our Contract Development Business and, to a lesser\nextent, government subsidies and license revenues. Our customer base presently comprises approximately 35\nclients who award us with work on a contract-by-contract basis. In 2006, our five largest clients accounted for\n56% of our Contract Development Business revenues. Our clients may resolve, on relatively short notice, to\nsuspend or terminate the development activities that we conduct on their behalf. We have in the past\nexperienced such project suspensions or terminations with significant clients. We expect that a small number of\nclients will continue to represent a significant part of our contract development revenues. In addition, our clients\nand target customers, as they try to reduce costs as a result of budgetary limits or changing priorities, may\nproceed without or with decreased assistance of biopharmaceutical services companies like us. The loss,\nmodification or delay of a large contract or of multiple contracts, or the inability to secure new contracts, could\nhave a material adverse effect on our operating results.\n", "page_number": 24, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.2631578947368421, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.41420624732563116, "height": 0.15104835258878907, "width": 0.7555958862673926}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-24-3", "text": "Risks Related to this Offer\n", "page_number": 24, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.4278990158322636, "lower_right_x": 0.3145795523290986, "lower_right_y": 0.4407359863072315, "height": 0.012836970474967901, "width": 0.1941923774954628}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-24-4", "text": "  The price of our Shares may be volatile and you may not be able to sell our Shares at or above the price\nyou pay for them.\n", "page_number": 24, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.4544287548138639, "lower_right_x": 0.8590441621294616, "lower_right_y": 0.48609328198545143, "height": 0.03166452717158752, "width": 0.7434966727162734}, "blob_type": "paragraph", "predictions": {}, "annotations": {"risk_factor": ["The price of our Shares may be volatile and you may not be able to sell our Shares at or above the priceyou pay for them."]}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-24-5", "text": "   We cannot predict the extent to which an active market for our Shares will develop or be sustained after this\nOffer, or how the development of such a market might affect the market price for our Shares. An illiquid market\nfor our Shares may result in lower trading prices and increased volatility, which could adversely affect the value\nof your investment. The average weekly trading volume of our Shares since our initial public offering (\u201cIPO\u201d)\nin October 2006 has been 106,277 Shares. We cannot assure you that this level of liquidity will be maintained.\n", "page_number": 24, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.4993581514762516, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.5682498930252461, "height": 0.06889174154899447, "width": 0.7555958862673926}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-24-6", "text": "  The Offer Price will be agreed between us and the Underwriters based on a number of factors, including\nmarket conditions in effect at the time of the Offer, which may not be indicative of future performance. The\nmarket price for our Shares may fall below the Offer Price. The market price of our Shares could fluctuate\nsubstantially due to a number of factors, including, but not limited to:\n", "page_number": 24, "bounding_box": {"top_left_x": 0.12099213551119177, "top_left_y": 0.5815147625160462, "lower_right_x": 0.8469449485783425, "lower_right_y": 0.6358579375267437, "height": 0.05434317501069752, "width": 0.7259528130671506}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-24-7", "text": "\u00b7   adverse results or delays in our clinical trials;\n\n\u00b7   the timing of achievement of our clinical, regulatory, partnering and other milestones, such as the\n    commencement of clinical development, the completion of a clinical trial, the receipt of regulatory\n    approval or the establishment of a partnership for one or more of our product candidates;\n\n\u00b7   announcement of EMEA, FDA or other regulatory authorities\u2019 approval or non-approval of our product\n    candidates or delays in their review processes;\n\n\u00b7   actions taken by regulatory authorities with respect to our product candidates, our clinical trials, our\n    facilities and operations, or our sales and marketing activities;\n\n\u00b7   the commercial success of any approved product;\n\n\u00b7   regulatory developments in the European Union, the United States and other jurisdictions;\n\n\u00b7   disruption of the manufacturing of essential materials that are incorporated in our product candidates;\n\n\u00b7   changes in the structure of healthcare payment systems;\n", "page_number": 24, "bounding_box": {"top_left_x": 0.13490623109497882, "top_left_y": 0.6499786050492083, "lower_right_x": 0.868723532970357, "lower_right_y": 0.9139922978177151, "height": 0.2640136927685067, "width": 0.7338173018753782}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-24-8", "text": "22\n", "page_number": 24, "bounding_box": {"top_left_x": 0.8608590441621294, "top_left_y": 0.9477963200684638, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9572100984167736, "height": 0.00941377834830981, "width": 0.019963702359346636}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-25-0", "text": "  \u00b7    any actual or threatened intellectual property infringement lawsuit or cancellation proceeding involving\n       us;\n\n  \u00b7    announcements of technological innovations or new products by us or our competitors;\n\n  \u00b7    a decline in our Contract Development Business;\n\n  \u00b7    market conditions for, or developments affecting, the biotechnology or pharmaceutical industries in\n       general or certain companies within these industries;\n\n  \u00b7    changes in financial estimates or recommendations by securities analysts;\n\n  \u00b7    sales of large blocks of our Shares;\n\n  \u00b7    sales of our Shares by our executive officers, directors and significant shareholders;\n\n  \u00b7    restatements of our financial results and/or material weaknesses in our internal controls;\n\n  \u00b7    the loss of any of our key personnel;\n\n  \u00b7    publication of research reports about us or the biopharmaceutical industry by securities or industry\n       analysts;\n\n  \u00b7    failure to meet or exceed securities analysts\u2019 expectations relating to our financial results;\n\n  \u00b7    speculation in the press or investment community generally;\n\n  \u00b7    general economic conditions, particularly as they impact consumer spending patterns; and\n\n  \u00b7    war, acts of terrorism and other man-made or natural disasters.\n\n  The stock markets in general, and the markets for biopharmaceutical stocks in particular, have experienced\nextreme volatility that has often been unrelated to the operating performance of particular companies. These\nbroad market fluctuations may adversely affect the trading price of our Shares.\n", "page_number": 25, "bounding_box": {"top_left_x": 0.12099213551119177, "top_left_y": 0.08515190415062045, "lower_right_x": 0.8705384150030248, "lower_right_y": 0.5579803166452717, "height": 0.47282841249465124, "width": 0.749546279491833}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-25-1", "text": "  If closing of the Offer does not take place on the Settlement Date or at all, subscriptions for our Offer\nShares will be disregarded.\n", "page_number": 25, "bounding_box": {"top_left_x": 0.1161524500907441, "top_left_y": 0.5703893881044073, "lower_right_x": 0.8439201451905626, "lower_right_y": 0.6003423192126658, "height": 0.029952931108258474, "width": 0.7277676950998184}, "blob_type": "headline", "predictions": {}, "annotations": {"risk_factor": ["If closing of the Offer does not take place on the Settlement Date or at all, subscriptions for our OfferShares will be disregarded."]}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-25-2", "text": "   The Settlement Date, on which the closing of the Offer is scheduled to take place, is expected to occur on or\nabout 3 December 2007. The closing of the Offer may not take place on the Settlement Date or at all if certain\nconditions or events referred to in the underwriting agreement (see \u201cUnderwriting\u201d) are not satisfied or waived\nor occur on or prior to such date. Such conditions include the receipt of officers\u2019 certificates and legal opinions\nand such events include the suspension of trading on Euronext Amsterdam or a material adverse change in our\nfinancial condition or business affairs or in the financial markets. If closing of the Offer does not take place on\nthe Settlement Date or at all, the Offer will be withdrawn, all subscriptions for our Offer Shares will be\ndisregarded, any allotments made will be deemed not to have been made and any subscription payments made\nwill be returned without interest or other compensation.\n", "page_number": 25, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.613607188703466, "lower_right_x": 0.8663036902601331, "lower_right_y": 0.7359863072314934, "height": 0.12237911852802741, "width": 0.7459165154264973}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-25-3", "text": "   The ownership of our Shares will continue to be highly concentrated and your interests may conflict with\nthe interests of our existing shareholders.\n", "page_number": 25, "bounding_box": {"top_left_x": 0.11675741076830005, "top_left_y": 0.7492511767222936, "lower_right_x": 0.8632788868723533, "lower_right_y": 0.7804878048780488, "height": 0.03123662815575523, "width": 0.7465214761040533}, "blob_type": "paragraph", "predictions": {}, "annotations": {"risk_factor": ["The ownership of our Shares will continue to be highly concentrated and your interests may conflict withthe interests of our existing shareholders."]}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-25-4", "text": "   Joost Holthuis, our co-founder and CEO, together with Prof. Daan Crommelin, our co-founder, Hans Pauli,\nour CFO, and our Senior Management, will beneficially own approximately 16.4% of our Shares upon\ncompletion of the Offer (excluding any Shares that may be purchased by them in the Offer and assuming we\nraise \u20ac25 million in the Offer, no exercise of the Overallotment Option and an Offer Price of \u20ac3.95. The other\nMajor Shareholders will also continue to own a significant number of our Shares following the Offer.\nAccordingly, these shareholders, when acting as a group, will continue to have significant influence over the\noutcome of corporate actions requiring shareholder approval, including the election of members of our\nSupervisory Board and Executive Board, any merger, consolidation or sale of all or substantially all of our\n", "page_number": 25, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.793752674368849, "lower_right_x": 0.8614640048396854, "lower_right_y": 0.9032948224219084, "height": 0.1095421480530594, "width": 0.7410768300060496}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-25-5", "text": "23\n", "page_number": 25, "bounding_box": {"top_left_x": 0.8608590441621294, "top_left_y": 0.9477963200684638, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9572100984167736, "height": 0.00941377834830981, "width": 0.019963702359346636}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-26-0", "text": "assets or any other significant corporate transaction. These shareholders could delay or prevent a change of\ncontrol of our company, even if such a change of control would benefit our other shareholders. The significant\nconcentration of share ownership may adversely affect the trading price of our Shares due to investors\u2019\nperception that conflicts of interest may exist or arise.\n", "page_number": 26, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.08515190415062045, "lower_right_x": 0.8656987295825771, "lower_right_y": 0.14035087719298245, "height": 0.055198973042362, "width": 0.7453115547489413}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-26-1", "text": "  Our Executive Board has broad discretion over the use of the net proceeds received by us from the Offer\nand may not apply the net proceeds effectively or in ways with which you agree.\n", "page_number": 26, "bounding_box": {"top_left_x": 0.1161524500907441, "top_left_y": 0.15233204963628583, "lower_right_x": 0.8638838475499092, "lower_right_y": 0.1822849807445443, "height": 0.029952931108258474, "width": 0.7477313974591651}, "blob_type": "paragraph", "predictions": {}, "annotations": {"risk_factor": ["Our Executive Board has broad discretion over the use of the net proceeds received by us from the Offerand may not apply the net proceeds effectively or in ways with which you agree."]}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-26-2", "text": "  Our Executive Board has broad discretion over the use of net proceeds from the sale of Offer Shares in the\nOffer. We intend to use the net proceeds from the Offer primarily for the further development of our product\ncandidates. In addition, we may use a portion of the net proceeds to in-license or acquire additional product\ncandidates or technologies.\n", "page_number": 26, "bounding_box": {"top_left_x": 0.12159709618874773, "top_left_y": 0.19469405220367994, "lower_right_x": 0.8566243194192378, "lower_right_y": 0.24989302524604193, "height": 0.05519897304236199, "width": 0.7350272232304901}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-26-3", "text": "   You will not have an opportunity, as part of your investment decision, to assess whether the net proceeds\nreceived by us are being used appropriately. We cannot assure you that our Executive Board will apply the net\nproceeds effectively or that the net proceeds will be invested to yield a favorable return.\n", "page_number": 26, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.2631578947368421, "lower_right_x": 0.8663036902601331, "lower_right_y": 0.30466409927257165, "height": 0.04150620453572956, "width": 0.7459165154264973}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-26-4", "text": "   Future sales, or the possibility of future sales, of a substantial amount of our Shares may depress the price\nof our Shares.\n", "page_number": 26, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.31792896876337184, "lower_right_x": 0.8717483363581368, "lower_right_y": 0.34745400085579803, "height": 0.029525032092426184, "width": 0.7513611615245009}, "blob_type": "paragraph", "predictions": {}, "annotations": {"risk_factor": ["Future sales, or the possibility of future sales, of a substantial amount of our Shares may depress the priceof our Shares."]}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-26-5", "text": "   Future sales of our Shares, or the perception that such sales will occur, could cause a decline in the market\nprice of our Shares. Upon completion of the Offer, 10,742,474 of our total Shares will be outstanding in addition\nto the 11,793,716 Shares currently owned by the Major Shareholders, assuming we raise \u20ac25 million in the\nOffer, no exercise of the Overallotment Option and an Offer Price of \u20ac3.95. In connection with the Offer, we\nand the members of our Executive Board and our Senior Management have agreed not to dispose in any way of\nany Shares or securities exchangeable or convertible into, or exercisable for, or repayable with our Shares for a\nperiod of at least 180 days from the date of the underwriting agreement, except with the prior written consent of\nCowen and certain other exceptions. We have also entered into a \u201crestricted sales\u201d agreement with our Major\nShareholders (excluding our CEO and Sodoro B.V., the personal holding company of our CEO), FormFarm\nHolding B.V., NPM Capital B.V. and 7X Life Sciences B.V., pursuant to which these shareholders have agreed,\nsubject to certain exceptions, not to dispose in any way of any Shares currently held by them during a period of\n60 days following the Listing Date, unless Cowen has given its prior written consent thereto, and to restrict such\ntransactions during a subsequent period of 120 days.\n", "page_number": 26, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.36243046640992727, "lower_right_x": 0.8802177858439202, "lower_right_y": 0.5408643560119811, "height": 0.17843388960205386, "width": 0.7598306110102844}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-26-6", "text": "   We cannot predict whether substantial numbers of our Shares will be sold in the open market following the\nexpiry of the applicable lock-up period. In particular, there can be no assurance that, after this period expires,\nthe current shareholders will not reduce their holdings of our Shares. Future sales of our Shares could be made\nby us, the Major Shareholders, other shareholders or through a capital increase undertaken by us for additional\nworking capital, to fund an acquisition or for another purpose. A sale of a substantial number of our Shares, or\nthe perception that such sale could occur, could materially and adversely affect the market price of our Shares\nand could also impede our ability to raise capital through the issue of equity securities in the future.\n", "page_number": 26, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.5541292255027813, "lower_right_x": 0.8663036902601331, "lower_right_y": 0.6499786050492083, "height": 0.09584937954642703, "width": 0.7459165154264973}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-26-7", "text": "We could become a passive foreign investment company for US federal income tax purposes.\n", "page_number": 26, "bounding_box": {"top_left_x": 0.13430127041742287, "top_left_y": 0.6619597774925118, "lower_right_x": 0.7810042347247429, "lower_right_y": 0.6782199400941378, "height": 0.016260162601625994, "width": 0.64670296430732}, "blob_type": "headline", "predictions": {}, "annotations": {"risk_factor": ["We could become a passive foreign investment company for US federal income tax purposes."]}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-26-8", "text": "   Although we believe that we are not a passive foreign investment company (\u201cPFIC\u201d) for US federal income\ntax purposes, this determination is based upon the best judgment of management as to the fair market value of\nour assets, including our intangibles. We have not sought or obtained an independent appraisal of our assets and\nbusiness. No assurance can be offered that our conclusions as to the values of our assets will not be challenged\nby the US Internal Revenue Service or that a court might not ultimately sustain such a challenge. Although we\ndo not believe that we are now, nor do we expect to become, a PFIC, this conclusion is a factual determination\nthat generally cannot be determined until the close of the taxable year in question and is made annually (based in\npart upon the value of our assets and ordinary shares) and thus may be subject to change. If we were to be a\nPFIC in any year, materially adverse consequences as described below under \u201dTaxation \u2013 Taxation in the United\nStates \u2013 Passive Foreign Investment Company Considerations\u201d could result for holders of our Shares that are\nsubject to taxation in the United States. Such investors are urged to consult their own tax advisers regarding the\npossibility of our being classified as a PFIC and the potential tax consequences arising from the ownership and\ndisposition of an interest in a PFIC.\n", "page_number": 26, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.6910569105691057, "lower_right_x": 0.8802177858439202, "lower_right_y": 0.8686350021394951, "height": 0.1775780915703894, "width": 0.7598306110102844}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-26-9", "text": "24\n", "page_number": 26, "bounding_box": {"top_left_x": 0.8608590441621294, "top_left_y": 0.9477963200684638, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9572100984167736, "height": 0.00941377834830981, "width": 0.019963702359346636}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-27-0", "text": "US and other non-Dutch holders of our Shares may not be able to exercise pre-emption rights.\n", "page_number": 27, "bounding_box": {"top_left_x": 0.13430127041742287, "top_left_y": 0.08301240907145914, "lower_right_x": 0.7967332123411979, "lower_right_y": 0.09927257167308515, "height": 0.016260162601626008, "width": 0.662431941923775}, "blob_type": "headline", "predictions": {}, "annotations": {"risk_factor": ["US and other non-Dutch holders of our Shares may not be able to exercise pre-emption rights."]}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-27-1", "text": "  In the event of an increase in our share capital, holders of our Shares are generally entitled to certain pre-\nemption rights, unless these rights are excluded by a resolution of the General Meeting of Shareholders or of the\nExecutive Board, if so designated by the General Meeting of Shareholders or pursuant to our Articles of\nAssociation.\n", "page_number": 27, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.11253744116388532, "lower_right_x": 0.8753781004234725, "lower_right_y": 0.1647411210954215, "height": 0.05220367993153617, "width": 0.7549909255898367}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-27-2", "text": "   In particular, US holders of our Shares may not be able to exercise pre-emption rights unless a registration\nstatement under the Securities Act is declared effective with respect to the Shares issuable upon exercise of such\nrights or an exemption from the registration requirements is available. We intend to evaluate at the time of any\nrights issue the cost and potential liabilities associated with any such registration statement, as well as the\nindirect benefits and costs to us of enabling the exercise by US holders of their pre-emption rights for our Shares\nand any other factors considered appropriate at the time. We will then make a decision as to whether to file such\na registration statement, although currently we do not expect that any registration statement would be filed. No\nassurance can be given that any registration statement would be filed or that any exemption from registration\nwould be available to enable the exercise of a US holder\u2019s pre-emption rights.\n", "page_number": 27, "bounding_box": {"top_left_x": 0.12099213551119177, "top_left_y": 0.1810012836970475, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.30466409927257165, "height": 0.12366281557552417, "width": 0.7598306110102843}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-27-3", "text": "   If securities or industry analysts do not publish research or reports about our business, or if they change\ntheir recommendations regarding our Shares adversely, the price and trading volume of our Shares could\ndecline.\n", "page_number": 27, "bounding_box": {"top_left_x": 0.11796733212341198, "top_left_y": 0.31750106974753955, "lower_right_x": 0.8650937689050212, "lower_right_y": 0.36114676936243045, "height": 0.0436456996148909, "width": 0.7471264367816093}, "blob_type": "paragraph", "predictions": {}, "annotations": {"risk_factor": ["If securities or industry analysts do not publish research or reports about our business, or if they changetheir recommendations regarding our Shares adversely, the price and trading volume of our Shares coulddecline."]}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-27-4", "text": "   The trading market for our Shares will be influenced by the research and reports that industry or securities\nanalysts publish about us or our business. If one or more of the analysts who cover us or our industry downgrade\nour Shares, the market price of our Shares would likely decline. If one or more of these analysts ceases coverage\nof us or fails to regularly publish reports on us, we could lose visibility in the financial markets, which could\ncause the market price of our Shares or trading volume to decline.\n", "page_number": 27, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.3761232349165597, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.4428754813863928, "height": 0.06675224646983313, "width": 0.7604355716878403}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-27-5", "text": "  As a new investor, you will experience immediate and substantial dilution in the net tangible book value of\nyour Shares.\n", "page_number": 27, "bounding_box": {"top_left_x": 0.11857229280096794, "top_left_y": 0.45528455284552843, "lower_right_x": 0.8729582577132486, "lower_right_y": 0.4843816859221224, "height": 0.02909713307659395, "width": 0.7543859649122807}, "blob_type": "paragraph", "predictions": {}, "annotations": {"risk_factor": ["As a new investor, you will experience immediate and substantial dilution in the net tangible book value ofyour Shares."]}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-27-6", "text": "  The Offer Price of our Shares is considerably more than the net tangible book value per Share of our\noutstanding Shares. Accordingly, investors purchasing Shares in the Offer will pay a price per Share that\nsubstantially exceeds the value of our assets after subtracting liabilities.\n", "page_number": 27, "bounding_box": {"top_left_x": 0.12159709618874773, "top_left_y": 0.4993581514762516, "lower_right_x": 0.8275862068965517, "lower_right_y": 0.540436456996149, "height": 0.04107830551989733, "width": 0.705989110707804}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-27-7", "text": "We do not intend to pay dividends for the foreseeable future.\n", "page_number": 27, "bounding_box": {"top_left_x": 0.13430127041742287, "top_left_y": 0.55198973042362, "lower_right_x": 0.5614035087719298, "lower_right_y": 0.5686777920410783, "height": 0.016688061617458283, "width": 0.4271022383545069}, "blob_type": "headline", "predictions": {}, "annotations": {"risk_factor": ["We do not intend to pay dividends for the foreseeable future."]}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-27-8", "text": "   We do not intend to pay any dividends for the foreseeable future. Payment of future dividends to shareholders\nwill effectively be at the discretion of the Executive Board, subject to the approval of the Supervisory Board\nafter taking into account various factors including our business prospects, cash requirements, financial\nperformance and new product development. In addition, payment of future dividends may be made only if our\nshareholders\u2019 equity exceeds the sum of our called up and paid-in share capital plus the reserves required to be\nmaintained by law and by our Articles of Association. Accordingly, investors cannot rely on dividend income\nfrom our Shares and any returns on an investment in our Shares will likely depend entirely upon any future\nappreciation in the price of our Shares. We can provide no assurance that the price of our Shares will appreciate\nafter the Offer or that the market price for our Shares will not fall below the Offer Price.\n", "page_number": 27, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.5815147625160462, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.7043217800599059, "height": 0.1228070175438597, "width": 0.7604355716878403}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-27-9", "text": "   Dutch law and our Articles of Association permit anti-takeover provisions that may prevent or discourage\ntakeover attempts that may be favorable to shareholders.\n", "page_number": 27, "bounding_box": {"top_left_x": 0.1161524500907441, "top_left_y": 0.7171587505348738, "lower_right_x": 0.8699334543254689, "lower_right_y": 0.7471116816431322, "height": 0.029952931108258474, "width": 0.7537810042347248}, "blob_type": "paragraph", "predictions": {}, "annotations": {"risk_factor": ["Dutch law and our Articles of Association permit anti-takeover provisions that may prevent or discouragetakeover attempts that may be favorable to shareholders."]}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-27-10", "text": "   Our Articles of Association allow us to implement anti-takeover measures that may have the effect of\npreventing, discouraging or delaying a change of control. Under the terms of two agreements, in certain\ncircumstances Stichting Continu\u00efteit OctoPlus is entitled to acquire from us, and we may demand that Stichting\nContinu\u00efteit OctoPlus acquires from us, preference shares up to a maximum of 100% of our total issued and\noutstanding share capital, excluding issued and outstanding preference shares. The issuance of preference shares\nin this manner would cause substantial dilution to the voting power of any shareholder, including a shareholder\nattempting to gain control of us, and could therefore have the effect of preventing, discouraging or delaying a\nchange of control that might have otherwise resulted in an opportunity for shareholders to sell our Shares at a\npremium to the then-prevailing market price. This anti-takeover measure may have an adverse effect on the\nmarket price of our Shares.\n", "page_number": 27, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.7595207531022679, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.8968763371844245, "height": 0.13735558408215665, "width": 0.7555958862673926}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-27-11", "text": "25\n", "page_number": 27, "bounding_box": {"top_left_x": 0.8608590441621294, "top_left_y": 0.9477963200684638, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9572100984167736, "height": 0.00941377834830981, "width": 0.019963702359346636}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-28-0", "text": "No minimum amount for the Offer.\n", "page_number": 28, "bounding_box": {"top_left_x": 0.13430127041742287, "top_left_y": 0.08301240907145914, "lower_right_x": 0.38898971566848156, "lower_right_y": 0.09970047068891741, "height": 0.01668806161745827, "width": 0.2546884452510587}, "blob_type": "headline", "predictions": {}, "annotations": {"risk_factor": ["No minimum amount for the Offer."]}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-28-1", "text": "   We have the right to proceed with the Offer even if we raise substantially less than we currently intend. No\nminimum number of Shares in the Offer has been set. The actual number of offered Shares will be confirmed in\nthe financial press in the Netherlands (including in the Daily Official List) together with the Offer Price.\nTherefore, (i) a reduced number of Shares could be available for trade on the market, which could limit their\nliquidity and (ii) our financial capacity might be reduced in view of our stated use of proceeds. We might\ntherefore reduce our level of investment or have to seek further external funding.\n", "page_number": 28, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.11253744116388532, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.1951219512195122, "height": 0.08258451005562688, "width": 0.7555958862673926}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-28-2", "text": "26\n", "page_number": 28, "bounding_box": {"top_left_x": 0.8608590441621294, "top_left_y": 0.9477963200684638, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9572100984167736, "height": 0.00941377834830981, "width": 0.019963702359346636}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-29-0", "text": "Important Information\n", "page_number": 29, "bounding_box": {"top_left_x": 0.38173018753781, "top_left_y": 0.10226786478391099, "lower_right_x": 0.6194797338173019, "lower_right_y": 0.11895592640136927, "height": 0.016688061617458283, "width": 0.2377495462794919}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-29-1", "text": "   No person is or has been authorized to give any information or to make any representation in connection with\nthe offer or sale of the Offer Shares, other than as contained in this Prospectus, and, if given or made, any other\ninformation or representation must not be relied upon as having been authorized by us or the Underwriters. The\ndelivery of this Prospectus at any time after the date hereof will not, under any circumstances, create any\nimplication that there has been no change in our affairs since the date hereof or that the information set forth in\nthis Prospectus is correct as of any time since its date.\n", "page_number": 29, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.1364997860504921, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.2186563970902867, "height": 0.0821566110397946, "width": 0.7555958862673926}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-29-2", "text": "   OctoPlus N.V. accepts responsibility for the information contained in this Prospectus. Having taken all\nreasonable care to ensure that such is the case, OctoPlus N.V. further declares that the information contained in\nthis Prospectus is, to the best of its knowledge, in accordance with the facts and contains no omission likely to\naffect its import.\n", "page_number": 29, "bounding_box": {"top_left_x": 0.12099213551119177, "top_left_y": 0.23234916559691912, "lower_right_x": 0.8705384150030248, "lower_right_y": 0.28712023962344885, "height": 0.054771074026529726, "width": 0.749546279491833}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-29-3", "text": "   In connection with the Offer, the Underwriters through Kempen & Co or its affiliates or agents as\nstabilization manager may over-allot or effect transactions that stabilize or maintain the market price of\nthe Shares at levels above those which might otherwise prevail in the open market. Such transactions may\nbe effected on Euronext Amsterdam in the over-the-counter market or otherwise. There is no assurance\nthat such stabilization will be undertaken and, if it is, it commences as early as the Listing Date, may be\ndiscontinued at any time and will end no later than 30 calendar days after the Listing Date.\n", "page_number": 29, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.3008130081300813, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.38339751818570816, "height": 0.08258451005562684, "width": 0.7604355716878403}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-29-4", "text": "Notice to Investors\n", "page_number": 29, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.39666238767650835, "lower_right_x": 0.25650332728372655, "lower_right_y": 0.4099272571673085, "height": 0.013264869490800135, "width": 0.13611615245009073}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-29-5", "text": "   The distribution of this Prospectus and the offering and sale of the Offer Shares offered hereby may be\nrestricted by law in certain jurisdictions. Persons in possession of this Prospectus are required to inform\nthemselves about and to observe any such restrictions. This Prospectus may not be used for, or in connection\nwith, and does not constitute, any offer to sell, or an invitation to purchase, any of the Offer Shares offered\nhereby in any jurisdiction in which such offer or invitation would be unlawful.\n", "page_number": 29, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.4240479246897732, "lower_right_x": 0.853599516031458, "lower_right_y": 0.4946512623020967, "height": 0.07060333761232351, "width": 0.7332123411978222}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-29-6", "text": "   The Offer Shares have not been approved or disapproved by the US Securities and Exchange Commission,\nany State securities commission in the United States or any other US regulatory authority, nor have any of the\nforegoing passed upon or endorsed the merits of the Offer or the accuracy or adequacy of this Prospectus. Any\nrepresentation to the contrary is a criminal offence in the United States.\n", "page_number": 29, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.5096277278562259, "lower_right_x": 0.8663036902601331, "lower_right_y": 0.5635430038510911, "height": 0.05391527599486523, "width": 0.7459165154264973}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-29-7", "text": "  NEITHER THE FACT THAT A REGISTRATION STATEMENT OR AN APPLICATION FOR A\nLICENCE HAS BEEN FILED UNDER CHAPTER 421-B OF THE NEW HAMPSHIRE REVISED\nSTATUTES WITH THE STATE OF NEW HAMPSHIRE NOR THE FACT THAT A SECURITY IS\nEFFECTIVELY REGISTERED OR A PERSON IS LICENSED IN THE STATE OF NEW HAMPSHIRE\nCONSTITUTES A FINDING BY THE SECRETARY OF STATE OF NEW HAMPSHIRE THAT ANY\nDOCUMENT FILED UNDER RSA 421-B IS TRUE, COMPLETE AND NOT MISLEADING. NEITHER\nANY SUCH FACT NOR THE FACT THAT AN EXEMPTION OR EXCEPTION IS AVAILABLE FOR A\nSECURITY OR A TRANSACTION MEANS THAT THE SECRETARY OF STATE OF NEW HAMPSHIRE\nHAS PASSED IN ANY WAY UPON THE MERITS OR QUALIFICATIONS OF, OR RECOMMENDED OR\nGIVEN APPROVAL TO, ANY PERSON, SECURITY OR TRANSACTION. IT IS UNLAWFUL TO MAKE,\nOR CAUSE TO BE MADE, TO ANY PROSPECTIVE PURCHASER, CUSTOMER OR CLIENT, ANY\nREPRESENTATION INCONSISTENT WITH THE PROVISIONS OF THIS PARAGRAPH.\n", "page_number": 29, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.5780915703893881, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.7394094993581515, "height": 0.1613179289687634, "width": 0.7555958862673926}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-29-8", "text": "Presentation of Financial and Other Information\n", "page_number": 29, "bounding_box": {"top_left_x": 0.12099213551119177, "top_left_y": 0.7560975609756098, "lower_right_x": 0.4724742891712039, "lower_right_y": 0.7667950363714163, "height": 0.010697475395806566, "width": 0.3514821536600121}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-29-9", "text": "   Our consolidated financial information in the Prospectus has been prepared in accordance with International\nFinancial Reporting Standards (\u201cIFRS\u201d). IFRS differ in certain significant respects from US GAAP as they\nrelate to our consolidated financial information. In making an investment decision, investors must rely upon\ntheir own examination of us, the terms of the Offer and the financial information provided herein. Potential\ninvestors should consult their own professional advisors for an understanding of the differences between IFRS\nand US GAAP. For a discussion of the main differences between IFRS and US GAAP as they relate to us, see\n\u201cSummary of Significant Differences between IFRS and US GAAP\u201d.\n", "page_number": 29, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.7834830979888746, "lower_right_x": 0.8656987295825771, "lower_right_y": 0.8797603765511339, "height": 0.09627727856225932, "width": 0.7453115547489413}, "blob_type": "paragraph", "predictions": {}, "annotations": {"accounting_standards": ["IFRS"]}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-29-10", "text": "27\n", "page_number": 29, "bounding_box": {"top_left_x": 0.8608590441621294, "top_left_y": 0.9477963200684638, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9572100984167736, "height": 0.00941377834830981, "width": 0.019963702359346636}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-30-0", "text": "   Certain figures contained in this Prospectus have been subject to rounding adjustments. Accordingly, in\ncertain instances the sum of the numbers in a column or a row in tables contained in this Prospectus may not\nconform exactly to the total figure given for that column or row.\n", "page_number": 30, "bounding_box": {"top_left_x": 0.12159709618874773, "top_left_y": 0.08515190415062045, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.12665810868635002, "height": 0.04150620453572958, "width": 0.7301875378100424}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-30-1", "text": "   All references in this Prospectus to \u201ceuros\u201d or \u201c\u20ac\u201d are to the currency introduced at the start of the third stage\nof the Economic and Monetary Union, pursuant to the Treaty establishing the European Economic Community,\nas amended by the Treaty on the European Union. All references to \u201cUS dollars\u201d, \u201cUS$\u201d or \u201c$\u201d are to the lawful\ncurrency of the United States.\n", "page_number": 30, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.1399229781771502, "lower_right_x": 0.8765880217785844, "lower_right_y": 0.1951219512195122, "height": 0.055198973042362015, "width": 0.7562008469449486}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-30-2", "text": "   Any financial information in this Prospectus that has not been extracted from our audited consolidated\nfinancial statements for the years 2004, 2005 and 2006 is unaudited. The figures relating to our condensed\nconsolidated interim financial statements for the first half of 2006 and 2007 are unaudited. However, the figures\nrelating to our condensed consolidated interim financial statements for the first half of 2006 and 2007 have been\nreviewed pursuant to the International Standard on Review Engagement 2410 by our independent auditor,\nDeloitte Accountants B.V. See \u201cIndex to Financial Statements \u2013 Condensed Consolidated Interim Financial\nStatements 30 June 2007 and 2006 \u2013 Review Report\u201d.\n", "page_number": 30, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.20838682071031236, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.30466409927257165, "height": 0.09627727856225929, "width": 0.7555958862673926}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-30-3", "text": "  Unless the context otherwise requires or it is expressly provided to the contrary, for calculation purposes this\nProspectus assumes no exercise of the Overallotment Option and an Offer Price of \u20ac3.95, the closing price of\nour Shares on 8 November 2007, and total Offer proceeds of \u20ac25 million.\n", "page_number": 30, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.31792896876337184, "lower_right_x": 0.8711433756805808, "lower_right_y": 0.3594351732991014, "height": 0.04150620453572956, "width": 0.7507562008469449}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-30-4", "text": "   On 4 October 2006 all non-ordinary shares were converted into the same number of ordinary shares with a\nnominal value of \u20ac1.00 and split into ordinary shares with a value of \u20ac0.01, following which the nominal value\nwas increased to \u20ac0.12 per share (the \u201cCapital Restructuring\u201d). The numbers of shares and exercise prices of\noptions and warrants which were outstanding prior to the Capital Restructuring are reflected in this Prospectus\nas if the Capital Restructuring already had taken place (unless otherwise indicated).\n", "page_number": 30, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.3761232349165597, "lower_right_x": 0.8663036902601331, "lower_right_y": 0.44330338040222506, "height": 0.06718014548566537, "width": 0.7459165154264973}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-30-5", "text": "Exchange Rates\n", "page_number": 30, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.4582798459563543, "lower_right_x": 0.2365396249243799, "lower_right_y": 0.4715447154471545, "height": 0.01326486949080019, "width": 0.1161524500907441}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-30-6", "text": "   We publish our consolidated financial statements in euros. The exchange rates below are provided solely for\ninformation and convenience. No representation is made that the euro could have been, or could be, converted\ninto US dollars at these rates.\n", "page_number": 30, "bounding_box": {"top_left_x": 0.12099213551119177, "top_left_y": 0.4856653829696192, "lower_right_x": 0.867513611615245, "lower_right_y": 0.5237483953786907, "height": 0.03808301240907147, "width": 0.7465214761040532}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-30-7", "text": "   The table below shows the high, low, average and end of period exchange rates expressed in US dollars per\n\u20ac1.00 for the years given, using the noon buying rate in New York City for cable transfers in foreign currencies\nas certified for customs purposes by the Federal Reserve Bank of New York (the \u201cNoon Buying Rate\u201d) for the\nperiods indicated.\n", "page_number": 30, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.540436456996149, "lower_right_x": 0.8705384150030248, "lower_right_y": 0.5952075310226786, "height": 0.0547710740265297, "width": 0.7501512401693889}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-30-8", "text": "Year ended 31 December                                                       High     Low              Average   End of Period\n                                                                                       (US Dollars per Euro)\n\n\n2003 ...................................................................    1.2597   1.0361            1.1323      1.2597\n2004 ...................................................................    1.3625   1.1801            1.2441      1.3538\n2005 ....................................................................   1.3476   1.1667            1.2444      1.1842\n2006 \u2026.\u2026\u2026\u2026\u2026.                                                                1.3327   1.1860            1.2563      1.3197\n2007 (through 8 November 2007)                                              1.4691   1.2904            1.3563      1.4691\n", "page_number": 30, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.6157466837826273, "lower_right_x": 0.9026013309134906, "lower_right_y": 0.7287120239623449, "height": 0.1129653401797176, "width": 0.7822141560798548}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-30-9", "text": "   The table below shows the high and low Noon Buying Rates expressed in US dollars per \u20ac1.00 for the first\nten months of 2007.\n", "page_number": 30, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.7462558836114677, "lower_right_x": 0.8596491228070176, "lower_right_y": 0.7753530166880617, "height": 0.029097133076594006, "width": 0.7392619479733817}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-30-10", "text": "                                                                                                                         High                Low\n                                                                                                                           (US Dollars per Euro)\n\n\nJanuary 2007 .......................................................................................................    1.3286              1.2904\nFebruary 2007 .....................................................................................................     1.3246              1.2933\nMarch 2007 .........................................................................................................    1.3374              1.3094\nApril 2007 ..........................................................................................................   1.3660              1.3363\nMay 2007.............................................................................................................   1.3616              1.3419\nJune 2007 ...........................................................................................................   1.3526              1.3295\n", "page_number": 30, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.7834830979888746, "lower_right_x": 0.882637628554144, "lower_right_y": 0.9088575096277278, "height": 0.1253744116388532, "width": 0.7622504537205081}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-30-11", "text": "28\n", "page_number": 30, "bounding_box": {"top_left_x": 0.8608590441621294, "top_left_y": 0.9477963200684638, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9572100984167736, "height": 0.00941377834830981, "width": 0.019963702359346636}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-31-0", "text": "July 2007 .............................................................................................................   1.3831   1.3592\nAugust 2007 ........................................................................................................      1.3808   1.3402\nSeptember 2007 ..................................................................................................         1.4219   1.3606\nOctober 2007.......................................................................................................       1.4468   1.4092\n", "page_number": 31, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.08515190415062045, "lower_right_x": 0.8469449485783425, "lower_right_y": 0.13692768506632436, "height": 0.05177578091570391, "width": 0.7265577737447066}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-31-1", "text": "On 8 November 2007, the Noon Buying Rate for the euro was \u20ac1.00 = $1.4691.\n", "page_number": 31, "bounding_box": {"top_left_x": 0.13914095583787053, "top_left_y": 0.15361574668378264, "lower_right_x": 0.6745311554748942, "lower_right_y": 0.16773641420624733, "height": 0.014120667522464686, "width": 0.5353901996370236}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-31-2", "text": "Enforceability of Judgments\n", "page_number": 31, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.18142918271287975, "lower_right_x": 0.32425892316999394, "lower_right_y": 0.1951219512195122, "height": 0.013692768506632452, "width": 0.20387174833635813}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-31-3", "text": "   We are a limited liability company incorporated under the laws of the Netherlands. Substantially all of the\nmembers of our Executive Board and Supervisory Board are resident outside the United States, and a substantial\nportion of our assets and the assets of such persons are located outside the United States. As a result, it may not\nbe possible for investors to effect service of process within the United States upon us or such persons, or to\nenforce against them in the Netherlands or elsewhere judgments obtained in US courts, including judgments\npredicated on the civil liability provisions of the securities laws of the United States or any state or territory\nwithin the United States.\n", "page_number": 31, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.20838682071031236, "lower_right_x": 0.8796128251663642, "lower_right_y": 0.30380830124090713, "height": 0.09542148053059477, "width": 0.7592256503327284}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-31-4", "text": "Market Data and Other Information from Third Parties\n", "page_number": 31, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.32135216089002994, "lower_right_x": 0.5275257108287962, "lower_right_y": 0.33204963628583656, "height": 0.010697475395806622, "width": 0.40713853599516037}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-31-5", "text": "   All references to market data, industry statistics and industry forecasts in this Prospectus consist of estimates\ncompiled by The World Health Organization, the US Centers for Disease Control and Prevention, the Public\nHealth Agency of Canada, the US National Institutes of Health, Datamonitor, Decision Resources, Reuters,\nIntercontinental Marketing Services, International Diabetes Federation, American Diabetes Association, equity\nresearch analysts, other biopharmaceutical companies and ourselves. Industry publications generally state that\ntheir information is obtained from sources they believe reliable but that the accuracy and completeness of such\ninformation is not guaranteed and that the projections they contain are based on a number of significant\nassumptions. Although we believe these sources are reliable, as we do not have access to the information,\nmethodology and other bases for such information, we have not independently verified the information and\ntherefore cannot guarantee its accuracy and completeness.\n", "page_number": 31, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.34873769790329484, "lower_right_x": 0.8705384150030248, "lower_right_y": 0.4848095849379546, "height": 0.13607188703465978, "width": 0.7501512401693889}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-31-6", "text": "   In this Prospectus, we make certain statements regarding our competitive position, the expected size of the\nmarkets for which we are developing our products and the side effects or efficacy of current treatments for the\nrelevant diseases. We believe these statements to be true based on market data and industry statistics which are\nin the public domain, but we have not independently verified the information and therefore cannot guarantee its\naccuracy and completeness.\n", "page_number": 31, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.4993581514762516, "lower_right_x": 0.8699334543254689, "lower_right_y": 0.5678219940094138, "height": 0.06846384253316218, "width": 0.7495462794918331}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-31-7", "text": "   The information in this Prospectus that has been sourced from third parties has been accurately reproduced\nand, as far as we are aware and able to ascertain from the information published by that third party, no facts\nhave been omitted that would render the reproduced information inaccurate or misleading. Although we believe\nthese sources are reliable, as we do not have access to the information, methodology and other bases for such\ninformation, we have not independently verified the information and therefore cannot guarantee its accuracy and\ncompleteness.\n", "page_number": 31, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.5815147625160462, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.6636713735558408, "height": 0.08215661103979466, "width": 0.7604355716878403}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-31-8", "text": "Documents Incorporated by Reference\n", "page_number": 31, "bounding_box": {"top_left_x": 0.12099213551119177, "top_left_y": 0.6773641420624733, "lower_right_x": 0.4016938898971567, "lower_right_y": 0.6910569105691057, "height": 0.013692768506632369, "width": 0.28070175438596495}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-31-9", "text": "  Our Articles of Association (statuten) are incorporated by reference into this Prospectus. See \u201cDescription of\nShare Capital and Corporate Governance\u201d. No other documents or information form part of, or are incorporated\nby reference into, this Prospectus.\n", "page_number": 31, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.7047496790757382, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.7462558836114677, "height": 0.04150620453572951, "width": 0.7555958862673926}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-31-10", "text": "29\n", "page_number": 31, "bounding_box": {"top_left_x": 0.8608590441621294, "top_left_y": 0.9477963200684638, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9572100984167736, "height": 0.00941377834830981, "width": 0.019963702359346636}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-32-0", "text": "Forward-Looking Statements\n", "page_number": 32, "bounding_box": {"top_left_x": 0.34785238959467635, "top_left_y": 0.10226786478391099, "lower_right_x": 0.6485178463399879, "lower_right_y": 0.11895592640136927, "height": 0.016688061617458283, "width": 0.30066545674531153}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-32-1", "text": "   This Prospectus contains forward-looking statements, including statements about our beliefs and\nexpectations. These statements are based on our current plans, estimates and projections, as well as our\nexpectations of external conditions and events. In particular the words \u201cexpect\u201d, \u201canticipate\u201d, \u201cpredict\u201d,\n\u201cestimate\u201d, \u201cproject\u201d, \u201cmay\u201d, \u201ccould\u201d, \u201cshould\u201d, \u201cwould\u201d, \u201cwill\u201d, \u201cintend\u201d, \u201cbelieve\u201d and similar expressions\nare intended to identify forward-looking statements. Forward-looking statements involve inherent risks and\nuncertainties and speak only as of the date they are made. We undertake no duty to and will not necessarily\nupdate any of them in light of new information or future events, except to the extent required by applicable law.\nWe caution investors that a number of important factors could cause actual results or outcomes to differ\nmaterially from those expressed in any forward-looking statements. These factors include, but are not limited to\nthose discussed under \u201cRisk Factors\u201d.\n", "page_number": 32, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.1364997860504921, "lower_right_x": 0.8723532970356926, "lower_right_y": 0.27043217800599056, "height": 0.13393239195549847, "width": 0.7519661222020568}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-32-2", "text": "30\n", "page_number": 32, "bounding_box": {"top_left_x": 0.8620689655172413, "top_left_y": 0.9477963200684638, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9572100984167736, "height": 0.00941377834830981, "width": 0.01875378100423475}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-33-0", "text": "Dividend Policy\n", "page_number": 33, "bounding_box": {"top_left_x": 0.4186327888687235, "top_left_y": 0.10269576379974327, "lower_right_x": 0.5807622504537205, "lower_right_y": 0.11938382541720154, "height": 0.01668806161745827, "width": 0.16212946158499703}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-33-1", "text": "  We currently intend to retain future earnings, if any, to finance the growth and development of our business.\nAs a result, we do not anticipate paying any dividends for the foreseeable future.\n", "page_number": 33, "bounding_box": {"top_left_x": 0.1161524500907441, "top_left_y": 0.13436029097133076, "lower_right_x": 0.8669086509376891, "lower_right_y": 0.16302952503209242, "height": 0.02866923406076166, "width": 0.750756200846945}, "blob_type": "paragraph", "predictions": {}, "annotations": {"dividend_policy": ["We currently intend to retain future earnings, if any, to finance the growth and development of our business.As a result, we do not anticipate paying any dividends for the foreseeable future.Our dividend policy will, however, be reviewed from time to time and payment of any future dividends willbe effectively at the discretion of the Executive Board, subject to approval of the Supervisory Board, after takinginto account various factors including our business prospects, cash requirements, financial performance, newproduct development, the payment on our preference shares, to the extent any are issued, in accordance with ourArticles of Association (see \u201cDescription of the Share Capital and Corporate Governance \u2013 Dividends and OtherDistributions\u201d) and the requirements of Dutch law. Under Dutch law, payment of dividends may be made only ifour shareholders\u2019 equity exceeds the sum of our called up and paid-in share capital plus the reserves required tobe maintained by law and by our Articles of Association."]}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-33-2", "text": "   Our dividend policy will, however, be reviewed from time to time and payment of any future dividends will\nbe effectively at the discretion of the Executive Board, subject to approval of the Supervisory Board, after taking\ninto account various factors including our business prospects, cash requirements, financial performance, new\nproduct development, the payment on our preference shares, to the extent any are issued, in accordance with our\nArticles of Association (see \u201cDescription of the Share Capital and Corporate Governance \u2013 Dividends and Other\nDistributions\u201d) and the requirements of Dutch law. Under Dutch law, payment of dividends may be made only if\nour shareholders\u2019 equity exceeds the sum of our called up and paid-in share capital plus the reserves required to\nbe maintained by law and by our Articles of Association.\n", "page_number": 33, "bounding_box": {"top_left_x": 0.1161524500907441, "top_left_y": 0.17586649550706032, "lower_right_x": 0.8832425892317, "lower_right_y": 0.2854086435601198, "height": 0.10954214805305948, "width": 0.7670901391409559}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-33-3", "text": "31\n", "page_number": 33, "bounding_box": {"top_left_x": 0.8620689655172413, "top_left_y": 0.9477963200684638, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9576379974326059, "height": 0.009841677364142098, "width": 0.01875378100423475}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-34-0", "text": "Use of Proceeds\n", "page_number": 34, "bounding_box": {"top_left_x": 0.4204476709013914, "top_left_y": 0.12965340179717585, "lower_right_x": 0.5807622504537205, "lower_right_y": 0.14377406931964057, "height": 0.014120667522464714, "width": 0.16031457955232914}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-34-1", "text": "   We expect to raise approximately \u20ac25 million in gross proceeds from the issue of Offer Shares in the Offer.\nThe net proceeds we will receive from the issue of Offer Shares in the Offer are estimated to be approximately\n\u20ac22.9 million after deducting the estimated underwriting fees and commissions and expenses of \u20ac2.1 million\npayable by us, assuming no exercise of the Overallotment Option. We intend to use the net proceeds we receive\nfrom the Offer primarily for:\n\n  \u00b7    Locteron development activities, including the Phase IIb study, and parallel thereto a study to enable\n       treatment of difficult-to-treat populations, and subsequent clinical studies and manufacturing and\n       material costs;\n\n  \u00b7    OP-286 CR development activities, including pre-clinical and clinical development studies;\n\n  \u00b7    OP-145 CSOM development activities, including the scheduled Phase III trial and further studies needed\n       to progress OP-145 CSOM to regulatory approval, as well as manufacturing and material costs;\n\n  \u00b7    pre-clinical research and development activities for both OctoVAX product candidates, HBV-OctoVAX\n       and JEV-OctoVAX, as well as subsequent clinical studies and manufacturing and material costs;\n\n  \u00b7    in-licensing or acquiring of additional product candidates or technologies;\n\n  \u00b7    other general corporate purposes, including expanding our facilities and other capital expenditures, and\n       working capital; and\n\n  \u00b7    acquisitions of complementary businesses if and when they present themselves.\n\n   This expected use of net proceeds of this Offer represents our current intentions based upon our present plans\nand business conditions. The amounts and timing of our actual expenditures depend on numerous factors,\nincluding the ongoing status of and results from clinical trials and other studies for Locteron and OP-145 CSOM\nas well as the development of our pre-clinical product portfolio and research being carried out, any\ncollaborations we may enter into with third parties for our product candidates, and any unforeseen cash needs.\nAs a result, the Executive Board will retain broad discretion over the allocation of the net proceeds from this\nOffer. We do not expect the net proceeds from this Offer to be sufficient to fund the completion of the\ndevelopment of any of our product candidates, and we expect that we will need to raise additional funds prior to\nbeing able to market any products.\n", "page_number": 34, "bounding_box": {"top_left_x": 0.11675741076830005, "top_left_y": 0.1621737270004279, "lower_right_x": 0.8802177858439202, "lower_right_y": 0.6332905434317501, "height": 0.4711168164313222, "width": 0.7634603750756201}, "blob_type": "paragraph", "predictions": {}, "annotations": {"expected_gross_proceeds": ["\u20ac25 million"], "offering_costs": [" \u20ac2.1"], "use_of_proceeds": ["Locteron development activities, including the Phase IIb study, and parallel thereto a study to enabletreatment of difficult-to-treat populations, and subsequent clinical studies and manufacturing andmaterial costs;", "OP-286 CR development activities, including pre-clinical and clinical development studies;", "OP-145 CSOM development activities, including the scheduled Phase III trial and further studies neededto progress OP-145 CSOM to regulatory approval, as well as manufacturing and material costs;", "pre-clinical research and development activities for both OctoVAX product candidates, HBV-OctoVAXand JEV-OctoVAX, as well as subsequent clinical studies and manufacturing and material costs;", "in-licensing or acquiring of additional product candidates or technologies;", "other general corporate purposes, including expanding our facilities and other capital expenditures, andworking capital; and", "acquisitions of complementary businesses if and when they present themselves."], "expected_net_proceeds": ["\u20ac22.9 million "]}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-34-2", "text": "   Pending use of the net proceeds of this Offer, we intend to invest the net proceeds in accordance with our\ninvestment policy guidelines, which currently provide for investment of funds in cash equivalents, government\nobligations, high grade and corporate notes and commercial paper.\n", "page_number": 34, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.6465554129225503, "lower_right_x": 0.8663036902601331, "lower_right_y": 0.6880616174582799, "height": 0.04150620453572962, "width": 0.7459165154264973}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-34-3", "text": "32\n", "page_number": 34, "bounding_box": {"top_left_x": 0.8620689655172413, "top_left_y": 0.9477963200684638, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9572100984167736, "height": 0.00941377834830981, "width": 0.01875378100423475}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-35-0", "text": "Capitalization and Indebtedness\n", "page_number": 35, "bounding_box": {"top_left_x": 0.33817301875378103, "top_left_y": 0.10226786478391099, "lower_right_x": 0.663036902601331, "lower_right_y": 0.11895592640136927, "height": 0.016688061617458283, "width": 0.32486388384754994}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-35-1", "text": "   The table below sets forth our unaudited consolidated cash and cash equivalents, capitalization and\nindebtedness as of 30 September 2007, as follows:\n", "page_number": 35, "bounding_box": {"top_left_x": 0.12159709618874773, "top_left_y": 0.1364997860504921, "lower_right_x": 0.8033877797943134, "lower_right_y": 0.16388532306375694, "height": 0.02738553701326485, "width": 0.6817906836055657}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-35-2", "text": "\u00b7   on an actual basis; and\n\n\u00b7   on a pro forma basis, as adjusted to reflect our receipt of the estimated net proceeds from the issue of the\n    Offer Shares in the Offer, after deducting the estimated underwriting fees and commissions and expenses\n    payable by us, based on gross proceeds from the Offer of \u20ac25 million, an Offer Price of \u20ac3.95, and no\n    exercise of the Overallotment Option.\n", "page_number": 35, "bounding_box": {"top_left_x": 0.1355111917725348, "top_left_y": 0.17800599058622166, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.2601626016260163, "height": 0.08215661103979463, "width": 0.7453115547489413}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-35-3", "text": "   The financial information in the table below has been extracted or derived from our September 2007\nmanagement accounts which have not been audited or reviewed and will not be published. You should read this\ntable together with our consolidated financial statements and unaudited condensed consolidated interim\nfinancial statements and their related notes, as well as the information under \u201cOperating and Financial Review\u201d\nappearing elsewhere in this Prospectus. The table below is prepared for illustrative purposes only and, because\nof its nature, may not give a true picture of our financial condition following the Offer.\n", "page_number": 35, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.2734274711168164, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.3560119811724433, "height": 0.08258451005562689, "width": 0.7555958862673926}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-35-4", "text": "                                             30 September 2007\n                                           Actual        As adjusted\n                                                        for the Offer\n                                                 (thousands)\nCash and cash equivalents1                 \u20ac8,133          \u20ac31,0332\n\nShare capital \u2013 ordinary shares             1,945            2,704\nShare capital \u2013 preferred shares            -                   -\nShare premium                              38,161           60,302\nRetained earnings (accumulated deficit)   (29,623)         (29,623)\nOther reserves                                381              381\nTotal equity                              \u20ac10,864          \u20ac33,764\n\nNon-current liabilities                     3,548             3,548\nCurrent liabilities3                        8,963             8,963\n\nTotal liabilities4                        \u20ac12,511          \u20ac12,511\nTotal capitalization                      \u20ac23,375          \u20ac46,275\n", "page_number": 35, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.37312794180573383, "lower_right_x": 0.7489413188142771, "lower_right_y": 0.670517757809157, "height": 0.2973898160034232, "width": 0.6285541439806412}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-35-5", "text": "1.    \u20ac3.5 million of short term deposits have been classified under other current assets.\n\n2.    The increase in cash and cash equivalents reflects the estimated net proceeds based on gross proceeds from the Offer of \u20ac25 million\n      and estimated underwriting fees and commissions and expenses payable by us of \u20ac2.1 million.\n\n3.    \u20ac2.1 million of bank overdrafts have been classified under current liabilities. This amount is secured by a pledge over the inventory,\n      equipment and receivables of OctoPlus Development B.V. to ABN AMRO Bank N.V. in connection with a credit facility.\n\n4.    No guarantees have been issued by others in respect of any of these liabilities.\n\n     As of 30 September 2007, our net asset value per share was \u20ac0.67 (unaudited).\n", "page_number": 35, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.6979032948224219, "lower_right_x": 0.8614640048396854, "lower_right_y": 0.8339751818570817, "height": 0.1360718870346599, "width": 0.7410768300060496}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-35-6", "text": "  As of 30 September 2007, our authorized capital amounted to \u20ac8,640,000 and was divided into 36,000,000\nordinary shares and 36,000,000 preference shares, all with a nominal value of \u20ac0.12 each. As of 30 September\n2007, 16,207,076 ordinary shares were outstanding and were fully paid up.\n", "page_number": 35, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.8485237483953787, "lower_right_x": 0.8656987295825771, "lower_right_y": 0.889602053915276, "height": 0.04107830551989733, "width": 0.7453115547489413}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-35-7", "text": "33\n", "page_number": 35, "bounding_box": {"top_left_x": 0.8620689655172413, "top_left_y": 0.9482242190842961, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9572100984167736, "height": 0.00898587933247752, "width": 0.01875378100423475}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-36-0", "text": "  See \u201cOperating and Financial Review \u2013 Contractual Obligations\u201d for information about certain contingent\nobligations of ours.\n", "page_number": 36, "bounding_box": {"top_left_x": 0.12159709618874773, "top_left_y": 0.08515190415062045, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.11253744116388532, "height": 0.027385537013264877, "width": 0.7301875378100424}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-36-1", "text": "34\n", "page_number": 36, "bounding_box": {"top_left_x": 0.8620689655172413, "top_left_y": 0.9477963200684638, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9572100984167736, "height": 0.00941377834830981, "width": 0.01875378100423475}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-37-0", "text": "                                 Selected Financial Information\n   Our selected consolidated financial information set forth below should be read in conjunction with\n\u201cOperating and Financial Review\u201d and our consolidated financial statements and unaudited condensed\nconsolidated interim financial statements and their related notes that appear elsewhere in this Prospectus. Our\nyear-end consolidated financial information has been extracted from our consolidated financial statements that\nhave been audited by Deloitte Accountants B.V., independent auditors. Our six month consolidated financial\ninformation has been extracted from our unaudited condensed consolidated interim financial statements as of\nand for the six month periods ended 30 June 2006 and 30 June 2007. The unaudited condensed consolidated\ninterim financial statements for the sixth month periods ended 30 June 2006 and 30 June 2007 have been\nreviewed by Deloitte Accountants B.V. See \u201cIndex to Financial Statements \u2013 Condensed Consolidated Interim\nFinancial Statements 30 June 2007 and 2006 \u2013 Review Report\u201d.\n\n   Our results for the six month period ended 30 June 2007 are not necessarily indicative of our results for the\nfull year. Our consolidated financial statements, from which the selected consolidated financial information set\nforth below has been derived, were prepared in accordance with IFRS, which may differ from US GAAP in\ncertain significant respects. For a discussion of the most significant differences between IFRS and US GAAP as\nthey relate to us, in particular regarding finance leases, intellectual property rights and business combinations,\nsee \u201cSummary of Significant Differences between IFRS and US GAAP\u201d. Our selected consolidated financial\ninformation set forth below may not contain all of the information that is important to you.\n", "page_number": 37, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.10226786478391099, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.38339751818570816, "height": 0.2811296534017972, "width": 0.7604355716878403}, "blob_type": "headline", "predictions": {}, "annotations": {"unaudited_interim_financial_statements": ["unaudited condensed consolidated interim financial statements as ofand for the six month periods ended 30 June 2006 and 30 June 2007."], "periods_of_unaudited_interim_fs": ["30 June 2006 and 30 June 2007"]}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-37-1", "text": "Consolidated Income Statement Information\n", "page_number": 37, "bounding_box": {"top_left_x": 0.12159709618874773, "top_left_y": 0.39666238767650835, "lower_right_x": 0.44162129461585, "lower_right_y": 0.4103551561831408, "height": 0.013692768506632425, "width": 0.3200241984271023}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-37-2", "text": "                                                    Year ended 31 December            Six months ended 30 June\n (in thousands)                              2004            2005          2006         2006            2007\n                                                                                     UNAUDITED     UNAUDITED\nService revenues                              \u20ac4,924         \u20ac6,563        \u20ac5,587       \u20ac3,157          \u20ac2,543\nRoyalty and license revenues                      60             60           332           30             213\nIncome from subsidies                            708            394           132           92             118\nOther income                                      26              -             -            -               -\nTotal (consolidated) revenues                  5,718          7,017         6,051        3,279           2,874\nRaw materials and auxiliaries                     70            237           180          100             191\nCost of contracted work and other external\ncharges                                           307         1,390          1,928        1,147          1,403\nEmployee benefits                               3,597         4,758          6,140        2,920          3,993\nDepreciation and amortization                     860           863          1,060          512            541\nOther costs                                     2,667         4,213          5,263        2,597          2,930\nTotal operating costs                           7,501       11,461         14,571         7,276          9,058\nOperating loss                                (1,783)       (4,444)        (8,520)      (3,997)        (6,184)\nInterest                                        (394)         (118)          (145)        (104)             63\nResult before corporate income taxes         \u20ac(2,177)      \u20ac(4,562)       \u20ac(8,665)     \u20ac(4,101)       \u20ac(6,121)\n", "page_number": 37, "bounding_box": {"top_left_x": 0.11070780399274047, "top_left_y": 0.4240479246897732, "lower_right_x": 0.9147005444646098, "lower_right_y": 0.6807873341891314, "height": 0.2567394094993582, "width": 0.8039927404718693}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-37-3", "text": "Segmented Income Statement Information\n", "page_number": 37, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.6944801026957638, "lower_right_x": 0.4246823956442831, "lower_right_y": 0.7086007702182285, "height": 0.01412066752246477, "width": 0.3042952208106473}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-37-4", "text": "                                             Year ended 31 December            Six months ended 30 June\n (in thousands)                       2004            2005          2006         2006           2007\n                                                                              UNAUDITED     UNAUDITED\nContract Development gross revenues   \u20ac5,444          \u20ac6,804        \u20ac8,504       \u20ac4,112          \u20ac4,533\nOperating costs                        4,631           6,086         7,869        3,854           4,257\nOperating profit                         813             718           635          258             276\n\nInter-segment (internal) revenues        772             366         2,927           955          2,084\n\nProducts & Drug Delivery revenues       1,046             579           474          122            425\nOperating costs                         3,642           5,776         9,287        4,339          6,770\nOperating loss                        (2,596)         (5,197)       (8,813)      (4,217)        (6,345)\n", "page_number": 37, "bounding_box": {"top_left_x": 0.11070780399274047, "top_left_y": 0.7210098416773641, "lower_right_x": 0.911070780399274, "lower_right_y": 0.9071459135643988, "height": 0.18613607188703463, "width": 0.8003629764065335}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-37-5", "text": "35\n", "page_number": 37, "bounding_box": {"top_left_x": 0.8620689655172413, "top_left_y": 0.9477963200684638, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9572100984167736, "height": 0.00941377834830981, "width": 0.01875378100423475}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-38-0", "text": "Unallocated costs                    -        35      (342)        (38)     (115)\n\nConsolidated operating loss   \u20ac(1,783)   \u20ac(4,444)   \u20ac(8,520)   \u20ac(3,997)   \u20ac(6,184)\n", "page_number": 38, "bounding_box": {"top_left_x": 0.11070780399274047, "top_left_y": 0.08172871202396234, "lower_right_x": 0.9147005444646098, "lower_right_y": 0.13008130081300814, "height": 0.0483525887890458, "width": 0.8039927404718693}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-38-1", "text": "Consolidated Balance Sheet Information\n", "page_number": 38, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.1433461703038083, "lower_right_x": 0.4107683000604961, "lower_right_y": 0.1540436456996149, "height": 0.010697475395806594, "width": 0.29038112522686027}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-38-2", "text": "                                      Year ended 31 December           Six months ended 30 June\n (in thousands)                2004            2005          2006        2006           2007\n                                                                      UNAUDITED     UNAUDITED\nIntangible fixed assets        \u20ac1,421          \u20ac1,705        \u20ac1,766      \u20ac1,725          \u20ac3,018\nOther fixed assets              6,054           6,289         7,366       6,363           6,638\nCurrent assets                  1,879          12,506        23,134       8,762          15,609\nTotal assets                    9,354          20,500        32,266      16,850          25,265\n\nEquity (deficit)               (1,356)         11,751        21,142       8,456         15,317\nNon-current liabilities          4,345          3,738         3,618       3,711          3,583\nCurrent liabilities              6,365          5,011         7,506       4,683          6,365\nTotal equity and liabilities   \u20ac9,354         \u20ac20,500       \u20ac32,266     \u20ac16,850        \u20ac25,265\n", "page_number": 38, "bounding_box": {"top_left_x": 0.11070780399274047, "top_left_y": 0.16730851519041506, "lower_right_x": 0.91167574107683, "lower_right_y": 0.33975181857081727, "height": 0.1724433033804022, "width": 0.8009679370840895}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-38-3", "text": "Consolidated Cash Flow Statement Information\n", "page_number": 38, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.35216089002995293, "lower_right_x": 0.46400483968542044, "lower_right_y": 0.36499786050492083, "height": 0.012836970474967901, "width": 0.34361766485178463}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-38-4", "text": "                                              Year ended 31 December            Six months ended 30 June\n (in thousands)                        2004            2005          2006         2006           2007\n                                                                               UNAUDITED     UNAUDITED\nResult before corporate income taxes   \u20ac(2,177)      \u20ac(4,562)       \u20ac(8,665)     \u20ac(4,101)       \u20ac(6,121)\nDepreciation and amortization               860           863          1,060          512            541\nChanges in working capital                2,265       (1,037)          1,195      (1,090)          (555)\nCash flow from operating activities         948       (4,736)        (6,410)      (4,679)        (6,135)\nCash flow from investing activities       (944)       (1,218)       (13,588)        (606)          3,938\nCash flow from financing activities       (923)       16,860          17,821           29             62\nNet cash flow                             (919)       10,906         (2,177)      (5,256)        (2,135)\n\nCash at beginning of period               (757)        (1,676)         9,230        9,230          7,053\nCash at end of period                   (1,676)          9,230         7,053        3,974          4,918\nNet cash flow                            \u20ac(919)       \u20ac10,906       \u20ac(2,177)     \u20ac(5,256)       \u20ac(2,135)\n", "page_number": 38, "bounding_box": {"top_left_x": 0.11070780399274047, "top_left_y": 0.37997432605905007, "lower_right_x": 0.9086509376890503, "lower_right_y": 0.5789473684210527, "height": 0.19897304236200258, "width": 0.7979431336963098}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-38-5", "text": "36\n", "page_number": 38, "bounding_box": {"top_left_x": 0.8620689655172413, "top_left_y": 0.9482242190842961, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9572100984167736, "height": 0.00898587933247752, "width": 0.01875378100423475}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-39-0", "text": "Operating and Financial Review\n", "page_number": 39, "bounding_box": {"top_left_x": 0.33817301875378103, "top_left_y": 0.10226786478391099, "lower_right_x": 0.661826981246219, "lower_right_y": 0.11938382541720154, "height": 0.017115960633290545, "width": 0.32365396249243794}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-39-1", "text": "   You should read the following in conjunction with the \u201cSelected Financial Information\u201d, our consolidated\nfinancial statements and unaudited condensed consolidated interim financial statements and their related notes\nthat appear elsewhere in this Prospectus. Our financial statements have been prepared in accordance with\nIFRS, which may differ from US GAAP in certain significant respects as they relate to us, in particular\nregarding finance leases, intellectual property rights and business combinations. For a discussion of the most\nsignificant differences between IFRS and US GAAP as they relate to us, see \u201cSummary of Significant\nDifferences between IFRS and US GAAP\u201d.\n", "page_number": 39, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.1364997860504921, "lower_right_x": 0.8711433756805808, "lower_right_y": 0.23234916559691912, "height": 0.09584937954642703, "width": 0.7555958862673926}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-39-2", "text": "   In addition to historical information, the following review includes forward-looking information that involves\nrisks, uncertainties and assumptions. Our actual results and the timing of events could differ materially from\nthose anticipated by these forward-looking statements as a result of many factors, including those discussed\nbelow and elsewhere in this Prospectus, particularly under \u201cRisk Factors\u201d and \u201cForward-Looking\nStatements\u201d.\n", "page_number": 39, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.24604193410355157, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.31322207958921694, "height": 0.06718014548566537, "width": 0.7555958862673926}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-39-3", "text": "Overview\n", "page_number": 39, "bounding_box": {"top_left_x": 0.12159709618874773, "top_left_y": 0.3281985451433462, "lower_right_x": 0.19298245614035087, "lower_right_y": 0.34146341463414637, "height": 0.01326486949080019, "width": 0.07138535995160314}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-39-4", "text": "   We are a product-oriented biopharmaceutical company committed to the development of improved\npharmaceutical products based on our proprietary drug delivery technologies that have fewer side effects,\nincreased patient convenience and better efficacy than existing products. We currently have five product\ncandidates in development, of which two are in Phase II clinical trials. Our lead product candidate, Locteron, is\na novel interferon alfa combined with our proprietary PolyActive drug delivery technology for the treatment of\nchronic hepatitis C infection. Locteron is designed to require less frequent administration and cause fewer side\neffects than marketed forms of interferon alfa which currently represent the standard of care for this illness. We\nhave completed patient treatment in a Phase IIa study of Locteron and intend to commence a Phase IIb clinical\ntrial in the middle of 2008. We also intend to commence a separate study in the United States in a difficult-to-\ntreat patient population later this year or in the first quarter of 2008. Our second clinical-stage product candidate\nis OP-145 CSOM, a novel proprietary peptide therapeutic for the treatment of chronic otitis media, also known\nas chronic middle ear infection, that is currently in Phase II clinical trials. In addition, we have three product\ncandidates in pre-clinical development. OP-286 CR is a controlled-release formulation of a GLP-1 analogue for\nthe treatment of type II diabetes. We are also developing single shot vaccines based on our proprietary\nOctoVAX platform, HBV-OctoVAX for hepatitis B vaccination and JEV-OctoVAX for Japanese encephalitis\nvaccination.\n", "page_number": 39, "bounding_box": {"top_left_x": 0.1161524500907441, "top_left_y": 0.3547282841249465, "lower_right_x": 0.8784029038112523, "lower_right_y": 0.5759520753102267, "height": 0.22122379118528024, "width": 0.7622504537205081}, "blob_type": "paragraph", "predictions": {}, "annotations": {"description_of_the_business": ["We are a product-oriented biopharmaceutical company committed to the development of improvedpharmaceutical products based on our proprietary drug delivery technologies that have fewer side effects,increased patient convenience and better efficacy than existing products. We currently have five productcandidates in development, of which two are in Phase II clinical trials. Our lead product candidate, Locteron, isa novel interferon alfa combined with our proprietary PolyActive drug delivery technology for the treatment ofchronic hepatitis C infection. Locteron is designed to require less frequent administration and cause fewer sideeffects than marketed forms of interferon alfa which currently represent the standard of care for this illness. Wehave completed patient treatment in a Phase IIa study of Locteron and intend to commence a Phase IIb clinicaltrial in the middle of 2008. We also intend to commence a separate study in the United States in a difficult-to-treat patient population later this year or in the first quarter of 2008. Our second clinical-stage product candidateis OP-145 CSOM, a novel proprietary peptide therapeutic for the treatment of chronic otitis media, also knownas chronic middle ear infection, that is currently in Phase II clinical trials. In addition, we have three productcandidates in pre-clinical development. OP-286 CR is a controlled-release formulation of a GLP-1 analogue forthe treatment of type II diabetes. We are also developing single shot vaccines based on our proprietaryOctoVAX platform, HBV-OctoVAX for hepatitis B vaccination and JEV-OctoVAX for Japanese encephalitisvaccination."]}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-39-5", "text": "   In addition to developing our own proprietary products, we provide advanced drug formulation and clinical\nscale manufacturing services to biotechnology and pharmaceutical companies worldwide. We have provided our\nservices to more than 100 clients that have progressed more than 40 products into clinical studies and six\nproducts on to the market. Currently, approximately 70% of our revenues from this business originate in Europe,\nwhile the remainder is sourced from clients in North America, the Far East and Australia. Since our\nestablishment in 1995 through 31 August 2007, our Contract Development Business has achieved \u20ac48 million in\ncumulative gross (non-consolidated) revenues, or \u20ac41 million of consolidated revenues, which excludes internal\nrevenues generated from supporting our own drug development programs (our Products and Drug Delivery\nBusiness). We have realized a positive operating result from this business in all but one year. The earnings and\nexpertise that we derive from rendering formulation and manufacturing services (our Contract Development\nBusiness) also support us in our own drug development programs. In addition, as we increase our focus on our\nproprietary product pipeline, our Contract Development Business has increasingly provided services to our\nProducts and Drug Delivery Business. From 2004 to 2006, our Total (consolidated) revenues increased from\n\u20ac5.7 million to \u20ac6.1 million, while our Inter-segment (internal) revenues increased from \u20ac0.8 million to \u20ac2.9\nmillion.\n", "page_number": 39, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.5883611467693625, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.7933247753530167, "height": 0.20496362858365424, "width": 0.7604355716878403}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-39-6", "text": "In October 2006, we completed our IPO on Euronext Amsterdam raising \u20ac20 million in gross proceeds.\n", "page_number": 39, "bounding_box": {"top_left_x": 0.13793103448275862, "top_left_y": 0.8091570389388104, "lower_right_x": 0.8366606170598911, "lower_right_y": 0.8241335044929397, "height": 0.014976465554129237, "width": 0.6987295825771325}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-39-7", "text": "Material Factors Affecting our Results of Operations and Financial Condition\n", "page_number": 39, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.8382541720154044, "lower_right_x": 0.6817906836055656, "lower_right_y": 0.8519469405220368, "height": 0.013692768506632369, "width": 0.5614035087719298}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-39-8", "text": "  We believe that the factors described in the following paragraphs have had and are expected to continue to\nhave a material effect on our operational results and financial condition.\n", "page_number": 39, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.8523748395378691, "lower_right_x": 0.8566243194192378, "lower_right_y": 0.8925973470261018, "height": 0.04022250748823275, "width": 0.736237144585602}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-39-9", "text": "37\n", "page_number": 39, "bounding_box": {"top_left_x": 0.8620689655172413, "top_left_y": 0.9477963200684638, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9572100984167736, "height": 0.00941377834830981, "width": 0.01875378100423475}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-40-0", "text": "Revenues\n", "page_number": 40, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.08515190415062045, "lower_right_x": 0.18874773139745918, "lower_right_y": 0.09841677364142062, "height": 0.013264869490800177, "width": 0.06836055656382337}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-40-1", "text": "Contract Development Business\n", "page_number": 40, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.11253744116388532, "lower_right_x": 0.34361766485178463, "lower_right_y": 0.12665810868635002, "height": 0.0141206675224647, "width": 0.22323049001814882}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-40-2", "text": "   Since our establishment in 1995 through 31 August 2007, our Contract Development Business has achieved\n\u20ac48 million in cumulative gross (non-consolidated) service revenues, including \u20ac7 million in Inter-segment\n(internal) revenues.\n", "page_number": 40, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.1399229781771502, "lower_right_x": 0.8663036902601331, "lower_right_y": 0.18142918271287975, "height": 0.04150620453572956, "width": 0.7459165154264973}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-40-3", "text": "   Since 2004, our Contract Development Business has provided active pharmaceutical formulation and\nmanufacturing services in relation to at least 30 different projects per year. These services typically include\nformulation, scale-up, manufacturing and stability testing of proteins, peptides and other large molecules for our\npharmaceutical and biotechnology clients. Annually, we commence work on approximately ten new projects\nand we have benefited to a significant extent from repeat business from our existing client base. Revenues per\nproject generally range from approximately \u20ac25,000 to \u20ac1.5 million. Typically, our clients are charged on an\nemployee man/hour basis for our development services, while manufacturing is charged on a lump-sum basis.\n\n   Our Contract Development Business is dependent on the overall development activity in the pharmaceutical\nand biotechnology sectors. In particular, in times when financing conditions for biotechnology companies are\nless favorable, our Contract Development Business typically experiences slower growth. Conversely, when\nfinancing is more readily available to fund development projects, our Contract Development Business grows\nmore rapidly.\n\n   In addition, the growth of our Contract Development Business is related to our ability to increase our capacity\nin terms of human and physical resources. If we were able to recruit a greater number of qualified personnel, we\nbelieve we would be able to grow our business more rapidly. During the period under review, we have generally\nexperienced an excess of demand for our Contract Development Business.\n", "page_number": 40, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.1951219512195122, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.44458707744972187, "height": 0.24946512623020967, "width": 0.7604355716878403}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-40-4", "text": "   Our Contract Development Business revenues tend to be concentrated, with a limited number of large\ncustomer assignments generating a significant percentage of revenues in any given year. Our largest customers\ndo, however, tend to change over time, as our large projects tend to last from two to five years on average, and\nare often then replaced by projects for different customers. Nevertheless, the loss of a large project can have a\nsignificant impact on our results, particularly if not replaced quickly by other projects. In 2006, we generated\napproximately 56% of our Total (consolidated) revenues in the Contract Development Business from our five\nlargest clients.\n", "page_number": 40, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.4582798459563543, "lower_right_x": 0.8663036902601331, "lower_right_y": 0.5541292255027813, "height": 0.09584937954642703, "width": 0.7459165154264973}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-40-5", "text": "Products and Drug Delivery Business\n", "page_number": 40, "bounding_box": {"top_left_x": 0.11857229280096794, "top_left_y": 0.5678219940094138, "lower_right_x": 0.38173018753781, "lower_right_y": 0.5819426615318785, "height": 0.014120667522464658, "width": 0.2631578947368421}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-40-6", "text": "   In addition to revenues from our Contract Development Business, since our establishment through 30 June\n2007, we have received \u20ac2.7 million in subsidies from the Dutch Ministry of Economic Affairs and the\nEuropean Union. Certain projects were completed or discontinued without utilizing the full amount of the\nsubsidy available. We remain eligible to receive a further \u20ac2.2 million pursuant to these grants. We do not\nforesee any immediate change in our ability to secure and draw down subsidy revenues.\n", "page_number": 40, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.5952075310226786, "lower_right_x": 0.8566243194192378, "lower_right_y": 0.6640992725716731, "height": 0.06889174154899447, "width": 0.736237144585602}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-40-7", "text": "   In addition, we have generated nominal revenues based on certain development and licensing agreements\nconcerning our product candidates and technologies. Our ability to generate additional royalty and license\nrevenues will depend on the continued success of our existing collaborations and our ability to enter into further\narrangements for the out-licensing of our technologies and product candidates.\n", "page_number": 40, "bounding_box": {"top_left_x": 0.12099213551119177, "top_left_y": 0.6773641420624733, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.7325631151048353, "height": 0.05519897304236199, "width": 0.7549909255898366}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-40-8", "text": "   In 2004, we entered into an agreement with SurModics, Inc. (\u201cSurModics\u201d) regarding the out-licensing of\ncertain applications in the field of drug-eluting medical devices based on our OctoDEX and PolyActive\ntechnologies. This agreement was replaced in 2007 by an agreement for the out-licensing of certain applications\nin the field of drug-eluting medical devices based on our PolyActive technology only. In accordance with our\nagreement with SurModics, we have received up-front and licensing fees and will continue to receive certain\nongoing licensing fees. Since 1 July 2006, we have also been entitled to royalties on sales of products\nincorporating our technologies made by SurModics and on royalty payments received by SurModics pursuant to\nthird party license agreements relying on our technologies and from 1 April 2012, we will be entitled to annual\nminimum royalty payments for the remaining term of the agreement.\n", "page_number": 40, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.7458279845956355, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.8694908001711597, "height": 0.12366281557552417, "width": 0.7555958862673926}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-40-9", "text": "38\n", "page_number": 40, "bounding_box": {"top_left_x": 0.8620689655172413, "top_left_y": 0.9482242190842961, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9572100984167736, "height": 0.00898587933247752, "width": 0.01875378100423475}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-41-0", "text": "   In November 2006, we granted a license to Green Cross Corporation of South Korea for the co-development\nand exclusive commercialization of OP-145 CSOM in the South Korean market for the treatment of chronic\nmiddle ear infection. In accordance with our agreement with Green Cross Corporation, we have received a\nnominal up-front milestone payment and may continue to receive ongoing milestone payments. In addition to\nthese milestone payments, Green Cross Corporation will be obligated to pay us certain royalties based on gross\nreceipts for sales of OP-145 CSOM by Green Cross Corporation. The exact royalty rate will be determined\npursuant to a formula set forth in the agreement, which we anticipate to result in a low double digit royalty rate.\nFurthermore, we are entitled to 50% of any amounts that Green Cross Corporation receives from its\nsublicensees.\n", "page_number": 41, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.08515190415062045, "lower_right_x": 0.8711433756805808, "lower_right_y": 0.20539152759948653, "height": 0.12023962344886609, "width": 0.7507562008469449}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-41-1", "text": "Operating Costs\n", "page_number": 41, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.2220795892169448, "lower_right_x": 0.24077434966727163, "lower_right_y": 0.2362002567394095, "height": 0.014120667522464714, "width": 0.12038717483363581}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-41-2", "text": "   Our operating costs consist of five categories: Raw materials and auxiliaries (primarily our polymers and\nactive pharmaceutical ingredients); Cost of contracted work and other external charges (primarily related to\nservices performed by contract research organizations); Employee benefits (primarily salaries and benefits);\nDepreciation and amortization; and Other costs (related to other personnel costs such as temporary personnel,\nrecruitment fees and training expenditures, marketing expenditures, professional advisors and general overhead,\nsuch as premises costs and office expenses). While we do not separately account for research and development\ncosts, we consider Raw materials and auxiliaries, Cost of contracted work and other external charges and\nEmployee benefits, to represent the majority of our research and development costs. Our direct and indirect\ncosts related to research and development in 2006, 2005 and 2004 amounted to \u20ac9.3 million, \u20ac5.8 million and\n\u20ac3.7 million, respectively.\n", "page_number": 41, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.24946512623020967, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.38682071031236626, "height": 0.1373555840821566, "width": 0.7555958862673926}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-41-3", "text": "   Raw materials and auxiliaries, as well as Cost of contracted work and other external charges, are allocated to\nour two business units as they are incurred. Employee benefits, Depreciation and amortization and Other costs\nare allocated to our two business units on the basis of the number of full time employees in each business unit.\n", "page_number": 41, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.40008557980316645, "lower_right_x": 0.8711433756805808, "lower_right_y": 0.441591784338896, "height": 0.04150620453572956, "width": 0.7507562008469449}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-41-4", "text": "  Approximately 1% of our total 2006 operating costs were related to Raw materials and auxiliaries.\nApproximately 13% of our total 2006 operating costs were related to Cost of contracted work and other external\ncharges. Approximately 43% of our total 2006 operating costs were related to Employee benefits.\nApproximately 7% of our total 2006 operating costs were related to Depreciation and amortization.\nApproximately 36% of our total 2006 operating costs were related to Other costs.\n", "page_number": 41, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.4548566538296962, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.5254599914420197, "height": 0.07060333761232351, "width": 0.7555958862673926}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-41-5", "text": "Results of Operations 2004, 2005, 2006 and Six Months Ended 30 June 2006 and 2007\n", "page_number": 41, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.540436456996149, "lower_right_x": 0.735632183908046, "lower_right_y": 0.553701326486949, "height": 0.01326486949080008, "width": 0.6152450090744102}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-41-6", "text": "Six Months Ended 30 June 2006 and 2007\n", "page_number": 41, "bounding_box": {"top_left_x": 0.11675741076830005, "top_left_y": 0.5678219940094138, "lower_right_x": 0.41984271022383546, "lower_right_y": 0.5785194694052204, "height": 0.010697475395806566, "width": 0.3030852994555354}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-41-7", "text": "Revenues (in thousands)                Six months ended 30 June                Change\n                                       2006                2007        \u20ac                %\n                                    (unaudited)        (unaudited)\nGross service revenues                   \u20ac4,112              \u20ac4,627           \u20ac515        13%\nInter-segment (internal) revenues         (955)              (2,084)       (1,129)         118\nConsolidated service revenues             3,157                2,543         (614)        (19)\nRoyalty and license revenues                 30                  213           183         610\nIncome from subsidies                        92                  118            26          28\nTotal (consolidated) revenues            \u20ac3,279              \u20ac2,874         \u20ac(405)      (12)%\n", "page_number": 41, "bounding_box": {"top_left_x": 0.10647307924984876, "top_left_y": 0.5917843388960206, "lower_right_x": 0.8905021173623714, "lower_right_y": 0.7222935387248609, "height": 0.13050919982884035, "width": 0.7840290381125227}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-41-8", "text": "   Gross service revenues increased by 13% as a result of increased capacity in our Contract Development\nBusiness due to additional hirings. Inter-segment (internal) revenues increased by 118% as a result of an\nincreased level of services provided by our Contract Development Business to our Products and Drug Delivery\nBusiness primarily for the development of Locteron and OP-145 CSOM. Consolidated service revenues\ndeclined by 19%, as a result of a shift of focus to supporting the development of our own product candidates.\n", "page_number": 41, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.7355584082156611, "lower_right_x": 0.8711433756805808, "lower_right_y": 0.8044501497646556, "height": 0.06889174154899447, "width": 0.7507562008469449}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-41-9", "text": "   Royalty and license revenues increased by 610% primarily as a result of increased payments by SurModics,\nafter the commencement of annual royalty payments under our agreement with SurModics in the second half of\n2006.\n", "page_number": 41, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.8177150192554558, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.8557980316645272, "height": 0.038083012409071415, "width": 0.7555958862673926}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-41-10", "text": "  Income from subsidies increased by 28% primarily as a result of higher subsidies received for a study we are\nconducting with Utrecht University for a novel drug delivery technology.\n", "page_number": 41, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.8724860932819855, "lower_right_x": 0.8705384150030248, "lower_right_y": 0.9002995293110826, "height": 0.02781343602909714, "width": 0.7501512401693889}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-41-11", "text": "39\n", "page_number": 41, "bounding_box": {"top_left_x": 0.8620689655172413, "top_left_y": 0.9477963200684638, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9572100984167736, "height": 0.00941377834830981, "width": 0.01875378100423475}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-42-0", "text": "Operating Costs (in thousands)                         Six months ended 30 June         Change\n                                                        2006              2007      \u20ac            %\n                                                     (unaudited)      (unaudited)\nRaw materials and auxiliaries                               \u20ac100            \u20ac191       \u20ac91           91%\nCost of contracted work and other external charges         1,147            1,403      256             22\nEmployee benefits                                          2,920            3,993    1,073             37\nDepreciation and amortization                                512              541       29              6\nOther costs                                                2,597            2,930      333             13\nTotal operating costs                                     \u20ac7,276           \u20ac9,058   \u20ac1,782           24%\n", "page_number": 42, "bounding_box": {"top_left_x": 0.11070780399274047, "top_left_y": 0.08258451005562688, "lower_right_x": 0.9165154264972777, "lower_right_y": 0.20881471972614463, "height": 0.12623020967051773, "width": 0.8058076225045372}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-42-1", "text": "  Raw materials and auxiliaries increased by 91%. Although a portion of this increase was due to increases in\nraw materials and auxiliaries used by our Contract Development Business in line with revenue growth, the\nmajority of the increase was due to increased development activities and materials used in our clinical trials for\nLocteron and OP-145 CSOM.\n", "page_number": 42, "bounding_box": {"top_left_x": 0.12099213551119177, "top_left_y": 0.2220795892169448, "lower_right_x": 0.8705384150030248, "lower_right_y": 0.27556696619597776, "height": 0.05348737697903297, "width": 0.749546279491833}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-42-2", "text": "   Cost of contracted work and other external charges increased by 22%, mainly as a result of the clinical trials\nfor Locteron and OP-145 CSOM.\n", "page_number": 42, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.290543431750107, "lower_right_x": 0.8656987295825771, "lower_right_y": 0.3170731707317073, "height": 0.026529738981600326, "width": 0.7453115547489413}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-42-3", "text": "   Employee benefits increased by 37%, predominantly as a result of the increase in staff from 125 employees\nas of 30 June 2006 to 153 employees as of 30 June 2007. The increase predominantly reflects the increase in\nemployees for the development of all of our product candidates.\n", "page_number": 42, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.33162173727000427, "lower_right_x": 0.8614640048396854, "lower_right_y": 0.3748395378690629, "height": 0.04321780059905861, "width": 0.7410768300060496}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-42-4", "text": "   Other costs increased by 13%, mainly due to greater overhead and equipment expenses as a result of an\nincrease in our number of staff.\n", "page_number": 42, "bounding_box": {"top_left_x": 0.12159709618874773, "top_left_y": 0.3898160034231921, "lower_right_x": 0.837265577737447, "lower_right_y": 0.41420624732563116, "height": 0.024390243902439046, "width": 0.7156684815486993}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-42-5", "text": "Years Ended 31 December 2005 and 2006\n", "page_number": 42, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.43089430894308944, "lower_right_x": 0.411373260738052, "lower_right_y": 0.441591784338896, "height": 0.010697475395806566, "width": 0.2909860859044162}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-42-6", "text": "Revenues (in thousands)             Year ended 31 December           Change\n                                    2005              2006      \u20ac             %\nGross service revenues                \u20ac6,929          \u20ac8,514    \u20ac1,585          23%\nInter-segment (internal) revenues      (366)          (2,927)   (2,561)          700\nConsolidated service revenues          6,563            5,587     (976)         (15)\nRoyalty and license revenues              60              332       272          453\nIncome from subsidies                    394              132     (262)         (66)\nTotal (consolidated) revenues         \u20ac7,017          \u20ac6,051     \u20ac(966)       (14)%\n", "page_number": 42, "bounding_box": {"top_left_x": 0.11070780399274047, "top_left_y": 0.4548566538296962, "lower_right_x": 0.9195402298850575, "lower_right_y": 0.566538296961917, "height": 0.11168164313222084, "width": 0.808832425892317}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-42-7", "text": "   Gross service revenues increased by 23%, primarily as a result of increased capacity in our Contract\nDevelopment Business, increased efficiency in our manufacturing facilities, increased internal demand for the\ndevelopment of our product candidates and a strong business environment for pharmaceutical services. During\nthis period, a significant part of the Contract Development Business supported the Products and Drug Delivery\nBusiness in the preparation of our Phase II clinical trials for Locteron and OP-145 CSOM, resulting in an\nincrease in Inter-segment (internal) revenues of 700%. Consolidated service revenues declined by 15%, as a\nresult of a shift of focus to supporting the development of our own product candidates.\n", "page_number": 42, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.5815147625160462, "lower_right_x": 0.8663036902601331, "lower_right_y": 0.6773641420624733, "height": 0.09584937954642714, "width": 0.7459165154264973}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-42-8", "text": "  Royalty and license revenues increased by 453%, as a result of the commencement of annual payments by\nSurModics in the second half of 2006.\n", "page_number": 42, "bounding_box": {"top_left_x": 0.12099213551119177, "top_left_y": 0.6910569105691057, "lower_right_x": 0.8566243194192378, "lower_right_y": 0.7154471544715447, "height": 0.024390243902439046, "width": 0.735632183908046}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-42-9", "text": "   Income from subsidies decreased by 66% primarily due to the completion of the subsidized portion of our\nhGH-OctoDEX product development program in the first quarter of 2005. In August 2007, we decided to\ndiscontinue development of our product candidate for controlled release of human growth hormone, hGH-\nOctoDEX, which had been, in Phase I clinical trials, in order to re-allocate our resources to our other product\ncandidates, which we believe will have greater commercial potential in light of the increasingly competitive\nmarket for human growth hormone. In addition, another subsidized pre-clinical research project was cancelled\nin the beginning of 2006.\n", "page_number": 42, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.732135216089003, "lower_right_x": 0.8632788868723533, "lower_right_y": 0.8284124946512623, "height": 0.09627727856225932, "width": 0.7428917120387175}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-42-10", "text": "40\n", "page_number": 42, "bounding_box": {"top_left_x": 0.8608590441621294, "top_left_y": 0.9477963200684638, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9572100984167736, "height": 0.00941377834830981, "width": 0.019963702359346636}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-43-0", "text": "Operating Costs (in thousands)                       Year ended 31 December          Change\n                                                     2005              2006      \u20ac            %\nRaw materials and auxiliaries                            \u20ac237            \u20ac180     \u20ac(57)       (24)%\nCost of contracted work and other external charges      1,390            1,928      538          39\nEmployee benefits                                       4,758            6,140    1,382          29\nDepreciation and amortization                             863            1,060      197          23\nOther costs                                             4,213            5,263    1,050          25\nTotal operating costs                                 \u20ac11,461          \u20ac14,571   \u20ac3,110        27%\n", "page_number": 43, "bounding_box": {"top_left_x": 0.11070780399274047, "top_left_y": 0.09542148053059478, "lower_right_x": 0.9165154264972777, "lower_right_y": 0.20539152759948653, "height": 0.10997004706889175, "width": 0.8058076225045372}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-43-1", "text": "  Raw materials and auxiliaries decreased by 24%, due to reduced purchases of interferon alfa in 2006\ncompared to 2005, following our entering into a collaboration agreement with Biolex under which Biolex\nprovides us with its proprietary interferon alfa.\n", "page_number": 43, "bounding_box": {"top_left_x": 0.12099213551119177, "top_left_y": 0.2186563970902867, "lower_right_x": 0.8324258923169994, "lower_right_y": 0.2601626016260163, "height": 0.04150620453572959, "width": 0.7114337568058076}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-43-2", "text": "  Cost of contracted work and other external charges increased by 39% primarily related to expenditures for the\ndevelopment of our product candidates. In particular, we incurred greater costs from the contract research\norganizations managing our clinical and pre-clinical trial activities, largely related to Locteron.\n", "page_number": 43, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.2734274711168164, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.314933675652546, "height": 0.04150620453572956, "width": 0.7604355716878403}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-43-3", "text": "  Employee benefits increased by 29% as a result of an increase in our number of staff from 110 as of 31\nDecember 2005 to 139 as of 31 December 2006.\n", "page_number": 43, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.33162173727000427, "lower_right_x": 0.8324258923169994, "lower_right_y": 0.355584082156611, "height": 0.023962344886606757, "width": 0.7120387174833636}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-43-4", "text": "   Other costs increased by 25%, mainly due to greater overhead and equipment expenses as a result of an\nincrease in our number of staff.\n", "page_number": 43, "bounding_box": {"top_left_x": 0.12159709618874773, "top_left_y": 0.3727000427899016, "lower_right_x": 0.8366606170598911, "lower_right_y": 0.3970902866923406, "height": 0.02439024390243899, "width": 0.7150635208711434}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-43-5", "text": "Years Ended 31 December 2004 and 2005\n", "page_number": 43, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.41377834830979887, "lower_right_x": 0.411373260738052, "lower_right_y": 0.4244758237056055, "height": 0.010697475395806622, "width": 0.2909860859044162}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-43-6", "text": "Revenues (in thousands)             Year ended 31 December          Change\n                                    2004              2005      \u20ac            %\nGross service revenues                \u20ac5,717           \u20ac6,929   \u20ac1,212            21%\nInter-segment (internal) revenues      (793)            (366)      427             (54)\nConsolidated service revenues          4,924            6,563    1,639               33\nRoyalty and license revenues              60               60        -                -\nIncome from subsidies                    708              394    (314)             (44)\nOther income                              26                -     (26)           (100)\nTotal (consolidated) revenues         \u20ac5,718           \u20ac7,017   \u20ac1,299            23%\n", "page_number": 43, "bounding_box": {"top_left_x": 0.11070780399274047, "top_left_y": 0.43774069319640563, "lower_right_x": 0.9165154264972777, "lower_right_y": 0.5639709028669234, "height": 0.1262302096705178, "width": 0.8058076225045372}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-43-7", "text": "  Gross service revenues increased by 21%, primarily as a result of a strong business environment for\npharmaceutical services and increased capacity in our Contract Development Business. We also commenced\nwork on 11 new projects during this period. Inter-segment (internal) revenues declined by 54% during this\nperiod, primarily due to our decision to terminate a pre-clinical research project at the end of 2004. In total,\nConsolidated service revenues increased by 33%.\n", "page_number": 43, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.5780915703893881, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.6469833119383825, "height": 0.06889174154899447, "width": 0.7313974591651543}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-43-8", "text": "   Royalty and license revenues in 2004 and 2005 reflect ongoing payments from SurModics pursuant to our\nlicense agreement covering the use of certain of our technologies in the area of drug-eluting medical devices.\n", "page_number": 43, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.6602481814291827, "lower_right_x": 0.8566243194192378, "lower_right_y": 0.6880616174582799, "height": 0.02781343602909714, "width": 0.736237144585602}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-43-9", "text": "   Income from subsidies declined because we completed subsidized work related to the hGH-OctoDEX project\nin the first quarter of 2005. Furthermore, a pre-clinical research project was terminated in the first quarter of\n2005, which involved subsidies from the Dutch Ministry of Economic Affairs.\n", "page_number": 43, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.7013264869490801, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.7428326914848096, "height": 0.04150620453572951, "width": 0.7555958862673926}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-43-10", "text": "Operating Costs (in thousands)                       Year ended 31 December          Change\n                                                     2004              2005      \u20ac            %\nRaw materials and auxiliaries                             \u20ac70            \u20ac237      \u20ac167           239%\nCost of contracted work and other external charges        307            1,390    1,083             353\nEmployee benefits                                       3,597            4,758    1,161              32\nDepreciation and amortization                             860              863        3               0\nOther costs                                             2,667            4,213    1,546              58\nTotal operating costs                                  \u20ac7,501          \u20ac11,461   \u20ac3,960            53%\n", "page_number": 43, "bounding_box": {"top_left_x": 0.11070780399274047, "top_left_y": 0.766367137355584, "lower_right_x": 0.9165154264972777, "lower_right_y": 0.8780487804878049, "height": 0.11168164313222084, "width": 0.8058076225045372}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-43-11", "text": "41\n", "page_number": 43, "bounding_box": {"top_left_x": 0.8608590441621294, "top_left_y": 0.9477963200684638, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9572100984167736, "height": 0.00941377834830981, "width": 0.019963702359346636}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-44-0", "text": "  Raw materials and auxiliaries increased by 239%, primarily due to increased development activities, in\nparticular, due to the purchase of interferon alfa.\n", "page_number": 44, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.08515190415062045, "lower_right_x": 0.8312159709618875, "lower_right_y": 0.11296534017971759, "height": 0.02781343602909714, "width": 0.7108287961282517}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-44-1", "text": "  Cost of contracted work and other external charges also increased due to greater activity involving the\ndevelopment of our product candidates. In particular, we incurred greater costs from the contract research\norganizations managing our clinical and pre-clinical trial activities, largely related to Locteron.\n", "page_number": 44, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.12623020967051776, "lower_right_x": 0.8318209316394435, "lower_right_y": 0.16773641420624733, "height": 0.04150620453572956, "width": 0.7114337568058077}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-44-2", "text": "   Employee benefits increased by 32%, due to an increase in the number of our employees from 93 as of 31\nDecember 2004 to 110 as of 31 December 2005. In addition, certain of our employees received benefit increases\nin 2004, in line with local employment trends.\n", "page_number": 44, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.1810012836970475, "lower_right_x": 0.8802177858439202, "lower_right_y": 0.22250748823277705, "height": 0.04150620453572956, "width": 0.7598306110102844}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-44-3", "text": "   Other costs increased by 58%, partly due to greater overhead and equipment expenses as a result of an\nincrease in our number of staff. Furthermore, we increased manufacturing activity in our pilot plant and we\nincurred additional expenses in relation to temporary personnel services and professional recruitment charges.\n", "page_number": 44, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.23577235772357724, "lower_right_x": 0.8608590441621294, "lower_right_y": 0.2772785622593068, "height": 0.04150620453572956, "width": 0.7404718693284936}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-44-4", "text": "Interest\n", "page_number": 44, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.2939666238767651, "lower_right_x": 0.17906836055656383, "lower_right_y": 0.30466409927257165, "height": 0.010697475395806566, "width": 0.05868118572292802}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-44-5", "text": "Interest Costs\n", "page_number": 44, "bounding_box": {"top_left_x": 0.1161524500907441, "top_left_y": 0.32135216089002994, "lower_right_x": 0.2177858439201452, "lower_right_y": 0.33204963628583656, "height": 0.010697475395806622, "width": 0.10163339382940109}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-44-6", "text": "   In April 2004, we acquired our main building, which we subsequently sold and leased back. A significant part\nof our interest costs in 2004 of \u20ac412,000 relates to this finance lease contract. The remaining part relates to\ninterest associated with other finance lease contracts and interest related to the utilization of part of our \u20ac2.0\nmillion credit facility, which we obtained from ABN AMRO Bank N.V. in 2004.\n", "page_number": 44, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.34873769790329484, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.40350877192982454, "height": 0.0547710740265297, "width": 0.7604355716878403}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-44-7", "text": "   In 2005, we repaid all the amounts drawn down under the \u20ac2.0 million credit facility with ABN AMRO Bank\nN.V., though this facility remains available to us. We did not have any other substantial debts in 2005. Interest\ncosts for 2005 amounted to \u20ac405,000 and primarily reflect the interest expenses associated with the finance\nlease contract for our main building and other finance lease contracts for our property, plant and equipment.\n", "page_number": 44, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.417201540436457, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.472400513478819, "height": 0.05519897304236199, "width": 0.7555958862673926}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-44-8", "text": "  In 2006, the interest costs of \u20ac391,000 were also mainly related to the finance lease contracts for our\nproperty, plant and equipment.\n", "page_number": 44, "bounding_box": {"top_left_x": 0.12099213551119177, "top_left_y": 0.4856653829696192, "lower_right_x": 0.8173018753781004, "lower_right_y": 0.5134788189987163, "height": 0.027813436029097083, "width": 0.6963097398669086}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-44-9", "text": "   For the six months ended 30 June 2007, the interest costs of \u20ac203,000 were also mainly related to the finance\nlease contracts for our property, plant and equipment.\n", "page_number": 44, "bounding_box": {"top_left_x": 0.12159709618874773, "top_left_y": 0.5267436884895165, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.5545571245186136, "height": 0.02781343602909714, "width": 0.7543859649122807}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-44-10", "text": "Interest Income\n", "page_number": 44, "bounding_box": {"top_left_x": 0.1161524500907441, "top_left_y": 0.5712451861360719, "lower_right_x": 0.2323049001814882, "lower_right_y": 0.5819426615318785, "height": 0.010697475395806566, "width": 0.1161524500907441}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-44-11", "text": "   Interest income reflects interest earned on our deposits of cash in interest bearing accounts. Interest income\nfor the six months ended 30 June 2007 and the years 2006, 2005 and 2004 amounted to \u20ac266,000, \u20ac246,000,\n\u20ac287,000 and \u20ac18,000, respectively.\n", "page_number": 44, "bounding_box": {"top_left_x": 0.12099213551119177, "top_left_y": 0.5986307231493367, "lower_right_x": 0.8614640048396854, "lower_right_y": 0.6401369276850664, "height": 0.04150620453572962, "width": 0.7404718693284936}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-44-12", "text": "Liquidity and Capital Resources\n", "page_number": 44, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.6534017971758665, "lower_right_x": 0.352692075015124, "lower_right_y": 0.6670945656824989, "height": 0.013692768506632369, "width": 0.2323049001814882}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-44-13", "text": "   Our primary sources of liquidity have been our funds generated from our Contract Development Business and\nequity and debt financing. We have also received some government subsidies and have generated limited license\nrevenues. With our change of focus from contract development to the development of proprietary product\ncandidates using our drug delivery technologies from the year 2000 onwards, our capital requirements have\nincreased and equity fund raising has been an increasingly important source of our liquidity.\n", "page_number": 44, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.6807873341891314, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.7496790757381258, "height": 0.06889174154899436, "width": 0.7604355716878403}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-44-14", "text": "   Following our incorporation in 1995, we completed our first equity financing round in December 2001, when\ntwo Dutch based venture capital investors, NPM Capital N.V. and 7X Life Sciences B.V., purchased ordinary\nshares for \u20ac3.0 million. The proceeds of this financing round were utilized to develop our proprietary\ntechnology platforms, OctoDEX and PolyActive.\n", "page_number": 44, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.762943945228926, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.8181429182712879, "height": 0.05519897304236199, "width": 0.7555958862673926}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-44-15", "text": "   Our acquisition of Chienna in March 2003 had a significant impact on our capital resources, due to the up-\nfront costs of the acquisition as well as costs due to Chienna\u2019s ongoing operating expenses.\n", "page_number": 44, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.8314077877620881, "lower_right_x": 0.8560193587416818, "lower_right_y": 0.8592212237911853, "height": 0.02781343602909714, "width": 0.735632183908046}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 16, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-44-16", "text": "  In September 2004, through our subsidiary OctoPlus Development B.V. we increased amounts available\nunder our credit facilities from \u20ac981,000 to \u20ac2.0 million through entering into a new facility with ABN AMRO\nBank N.V. This credit line remains available to us. As collateral for this facility, OctoPlus Development B.V.\n", "page_number": 44, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.8724860932819855, "lower_right_x": 0.868723532970357, "lower_right_y": 0.9139922978177151, "height": 0.04150620453572962, "width": 0.7483363581367212}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 17, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-44-17", "text": "42\n", "page_number": 44, "bounding_box": {"top_left_x": 0.8608590441621294, "top_left_y": 0.9477963200684638, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9572100984167736, "height": 0.00941377834830981, "width": 0.019963702359346636}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-45-0", "text": "provided a pledge over its equipment, inventories and receivables. OctoPlus N.V. is jointly and severally liable\nfor the debt. In addition, the facility agreement contains a covenant that requires that OctoPlus Development\nB.V.\u2019s shareholders equity shall equal at least 25% of its total assets.\n", "page_number": 45, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.08515190415062045, "lower_right_x": 0.8699334543254689, "lower_right_y": 0.12665810868635002, "height": 0.04150620453572958, "width": 0.7495462794918331}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-45-1", "text": "   In January 2005, we issued 6,861,500 preference shares (which were converted into ordinary shares pursuant\nto the Capital Restructuring; see under \u201cImportant Information \u2013 Presentation of Financial and Other\nInformation\u201d) and a subordinated convertible bond, raising a total of \u20ac18.4 million. Investors in this round of\nfinancing included Life Sciences Partners B.V., S.R. One, Limited, Innoven Partenaires S.A., Fortis N.V./S.A.,\nSurModics and several members of our management team. The stated use of proceeds of the 2005 financing\nincluded the further development of our proprietary technologies and our portfolio of product candidates.\n", "page_number": 45, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.1399229781771502, "lower_right_x": 0.8753781004234725, "lower_right_y": 0.22250748823277705, "height": 0.08258451005562686, "width": 0.7549909255898367}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-45-2", "text": "   In June 2006, we issued a further 278,600 preference shares (which were converted into ordinary shares\npursuant to the Capital Restructuring; see \u201cImportant Information \u2013 Presentation of Financial and Other\nInformation\u201d) and a subordinated convertible bond as part of a second closing related to the January 2005\nfinancing round. As a result, we raised an additional \u20ac0.7 million, which was received in July 2006.\n", "page_number": 45, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.23577235772357724, "lower_right_x": 0.8366606170598911, "lower_right_y": 0.29097133076593923, "height": 0.05519897304236199, "width": 0.7162734422262553}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-45-3", "text": "  On 9 October 2006, we issued 4,301,076 ordinary shares pursuant to our IPO and raised \u20ac20 million in gross\nproceeds.\n", "page_number": 45, "bounding_box": {"top_left_x": 0.12099213551119177, "top_left_y": 0.3042362002567394, "lower_right_x": 0.8711433756805808, "lower_right_y": 0.33204963628583656, "height": 0.02781343602909714, "width": 0.7501512401693889}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-45-4", "text": "Cash Flows\n", "page_number": 45, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.34873769790329484, "lower_right_x": 0.20326678765880218, "lower_right_y": 0.3594351732991014, "height": 0.010697475395806566, "width": 0.08287961282516637}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-45-5", "text": "   In 2004, we reported a positive net cash flow from operating activities amounting to \u20ac948,000. As a result of\ninvestments in plant and equipment, we reported a negative cash flow from investment of \u20ac944,000, while the\nredemption of various borrowings resulted in a further \u20ac923,000 negative net cash flow. As a result we posted a\nnegative net cash flow in 2004 of \u20ac919,000.\n", "page_number": 45, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.3761232349165597, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.4300385109114249, "height": 0.05391527599486523, "width": 0.7555958862673926}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-45-6", "text": "   In 2005, we reported a negative net cash flow from operating activities of \u20ac4.8 million. Investments in plant\nand equipment and intangible assets amounted to \u20ac1.2 million. Net positive cash flow from all financing\nactivities, including the issue of equity and a subordinated convertible bond, repayment of finance lease\nobligations and repayment of borrowings outstanding under our credit facility amounted to \u20ac16.9 million. As a\nresult, the positive net cash flow from all operating, investing and financing activities in 2005 was \u20ac10.9 million.\n", "page_number": 45, "bounding_box": {"top_left_x": 0.12099213551119177, "top_left_y": 0.44458707744972187, "lower_right_x": 0.8790078644888082, "lower_right_y": 0.513050919982884, "height": 0.06846384253316212, "width": 0.7580157289776164}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-45-7", "text": "   In 2006, we reported a negative net cash flow from operating activities of \u20ac6.4 million. Investments in plant\nand equipment and intangible assets amounted to \u20ac1.1 million and \u20ac12.5 million of the IPO proceeds were\ninvested in short-term and long-term deposits, resulting in a negative net cash flow from investing activities of\n\u20ac13.6 million. The positive net cash flow from financing activities amounted to \u20ac17.8 million, and all related to\nour IPO. As a result, the negative net cash flow from all operating, investing and financing activities in 2006\nwas \u20ac2.2 million. Cash, cash equivalents, deposits and bank overdrafts increased from \u20ac9.2 million to \u20ac19.6\nmillion during the year in 2006.\n", "page_number": 45, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.5267436884895165, "lower_right_x": 0.8711433756805808, "lower_right_y": 0.6225930680359435, "height": 0.09584937954642703, "width": 0.7507562008469449}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-45-8", "text": "   In the first half of 2007, we reported a negative net cash flow from operating activities of \u20ac6.1 million.\nInvestments in intangible and tangible assets amounted to \u20ac2.0 million in total, of which \u20ac1.3 million related to\nthe additional patents acquired from IsoTis N.V. (\u201cIsoTis\u201d) in April 2007. Matured deposits amounting to \u20ac5.9\nmillion are also reflected in the cash flow from investing activities, resulting in a reported \u20ac3.9 million positive\nnet cash flow from investing activities for the first half of 2007. The exercise of options resulted in a \u20ac0.1\nmillion positive cash flow received from financing activities. As a result, the total negative net cash flow from\nall operating, investing and financing activities in the first half of 2007 was \u20ac2.1 million. Cash, cash equivalents,\ndeposits and bank overdrafts decreased from \u20ac19.6 million to \u20ac11.5 million during the first half of 2007.\n", "page_number": 45, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.636285836542576, "lower_right_x": 0.8796128251663642, "lower_right_y": 0.7462558836114677, "height": 0.10997004706889169, "width": 0.7592256503327284}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-45-9", "text": "   Since 2002, our expenses in technology and product development have exceeded net operating profits from\nour Contract Development Business. For the next several years, we expect expenses for technology and product\ndevelopment to significantly exceed the net cash flow from our Contract Development Business. We believe the\ncosts for the pre-clinical and clinical trials of our product candidates will exceed any income that we may\nreceive from subsidies and license revenues under our current agreements. In addition to a consolidated net\noperating loss, we expect to make significant investments in equipment for expanding our facilities.\n", "page_number": 45, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.7595207531022679, "lower_right_x": 0.8753781004234725, "lower_right_y": 0.8421052631578947, "height": 0.08258451005562684, "width": 0.7549909255898367}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-45-10", "text": "Principal Investments\n", "page_number": 45, "bounding_box": {"top_left_x": 0.11736237144585603, "top_left_y": 0.8553701326486949, "lower_right_x": 0.27586206896551724, "lower_right_y": 0.8694908001711597, "height": 0.01412066752246477, "width": 0.1584996975196612}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-45-11", "text": "   In 2004, our investments in plant and equipment and intangible assets amounted to \u20ac944,000. The majority of\nthis amount relates to equipment for our manufacturing plant.\n", "page_number": 45, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.8840393667094566, "lower_right_x": 0.8802177858439202, "lower_right_y": 0.9122807017543859, "height": 0.028241335044929317, "width": 0.7598306110102844}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-45-12", "text": "43\n", "page_number": 45, "bounding_box": {"top_left_x": 0.8608590441621294, "top_left_y": 0.9482242190842961, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9572100984167736, "height": 0.00898587933247752, "width": 0.019963702359346636}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-46-0", "text": "   In 2005, our investments in plant and equipment and intangible assets amounted to \u20ac1.2 million.\nApproximately 75% of this amount relates to production and laboratory equipment, the remainder being largely\nfor computers and software.\n", "page_number": 46, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.08515190415062045, "lower_right_x": 0.8711433756805808, "lower_right_y": 0.12665810868635002, "height": 0.04150620453572958, "width": 0.7507562008469449}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-46-1", "text": "  In 2006, our investments in plant and equipment and intangible assets amounted to \u20ac1.1 million.\nApproximately 50% relates to equipment for our laboratories and pilot plant. The remaining amount is almost\nequally divided over computers and software on the one hand and costs for design of the pilot plant for the new\nbuilding.\n", "page_number": 46, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.1399229781771502, "lower_right_x": 0.8711433756805808, "lower_right_y": 0.1951219512195122, "height": 0.055198973042362015, "width": 0.7507562008469449}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-46-2", "text": "   In the first half of 2007, our investments in intangible and tangible assets amounted to \u20ac2.0 million in total, of\nwhich \u20ac1.3 million related to the additional patents acquired from IsoTis in April 2007, the remaining amount is\nprimarily related to the design of the pilot plant for the new building.\n", "page_number": 46, "bounding_box": {"top_left_x": 0.12099213551119177, "top_left_y": 0.20838682071031236, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.24989302524604193, "height": 0.04150620453572956, "width": 0.7598306110102843}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-46-3", "text": "Working Capital Statement\n", "page_number": 46, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.26658108686350024, "lower_right_x": 0.3145795523290986, "lower_right_y": 0.27899015832263585, "height": 0.012409071459135612, "width": 0.1941923774954628}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-46-4", "text": "   Our current cash resources, together with our existing financing facilities, do not provide us with sufficient\nworking capital for the next 12 months following the date of this Prospectus. However, we do have sufficient\nworking capital until into the second quarter of 2008. If the Offer should be withdrawn, we require additional\nfunds of approximately \u20ac10 million to cover the deficit in our working capital for the next 12 months following\nthe date of this Prospectus. In the event we are unable to raise such amount from other sources, we would need\nto scale back our operations and development programs in order to preserve our cash resources such that we\nwould have sufficient working capital for the 12 months following the date of this Prospectus. This working\ncapital statement covers us and all our current subsidiaries.\n", "page_number": 46, "bounding_box": {"top_left_x": 0.1161524500907441, "top_left_y": 0.290543431750107, "lower_right_x": 0.8650937689050212, "lower_right_y": 0.40136927685066326, "height": 0.11082584510055626, "width": 0.7489413188142771}, "blob_type": "paragraph", "predictions": {}, "annotations": {"working_capital_statement": ["Our current cash resources, together with our existing financing facilities, do not provide us with sufficientworking capital for the next 12 months following the date of this Prospectus. However, we do have sufficientworking capital until into the second quarter of 2008. If the Offer should be withdrawn, we require additionalfunds of approximately \u20ac10 million to cover the deficit in our working capital for the next 12 months followingthe date of this Prospectus. In the event we are unable to raise such amount from other sources, we would needto scale back our operations and development programs in order to preserve our cash resources such that wewould have sufficient working capital for the 12 months following the date of this Prospectus. This workingcapital statement covers us and all our current subsidiaries.If the Offer is completed, the expected net proceeds of the Offer together with our current cash resources andour existing financing facilities provide us with sufficient working capital for at least the next 12 monthsfollowing the date of this Prospectus."]}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-46-5", "text": "   If the Offer is completed, the expected net proceeds of the Offer together with our current cash resources and\nour existing financing facilities provide us with sufficient working capital for at least the next 12 months\nfollowing the date of this Prospectus.\n", "page_number": 46, "bounding_box": {"top_left_x": 0.1161524500907441, "top_left_y": 0.41420624732563116, "lower_right_x": 0.8669086509376891, "lower_right_y": 0.45528455284552843, "height": 0.041078305519897274, "width": 0.750756200846945}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-46-6", "text": "Contractual Obligations\n", "page_number": 46, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.4719726144629867, "lower_right_x": 0.294615849969752, "lower_right_y": 0.4856653829696192, "height": 0.01369276850663248, "width": 0.17422867513611617}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-46-7", "text": "   It is our policy to lease our property, plant and equipment in order to reduce the substantial cash outlay\nassociated with investments in property, plant and equipment. We have sold and leased back our headquarters\nfor a period of twenty years and, together with some other finance lease obligations, this has resulted in total\nfinance lease obligations of \u20ac7.7 million as of 31 December 2004, \u20ac7.5 million as of 31 December 2005 and\n\u20ac7.2 million as of 31 December 2006. In addition, we have signed a long-term finance lease contract with the\nowner of our current headquarters for additional office, laboratory and production facilities, resulting in an\nadditional future finance lease commitment of \u20ac15.0 million as of 31 December 2006. These facilities are\ncurrently being built on a location adjacent to our headquarters and are expected to be ready in the first half of\n2008. Once these facilities are ready, we will have a total of at least 5,238 m2 of offices, laboratories and pilot\nplant space available under long-term lease contracts to accommodate our anticipated growth. In the first half of\n2008, we will vacate our temporary facilities, currently occupied by us under short-term lease contracts. In\n2006, our total finance lease and operating lease payments approximated \u20ac756,000. Approximately \u20ac400,000 of\nthis amount was related to the lease of our headquarters, \u20ac255,000 was related to operating lease contracts,\nmainly comprising rental charges for the neighboring facilities referred to above, and \u20ac101,000 was related to\nfinance lease payments for other property, plant and equipment, mainly laboratory equipment.\n", "page_number": 46, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.4993581514762516, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.7051775780915703, "height": 0.2058194266153187, "width": 0.7555958862673926}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-46-8", "text": "   The following table sets out our payment obligations under contracts as of 31 August 2007 that provide for\nfixed and determinable payments over the periods indicated.\n", "page_number": 46, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.7184424475823705, "lower_right_x": 0.8614640048396854, "lower_right_y": 0.7462558836114677, "height": 0.02781343602909714, "width": 0.7410768300060496}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-46-9", "text": "                      2007         2008         2009 and 2010     2011 and later\n\nFinance leases1        \u20ac576,000    \u20ac1,226,000        \u20ac2,344,000       \u20ac18,020,000\nRoyalty obligations           -        38,000                 -                 -\nOther operating         555,000       105,000                 -                 -\ncommitments\nOperating leases         144,000       19,000            14,000            90,000\nCapital obligations      960,000    4,314,000                 -                 -\nTotal                 \u20ac2,235,000   \u20ac5,702,000        \u20ac2,358,000       \u20ac18,110,000\n", "page_number": 46, "bounding_box": {"top_left_x": 0.10586811857229281, "top_left_y": 0.7569533590072742, "lower_right_x": 0.8862673926194797, "lower_right_y": 0.8900299529311082, "height": 0.13307659392383397, "width": 0.7803992740471869}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-46-10", "text": "1.   An amount of \u20ac15 million is contingent on the completion and delivery to us of our new facilities.\n", "page_number": 46, "bounding_box": {"top_left_x": 0.14095583787053842, "top_left_y": 0.9032948224219084, "lower_right_x": 0.7114337568058077, "lower_right_y": 0.9139922978177151, "height": 0.010697475395806677, "width": 0.5704779189352692}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-46-11", "text": "44\n", "page_number": 46, "bounding_box": {"top_left_x": 0.8608590441621294, "top_left_y": 0.9477963200684638, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9572100984167736, "height": 0.00941377834830981, "width": 0.019963702359346636}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-47-0", "text": "   The capital obligations set forth in the table above relate to the additional office, laboratory and production\nfacilities currently being built adjacent to our current headquarters. Although the building will be leased, some\nof the dedicated equipment and a portion of the tailor-made production facilities will be acquired by us directly.\n", "page_number": 47, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.08515190415062045, "lower_right_x": 0.8711433756805808, "lower_right_y": 0.12665810868635002, "height": 0.04150620453572958, "width": 0.7507562008469449}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-47-1", "text": "   The royalty obligations mentioned in the table comprise royalties payable to the Leiden University Medical\nCenter (\u201cLUMC\u201d). Pursuant to our license agreement with LUMC for OP-145 CSOM, we may also be obliged\nto pay royalties on future sales, in addition to the royalty payment amounting to \u20ac38,000, as set forth in the table\nabove.\n", "page_number": 47, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.1399229781771502, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.19341035515618313, "height": 0.05348737697903294, "width": 0.7555958862673926}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-47-2", "text": "   In addition, other amounts that we may be obligated to pay under our existing contractual relationships that\nare not currently fixed and determinable include royalty and milestone payments under our agreements with\nUtrecht University, IsoTis and Theratechnologies, Inc. (\u201cTheratechnologies\u201d). Upon entering into the license\nagreement regarding the OctoDEX technology with Utrecht University, we agreed that we would pay royalties\non either net sales of products in the event that we undertake commercialization of a final product, or on\nroyalties received from third parties. Pursuant to our agreement with IsoTis, IsoTis is entitled to royalty\npayments on our revenues from the sale of products using the PolyActive technology acquired from IsoTis and\nmilestone payments we receive related to product candidates using such PolyActive technology. Payments\nunder this agreement continue until the end of the life of the patents currently in the PolyActive patent portfolio.\n", "page_number": 47, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.20838682071031236, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.33204963628583656, "height": 0.1236628155755242, "width": 0.7555958862673926}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-47-3", "text": "   Pursuant to our agreement with Theratechnologies, Theratechnologies is entitled to multiple development,\nregulatory and sales milestone payments for each product incorporating the licensed technology. We currently\nintend to develop one product, OP-286 CR, under our agreement with Theratechnologies. The sum of these\nmilestone payments amounts to \u20ac35.7 million per product if all milestones are met, with the milestone payments\nincreasing as the development of the product progresses. The regulatory and sales-related milestone payments\naccount for approximately 80% of the total milestone payments. We have the right to satisfy developmental\nmilestone payments of up to \u20ac7.7 million per product by issuing Shares to Theratechnologies with a value equal\nto the amount of the required payment. This right is subject to certain conditions and limitations. In addition to\nmilestone payments, we are required to make low single-digit royalty payments based on sales of products\nincorporating the licensed technology.\n", "page_number": 47, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.3453145057766367, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.48267008985879334, "height": 0.13735558408215665, "width": 0.7555958862673926}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-47-4", "text": "   Although most of the subsidies we have received from the Dutch Ministry of Economic Affairs and the\nEuropean Union are provided without repayment obligations, the subsidy related to the hGH-OctoDEX project\nwas provided on the basis of a \u201csoft loan\u201d, pursuant to which monies borrowed are repaid on the basis of\nrevenues generated from this project. As we have discontinued this project, we anticipate that we will not have\nto repay the \u201csoft loan\u201d.\n", "page_number": 47, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.4959349593495935, "lower_right_x": 0.8663036902601331, "lower_right_y": 0.5648267008985879, "height": 0.06889174154899441, "width": 0.7459165154264973}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-47-5", "text": "  We expect to be able to meet these contractual obligations from our anticipated revenues, as well as from the\nproceeds of the Offer. A significant part of our contractual obligations are contingent upon reaching various\nmilestones, including commercialization milestones.\n", "page_number": 47, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.5815147625160462, "lower_right_x": 0.8711433756805808, "lower_right_y": 0.621737270004279, "height": 0.04022250748823286, "width": 0.7507562008469449}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-47-6", "text": "Off Balance Sheet Arrangements\n", "page_number": 47, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.636285836542576, "lower_right_x": 0.3569267997580157, "lower_right_y": 0.6499786050492083, "height": 0.013692768506632369, "width": 0.2365396249243799}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-47-7", "text": "  We have no off balance sheet arrangements other than those presented above.\n\nCritical Accounting Policies and Estimates\n", "page_number": 47, "bounding_box": {"top_left_x": 0.12159709618874773, "top_left_y": 0.6636713735558408, "lower_right_x": 0.663036902601331, "lower_right_y": 0.7051775780915703, "height": 0.04150620453572951, "width": 0.5414398064125833}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-47-8", "text": "   Our discussion and analysis of our financial position and results of operations are based on our consolidated\nfinancial statements, which have been prepared in accordance with IFRS. The preparation of these financial\nstatements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities,\nrevenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis, we\nevaluate our estimates based on historical experience and make various assumptions which we believe to be\nreasonable under the circumstances, the results of which form the basis for making judgments about the carrying\nvalues of assets and liabilities that are not readily apparent from other sources. Actual results may differ from\nthese estimates under different assumptions or conditions.\n", "page_number": 47, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.7184424475823705, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.8284124946512623, "height": 0.1099700470688918, "width": 0.7604355716878403}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-47-9", "text": "   A summary of our significant accounting policies is contained in our consolidated financial statements, which\nare included in this Prospectus. We consider the following accounting policies to be critical to the understanding\nof the results of our operations.\n", "page_number": 47, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.8416773641420625, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.883183568677792, "height": 0.04150620453572951, "width": 0.7604355716878403}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-47-10", "text": "45\n", "page_number": 47, "bounding_box": {"top_left_x": 0.8608590441621294, "top_left_y": 0.9477963200684638, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9572100984167736, "height": 0.00941377834830981, "width": 0.019963702359346636}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-48-0", "text": "Impairment Test of Goodwill and Patents\n", "page_number": 48, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.08515190415062045, "lower_right_x": 0.42105263157894735, "lower_right_y": 0.09841677364142062, "height": 0.013264869490800177, "width": 0.30066545674531153}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-48-1", "text": "   In performing impairment testing of goodwill and patents, we make significant judgments and estimates to\ndetermine whether the cash flows we believe can be generated on the basis of these patents exceed the carrying\nvalue of our patents and goodwill. Determining cash flows requires the use of judgments and estimates that have\nbeen included in our strategic plans and long-term forecasts. The data necessary for performing the impairment\ntests are based on our estimates of future cash flows. The discount rates used are estimated pre-tax rates which\nreflect specific risks relating to the relevant segment.\n", "page_number": 48, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.11253744116388532, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.1951219512195122, "height": 0.08258451005562688, "width": 0.7604355716878403}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-48-2", "text": "Corporate Income Taxes\n", "page_number": 48, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.21181001283697048, "lower_right_x": 0.29945553539019965, "lower_right_y": 0.22593068035943517, "height": 0.014120667522464686, "width": 0.17906836055656383}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-48-3", "text": "   We have a history of tax losses and recognize deferred tax assets arising from unused tax losses or tax credits\nonly to the extent that the relevant fiscal unity has sufficient taxable temporary differences or there is convincing\nother evidence that sufficient taxable profit will be available against which the unused tax losses or unused tax\ncredits can be utilized by the fiscal unity. Our management\u2019s judgment is that sufficient convincing other\nevidence is not currently available and a deferred tax asset is therefore only recognized to the extent that a fiscal\nunity has sufficient taxable temporary differences.\n", "page_number": 48, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.24261874197689345, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.32691484809584936, "height": 0.08429610611895591, "width": 0.7604355716878403}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-48-4", "text": "Share-Based Payments\n", "page_number": 48, "bounding_box": {"top_left_x": 0.12099213551119177, "top_left_y": 0.3418913136499786, "lower_right_x": 0.2849364791288566, "lower_right_y": 0.3551561831407788, "height": 0.01326486949080019, "width": 0.16394434361766486}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-48-5", "text": "   Share options granted to our employees are measured at the fair value of the equity instruments granted\n(indirect method of measurement). Fair value is determined through the use of an option-pricing model, known\nas the Binomial method, which considers, among others, the following variables:\n", "page_number": 48, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.3727000427899016, "lower_right_x": 0.8711433756805808, "lower_right_y": 0.41377834830979887, "height": 0.041078305519897274, "width": 0.7507562008469449}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-48-6", "text": "The exercise price of the option;\n\nThe expected life of the option;\n\nThe current value of the underlying Shares;\n\nThe expected volatility of the share price, calculated considering the effect of dividends on the share\nprice;\n\nThe dividends expected on the Shares; and\n\nThe risk-free interest rate for the life of the option.\n", "page_number": 48, "bounding_box": {"top_left_x": 0.16878402903811252, "top_left_y": 0.43089430894308944, "lower_right_x": 0.8469449485783425, "lower_right_y": 0.5986307231493367, "height": 0.1677364142062473, "width": 0.67816091954023}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-48-7", "text": "\u00b7\n", "page_number": 48, "bounding_box": {"top_left_x": 0.1367211131276467, "top_left_y": 0.4347454000855798, "lower_right_x": 0.14519056261343014, "lower_right_y": 0.4411638853230638, "height": 0.006418485237483951, "width": 0.008469449485783431}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-48-8", "text": "\u00b7\n", "page_number": 48, "bounding_box": {"top_left_x": 0.1355111917725348, "top_left_y": 0.46255883611467696, "lower_right_x": 0.14519056261343014, "lower_right_y": 0.4689773213521609, "height": 0.006418485237483951, "width": 0.009679370840895346}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-48-9", "text": "", "page_number": 48, "bounding_box": {"top_left_x": 0.1367211131276467, "top_left_y": 0.49293966623876767, "lower_right_x": 0.14277071990320628, "lower_right_y": 0.4959349593495935, "height": 0.002995293110825803, "width": 0.006049606775559574}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-48-10", "text": "\u00b7\n", "page_number": 48, "bounding_box": {"top_left_x": 0.1355111917725348, "top_left_y": 0.5198973042362003, "lower_right_x": 0.14519056261343014, "lower_right_y": 0.5254599914420197, "height": 0.005562687205819428, "width": 0.009679370840895346}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-48-11", "text": "\u00b7\n", "page_number": 48, "bounding_box": {"top_left_x": 0.1355111917725348, "top_left_y": 0.5609756097560976, "lower_right_x": 0.14519056261343014, "lower_right_y": 0.5673940949935815, "height": 0.006418485237483895, "width": 0.009679370840895346}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-48-12", "text": "\u00b7\n", "page_number": 48, "bounding_box": {"top_left_x": 0.1355111917725348, "top_left_y": 0.5883611467693625, "lower_right_x": 0.14519056261343014, "lower_right_y": 0.5952075310226786, "height": 0.0068463842533161845, "width": 0.009679370840895346}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-48-13", "text": "  For our share option plans, we believe that the Binomial method is most appropriate for determining fair\nvalues as this method allows accounting for non-transferability, vesting conditions and early exercise.\n", "page_number": 48, "bounding_box": {"top_left_x": 0.12099213551119177, "top_left_y": 0.6123234916559692, "lower_right_x": 0.8415003024803388, "lower_right_y": 0.6401369276850664, "height": 0.02781343602909714, "width": 0.720508166969147}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-48-14", "text": "   At the time of the preparation of our 2006 financial report, we did not have sufficient share price information,\nas we had only recently been listed. Consequently, we needed to estimate the fair value of our Shares and the\nexpected volatility of that value, for which we have also used the historical weekly volatility of our peers. In the\nfuture, we will use share price information including of our Shares and those of our peers, as we have been\npublicly listed now for a considerable period of time and sufficient share price information is available.\n", "page_number": 48, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.6568249893025246, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.725716730851519, "height": 0.06889174154899436, "width": 0.7555958862673926}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-48-15", "text": "  The result of the share option valuations and the related compensation expense is dependent on the model and\ninput parameters used. Even though we consider the fair values reasonable and defensible based on the\nmethodologies applied and the information available, others might derive at a different fair value for each of our\nshare option plans.\n", "page_number": 48, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.7424047924689773, "lower_right_x": 0.8802177858439202, "lower_right_y": 0.7976037655113393, "height": 0.05519897304236199, "width": 0.7598306110102844}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 16, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-48-16", "text": "Capitalization of Development Costs\n", "page_number": 48, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.8177150192554558, "lower_right_x": 0.382335148215366, "lower_right_y": 0.8305519897304237, "height": 0.012836970474967901, "width": 0.2619479733817302}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 17, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-48-17", "text": "   Costs incurred on development projects are recognized as intangible assets when it is probable that a project\nwill be a success considering its commercial and technological feasibility. Our management\u2019s judgment is\nrequired in determining when we should start capitalizing our development costs. Our management determined\nthat commercial and technological feasibility is, in general, probable when we file for regulatory approval for\ncommercial production and costs can be measured reliably. As of 31 December 2006, we had not filed for\n", "page_number": 48, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.8451005562687206, "lower_right_x": 0.8705384150030248, "lower_right_y": 0.9127086007702182, "height": 0.0676080445014976, "width": 0.7501512401693889}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 18, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-48-18", "text": "46\n", "page_number": 48, "bounding_box": {"top_left_x": 0.8608590441621294, "top_left_y": 0.9482242190842961, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9572100984167736, "height": 0.00898587933247752, "width": 0.019963702359346636}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-49-0", "text": "regulatory approval of any product candidate based on our proprietary drug delivery technologies or for\nregulatory approval of one of our product candidates. Accordingly, based on our management\u2019s assessment of\ncommercial and technological feasibility, no development costs have been recognized as intangible assets in our\nconsolidated financial statements.\n", "page_number": 49, "bounding_box": {"top_left_x": 0.12159709618874773, "top_left_y": 0.08515190415062045, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.13692768506632436, "height": 0.05177578091570391, "width": 0.7543859649122807}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-49-1", "text": "Revenue Recognition\n", "page_number": 49, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.15703893881044073, "lower_right_x": 0.2716273442226255, "lower_right_y": 0.17115960633290545, "height": 0.014120667522464714, "width": 0.1512401693889897}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-49-2", "text": "Service Revenues\n", "page_number": 49, "bounding_box": {"top_left_x": 0.11675741076830005, "top_left_y": 0.18485237483953787, "lower_right_x": 0.24198427102238354, "lower_right_y": 0.19768934531450577, "height": 0.012836970474967901, "width": 0.12522686025408347}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-49-3", "text": "   Sales of services are recognized in the accounting period in which the services are rendered, by reference to\nthe stage of completion of the specific transaction, when the outcome of a transaction can be estimated reliably.\nThe stage of completion is assessed on the basis of the actual service provided as a proportion of the total\nservices to be provided.\n", "page_number": 49, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.21181001283697048, "lower_right_x": 0.8705384150030248, "lower_right_y": 0.2682926829268293, "height": 0.0564826700898588, "width": 0.7501512401693889}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-49-4", "text": "License and Royalty Revenues\n", "page_number": 49, "bounding_box": {"top_left_x": 0.11796733212341198, "top_left_y": 0.28369704749679076, "lower_right_x": 0.3339382940108893, "lower_right_y": 0.29696191698759095, "height": 0.01326486949080019, "width": 0.21597096188747733}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-49-5", "text": "   License and royalty revenues include amounts earned from third parties with licenses and/or options to our\nintellectual property. License and royalty revenues are recognized when earned in accordance with the substance\nand under the terms of the related agreements and when it is probable that the economic benefits associated with\nthe transaction will flow to the entity and the amount of the revenue can be measured reliably. In situations\nwhere we have continuing performance obligations, revenues related to license fee payments are deferred and\nthe related revenue is recognized in the period of expected performance.\n", "page_number": 49, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.3110825845100556, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.392811296534018, "height": 0.08172871202396237, "width": 0.7604355716878403}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-49-6", "text": "Multiple Element Arrangements\n", "page_number": 49, "bounding_box": {"top_left_x": 0.1161524500907441, "top_left_y": 0.4103551561831408, "lower_right_x": 0.3472474289171204, "lower_right_y": 0.4244758237056055, "height": 0.014120667522464714, "width": 0.2310949788263763}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-49-7", "text": "   In certain circumstances, it is necessary to apply the recognition criteria to the separately identifiable\ncomponents of a single transaction in order to reflect the substance of the transaction. Conversely, the\nrecognition criteria are applied to two or more transactions together when they are linked in such a way that the\ncommercial effect cannot be understood without reference to the series of transactions as a whole.\n", "page_number": 49, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.43774069319640563, "lower_right_x": 0.8711433756805808, "lower_right_y": 0.49208386820710315, "height": 0.05434317501069752, "width": 0.7507562008469449}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-49-8", "text": "   We offer arrangements whereby a customer licenses the right to use our intellectual property and purchases\nresearch and development services under one arrangement. When such multiple element arrangements exist, an\nelement is accounted for as a separable element if it has value to the customer on a stand-alone basis and the fair\nvalue can be determined objectively and reliably.\n", "page_number": 49, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.5096277278562259, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.5648267008985879, "height": 0.05519897304236199, "width": 0.7555958862673926}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-49-9", "text": "   When license revenues and service revenues are identified as separable elements in a multiple element\ntransaction, the license revenue recognized is determined based on the fair value of the license in relation to the\nfair value of the arrangement taken as a whole and is recognized in accordance with the accounting policy for\nlicense and royalty revenues as discussed above. The revenue relating to the service element, which represents\nthe fair value of the servicing arrangement in relation to the fair value of the arrangement, is recognized over the\nservice period. The fair values of each element are determined based on the current market price of each of the\nelements when sold separately.\n", "page_number": 49, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.5815147625160462, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.6777920410783055, "height": 0.09627727856225932, "width": 0.7604355716878403}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-49-10", "text": "Lease Accounting\n", "page_number": 49, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.6979032948224219, "lower_right_x": 0.25105868118572294, "lower_right_y": 0.711168164313222, "height": 0.01326486949080019, "width": 0.13067150635208713}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-49-11", "text": "   Evaluating the substance of a lease agreement involves complex accounting judgments under International\nAccounting Standards (IAS) 17. For our existing lease agreements, we have evaluated whether or not significant\nrisks and rewards have been transferred and have accounted for leases, especially with regard to land and\nbuildings, on that basis.\n", "page_number": 49, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.7287120239623449, "lower_right_x": 0.8802177858439202, "lower_right_y": 0.7834830979888746, "height": 0.0547710740265297, "width": 0.7598306110102844}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-49-12", "text": "47\n", "page_number": 49, "bounding_box": {"top_left_x": 0.8608590441621294, "top_left_y": 0.9477963200684638, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9572100984167736, "height": 0.00941377834830981, "width": 0.019963702359346636}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-50-0", "text": "Business\n", "page_number": 50, "bounding_box": {"top_left_x": 0.4543254688445251, "top_left_y": 0.10226786478391099, "lower_right_x": 0.5420447670901392, "lower_right_y": 0.11596063329054343, "height": 0.013692768506632438, "width": 0.08771929824561403}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-50-1", "text": "Overview\n", "page_number": 50, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.1364997860504921, "lower_right_x": 0.19358741681790684, "lower_right_y": 0.14890885750962773, "height": 0.01240907145913564, "width": 0.07320024198427103}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-50-2", "text": "   We are a product-oriented biopharmaceutical company committed to the development of improved\npharmaceutical products based on our proprietary drug delivery technologies that have fewer side effects,\nincreased patient convenience and better efficacy than existing products. We currently have five product\ncandidates in development, of which two are in Phase II clinical trials. Our lead product candidate, Locteron, is\na novel interferon alfa combined with our proprietary PolyActive drug delivery technology for the treatment of\nchronic hepatitis C infection. Locteron is designed to require less frequent administration and cause fewer side\neffects than marketed forms of interferon alfa which currently represent the standard of care for this illness. We\nhave completed patient treatment in a Phase IIa study of Locteron and intend to commence a Phase IIb clinical\ntrial in the middle of 2008. We also intend to commence a separate study in the United States in a difficult-to-\ntreat patient population later this year or in the first quarter of 2008. Our second clinical-stage product candidate\nis OP-145 CSOM, a novel proprietary peptide therapeutic, for the treatment of chronic otitis media, also known\nas chronic middle ear infection, that is currently in Phase II clinical trials. In addition, we have three product\ncandidates in pre-clinical development. OP-286 CR is a controlled-release formulation of a GLP-1 analogue for\nthe treatment of type II diabetes. We are also developing single shot vaccines based on our proprietary\nOctoVAX platform, HBV OctoVAX for hepatitis B vaccination and JEV OctoVAX for Japanese encephalitis\nvaccination.\n", "page_number": 50, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.16388532306375694, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.37997432605905007, "height": 0.21608900299529313, "width": 0.7555958862673926}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-50-3", "text": "   We use our proprietary drug delivery systems, including OctoDEX and PolyActive, to develop products that\nprovide controlled and prolonged release of a drug, which enables reduced dosing frequency and reduced side\neffects with comparable or better efficacy relative to immediate release drugs. Rather than seeking to discover\nnovel drug candidates through early stage research activities, we focus on the development of long-acting,\ncontrolled-release versions of known protein therapeutics and other drugs. In contrast to certain other\napproaches to improve the clinical benefit of protein therapeutics, such as chemical modification (including\npegylation and polymer conjugates) or protein engineering (including changes in primary structure and fusion),\nour technologies have the advantage of efficiently and gradually delivering a drug in its native form. We believe\nthat products based on our OctoDEX and PolyActive technologies can be applied in many therapeutic areas.\nHowever, our current product focus is primarily directed at improving the treatment or prevention of viral and\nbacterial infections as well as treatment of metabolic disorders.\n", "page_number": 50, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.39666238767650835, "lower_right_x": 0.8753781004234725, "lower_right_y": 0.5455712451861361, "height": 0.14890885750962773, "width": 0.7549909255898367}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-50-4", "text": "   In addition to developing our own proprietary products, we provide advanced drug formulation and clinical\nscale manufacturing services to biotechnology and pharmaceutical companies worldwide. Since our\nestablishment in 1995 through 31 August 2007, our Contract Development Business has achieved \u20ac41 million of\nconsolidated revenues. We have realized a positive operating result from this business in all but one year. The\nearnings and expertise that we derive from rendering formulation and manufacturing services also support us in\nour own drug development programs.\n", "page_number": 50, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.5609756097560976, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.6435601198117245, "height": 0.08258451005562684, "width": 0.7604355716878403}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-50-5", "text": "   Our Executive Board and Senior Management have many years of experience in the areas of clinical\ndevelopment, drug delivery, pharmaceutical formulation and manufacturing, business development and finance.\nOur main facilities are located in Leiden, the Netherlands, and include a small-scale cGMP manufacturing plant\nand offices, which we lease under a long-term contract. We have also entered into an agreement to lease a\npurpose-built facility which is being built adjacent to our current main facilities. This new facility is expected to\nbe ready in the first half of 2008. We opened a business development office in Cambridge, Massachusetts,\nUnited States in 2006.\n", "page_number": 50, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.6568249893025246, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.753102267864784, "height": 0.09627727856225932, "width": 0.7555958862673926}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-50-6", "text": "As of 31 August 2007, we employed 157 people, two of whom are located in our office in Cambridge.\n", "page_number": 50, "bounding_box": {"top_left_x": 0.1385359951603146, "top_left_y": 0.766367137355584, "lower_right_x": 0.8257713248638838, "lower_right_y": 0.7839109970047069, "height": 0.01754385964912286, "width": 0.6872353297035693}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-50-7", "text": "History\n", "page_number": 50, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.7971758664955071, "lower_right_x": 0.17846339987900786, "lower_right_y": 0.8104407359863073, "height": 0.01326486949080019, "width": 0.05807622504537205}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-50-8", "text": "   We were founded in 1995 by Joost Holthuis, Ph.D., our CEO, and Prof. Daan Crommelin, Ph.D., the\nchairperson of our Scientific Advisory Board. Initially, we focused on providing pharmaceutical and\nbiotechnology companies with advanced drug formulation and clinical scale manufacturing services. Starting in\n1996, we entered into a number of agreements with Utrecht University by which we received a worldwide\nexclusive license to our OctoDEX technology. While we continued to successfully grow our Contract\nDevelopment Business, we made the strategic decision in early 2000 to start to exploit our expertise in the drug\n", "page_number": 50, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.8245614035087719, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.9062901155327343, "height": 0.08172871202396237, "width": 0.7555958862673926}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-50-9", "text": "48\n", "page_number": 50, "bounding_box": {"top_left_x": 0.8608590441621294, "top_left_y": 0.9486521181001284, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9572100984167736, "height": 0.00855798031664523, "width": 0.019963702359346636}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-51-0", "text": "delivery area and the versatility of our OctoDEX platform by expanding into the development of proprietary\nproducts.\n", "page_number": 51, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.08515190415062045, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.11253744116388532, "height": 0.027385537013264877, "width": 0.7313974591651543}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-51-1", "text": "   In 2001, we raised \u20ac3 million from NPM Capital N.V. and 7X Life Sciences B.V. in order to progress\nOctoDEX-based product candidates into clinical trials. In 2003, we were able to broaden our technology base by\ngaining access to a second drug delivery system, PolyActive, through the acquisition of Chienna B.V. from\nIsoTis N.V.\n", "page_number": 51, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.12623020967051776, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.17886178861788618, "height": 0.05263157894736842, "width": 0.7604355716878403}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-51-2", "text": "   In 2005, Life Sciences Partners B.V., S.R. One, Limited, Innoven Partenaires S.A., Fortis Bank N.V./S.A.,\nSurModics and certain other parties invested \u20ac18.4 million in us, which allowed us to fund further development\nof our proprietary technologies and our portfolio of product candidates.\n", "page_number": 51, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.19469405220367994, "lower_right_x": 0.8711433756805808, "lower_right_y": 0.2362002567394095, "height": 0.04150620453572956, "width": 0.7507562008469449}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-51-3", "text": "  In October 2006, we completed our IPO on Euronext Amsterdam raising \u20ac20 million in gross proceeds,\nwhich allowed us to continue our drug development efforts.\n", "page_number": 51, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.24946512623020967, "lower_right_x": 0.8366606170598911, "lower_right_y": 0.2772785622593068, "height": 0.02781343602909714, "width": 0.7162734422262553}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-51-4", "text": "Strategy\n", "page_number": 51, "bounding_box": {"top_left_x": 0.12099213551119177, "top_left_y": 0.2939666238767651, "lower_right_x": 0.1839080459770115, "lower_right_y": 0.306803594351733, "height": 0.012836970474967901, "width": 0.06291591046581972}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-51-5", "text": "   We aim to leverage our broad expertise in pharmaceutical development and drug delivery in order to develop\npharmaceutical products which improve existing approaches to the treatment of serious illnesses. Key elements\nof our corporate strategy include:\n", "page_number": 51, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.32135216089002994, "lower_right_x": 0.8753781004234725, "lower_right_y": 0.362002567394095, "height": 0.04065040650406504, "width": 0.7549909255898367}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-51-6", "text": "\u00b7   Advance the development of our lead product candidates. Our primary focus is on the aggressive\n    development of our most advanced product candidates so that they may be submitted for regulatory\n    approval. We currently have two product candidates in clinical trials. We have completed patient\n    treatment in a Phase IIa clinical trial of our lead product candidate Locteron for the treatment of chronic\n    HCV infection and are preparing for a Phase IIb clinical trial, which we expect to commence in the\n    middle of 2008. We also intend to commence a separate study in the United States in a difficult-to-treat\n    patient population later this year or in the first quarter of 2008. In addition, we are conducting a Phase II\n    clinical trial of OP-145 CSOM, our novel peptide for the treatment of chronic middle ear infection. The\n    treatment of patients in this study is expected to be completed by the end of 2007, and we expect to\n    report results in the first half of 2008.\n\n\u00b7   Continue to expand our product candidate portfolio by combining our drug delivery technologies\n    with known biopharmaceutical drugs or other therapeutics in need of clinical improvement. We\n    primarily intend to apply our proprietary drug delivery technologies to those product opportunities where\n    we can capitalize on the known safety, efficacy and often established drug development history of\n    existing drugs. We believe that our technologies may allow us to improve the performance of many of\n    these known biopharmaceutical drugs, of which drawbacks may include frequent or inconvenient dosing\n    schedules, injection site reactions, strong side effects and/or limited efficacy. More opportunistically, we\n    also intend to acquire or in-license product candidates in pre-clinical or clinical development that we\n    believe have clear potential for an improved clinical profile upon combination with one of our drug\n    delivery technologies. We would require such development programs to be synergistic with our then\n    existing product portfolio. Our goal is to initiate one new development program per year.\n\n\u00b7   Capture value by entering into partnerships with large pharmaceutical or biotechnology\n    companies for our product candidates. We intend to create value by licensing our product candidates\n    for further development and commercialization at a stage where the risk/reward balance would make\n    such partnership attractive for us. In most cases, this would typically occur with the completion of Phase\n    II clinical trials. For product candidates that target smaller markets, we may decide to complete the\n    development process ourselves and establish a commercial infrastructure to directly commercialize such\n    products in certain territories.\n\n\u00b7   Further expand the potential applications of our drug delivery platforms. We believe that our\n    proprietary drug delivery technologies have broad applicability. We continually seek to improve and find\n    new applications for our OctoDEX and PolyActive platforms in order to remain competitive in\n    developing controlled release formulations of many classes of drugs and therapeutic proteins. As an\n    example, we have developed a modified version of our OctoDEX technology, OctoVAX, as a basis for\n    an innovative, single-shot approach to prophylactic vaccines. We believe that OctoDEX and PolyActive\n    can be used to enhance the performance of a range of therapeutics. We intend to leverage our\n", "page_number": 51, "bounding_box": {"top_left_x": 0.13490623109497882, "top_left_y": 0.3761232349165597, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.8964484381685922, "height": 0.5203252032520325, "width": 0.7459165154264973}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-51-7", "text": "technologies by entering into selective co-development agreements, whereby we would develop products\n", "page_number": 51, "bounding_box": {"top_left_x": 0.1693889897156685, "top_left_y": 0.8968763371844245, "lower_right_x": 0.8802177858439202, "lower_right_y": 0.9105691056910569, "height": 0.013692768506632369, "width": 0.7108287961282517}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-51-8", "text": "49\n", "page_number": 51, "bounding_box": {"top_left_x": 0.8608590441621294, "top_left_y": 0.9477963200684638, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9572100984167736, "height": 0.00941377834830981, "width": 0.019963702359346636}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-52-0", "text": "based on our drug delivery technologies for third parties on a fee-for-services basis, and would include\nlicense fees and royalties. In addition, we may enter into collaboration agreements in non-core areas,\nsuch as medical devices. As an example, we have entered into a collaboration agreement with SurModics\nto apply our PolyActive technology to the development of drug-eluting medical devices. We may also\nacquire or in-license other technologies that are complementary to our existing platforms.\n", "page_number": 52, "bounding_box": {"top_left_x": 0.16878402903811252, "top_left_y": 0.08515190415062045, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.1540436456996149, "height": 0.06889174154899445, "width": 0.7120387174833636}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-52-1", "text": "Our Product Candidates\n", "page_number": 52, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.16730851519041506, "lower_right_x": 0.3000604960677556, "lower_right_y": 0.1797175866495507, "height": 0.01240907145913564, "width": 0.17967332123411978}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-52-2", "text": "The following table summarizes key information about our product candidates.\n", "page_number": 52, "bounding_box": {"top_left_x": 0.1355111917725348, "top_left_y": 0.19469405220367994, "lower_right_x": 0.6721113127646703, "lower_right_y": 0.20881471972614463, "height": 0.014120667522464686, "width": 0.5366001209921355}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-52-3", "text": "Product Candidate   Indication         Stage of       Partner Status     Next Expected\n                                       Development                       Development\n                                                                         Milestone\nLocteron            Chronic HCV        Phase IIa      Co-development     Commence Phase\n                    Infection                         with Biolex        IIb trial in the\n                                                                         middle of 2008\n\nOP-145 CSOM         Chronic Middle     Phase II       Co-development     Announce Phase II\n                    Ear Infection                     with Green Cross   data in H1:2008\n                                                      Corporation1\n\nOP-286 CR           Type II Diabetes   Pre-clinical   None2              Commence pre-\n                                                                         clinical proof-of-\n                                                                         concept study in\n                                                                         H1:2008\n\nHBV-OctoVAX         Prophylactic       Pre-clinical   Co-development     Commence Phase I\n                    Hepatitis B                       with SciGen3       study in Q1:2009\n                    Vaccination\n\nJEV-OctoVAX         Prophylactic       Pre-clinical   Co-development     Commence Phase I\n                    Japanese                          with SingVax       study in H1:2009\n                    Encephalitis\n                    Vaccination\n", "page_number": 52, "bounding_box": {"top_left_x": 0.11010284331518451, "top_left_y": 0.22250748823277705, "lower_right_x": 0.8747731397459165, "lower_right_y": 0.5511339323919555, "height": 0.32862644415917847, "width": 0.764670296430732}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-52-4", "text": "1.\n     In November 2006, we concluded an out-licensing agreement with Green Cross Corporation of South\n     Korea for the co-development of OP-145 CSOM and the exclusive commercialization of OP-145\n     CSOM in the South Korean market.\n2.\n     In September 2007, we concluded an in-licensing agreement with Theratechnologies for OP-286, the\n     GLP-1 analogue that is the active agent in OP-286 CR.\n3.\n     In June 2005, we entered into a non-exclusive collaboration agreement with SciGen Ltd. If our proof-\n     of-concept study is successful, we and SciGen may agree to continue with the development and\n     commercialization of HBV-OctoVAX, based on our respective technologies, on an exclusive basis.\n", "page_number": 52, "bounding_box": {"top_left_x": 0.16515426497277677, "top_left_y": 0.5588361146769363, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.6846384253316218, "height": 0.1258023106546855, "width": 0.7108287961282517}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-52-5", "text": "Locteron for Chronic Hepatitis C\n", "page_number": 52, "bounding_box": {"top_left_x": 0.37749546279491836, "top_left_y": 0.6979032948224219, "lower_right_x": 0.6194797338173019, "lower_right_y": 0.7120239623448866, "height": 0.01412066752246477, "width": 0.24198427102238357}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-52-6", "text": "   Our lead product candidate is Locteron, a proprietary controlled release formulation of interferon alfa. We\nhave completed patient treatment in a Phase IIa clinical trial and are preparing for a Phase IIb trial, which we\nexpect to commence in the middle of 2008. We also intend to commence a separate study in the United States in\na difficult-to-treat patient population later this year or in the first quarter of 2008. The primary indication for\nLocteron is the treatment of chronic infection by the hepatitis C virus (\u201cHCV\u201d). Hepatitis C is a common\ndisease, affecting over 180 million people worldwide. Infection by HCV is a very serious medical condition that\ncan lead to cirrhosis of the liver, a condition where healthy liver cells are killed by infection with HCV and are\nreplaced by scar tissue. Resulting damage to the liver can lead to impaired liver function, liver cancer and\nultimately death.\n", "page_number": 52, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.7252888318356868, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.848951647411211, "height": 0.12366281557552417, "width": 0.7555958862673926}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-52-7", "text": "  The current standard of care for the treatment of HCV infection consists of a combination of ribavirin with\none of two currently approved pegylated interferon alfa products, PEG-Intron marketed by Schering-Plough or\nPegasys marketed by Roche. However, this treatment approach is frequently characterized by severe acute side\n", "page_number": 52, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.8656397090286693, "lower_right_x": 0.8711433756805808, "lower_right_y": 0.905862216516902, "height": 0.04022250748823275, "width": 0.7507562008469449}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-52-8", "text": "50\n", "page_number": 52, "bounding_box": {"top_left_x": 0.8608590441621294, "top_left_y": 0.9477963200684638, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9572100984167736, "height": 0.00941377834830981, "width": 0.019963702359346636}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-53-0", "text": "effects that hamper widespread use and result in poor patient compliance. We believe that Locteron has the\npotential to offer substantial improvements in the management of chronic HCV infection.\n", "page_number": 53, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.08515190415062045, "lower_right_x": 0.8421052631578947, "lower_right_y": 0.11296534017971759, "height": 0.02781343602909714, "width": 0.7217180883242589}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-53-1", "text": "   Locteron combines interferon alfa produced by our co-development partner, Biolex, with our proprietary\nPolyActive microspheres. This product is designed to gradually release its active pharmaceutical ingredient over\na 14 day period after a single injection. Currently marketed pegylated interferons are dosed once-every-week.\nBy releasing interferon alfa in the body in a gradual manner, our PolyActive microspheres avoid the high initial\nblood levels of the active drug that characterize the current standard of care. We believe that these high initial\nlevels of interferon alfa contribute to the acute flu-like symptoms commonly associated with the current\nstandard of care. Locteron aims to provide at least the same therapeutic benefit to HCV patients with fewer, less\nsevere and less frequent side effects and a more convenient dosing schedule.\n", "page_number": 53, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.12623020967051776, "lower_right_x": 0.8777979431336963, "lower_right_y": 0.2362002567394095, "height": 0.10997004706889174, "width": 0.7574107683000605}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-53-2", "text": "   We believe that an improved side effect profile will lead to enhanced patient compliance, which in turn will\nresult in superior therapeutic outcomes. We also believe that Locteron\u2019s intended superior side effect profile\nmay attract and maintain patients on therapy who currently delay or refuse treatment. The data from the trials we\nhave conducted to date indicate that Locteron could be dosed once-every-two-weeks, which is a substantial\nimprovement over currently marketed pegylated interferons that require weekly injections. We believe there is a\nstrong correlation between reducing the dosing frequency of interferon therapy and improving patient\ncompliance, in particular in light of the current 48-week treatment period for HCV genotype 1, the HCV variant\nmost prevalent in Western countries.\n", "page_number": 53, "bounding_box": {"top_left_x": 0.12099213551119177, "top_left_y": 0.24946512623020967, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.3594351732991014, "height": 0.10997004706889174, "width": 0.7598306110102843}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-53-3", "text": "   In 2006, we completed a Phase I clinical study where the safety, pharmacokinetics and pharmacodynamics of\nLocteron were investigated in healthy volunteers. Results of this Phase I clinical trial showed that a single dose\nof Locteron was safe and well tolerated. In particular, groups receiving Locteron reported fewer, less severe and\nshorter lasting flu-like symptoms than those subjects receiving PEG-Intron, a commonly prescribed pegylated\ninterferon.\n", "page_number": 53, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.3727000427899016, "lower_right_x": 0.8802177858439202, "lower_right_y": 0.44030808729139925, "height": 0.06760804450149765, "width": 0.7598306110102844}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-53-4", "text": "   In addition, we have completed patient treatment in a 12-week Phase IIa clinical trial to evaluate the safety,\ntolerability and preliminary efficacy of Locteron administered once-every-two-weeks in combination with\nribavirin in treatment-na\u00efve hepatitis C patients. Results of the study showed that Locteron was generally safe\nand well tolerated. In addition, the results to date have shown that 12 weeks of treatment with Locteron in\ncombination with ribavirin was effective in reducing hepatitis C virus levels.\n", "page_number": 53, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.45528455284552843, "lower_right_x": 0.8614640048396854, "lower_right_y": 0.5267436884895165, "height": 0.07145913564398804, "width": 0.7410768300060496}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-53-5", "text": "Disease Background, Market Opportunity and Limitations of Existing Products\n", "page_number": 53, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.540436456996149, "lower_right_x": 0.6920750151240169, "lower_right_y": 0.553701326486949, "height": 0.01326486949080008, "width": 0.5716878402903811}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-53-6", "text": "   Hepatitis C is a disease of the liver caused by infection with HCV. Proper function of the liver is essential to\nhuman health. The liver removes or neutralizes unwanted substances from the blood, aids in the absorption of\nnutrients, produces immune agents to control infection, and removes microbes from the blood. It makes proteins\nthat regulate blood clotting and produces bile to help absorb fats and fat-soluble vitamins.\n", "page_number": 53, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.5678219940094138, "lower_right_x": 0.8753781004234725, "lower_right_y": 0.6221651690201112, "height": 0.05434317501069741, "width": 0.7549909255898367}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-53-7", "text": "   HCV infects liver cells and can cause the liver to become inflamed. Over time, such infection can lead to\ncirrhosis, a condition where scar tissue replaces normal, healthy liver tissue, causing a deterioration in liver\nfunction. Damage to the liver due to HCV infection can lead to liver cancer or outright liver failure. Initial\nexposure to HCV elicits an immune response directed against the infected liver cells. However, most patients\ninfected with HCV are unable to generate an immune response sufficient to eradicate the virus entirely, resulting\nin chronic infection with HCV. Patients may not realize that they have been infected with HCV until 10 to 30\nyears after initial exposure, in part because of the lack of obvious symptoms.\n", "page_number": 53, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.636285836542576, "lower_right_x": 0.8802177858439202, "lower_right_y": 0.7325631151048353, "height": 0.09627727856225932, "width": 0.7598306110102844}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-53-8", "text": "   The World Health Organization (the \u201cWHO\u201d) estimates that 180 million people globally are infected with\nHCV, with 3 to 4 million new infections per year. Approximately 70% of these cases will not resolve during the\nacute stage of infection and will result in chronic disease. Of these patients who progress to chronic hepatitis,\naccording to the WHO, 10-20% will develop cirrhosis within 20 years, while some 30% of cirrhotic patients\ndevelop clinical liver decompensation over a period of ten years. HCV infection is the leading cause of liver\ntransplantations in the United States where approximately 10,000 deaths per year are attributed to complications\nresulting from HCV infection. The Centers for Disease Control (the \u201cCDC\u201d) of the US National Institutes of\nHealth (the \u201cNIH\u201d) estimates that 5% of HCV infected patients will eventually develop end-stage liver failure\nrequiring a liver transplant in order to survive. Published reports indicate that the number of liver cirrhosis and\ncancer cases due to HCV infection will further increase in the coming 10 to 20 years. The population of patients\nwith chronic HCV infection in Europe and the United States is estimated at 6 million and 3.2 million,\nrespectively.\n", "page_number": 53, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.7458279845956355, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.9105691056910569, "height": 0.16474112109542138, "width": 0.7555958862673926}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-53-9", "text": "51\n", "page_number": 53, "bounding_box": {"top_left_x": 0.8608590441621294, "top_left_y": 0.9477963200684638, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9572100984167736, "height": 0.00941377834830981, "width": 0.019963702359346636}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-54-0", "text": "   There are at least six different strains of HCV, known as genotypes. Of those, genotype 1 is most commonly\nfound in the United States and most parts of Europe. Genotype 1 is considered to be least responsive to\ntreatment and requires the longest time on therapy. Large-scale clinical trials have demonstrated that the current\nstandard of care induces a successful response in approximately 50% of patients.\n", "page_number": 54, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.08515190415062045, "lower_right_x": 0.8753781004234725, "lower_right_y": 0.14035087719298245, "height": 0.055198973042362, "width": 0.7549909255898367}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-54-1", "text": "   The relative treatment rate for HCV infection is very low. It is estimated that only 22% of chronically\ninfected HCV carriers in the United States receive treatment. In other developed countries it is estimated that\nonly 12-13% of infected patients receive treatment. This undertreatment is caused by a number of factors,\nincluding absence of symptoms indicating infection, absence of sufficiently serious inflammatory damage to the\nliver to warrant treatment and the unpleasant and lengthy nature of treatment with interferon for chronic HCV\ninfection.\n", "page_number": 54, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.15361574668378264, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.23277706461275138, "height": 0.07916131792896874, "width": 0.7555958862673926}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-54-2", "text": "   The current standard of care for chronic HCV infection in developed countries involves a combination of\npegylated interferon alfa and a generic anti-viral drug known as ribavirin. Interferon alfa is an anti-viral\nglycoprotein naturally produced by the human immune system in response to a viral infection. While interferon\nalfa is known to contribute to the eradication of the invading virus, it has historically been associated with\nsignificant adverse side effects. The most common side effects are often referred to as \u201cflu-like symptoms\u201d,\nwhich include fatigue, drowsiness, weight loss, dizziness, muscle ache, nausea, vomiting, loss of taste, diarrhea\nand headache.\n", "page_number": 54, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.24946512623020967, "lower_right_x": 0.8711433756805808, "lower_right_y": 0.34403080872913994, "height": 0.09456568249893027, "width": 0.7507562008469449}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-54-3", "text": "   In order to stimulate and assist the immune system in its response to chronic HCV infection, pegylated\ninterferon alfa is given to patients on a weekly basis. However, interferon alfa causes flu-like symptoms, and\nthis therapy results in severe side effects in a large majority of patients. Many patients with chronic HCV\ninfection experience no hepatitis-related symptoms and therefore are more likely to discontinue therapy when\nconfronted with the severe side effects of the current standard of care. According to a recent study conducted by\nthe Public Health Agency of Canada, adverse events associated with interferon therapy resulted in a 21%\ncessation rate in HCV patients undergoing the 48 weeks of treatment.\n", "page_number": 54, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.3590072742832692, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.45528455284552843, "height": 0.09627727856225926, "width": 0.7555958862673926}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-54-4", "text": "   Until 1998, Schering-Plough\u2019s Intron A, a non-modified interferon alfa, was the standard of care for the\ntreatment of chronic HCV infection. However, the introduction of pegylation technology saw a rapid shift away\nfrom this product to new versions of interferon alfa which were combined with this drug delivery technology.\nPegylation is a technique that involves the attachment of large polyethylene glycol (\u201cPEG\u201d) polymers to each\ninterferon molecule, thereby lengthening its circulation time in the body. As a result, a more convenient dosing\nschedule was achieved (once per week versus three times per week) and longer blood circulation of pegylated\ninterferon at clinically relevant levels resulted in greater efficacy. However, the flu-like symptoms associated\nwith standard interferon therapy continue to apply to therapy with pegylated interferons albeit with less\nfrequency as such side effects typically manifest themselves within a short period after dosing. Pegylated\nversions of interferon were introduced in 2001. Between 2001 and 2005 the market for interferon alfa almost\ndoubled. Pegylated versions of interferon now account for approximately 88% of the interferon sales.\n", "page_number": 54, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.46983311938382544, "lower_right_x": 0.8753781004234725, "lower_right_y": 0.6195977749251177, "height": 0.14976465554129226, "width": 0.7549909255898367}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-54-5", "text": "   Combination therapy with pegylated interferon and ribavirin is expensive. In the United States, a 48-week\ncourse of interferon alfa therapy costs approximately $16,000. Worldwide sales for hepatitis C therapeutics were\nestimated at $4 billion in 2005.\n", "page_number": 54, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.636285836542576, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.6743688489516474, "height": 0.038083012409071415, "width": 0.7604355716878403}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-54-6", "text": "   Analysts have forecasted that the market for HCV therapeutics in general will grow at 9-12% per year\nthrough 2010 and that sales of interferons will amount to approximately $5 billion in 2011. This growth is\nexpected to be driven by the following factors:\n", "page_number": 54, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.6910569105691057, "lower_right_x": 0.8354506957047791, "lower_right_y": 0.7325631151048353, "height": 0.04150620453572962, "width": 0.7150635208711433}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-54-7", "text": "\u00b7   Increased Diagnosis Rates and Enhanced Public Education Campaigns. An increasing number of\n    patients who have been chronically infected with HCV for periods often in excess of 15 years will\n    present with advanced liver disease, necessitating therapeutic intervention. Furthermore, diagnostic tests\n    for the detection of HCV are expected to become more widely available. In addition, public health\n    authorities have launched education campaigns to encourage high risk groups to seek diagnosis and\n    treatment.\n\n\u00b7   Development of Improved and/or Novel Therapies. New treatment options which are safer and more\n    effective should increase the number of patients that seek or are referred for treatment. We believe that\n    these advanced therapies will overcome currently high levels of patient apathy which result from the\n    limited efficacy and severe side effects of current therapies.\n", "page_number": 54, "bounding_box": {"top_left_x": 0.13490623109497882, "top_left_y": 0.7458279845956355, "lower_right_x": 0.8753781004234725, "lower_right_y": 0.8968763371844245, "height": 0.15104835258878901, "width": 0.7404718693284937}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-54-8", "text": "52\n", "page_number": 54, "bounding_box": {"top_left_x": 0.8608590441621294, "top_left_y": 0.9477963200684638, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9572100984167736, "height": 0.00941377834830981, "width": 0.019963702359346636}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-55-0", "text": "Treatment of Non-Responders. With the development of new and improved therapeutics for chronic\nHCV infection, patients who did not respond to standard therapy will undergo further treatment with\nnew products. Large-scale clinical trials have demonstrated that approximately 50% of HCV patients\nwith chronic genotype 1 infection respond to the current standard of care.\n", "page_number": 55, "bounding_box": {"top_left_x": 0.16878402903811252, "top_left_y": 0.08515190415062045, "lower_right_x": 0.8614640048396854, "lower_right_y": 0.14035087719298245, "height": 0.055198973042362, "width": 0.6926799758015729}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-55-1", "text": "\u00b7\n", "page_number": 55, "bounding_box": {"top_left_x": 0.1367211131276467, "top_left_y": 0.08900299529311083, "lower_right_x": 0.14519056261343014, "lower_right_y": 0.09542148053059478, "height": 0.006418485237483951, "width": 0.008469449485783431}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-55-2", "text": "Anticipated Advantages of Locteron\n", "page_number": 55, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.15361574668378264, "lower_right_x": 0.382335148215366, "lower_right_y": 0.16773641420624733, "height": 0.014120667522464686, "width": 0.2619479733817302}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-55-3", "text": "   Locteron is designed to be a best-in-class therapeutic for patients with chronic HCV infection. We believe\nthat Locteron will offer patients an effective and more convenient treatment for chronic HCV infection because\nof the following advantages over currently marketed pegylated interferons:\n", "page_number": 55, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.1810012836970475, "lower_right_x": 0.8711433756805808, "lower_right_y": 0.22250748823277705, "height": 0.04150620453572956, "width": 0.7507562008469449}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-55-4", "text": "More Convenient Dosing Schedule. We have demonstrated in clinical studies that Locteron gradually\nreleases interferon alfa over a two-week period. If clinical efficacy with this dosing interval is confirmed\nin larger clinical studies, we may be able to market Locteron as a once-every-two-weeks therapy as\nopposed to current weekly therapy. This would reduce the burden on patients and we believe would\nlikely lead to greater patient compliance with therapy schedules.\n\nFewer, Less Severe and Less Frequent Side Effects. By releasing interferon gradually over a two-\nweek period, Locteron is able to avoid the high initial blood concentrations of interferon that are\nassociated with administration of pegylated proteins. By avoiding these high blood levels we believe that\nthe number, severity and duration of severe side effects can be reduced. The reduction in side effects is\naided by the once-every-two-weeks dosing schedule, as the most severe flu-like symptoms occur shortly\nafter injection.\n\nImproved Efficacy. We believe that Locteron may provide patients with longer periods of exposure of\ninfected tissues to clinically relevant levels of interferon when compared to pegylated interferons.\nFurthermore, Locteron may increase patient compliance due to more convenient dosing schedules.\nUnlike currently marketed pegylated interferons, Locteron\u2019s interferon alfa is not chemically modified\nby conjugation with PEG. We believe that Locteron\u2019s interferon more closely mimics naturally\noccurring interferon as it is produced by the body. We believe each of these factors may lead to\nimproved efficacy.\n", "page_number": 55, "bounding_box": {"top_left_x": 0.16878402903811252, "top_left_y": 0.23577235772357724, "lower_right_x": 0.8802177858439202, "lower_right_y": 0.5121951219512195, "height": 0.2764227642276423, "width": 0.7114337568058077}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-55-5", "text": "", "page_number": 55, "bounding_box": {"top_left_x": 0.1367211131276467, "top_left_y": 0.24304664099272572, "lower_right_x": 0.14277071990320628, "lower_right_y": 0.24604193410355157, "height": 0.0029952931108258585, "width": 0.006049606775559574}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-55-6", "text": "\u00b7\n", "page_number": 55, "bounding_box": {"top_left_x": 0.1355111917725348, "top_left_y": 0.3247753530166881, "lower_right_x": 0.14519056261343014, "lower_right_y": 0.33119383825417203, "height": 0.006418485237483951, "width": 0.009679370840895346}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-55-7", "text": "\u00b7\n", "page_number": 55, "bounding_box": {"top_left_x": 0.1355111917725348, "top_left_y": 0.4206247325631151, "lower_right_x": 0.14519056261343014, "lower_right_y": 0.42704321780059906, "height": 0.006418485237483951, "width": 0.009679370840895346}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-55-8", "text": "Locteron Development Activities and Strategy\n", "page_number": 55, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.5267436884895165, "lower_right_x": 0.45493042952208107, "lower_right_y": 0.540436456996149, "height": 0.01369276850663248, "width": 0.33454325468844526}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-55-9", "text": "   We have completed patient treatment with Locteron in a Phase IIa study in HCV patients. We are preparing\nfor Locteron to enter a Phase IIb study in the middle of 2008. We also intend to commence a separate study in\nthe United States in a difficult-to-treat patient population later this year or in the first quarter of 2008.\n", "page_number": 55, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.5541292255027813, "lower_right_x": 0.8663036902601331, "lower_right_y": 0.5952075310226786, "height": 0.04107830551989733, "width": 0.7459165154264973}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-55-10", "text": "Locteron Phase I Study\n", "page_number": 55, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.6089002995293111, "lower_right_x": 0.2849364791288566, "lower_right_y": 0.6230209670517758, "height": 0.014120667522464658, "width": 0.16938898971566846}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-55-11", "text": "   In April 2006, we completed a single escalating dose Phase I clinical study of Locteron in healthy volunteers.\nThe Locteron Phase I study was a double-blind, randomized, placebo-controlled, single-dose escalation study in\n27 healthy male volunteers designed to evaluate the safety, pharmacokinetics and pharmacodynamics of\nLocteron in comparison with PEG-Intron. The Phase I results showed that Locteron was safe and well tolerated.\nSubjects receiving Locteron reported flu-like symptoms that were fewer, less severe and of shorter duration than\nin the subjects receiving PEG-Intron. None of the subjects receiving Locteron reported any serious adverse\nevents at any dosage level.\n", "page_number": 55, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.636285836542576, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.7325631151048353, "height": 0.09627727856225932, "width": 0.7604355716878403}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-55-12", "text": "   Furthermore, Locteron was shown to have a positive effect on two biomarkers that are believed to correlate to\nthe performance of interferons in the target patient population, which we believe provided a preliminary\nindication of efficacy. The first biomarker, an enzyme known as 2\u20195\u2019-oligoadenylate synthetase (\u201cOAS\u201d), is a\nbiological marker for the activity of interferon alfa. In the Phase I study, Locteron resulted in a sustained\nincrease in OAS levels. The second biomarker, neopterin, is an early indicator of cell-mediated immunity. It is\ngenerally accepted that elevated levels of neopterin indicate that an immune response has been induced by the\npresence of interferon in the blood stream. The results of the Phase I study indicate that subjects receiving\nLocteron at all three doses had a sustained immune response induced by the presence of Locteron.\n", "page_number": 55, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.7458279845956355, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.8557980316645272, "height": 0.10997004706889169, "width": 0.7604355716878403}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-55-13", "text": "53\n", "page_number": 55, "bounding_box": {"top_left_x": 0.8608590441621294, "top_left_y": 0.9477963200684638, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9572100984167736, "height": 0.00941377834830981, "width": 0.019963702359346636}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-56-0", "text": "Locteron Phase IIa Study\n", "page_number": 56, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.08515190415062045, "lower_right_x": 0.3000604960677556, "lower_right_y": 0.09927257167308515, "height": 0.0141206675224647, "width": 0.18451300665456744}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-56-1", "text": "   The Locteron Phase IIa study, known as SELECT-1 (Safety and Efficacy of Locteron; European Clinical\nTrial-1), was a European multi-center, open label study in 32 treatment-na\u00efve patients with genotype I chronic\nHCV. The study was designed to test the safety and tolerability of Locteron and to evaluate preliminary efficacy\nover a course of multiple injections. The goal was to select doses to be tested in a subsequent Phase IIb study,\nwhich will be designed to examine the potential efficacy of Locteron. As part of this clinical trial, we evaluated\nthe safety and tolerability of Locteron in patients over a 12-week period. In addition, we analyzed early viral\nresponse (\u201cEVR\u201d), which is defined as a reduction of at least two logs in hepatitis C virus after 12 weeks of\ntreatment, and assessed OAS and neopterin levels.\n", "page_number": 56, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.11253744116388532, "lower_right_x": 0.8747731397459165, "lower_right_y": 0.2220795892169448, "height": 0.10954214805305947, "width": 0.7543859649122807}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-56-2", "text": "   A total of 32 patients were enrolled and tested in the Phase IIa study. Each subject was treated for 12 weeks,\nreceiving six injections of Locteron in accordance with our proposed once-every-two-weeks dosing schedule.\nInitially, doses of 160\u00b5g, 320\u00b5g and 480\u00b5g were given to three cohorts consisting of eight patients each. Based\non a favorable safety review of the results from the first three cohorts, a fourth cohort of eight patients received\n640\u00b5g of Locteron per injection. All patients also received oral ribavirin in accordance with standard\ncombination therapy practices for the use of pegylated interferons. Following this initial 12-week period, all\npatients ceased treatment with Locteron and were offered PEG-Intron with ribavirin in accordance with the\ncurrent standard of care.\n", "page_number": 56, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.23577235772357724, "lower_right_x": 0.8711433756805808, "lower_right_y": 0.34403080872913994, "height": 0.1082584510055627, "width": 0.7507562008469449}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-56-3", "text": "   The results of the study showed that 12 weeks of treatment with Locteron in combination with ribavirin was\neffective in reducing hepatitis C virus levels. As illustrated in the graph below, patients in each of the four\ncohorts showed anti-viral response.\n", "page_number": 56, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.3590072742832692, "lower_right_x": 0.8663036902601331, "lower_right_y": 0.40051347881899874, "height": 0.04150620453572956, "width": 0.7459165154264973}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-56-4", "text": "     Viral Response to Treatment with Locteron and Ribavirin\nAverage Log Reduction in Hepatitis C Virus from Baseline at 12 Weeks\n", "page_number": 56, "bounding_box": {"top_left_x": 0.294615849969752, "top_left_y": 0.417201540436457, "lower_right_x": 0.7065940713853599, "lower_right_y": 0.4407359863072315, "height": 0.023534445870774467, "width": 0.4119782214156079}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-56-5", "text": "SELECT-1 Trial = 160\n\n \n\n4\n0 14 28 42 56 70 64\nDays", "page_number": 56, "bounding_box": {"top_left_x": 0.28977616454930427, "top_left_y": 0.48267008985879334, "lower_right_x": 0.7162734422262553, "lower_right_y": 0.7205819426615319, "height": 0.23791185280273852, "width": 0.42649727767695106}, "blob_type": "image", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-56-6", "text": "   The viral response in the study was dose dependent as patients treated in the 320\u00b5g, 480\u00b5g and 640\u00b5g dose\ncohorts achieved greater reduction in hepatitis C virus than patients in the 160\u00b5g dose cohort at all measurement\ntimes. Average viral reduction after 12 weeks of treatment for patients in the 320\u00b5g, 480\u00b5g and 640\u00b5g dose\ncohorts was 4.48, 4.22 and 4.72 logs, respectively, compared to 1.83 logs in the lowest dose of 160\u00b5g.\n", "page_number": 56, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.762943945228926, "lower_right_x": 0.8802177858439202, "lower_right_y": 0.8181429182712879, "height": 0.05519897304236199, "width": 0.7598306110102844}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-56-7", "text": "   Furthermore, the percentage of patients who achieved EVR was 87.5%, 100% and 100% in the 320\u00b5g, 480\u00b5g\nand 640\u00b5g dose cohorts, respectively, compared to 37.5% in the 160\u00b5g dose cohort. This includes data from the\nlast observation of one patient who discontinued 640 \u00b5g treatment before the EVR endpoint was reached at 12\nweeks. In each of the 320 \u00b5g and 480\u00b5g cohorts, five of the eight patients, or 62.5%, had undetectable (or less\nthan 28 IU/ml) levels of hepatitis C virus after 12 weeks of treatment, compared to one patient, or 12.5%, of the\n", "page_number": 56, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.8314077877620881, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9002995293110826, "height": 0.06889174154899447, "width": 0.7604355716878403}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-56-8", "text": "54\n", "page_number": 56, "bounding_box": {"top_left_x": 0.8608590441621294, "top_left_y": 0.9477963200684638, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9572100984167736, "height": 0.00941377834830981, "width": 0.019963702359346636}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-57-0", "text": "eight patients in the 160\u00b5g cohort. In the 640\u00b5g cohort, four of the seven patients who completed the trial had\nundetectable levels of hepatitis C virus after 12 weeks of treatment.\n", "page_number": 57, "bounding_box": {"top_left_x": 0.12099213551119177, "top_left_y": 0.08515190415062045, "lower_right_x": 0.8614640048396854, "lower_right_y": 0.11296534017971759, "height": 0.02781343602909714, "width": 0.7404718693284936}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-57-1", "text": "   The viral responses of patients in the study at 12 weeks compared favorably to results reported in prior\nclinical trials for other interferons. In particular, we believe the viral responses reported for the three higher\ncohorts, 320\u00b5g, 480\u00b5g and 640\u00b5g doses, indicate that Locteron has the potential to provide efficacy equal to or\nbetter than currently marketed hepatitis C treatments.\n", "page_number": 57, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.12623020967051776, "lower_right_x": 0.8711433756805808, "lower_right_y": 0.18142918271287975, "height": 0.05519897304236199, "width": 0.7507562008469449}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-57-2", "text": "   In addition, the trial results demonstrated that Locteron was generally safe and well tolerated. We assessed\nthe safety and tolerability of Locteron based on the frequency and severity of adverse events. The frequency of\nadverse events was determined based on the number of patients who experienced adverse events. The severity of\nadverse events was determined based on a rating system that is commonly used in clinical trials. Mild adverse\nevents are characterized by symptoms which are easily tolerated. Moderate adverse events are those that cause\nsufficient discomfort to interfere with the patient\u2019s usual activities. Severe adverse events are those which\nincapacitate and prevent the patient from engaging in normal activities, such as work. Serious adverse events are\ndefined as adverse events that require hospitalization or are considered life threatening or result in death.\n", "page_number": 57, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.19469405220367994, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.30466409927257165, "height": 0.10997004706889171, "width": 0.7604355716878403}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-57-3", "text": "   In all four cohorts of the study, the majority of the adverse events was classified as mild and all adverse\nevents were limited to flu-like symptoms and other side effects that are typically associated with interferon\ntreatment in this patient population. In the first three cohorts, 160\u00b5g, 320\u00b5g and 480\u00b5g, no serious adverse\nevents were observed and over 90% of the adverse events were classified as mild. Only one adverse event in\nthese cohorts was classified as severe, which was one patient in the 320\u00b5g cohort, who experienced fever of\nsevere intensity. In addition, in the first three cohorts, only two patients required dose reductions, including one\npatient in the 320\u00b5g cohort due to a low neutrophil count and one patient in the 480\u00b5g cohort due to a low\nplatelet count. Both of these side effects are common with interferon treatment. Importantly, no patients in the\nfirst three cohorts discontinued treatment over the 12-week period.\n", "page_number": 57, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.31792896876337184, "lower_right_x": 0.8711433756805808, "lower_right_y": 0.441591784338896, "height": 0.12366281557552417, "width": 0.7507562008469449}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-57-4", "text": "   In the 640\u00b5g cohort, over 85% of the adverse events was classified as mild. At the highest dose level, one\nserious adverse event was observed. One patient was hospitalized because of a low neutrophil count and middle\near infection. This patient received a reduced dose of Locteron of 160\u00b5g and subsequently discontinued\ntreatment with Locteron after the fifth dose. All other patients in this cohort completed the full Locteron\ntreatment.\n", "page_number": 57, "bounding_box": {"top_left_x": 0.12099213551119177, "top_left_y": 0.4548566538296962, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.5237483953786907, "height": 0.06889174154899447, "width": 0.7549909255898366}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-57-5", "text": "   We believe the safety and tolerability results position Locteron favorably compared to other treatments\nbecause patients receiving Locteron experienced side effects that were less frequent and less severe than those\nreported in the results of previous clinical trials for the currently marketed pegylated interferons and Albuferon,\na long-acting formulation of interferon alfa being developed by Human Genome Sciences and Novartis.\n", "page_number": 57, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.540436456996149, "lower_right_x": 0.8693284936479129, "lower_right_y": 0.5943517329910141, "height": 0.05391527599486512, "width": 0.7489413188142771}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-57-6", "text": "Planned Locteron Phase IIb Study\n", "page_number": 57, "bounding_box": {"top_left_x": 0.1191772534785239, "top_left_y": 0.6089002995293111, "lower_right_x": 0.3629764065335753, "lower_right_y": 0.6225930680359435, "height": 0.013692768506632369, "width": 0.24379915305505143}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-57-7", "text": "   We intend to accumulate further data about the clinical benefits of Locteron in a Phase IIb study. The Phase\nIIb study, known as SELECT-2 (Safety and Efficacy of Locteron; European Clinical Trial-2) will seek to\nexamine the efficacy of Locteron in direct comparison with a pegylated interferon, in addition to evaluating its\nsafety and tolerability profile in approximately 100 patients.\n", "page_number": 57, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.636285836542576, "lower_right_x": 0.8663036902601331, "lower_right_y": 0.691484809584938, "height": 0.05519897304236199, "width": 0.7459165154264973}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-57-8", "text": "   We plan to conduct a multi-center, double-blind trial of Locteron, testing three different doses in treatment-\nna\u00efve patients for 48 weeks, the typical treatment period for patients suffering from chronic HCV infection with\ngenotype 1. These three Locteron patient cohorts will be compared with one equally sized cohort of patients\nreceiving PEG-Intron. All four patient cohorts will receive ribavirin treatment contemporaneously with\ninterferon therapy. The 12-week response data from this study are expected to provide significant guidance\nregarding the clinically appropriate dose of Locteron for our Phase III study.\n", "page_number": 57, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.7047496790757382, "lower_right_x": 0.8711433756805808, "lower_right_y": 0.787334189131365, "height": 0.08258451005562684, "width": 0.7507562008469449}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-57-9", "text": "Planned Locteron Tolerability Study Enabling Treatment in Difficult-to-Treat Patient Population\n", "page_number": 57, "bounding_box": {"top_left_x": 0.11857229280096794, "top_left_y": 0.8005990586221652, "lower_right_x": 0.7973381730187538, "lower_right_y": 0.8147197261446298, "height": 0.014120667522464658, "width": 0.6787658802177858}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-57-10", "text": "   As a part of our clinical development strategy for Locteron, we are preparing a parallel program to\ndemonstrate the efficacy and safety of Locteron in difficult-to-treat patient populations, including African-\nAmericans. These populations are underserved in terms of effective HCV treatments, as these populations\ntypically respond poorly to interferons. We believe that Locteron, because of its expected tolerability profile at\nhigh doses, has the potential to improve treatment response in these populations. Because of the higher\nincidence of scarring associated with injections in highly pigmented people in general, we are preparing for an\n", "page_number": 57, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.82798459563543, "lower_right_x": 0.8663036902601331, "lower_right_y": 0.9105691056910569, "height": 0.08258451005562684, "width": 0.7459165154264973}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-57-11", "text": "55\n", "page_number": 57, "bounding_box": {"top_left_x": 0.8608590441621294, "top_left_y": 0.9477963200684638, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9572100984167736, "height": 0.00941377834830981, "width": 0.019963702359346636}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-58-0", "text": "initial dedicated study focusing on local tolerability of Locteron in non-African-American difficult-to-treat\npatients. This study will evaluate the safety and tolerability of subcutaneous injections of 320 \u00b5g and 640 \u00b5g of\nLocteron dosed every two weeks for four weeks, followed by a four-week observation period, and will include\nextensive dermatological assessments. This clinical study would be conducted in the United States under an\nInvestigational New Drug application and will precede a further safety, tolerability and preliminary efficacy\nstudy in difficult-to-treat patients, including African-Americans.\n", "page_number": 58, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.08515190415062045, "lower_right_x": 0.8711433756805808, "lower_right_y": 0.16773641420624733, "height": 0.08258451005562688, "width": 0.7507562008469449}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-58-1", "text": "   We held a \u201cpre-IND\u201d meeting with the FDA to discuss the Chemistry Manufacturing and Controls (\u201cCMC\u201d)\npackage, the pre-clinical safety program and the intended design of our Phase IIb trial. At the meeting, we\nreceived in-principle agreement from the FDA for our plans for the Phase IIb study. We have received similar\nagreement from the Dutch Medical Evaluation Board.\n", "page_number": 58, "bounding_box": {"top_left_x": 0.12099213551119177, "top_left_y": 0.1810012836970475, "lower_right_x": 0.8711433756805808, "lower_right_y": 0.2362002567394095, "height": 0.055198973042362015, "width": 0.7501512401693889}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-58-2", "text": "Manufacturing\n", "page_number": 58, "bounding_box": {"top_left_x": 0.12099213551119177, "top_left_y": 0.24989302524604193, "lower_right_x": 0.2323049001814882, "lower_right_y": 0.2635857937526744, "height": 0.013692768506632452, "width": 0.11131276467029642}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-58-3", "text": "  BLX-883, the interferon alfa ingredient in Locteron, is produced in accordance with cGMP by our co-\ndevelopment partner, Biolex, at its facilities in North Carolina. BLX-883 is produced in genetically engineered\nLemna, a clonal higher aquatic plant system. Biolex will be responsible for the manufacture of all future\nsupplies of BLX-883, both for clinical trials and for eventual commercial supply.\n", "page_number": 58, "bounding_box": {"top_left_x": 0.11796733212341198, "top_left_y": 0.2768506632434745, "lower_right_x": 0.8656987295825771, "lower_right_y": 0.33204963628583656, "height": 0.05519897304236204, "width": 0.7477313974591651}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-58-4", "text": "   We are manufacturing Locteron by combining our PolyActive microspheres with BLX-883 for the Phase II\nclinical studies in our licensed pilot plant facility in Leiden, the Netherlands. As we plan to out-license Locteron\nbefore commencing Phase III clinical trials, the manufacturing of Locteron required for Phase III clinical trials\nand for any future commercial supply will be decided in conjunction with Biolex and a future commercialization\npartner.\n", "page_number": 58, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.34873769790329484, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.4146341463414634, "height": 0.06589644843816855, "width": 0.7604355716878403}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-58-5", "text": "Marketing and Sales\n", "page_number": 58, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.43089430894308944, "lower_right_x": 0.27041742286751363, "lower_right_y": 0.4441591784338896, "height": 0.013264869490800135, "width": 0.15003024803387782}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-58-6", "text": "   Before commencing Phase III clinical trials, we and Biolex intend to enter into one or more commercial\npartnerships with third parties, under which such third parties would assume responsibility for further clinical\ntrials, registration and commercialization of Locteron in all major markets. As part of that commercial\npartnership, we and/or Biolex may decide to retain certain rights for the co-promotion of Locteron in certain\ngeographic areas.\n", "page_number": 58, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.4582798459563543, "lower_right_x": 0.8560193587416818, "lower_right_y": 0.5267436884895165, "height": 0.06846384253316218, "width": 0.735632183908046}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-58-7", "text": "Other Indications for Locteron\n", "page_number": 58, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.540436456996149, "lower_right_x": 0.34361766485178463, "lower_right_y": 0.5515618314077878, "height": 0.011125374411638855, "width": 0.22323049001814882}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-58-8", "text": "   In addition to the treatment of chronic HCV infection, interferon alfa is registered or in development for the\ntreatment of a number of other diseases, such as hepatitis B, AIDS-related Kaposi\u2019s sarcoma and malignant\nmelanoma. We or a future commercial partner may consider seeking approval for Locteron for the treatment of\nthese or other additional indications at some point in the future. We anticipate that separate clinical development\nprograms would need to be undertaken in order to gain approval of Locteron for these additional indications.\n", "page_number": 58, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.5678219940094138, "lower_right_x": 0.8802177858439202, "lower_right_y": 0.6367137355584083, "height": 0.06889174154899447, "width": 0.7598306110102844}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-58-9", "text": "OP-145 CSOM for Chronic Middle Ear Infection\n", "page_number": 58, "bounding_box": {"top_left_x": 0.32425892316999394, "top_left_y": 0.6499786050492083, "lower_right_x": 0.677555958862674, "lower_right_y": 0.6640992725716731, "height": 0.01412066752246477, "width": 0.35329703569268}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-58-10", "text": "   OP-145 CSOM is our novel, proprietary peptide therapeutic in Phase II clinical development for the treatment\nof chronic middle ear infection (also referred to as chronic otitis media), administered locally through an eardrop\nformulation. Chronic middle ear infection is one of the most common childhood chronic infectious diseases\nworldwide. It is the most frequently recorded diagnosis for children in the United States and is the most\ncommon reason for a child being prescribed oral antibiotics. We believe that worldwide approximately 200\nmillion people have a chronic middle ear infection. Approximately 60% of those suffering from chronic middle\near infection experience some degree of hearing impairment as a result of infection.\n", "page_number": 58, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.6773641420624733, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.7736414206247325, "height": 0.0962772785622592, "width": 0.7604355716878403}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-58-11", "text": "   Acute middle ear infections are caused by a range of microbes, including bacteria and various fungi. These\nacute infections are usually easily eradicated by the use of common antibiotics. However, a more serious\ncondition may occur when certain toxic microbial degradation products linger in the mucus of the middle ear\nafter the eradication of the microbes associated with an acute infection. In these circumstances, we believe the\npresence of these toxins contributes to chronic middle ear infection. The toxins associated with chronic middle\near infection are unresponsive to traditional antibiotics. Often, surgical procedures are required to treat these\nchronic infections and clear the degradation products from the site of infection.\n", "page_number": 58, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.7903294822421908, "lower_right_x": 0.8644888082274652, "lower_right_y": 0.8848951647411211, "height": 0.09456568249893027, "width": 0.7441016333938294}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-58-12", "text": "56\n", "page_number": 58, "bounding_box": {"top_left_x": 0.8608590441621294, "top_left_y": 0.9477963200684638, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9572100984167736, "height": 0.00941377834830981, "width": 0.019963702359346636}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-59-0", "text": "   OP-145 CSOM is designed to neutralize these toxins at the site of infection and to locally restore the body\u2019s\nnatural clearance mechanism. We have demonstrated in pre-clinical studies that OP-145 CSOM binds to and\nclears two important bacterial toxins known as lipopolysaccharide (\u201cLPS\u201d) and lipoteichoic acid (\u201cLTA\u201d). Both\nLPS and LTA are common constituents in the cell walls of bacteria and are released into the middle ear when\nthe various bacteria that cause middle ear infection are destroyed by the immune system or by antibiotics.\n", "page_number": 59, "bounding_box": {"top_left_x": 0.12099213551119177, "top_left_y": 0.08515190415062045, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.1540436456996149, "height": 0.06889174154899445, "width": 0.7549909255898366}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-59-1", "text": "   In addition, we have demonstrated in pre-clinical studies that OP-145 CSOM interacts with lipid components\non the surface of bacteria typically associated with chronic middle ear infection. By binding to these surface\ncomponents, OP-145 CSOM destabilizes the cell membrane leading to bacterial cell death. In light of these two\ncharacteristics, we believe that OP-145 CSOM may offer benefits for patients with chronic middle ear infection\nthat cannot be treated adequately with current therapies.\n", "page_number": 59, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.16730851519041506, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.2362002567394095, "height": 0.06889174154899444, "width": 0.7555958862673926}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-59-2", "text": "   In April 2006, we completed a Phase I/IIa safety and tolerability study comprising a dose-ranging assessment\nin 16 therapy-resistant patients who had average disease duration of 17 years. Results from this study show that\nOP-145 CSOM was safe and well tolerated.\n", "page_number": 59, "bounding_box": {"top_left_x": 0.12159709618874773, "top_left_y": 0.24946512623020967, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.28968763371844247, "height": 0.040222507488232806, "width": 0.7543859649122807}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-59-3", "text": "  We are currently conducting a double-blind, placebo-controlled Phase II study in 52 patients. We expect to\ncomplete patient treatment by the end of 2007 and plan to announce the trial results in the first half of 2008.\n", "page_number": 59, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.3042362002567394, "lower_right_x": 0.8566243194192378, "lower_right_y": 0.33204963628583656, "height": 0.02781343602909714, "width": 0.736237144585602}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-59-4", "text": "Disease Background, Market Opportunity and Limitations of Existing Products\n", "page_number": 59, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.34873769790329484, "lower_right_x": 0.6920750151240169, "lower_right_y": 0.36157466837826274, "height": 0.012836970474967901, "width": 0.5716878402903811}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-59-5", "text": "   The middle ear is a hollow chamber in the bone of the skull. A thin membrane, the eardrum or tympanic\nmembrane, separates the middle ear from the outside world. The Eustachian tube, a narrow passage, connects\nthe middle ear to the back of the nose. The Eustachian tube is closed until a swallowing movement pulls it open\nand allows air to flow from the nose into the middle ear. The fresh air balances pressure inside the middle ear\nand outside the head. Normally, the pressure difference arises from oxygen absorption by the cells lining the\nmiddle ear.\n", "page_number": 59, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.3761232349165597, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.45528455284552843, "height": 0.07916131792896874, "width": 0.7555958862673926}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-59-6", "text": "   If the Eustachian tube becomes blocked, the air pressure in the middle ear cannot equalize properly. Negative\npressure develops and if the obstruction is prolonged, fluid may be drawn into the air space of the middle ear\nfrom surrounding tissue. Many infections may give rise to this situation, including infection with the common\ncold or a flu virus. The common cold is a frequent cause of acute middle ear infections in children. Acute\nmiddle ear infections typically resolve without treatment, but may in certain circumstances require a course of\nantibiotics or steroids. Acute middle ear infections are a common reason for the placement of artificial tubes in\nthe eardrums of children and adults in order to release pressure and promote the discharge of debris.\n", "page_number": 59, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.4719726144629867, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.5678219940094138, "height": 0.09584937954642708, "width": 0.7555958862673926}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-59-7", "text": "   If the blockage of the Eustachian tube persists, negative pressure in the middle ear or alternating periods of\nnegative, normal and positive pressure may deform the eardrum. These changes may cause hearing loss and a\nsensation of pressure. In chronic infections, a majority of patients will develop severely distorted eardrums that\nwill eventually become perforated. When there is a hole in the eardrum, the natural protection of the middle ear\nfrom the environment is lost. Water and bacteria can enter the middle ear from the ear canal causing\ninflammation and infection.\n", "page_number": 59, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.5815147625160462, "lower_right_x": 0.8711433756805808, "lower_right_y": 0.660676080445015, "height": 0.07916131792896886, "width": 0.7507562008469449}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-59-8", "text": "   Acute infections in the middle ear can lead to a vicious cycle of inflammatory reactions which leads to\nchronic middle ear infection. As a result of incomplete recovery from an initial bacterial infection, tissue in the\nmiddle ear may become inflamed. As a result of this inflammation, this tissue becomes more susceptible to\nrecurrent and persistent re-infection by the same or other infectious microbes. During these infections, bacterial\ntoxins such as LPS and LTA play a large role in continuing the vicious process of infections. These toxins can\ninduce an inflammatory reaction in the middle ear and can induce injury to the tissue lining the middle ear, the\nso-called mucous membrane. Initially, mucous secretions become thicker, and therefore less likely to drain, if at\nall. Subsequently, the membranes themselves begin to thicken and become inflamed. The natural defense\nmechanisms of the Eustachian tube and middle ear begin to fail and are unable to restore a healthy balance.\n", "page_number": 59, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.6773641420624733, "lower_right_x": 0.8753781004234725, "lower_right_y": 0.8010269576379975, "height": 0.12366281557552417, "width": 0.7549909255898367}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-59-9", "text": "  Chronic local inflammation can cause erosion of the ossicles and the walls of the middle and inner ear.\nPatients with chronic middle ear infection may experience hearing loss, imbalance, or weakness of facial\nmovement on the affected side.\n", "page_number": 59, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.8142918271287976, "lower_right_x": 0.8312159709618875, "lower_right_y": 0.8536585365853658, "height": 0.03936670945656828, "width": 0.7108287961282517}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-59-10", "text": "   Most patients with infections of the middle ear are treated initially with antibiotics. These can be either\nsystemically applied or delivered directly into the ear through the use of liquid drops. However, antibiotic\ntreatment of chronic middle ear infection has limited efficacy. As antibiotics do not assist in the removal or\n", "page_number": 59, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.8690629011553274, "lower_right_x": 0.8421052631578947, "lower_right_y": 0.9105691056910569, "height": 0.04150620453572951, "width": 0.7217180883242589}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-59-11", "text": "57\n", "page_number": 59, "bounding_box": {"top_left_x": 0.8608590441621294, "top_left_y": 0.9477963200684638, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9572100984167736, "height": 0.00941377834830981, "width": 0.019963702359346636}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-60-0", "text": "degradation of LPS and LTA, there is a risk of infection re-emergence. When bacteria are not fully eradicated\nfrom the middle ear and inflammatory conditions persist due to the presence of LPS and LTA there is a\nconsiderable risk of the development of antibiotic-resistant bacteria colonizing the middle ear. The use of\nadditional antibiotics typically does not assist in the clearance of these resistant bacteria nor will they assist in\nthe removal of bacterial toxins such as LPS and LTA.\n", "page_number": 60, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.08515190415062045, "lower_right_x": 0.8614640048396854, "lower_right_y": 0.15062045357295678, "height": 0.06546854942233633, "width": 0.7410768300060496}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-60-1", "text": "   In the event that patients do not respond to multiple courses of antibiotic treatment, surgery on the middle ear\nis often performed in a bid to clear the mucus of toxins and thereby alleviate recurrent inflammation.\nUnfortunately, a significant number of patients do not benefit from surgery and will experience recurrent\ninfection after this interventional procedure.\n", "page_number": 60, "bounding_box": {"top_left_x": 0.12099213551119177, "top_left_y": 0.16730851519041506, "lower_right_x": 0.8753781004234725, "lower_right_y": 0.2220795892169448, "height": 0.054771074026529726, "width": 0.7543859649122807}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-60-2", "text": "    Chronic middle ear infection is one of the most common childhood chronic infectious diseases worldwide. It\nis the most frequently recorded diagnosis for children in the United States and is the most common reason for a\nchild being prescribed oral antibiotics. We believe that worldwide approximately 200 million people have a\nchronic middle ear infection. Approximately 60% of those suffering from chronic middle ear infection\nexperience some degree of hearing impairment. We believe that approximately $400 million is spent on\nantibiotic treatment of chronic middle ear infection annually.\n", "page_number": 60, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.23577235772357724, "lower_right_x": 0.8711433756805808, "lower_right_y": 0.31835686777920413, "height": 0.08258451005562689, "width": 0.7507562008469449}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-60-3", "text": "Anticipated Advantages of OP-145 CSOM\n", "page_number": 60, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.33504492939666236, "lower_right_x": 0.42589231699939506, "lower_right_y": 0.34745400085579803, "height": 0.012409071459135668, "width": 0.30550514216575925}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-60-4", "text": "   We have demonstrated in pre-clinical studies that OP-145 CSOM has a different mechanism of action than\ncurrently approved treatments for chronic middle ear infection. Anticipated advantages of OP-145 CSOM\ninclude:\n", "page_number": 60, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.36243046640992727, "lower_right_x": 0.8560193587416818, "lower_right_y": 0.40051347881899874, "height": 0.03808301240907147, "width": 0.735632183908046}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-60-5", "text": "\u00b7   Dual Mechanism of Action. We believe that we may be able to achieve better outcomes for patients as\n    a result of the dual mechanism of action of OP-145 CSOM that combines antibacterial traits with anti-\n    inflammatory effects as levels of the toxins LPS and LTA are reduced in the mucus of the middle ear.\n\n\u00b7   Reduced Risk of Resistance. The antibacterial activity of OP-145 CSOM targets constituent elements\n    of the surface of bacterial cells which are integral to bacterial survival and inherently less subject to\n    mutation, thereby reducing the risk of resistant strains of bacteria developing. Furthermore, the clearance\n    activity of OP-145 CSOM is not expected to be subject to resistance.\n\n\u00b7   Alternative to Continued Antibiotic Treatment and Surgery. OP-145 CSOM is administered by\n    patients and delivered via liquid drops and could serve as an alternative therapy to continued treatment\n    with antibiotics or eventually surgery.\n", "page_number": 60, "bounding_box": {"top_left_x": 0.13490623109497882, "top_left_y": 0.417201540436457, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.5819426615318785, "height": 0.16474112109542144, "width": 0.7459165154264973}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-60-6", "text": "Development Activities and Strategies\n", "page_number": 60, "bounding_box": {"top_left_x": 0.12099213551119177, "top_left_y": 0.5952075310226786, "lower_right_x": 0.39201451905626133, "lower_right_y": 0.6093281985451433, "height": 0.014120667522464658, "width": 0.2710223835450696}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-60-7", "text": "   Based on the anticipated advantages of OP-145 CSOM, we intend initially to focus on chronic middle ear\ninfection patients who do not respond to current treatment approaches, including patients who have recurrent\nchronic middle ear infection despite having undergone surgery. All patients in our past and planned clinical\ntrials have perforated eardrums.\n", "page_number": 60, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.6225930680359435, "lower_right_x": 0.8566243194192378, "lower_right_y": 0.6777920410783055, "height": 0.05519897304236199, "width": 0.736237144585602}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-60-8", "text": "    In the pre-clinical studies of OP-145 CSOM that we have conducted to date, such as the typical tests used to\nexamine the toxicological profile of new therapeutic agents, we did not see evidence of skin or lasting eye\nirritation in animal models.\n", "page_number": 60, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.6910569105691057, "lower_right_x": 0.8663036902601331, "lower_right_y": 0.7325631151048353, "height": 0.04150620453572962, "width": 0.7459165154264973}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-60-9", "text": "OP-145 CSOM Phase I/IIa Clinical Study in Chronic Middle Ear Infection\n", "page_number": 60, "bounding_box": {"top_left_x": 0.12099213551119177, "top_left_y": 0.7492511767222936, "lower_right_x": 0.6430732002419842, "lower_right_y": 0.7633718442447582, "height": 0.014120667522464658, "width": 0.5220810647307924}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-60-10", "text": "   We have completed a Phase I/IIa safety and tolerability study that included a dose-ranging assessment in 16\ntherapy-resistant patients with average disease duration of 17 years. Certain patients in this study had also\nundergone surgery for treatment of resistant chronic middle ear infection without a successful clinical outcome.\nAll patients had perforated eardrums. OP-145 CSOM was delivered via liquid drops into the ear canal and was\nadministered twice a day for two weeks. Four different dosages were tested: 0.25mg/mL, 0.5mg/mL, 1.0mg/mL\nand 2.0mg/mL.\n", "page_number": 60, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.7766367137355584, "lower_right_x": 0.8735632183908046, "lower_right_y": 0.8579375267436885, "height": 0.08130081300813008, "width": 0.7531760435571688}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-60-11", "text": "  This study assessed the safety and tolerability of OP-145 CSOM through an examination of hearing levels\nand serum analysis. In addition, we also examined the efficacy of OP-145 CSOM, though this was not a\n", "page_number": 60, "bounding_box": {"top_left_x": 0.12099213551119177, "top_left_y": 0.8724860932819855, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.8998716302952503, "height": 0.02738553701326485, "width": 0.7307924984875983}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-60-12", "text": "58\n", "page_number": 60, "bounding_box": {"top_left_x": 0.8608590441621294, "top_left_y": 0.9477963200684638, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9572100984167736, "height": 0.00941377834830981, "width": 0.019963702359346636}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-61-0", "text": "statistical endpoint of the trial. Efficacy was measured through the application of a mucosal endoscopic score,\nwhich gauged the level of inflammation of the mucus in the middle ear of all patients.\n", "page_number": 61, "bounding_box": {"top_left_x": 0.12099213551119177, "top_left_y": 0.08515190415062045, "lower_right_x": 0.8614640048396854, "lower_right_y": 0.11296534017971759, "height": 0.02781343602909714, "width": 0.7404718693284936}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-61-1", "text": "   The results of this study demonstrated that OP-145 CSOM was safe and well tolerated at all dose levels. In\naddition, nine out of 16 patients showed either full recovery or a meaningful improvement after the two week\ncourse of therapy. In particular, seven of the 16 subjects participating in this study reported dry ears (indicating\na complete response) 12 weeks after commencing therapy, the end of the patient follow-up period.\n", "page_number": 61, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.12623020967051776, "lower_right_x": 0.8705384150030248, "lower_right_y": 0.18142918271287975, "height": 0.05519897304236199, "width": 0.7501512401693889}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-61-2", "text": "   Based on these results, we have decided to further develop OP-145 CSOM and have commenced a Phase II\nclinical study specifically designed to assess safety and efficacy. Based on our Phase I/IIa study of OP-145\nCSOM, we selected a 0.5mg/mL concentration for further clinical trials.\n", "page_number": 61, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.19469405220367994, "lower_right_x": 0.8602540834845736, "lower_right_y": 0.2362002567394095, "height": 0.04150620453572956, "width": 0.7398669086509377}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-61-3", "text": "OP-145 CSOM Phase II Clinical Study in Chronic Middle Ear Infection\n", "page_number": 61, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.25288831835686776, "lower_right_x": 0.6243194192377496, "lower_right_y": 0.2652973898160034, "height": 0.012409071459135668, "width": 0.5039322444041138}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-61-4", "text": "   We are currently evaluating OP-145 CSOM in a double blind, placebo-controlled Phase II study in 52\npatients in the Netherlands. The clinical endpoints of the study are the safety and efficacy of OP-145 CSOM.\nThis Phase II study was initially carried out in three sites, but we have recently expanded the study to nine\nclinical centers, following slower than expected patient enrollment. We expect to complete patient treatment in\nthis trial by the end of 2007 and expect to announce results from this study in the first half of 2008.\n", "page_number": 61, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.28027385537013266, "lower_right_x": 0.8656987295825771, "lower_right_y": 0.3478818998716303, "height": 0.06760804450149765, "width": 0.7453115547489413}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-61-5", "text": "Other Indications for OP-145\n", "page_number": 61, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.36243046640992727, "lower_right_x": 0.3339382940108893, "lower_right_y": 0.37312794180573383, "height": 0.010697475395806566, "width": 0.2135511191772535}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-61-6", "text": "   Given its mechanism of action, we believe that there is potential to expand OP-145 into other indications\nwhere the persistent infection of body cavities exposed to the external environment may give rise to chronic\nailments. In particular, we are considering further development of OP-145 for the treatment of chronic sinusitis.\nChronic sinusitis is a very common disease affecting 33 million patients in the United States per year, for which\nthere is no currently approved therapy. In addition, periodontitis (infection at the interface between the teeth and\nthe gums) and a range of eye infections fall within the potential scope of OP-145, as bacterial infection of\nmucous membranes is involved in these conditions. We or a future partner may consider seeking approval for\nOP-145 for the treatment of these or other additional indications at some point in the future. We anticipate that\nseparate clinical development programs would need to be undertaken to gain approval of OP-145 for these\nadditional indications.\n", "page_number": 61, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.3898160034231921, "lower_right_x": 0.8753781004234725, "lower_right_y": 0.5237483953786907, "height": 0.13393239195549855, "width": 0.7549909255898367}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-61-7", "text": "Manufacturing\n", "page_number": 61, "bounding_box": {"top_left_x": 0.12099213551119177, "top_left_y": 0.540436456996149, "lower_right_x": 0.2323049001814882, "lower_right_y": 0.5541292255027813, "height": 0.013692768506632369, "width": 0.11131276467029642}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-61-8", "text": "   The initial supply of OP-145 CSOM for clinical trials was provided by our licensor of OP-145 CSOM,\nLUMC. We have entered into an agreement with a commercial peptide manufacturer for the larger scale\nproduction of OP-145 CSOM for advanced clinical trials. Optimization of the formulation of OP-145 CSOM\nmay involve a switch in salt form, switch in excipients and the execution of a pre-clinical or clinical bridging\nstudy. This decision shall be taken in light of pending pre-clinical data and regulatory feedback.\n", "page_number": 61, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.5678219940094138, "lower_right_x": 0.8566243194192378, "lower_right_y": 0.6367137355584083, "height": 0.06889174154899447, "width": 0.736237144585602}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-61-9", "text": "Marketing and Sales\n", "page_number": 61, "bounding_box": {"top_left_x": 0.12099213551119177, "top_left_y": 0.6508344030808729, "lower_right_x": 0.2710223835450696, "lower_right_y": 0.6640992725716731, "height": 0.01326486949080019, "width": 0.15003024803387782}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-61-10", "text": "   We intend to make a decision regarding our commercialization strategy for OP-145 CSOM upon completion\nof our Phase II clinical trials. We may decide to complete the development of OP-145 CSOM ourselves and\ncommercialize the product in certain territories. In November 2006, we entered into an out-licensing agreement\nwith Green Cross Corporation for the co-development and exclusive commercialization of OP-145 CSOM for\nthe treatment of chronic middle ear infection in South Korea.\n", "page_number": 61, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.6773641420624733, "lower_right_x": 0.8711433756805808, "lower_right_y": 0.7462558836114677, "height": 0.06889174154899436, "width": 0.7507562008469449}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-61-11", "text": "OP-286 CR for Type II Diabetes\n", "page_number": 61, "bounding_box": {"top_left_x": 0.3914095583787054, "top_left_y": 0.762943945228926, "lower_right_x": 0.6243194192377496, "lower_right_y": 0.7757809157038938, "height": 0.012836970474967901, "width": 0.2329098608590442}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-61-12", "text": "   OP-286 CR is our product candidate for the treatment of type II diabetes that is currently in pre-clinical\ndevelopment. OP-286 CR is a controlled-release formulation of OP-286, a GLP-1 analogue we in-licensed from\nTheratechnologies in September 2007. We intend to combine OP-286 with one of our drug delivery\ntechnologies to enable once-every-two-weeks or less frequent administration.\n", "page_number": 61, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.7903294822421908, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.844244758237056, "height": 0.05391527599486523, "width": 0.7604355716878403}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-61-13", "text": "   Type II diabetes, the most common form of diabetes, is a chronic disease in which the body is unable to use\ninsulin properly, resulting in high blood glucose levels. Diabetes may lead to serious health problems, such as\nheart disease and stroke, blindness, nerve damage and kidney failure. As a result, people with diabetes are\nestimated to be twice as likely to have a heart attack or stroke as people who do not have diabetes. Diabetes\n", "page_number": 61, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.858793324775353, "lower_right_x": 0.8663036902601331, "lower_right_y": 0.9135643988018828, "height": 0.05477107402652981, "width": 0.7459165154264973}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-61-14", "text": "59\n", "page_number": 61, "bounding_box": {"top_left_x": 0.8608590441621294, "top_left_y": 0.9477963200684638, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9572100984167736, "height": 0.00941377834830981, "width": 0.019963702359346636}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-62-0", "text": "affects approximately 246 million people worldwide, and the prevalence is projected to increase significantly in\nthe coming years, primarily driven by an increase in obesity, more sedentary lifestyles and, in the developed\nworld, aging populations.\n", "page_number": 62, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.08515190415062045, "lower_right_x": 0.8717483363581368, "lower_right_y": 0.12665810868635002, "height": 0.04150620453572958, "width": 0.7513611615245009}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-62-1", "text": "   Because type II diabetes is associated with excess body fat and physical inactivity, treatment typically begins\nwith healthy diet and exercise. If this is not adequate, patients are given oral anti-diabetic treatments, either\nalone or in combination. In addition, GLP-1 analogues may be prescribed due to their multiple gluco-regulatory\neffects and their demonstrated ability to promote weight loss. Ultimately, insulin injections may be necessary to\nmanage type II diabetes.\n", "page_number": 62, "bounding_box": {"top_left_x": 0.12099213551119177, "top_left_y": 0.1399229781771502, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.20838682071031236, "height": 0.06846384253316218, "width": 0.7549909255898366}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-62-2", "text": "   We anticipate that OP-286 CR will initially be targeted at type II diabetes patients for whom oral anti-diabetic\ntreatments alone are not sufficient, but who do not yet require insulin injections. We anticipate that a once-\nevery-two-weeks or less frequent administration will represent a significant convenience advantage for patients\nas compared to the currently marketed GLP-1 analogue, which requires two injections per day. In addition, over\ntime, we expect GLP-1 analogues to become increasingly important in the treatment paradigm as they are\nincreasingly prescribed in combination with and as substitutes for oral treatments. In addition, we believe GLP-1\nanalogues will be used to delay the use of insulin due to the weight loss benefit, which is important given the\nassociation of type II diabetes with obesity.\n", "page_number": 62, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.2220795892169448, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.33204963628583656, "height": 0.10997004706889177, "width": 0.7604355716878403}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-62-3", "text": "   Theratechnologies has completed initial pre-clinical studies of OP-286, and we plan to expand and complete\nthe pre-clinical profiling of OP-286. After completing the pharmacological profiling of OP-286 and after\ncompleting the initial pre-clinical safety studies, we intend to initiate clinical development of OP-286 CR,\nprovided that the results support that decision.\n", "page_number": 62, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.3453145057766367, "lower_right_x": 0.8693284936479129, "lower_right_y": 0.40051347881899874, "height": 0.05519897304236204, "width": 0.7489413188142771}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-62-4", "text": "Disease Background, Market Opportunity and Limitations of Existing Products\n", "page_number": 62, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.41377834830979887, "lower_right_x": 0.6920750151240169, "lower_right_y": 0.4278990158322636, "height": 0.014120667522464714, "width": 0.5716878402903811}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-62-5", "text": "   Type II diabetes is a metabolic disease characterized by high levels of blood glucose, resulting from the\ninability of the body to use insulin efficiently. Glucose, a simple sugar, is used by cells as a source of energy and\nis essential for normal cell function. Insulin is a peptide hormone naturally secreted by the pancreas to regulate\nglucose. In healthy people, when blood glucose levels are increased after eating, beta cells in the pancreas\nrelease insulin to move glucose into the cells of the body. In people with type II diabetes, however, the cells do\nnot respond sufficiently to the insulin. As a result, glucose builds up in the blood instead of going into cells,\ndepriving the cells of energy needed to function properly.\n", "page_number": 62, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.4411638853230638, "lower_right_x": 0.8777979431336963, "lower_right_y": 0.5400085579803167, "height": 0.09884467265725289, "width": 0.7574107683000605}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-62-6", "text": "   Type II diabetes usually begins as insulin resistance, a condition in which cells do not respond to insulin\nproperly. In the early stages of the disease, beta cells can compensate for insulin resistance by producing excess\namounts of insulin. Eventually, however, due to beta cell loss and beta cell dysfunction, the pancreas may no\nlonger be able to produce enough insulin to overcome insulin resistance, resulting in type II diabetes. Over time,\ntype II diabetes may lead to serious complications, including heart disease and stroke, blindness, nerve damage\nand kidney disease.\n", "page_number": 62, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.5541292255027813, "lower_right_x": 0.8753781004234725, "lower_right_y": 0.6354300385109114, "height": 0.08130081300813008, "width": 0.7549909255898367}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-62-7", "text": "    The International Diabetes Federation estimates that approximately 246 million people worldwide have\ndiabetes and projects this number to increase to 380 million in 2025 with type II diabetes representing 85% to\n95% of diabetes cases. According to the American Diabetes Association, an estimated 21 million people in the\nUnited States, or 7% of the population, has diabetes, and approximately one-third of these people do not know\nthey have the disease. In the United States, diabetes is reported to be the sixth leading cause of death and the\nfifth leading cause of death from disease. On a global basis, the International Diabetes Federation expects\ndiabetes to cause 3.8 million deaths in 2007, representing approximately 6% of mortality.\n", "page_number": 62, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.6499786050492083, "lower_right_x": 0.8656987295825771, "lower_right_y": 0.7458279845956355, "height": 0.09584937954642714, "width": 0.7453115547489413}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-62-8", "text": "   The treatment of type II diabetes typically starts with management of diet and exercise; however, this may not\nbe an effective long-term solution for many patients. When diet and exercise are no longer sufficient, treatment\nbegins with non-insulin oral medications. These oral treatments include metformin, sulfonylureas and\nthiazolidinediones, which act by decreasing glucose production in the liver, increasing insulin secretion and\nimproving insulin sensitivity, respectively. While effective, many oral anti-diabetics are associated with\nsignificant side effects, including weight gain, hypertension and gastrointestinal side effects. In addition, these\noral treatments typically have a limited duration of effectiveness, with most patients requiring a change of\ntherapy or additional medication after five years.\n", "page_number": 62, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.7595207531022679, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.8690629011553274, "height": 0.10954214805305951, "width": 0.7604355716878403}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-62-9", "text": "  When monotherapy fails, combination therapy with two oral agents from different classes may be required. It\nmay also be necessary to add a third agent, such as a GLP-1 analogue or a dipeptidyl peptidase-4 (\u201cDPP-4\u201d)\n", "page_number": 62, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.8827556696619597, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.9105691056910569, "height": 0.02781343602909714, "width": 0.7555958862673926}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-62-10", "text": "60\n", "page_number": 62, "bounding_box": {"top_left_x": 0.8608590441621294, "top_left_y": 0.9477963200684638, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9572100984167736, "height": 0.00941377834830981, "width": 0.019963702359346636}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-63-0", "text": "inhibitor. GLP-1 is an incretin hormone secreted by the L-cells of the intestine after food intake with multiple\ngluco-regulatory mechanisms of action. GLP-1 has been shown to improve beta cell function, stimulate glucose-\ndependent insulin secretion and suppress levels of glucagon, a hormone that causes the release of glucose from\nthe liver. In addition, GLP-1 delays gastric emptying, thereby limiting the rate at which glucose is absorbed in\nthe small intestine, and promotes satiety, which reduces food intake and promotes weight loss. GLP-1 analogues\nwork to mimic the effects of GLP-1, and DPP-4 inhibitors act by inhibiting the enzyme DPP-4, which is\nresponsible for the inactivation of GLP-1, thereby also resulting in higher GLP-1 levels.\n", "page_number": 63, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.08515190415062045, "lower_right_x": 0.8784029038112523, "lower_right_y": 0.1810012836970475, "height": 0.09584937954642704, "width": 0.7580157289776165}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-63-1", "text": "   There is currently only one GLP-1 analogue on the market, Byetta from Amylin and Eli Lilly, which is a\ntwice-daily subcutaneous injection to be administered 60 minutes before meals. Byetta has been associated with\nnausea, vomiting and diarrhea. In addition, we believe the twice-daily dosing regime is considered inconvenient\nfor patients. There is currently also one DPP-4 inhibitor on the market. Merck & Co.\u2019s Januvia (sitagliptin) and\none under FDA review, Novartis\u2019s Galvus (vildagliptin). While DPP-4 inhibitors may be administered orally\nand have not been associated with nausea, they have not demonstrated the weight loss benefits of, and we\nbelieve they are less potent than, GLP-1 analogues.\n", "page_number": 63, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.19469405220367994, "lower_right_x": 0.8753781004234725, "lower_right_y": 0.29097133076593923, "height": 0.09627727856225929, "width": 0.7549909255898367}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-63-2", "text": "   If these treatments are not effective, insulin therapy, including insulin injections, will be required. Amylin\nestimates that approximately 25% of diabetes patients are not adequately treated with oral anti-diabetics alone,\nbut are not yet insulin-dependent. We expect the market to expand in coming years as GLP-1 analogues are used\nearlier in the treatment paradigm in combination with or as substitutes for oral treatments. In addition, GLP -1\nanalogues may delay the need for insulin-based therapy, thereby increasing the number of patients eligible for\nGLP-1 therapy at the other end of the treatment paradigm. The current market size for GLP-1 based therapies is\napproximately $430 million. We believe that the market for GLP-1 analogues could reach $4 billion by 2015.\n", "page_number": 63, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.3042362002567394, "lower_right_x": 0.8784029038112523, "lower_right_y": 0.40051347881899874, "height": 0.09627727856225932, "width": 0.7580157289776165}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-63-3", "text": "Anticipated Advantages of OP-286 CR\n", "page_number": 63, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.41377834830979887, "lower_right_x": 0.4016938898971567, "lower_right_y": 0.4278990158322636, "height": 0.014120667522464714, "width": 0.2813067150635209}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-63-4", "text": "  We believe OP- 286 CR has the potential to be an effective treatment for type II diabetes. We anticipate that\nOP-286 CR will be an alternative to other GLP-1 analogues and that it may be used in combination with or as a\nsubstitute for oral anti-diabetic treatments and short-acting insulin, such as inhaled insulin. We believe our\nproduct candidate will offer the following advantages over these treatments:\n", "page_number": 63, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.4411638853230638, "lower_right_x": 0.8711433756805808, "lower_right_y": 0.49636285836542576, "height": 0.05519897304236199, "width": 0.7507562008469449}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-63-5", "text": "\u00b7   Improved Convenience and Compliance. We intend to develop OP-286 CR for once-every-two-weeks\n    or less frequent administration. Currently, there is only one GLP-1 analogue on the market and it is\n    administered as a twice-daily subcutaneous injection. There are also once-daily and once-weekly product\n    candidates in late stage development. We believe that an alternative that requires less frequent\n    administration will provide a significant convenience benefit over these other treatment regimes, which\n    may result in greater patient compliance.\n\n\u00b7   Weight Loss Benefits. Due to the effects of GLP-1 analogues on gastric emptying, they have been\n    demonstrated to promote weight loss. In contrast, sulfonylureas and insulin have been shown to lead to\n    weight gain. We believe a treatment that promotes weight loss will be a significant advantage in the\n    treatment of type II diabetes, which is known to be associated with obesity.\n\n\u00b7   Improved tolerability. GLP-1 analogues currently marketed or in development are characterized by\n    poor gastro-intestinal tolerability, in particular at onset of treatment. We believe this poor tolerability is\n    mediated by the high peak plasma levels associated with these products. OP-286 CR is designed to\n    provide efficacy that will be at least similar to products currently marketed or in development, with\n    improved tolerability, since the GLP-1 analogue will be released gradually over weeks without the rapid\n    increases in plasma levels.\n", "page_number": 63, "bounding_box": {"top_left_x": 0.13490623109497882, "top_left_y": 0.5096277278562259, "lower_right_x": 0.8802177858439202, "lower_right_y": 0.7586649550706034, "height": 0.2490372272143775, "width": 0.7453115547489414}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-63-6", "text": "Development Activities and Strategies\n", "page_number": 63, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.7732135216089003, "lower_right_x": 0.39201451905626133, "lower_right_y": 0.787334189131365, "height": 0.014120667522464658, "width": 0.2716273442226255}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-63-7", "text": "  Theratechnologies has conducted several pre-clinical studies of OP-286, which we believe have indicated\npotency and duration of effect of OP-286. We plan to expand and complete the pre-clinical profiling. After\ncompleting the pharmacological profiling of OP-286 and after completing the initial pre-clinical safety studies,\nwe intend to initiate clinical development of OP-286 CR, provided that the pre-clinical results are positive.\n", "page_number": 63, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.8005990586221652, "lower_right_x": 0.8663036902601331, "lower_right_y": 0.8553701326486949, "height": 0.0547710740265297, "width": 0.7459165154264973}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-63-8", "text": "  We believe that the pre-clinical studies conducted by Theratechnologies indicate that OP-286 can be used\nwith different delivery methods. We intend to combine OP-286 with one of our drug delivery technologies to\nenable a controlled-release formulation which can be administered once-every-two-weeks or less frequently. We\n", "page_number": 63, "bounding_box": {"top_left_x": 0.12099213551119177, "top_left_y": 0.8690629011553274, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9101412066752247, "height": 0.04107830551989733, "width": 0.7598306110102843}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-63-9", "text": "61\n", "page_number": 63, "bounding_box": {"top_left_x": 0.8608590441621294, "top_left_y": 0.9477963200684638, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9572100984167736, "height": 0.00941377834830981, "width": 0.019963702359346636}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-64-0", "text": "have initiated formulation work on OP-286 to develop a controlled-release formulation of this GLP-1 analogue\nand will conduct a feasibility study to determine whether our formulation results in reproducible, predictable\nand sustained plasma levels of OP-286 without significant burst effect. Subject to the successful completion of\nthe feasibility study, we intend to conduct additional pre-clinical pharmacology and toxicology studies.\n", "page_number": 64, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.08515190415062045, "lower_right_x": 0.8711433756805808, "lower_right_y": 0.14035087719298245, "height": 0.055198973042362, "width": 0.7507562008469449}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-64-1", "text": "  The initial phase of the clinical development will be focused on demonstrating safety and tolerability of OP-\n286 in healthy subjects, followed by obtaining initial proof-of-concept in type II diabetes patients. Subject to the\nsuccessful completion of these studies and a pharmacokinetic bridging study we intend to initiate a Phase IIb\nprogram with OP-286 CR.\n", "page_number": 64, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.15361574668378264, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.20881471972614463, "height": 0.05519897304236199, "width": 0.7555958862673926}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-64-2", "text": "Manufacturing\n", "page_number": 64, "bounding_box": {"top_left_x": 0.12099213551119177, "top_left_y": 0.22250748823277705, "lower_right_x": 0.2323049001814882, "lower_right_y": 0.2362002567394095, "height": 0.013692768506632452, "width": 0.11131276467029642}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-64-3", "text": "    As part of our arrangements with Theratechnologies, we have received a limited supply of OP-286, which we\nare using for initial studies. We plan to utilize a contract manufacturing organization to produce OP-286 for\nsubsequent studies. We intend to initiate manufacturing of a pilot batch with a manufacturing organization and,\nif successful, to enter into an agreement for larger scale production.\n", "page_number": 64, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.24946512623020967, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.30466409927257165, "height": 0.05519897304236199, "width": 0.7555958862673926}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-64-4", "text": "OctoVAX for Hepatitis B and Japanese Encephalitis\n", "page_number": 64, "bounding_box": {"top_left_x": 0.30913490623109496, "top_left_y": 0.32135216089002994, "lower_right_x": 0.6866303690260133, "lower_right_y": 0.33418913136499784, "height": 0.012836970474967901, "width": 0.3774954627949183}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-64-5", "text": "Background\n", "page_number": 64, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.34873769790329484, "lower_right_x": 0.21234119782214156, "lower_right_y": 0.36243046640992727, "height": 0.013692768506632425, "width": 0.09195402298850575}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-64-6", "text": "  Vaccines play an essential role in the prevention of many wide-spread and communicable diseases, such as\nhepatitis B, pneumococcal infection and polio. By providing immunity to large segments of the population,\nprophylactic vaccines have had a major impact on the course of human health in both the developed and\ndeveloping world. Prophylactic vaccines are used either in broad immunization programs, aimed at protecting\nwhole populations from a particular disease, or are targeted towards specific populations considered to be at\nparticular risk of contracting certain infectious diseases, including international travelers, immunocompromised\npatients and healthcare workers.\n", "page_number": 64, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.3761232349165597, "lower_right_x": 0.8705384150030248, "lower_right_y": 0.4719726144629867, "height": 0.09584937954642703, "width": 0.7501512401693889}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-64-7", "text": "   Many vaccines require multiple injections over several weeks or months in order to induce a sufficient\nimmune response that will engender long-term protection. Due to this inconvenient vaccination schedule, a\nsignificant portion of the intended target population does not finish the complete regimen of required injections,\ndoes not finish the regimen in time or does not start the vaccination process at all, leading to sub-optimal\nprotection. Development of vaccination regimens that require fewer doses is expected to have a significant\nimpact on overall vaccination coverage and vaccination compliance rates.\n", "page_number": 64, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.4856653829696192, "lower_right_x": 0.8753781004234725, "lower_right_y": 0.5682498930252461, "height": 0.08258451005562689, "width": 0.7549909255898367}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-64-8", "text": "   When administering vaccinations, the first injection is referred to as a \u201cprime\u201d and subsequent injections are\nreferred to as \u201cboosts\u201d. Many of the current efforts aimed at developing new vaccines or improving the efficacy\nof existing vaccines focus on improving the active ingredients in the vaccine, which in many cases will still\nrequire multiple injections in order to be effective.\n", "page_number": 64, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.5815147625160462, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.6367137355584083, "height": 0.0551989730423621, "width": 0.7555958862673926}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-64-9", "text": "Our Approach\n", "page_number": 64, "bounding_box": {"top_left_x": 0.12159709618874773, "top_left_y": 0.6499786050492083, "lower_right_x": 0.22686025408348456, "lower_right_y": 0.6640992725716731, "height": 0.01412066752246477, "width": 0.10526315789473684}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-64-10", "text": "   Our vaccine approach is focused on developing a new generation of more patient-friendly vaccines which are\ndesigned to induce a long-term immune protection based on one single injection. More specifically, we have\nmodified our proprietary OctoDEX technology for vaccine applications (\u201cOctoVAX\u201d), which we use in\ncombination with the vaccine component to develop vaccine products with a view to generate both an\nimmediate \u201cprime\u201d effect as well as subsequent \u201cboosts\u201d via a single shot. We believe that the convenience\noffered by our single shot approach to vaccine therapy could greatly improve the rates of effective immunization\nby simplifying and enhancing patient compliance.\n", "page_number": 64, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.6773641420624733, "lower_right_x": 0.8802177858439202, "lower_right_y": 0.7736414206247325, "height": 0.0962772785622592, "width": 0.7598306110102844}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-64-11", "text": "   The key advantage of our proprietary OctoVAX technology over other vaccination approaches is that our\nmethod has the potential for combining a prime and a boost release in one-single shot. In pre-clinical studies in\nmice, we have demonstrated that a single injection of a vaccine delivered with our OctoVAX technology\ngenerated a prime and a delayed release of the therapeutic protein, and resulted in a similar antibody response as\ncompared to two injections of the same vaccine given several weeks apart. Based on these results, we believe\nthat using our OctoVAX technology we can design our microspheres to control the initiation and the rate of the\nrelease of the therapeutic component of our vaccine product. Currently, we intend to use a widely-used adjuvant,\naluminum hydroxide, which we believe can maintain its desired immune stimulation effect weeks after\ninjection, as a separate component of our single-shot vaccines.\n", "page_number": 64, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.7903294822421908, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9122807017543859, "height": 0.12195121951219512, "width": 0.7604355716878403}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-64-12", "text": "62\n", "page_number": 64, "bounding_box": {"top_left_x": 0.8608590441621294, "top_left_y": 0.9477963200684638, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9572100984167736, "height": 0.00941377834830981, "width": 0.019963702359346636}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-65-0", "text": "  We believe that our OctoVAX technology may be applied to develop a range of single-shot vaccination\nproducts for the following reasons:\n", "page_number": 65, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.08515190415062045, "lower_right_x": 0.8348457350272233, "lower_right_y": 0.11296534017971759, "height": 0.02781343602909714, "width": 0.7144585601935874}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-65-1", "text": "\u00b7   Flexible Carrier Mechanism. Our proprietary microspheres have the ability to entrap proteins with a\n    molecular weight as low as ten kilodaltons (kDa), as well as whole particles, such as live or attenuated\n    viruses. This proprietary system is therefore able to encapsulate a broad range of viral particles and is\n    well suited for innovative vaccine applications.\n\n\u00b7   Flexible, Non-Disruptive Manufacturing and Loading Process. The biological activity of the relevant\n    protein or virus should be maintained during our proprietary manufacturing process which loads the\n    protein or virus into our microspheres. As a result, we anticipate that the biological activity of the\n    delivered material will be maintained upon injection and at the time of its release into the blood stream.\n", "page_number": 65, "bounding_box": {"top_left_x": 0.13490623109497882, "top_left_y": 0.12623020967051776, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.24989302524604193, "height": 0.12366281557552417, "width": 0.7410768300060496}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-65-2", "text": "  Based on the pre-clinical results to date, we intend to initiate Phase I clinical trials with our first single shot\nvaccine candidate HBV-OctoVAX in the first quarter of 2009, followed by additional Phase I clinical trials for\nour second single shot vaccine candidate JEV-OctoVAX.\n", "page_number": 65, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.2631578947368421, "lower_right_x": 0.8663036902601331, "lower_right_y": 0.30466409927257165, "height": 0.04150620453572956, "width": 0.7459165154264973}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-65-3", "text": "Market Opportunity\n", "page_number": 65, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.32135216089002994, "lower_right_x": 0.26981246218995764, "lower_right_y": 0.3346170303808301, "height": 0.01326486949080019, "width": 0.14942528735632182}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-65-4", "text": "   In 2002, the market for prophylactic vaccines was worth an estimated $5 billion to $7 billion. Worldwide\nvaccine sales are expected to grow to over $11 billion by 2010, almost exclusively driven by new product\ninnovation.\n", "page_number": 65, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.34873769790329484, "lower_right_x": 0.8469449485783425, "lower_right_y": 0.38682071031236626, "height": 0.038083012409071415, "width": 0.7265577737447066}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-65-5", "text": "   Currently, a considerable number of major vaccines, including the pneumococcal, hepatitis B and anthrax\nvaccines, require multiple injections over several weeks or months in order to induce a sufficient immune\nresponse and thereby to convey long-term protection. As a consequence, a significant number of those receiving\nthe initial prime injection for protection against these diseases do not finish the complete regimen or do not\nfinish it in a timely manner, leading to sub-optimal protection.\n", "page_number": 65, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.40350877192982454, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.4719726144629867, "height": 0.06846384253316218, "width": 0.7555958862673926}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-65-6", "text": "Our OctoVAX Product Candidates\n", "page_number": 65, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.4856653829696192, "lower_right_x": 0.37265577737447064, "lower_right_y": 0.49636285836542576, "height": 0.010697475395806566, "width": 0.25226860254083483}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-65-7", "text": "  Although our technology may be applicable to a wide variety of vaccines, we have decided to focus initially\non market opportunities in the areas of hepatitis B and Japanese encephalitis.\n", "page_number": 65, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.513050919982884, "lower_right_x": 0.8650937689050212, "lower_right_y": 0.5408643560119811, "height": 0.02781343602909714, "width": 0.7447065940713854}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-65-8", "text": "HBV-OctoVAX for Hepatitis B Vaccination\n", "page_number": 65, "bounding_box": {"top_left_x": 0.11978221415607986, "top_left_y": 0.5541292255027813, "lower_right_x": 0.42589231699939506, "lower_right_y": 0.5682498930252461, "height": 0.01412066752246477, "width": 0.3061101028433152}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-65-9", "text": "   The WHO describes hepatitis B as one of the major diseases of mankind and a serious global public health\nproblem. Of the 2 billion people who have been infected with the hepatitis B virus, more than 350 million\npeople have chronic infections. About 90% of infants infected during the first year of life and 30-50% of\nchildren infected between one and four years of age develop chronic infection. In persons over the age of five\nyears, approximately 6% of infected individuals become chronic carriers of the hepatitis B virus. These chronic\ncarriers of the hepatitis B virus are at high risk of developing hepatic necrosis, cirrhosis, and liver cancer,\ndiseases that result in about one million deaths annually. Prophylactic vaccines for hepatitis B infection are\navailable and can prevent the development of chronic infections and thereby reduce associated morbidity and\nmortality. The worldwide market for hepatitis B vaccines is estimated at over $1 billion. Although vaccination\nagainst infection by hepatitis B is part of a national immunization program in many countries, still large\nnumbers of individuals born prior to the implementation of these programs are unvaccinated and are at risk of\nthe disease. Furthermore, the current technology employed in marketed hepatitis B vaccines necessitates that\nsubjects receive multiple shots over a six month period, leading to poor patient compliance with dosing\nregimens. According to a survey of US adolescents and adults published by the CDC, only 53% of those who\nreceived the first dose of hepatitis B vaccine received the second dose, and only 30% received the third. We\nbelieve that compliance rates in other countries are similarly low. In addition, most of the current hepatitis B\nvaccines have a substantial non-response rate which means that such individuals are not fully immunized when\ninjected by such vaccines.\n", "page_number": 65, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.5815147625160462, "lower_right_x": 0.8711433756805808, "lower_right_y": 0.8284124946512623, "height": 0.24689773213521615, "width": 0.7507562008469449}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-65-10", "text": "  Through the development of a single shot hepatitis B vaccine, we intend to initially focus on meeting the high\nmedical needs of travelers to areas where hepatitis B is endemic, to non-responders to the currently marketed\nvaccines, healthcare workers, emergency response personnel and immunocompromised individuals. These niche\ngroups are at increased risk of becoming chronic carriers of the hepatitis B virus and will benefit most from an\nimproved hepatitis B vaccine, which is conveniently administered in a single shot. In the longer term, having\n", "page_number": 65, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.8416773641420625, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9118528027385537, "height": 0.07017543859649122, "width": 0.7604355716878403}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-65-11", "text": "63\n", "page_number": 65, "bounding_box": {"top_left_x": 0.8608590441621294, "top_left_y": 0.9477963200684638, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9572100984167736, "height": 0.00941377834830981, "width": 0.019963702359346636}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-66-0", "text": "attempted to address the needs of these niche groups, we may also decide to expand our focus to participate in\nchildhood immunization programs.\n", "page_number": 66, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.08515190415062045, "lower_right_x": 0.8614640048396854, "lower_right_y": 0.11296534017971759, "height": 0.02781343602909714, "width": 0.7410768300060496}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-66-1", "text": "Status of Development\n", "page_number": 66, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.12623020967051776, "lower_right_x": 0.2807017543859649, "lower_right_y": 0.14035087719298245, "height": 0.014120667522464686, "width": 0.16031457955232908}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-66-2", "text": "   We have an ongoing pre-clinical program to test several different hepatitis B vaccines in combination with\nOctoVAX for the development of a single shot product. We have entered into a non-exclusive feasibility\nagreement with SciGen, Ltd., which has developed and manufactures a proprietary, multi-shot hepatitis B\nvaccine under the brand name Sci-B-Vac, which is marketed in the Philippines, Hong Kong, Singapore and\nVietnam. In contrast to most currently marketed hepatitis B vaccines, which are produced through recombinant\ntechnology in yeast and contain only one epitope, Sci-B-Vac is produced in mammalian cell culture and has\nthree epitopes. Sci-B-Vac is more immunogenic than yeast-derived vaccines, leading to faster onset of\nprotection and a higher percentage of successfully immunized subjects.\n", "page_number": 66, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.15361574668378264, "lower_right_x": 0.8711433756805808, "lower_right_y": 0.2635857937526744, "height": 0.10997004706889174, "width": 0.7507562008469449}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-66-3", "text": "   In a proof-of-concept study in mice, we showed that a single shot of our mammalian-based HBV-OctoVAX\nformulation with aluminum hydroxide adjuvant had a stronger immunological response than two separate\ninjections of yeast-based vaccine with the same adjuvant and in a comparable aggregate dose. With HBV-\nOctoVAX, antibody titers on the 56th day of the study were approximately twice as high compared with the\nsequentially dosed yeast vaccine.\n", "page_number": 66, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.2768506632434745, "lower_right_x": 0.8656987295825771, "lower_right_y": 0.345742404792469, "height": 0.06889174154899447, "width": 0.7453115547489413}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-66-4", "text": "   Upon completion of our pre-clinical development program, we intend to select a hepatitis B antigen for use\nwith our OctoVAX technology for further development. We and SciGen have decided to continue the program\nwith the Sci-B-Vac antigen and intend to commence clinical trials in the first quarter of 2009, subject to\nreaching a final agreement relating to this further development.\n", "page_number": 66, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.36243046640992727, "lower_right_x": 0.8663036902601331, "lower_right_y": 0.4159178433889602, "height": 0.05348737697903294, "width": 0.7459165154264973}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-66-5", "text": "JEV-OctoVAX for Japanese Encephalitis Vaccination\n", "page_number": 66, "bounding_box": {"top_left_x": 0.12099213551119177, "top_left_y": 0.43089430894308944, "lower_right_x": 0.4984875983061101, "lower_right_y": 0.4441591784338896, "height": 0.013264869490800135, "width": 0.37749546279491836}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-66-6", "text": "   Japanese encephalitis is a severe mosquito-borne viral infection caused by the Japanese encephalitis virus\n(\u201cJEV\u201d) that results in encephalitis (inflammation of the brain) in humans. Mild infection may result in\nheadache and fever, whereas severe cases lead to high fevers, seizures, paralysis, coma and potentially death.\nAccording to the WHO, approximately 50,000 cases are reported in Asia annually, with approximately 15,000\ndeaths attributed directly to infection with JEV.\n", "page_number": 66, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.4582798459563543, "lower_right_x": 0.8650937689050212, "lower_right_y": 0.5267436884895165, "height": 0.06846384253316218, "width": 0.7447065940713854}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-66-7", "text": "   Approximately 3 billion people live in JEV-endemic areas. In addition, the virus presents a threat to travelers\nfrom non-endemic countries visiting endemic areas. With the rapid and continued growth of international travel,\nthe number of people potentially exposed to JEV is expected to increase. Industry participants estimate that the\nmarket for Japanese encephalitis vaccines will grow to $400 million annually with the introduction of improved\nproducts.\n", "page_number": 66, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.540436456996149, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.6089002995293111, "height": 0.06846384253316218, "width": 0.7555958862673926}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-66-8", "text": "   There is currently a marketed Japanese encephalitis vaccine available, known as JE-VAX. It is produced by\nthe Research Foundation for Microbial Diseases of Osaka University and is marketed by sanofi-pasteur, the\nvaccine business of sanofi-aventis SA. JE-VAX is known to have a number of important limitations. Firstly, this\nvaccine requires three separate injections over a period of one month, and has been shown to be protective in\n75-90% of subjects, which is a relatively low response rate for a prophylactic vaccine. Furthermore, as JE-VAX\nis derived from mouse brains, the manufacturing costs of the product are relatively high. There are also concerns\nabout the safety of JE-VAX as severe side effects including neurological reactions have been observed. As a\nresult, subjects receiving the vaccine for JEV infection are advised to remain within close proximity of medical\ncare for ten days after receiving the vaccine.\n", "page_number": 66, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.6225930680359435, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.7462558836114677, "height": 0.12366281557552417, "width": 0.7604355716878403}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-66-9", "text": "   Through the combination of a new JEV antigen derived from a human cell line with our OctoVAX\ntechnology, we intend to develop a single-shot vaccine product for travelers to areas where JEV is endemic. In\naddition, the use of a new antigen may improve the safety and the efficacy profile as compared to JE-VAX.\n", "page_number": 66, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.7595207531022679, "lower_right_x": 0.8663036902601331, "lower_right_y": 0.8010269576379975, "height": 0.04150620453572962, "width": 0.7459165154264973}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-66-10", "text": "Status of Development\n", "page_number": 66, "bounding_box": {"top_left_x": 0.11675741076830005, "top_left_y": 0.8142918271287976, "lower_right_x": 0.2807017543859649, "lower_right_y": 0.8284124946512623, "height": 0.01412066752246477, "width": 0.16394434361766486}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-66-11", "text": "   We have entered into an exclusive co-development agreement with SingVax Pte. Ltd. for the development of\nJEV-OctoVAX. SingVax has obtained a license to a human cell line based on the PER.C6 technology of Crucell\nN.V. for the manufacturing of bulk JEV product. Under the terms of our agreement, SingVax will be responsible\nfor the supply of bulk antigen based on inactivated whole cell Japanese encephalitis virus, and we will be\n", "page_number": 66, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.8421052631578947, "lower_right_x": 0.8790078644888082, "lower_right_y": 0.8985879332477535, "height": 0.056482670089858855, "width": 0.7586206896551724}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-66-12", "text": "64\n", "page_number": 66, "bounding_box": {"top_left_x": 0.8608590441621294, "top_left_y": 0.9477963200684638, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9572100984167736, "height": 0.00941377834830981, "width": 0.019963702359346636}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-67-0", "text": "responsible for incorporating these antigens within our OctoVAX microspheres and manufacturing the final\nproduct. We and SingVax will jointly carry out pre-clinical, clinical and regulatory activities.\n", "page_number": 67, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.08515190415062045, "lower_right_x": 0.8463399879007865, "lower_right_y": 0.11296534017971759, "height": 0.02781343602909714, "width": 0.7259528130671506}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-67-1", "text": "   We are currently performing pre-clinical experiments with SingVax to select the most promising formulation\nfor further development. We anticipate that Phase I clinical trials of JEV-OctoVAX will commence in the first\nhalf of 2009.\n", "page_number": 67, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.12623020967051776, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.1647411210954215, "height": 0.03851091142490373, "width": 0.7555958862673926}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-67-2", "text": "hGH-OctoDEX for Growth Hormone Deficiency\n", "page_number": 67, "bounding_box": {"top_left_x": 0.323653962492438, "top_left_y": 0.1810012836970475, "lower_right_x": 0.676950998185118, "lower_right_y": 0.1951219512195122, "height": 0.014120667522464714, "width": 0.35329703569267995}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-67-3", "text": "   In August 2007, we announced that we had discontinued the development of hGH-OctoDEX, our product\ncandidate for controlled release of human growth hormone, which had been in Phase I clinical development. We\ndiscontinued hGH-OctoDEX in order to re-allocate our resources to our other product candidates, which we\nbelieve will have greater commercial potential in light of the increasingly competitive market for human growth\nhormone.\n", "page_number": 67, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.20838682071031236, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.2764227642276423, "height": 0.06803594351732992, "width": 0.7604355716878403}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-67-4", "text": "Our Research and Development Strategy\n", "page_number": 67, "bounding_box": {"top_left_x": 0.12099213551119177, "top_left_y": 0.2939666238767651, "lower_right_x": 0.41560798548094374, "lower_right_y": 0.306803594351733, "height": 0.012836970474967901, "width": 0.294615849969752}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-67-5", "text": "   Our research and development strategy is to focus on developing novel formulations of existing\npharmaceuticals based on our proprietary drug delivery technologies, including OctoDEX and PolyActive.\nRather than seeking to discover novel drug candidates through early stage research activities, we seek to in-\nlicense known protein therapeutics or other drugs, which we can optimize using our in-house development\nexpertise or by combining with our technologies to develop new proprietary products that have fewer side\neffects, increased patient convenience and better efficacy.\n", "page_number": 67, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.32135216089002994, "lower_right_x": 0.8463399879007865, "lower_right_y": 0.4030808729139923, "height": 0.08172871202396237, "width": 0.7259528130671506}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-67-6", "text": "Our Proprietary Drug Delivery Technologies\n", "page_number": 67, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.417201540436457, "lower_right_x": 0.4452510586811857, "lower_right_y": 0.43089430894308944, "height": 0.013692768506632425, "width": 0.3248638838475499}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-67-7", "text": "   Our major technology platforms, OctoDEX and PolyActive, have been developed to deliver active\ncompounds in a more convenient, safe and effective manner than conventional formulations. They are\nparticularly suitable for injectable products incorporating drugs and larger molecules. By combining our\ntechnologies with such compounds, we aim to create novel drugs with superior performance characteristics. One\nof the key features of both technology platforms is that they are capable of controlling the release of the\nincorporated compounds, resulting in long-acting products with systemic and/or local effectiveness. Moreover,\nwe believe that controlled release systems based on OctoDEX and PolyActive are competitive as they can be\ndesigned to exhibit predictable, sustained release profiles of the pharmaceutical agent without any significant\nburst effect.\n", "page_number": 67, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.44458707744972187, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.5648267008985879, "height": 0.12023962344886602, "width": 0.7604355716878403}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-67-8", "text": "   Depending on the individual properties of a candidate compound, we select the technology platform with the\nhighest potential for achieving an attractive product profile. We frequently observe a strong correlation between\nthe release characteristics obtained in vitro and in vivo, which helps us in evaluating the suitability of our drug\ndelivery systems as a carrier for a specific compound at an early stage.\n", "page_number": 67, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.5815147625160462, "lower_right_x": 0.8753781004234725, "lower_right_y": 0.6367137355584083, "height": 0.0551989730423621, "width": 0.7549909255898367}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-67-9", "text": "OctoDEX\n", "page_number": 67, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.6504065040650406, "lower_right_x": 0.18874773139745918, "lower_right_y": 0.6640992725716731, "height": 0.01369276850663248, "width": 0.06836055656382337}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-67-10", "text": "   OctoDEX is our drug delivery system based on cross-linked, dextran-derived polymers. The technology was\noriginally invented at Utrecht University, and has been further developed by us. Our OctoDEX-based products\nconsist of injectable, biodegradable microspheres based on dextran polymers that enable the controlled delivery\nof biopharmaceuticals.\n", "page_number": 67, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.6773641420624733, "lower_right_x": 0.8711433756805808, "lower_right_y": 0.7325631151048353, "height": 0.05519897304236199, "width": 0.7507562008469449}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-67-11", "text": "   Applying our proprietary, all-aqueous emulsion process, we use the OctoDEX polymers to create hydrogel\nmicrospheres incorporating biopharmaceutical ingredients. We believe that, due to the hydrophilic nature of the\ncarrier and the absence of potentially harmful organic solvents in the manufacturing process, OctoDEX\nmicrospheres are compatible with a large number of biopharmaceuticals. As our drug-loaded OctoDEX\nmicrospheres can be suspended in a small liquid volume, they can be administered by subcutaneous injection.\n", "page_number": 67, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.7492511767222936, "lower_right_x": 0.8711433756805808, "lower_right_y": 0.8177150192554558, "height": 0.06846384253316218, "width": 0.7507562008469449}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-67-12", "text": "   The manufacture of OctoDEX microspheres involves the preparation of an emulsion in which an aqueous\nsolution of a modified dextran and a drug substance is dispersed as fine droplets within an aqueous solution of\npolyethylene glycol. Polyethylene glycol is used as an excipient in this process and is not involved in any\nchemical conjugation. Upon cross-linking of the dextran, the droplets solidify as microspheres, incorporating the\nactive ingredient within their polymeric network. We then remove excess reactants from the resulting\nsuspension, after which drug-filled, gel-type microspheres remain. We have successfully scaled-up this process\n", "page_number": 67, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.8314077877620881, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9127086007702182, "height": 0.08130081300813008, "width": 0.7604355716878403}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-67-13", "text": "65\n", "page_number": 67, "bounding_box": {"top_left_x": 0.8608590441621294, "top_left_y": 0.9477963200684638, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9572100984167736, "height": 0.00941377834830981, "width": 0.019963702359346636}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-68-0", "text": "under cGMP conditions in our small-scale manufacturing facilities, enabling us to supply materials for clinical\ndevelopment.\n", "page_number": 68, "bounding_box": {"top_left_x": 0.12099213551119177, "top_left_y": 0.08515190415062045, "lower_right_x": 0.8638838475499092, "lower_right_y": 0.11253744116388532, "height": 0.027385537013264877, "width": 0.7428917120387174}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-68-1", "text": "   We have successfully used OctoDEX for the controlled delivery of several therapeutic proteins in a number\nof in vitro and in vivo studies. Our proprietary microspheres have the ability to entrap proteins with a molecular\nweight as low as ten kilodaltons (kDa), as well as whole particles, such as live or attenuated viruses.\n", "page_number": 68, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.12623020967051776, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.16773641420624733, "height": 0.04150620453572956, "width": 0.7555958862673926}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-68-2", "text": "PolyActive\n", "page_number": 68, "bounding_box": {"top_left_x": 0.11736237144585603, "top_left_y": 0.18142918271287975, "lower_right_x": 0.19782214156079855, "lower_right_y": 0.1951219512195122, "height": 0.013692768506632452, "width": 0.08045977011494253}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-68-3", "text": "   PolyActive is our drug delivery system based on a series of biodegradable polyethers and polyesters. We\nacquired the PolyActive drug delivery technology as part of our acquisition of Chienna from IsoTis in 2003.\nPolyActive was first introduced as a biomaterial over 15 years ago. Since then, it has been used in medical\ndevices for orthopedic and wound repair applications in over 5,000 patients, and two medical devices based on\nPolyActive polymers have received FDA approval to date. We have access to a detailed safety and toxicity file\nconcerning the PolyActive polymer that was prepared by IsoTis, the former owner of the PolyActive\ntechnology, and was filed with the FDA for the use of PolyActive in medical devices.\n", "page_number": 68, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.20838682071031236, "lower_right_x": 0.8663036902601331, "lower_right_y": 0.30466409927257165, "height": 0.09627727856225929, "width": 0.7459165154264973}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-68-4", "text": "   We focus on the use of PolyActive to create injectable and biodegradable microspheres that enable the\ncontrolled release of biopharmaceuticals. PolyActive refers to polyetheresters comprising blocks of\npolybutylene terephthalate and polyethylene glycol. By varying the length and composition of these PolyActive\npolymers, we can tailor the drug release profile of our product candidates. Similarly to OctoDEX, we have\ntested various compositions of PolyActive in order to establish different in vitro release profiles of our\nPolyActive platform. Depending on the design and composition of the PolyActive-based microspheres, we have\nobtained release profiles ranging from one week to several months.\n", "page_number": 68, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.32135216089002994, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.4159178433889602, "height": 0.09456568249893027, "width": 0.7555958862673926}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-68-5", "text": "  We have successfully used PolyActive for controlled release of several therapeutic biopharmaceuticals in a\nnumber of in vitro and in vivo studies. Attractive candidates that could potentially be delivered by PolyActive\nmicrospheres include therapeutic proteins, peptides and small lipophilic molecules.\n", "page_number": 68, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.43089430894308944, "lower_right_x": 0.8614640048396854, "lower_right_y": 0.4711168164313222, "height": 0.04022250748823275, "width": 0.7410768300060496}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-68-6", "text": "  We are capable of manufacturing PolyActive microspheres under cGMP conditions in our small-scale\nmanufacturing facilities, using a well-established four-step procedure based on a double-emulsion protocol.\n", "page_number": 68, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.4856653829696192, "lower_right_x": 0.8415003024803388, "lower_right_y": 0.5134788189987163, "height": 0.027813436029097083, "width": 0.721113127646703}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-68-7", "text": "Contract Development\n", "page_number": 68, "bounding_box": {"top_left_x": 0.12159709618874773, "top_left_y": 0.5267436884895165, "lower_right_x": 0.2849364791288566, "lower_right_y": 0.5400085579803167, "height": 0.01326486949080019, "width": 0.16333938294010888}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-68-8", "text": "   Our Contract Development Business is operated by our subsidiary OctoPlus Development B.V. Over the last\n12 years, we have become a leading European provider of advanced drug formulation and clinical scale\nmanufacturing services to the pharmaceutical and biotechnology industries, with a focus on difficult-to-\nformulate active pharmaceutical ingredients. All activities within our Contract Development Business are\nperformed in our dedicated facilities in Leiden, the Netherlands, where we operate a cGMP pilot plant for\nmanufacturing of final product for pre-clinical and clinical trials. As of 31 August 2007, we employed 59 people\nin our Contract Development Business. We offer a comprehensive range of services, including formulation,\nanalytical development and production of both biological products, such as peptides, proteins and DNA, as well\nas conventional synthetic small molecules. We have strong experience in parenteral formulations. Our cGMP\npilot plant allows us to offer our customers a full range of sterile pharmaceutical production options, including\nfreeze drying. We believe we have a specific expertise in the area of low-soluble compounds.\n", "page_number": 68, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.5541292255027813, "lower_right_x": 0.8784029038112523, "lower_right_y": 0.7051775780915703, "height": 0.15104835258878901, "width": 0.7580157289776165}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-68-9", "text": "   We have successfully provided the services of our Contract Development Business on a fee-for-service basis\nto a diverse and international group of more than 100 pharmaceutical and biotechnology companies, focusing\nmainly on protein therapeutics and to a lesser extent on small molecule drugs. Since our establishment in 1995\nthrough 31 August 2007, we have achieved \u20ac48 million in cumulative gross (non-consolidated) revenues from\nthis business, including inter-segment (internal) revenues of \u20ac7 million from our Products and Drug Delivery\nBusiness, and we have realized a positive operating result from this business in all but one year. Typically, our\nclients are charged on an hourly basis for our development services, while manufacturing is charged on a lump-\nsum basis.\n", "page_number": 68, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.7184424475823705, "lower_right_x": 0.8711433756805808, "lower_right_y": 0.8249893025246042, "height": 0.1065468549422337, "width": 0.7507562008469449}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-68-10", "text": "   We have established a strong competitive position in the market for contract formulation and manufacturing\nof clinical-grade products, particularly in the area of complex pharmaceutical formulations for therapeutic\nproteins. We were among the first independent companies to be active in this specific segment in Europe,\nallowing us to build significant in-house expertise in formulation and manufacturing processes. We believe that\nour capabilities in the Contract Development Business are demonstrated by our high rates of repeat business.\n", "page_number": 68, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.8416773641420625, "lower_right_x": 0.8711433756805808, "lower_right_y": 0.9105691056910569, "height": 0.06889174154899436, "width": 0.7507562008469449}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-68-11", "text": "66\n", "page_number": 68, "bounding_box": {"top_left_x": 0.8608590441621294, "top_left_y": 0.9477963200684638, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9572100984167736, "height": 0.00941377834830981, "width": 0.019963702359346636}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-69-0", "text": "   We plan to focus our Contract Development Business on higher-margin projects. In particular, we intend to\nfocus on co-development agreements with pharmaceutical companies, whereby we would develop product\ncandidates based on our drug delivery technologies for third parties. The development work we would conduct\nunder these agreements would be done on a fee-for-services basis and would include the payment of license fees\nand royalties, enabling us to participate in the revenues in the event the product is successfully developed and\ncommercialized. We have recently initiated our first co-development projects and are currently discussing other\nprojects.\n", "page_number": 69, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.08515190415062045, "lower_right_x": 0.8765880217785844, "lower_right_y": 0.18142918271287975, "height": 0.0962772785622593, "width": 0.7562008469449486}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-69-1", "text": "Our Expertise\n", "page_number": 69, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.19469405220367994, "lower_right_x": 0.22262552934059285, "lower_right_y": 0.2079589216944801, "height": 0.013264869490800163, "width": 0.10223835450695704}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-69-2", "text": "   Our goal is to deliver successful outcomes to our customers by providing the highest quality of service,\nflexibility and expertise. We have well-established capacities and expertise in the fields of product\nmanufacturing and state-of-the-art formulation techniques. For example, we have developed various protein\nformulations, including freeze dried proteins, liposomal and other lipid-based products, micro/nanoparticles,\nimmunotherapeutic formulations, as well as DNA-containing formulations for our clients. Primarily, we\nformulate products that are intended for parenteral administration. In addition, we have successfully developed a\npulmonary liposome formulation, a protein product for colon targeting, protein-containing gels as well as\npulmonary and topical formulations of oligonucleotides. We believe our achievements in the Contract\nDevelopment Business have made us well-known to the pharmaceutical and biotechnology industries as a\nquality service provider for the development of critical and complex formulations.\n", "page_number": 69, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.2220795892169448, "lower_right_x": 0.8796128251663642, "lower_right_y": 0.3594351732991014, "height": 0.13735558408215662, "width": 0.7592256503327284}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-69-3", "text": "The capacities of our Contract Development Business are set out below:\n", "page_number": 69, "bounding_box": {"top_left_x": 0.13490623109497882, "top_left_y": 0.3727000427899016, "lower_right_x": 0.6243194192377496, "lower_right_y": 0.38682071031236626, "height": 0.014120667522464658, "width": 0.4894131881427708}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-69-4", "text": "\u00b7   Characterization. We have an analytical group capable of characterizing the therapeutic substance\n    provided by our clients and analyzing the formulated products. Our characterization capacities include\n    the analysis of biopharmaceuticals for which we use state-of-the-art technologies.\n\n\u00b7   Pre-formulation and formulation. We have developed specialized formulation technologies based on\n    liposomes, lipid complexes, emulsions and microspheres. Our core competencies in this area include the\n    formulation of proteins using liposomes, and the solubilization of low soluble compounds. Our\n    capabilities include the ability to freeze dry small-scale clinical batches of therapeutic proteins. We can\n    formulate high-potency compounds, such as cytostatics and hormones, on a laboratory scale.\n\n\u00b7   Drug delivery systems. We use our expertise in drug delivery systems as an integral part of our\n    formulation services. These systems include off-patent technologies based on liposomes, micelles and\n    dispersions, as well as our proprietary systems based on sugar glasses and specialized dispersions.\n\n\u00b7   Analytical development and validation. We apply commonly used procedures in the\n    biopharmaceutical industry for analytical development and validation. In order to maintain and\n    strengthen our position we also develop and evaluate novel analytical techniques.\n\n\u00b7   Clinical manufacturing. We have the capacity to manufacture a wide range of liquid and semi-solid\n    biopharmaceutical products, including injectable, oral, dermal and pulmonary formulations, for use in\n    clinical trials. Our facilities comprise a fully equipped production area for aseptic filling of liquid\n    formulations, freeze drying and colloidal preparations. In addition, we are capable of formulating solid\n    pharmaceuticals on a laboratory scale. With a current manufacturing capacity of 3,000 units per batch,\n    we can produce sufficient materials for toxicology, Phase I and Phase II clinical trials. We intend to\n    increase our manufacturing capacity in 2008 up to a maximum of 20,000 units per batch.\n\n\u00b7   Stability studies. We perform stability studies in accordance with the International Conference on\n    Harmonization guidelines.\n", "page_number": 69, "bounding_box": {"top_left_x": 0.13490623109497882, "top_left_y": 0.40008557980316645, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.787334189131365, "height": 0.38724860932819855, "width": 0.7410768300060496}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-69-5", "text": "Our Customer Base\n", "page_number": 69, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.8014548566538297, "lower_right_x": 0.26073805202661826, "lower_right_y": 0.8138639281129654, "height": 0.012409071459135723, "width": 0.14035087719298245}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-69-6", "text": "   Since establishment, our Contract Development Business has provided services to more than 100 clients in a\ntotal of approximately 250 projects. We have contributed to approximately 40 different products that have been\nprogressed by our clients into clinical development, and to six products that have received regulatory approval.\nCurrently, our active customer base comprises around 25 clients, which are located world-wide and include\nsmall, medium and large biotechnology as well as pharmaceutical companies. Contracts with our customers\nvary in size and duration, ranging from projects lasting only a few months to several years. Historically,\n", "page_number": 69, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.82798459563543, "lower_right_x": 0.8711433756805808, "lower_right_y": 0.9122807017543859, "height": 0.08429610611895588, "width": 0.7507562008469449}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-69-7", "text": "67\n", "page_number": 69, "bounding_box": {"top_left_x": 0.8608590441621294, "top_left_y": 0.9477963200684638, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9572100984167736, "height": 0.00941377834830981, "width": 0.019963702359346636}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-70-0", "text": "revenues generated from individual contracts have generally been in the range of \u20ac25,000 to \u20ac1.5 million. In\n2006, our five largest clients represented 56% of our Contract Development Business revenues. In the same\nyear, we generated approximately 70% of the revenues of our Contract Development Business from Europe,\nwhile the remainder was sourced from North America, the Far East and Australia.\n", "page_number": 70, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.08515190415062045, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.14035087719298245, "height": 0.055198973042362, "width": 0.7313974591651543}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-70-1", "text": "Intellectual Property\n", "page_number": 70, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.15361574668378264, "lower_right_x": 0.27041742286751363, "lower_right_y": 0.16773641420624733, "height": 0.014120667522464686, "width": 0.15003024803387782}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-70-2", "text": "  We consider patents and other intellectual property rights to be vital to the success of our business. It is our\npolicy to actively seek patent protection for our know-how, technologies, products, and their uses. Therefore, we\nanalyze the results of our research and development activities to identify patentable subject-matter and file new\npatent applications as appropriate. In addition, we will continue to evaluate and potentially acquire externally\ngenerated intellectual property to further improve our competitive position.\n", "page_number": 70, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.1810012836970475, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.24989302524604193, "height": 0.06889174154899444, "width": 0.7604355716878403}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-70-3", "text": "   Patents are the cornerstone of our proprietary protection, but we may also seek other registered intellectual\nproperty rights such as trademarks or utility models. In addition, we make use of trade secrets whenever\nindicated. In an effort to maintain the ownership of our proprietary information, we require our consultants,\nadvisors and collaborators to execute confidentiality and invention assignment agreements. With respect to our\nemployees, under Dutch law, employers own the intellectual property rights of inventions made by their\nemployees during the course of their employment.\n", "page_number": 70, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.2631578947368421, "lower_right_x": 0.868118572292801, "lower_right_y": 0.345742404792469, "height": 0.08258451005562689, "width": 0.7477313974591652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-70-4", "text": "   It is our intention to seek protection for any of our inventions that hold future value for in-house development\nor out-licensing. We file and maintain our patents in countries and jurisdictions which we consider most\nimportant to our business. These typically include the major European jurisdictions, the United States, often also\nJapan and, depending on the invention, other attractive markets or countries playing an important role in the\npharmaceutical industries.\n", "page_number": 70, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.36243046640992727, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.4283269148480959, "height": 0.06589644843816861, "width": 0.7604355716878403}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-70-5", "text": "   According to our patent strategy, we aim at building strong patent portfolios to protect our know-how broadly\non the drug delivery technology level as well as on the more specific product level in order to maximize the\nstrength and duration of protection. Consequently, we expect that every major product based on one of our\nproprietary delivery technologies will eventually be covered by at least one delivery platform patent and at least\none product-specific patent.\n", "page_number": 70, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.44458707744972187, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.5121951219512195, "height": 0.06760804450149765, "width": 0.7604355716878403}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-70-6", "text": "   At present, we hold 28 patent families comprising 175 granted national patents and 90 pending national and\ninternational patent applications. Many of these patents have been filed in our own name, while for certain\nothers we hold exclusive licenses. A small number of our patents and patent applications are jointly held with\nour collaboration partners.\n", "page_number": 70, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.5267436884895165, "lower_right_x": 0.8656987295825771, "lower_right_y": 0.581086863500214, "height": 0.05434317501069752, "width": 0.7453115547489413}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-70-7", "text": "  OCTOPLUS is a registered trademark in the European Union. CHIENNA is a registered trademark in the\nEuropean Union, the United States and Japan. OCTODEX is a registered trademark in the Benelux countries.\nPOLYACTIVE is a registered trademark in the United States, the European Union, Australia, Japan, China and\nNorway.\n", "page_number": 70, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.5952075310226786, "lower_right_x": 0.8711433756805808, "lower_right_y": 0.6499786050492083, "height": 0.0547710740265297, "width": 0.7507562008469449}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-70-8", "text": "Drug Delivery Technologies\n", "page_number": 70, "bounding_box": {"top_left_x": 0.1161524500907441, "top_left_y": 0.6636713735558408, "lower_right_x": 0.31820931639443434, "lower_right_y": 0.6777920410783055, "height": 0.014120667522464658, "width": 0.20205686630369024}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-70-9", "text": "   Our OctoDEX delivery technology platform, along with its variants and potential technology extensions, is\ncovered by 13 patent families. These patents were filed between 1997 and 2007. It is therefore expected that\nthese patents will expire between 2017 and 2027. Key patents covering the basic principles behind our\nOctoDEX technology as it is presently employed in our product development programs include the granted\nEuropean patents EP 941 068, EP 1 371 364, and the corresponding US patent US 6,303,148 and the European\npatent EP 910 412 and the corresponding US patents US 6,497,903 and US 7,060,296, in respect of which we\nhave an exclusive license from Utrecht University. These patents cover the fundamental chemical (polymers,\nsubstituents, spacers and crosslinking methods), physical (hydrogels, microspheres and drug-containing\ncompositions), and engineering features (methods for making microspheres) of our OctoDEX drug carriers.\nThey are expected to expire in 2016/2017.\n", "page_number": 70, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.6910569105691057, "lower_right_x": 0.8669086509376891, "lower_right_y": 0.8284124946512623, "height": 0.13735558408215665, "width": 0.7465214761040533}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-70-10", "text": "   The other OctoDEX patent families relate to potential improvements and extensions of our technology\nplatform, some of which are currently under feasibility investigations. Granted patents relating to these\nimprovements include EP 1 183 016, EP 1 255 534 and US 6,395,302. Patent applications in this category\ninclude the regional/national applications following from the international patent applications WO 2003/035244,\nWO 2005/054318, WO 2005/087201, WO 2005/110377 and WO 2006/071110.\n", "page_number": 70, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.8416773641420625, "lower_right_x": 0.8802177858439202, "lower_right_y": 0.9105691056910569, "height": 0.06889174154899436, "width": 0.7598306110102844}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-70-11", "text": "68\n", "page_number": 70, "bounding_box": {"top_left_x": 0.8608590441621294, "top_left_y": 0.9477963200684638, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9572100984167736, "height": 0.00941377834830981, "width": 0.019963702359346636}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-71-0", "text": "   Our PolyActive drug delivery technology platform is covered by 7 patent families. These patents were filed\nbetween 1996 and 2007 and it is therefore expected that these patents will expire between 2016 and 2027.\n", "page_number": 71, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.08515190415062045, "lower_right_x": 0.8644888082274652, "lower_right_y": 0.11296534017971759, "height": 0.02781343602909714, "width": 0.7441016333938294}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-71-1", "text": "   The polyetherester copolymers which form the basis of the PolyActive technology platform were known for a\nnumber of years before their usefulness for drug delivery applications was discovered. Therefore, our patent\nprotection in this area focuses on basic physical and pharmaceutical features, and in particular on the uses of the\ncopolymers as drug carriers. Among the patents which play a key role in the PolyActive portfolio are the\ngranted European patents EP 830 859 and EP 1 247 522, and the corresponding granted US patent US\n5,980,948, which are expected to expire in 2016/2017. We own certain further patents and patent applications\nthat relate to specific manufacturing methods, medical devices and components as well as other extensions of\nthe PolyActive technology.\n", "page_number": 71, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.12623020967051776, "lower_right_x": 0.8765880217785844, "lower_right_y": 0.2362002567394095, "height": 0.10997004706889174, "width": 0.7562008469449486}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-71-2", "text": "Products\n", "page_number": 71, "bounding_box": {"top_left_x": 0.11736237144585603, "top_left_y": 0.24946512623020967, "lower_right_x": 0.1839080459770115, "lower_right_y": 0.26272999572100986, "height": 0.01326486949080019, "width": 0.06654567453115547}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-71-3", "text": "   We have filed an international patent application WO 2006/085747 covering the formulation of Locteron\nwhich is based on the PolyActive delivery technology. We expect that European, US and other national patents\nbased on this international patent application will cover Locteron and possibly comparable products involving\nthe delivery of interferon alfa by microspheres. In the event that these patents are granted, they could provide\nexclusive protection for Locteron until 2026. In 2007, we and our partner Biolex have filed a US provisional\npatent application relating to the administration profile of Locteron based on the data obtained in the Phase IIa\nclinical trials. We currently intend to continue this US provisional patent application as an international\napplication in 2008. In case one or more national/regional patents issue from such international application, the\npatent protection of the administration profile may provide further exclusive protection for Locteron until 2028.\n", "page_number": 71, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.2768506632434745, "lower_right_x": 0.8711433756805808, "lower_right_y": 0.40051347881899874, "height": 0.12366281557552422, "width": 0.7507562008469449}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-71-4", "text": "  Jointly with the LUMC, we have filed two international patent applications WO 2004/067563 and WO\n2006/011792 covering OP-145 CSOM and its therapeutic applications in several important jurisdictions. If these\napplications lead to granted patents, they could provide exclusive protection until at least 2024.\n", "page_number": 71, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.41377834830979887, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.45699614890885754, "height": 0.043217800599058664, "width": 0.7604355716878403}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-71-5", "text": "  In spite of our efforts, it is possible that our patent applications will not be granted, or that the scope of\nprotection allowed under any issued patent may not provide adequate protection for our technologies and\nproducts. In addition, it is possible that any of our patents may be challenged and invalidated by third parties.\nCompetitors may find means to circumvent patents held by us or our licensors. We may not be able to enforce\nany of our patents against infringers in any country or region important to our business.\n", "page_number": 71, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.4719726144629867, "lower_right_x": 0.8614640048396854, "lower_right_y": 0.5395806589644844, "height": 0.06760804450149765, "width": 0.7410768300060496}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-71-6", "text": "  Even though we believe that we are free to commercialize our technologies and products with respect to their\nmajor envisioned uses, there is a risk that we may inadvertently infringe prior or future patents owned by others.\nWe may need to acquire licenses for patents held by third parties to re-establish or maintain our freedom to\noperate, possibly on unfavorable terms.\n", "page_number": 71, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.5541292255027813, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.6084724005134788, "height": 0.05434317501069752, "width": 0.7555958862673926}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-71-7", "text": "Collaborations\n", "page_number": 71, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.6225930680359435, "lower_right_x": 0.22686025408348456, "lower_right_y": 0.6332905434317501, "height": 0.010697475395806566, "width": 0.10647307924984875}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-71-8", "text": "  We have entered into several collaborative arrangements with other biopharmaceutical companies and certain\nacademic institutions. Our most important collaborations are summarized below.\n", "page_number": 71, "bounding_box": {"top_left_x": 0.12159709618874773, "top_left_y": 0.6499786050492083, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.6777920410783055, "height": 0.02781343602909714, "width": 0.7543859649122807}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-71-9", "text": "Biolex Therapeutics, Inc.\n", "page_number": 71, "bounding_box": {"top_left_x": 0.11857229280096794, "top_left_y": 0.6910569105691057, "lower_right_x": 0.29522081064730793, "lower_right_y": 0.7051775780915703, "height": 0.014120667522464658, "width": 0.17664851784634}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-71-10", "text": "   In February 2005, we entered into an exclusive co-development agreement with Biolex for the development\nof Locteron, continuing a cooperation that started at the end of 2003. Locteron combines our proprietary\nPolyActive drug delivery technology with BLX-883, a proprietary interferon alfa produced by Biolex.\n", "page_number": 71, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.7184424475823705, "lower_right_x": 0.8663036902601331, "lower_right_y": 0.7599486521181001, "height": 0.04150620453572962, "width": 0.7459165154264973}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-71-11", "text": "   Pursuant to the agreement, all external costs are shared equally by the parties. In the event that the Phase II\ntrials of Locteron are successful, we and Biolex intend to seek one or more development and commercialization\npartners for this product to assist us in gaining regulatory approval and sales access in our key markets,\nprimarily North America, Europe and Japan. We will share any profits from the commercialization of Locteron\non an equal basis with Biolex. Either of us may decide to retain co-marketing rights for Locteron in certain\njurisdictions.\n", "page_number": 71, "bounding_box": {"top_left_x": 0.11736237144585603, "top_left_y": 0.7766367137355584, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.8575096277278562, "height": 0.08087291399229779, "width": 0.7586206896551724}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-71-12", "text": "  Our agreement with Biolex provides both parties with a right to terminate the agreement at will at pre-\ndetermined points. Furthermore, either party can terminate the agreement at will at any other time by providing\nwritten notice. In the event that one party decides to terminate the agreement at will, residual obligations and\n", "page_number": 71, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.8724860932819855, "lower_right_x": 0.8705384150030248, "lower_right_y": 0.9127086007702182, "height": 0.04022250748823275, "width": 0.7501512401693889}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-71-13", "text": "69\n", "page_number": 71, "bounding_box": {"top_left_x": 0.8608590441621294, "top_left_y": 0.9477963200684638, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9572100984167736, "height": 0.00941377834830981, "width": 0.019963702359346636}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-72-0", "text": "rights may exist for the terminating party, including an obligation to manufacture its respective component of\nthe Locteron product or to grant a royalty-bearing license for the manufacture of this component. In addition,\neither party may terminate the agreement in the event that the parties have not entered into a commercialization\nagreement for Locteron within a predetermined period after regulatory approval. We and Biolex have agreed to\nindemnify each other against certain liabilities, but these indemnities are limited in scope and amount.\n", "page_number": 72, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.08515190415062045, "lower_right_x": 0.8705384150030248, "lower_right_y": 0.1540436456996149, "height": 0.06889174154899445, "width": 0.7501512401693889}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-72-1", "text": "Erasmus University\n", "page_number": 72, "bounding_box": {"top_left_x": 0.1161524500907441, "top_left_y": 0.16730851519041506, "lower_right_x": 0.2613430127041742, "lower_right_y": 0.18142918271287975, "height": 0.014120667522464686, "width": 0.1451905626134301}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-72-2", "text": "   In September 2004, we entered into a research and development agreement with the Thorax Center of\nErasmus University Medical Center (the \u201cThorax Center\u201d) in Rotterdam, the Netherlands, for a novel treatment\nof myocardial (cardiac muscle) regeneration. Under the agreement, we will own all intellectual property\nresulting from the study and the Thorax Center will receive a non-exclusive, royalty-free license to this\nintellectual property. We will also pay a royalty to the Thorax Center based on our total revenues in respect of\nlicenses we grant to third parties, subject to an overall cap. Either party may, with due notice, terminate this\nresearch and development agreement at will. This collaboration is subsidized by the Dutch Ministry of\nEconomic Affairs.\n", "page_number": 72, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.19469405220367994, "lower_right_x": 0.8711433756805808, "lower_right_y": 0.30466409927257165, "height": 0.10997004706889171, "width": 0.7507562008469449}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-72-3", "text": "Green Cross Corporation\n", "page_number": 72, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.32135216089002994, "lower_right_x": 0.2988505747126437, "lower_right_y": 0.3337612323491656, "height": 0.012409071459135668, "width": 0.1784633998790079}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-72-4", "text": "   In November 2006, we licensed OP-145 CSOM for the treatment of chronic middle ear infection to Green\nCross Corporation for the exclusive sale and distribution in South Korea of products based thereon. In addition,\nwe have agreed to perform development work for Green Cross Corporation with respect to the formulation of an\nOP-145 CSOM product and provide the active ingredients necessary for Green Cross Corporation to perform the\nstudies for registration of the OP-145 CSOM product in South Korea free of charge. After the OP-145 CSOM\nPhase II study has been successfully completed, we plan to initiate an international multicenter clinical Phase III\nprogram in which Green Cross Corporation will be responsible for conducting the clinical trials in South Korea.\n", "page_number": 72, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.34873769790329484, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.44330338040222506, "height": 0.09456568249893021, "width": 0.7604355716878403}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-72-5", "text": "   Green Cross Corporation is required to pay us a number of nominal milestone payments. Future milestone\npayments are due upon the grant of a certain patent, upon submission for approval of the clinical study in South\nKorea and upon the commercial launch of the product based upon OP-145 CSOM. Green Cross Corporation is\nrequired to pay us royalties based on gross receipts for sales of OP-145 CSOM by Green Cross Corporation,\nwhereby both parties aim for a low double digit royalty rate. Furthermore, we are entitled to 50% of any\namounts that Green Cross Corporation receives from its sublicensees.\n", "page_number": 72, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.4582798459563543, "lower_right_x": 0.8705384150030248, "lower_right_y": 0.5395806589644844, "height": 0.08130081300813008, "width": 0.7501512401693889}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-72-6", "text": "   The agreement shall remain in effect until the expiration of the last valid patent relating to the OP-145 CSOM\ntechnology licensed or, if later, 15 years after the launch of the product in South Korea. The agreement may be\nterminated by either party upon a specified notice period or by either party at any time for unremedied default.\n", "page_number": 72, "bounding_box": {"top_left_x": 0.12099213551119177, "top_left_y": 0.5541292255027813, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.5947796320068464, "height": 0.04065040650406504, "width": 0.7598306110102843}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-72-7", "text": "InnoCore Technologies B.V.\n", "page_number": 72, "bounding_box": {"top_left_x": 0.1161524500907441, "top_left_y": 0.6089002995293111, "lower_right_x": 0.3194192377495463, "lower_right_y": 0.6230209670517758, "height": 0.014120667522464658, "width": 0.20326678765880218}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-72-8", "text": "   In August 2004, we entered into an agreement with InnoCore Technologies B.V. to collaborate on the\ndevelopment of a system for pharmaceutical drug delivery called SynBiosys, based on certain InnoCore\npolymers that can be used to encapsulate active ingredients. We believe that certain aspects of the SynBiosys\nsystem are complementary to our OctoDEX and PolyActive delivery technologies. We and InnoCore will\ncollaborate on identifying potential third parties whose compounds may benefit from the application of the\nSynBiosys technology. We and InnoCore will share any payments received from third parties based on a pre-\ndetermined formula. To date, we have not identified any third parties for this collaboration. After an initial five-\nyear term, the agreement is automatically renewed for successive one-year periods, unless terminated by either\nparty.\n", "page_number": 72, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.636285836542576, "lower_right_x": 0.8717483363581368, "lower_right_y": 0.7599486521181001, "height": 0.12366281557552417, "width": 0.7513611615245009}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-72-9", "text": "IsoTis N.V.\n", "page_number": 72, "bounding_box": {"top_left_x": 0.1161524500907441, "top_left_y": 0.7732135216089003, "lower_right_x": 0.1984271022383545, "lower_right_y": 0.787334189131365, "height": 0.014120667522464658, "width": 0.0822746521476104}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-72-10", "text": "   We have had a partnership with IsoTis since 1999. Through our acquisition in 2003 of Chienna B.V., a\nsubsidiary of IsoTis, we acquired from IsoTis patents and licenses to patents relating to the PolyActive\ntechnology. The license agreement with IsoTis was terminated in April 2007 and replaced by a new agreement.\nUnder the 2007 agreement, we acquired the patents not then owned by us relating to the PolyActive technology,\nexcept for the patent family covering IsoTis\u2019 SynPlugTM product. In connection with the acquisition of the\npatents relating to the PolyActive technology, we took over IsoTis' rights as licensor of these patents.\nFurthermore, the 2007 agreement provided for the transfer to us of the PolyActive name and trademarks. IsoTis\nretains an exclusive, world-wide, royalty-free license with a right to grant sub-licenses to make, use, sell, market\n", "page_number": 72, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.8005990586221652, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9105691056910569, "height": 0.10997004706889169, "width": 0.7604355716878403}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-72-11", "text": "70\n", "page_number": 72, "bounding_box": {"top_left_x": 0.8620689655172413, "top_left_y": 0.9477963200684638, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9572100984167736, "height": 0.00941377834830981, "width": 0.01875378100423475}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-73-0", "text": "and develop any PolyActive rights relating to osseouschondral and/or osteochondral plugs, fillers, cement\nrestrictors (including IsoTis\u2019 product SynPlug\u2122) and an exclusive, world-wide, royalty-free license with a right\nto grant sub-licenses to make, use, sell, market and develop any PolyActive rights owned by us related to the use\nof the PolyActive technology in a medical device to be used to measure and/or monitor blood glucose.\n", "page_number": 73, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.08515190415062045, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.14035087719298245, "height": 0.055198973042362, "width": 0.7604355716878403}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-73-1", "text": "   Under the 2007 agreement, IsoTis is entitled to a low single-digit royalty on our revenues of PolyActive-\nbased products. In addition, we will owe Technologiestichting STW, a non-profit organization associated with\nthe Netherlands Ministry of Economic Affairs and the Ministry of Education and Science providing research\ngrants, a low single-digit royalty on the revenues of PolyActive-based products for the duration of the base\npatent, which expires in 2016. The term of the 2007 agreement is until the expiration of the last valid patent\nrights licensed to IsoTis.\n", "page_number": 73, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.15361574668378264, "lower_right_x": 0.8614640048396854, "lower_right_y": 0.2362002567394095, "height": 0.08258451005562686, "width": 0.7410768300060496}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-73-2", "text": "   Pursuant to our supply agreement with IsoTis, we have long-term access to a continued supply of PolyActive\npolymers. We also have access to updates of the Device Master File provided to the FDA and as maintained by\nIsoTis. In the event IsoTis wishes to sell the production equipment of PolyActive polymers to a third party, we\nhave a first right of refusal to purchase the production equipment from IsoTis. In the event we do not purchase\nthis equipment, IsoTis is obligated to ensure uninterrupted supply of PolyActive to us by the third party supplier\nunder the same terms and conditions as the current arrangement.\n", "page_number": 73, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.24946512623020967, "lower_right_x": 0.8753781004234725, "lower_right_y": 0.33204963628583656, "height": 0.08258451005562689, "width": 0.7549909255898367}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-73-3", "text": "Leiden University Medical Center\n", "page_number": 73, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.34873769790329484, "lower_right_x": 0.35813672111312767, "lower_right_y": 0.3607188703465982, "height": 0.011981172443303378, "width": 0.2425892316999395}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-73-4", "text": "   In 2002, we entered into a co-operation and license agreement with LUMC for OP-145 CSOM. Pursuant to\nthat agreement, we were granted rights to develop OP-145 CSOM for the treatment of chronic middle ear\ninfection and chronic infections of the upper respiratory tract. In March 2006, we amended our agreement with\nLUMC, so that we now have rights to develop OP-145 CSOM for all indications.\n", "page_number": 73, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.3761232349165597, "lower_right_x": 0.8663036902601331, "lower_right_y": 0.42961061189559263, "height": 0.05348737697903294, "width": 0.7459165154264973}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-73-5", "text": "   We have paid both a nominal up-front license fee and a nominal minimum royalty for the first year of our\ndevelopment program to LUMC and will pay a further nominal minimum royalty for the second year of our\ndevelopment program to LUMC. We will owe LUMC royalties based on net sales of OP-145 CSOM. We have\nalso agreed to pay LUMC a certain percentage of any sub-license revenues we receive in relation to OP-145\nCSOM.\n", "page_number": 73, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.44458707744972187, "lower_right_x": 0.8663036902601331, "lower_right_y": 0.5100556268720582, "height": 0.06546854942233632, "width": 0.7459165154264973}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-73-6", "text": "   The license agreement provides LUMC with certain termination rights if we do not pursue the development\nof OP-145 CSOM for a specified period of time. Furthermore, if we are responsible for a delay in the\ncommercialization of OP-145 CSOM in a specific territory and for a specific indication, LUMC may terminate\nour rights to OP-145 CSOM as they relate to that territory and indication.\n", "page_number": 73, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.5267436884895165, "lower_right_x": 0.8663036902601331, "lower_right_y": 0.581086863500214, "height": 0.05434317501069752, "width": 0.7459165154264973}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-73-7", "text": "SciGen Ltd.\n", "page_number": 73, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.5952075310226786, "lower_right_x": 0.20205686630369027, "lower_right_y": 0.6059050064184852, "height": 0.010697475395806566, "width": 0.08166969147005446}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-73-8", "text": "   In June 2005, we entered into a non-exclusive feasibility agreement with SciGen, which has developed and\nmanufactures a proprietary, multi-shot hepatitis B vaccine under the brand name Sci-B-Vac, which is marketed\nin the Philippines, Hong Kong, Singapore and Vietnam. Pursuant to our agreement, we will study the feasibility\nof developing a single-shot hepatitis B vaccine based on Sci-B-Vac referred to as HBV-OctoVAX. If our proof-\nof-concept study is successful, we and SciGen may decide to continue with the development and\ncommercialization of a single-shot vaccine for hepatitis B on an exclusive basis, based on our respective\ntechnologies. We and SciGen have agreed to indemnify each other against certain liabilities, but these\nindemnities are limited in scope and amount. Either party may terminate this agreement at will subject to a\nspecified notice period.\n", "page_number": 73, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.6225930680359435, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.7462558836114677, "height": 0.12366281557552417, "width": 0.7555958862673926}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-73-9", "text": "SingVax Pte. Ltd.\n", "page_number": 73, "bounding_box": {"top_left_x": 0.11675741076830005, "top_left_y": 0.7595207531022679, "lower_right_x": 0.24198427102238354, "lower_right_y": 0.7736414206247325, "height": 0.014120667522464658, "width": 0.12522686025408347}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-73-10", "text": "   In September 2005, we entered into an exclusive co-development agreement with SingVax for the\ndevelopment of a single-shot vaccine for Japanese encephalitis. Under our agreement, SingVax is responsible\nfor a range of vaccine development activities, including development and production of JEV particles and\ncGMP manufacturing of the attenuated Japanese encephalitis virus.\n", "page_number": 73, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.7869062901155327, "lower_right_x": 0.8614640048396854, "lower_right_y": 0.8421052631578947, "height": 0.05519897304236199, "width": 0.7410768300060496}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-73-11", "text": "   In connection with the manufacturing of bulk JEV product, SingVax has obtained a license to the PER.C6\ntechnology of Crucell N.V. Under the arrangement between SingVax and Crucell, Crucell has a right of first\nnegotiation for the sale of any traveler\u2019s vaccine produced by SingVax that uses the PER.C6 technology for\nterritories outside of the Asia Pacific region.\n", "page_number": 73, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.8553701326486949, "lower_right_x": 0.8511796733212341, "lower_right_y": 0.9122807017543859, "height": 0.05691056910569103, "width": 0.7307924984875983}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-73-12", "text": "71\n", "page_number": 73, "bounding_box": {"top_left_x": 0.8620689655172413, "top_left_y": 0.9477963200684638, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9572100984167736, "height": 0.00941377834830981, "width": 0.01875378100423475}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-74-0", "text": "  Pursuant to the terms of our agreement with SingVax, we are responsible for formulation development and\ncGMP manufacture of JEV-OctoVAX. We will share equally with SingVax all external and production costs\nand profits associated with the development of JEV-OctoVAX.\n", "page_number": 74, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.08515190415062045, "lower_right_x": 0.8590441621294616, "lower_right_y": 0.12665810868635002, "height": 0.04150620453572958, "width": 0.7386569872958257}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-74-1", "text": "   Our agreement with SingVax provides both parties with a right to terminate the agreement at will at pre-\ndetermined points. In the event that one party decides to terminate the agreement at will, residual obligations\nand rights may exist for the terminating party, including an obligation to manufacture its respective component\nof the JEV-OctoVAX product or to grant a royalty-bearing license for the manufacture of this component. In\naddition, either party may terminate the agreement in the event that the parties have not entered into a\ncommercialization agreement for JEV-OctoVAX within a predetermined period after regulatory approval. We\nand SingVax have agreed to indemnify each other against certain liabilities, but these indemnities are limited in\nscope and amount.\n", "page_number": 74, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.1399229781771502, "lower_right_x": 0.8711433756805808, "lower_right_y": 0.24989302524604193, "height": 0.10997004706889174, "width": 0.7507562008469449}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-74-2", "text": "SurModics, Inc.\n", "page_number": 74, "bounding_box": {"top_left_x": 0.11675741076830005, "top_left_y": 0.2631578947368421, "lower_right_x": 0.2323049001814882, "lower_right_y": 0.2772785622593068, "height": 0.014120667522464714, "width": 0.11554748941318814}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-74-3", "text": "   In June 2004, we provided SurModics with a worldwide exclusive license for the use of PolyActive and\nOctoDEX in the development of site-specific, local acting, drug-eluting implants, such as stents and ophthalmic\ndevices. In February 2007, we entered into an agreement with SurModics amending the 2004 agreement,\nregarding the out-licensing of certain applications in the field of drug-eluting medical devices based on our\nPolyActive technology only. As a result of the 2007 amendment, certain royalty payment obligations under the\nold agreement were renegotiated and replaced by fixed annual license payments for the period until 31 March\n2012 with the potential for sales based royalties. Thereafter, SurModics will pay certain minimum annual\nroyalty payments. Under the 2007 amendment, the ongoing license payments will be less than the annual\nminimum royalties which had been agreed under the 2004 agreement. SurModics may terminate the license at\nwill, subject to a specified notice period.\n", "page_number": 74, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.290543431750107, "lower_right_x": 0.8741681790683605, "lower_right_y": 0.4278990158322636, "height": 0.1373555840821566, "width": 0.7537810042347247}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-74-4", "text": "Theratechnologies, Inc.\n", "page_number": 74, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.44458707744972187, "lower_right_x": 0.2837265577737447, "lower_right_y": 0.45742404792468977, "height": 0.012836970474967901, "width": 0.1633393829401089}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-74-5", "text": "   In September 2007, we concluded a license agreement with Theratechnologies pursuant to which we were\ngranted a world-wide exclusive license to certain GLP-1 analogues, comprising a number of different\ncompounds. In consideration for the license granted under this agreement, we have granted to Theratechnologies\noptions to acquire 200,000 Shares (see \u201cDescription of Share Capital and Corporate Governance \u2013 Share Capital\n\u2013 Outstanding Warrants and Options\u201d).\n", "page_number": 74, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.4719726144629867, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.5395806589644844, "height": 0.06760804450149765, "width": 0.7604355716878403}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-74-6", "text": "   Under the license agreement, multiple development, regulatory and sales milestone payments are due for each\nproduct incorporating the licensed technology. The sum of these milestone payments amounts to \u20ac35.7 million\nper product if all milestones are met, with the milestone payments increasing as the development of the product\nprogresses. The regulatory and sales related milestone payments account for approximately 80% of the total\nmilestone payments. We have the right to satisfy developmental milestone payments of up to \u20ac7.7 million per\nproduct by issuing Shares to Theratechnologies with a value equal to the amount of the required payment. This\nright is subject to certain conditions and limitations. In addition to milestone payments, we are required to make\nlow single-digit royalty payments based on sales of products incorporating the licensed technology. The term of\nthe agreement is until the expiration of the last patent, however, the agreement may be terminated for\nunremedied breach.\n", "page_number": 74, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.5541292255027813, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.6880616174582799, "height": 0.13393239195549855, "width": 0.7604355716878403}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-74-7", "text": "Utrecht University\n", "page_number": 74, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.7047496790757382, "lower_right_x": 0.2516636418632789, "lower_right_y": 0.7184424475823705, "height": 0.013692768506632369, "width": 0.13127646702964307}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-74-8", "text": "   Starting in 1996, we executed several agreements with Utrecht University, whereby Utrecht University\ngranted us an exclusive license to all patents related to the OctoDEX technology. Pursuant to the relevant\nagreements, Utrecht University is entitled to receive royalties from us based either on our own sales of products\nthat use the OctoDEX technology or on royalties that we receive from third parties, based on the sale of\nproducts using the OctoDEX technology. In addition, as part of our agreement with Utrecht University, we\nsponsor a Ph.D. position in the Department of Pharmaceutics and costs associated with this sponsorship can be\noffset against any royalties owed by us.\n", "page_number": 74, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.732135216089003, "lower_right_x": 0.8711433756805808, "lower_right_y": 0.8284124946512623, "height": 0.09627727856225932, "width": 0.7507562008469449}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-74-9", "text": "Government Regulation and Product Approval\n", "page_number": 74, "bounding_box": {"top_left_x": 0.12159709618874773, "top_left_y": 0.8416773641420625, "lower_right_x": 0.4646098003629764, "lower_right_y": 0.8557980316645272, "height": 0.014120667522464658, "width": 0.3430127041742287}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-74-10", "text": "  Our business is subject to extensive government regulation. Regulation by governmental authorities in the\nEuropean Union, the United States and other jurisdictions is a significant factor in the development,\nmanufacture and marketing of drugs and in ongoing research and development activities. All of our product\n", "page_number": 74, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.8690629011553274, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.9105691056910569, "height": 0.04150620453572951, "width": 0.7313974591651543}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-74-11", "text": "72\n", "page_number": 74, "bounding_box": {"top_left_x": 0.8620689655172413, "top_left_y": 0.9477963200684638, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9572100984167736, "height": 0.00941377834830981, "width": 0.01875378100423475}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-75-0", "text": "candidates will require regulatory approval by governmental agencies prior to commercialization. In particular,\npharmaceuticals are subject to rigorous pre-clinical and clinical trials and other pre-marketing approval\nrequirements by the EMEA, the FDA and other regulatory authorities in the European Union, the United States\nand other jurisdictions.\n", "page_number": 75, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.08515190415062045, "lower_right_x": 0.8711433756805808, "lower_right_y": 0.1399229781771502, "height": 0.05477107402652974, "width": 0.7507562008469449}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-75-1", "text": "Regulation in the United States\n", "page_number": 75, "bounding_box": {"top_left_x": 0.11736237144585603, "top_left_y": 0.15361574668378264, "lower_right_x": 0.338777979431337, "lower_right_y": 0.16773641420624733, "height": 0.014120667522464686, "width": 0.22141560798548093}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-75-2", "text": "   The development, testing, manufacturing, labeling, advertising, promotion, distribution, export and marketing\nof our product candidates are subject to extensive regulation by governmental authorities in the United States.\nThe FDA, under the Federal Food, Drug and Cosmetic Act, regulates the approval and marketing of\npharmaceutical drugs in the United States. The steps required before a drug may be approved for marketing in\nthe United States generally include, among others:\n", "page_number": 75, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.1810012836970475, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.24989302524604193, "height": 0.06889174154899444, "width": 0.7604355716878403}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-75-3", "text": "\u00b7   pre-clinical laboratory models and tests, including animal testing;\n\n\u00b7   the submission to the FDA of an IND Application for human clinical testing, which must become\n    effective before human clinical trials commence;\n\n\u00b7   adequate and well-controlled human clinical trials to establish the safety and efficacy of the drug;\n\n\u00b7   the submission to the FDA of a new drug application (\u201cNDA\u201d);\n\n\u00b7   satisfactory completion of an FDA inspection of the manufacturing facilities at which the drug is made\n    to assess compliance with current cGMP and, at the FDA\u2019s option, an FDA audit of the clinical trial sites\n    that generated the data in support of the NDA; and\n\n\u00b7   FDA review and approval of the NDA.\n", "page_number": 75, "bounding_box": {"top_left_x": 0.13490623109497882, "top_left_y": 0.2640136927685066, "lower_right_x": 0.8802177858439202, "lower_right_y": 0.4587077449721866, "height": 0.19469405220367997, "width": 0.7453115547489414}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-75-4", "text": "   Moreover, post-approval studies, monitoring or clinical experience may reveal issues relating to safety and\nefficacy that were not previously known or fully understood, and these may require changes to or even the\nsuspension of approved NDAs.\n", "page_number": 75, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.4719726144629867, "lower_right_x": 0.8566243194192378, "lower_right_y": 0.5134788189987163, "height": 0.04150620453572956, "width": 0.736237144585602}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-75-5", "text": "   The testing and approval process requires substantial time, effort and financial resources, and the receipt,\ntiming, and conditions of any approval are uncertain. Pre-clinical studies include laboratory evaluations of the\nproduct candidate, model studies to assess the potential safety and efficacy of the product candidate, and testing\nin animals. The results of the pre-clinical studies, together with manufacturing information and analytical data,\nare submitted to the FDA as part of the IND, which must become effective before clinical trials may be\ncommenced.\n", "page_number": 75, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.5267436884895165, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.6089002995293111, "height": 0.08215661103979466, "width": 0.7555958862673926}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-75-6", "text": "   All aspects of drug development and manufacture require compliance on a continuing basis with various\nregulatory obligations, including the cGMP regulations.\n", "page_number": 75, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.6260162601626016, "lower_right_x": 0.8421052631578947, "lower_right_y": 0.652545999144202, "height": 0.02652973898160038, "width": 0.7217180883242589}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-75-7", "text": "Clinical Trial Approval\n", "page_number": 75, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.6670945656824989, "lower_right_x": 0.2849364791288566, "lower_right_y": 0.6812152332049636, "height": 0.014120667522464658, "width": 0.1645493042952208}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-75-8", "text": "   Clinical trials involve the administration of the product candidates to patients or healthy volunteers under the\nsupervision of a qualified principal investigator. Further, each clinical trial must be reviewed and approved by\nan independent institutional review board at or servicing each institution at which the clinical trial will be\nconducted. The independent institutional review board will consider, among other things, ethical factors, the\nsafety of human subjects and the possible liability of the institution.\n", "page_number": 75, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.6944801026957638, "lower_right_x": 0.8711433756805808, "lower_right_y": 0.762943945228926, "height": 0.06846384253316218, "width": 0.7507562008469449}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-75-9", "text": "  Clinical trials typically are conducted in three sequential phases prior to approval, but the phases may\noverlap. These phases generally include the following:\n", "page_number": 75, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.7766367137355584, "lower_right_x": 0.8203266787658802, "lower_right_y": 0.8044501497646556, "height": 0.02781343602909714, "width": 0.6999395039322444}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-75-10", "text": "Phase I. Phase I clinical trials involve the initial introduction of the drug into human subjects, frequently\nhealthy volunteers. These studies are designed to determine the safety and tolerability of the drug in\nhumans, the adverse effects associated with increasing doses and, if possible, to gain early evidence of\neffectiveness. In Phase I, the drug is usually tested for safety, including adverse effects, dosage\ntolerance, absorption, distribution, metabolism, excretion and pharmacodynamics.\n", "page_number": 75, "bounding_box": {"top_left_x": 0.16878402903811252, "top_left_y": 0.8177150192554558, "lower_right_x": 0.8753781004234725, "lower_right_y": 0.8866067608044501, "height": 0.06889174154899436, "width": 0.70659407138536}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-75-11", "text": "\u00b7\n", "page_number": 75, "bounding_box": {"top_left_x": 0.1355111917725348, "top_left_y": 0.8224219084296106, "lower_right_x": 0.14458560193587416, "lower_right_y": 0.8284124946512623, "height": 0.005990586221651717, "width": 0.009074410163339375}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-75-12", "text": "73\n", "page_number": 75, "bounding_box": {"top_left_x": 0.8620689655172413, "top_left_y": 0.9477963200684638, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9572100984167736, "height": 0.00941377834830981, "width": 0.01875378100423475}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-76-0", "text": "\u00b7   Phase II. Phase II clinical trials usually involve studies in a limited patient population to (i) determine\n    dosage tolerance and optimal dosage; (ii) identify possible adverse effects and safety risks and (iii)\n    evaluate the efficacy of the drug for specific, targeted indications. Although there are no statutory or\n    regulatory definitions for Phase IIa and Phase IIb, Phase IIa is commonly used to describe a Phase II\n    clinical trial evaluating adverse effects, safety risks and preliminary efficacy; and Phase IIb is commonly\n    used to describe a subsequent Phase II clinical trial that also evaluates dosage tolerance and optimal\n    dosage.\n\n\u00b7   Phase III. If a compound is found to be potentially effective and to have an acceptable safety profile in\n    Phase II studies, the clinical trial program will be expanded to further demonstrate clinical efficacy,\n    confirm optimal dosage and safety within an expanded patient population at geographically dispersed\n    clinical trial sites. Phase III studies usually include several hundred to several thousand patients.\n\n\u00b7   Phase IV. Phase IV clinical trials are studies required of or agreed to by a sponsor that are conducted\n    after the FDA has approved a drug for marketing. These studies are used to gain additional experience\n    from the treatment of patients in the intended therapeutic indication and to document a clinical benefit in\n    the case of drugs approved under accelerated approval regulations. If the FDA approves a drug while a\n    company has ongoing clinical trials that were not necessary for approval, a company may be able to use\n    the data from these clinical trials to meet all or part of any Phase IV clinical trial requirement. These\n    clinical trials are often referred to as Phase III/IV post approval clinical trials. Failure to promptly\n    conduct Phase IV clinical trials could result in withdrawal of approval for drugs approved under\n", "page_number": 76, "bounding_box": {"top_left_x": 0.13490623109497882, "top_left_y": 0.08515190415062045, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.37312794180573383, "height": 0.28797603765511337, "width": 0.7410768300060496}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-76-1", "text": "conduct Phase IV clinical trials co\naccelerated approval regulations.\n", "page_number": 76, "bounding_box": {"top_left_x": 0.1693889897156685, "top_left_y": 0.37312794180573383, "lower_right_x": 0.39201451905626133, "lower_right_y": 0.38682071031236626, "height": 0.013692768506632425, "width": 0.22262552934059285}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-76-2", "text": "   In the case of drugs for the treatment of severe or life threatening diseases, the initial clinical trials are\nsometimes done in patients rather than in healthy volunteers. Since these patients are affected already with the\ntarget disease, it is possible that such clinical trials may provide evidence of efficacy traditionally obtained in\nPhase II clinical trials. These trials are referred to frequently as Phase I/II clinical trials. We, the FDA or an\nindependent review board may suspend clinical trials at any time on various grounds, including a finding that\nthe patients or volunteers are being exposed to an unacceptable health risk.\n", "page_number": 76, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.40008557980316645, "lower_right_x": 0.8608590441621294, "lower_right_y": 0.48267008985879334, "height": 0.08258451005562689, "width": 0.7404718693284936}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-76-3", "text": "Marketing Approval\n", "page_number": 76, "bounding_box": {"top_left_x": 0.1161524500907441, "top_left_y": 0.4993581514762516, "lower_right_x": 0.26436781609195403, "lower_right_y": 0.5121951219512195, "height": 0.012836970474967901, "width": 0.14821536600120994}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-76-4", "text": "   The results of pre-clinical and clinical trials, together with detailed information on the manufacture and\ncomposition of the drug and proposed labeling, are submitted to the FDA in the form of an NDA requesting\napproval to market the drug. In its review of NDA submissions, the FDA has broad discretion to require an\napplicant to generate additional pre-clinical and clinical data related to the product candidate\u2019s safety and\nefficacy.\n", "page_number": 76, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.5267436884895165, "lower_right_x": 0.8469449485783425, "lower_right_y": 0.5943517329910141, "height": 0.0676080445014976, "width": 0.7265577737447066}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-76-5", "text": "   Before approving an NDA, the FDA will inspect the facilities at which the drug is manufactured, whether\nours or our third party manufacturer\u2019s, and will not approve the drug unless the manufacturing facility complies\nwith cGMP. Once the NDA submission has been accepted for filing, the FDA typically takes at least one year to\nreview the application and respond to the applicant. The review process is often significantly extended by FDA\nrequests for additional information or clarification. The FDA may delay approval of an NDA if applicable\nregulatory criteria are not satisfied, require additional testing or information and/or require post-marketing\ntesting and surveillance to monitor safety or efficacy of a drug. FDA approval of any NDA submitted by us will\nbe at a time the FDA chooses. Also, if regulatory approval of a drug is granted, such approval may entail\nlimitations on the indicated uses for which such drug may be marketed. Once approved, the FDA may withdraw\nthe drug approval if compliance with pre or post-marketing regulatory requirements and conditions of approvals\nis not maintained or if problems occur after the drug reaches the marketplace. In addition, the FDA may require\npost-marketing studies, referred to as Phase IV studies, to monitor the effect of approved drugs and may limit\nfurther marketing of the drug based on the results of these post-marketing studies.\n", "page_number": 76, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.6089002995293111, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.787334189131365, "height": 0.17843388960205386, "width": 0.7555958862673926}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-76-6", "text": "   If we obtain regulatory approval for a drug, this clearance will be limited to those diseases and conditions for\nwhich the drug is safe and effective, as demonstrated through clinical trials. Even if this regulatory approval is\nobtained, a marketed drug, its manufacturer and its manufacturing facilities are subject to continual review and\nperiodic inspections by the FDA for compliance with cGMP and other regulatory requirements. Discovery of\npreviously unknown problems with a medicine, device, manufacturer or facility may result in restrictions on the\nmarketing or manufacturing of an approved drug, including costly recalls or withdrawal of the drug from the\nmarket. Further, the FDA closely regulates the post-approval marketing and promotion of drugs, including\nstandards and regulations for direct-to-consumer advertising, off-label promotion, industry-sponsored scientific\n", "page_number": 76, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.8005990586221652, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.9097133076593924, "height": 0.10911424903722722, "width": 0.7555958862673926}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-76-7", "text": "74\n", "page_number": 76, "bounding_box": {"top_left_x": 0.8620689655172413, "top_left_y": 0.9477963200684638, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9572100984167736, "height": 0.00941377834830981, "width": 0.01875378100423475}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-77-0", "text": "and educational activities and promotional activities involving the Internet. Upon approval, a drug may only be\nmarketed for the approved indications in the approved dosage forms and at the approved doses. Failure to\ncomply with these requirements can result in adverse publicity, warning letters, corrective advertising and\npotential civil and criminal penalties. In addition, if there are any modifications to the drug, including changes in\nindication, labeling, or manufacturing processes or facilities, we may be required to submit and obtain FDA\napproval of a new or supplemental NDA. The FDA has broad post-market regulatory and enforcement powers,\nincluding the ability to suspend or delay issuance of approvals, seize or recall drugs, withdraw approvals, enjoin\nviolations and institute criminal prosecution.\n", "page_number": 77, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.08515190415062045, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.1951219512195122, "height": 0.10997004706889175, "width": 0.7604355716878403}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-77-1", "text": "   Our Contract Development Business involves drug development and manufacture on behalf of third parties.\nBoth of these activities, comprising decision making processes, manufacturing processes, procurement,\nmanufacture, storage, shipping and recordkeeping, must comply with the FDA's cGMP regulation, among other\nrequirements. FDA oversight, including facility inspections, is ongoing, and a failure to comply with applicable\nrequirements can result in adverse publicity, warning letters, civil and criminal liability, and restrictions on\nand/or prohibitions against the performance of these activities, any of which may result in a loss of business.\n", "page_number": 77, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.20838682071031236, "lower_right_x": 0.8729582577132486, "lower_right_y": 0.29097133076593923, "height": 0.08258451005562686, "width": 0.7525710828796128}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-77-2", "text": "Pricing and Reimbursement\n", "page_number": 77, "bounding_box": {"top_left_x": 0.11736237144585603, "top_left_y": 0.3042362002567394, "lower_right_x": 0.3194192377495463, "lower_right_y": 0.31835686777920413, "height": 0.014120667522464714, "width": 0.20205686630369024}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-77-3", "text": "   Our ability to commercialize successfully and attract strategic partners for our product candidates depends in\nsignificant part on the availability of adequate coverage and reimbursement from third-party payers, including,\nin the United States, governmental payers such as the Medicare and Medicaid programs, managed care\norganizations, and private health insurers. Third-party payers are increasingly challenging prices charged for\ndrugs and services and examining their cost effectiveness, in addition to their safety and efficacy. We may need\nto conduct expensive pharmaco-economic studies in order to demonstrate the cost effectiveness of any future\ndrugs. Even with studies, our product candidates may be considered less safe, less effective or less cost effective\nthan existing drugs, and third-party payers therefore may not provide coverage and reimbursement for our\nproduct candidates, in whole or in part.\n", "page_number": 77, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.33162173727000427, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.45528455284552843, "height": 0.12366281557552417, "width": 0.7555958862673926}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-77-4", "text": "   Political, economic and regulatory influences are subjecting the healthcare industry in the United States to\nfundamental changes. There have been and we expect there will continue to be a number of legislative and\nregulatory proposals to change the healthcare system in ways that could significantly affect our business. For\nexample, the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (\u201cMMA\u201d), among\nother things, established a new Part D prescription drug benefit that began on 1 January 2006 and changed\ncoverage and reimbursement for drugs and devices under existing benefits. We anticipate that the US Congress,\nstate legislatures and the private sector will continue to consider and may adopt healthcare policies intended to\ncurb rising healthcare costs. These cost-containment measures include:\n", "page_number": 77, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.4685494223363286, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.5785194694052204, "height": 0.10997004706889174, "width": 0.7555958862673926}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-77-5", "text": "\u00b7   controls on government-funded reimbursement for medical drugs and services;\n\n\u00b7   controls on healthcare providers;\n\n\u00b7   challenges to the pricing of medical drugs and services or limits or prohibitions on reimbursement for\n    specific drugs and therapies through other means;\n\n\u00b7   reform of drug importation laws; and\n\n\u00b7   expansion of use of managed care systems in which healthcare providers contract to provide\n    comprehensive healthcare for a fixed cost per person.\n", "page_number": 77, "bounding_box": {"top_left_x": 0.13490623109497882, "top_left_y": 0.5952075310226786, "lower_right_x": 0.8560193587416818, "lower_right_y": 0.7462558836114677, "height": 0.15104835258878901, "width": 0.721113127646703}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-77-6", "text": "   We are unable to predict what additional legislation, regulations or policies, if any, relating to the healthcare\nindustry or third-party coverage and reimbursement may be enacted in the future or what effect such legislation,\nregulations or policies would have on our business. Any cost containment measures, including those listed\nabove, or other healthcare system reforms that are adopted could have a material adverse effect on our ability to\noperate profitably.\n", "page_number": 77, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.7595207531022679, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.8284124946512623, "height": 0.06889174154899447, "width": 0.7555958862673926}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-77-7", "text": "   Drug pricing may also be affected materially by the approval of generic drugs by the FDA. Generic drugs\nmay be approved upon the expiration of applicable patents and periods of regulatory exclusivity. They require\nthe submission of an abbreviated new drug application, which must contain, among other things, studies\nshowing the comparability of the generic product to the pioneer product approved pursuant to an NDA. The\nentry of a generic competitor typically results in a substantial reduction in effective pricing. While the generic\n", "page_number": 77, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.8416773641420625, "lower_right_x": 0.8614640048396854, "lower_right_y": 0.9122807017543859, "height": 0.0706033376123234, "width": 0.7410768300060496}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-77-8", "text": "75\n", "page_number": 77, "bounding_box": {"top_left_x": 0.8620689655172413, "top_left_y": 0.9477963200684638, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9572100984167736, "height": 0.00941377834830981, "width": 0.01875378100423475}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-78-0", "text": "drug process is not technically available to biologic drugs in the United States, regulatory and legislative\ndevelopments may permit therapeutically substitutable versions of innovator biologics to receive approval\nfollowing abbreviated review.\n", "page_number": 78, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.08515190415062045, "lower_right_x": 0.837265577737447, "lower_right_y": 0.12665810868635002, "height": 0.04150620453572958, "width": 0.7168784029038112}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-78-1", "text": "Regulation in the European Union\n", "page_number": 78, "bounding_box": {"top_left_x": 0.11736237144585603, "top_left_y": 0.1399229781771502, "lower_right_x": 0.3629764065335753, "lower_right_y": 0.1540436456996149, "height": 0.014120667522464714, "width": 0.24561403508771928}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-78-2", "text": "  Clinical trials, the regulatory approval process, and safety monitoring of drugs and drug manufacturers in the\nEuropean Union proceed in much the same manner as they do in the United States. Therefore, many of the\nconcepts discussed above under \u201c \u2013 Regulation in the United States\u201d apply similarly in the context of the\nEuropean Union. In addition, drugs are subject to extensive price and reimbursement regulation of the European\nUnion member states.\n", "page_number": 78, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.16730851519041506, "lower_right_x": 0.8753781004234725, "lower_right_y": 0.23491655969191272, "height": 0.06760804450149765, "width": 0.7549909255898367}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-78-3", "text": "Clinical Trial Approval\n", "page_number": 78, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.25288831835686776, "lower_right_x": 0.2849364791288566, "lower_right_y": 0.2652973898160034, "height": 0.012409071459135668, "width": 0.1645493042952208}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-78-4", "text": "    Pursuant to the Clinical Trials Directive 2001/20/EC, a system for the approval of clinical trials in the\nEuropean Union has been implemented through national legislation of the member states. Under this system,\napproval must be obtained from the competent national authority of an European Union member state in which\nit is intended to conduct the study. Furthermore, a clinical trial may only be started after a competent ethics\ncommittee has issued a favorable opinion on the clinical trial application which must be supported by an\ninvestigational medicinal product dossier with supporting information prescribed by the Clinical Trials Directive\nand further detailed in applicable guidance documents.\n", "page_number": 78, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.28027385537013266, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.37526743688489517, "height": 0.0949935815147625, "width": 0.7604355716878403}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-78-5", "text": "Marketing Approval\n", "page_number": 78, "bounding_box": {"top_left_x": 0.1161524500907441, "top_left_y": 0.3898160034231921, "lower_right_x": 0.2661826981246219, "lower_right_y": 0.40350877192982454, "height": 0.013692768506632425, "width": 0.15003024803387782}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-78-6", "text": "   Drug marketing approval in the European Union member states proceeds under one of four approval\nprocedures: a centralized approval procedure, a mutual recognition procedure, a decentralized procedure or a\nnational procedure.\n", "page_number": 78, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.417201540436457, "lower_right_x": 0.8542044767090139, "lower_right_y": 0.4582798459563543, "height": 0.041078305519897274, "width": 0.7338173018753781}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-78-7", "text": "   Certain drugs defined as medicinal products developed by means of biotechnological processes must undergo\nthe centralized approval procedure for marketing approval, which, if granted, is automatically valid in all\nEuropean Union member states. The EMEA and the European Commission administer the centralized\nmarketing approval process. This procedure is mandatory for biotechnological DNA and gene therapy products,\nproducts containing new active substance for the treatment of acquired immune deficiency syndrome (AIDS),\ncancer, neurodegenerative disorder or diabetes, orphan drugs and, starting 20 May 2008, also for pharmaceutical\nproducts containing a new chemical substance for the treatment of auto-immune diseases, other immune\ndysfunctions and viral diseases.\n", "page_number": 78, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.4719726144629867, "lower_right_x": 0.8765880217785844, "lower_right_y": 0.5819426615318785, "height": 0.10997004706889174, "width": 0.7562008469449486}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-78-8", "text": "   The centralized approval procedure is optional for new medicinal products containing a new active substance\nand other medicinal products that are sufficiently innovative in the eyes of the EMEA. The applicant has to\nshow that the medicinal product concerned shows a significant therapeutic, scientific or technical innovation or\nthat the granting of authorization is in the interest of patients at a community level.\n", "page_number": 78, "bounding_box": {"top_left_x": 0.12099213551119177, "top_left_y": 0.5952075310226786, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.6504065040650406, "height": 0.05519897304236199, "width": 0.7549909255898366}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-78-9", "text": "   Under the centralized approval procedure, the EMEA\u2019s Committee for Medicinal Products for Human Use\n(\u201cCHMP\u201d) serves as the scientific committee that renders opinions about the safety, efficacy and quality of\nhuman product candidates on behalf of the EMEA. The CHMP is composed of experts nominated by each\nmember state\u2019s national drug authority, one of them to be appointed to act as rapporteur for the co-ordination of\nthe evaluation with the possible assistance of a further member of the Committee acting as a co-rapporteur.\nCHMP has 210 days, or longer if additional information is requested, to give its opinion to the EMEA as to\nwhether a marketing approval should be granted. This process is complex and involves extensive consultation\nwith the regulatory authorities of member states and a number of experts.\n", "page_number": 78, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.6636713735558408, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.7736414206247325, "height": 0.10997004706889169, "width": 0.7555958862673926}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-78-10", "text": "  If the centralized procedure is not mandatory, there are three alternatives procedures. If marketing\nauthorization in only one member state is preferred, an application can be filed with the national competent\nauthority of a member state. The other two options are a mutual recognition by European Union member states\nand the decentralized procedure.\n", "page_number": 78, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.7869062901155327, "lower_right_x": 0.8663036902601331, "lower_right_y": 0.8421052631578947, "height": 0.05519897304236199, "width": 0.7459165154264973}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-78-11", "text": "  If an authorization has been granted by one member state (the \u201cReference Member State\u201d), an application\nmay be made for mutual recognition in one or more other member states (the \u201cConcerned Member State(s)\u201d).\nBefore submitting the application for mutual recognition, the holder of the authorization requests the Reference\nMember State to prepare an assessment report or update an existing report in respect of the drug concerned. The\n", "page_number": 78, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.8553701326486949, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.9122807017543859, "height": 0.05691056910569103, "width": 0.7555958862673926}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-78-12", "text": "76\n", "page_number": 78, "bounding_box": {"top_left_x": 0.8620689655172413, "top_left_y": 0.9477963200684638, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9572100984167736, "height": 0.00941377834830981, "width": 0.01875378100423475}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-79-0", "text": "assessment report has to be provided, as well as forwarded, to the Concerned Member State(s) within 90 days of\nthe receipt of the request. The holder of the marketing authorization also files the application(s) with the EMEA.\nUnless a member state considers that there are grounds for supposing that the applied for marketing\nauthorization may present a risk to public health, each Concerned Member State recognizes the marketing\nauthorization granted by the Reference Member State within 90 days of receipt of the application and the\nassessment report.\n", "page_number": 79, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.08515190415062045, "lower_right_x": 0.8796128251663642, "lower_right_y": 0.16730851519041506, "height": 0.08215661103979462, "width": 0.7592256503327284}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-79-1", "text": "   If the member states have not reached an agreement within said time limit they shall directly refer the matter\nto the EMEA. The Committee for Proprietary Medicinal Products (\u201cCPMP\u201d), which is a part of the EMEA,\nshall review the matter and issue a reasoned opinion within 90 days. If several applications have been made for\na particular drug and member states have adopted divergent decisions concerning the authorization of the drug\nor its suspension or withdrawal, a member state, the European Commission or the marketing authorization\nholder may refer the matter to the CPMP. In that case, the 90-day period may be extended. The procedure before\nthe CPMP is a form of arbitration.\n", "page_number": 79, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.1810012836970475, "lower_right_x": 0.8802177858439202, "lower_right_y": 0.2738553701326487, "height": 0.09285408643560122, "width": 0.7598306110102844}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-79-2", "text": "  After the CPMP has heard both sides of the argument, the Committee forwards its final opinion to the\nEuropean Commission. The European Commission prepares a draft of the decision to be taken in respect of the\napplication, taking into account European Union law, within 30 days of the receipt of the opinion.\n", "page_number": 79, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.290543431750107, "lower_right_x": 0.8705384150030248, "lower_right_y": 0.33204963628583656, "height": 0.04150620453572956, "width": 0.7501512401693889}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-79-3", "text": "   The fourth option is the decentralized procedure. For all other pharmaceutical drugs for which no marketing\nauthorization has been granted in a member state, a marketing authorization can be obtained from the competent\nmember state authorities through a decentralized procedure. A marketing authorization may only be granted to\nan applicant established in the European Union. A member state has to ensure that the procedure for granting an\nauthorization is completed within 210 days of the submission of a valid application. Authorizations are valid for\nfive years and are renewable for consecutive five-year periods.\n", "page_number": 79, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.3453145057766367, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.4278990158322636, "height": 0.08258451005562689, "width": 0.7555958862673926}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-79-4", "text": "   When appropriate, we may seek accelerated approval for our drug candidates. We cannot predict whether any\nof our drug candidates will obtain such designations, or the ultimate impact, if any, of such designations on the\ntiming, conditions, or likelihood of EMEA approval.\n", "page_number": 79, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.4411638853230638, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.48352588789045786, "height": 0.042362002567394086, "width": 0.7555958862673926}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-79-5", "text": "   After a drug has been approved and launched, it is a condition of maintaining the marketing approval that all\naspects relating to its quality, safety and efficacy must be kept under review. Sanctions may be imposed for\nfailure to adhere to the conditions of the marketing approval. In extreme cases, the approval may be revoked\nresulting in withdrawal of the product from sale.\n", "page_number": 79, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.4993581514762516, "lower_right_x": 0.8705384150030248, "lower_right_y": 0.5532734274711169, "height": 0.05391527599486523, "width": 0.7501512401693889}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-79-6", "text": "   Even if a drug has received marketing approval, national pricing and reimbursement rules will apply, which\nmay delay, or effectively prevent, commercialization or make commercialization substantially less profitable\nthan anticipated, or even uneconomical.\n", "page_number": 79, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.5678219940094138, "lower_right_x": 0.8663036902601331, "lower_right_y": 0.6084724005134788, "height": 0.04065040650406504, "width": 0.7459165154264973}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-79-7", "text": "Manufacturing\n", "page_number": 79, "bounding_box": {"top_left_x": 0.1161524500907441, "top_left_y": 0.6225930680359435, "lower_right_x": 0.2323049001814882, "lower_right_y": 0.6367137355584083, "height": 0.01412066752246477, "width": 0.1161524500907441}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-79-8", "text": "   The manufacturing of investigational drugs used in clinical trials as well as the manufacturing of approved\ndrugs must be conducted in strict compliance with the EMEA\u2019s cGMP and comparable requirements of other\nregulatory bodies, which mandate the methods, facilities, and controls used in manufacturing, processing, and\npackaging of drugs to assure their safety and identity. The EMEA enforces its cGMP requirements through\nmandatory registration of facilities and inspections of those facilities. Failure to comply with these requirements\ncould interrupt supply and result in delays, unanticipated costs and lost revenues, and subject the applicant to\npotential legal or regulatory action, including but not limited to warning letters, suspension of manufacturing,\nseizure of product, injunctive action or possible civil and criminal penalties.\n", "page_number": 79, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.6499786050492083, "lower_right_x": 0.8753781004234725, "lower_right_y": 0.7599486521181001, "height": 0.1099700470688918, "width": 0.7549909255898367}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-79-9", "text": "   A manufacturers\u2019 license is a legal prerequisite for the manufacturing of investigational drugs for use in\nclinical trials and of approved drugs for sale within the European Union.\n", "page_number": 79, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.7732135216089003, "lower_right_x": 0.837265577737447, "lower_right_y": 0.8010269576379975, "height": 0.02781343602909714, "width": 0.7168784029038112}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-79-10", "text": "Marketing and Promotion\n", "page_number": 79, "bounding_box": {"top_left_x": 0.1161524500907441, "top_left_y": 0.8142918271287976, "lower_right_x": 0.3042952208106473, "lower_right_y": 0.8284124946512623, "height": 0.01412066752246477, "width": 0.1881427707199032}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-79-11", "text": "   The EMEA also regulates the marketing and promotion of approved drugs, including industry-sponsored\ncontinuing medical education, direct-to-consumer, advertising, and direct physician sales, to ensure that\ninformation provided by applicants regarding their products is truthful, balanced, and accurately reflects the\nsafety and efficacy claims approved by the EMEA. Failure to comply with these requirements can result in\nadverse publicity, warning letters, corrective advertising and potential civil and criminal penalties.\n", "page_number": 79, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.8416773641420625, "lower_right_x": 0.8469449485783425, "lower_right_y": 0.9122807017543859, "height": 0.0706033376123234, "width": 0.7265577737447066}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-79-12", "text": "77\n", "page_number": 79, "bounding_box": {"top_left_x": 0.8620689655172413, "top_left_y": 0.9477963200684638, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9572100984167736, "height": 0.00941377834830981, "width": 0.01875378100423475}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-80-0", "text": "Regulatory Data Protection and Marketing Exclusivity\n", "page_number": 80, "bounding_box": {"top_left_x": 0.11736237144585603, "top_left_y": 0.08515190415062045, "lower_right_x": 0.499697519661222, "lower_right_y": 0.09927257167308515, "height": 0.0141206675224647, "width": 0.38233514821536596}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-80-1", "text": "   Without prejudice to the law on the protection of industrial and commercial property, all applications for\nmarketing approval submitted on or after 20 November 2005, receive an 8+2+1 protection regime. This regime\nconsists of a regulatory data protection period of eight years plus a marketing exclusivity of ten years plus an\nadditional marketing exclusivity of one further year if, during the first eight years of those ten years, the\nmarketing approval holder obtains an approval for one or more new therapeutic indications which, during the\nscientific evaluation prior to their approval, are determined to bring a significant clinical benefit in comparison\nwith existing therapies. Under the current rules, a third party may reference the pre-clinical and clinical data of\nthe original sponsor beginning eight years after first European approval, but can only market a generic version\nafter ten (or 11) years have lapsed.\n", "page_number": 80, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.11253744116388532, "lower_right_x": 0.868723532970357, "lower_right_y": 0.2362002567394095, "height": 0.12366281557552418, "width": 0.7483363581367212}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-80-2", "text": "Pricing and Reimbursement\n", "page_number": 80, "bounding_box": {"top_left_x": 0.11736237144585603, "top_left_y": 0.24946512623020967, "lower_right_x": 0.3194192377495463, "lower_right_y": 0.2635857937526744, "height": 0.014120667522464714, "width": 0.20205686630369024}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-80-3", "text": "   Regulatory approval of pricing and reimbursement is required in most countries other than the United States.\nRegulators in some European countries condition their reimbursement of a drug on the agreement of the seller\nnot to sell the drug for more than a specified price or in more than specified quantities per year in their\ncountries. In some cases, the price established in any of these countries may serve as a benchmark in the other\ncountries. As a result, the price approved in connection with the first approval obtained in any of these European\ncountries may serve as the maximum price that may be approved in the other European countries. Further, a\nprice approved in one of these European countries that is lower than the price previously approved in the other\nEuropean countries may require a reduction in the prices in those other European countries. In such event, the\nresulting prices may be insufficient to generate an acceptable return on investment in the drug, or the product\ncould be imported from a country where it is cheaper.\n", "page_number": 80, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.2768506632434745, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.41420624732563116, "height": 0.13735558408215665, "width": 0.7604355716878403}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-80-4", "text": "Regulation in Other Countries\n", "page_number": 80, "bounding_box": {"top_left_x": 0.11796733212341198, "top_left_y": 0.43089430894308944, "lower_right_x": 0.3339382940108893, "lower_right_y": 0.44373127941805734, "height": 0.012836970474967901, "width": 0.21597096188747733}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-80-5", "text": "   Approval of a drug by comparable regulatory authorities may be necessary in other countries prior to the\ncommencement of marketing of the drug in those countries, whether or not US or European Union approval has\nbeen obtained. The approval procedure varies among countries and can involve requirements for additional\ntesting. The time required may differ from that required for approval in the United States or the European\nUnion. In general, each country has its own procedures and requirements, many of which are time consuming\nand expensive. Thus, there can be substantial delays in obtaining required approvals from foreign regulatory\nauthorities after the relevant applications are filed.\n", "page_number": 80, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.4582798459563543, "lower_right_x": 0.8753781004234725, "lower_right_y": 0.5532734274711169, "height": 0.09499358151476256, "width": 0.7549909255898367}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-80-6", "text": "   The Japanese approval agency requires that tests be conducted on Japanese subjects to determine appropriate\ndosages for Japanese patients. In particular, the Japanese approval agency may request dedicated clinical\nbridging studies to prove comparability of clinical results between non-Japanese and Japanese patients. Also,\nother parts of the clinical program may need to be repeated in Japan. This may therefore result in a delay in\nintroducing a drug developed outside of Japan to the Japanese market.\n", "page_number": 80, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.5678219940094138, "lower_right_x": 0.8705384150030248, "lower_right_y": 0.6358579375267437, "height": 0.06803594351732989, "width": 0.7501512401693889}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-80-7", "text": "Competition\n", "page_number": 80, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.6499786050492083, "lower_right_x": 0.21294615849969753, "lower_right_y": 0.6628155755241762, "height": 0.012836970474967901, "width": 0.09255898366606172}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-80-8", "text": "   The pharmaceutical and biotechnology industries are highly competitive and subject to rapid technological\nchange. Any product candidates that we successfully develop will compete with existing and future therapies.\nThere are many organizations, including pharmaceutical companies, biotechnology companies, academic\nlaboratories, research institutions, governmental agencies and public and private universities, which are actively\nengaged in developing products that target the same markets as our product candidates. Many of these entities\nhave financial and other resources substantially greater than our own. In addition, many of our competitors have\nsignificantly greater experience in manufacturing, pre-clinical testing, conducting clinical trials, obtaining\nregulatory approvals and marketing than we do. These entities also compete with us in recruiting and retaining\nqualified scientific and management personnel, as well as in acquiring products and technologies\ncomplementary to, or necessary for, our programs. Moreover, there can be no assurance that our competitors\nwill not obtain patent protection or other intellectual property rights that would make it difficult or impossible\nfor us to market our products. As a result, there can be no assurance that we will be able to compete effectively\nagainst these companies or their products.\n", "page_number": 80, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.6773641420624733, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.8557980316645272, "height": 0.17843388960205386, "width": 0.7555958862673926}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-80-9", "text": "Our ability to compete successfully will depend largely on our ability to:\n", "page_number": 80, "bounding_box": {"top_left_x": 0.13914095583787053, "top_left_y": 0.8690629011553274, "lower_right_x": 0.6285541439806412, "lower_right_y": 0.883183568677792, "height": 0.014120667522464658, "width": 0.4894131881427707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-80-10", "text": "78\n", "page_number": 80, "bounding_box": {"top_left_x": 0.8620689655172413, "top_left_y": 0.9482242190842961, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9572100984167736, "height": 0.00898587933247752, "width": 0.01875378100423475}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-81-0", "text": "\u00b7   advance the development of our product candidates, including the enrollment of patients for our clinical\n    trials;\n\n\u00b7   demonstrate the safety, convenience of use and clinical efficacy of our product candidates;\n\n\u00b7   obtain regulatory approval for our product candidates in their respective indications;\n\n\u00b7   commercialize our product candidates successfully based on potential advantages of our products over\n    alternative treatment methods;\n\n\u00b7   successfully collaborate with pharmaceutical and biotechnology companies in the discovery,\n    development and commercialization of new products;\n\n\u00b7   obtain intellectual property protection for our products and technologies; and\n\n\u00b7   attract and retain qualified personnel.\n", "page_number": 81, "bounding_box": {"top_left_x": 0.1355111917725348, "top_left_y": 0.08515190415062045, "lower_right_x": 0.8711433756805808, "lower_right_y": 0.3076593923833975, "height": 0.22250748823277705, "width": 0.735632183908046}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-81-1", "text": "   We have noted below existing and potential competition for each of our products under development, as well\nas for our drug delivery technologies and our Contract Development Business. In addition to these competitors,\nour product candidates under development may also face competition from existing or new products we are\ncurrently unaware of.\n", "page_number": 81, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.32135216089002994, "lower_right_x": 0.8717483363581368, "lower_right_y": 0.376551133932392, "height": 0.05519897304236204, "width": 0.7513611615245009}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-81-2", "text": "Products\n", "page_number": 81, "bounding_box": {"top_left_x": 0.11736237144585603, "top_left_y": 0.3910997004706889, "lower_right_x": 0.1839080459770115, "lower_right_y": 0.40350877192982454, "height": 0.012409071459135612, "width": 0.06654567453115547}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-81-3", "text": "Locteron\n", "page_number": 81, "bounding_box": {"top_left_x": 0.13490623109497882, "top_left_y": 0.4201968335472828, "lower_right_x": 0.20024198427102238, "lower_right_y": 0.43046640992725715, "height": 0.010269576379974332, "width": 0.06533575317604357}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-81-4", "text": "  We believe that in the near to medium term interferon alfa will remain a principal element in the treatment of\nHCV.\n", "page_number": 81, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.44801026957637996, "lower_right_x": 0.8741681790683605, "lower_right_y": 0.472400513478819, "height": 0.024390243902439046, "width": 0.7537810042347247}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-81-5", "text": "   We anticipate that Locteron, if approved, would compete with two approved pegylated interferon alfa\nproducts for the treatment of chronic HCV infections. These two products are Pegasys (marketed by Roche) and\nPEG-Intron (marketed by Schering-Plough). In addition, Locteron would face competition from conventional,\nunmodified forms of interferon, including Roferon-A (marketed by Roche), Intron A (marketed by Schering-\nPlough), and Infergen (marketed by Valeant Pharmaceuticals International and Astellas Pharma Inc.). In\naddition, we are aware of other long-acting interferon alfa treatments currently in clinical development,\nincluding Albuferon (in development by Human Genome Sciences, Inc. in collaboration with Novartis AG) as\nwell as product candidates from Flamel Technologies SA, Intarcia Therapeutics, Inc., Maxygen Inc. (in\ncollaboration with Roche) and Nautilus Biotech S.A.\n", "page_number": 81, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.4890885750962773, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.6114676936243046, "height": 0.12237911852802735, "width": 0.7555958862673926}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-81-6", "text": "OP-145 CSOM\n", "page_number": 81, "bounding_box": {"top_left_x": 0.1397459165154265, "top_left_y": 0.6260162601626016, "lower_right_x": 0.24682395644283123, "lower_right_y": 0.6367137355584083, "height": 0.010697475395806677, "width": 0.10707803992740472}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-81-7", "text": "   We anticipate that OP-145 CSOM, if approved, would compete with other products that are currently\nmarketed for the treatment of chronic middle ear infection. The current standard of care for the treatment of\nchronic middle ear infection involves the use of antibiotics, which are delivered either systemically or as\neardrops to destroy bacteria and corticosteroids which reduce inflammation of the mucus of the middle ear. For\npatients who become refractory to this therapy, a surgical intervention may be necessary in order to remove\nresistant infectious material and inflamed mucus. Antibiotics prescribed for chronic middle ear infection include\nCipro HC Otic, a combination of ciprofloxacin hydrochloride and hydrocortisone otic suspension that is\nmarketed by Alcon, Inc., and Floxin Otic (ofloxacin otic), which is marketed by Daiichi Sankyo, Inc. We are\naware that Kyoto Pharmaceutical Industries is currently seeking Japanese registration of ceftizoxime alapivoxil,\na product that inhibits bacterial cell wall synthesis to treat bacterial infections including chronic middle ear\ninfection. In addition, we understand that Arriva Pharmaceuticals Inc. and ProMetic Life Sciences are jointly\ndeveloping a product for otitis media and other indications.\n", "page_number": 81, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.6534017971758665, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.8177150192554558, "height": 0.1643132220795892, "width": 0.7555958862673926}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-81-8", "text": "OP-286 CR\n", "page_number": 81, "bounding_box": {"top_left_x": 0.13793103448275862, "top_left_y": 0.8314077877620881, "lower_right_x": 0.2177858439201452, "lower_right_y": 0.842533162173727, "height": 0.011125374411638855, "width": 0.07985480943738657}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-81-9", "text": "   We anticipate that OP-286 CR, our GLP-1 analogue product candidate, if approved, would face competition\nfrom Byetta (exenatide), the GLP-1 analogue marketed by Amylin and Eli Lilly. In addition, we are aware of\nseveral other GLP-1 analogues currently in late stage clinical development, including Byetta LAR, a once-\nweekly formulation or exenatide being developed by Amylin and Eli Lilly with drug delivery technology from\n", "page_number": 81, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.858793324775353, "lower_right_x": 0.8663036902601331, "lower_right_y": 0.9139922978177151, "height": 0.0551989730423621, "width": 0.7459165154264973}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-81-10", "text": "79\n", "page_number": 81, "bounding_box": {"top_left_x": 0.8620689655172413, "top_left_y": 0.9477963200684638, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9572100984167736, "height": 0.00941377834830981, "width": 0.01875378100423475}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-82-0", "text": "Alkermes, and liraglutide, a once-daily formulation from Novo Nordisk. There are also other long-acting GLP-1\nanalogues in earlier stages of clinical development. In addition, we believe OP-286 CR could potentially face\ncompetition from oral DPP-4 inhibitors, including Merck & Co.\u2019s Januvia (sitagliptin) and Novartis\u2019s Galvus\n(vildagliptin).\n", "page_number": 82, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.08515190415062045, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.14035087719298245, "height": 0.055198973042362, "width": 0.7555958862673926}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-82-1", "text": "HBV-OctoVAX\n", "page_number": 82, "bounding_box": {"top_left_x": 0.13490623109497882, "top_left_y": 0.15361574668378264, "lower_right_x": 0.24682395644283123, "lower_right_y": 0.1643132220795892, "height": 0.010697475395806566, "width": 0.11191772534785241}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-82-2", "text": "   We anticipate that HBV-OctoVAX, if approved, would face competition from currently marketed hepatitis B\nvaccines, all of which require multiple injections in order to induce immunity. These vaccines include Engerix-\nB, marketed by GlaxoSmithKline plc, and Recombivax, marketed by Merck & Co, Inc. Twinrix, marketed by\nGlaxoSmithKline, is a combined hepatitis A and B vaccine specifically marketed to international travelers who\nmay be exposed in endemic areas. In addition to these marketed products, we are aware that Dynavax\nTechnologies Corporation has two vaccine candidates for hepatitis B in late stage clinical development.\n", "page_number": 82, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.1810012836970475, "lower_right_x": 0.8753781004234725, "lower_right_y": 0.2635857937526744, "height": 0.08258451005562689, "width": 0.7549909255898367}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-82-3", "text": "JEV-OctoVAX\n", "page_number": 82, "bounding_box": {"top_left_x": 0.13490623109497882, "top_left_y": 0.2768506632434745, "lower_right_x": 0.24198427102238354, "lower_right_y": 0.28968763371844247, "height": 0.012836970474967957, "width": 0.10707803992740472}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-82-4", "text": "   We anticipate that JEV-OctoVAX, if approved, would face competition from JE VAX, a three dose vaccine\nmarketed by sanofi-pasteur, the vaccines business of sanofi-aventis SA. We are also aware of two other\nJapanese encephalitis vaccines that are manufactured in China, primarily for domestic use. We are further aware\nof two JEV vaccines in Phase III clinical development by Intercell AG (in collaboration with Novartis) and\nAcambis plc.\n", "page_number": 82, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.3076593923833975, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.37526743688489517, "height": 0.06760804450149765, "width": 0.7555958862673926}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-82-5", "text": "Drug Delivery Technologies\n", "page_number": 82, "bounding_box": {"top_left_x": 0.1161524500907441, "top_left_y": 0.3898160034231921, "lower_right_x": 0.31820931639443434, "lower_right_y": 0.40350877192982454, "height": 0.013692768506632425, "width": 0.20205686630369024}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-82-6", "text": "  There are many other companies developing controlled release drug delivery systems, some of which may\ncompete with us in respect of our products in the future.\n", "page_number": 82, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.417201540436457, "lower_right_x": 0.8554143980641258, "lower_right_y": 0.44458707744972187, "height": 0.02738553701326485, "width": 0.73502722323049}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-82-7", "text": "Contract Development Business\n", "page_number": 82, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.4582798459563543, "lower_right_x": 0.3430127041742287, "lower_right_y": 0.472400513478819, "height": 0.014120667522464714, "width": 0.22262552934059288}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-82-8", "text": "   Our Contract Development Business faces competition from companies that are active in providing\nformulation and clinical trial manufacturing services. A number of large contract manufacturing organizations\noffer development services and manufacturing of clinical trial material as part of an extensive service package.\nIn addition, we face significant competition from smaller, more specialized firms such as Aptuit Ltd., Evotec\nAG, Formatech, Inc., MedPharm Ltd., MP5 s.a.r.l. and Patheon, Inc. These firms typically focus on a specific\npart of the formulation market, such as biopharmaceuticals, low soluble compounds, oral drug delivery or\npulmonary drug delivery. Such firms may offer formulation development services in combination with\nproprietary drug delivery technologies or bulk manufacturing capacity.\n", "page_number": 82, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.4856653829696192, "lower_right_x": 0.8663036902601331, "lower_right_y": 0.5956354300385109, "height": 0.10997004706889174, "width": 0.7459165154264973}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-82-9", "text": "Facilities\n", "page_number": 82, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.6089002995293111, "lower_right_x": 0.18874773139745918, "lower_right_y": 0.6230209670517758, "height": 0.014120667522464658, "width": 0.06836055656382337}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-82-10", "text": "   Our registered main place of business is located at Zernikedreef 12, 2333 CL Leiden, the Netherlands. These\n1,725 m2 facilities comprise laboratories, a small-scale cGMP manufacturing plant and offices. We entered into\na long-term lease for these premises with a remaining period of almost 17 years. In addition, we rent two other\ntemporary facilities in Leiden, consisting of a total of 1,106 m2 of laboratories and office space. We have also\nentered into an agreement to lease a purpose-built facility of 3,513 m2, which is being built adjacent to our\ncurrent main facilities. This new facility is expected to be ready in the first half of 2008. The duration of this\nlease agreement is 20 years. We will vacate the 1,106 m2 of temporary facilities upon occupation of the new\nfacility.\n", "page_number": 82, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.636285836542576, "lower_right_x": 0.8711433756805808, "lower_right_y": 0.7462558836114677, "height": 0.10997004706889169, "width": 0.7507562008469449}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-82-11", "text": "   In 2006, we opened a business development office in Cambridge, Massachusetts, United States, where we\nlease approximately 125 m2 of office space.\n", "page_number": 82, "bounding_box": {"top_left_x": 0.12220205686630368, "top_left_y": 0.762943945228926, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.7907573812580231, "height": 0.02781343602909714, "width": 0.7295825771324864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-82-12", "text": "Legal Proceedings\n", "page_number": 82, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.8040222507488233, "lower_right_x": 0.2516636418632789, "lower_right_y": 0.8177150192554558, "height": 0.01369276850663248, "width": 0.13127646702964307}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-82-13", "text": "  In 2004, we commenced opposition proceedings against a European patent application filed by Schering-\nPlough covering the administration of interferon alfa for the treatment of HCV within a specific dosing range.\nAlthough we believe Locteron will fall outside the claimed dosing range, we intend to continue our opposition\nproceedings in order to preserve flexibility in our further development activities. Schering-Plough currently\nholds a granted US patent comparable in its coverage to the European patent application we are opposing. If\nLocteron is formulated with a dose of interferon alfa that falls within the covered dosing range, we could be\n", "page_number": 82, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.8314077877620881, "lower_right_x": 0.8663036902601331, "lower_right_y": 0.9135643988018828, "height": 0.08215661103979466, "width": 0.7459165154264973}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-82-14", "text": "80\n", "page_number": 82, "bounding_box": {"top_left_x": 0.8614640048396854, "top_left_y": 0.9477963200684638, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9572100984167736, "height": 0.00941377834830981, "width": 0.019358741681790637}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-83-0", "text": "precluded from commercializing Locteron in the United States. In such event, we would consider commencing\nlegal proceedings to invalidate the US patent.\n", "page_number": 83, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.08515190415062045, "lower_right_x": 0.8663036902601331, "lower_right_y": 0.11296534017971759, "height": 0.02781343602909714, "width": 0.7459165154264973}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-83-1", "text": "Employees\n", "page_number": 83, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.12623020967051776, "lower_right_x": 0.1984271022383545, "lower_right_y": 0.14035087719298245, "height": 0.014120667522464686, "width": 0.07803992740471868}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-83-2", "text": "   We believe that our success will depend on our ability to attract, retain and motivate key employees. At the\nend of 2004, 2005 and 2006, we had 93, 110 and 139 employees, respectively. As of 31 August 2007, we had a\ntotal of 157 employees, of whom 155 were located in the Netherlands and two were located in the United States,\nrepresenting 144 full-time employees. Of these employees, 59 worked for the Contract Development Business\nand 53 worked for the Products and Drug Delivery Business. A further 45 employees were not specifically\nassigned to either business unit.\n", "page_number": 83, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.15361574668378264, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.2362002567394095, "height": 0.08258451005562686, "width": 0.7555958862673926}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-83-3", "text": "   We believe that relations with our employees are good. None of our employees is represented under a\ncollective bargaining agreement. As required by Dutch law, we have established a works council. We believe\nthat relations with our works council are good (see \u201cManagement and Employees \u2013 Works Council\u201d).\n", "page_number": 83, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.24946512623020967, "lower_right_x": 0.8566243194192378, "lower_right_y": 0.29097133076593923, "height": 0.04150620453572956, "width": 0.736237144585602}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-83-4", "text": "81\n", "page_number": 83, "bounding_box": {"top_left_x": 0.8614640048396854, "top_left_y": 0.9477963200684638, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9572100984167736, "height": 0.00941377834830981, "width": 0.019358741681790637}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-84-0", "text": "Management and Employees\n", "page_number": 84, "bounding_box": {"top_left_x": 0.352692075015124, "top_left_y": 0.10269576379974327, "lower_right_x": 0.6436781609195402, "lower_right_y": 0.11895592640136927, "height": 0.016260162601626008, "width": 0.2909860859044162}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-84-1", "text": "General\n", "page_number": 84, "bounding_box": {"top_left_x": 0.12159709618874773, "top_left_y": 0.13692768506632436, "lower_right_x": 0.17785843920145192, "lower_right_y": 0.14719726144629866, "height": 0.010269576379974305, "width": 0.05626134301270419}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-84-2", "text": "   Set out below is a summary of relevant information concerning our Executive Board, Supervisory Board,\nSenior Management, Scientific Advisory Board and other employees. In addition, we set out a brief summary of\ncertain significant provisions of Dutch corporate law and our Articles of Association in respect of our Executive\nBoard and Supervisory Board. See \u201cDescription of Share Capital and Corporate Governance\u201d.\n", "page_number": 84, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.16388532306375694, "lower_right_x": 0.8796128251663642, "lower_right_y": 0.21908429610611896, "height": 0.055198973042362015, "width": 0.7592256503327284}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-84-3", "text": "Management Structure\n", "page_number": 84, "bounding_box": {"top_left_x": 0.12099213551119177, "top_left_y": 0.23320496362858364, "lower_right_x": 0.29038112522686027, "lower_right_y": 0.24646983311938384, "height": 0.01326486949080019, "width": 0.16938898971566851}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-84-4", "text": "  We have a two-tier board structure, consisting of an Executive Board (Directie) and a Supervisory Board\n(Raad van Commissarissen).\n", "page_number": 84, "bounding_box": {"top_left_x": 0.12099213551119177, "top_left_y": 0.259734702610184, "lower_right_x": 0.8469449485783425, "lower_right_y": 0.28754813863928114, "height": 0.02781343602909714, "width": 0.7259528130671506}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-84-5", "text": "Executive Board\n", "page_number": 84, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.3042362002567394, "lower_right_x": 0.2413793103448276, "lower_right_y": 0.31450577663671375, "height": 0.010269576379974332, "width": 0.12099213551119178}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-84-6", "text": "Powers, Composition and Function\n", "page_number": 84, "bounding_box": {"top_left_x": 0.1191772534785239, "top_left_y": 0.33162173727000427, "lower_right_x": 0.367816091954023, "lower_right_y": 0.3453145057766367, "height": 0.013692768506632425, "width": 0.24863883847549909}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-84-7", "text": "   The Executive Board is responsible for the day-to-day management of our operations under the supervision\nof the Supervisory Board. The Executive Board is required to keep the Supervisory Board informed, consult\nwith the Supervisory Board on important matters and submit certain important decisions to the Supervisory\nBoard for its approval, as more fully described below.\n", "page_number": 84, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.3590072742832692, "lower_right_x": 0.8602540834845736, "lower_right_y": 0.41377834830979887, "height": 0.0547710740265297, "width": 0.7398669086509377}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-84-8", "text": "   The Executive Board may perform all acts necessary or useful for achieving our corporate purpose, save for\nthose acts that are prohibited by law or by our Articles of Association. The Executive Board as a whole is\nauthorized to represent us, as are any two members of the Executive Board acting jointly.\n", "page_number": 84, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.4274711168164313, "lower_right_x": 0.8656987295825771, "lower_right_y": 0.4689773213521609, "height": 0.04150620453572962, "width": 0.7453115547489413}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-84-9", "text": "   Our Articles of Association provide that the number of members of the Executive Board will be determined\nby the Supervisory Board, and that the Executive Board will consist of at least one member. In the event that the\nExecutive Board comprises two or more members, the Supervisory Board may attribute specific titles to\nindividual members of the Executive Board, such as \u201cChief Executive Officer\u201d, \u201cChief Financial Officer\u201d and\n\u201cChief Operating Officer\u201d.\n", "page_number": 84, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.48224219084296105, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.5511339323919555, "height": 0.06889174154899447, "width": 0.7555958862673926}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-84-10", "text": "   Members of the Executive Board are appointed by the General Meeting of Shareholders following a proposal\nby the Supervisory Board. The current members of the Executive Board have been appointed for an indefinite\nperiod of time. In view of the Dutch Corporate Governance Code, our Articles of Association provide (i) that\nnew members of the Executive Board are appointed for a maximum term of four years, unless provided\notherwise in the resolution to appoint such member and (ii) that a retiring member of the Executive Board can\nbe re-appointed immediately for a term of not more than four years at a time.\n", "page_number": 84, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.5643988018827557, "lower_right_x": 0.8747731397459165, "lower_right_y": 0.6469833119383825, "height": 0.08258451005562684, "width": 0.7543859649122807}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-84-11", "text": "  The General Meeting of Shareholders may suspend or dismiss Executive Board members at any time. The\nSupervisory Board may also suspend Executive Board members at any time.\n", "page_number": 84, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.6602481814291827, "lower_right_x": 0.8566243194192378, "lower_right_y": 0.6880616174582799, "height": 0.02781343602909714, "width": 0.736237144585602}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-84-12", "text": "  Under our Articles of Association, the following decisions of the Executive Board must be approved by the\nSupervisory Board:\n", "page_number": 84, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.7047496790757382, "lower_right_x": 0.8614640048396854, "lower_right_y": 0.7325631151048353, "height": 0.02781343602909714, "width": 0.7410768300060496}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-84-13", "text": "\u00b7   the acquiring, alienating, encumbering, leasing, letting and in any other way obtaining and giving the use\n    or benefit of registered property;\n\n\u00b7   entering into agreements, whereby bank credit is granted to us;\n\n\u00b7   lending and borrowing money, with the exception of acquiring money under a credit already granted to\n    us by a bank;\n\n\u00b7   entering into agreements by which we bind ourselves as guarantor or as severally liable co-debtor, or\n    otherwise bind ourselves as security for a debt of a third party;\n\n\u00b7   adoption of our annual budget;\n", "page_number": 84, "bounding_box": {"top_left_x": 0.1355111917725348, "top_left_y": 0.7458279845956355, "lower_right_x": 0.8790078644888082, "lower_right_y": 0.9105691056910569, "height": 0.16474112109542138, "width": 0.7434966727162734}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-84-14", "text": "82\n", "page_number": 84, "bounding_box": {"top_left_x": 0.8614640048396854, "top_left_y": 0.9477963200684638, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9572100984167736, "height": 0.00941377834830981, "width": 0.019358741681790637}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-85-0", "text": "\u00b7   our operational and financial objectives;\n\n\u00b7   our long-term strategic policy and business plans and the parameters to be applied in relation to our\n    strategy, for example in respect of our financial ratios;\n\n\u00b7   strategic issues and alliances;\n\n\u00b7   the sale or disposition of all, or an essential part of our assets;\n\n\u00b7   the issuance and acquisition of shares and debentures chargeable against us or chargeable against a\n    limited partnership, or a general partnership of which we are a fully liable partner;\n\n\u00b7   petition for quotation, or withdrawal of quotation from a price list of any stock exchange of any listed\n    securities;\n\n\u00b7   entering into or terminating long-term co-operation by us with another legal entity, company, or with a\n    limited partnership or general partnership of which we are the fully liable partner, if such co-operation or\n    termination of co-operation is of major significance to us;\n\n\u00b7   participating by us in the capital of another company;\n\n\u00b7   investments requiring an amount equal to at least one fourth of our issued capital plus reserves,\n    according to our balance sheet and explanatory notes;\n\n\u00b7   a proposal to dissolve us, a proposal for a legal merger or a legal split-up, within the meaning of Title 7,\n    Book 2 of the Dutch Civil Code, a proposal to decrease our issued capital, and a proposal to amend our\n    Articles of Association;\n\n\u00b7   filing a petition for bankruptcy or for suspension of payments;\n\n\u00b7   a significant change in the employment conditions of a substantial number of our employees and a\n    termination of the employment of a considerable number of our employees simultaneously or within a\n    short period of time;\n\n\u00b7   the entering into and changing of employment agreements, whereby a remuneration is granted which\n    exceeds the annual maximum amount determined by the Supervisory Board and notified to the\n    Executive Board in writing;\n\n\u00b7   the entering into and termination of employment agreements with (proposed) members of our\n    management;\n\n\u00b7   establishing pension plans and granting pension rights in excess of those arising from existing\n    arrangements;\n\n\u00b7   adoption of employee stock-option plans;\n\n\u00b7   appointing staff members as officer with the general or limited power to represent us and determining\n    their authority and title; and\n\n\u00b7   being a party to legal proceedings, including conducting arbitration proceedings, with the exception of\n    taking legal measures that cannot be delayed, and making settlements.\n", "page_number": 85, "bounding_box": {"top_left_x": 0.13490623109497882, "top_left_y": 0.08515190415062045, "lower_right_x": 0.8802177858439202, "lower_right_y": 0.7941805733846812, "height": 0.7090286692340607, "width": 0.7453115547489414}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-85-1", "text": "   The Supervisory Board may determine that a resolution as referred to above shall not require its approval if\nthe amount involved does not exceed a value fixed by the Supervisory Board and notified to the Executive\nBoard in writing. The Supervisory Board shall be entitled to require further resolutions of the Executive Board\nin addition to those listed above to be subject to their approval. Such further resolutions shall be clearly\nspecified and notified to the Executive Board in writing. The absence of approval of the Supervisory Board shall\nnot affect the authority of the Executive Board or its members to represent the Company.\n", "page_number": 85, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.8074454428754814, "lower_right_x": 0.8784029038112523, "lower_right_y": 0.8891741548994437, "height": 0.08172871202396237, "width": 0.7580157289776165}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-85-2", "text": "83\n", "page_number": 85, "bounding_box": {"top_left_x": 0.8614640048396854, "top_left_y": 0.9477963200684638, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9572100984167736, "height": 0.00941377834830981, "width": 0.019358741681790637}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-86-0", "text": "  Furthermore, the Executive Board shall at least once a year inform the Supervisory Board in writing of the\nkey elements of our strategic policy, our general and financial risks and our management and control system.\n", "page_number": 86, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.08515190415062045, "lower_right_x": 0.8566243194192378, "lower_right_y": 0.11296534017971759, "height": 0.02781343602909714, "width": 0.736237144585602}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-86-1", "text": "Members of the Executive Board\n", "page_number": 86, "bounding_box": {"top_left_x": 0.1161524500907441, "top_left_y": 0.12623020967051776, "lower_right_x": 0.3514821536600121, "lower_right_y": 0.14035087719298245, "height": 0.014120667522464686, "width": 0.23532970356926802}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-86-2", "text": "The Executive Board is currently composed of the following two members:\n", "page_number": 86, "bounding_box": {"top_left_x": 0.13490623109497882, "top_left_y": 0.15447154471544716, "lower_right_x": 0.6485178463399879, "lower_right_y": 0.16773641420624733, "height": 0.013264869490800163, "width": 0.5136116152450091}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-86-3", "text": "Name                          Age    Position                  Member Since       Term\nJoost Holthuis............... 53     Chief Executive Officer   20 July 19951      Indefinite\nHans Pauli .................... 47   Chief Financial Officer   22 December 2004   Indefinite\n", "page_number": 86, "bounding_box": {"top_left_x": 0.11857229280096794, "top_left_y": 0.19811724433033803, "lower_right_x": 0.8711433756805808, "lower_right_y": 0.23406076166024817, "height": 0.035943517329910135, "width": 0.7525710828796128}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-86-4", "text": "1   From 20 July 1995 until 1 June 2004, Mr. Holthuis served as our Managing Director through his personal holding company Sodoro\n    B.V., previously named Holthuis-Bernaerts Holding B.V.\n", "page_number": 86, "bounding_box": {"top_left_x": 0.13611615245009073, "top_left_y": 0.24946512623020967, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.2729995721009842, "height": 0.023534445870774523, "width": 0.7447065940713853}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-86-5", "text": "  The business address of both members of the Executive Board is Zernikedreef 12, 2333 CL Leiden, the\nNetherlands.\n", "page_number": 86, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.28712023962344885, "lower_right_x": 0.837265577737447, "lower_right_y": 0.3115104835258879, "height": 0.024390243902439046, "width": 0.7168784029038112}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-86-6", "text": "Joost Holthuis \u2013 Chief Executive Officer and Co-Founder\n", "page_number": 86, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.3281985451433462, "lower_right_x": 0.5130066545674531, "lower_right_y": 0.3423192126658109, "height": 0.014120667522464714, "width": 0.3926194797338173}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-86-7", "text": "   Mr. Holthuis graduated from the University of Leiden with a Master\u2019s Degree in Pharmacy in 1980. After\nobtaining his Ph.D. and working as an Assistant Professor at Utrecht University, in 1988 he became the Director\nof Analytical Laboratories and Product Development at the Dutch subsidiary of Chiron Corporation. He is also\nco-chairman of the board of the Netherlands Biotechnology Association (NIABA), chairman of the BioPartner\nCenter Foundation, member of the board of the foundation \u201cStichting Top Institute Pharma\u201d as well as a\nmember of the board of the \u201cAdviescommissie IS\u201d of the Dutch Ministry of Economic Affairs. Mr. Holthuis is\nalso a member of the Netherlands Academy of Technology and Innovation. During his academic career, Mr.\nHolthuis published more than 50 scientific publications.\n", "page_number": 86, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.355584082156611, "lower_right_x": 0.8802177858439202, "lower_right_y": 0.46555412922550277, "height": 0.10997004706889174, "width": 0.7598306110102844}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-86-8", "text": "Hans Pauli \u2013 Chief Financial Officer\n", "page_number": 86, "bounding_box": {"top_left_x": 0.11796733212341198, "top_left_y": 0.47881899871630296, "lower_right_x": 0.37265577737447064, "lower_right_y": 0.49293966623876767, "height": 0.014120667522464714, "width": 0.25468844525105866}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-86-9", "text": "   Mr. Pauli holds a Bachelor\u2019s Degree (Hons.) in Business Studies from Ealing College, London, where he\nreceived the Keith Wilshire Memorial Prize, and a Master\u2019s Degree in Fiscal Economics from the University of\nAmsterdam. He began his career at Staal Bankiers N.V. in 1985 and joined Rabobank Nederland in 1987, where\nhe served as manager of the New Issue and Syndication Department. He became Senior Manager, Investment\nBanking at Barclays de Zoete Wedd Nederland N.V. in 1988 and joined Nationale Investeringsbank N.V. as a\nSenior Manager, Investment Banking in 1992. From 1996 to 1999, Mr. Pauli served as Chief Financial Officer\nof Pharming Group N.V., during which period he was responsible for various financing activities, eventually\nleading to that company\u2019s initial public offering. Since 1999, Mr. Pauli has held positions as Chief Financial\nOfficer at various other companies, including RING!Rosa Products N.V., Secon Group B.V. and PamGene B.V.\nHe joined us in 2003. Mr. Pauli is member of the supervisory board of each of BAC B.V. and MedSciences II\nB.V. From 2003 to 30 September 2007, he served as chairman of the supervisory board of Henzo International\nGroup B.V.\n", "page_number": 86, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.5066324347454001, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.6709456568249893, "height": 0.1643132220795892, "width": 0.7555958862673926}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-86-10", "text": "Supervisory Board\n", "page_number": 86, "bounding_box": {"top_left_x": 0.12099213551119177, "top_left_y": 0.6876337184424476, "lower_right_x": 0.2571082879612825, "lower_right_y": 0.7004706889174155, "height": 0.012836970474967901, "width": 0.13611615245009073}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-86-11", "text": "Powers, Composition and Function\n", "page_number": 86, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.7150192554557124, "lower_right_x": 0.36721113127646704, "lower_right_y": 0.7282841249465126, "height": 0.01326486949080019, "width": 0.2516636418632789}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-86-12", "text": "   The Supervisory Board is responsible for supervising the conduct of and providing advice to the Executive\nBoard and supervising our business generally. In performing its duties, the Supervisory Board is required to act\nin the interests of our business as a whole. The members of the Supervisory Board are not, however, authorized\nto represent us in dealings with third parties.\n", "page_number": 86, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.7424047924689773, "lower_right_x": 0.8711433756805808, "lower_right_y": 0.7971758664955071, "height": 0.05477107402652981, "width": 0.7507562008469449}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-86-13", "text": "   Our Articles of Association provide that the number of Supervisory Board members will be determined by\nthe Supervisory Board.\n", "page_number": 86, "bounding_box": {"top_left_x": 0.12159709618874773, "top_left_y": 0.8108686350021395, "lower_right_x": 0.8566243194192378, "lower_right_y": 0.8386820710312366, "height": 0.02781343602909714, "width": 0.7350272232304901}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-86-14", "text": "  Our Articles of Association provide that the General Meeting of Shareholders appoints the members of the\nSupervisory Board following a proposal by the Supervisory Board. The current members of the Supervisory\nBoard have been appointed for the term set out in the table below. In view of the Dutch Corporate Governance\nCode, the Articles of Association will provide that any newly appointed member of our Supervisory Board will\n", "page_number": 86, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.8519469405220368, "lower_right_x": 0.8711433756805808, "lower_right_y": 0.9071459135643988, "height": 0.05519897304236199, "width": 0.7507562008469449}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-86-15", "text": "84\n", "page_number": 86, "bounding_box": {"top_left_x": 0.8614640048396854, "top_left_y": 0.9477963200684638, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9572100984167736, "height": 0.00941377834830981, "width": 0.019358741681790637}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-87-0", "text": "serve for a maximum of four years, unless provided otherwise in the resolution to appoint the Supervisory Board\nmember in question, and may only be reappointed twice. The General Meeting of Shareholders appoints a\nchairperson and the Supervisory Board appoints a deputy chairperson from amongst its members.\n", "page_number": 87, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.08515190415062045, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.12665810868635002, "height": 0.04150620453572958, "width": 0.7604355716878403}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-87-1", "text": "   Under our Articles of Association, the General Meeting of Shareholders may suspend or dismiss Supervisory\nBoard members at any time. The Articles of Association provide that the Supervisory Board members shall\nretire periodically in accordance with a rotation plan to be drawn up by the Supervisory Board.\n", "page_number": 87, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.1399229781771502, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.18142918271287975, "height": 0.04150620453572956, "width": 0.7555958862673926}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-87-2", "text": "   Under the Articles of Association, the Supervisory Board can only adopt resolutions by an absolute majority\nof the total number of votes to be cast in a meeting where the majority of the Supervisory Board members then\nin office are present or represented. Each member of the Supervisory Board shall be entitled to one vote.\n", "page_number": 87, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.19469405220367994, "lower_right_x": 0.8711433756805808, "lower_right_y": 0.2362002567394095, "height": 0.04150620453572956, "width": 0.7507562008469449}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-87-3", "text": "Members of the Supervisory Board\n", "page_number": 87, "bounding_box": {"top_left_x": 0.1161524500907441, "top_left_y": 0.25288831835686776, "lower_right_x": 0.3629764065335753, "lower_right_y": 0.2652973898160034, "height": 0.012409071459135668, "width": 0.24682395644283123}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-87-4", "text": "The Supervisory Board is composed of the following members:\n", "page_number": 87, "bounding_box": {"top_left_x": 0.13914095583787053, "top_left_y": 0.28027385537013266, "lower_right_x": 0.5662431941923775, "lower_right_y": 0.2935387248609328, "height": 0.013264869490800135, "width": 0.4271022383545069}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-87-5", "text": "Name                  Age   Position        Member Since      Term Expires\nHans Stellingsma      50    Chairperson     1 April 2001      2010\nPhilip Smith1         58    Member          19 January 2005   2009\nRen\u00e9 Kuijten2         43    Member          19 January 2005   2008\nPaul Toon3            39    Member          19 January 2005   2007\nFrans Eelkman Rooda   55    Future member   -                 2010\nSimon Sturge          48    Future member   -                 2008\nOlivier Jacquesson    58    Future member   -                 2011\n", "page_number": 87, "bounding_box": {"top_left_x": 0.1161524500907441, "top_left_y": 0.3076593923833975, "lower_right_x": 0.8608590441621294, "lower_right_y": 0.41420624732563116, "height": 0.10654685494223365, "width": 0.7447065940713853}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-87-6", "text": "1\n    Mr. Smith is General Partner of S.R. One, one of our Major Shareholders and therefore not\n    independent within the meaning of the Dutch Corporate Governance Code.\n2\n    Mr. Kuijten is General Partner of Life Sciences Partners, one of our Major Shareholders and therefore\n    not independent within the meaning of the Dutch Corporate Governance Code.\n3\n    Until June 2007, Mr. Toon has been Director of Innoven Partenaires, one of our Major Shareholders.\n    Until that date he was not independent within the meaning of the Dutch Corporate Governance Code.\n", "page_number": 87, "bounding_box": {"top_left_x": 0.13490623109497882, "top_left_y": 0.4274711168164313, "lower_right_x": 0.8656987295825771, "lower_right_y": 0.5408643560119811, "height": 0.11339323919554983, "width": 0.7307924984875983}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-87-7", "text": "  At our General Meeting of Shareholders, which is scheduled to take place on 18 December 2007, we will\npropose to appoint Messrs. Eelkman Rooda, Sturge and Jacquesson, and grant discharge to Messrs. Kuijten and\nToon who will resign on the same date.\n", "page_number": 87, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.5541292255027813, "lower_right_x": 0.8711433756805808, "lower_right_y": 0.5952075310226786, "height": 0.04107830551989733, "width": 0.7507562008469449}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-87-8", "text": "  The business address of all members of our Supervisory Board is Zernikedreef 12, 2333 CL Leiden, the\nNetherlands.\n", "page_number": 87, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.6089002995293111, "lower_right_x": 0.837265577737447, "lower_right_y": 0.6332905434317501, "height": 0.024390243902438935, "width": 0.7168784029038112}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-87-9", "text": "Hans Stellingsma \u2013 Chairperson\n", "page_number": 87, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.6504065040650406, "lower_right_x": 0.34361766485178463, "lower_right_y": 0.6640992725716731, "height": 0.01369276850663248, "width": 0.22323049001814882}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-87-10", "text": "   Mr. Stellingsma obtained a Master\u2019s Degree from Utrecht University and a postgraduate degree (M.Phil.)\nfrom Glasgow University. He attended the Advanced Management Program at Harvard Business School. He has\nheld numerous senior positions at a range of businesses in the Netherlands. In particular, he has served as a\nManaging Director at Microsoft\u2019s Dutch subsidiary and as Senior Vice President at KPN N.V. between 1993\nand 1996. From 1996 to 1998, he was a member of the managing board of Origin N.V. and then he became the\nChief Executive Officer of Content N.V. He was also the Managing Partner at Arthur D. Little in the\nNetherlands and a Senior Partner with Monitor, both global strategy consulting firms (1999 \u2013 2004). Currently,\nMr. Stellingsma is a Partner at Quintel, a strategy consultancy, and serves on the supervisory boards of Nova\nMedia Holding B.V., Vergouwen Overduin B.V., MTel B.V. and Fenestrae B.V.\n", "page_number": 87, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.6773641420624733, "lower_right_x": 0.8802177858439202, "lower_right_y": 0.8010269576379975, "height": 0.12366281557552417, "width": 0.7598306110102844}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-87-11", "text": "Philip Smith \u2013 Member\n", "page_number": 87, "bounding_box": {"top_left_x": 0.11857229280096794, "top_left_y": 0.8142918271287976, "lower_right_x": 0.2807017543859649, "lower_right_y": 0.8284124946512623, "height": 0.01412066752246477, "width": 0.16212946158499697}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-87-12", "text": "   Mr. Smith obtained a Bachelor\u2019s Degree in Chemistry from the University of Maine, and a Master\u2019s Degree\nand Ph.D. in Medicinal Chemistry/Pharmacology from Northeastern University. He was an Assistant Professor\nat the University of Kansas Medical Center from 1981 to 1985. From 1986 to 2002, Mr. Smith held positions of\nincreasing responsibility within the Pharmaceutical Development Group at SmithKline\nBeecham/GlaxoSmithKline, where he lead an international group responsible for the identification and\n", "page_number": 87, "bounding_box": {"top_left_x": 0.12099213551119177, "top_left_y": 0.8451005562687206, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.9127086007702182, "height": 0.0676080445014976, "width": 0.7549909255898366}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-87-13", "text": "85\n", "page_number": 87, "bounding_box": {"top_left_x": 0.8614640048396854, "top_left_y": 0.9477963200684638, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9572100984167736, "height": 0.00941377834830981, "width": 0.019358741681790637}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-88-0", "text": "recommendation of internal drug delivery technologies for product development. In June 2002, Mr. Smith\njoined S.R. One, Limited, where he has been a General Partner since January 2003. He is currently on the board\nof directors of Cydex Inc., Redpoint Bio Corp., Onyvax Ltd., Trinity Biosystems, Inc. and Avantium B.V., and\nis an observer on the board of directors of Scynexis, Inc.\n", "page_number": 88, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.08515190415062045, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.14035087719298245, "height": 0.055198973042362, "width": 0.7604355716878403}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-88-1", "text": "Ren\u00e9 Kuijten \u2013 Member\n", "page_number": 88, "bounding_box": {"top_left_x": 0.11857229280096794, "top_left_y": 0.15361574668378264, "lower_right_x": 0.2849364791288566, "lower_right_y": 0.16773641420624733, "height": 0.014120667522464686, "width": 0.16636418632788869}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-88-2", "text": "   Mr. Kuijten obtained his Medical Doctor Degree from Utrecht University, having obtained additional training\nat Harvard Medical School and the Mayo Clinics. He completed his Ph.D. at the University of Pennsylvania,\nwhere he published, among others, in the New England Journal of Medicine and Cancer Research. He received\nresearch awards from the World Health Organization and the International Union Against Cancer, and was\nhonored with the Talma Eijkman Prize and the U-Gene Research Award for his scientific endeavors. He\nreceived an MBA from INSEAD in Fontainebleau, France. From 1992 to 2000, Mr. Kuijten was a Senior\nConsultant at McKinsey & Company, where he was co-leader of the European Pharmaceuticals and Healthcare\nPractice. He joined Life Sciences Partners in 2001 as a General Partner. On behalf of Life Sciences Partners, he\nserves or has served on the supervisory boards or as a non-executive director of KuDOS Ltd., DNage B.V.,\nKreatech Holding B.V., Hybrigenics S.A., Trinity Biosystems, BMEYE, Nexstim, Ipsat and Syntaxin. Mr.\nKuijten is currently board member of the NVP (Nederlandse Vereniging van Participatiemaatschappijen), the\nMcKinsey Alumni Association, the Max Geldens Society, and the Stichting Steun Emma Kinderziekenhuis. He\nhas participated in a committee of the Royal Netherlands Academy of Sciences advising the Dutch government\non gene patenting.\n", "page_number": 88, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.1810012836970475, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.37312794180573383, "height": 0.19212665810868634, "width": 0.7555958862673926}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-88-3", "text": "Paul Toon \u2013 Member\n", "page_number": 88, "bounding_box": {"top_left_x": 0.11857229280096794, "top_left_y": 0.386392811296534, "lower_right_x": 0.2661826981246219, "lower_right_y": 0.3992297817715019, "height": 0.012836970474967901, "width": 0.147610405323654}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-88-4", "text": "   Mr. Toon holds a Bachelor\u2019s Degree (Hons.) from Oxford University and has 15 years experience in advising,\ninvesting in and managing life science and technology companies. He began his career at Merrill Lynch in the\nEuropean Mergers &Acquisitions Group, focusing primarily on healthcare. He subsequently joined a drug\ndevelopment consultancy, developing a healthcare M&A practice over the course of six years. Mr. Toon then\nco-founded, and was COO, of an information technology start up company, completing two fundraising rounds\nto create a proprietary software platform to manage R&D investment. Subsequently, he invested in, and became\nCOO and Commercial Director of, a neuroscience biotechnology company leading two private funding rounds.\nHe joined Innoven Partenaires in 2004, where he served as a Managing Partner until June 2007. He was also a\nboard member of 20/10 Perfect Vision Optische Geraete GmbH. Currently, Mr. Toon is a board member of\nAlba Cosmetics, Ltd and CMC Biopharmaceuticals A/S.\n", "page_number": 88, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.41377834830979887, "lower_right_x": 0.8802177858439202, "lower_right_y": 0.5511339323919555, "height": 0.13735558408215665, "width": 0.7598306110102844}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-88-5", "text": "Frans Eelkman Rooda \u2013 Future Member\n", "page_number": 88, "bounding_box": {"top_left_x": 0.11978221415607986, "top_left_y": 0.5678219940094138, "lower_right_x": 0.396854204476709, "lower_right_y": 0.5780915703893881, "height": 0.010269576379974277, "width": 0.2770719903206291}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-88-6", "text": "   Mr. Eelkman Rooda obtained a Master\u2019s Degree in Econometrics from Erasmus University Rotterdam and a\nMaster\u2019s Degree in Business Administration from Dartmouth College. In 1977, he started his career with Esso\nNederland B.V. and was subsequently employed by Esso Europe Inc. After that, he held positions of increasing\nresponsibility at McKinsey and Company from 1982 to 1987 and 1989 to 1997. From 1987 to 1989, he worked\nas Department Manager Securities and Syndicates for the Algemene Bank Nederland (ABN) N.V. Currently, Mr.\nEelkman Rooda is Chief Financial Officer of OPG Group N.V. He is also a member of the supervisory board of\nDe Lage Landen International B.V. and a member of the General Council of the Confederation of Netherlands\nIndustry and Employers (VNO-NCW).\n", "page_number": 88, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.5952075310226786, "lower_right_x": 0.8790078644888082, "lower_right_y": 0.7051775780915703, "height": 0.10997004706889169, "width": 0.76346037507562}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-88-7", "text": "Simon Sturge \u2013 Future Member\n", "page_number": 88, "bounding_box": {"top_left_x": 0.12099213551119177, "top_left_y": 0.7184424475823705, "lower_right_x": 0.3339382940108893, "lower_right_y": 0.7325631151048353, "height": 0.01412066752246477, "width": 0.21294615849969756}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-88-8", "text": "   Mr. Sturge obtained a Bachelor\u2019s Degree (Hons.) in Biology from Sussex University. He has over 20 years of\nexperience in the pharmaceutical industry. From 1980 to 1988, he worked as a Division Manager for NAPP\nLaboratories Ltd. After that, he joined the Celltech Group (now part of UCB), where he held several positions.\nIn 1997, he founded RiboTargets, when it was spun out from the Medical Research Council\u2019s Laboratory of\nMolecular Biology. He remained Chief Executive Officer of RiboTargets Holdings until 2003. He also held a\nnon-executive directorship with Metalogic Systems Ltd. until 2005. Since 2003, Mr. Sturge has been Chief\nExecutive Officer of Vernalis Group plc. He is also a non-executive director of the Bio Industry Association.\n", "page_number": 88, "bounding_box": {"top_left_x": 0.11675741076830005, "top_left_y": 0.7458279845956355, "lower_right_x": 0.8802177858439202, "lower_right_y": 0.8421052631578947, "height": 0.0962772785622592, "width": 0.7634603750756201}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-88-9", "text": "Olivier Jacquesson \u2013 Future Member\n", "page_number": 88, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.8553701326486949, "lower_right_x": 0.37447065940713853, "lower_right_y": 0.8694908001711597, "height": 0.01412066752246477, "width": 0.2540834845735027}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-88-10", "text": "  Mr. Jacquesson obtained a degree in Engineering from the Ecole Centrale in Lille, France. He obtained a\npost-graduate degree in Advanced Studies in Automation and in Business Management from the University of\n", "page_number": 88, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.8827556696619597, "lower_right_x": 0.8656987295825771, "lower_right_y": 0.9105691056910569, "height": 0.02781343602909714, "width": 0.7501512401693889}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-88-11", "text": "86\n", "page_number": 88, "bounding_box": {"top_left_x": 0.8614640048396854, "top_left_y": 0.9477963200684638, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9572100984167736, "height": 0.00941377834830981, "width": 0.019358741681790637}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-89-0", "text": "Lille. He started his career as a consultant for the Bossard Consulting Group. From 1976 to 2004, he held\npositions of increasing responsibility at Aventis, being the Vice President of Operations from 1999 to 2004.\nFrom 2004 to 2007, Mr. Jacquesson was Senior Vice President Corporate Business Development for Sanofi\nAventis SA. From 2004 to 2006, he was a partner at B.M.S., Procter & Gamble and Altana and a board member\nof Fujisawa and Daichi. Currently, Mr. Jacquesson serves as board member of MERIAL.\n", "page_number": 89, "bounding_box": {"top_left_x": 0.1161524500907441, "top_left_y": 0.08515190415062045, "lower_right_x": 0.8802177858439202, "lower_right_y": 0.1540436456996149, "height": 0.06889174154899445, "width": 0.7640653357531761}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-89-1", "text": "Senior Management\n", "page_number": 89, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.16730851519041506, "lower_right_x": 0.26799758015728975, "lower_right_y": 0.18142918271287975, "height": 0.014120667522464686, "width": 0.14761040532365394}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-89-2", "text": " Our Executive Board is supported by the following members of the management team (\u201cSenior\nManagement\u201d):\n", "page_number": 89, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.19469405220367994, "lower_right_x": 0.7840290381125227, "lower_right_y": 0.22250748823277705, "height": 0.02781343602909711, "width": 0.6636418632788869}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-89-3", "text": "Leo de Leede \u2013 Director, Pre-Clinical Development\n", "page_number": 89, "bounding_box": {"top_left_x": 0.11796733212341198, "top_left_y": 0.23577235772357724, "lower_right_x": 0.47428917120387176, "lower_right_y": 0.24989302524604193, "height": 0.014120667522464686, "width": 0.3563218390804598}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-89-4", "text": "   Mr. de Leede studied Pharmacy at the University of Leiden and became a registered pharmacist in 1979. He\nreceived his Ph.D. from the University of Leiden in 1983. Mr. de Leede began his career as a scientist and\nGroup Leader at the Department of Pharmaceutical R&D of N.V. Organon. In 1986, he became a Manager of\nthe central R&D facilities of Gist-brocades N.V., responsible for the biopharmaceutical and pharmacological\nresearch of the pharmaceutical division. In 1991, he joined Yamanouchi Europe B.V. where he served as Plant\nManager, Senior Project Leader, Senior Manager of the European pharmaceutical research and development\nfacilities, and Senior Director, Pre-Clinical Development Europe. Mr. de Leede joined us in 2001 and he\nbecame Director, Pre-Clinical Development in 2006. He is also a board member of FIGON (Netherlands\nFederation for Innovative Drug Research). Mr. de Leede is the author or co-author of over 40 scientific\npublications.\n", "page_number": 89, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.26658108686350024, "lower_right_x": 0.8663036902601331, "lower_right_y": 0.40094137783483097, "height": 0.13436029097133073, "width": 0.7459165154264973}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-89-5", "text": "Gerben Moolhuizen \u2013 Chief Business Officer\n", "page_number": 89, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.417201540436457, "lower_right_x": 0.42589231699939506, "lower_right_y": 0.4300385109114249, "height": 0.012836970474967901, "width": 0.30550514216575925}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-89-6", "text": "   Mr. Moolhuizen received a Master\u2019s Degree in Medical Biology from Utrecht University in 1991, studied at\nTohoku University, Sendai, Japan and received an MBA from the Erasmus University of Rotterdam School of\nManagement. He then joined Pharming Group N.V. where he held positions in Business Development,\neventually becoming Director, Business Development. In 1997, Mr. Moolhuizen joined ASD B.V. (currently\nPrimagen B.V.) where he became Vice-President, Business Development in 1999. He joined us in 2001, as\nSenior Manager, Business Development and Director, OctoPlus Products. He became Chief Business Officer in\nJanuary 2006.\n", "page_number": 89, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.44458707744972187, "lower_right_x": 0.8747731397459165, "lower_right_y": 0.540436456996149, "height": 0.09584937954642708, "width": 0.7543859649122807}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-89-7", "text": "Vivian Jack \u2013 Director, Quality Assurance\n", "page_number": 89, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.5541292255027813, "lower_right_x": 0.4107683000604961, "lower_right_y": 0.5682498930252461, "height": 0.01412066752246477, "width": 0.29038112522686027}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-89-8", "text": "  Ms. Jack obtained a Master\u2019s Degree in Pharmacy from the University of Groningen in 1999. Ms. Jack joined\nAlpharma B.V. in 2000, where she served as a MRP Registration Coordinator. In 2001, she joined Merck, Sharp\n& Dohme B.V. to serve as a Production Pharmacist. From 2004 to 2007, she served as Supervisor / Qualified\nPerson at Merck, Sharp & Dohme B.V. Ms. Jack joined us in May 2007 as Director, Quality Assurance.\n", "page_number": 89, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.5815147625160462, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.6367137355584083, "height": 0.0551989730423621, "width": 0.7604355716878403}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-89-9", "text": "Alexander Willemse \u2013 Director, Contract Development\n", "page_number": 89, "bounding_box": {"top_left_x": 0.11857229280096794, "top_left_y": 0.6499786050492083, "lower_right_x": 0.49304295220810646, "lower_right_y": 0.6640992725716731, "height": 0.01412066752246477, "width": 0.37447065940713853}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-89-10", "text": "   Mr. Willemse obtained a Master\u2019s Degree in Chemical Technology from the Delft University of Technology\nin 1994, where he also received a Ph.D. in Chemical Process Technology in 1998. Subsequently, he joined the\nProduct Development Department of N.V. Organon where he briefly served as a Process Technologist and\nbecame Group Leader, Solids in 1998 and Senior Group Leader, Solids in 2002. In 2002, Mr. Willemse was a\nmember of the Technical Committee of the 4th World Congress on Particle Technology in Sydney, Australia. He\njoined us in February 2003, and became Director, Contract Development in 2006. Mr. Willemse is the author or\nco-author of approximately 20 scientific publications.\n", "page_number": 89, "bounding_box": {"top_left_x": 0.11978221415607986, "top_left_y": 0.6782199400941378, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.7736414206247325, "height": 0.09542148053059474, "width": 0.7610405323653963}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-89-11", "text": "Ewoud-Jan van Hoogdalem \u2013 Chief Medical Officer\n", "page_number": 89, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.7903294822421908, "lower_right_x": 0.47428917120387176, "lower_right_y": 0.8040222507488233, "height": 0.01369276850663248, "width": 0.35390199637023595}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-89-12", "text": "   Mr. van Hoogdalem obtained a Master\u2019s Degree in Pharmacy from the University of Leiden in 1983. He\nreceived a Ph.D. in Pharmacology from the University of Leiden in 1989. Mr. van Hoogdalem joined Gist-\nbrocades N.V. in 1989, where he served as a Research Scientist and joined Brocades Pharma B.V. in 1991 also\nas a Research Scientist. In 1994, he joined Yamanouchi Europe B.V., where he served as Head of the\nBiopharmaceutical Department, Head of the Section, Bioanalysis & Drug Metabolism of the Clinical\nPharmacology Department and European Project Leader of the Project Management Department. In 2000, he\njoined pharmaceutical research operations of Johnson & Johnson, where he served as Associate Director,\n", "page_number": 89, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.8177150192554558, "lower_right_x": 0.8663036902601331, "lower_right_y": 0.9127086007702182, "height": 0.09499358151476245, "width": 0.7507562008469449}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-89-13", "text": "87\n", "page_number": 89, "bounding_box": {"top_left_x": 0.8614640048396854, "top_left_y": 0.9477963200684638, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9572100984167736, "height": 0.00941377834830981, "width": 0.019358741681790637}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-90-0", "text": "Clinical Drug Evaluation (Netherlands/United Kingdom), Director, Experimental Medicine and Lead Scientist,\nInternal Medicine (Belgium). Mr. van Hoogdalem joined us in January 2006 as Chief Medical Officer. He is\nalso a board member of the foundation \u201cOrganization Anselmus Colloquium\u201d and the foundation \u201cOrganization\nEACPT2007\u201d. Mr. van Hoogdalem is the author or co-author of approximately 30 scientific publications.\n", "page_number": 90, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.08515190415062045, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.14035087719298245, "height": 0.055198973042362, "width": 0.7555958862673926}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-90-1", "text": "Supervisory Board Committees\n", "page_number": 90, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.15361574668378264, "lower_right_x": 0.3484573502722323, "lower_right_y": 0.16773641420624733, "height": 0.014120667522464686, "width": 0.22807017543859648}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-90-2", "text": "  Our Supervisory Board has appointed from among its members an Audit Committee and a Remuneration and\nNominating Committee. These committees prepare the decision making of the Supervisory Board.\n", "page_number": 90, "bounding_box": {"top_left_x": 0.12099213551119177, "top_left_y": 0.1810012836970475, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.20881471972614463, "height": 0.02781343602909714, "width": 0.7549909255898366}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-90-3", "text": "Audit Committee\n", "page_number": 90, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.2255027813436029, "lower_right_x": 0.24077434966727163, "lower_right_y": 0.23534445870774498, "height": 0.00984167736414207, "width": 0.12522686025408347}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-90-4", "text": "   Our Audit Committee assists the Supervisory Board in monitoring our systems of internal controls, the\nintegrity of our financial reporting process and the contents of our financial statements and reports. The Audit\nCommittee also assists the Supervisory Board in assessing and mitigating our business and financial risks.\n", "page_number": 90, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.25288831835686776, "lower_right_x": 0.8614640048396854, "lower_right_y": 0.29311082584510056, "height": 0.040222507488232806, "width": 0.7410768300060496}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-90-5", "text": "   The Audit Committee shall meet at least twice a year and shall also meet each time we propose to issue a\npress release containing our financial figures.\n", "page_number": 90, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.3076593923833975, "lower_right_x": 0.8469449485783425, "lower_right_y": 0.3346170303808301, "height": 0.026957637997432615, "width": 0.7265577737447066}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-90-6", "text": "   The Audit Committee consists of Mr. Kuijten (chairperson) and Mr. Stellingsma. Upon the appointment of\nMr. Eelkman Rooda as member of our Supervisory Board, he will replace Mr. Kuijten as chairperson of the\nAudit Committee. Upon the appointment of Mr. Jacquesson as member of our Supervisory Board, he will join\nthe Audit Committee.\n", "page_number": 90, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.34873769790329484, "lower_right_x": 0.8608590441621294, "lower_right_y": 0.40051347881899874, "height": 0.051775780915703895, "width": 0.7404718693284936}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-90-7", "text": "Remuneration and Nominating Committee\n", "page_number": 90, "bounding_box": {"top_left_x": 0.11736237144585603, "top_left_y": 0.417201540436457, "lower_right_x": 0.4204476709013914, "lower_right_y": 0.4313222079589217, "height": 0.014120667522464658, "width": 0.30308529945553536}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-90-8", "text": "   Our Remuneration and Nominating Committee advises the Supervisory Board on the remuneration of the\nmembers of the Executive Board and monitors our remuneration policy, which covers bonus plans for our\nSenior Management and members of the Executive Board. The Remuneration and Nominating Committee\nfurther advises on the selection criteria and appointment procedures for members of the Executive Board and\nmembers of the Supervisory Board, the proposals for appointments and reappointments, and the policy of the\nExecutive Board on selection criteria and appointment procedures for our Senior Management. It also assesses\nthe functioning of individual members of the Supervisory Board and the Executive Board.\n", "page_number": 90, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.44458707744972187, "lower_right_x": 0.8644888082274652, "lower_right_y": 0.5408643560119811, "height": 0.09627727856225926, "width": 0.7441016333938294}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-90-9", "text": "  The Remuneration and Nominating Committee consists of Mr. Stellingsma (chairperson), Mr. Smith and Mr.\nKuijten. Upon the appointment Mr. Sturge as member of our Supervisory Board, he will replace Mr. Kuijten as\nmember of the Remuneration and Nominating Committee.\n", "page_number": 90, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.5541292255027813, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.5956354300385109, "height": 0.04150620453572962, "width": 0.7555958862673926}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-90-10", "text": "Remuneration Policy\n", "page_number": 90, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.6123234916559692, "lower_right_x": 0.2752571082879613, "lower_right_y": 0.6251604621309371, "height": 0.012836970474967901, "width": 0.15486993345432548}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-90-11", "text": "  According to our Articles of Association, the General Meeting of Shareholders adopts the remuneration\npolicy in respect of the remuneration of the Executive Board. The Supervisory Board establishes the\nremuneration of the individual members of the Executive Board, taking into account the policy adopted by the\nGeneral Meeting of Shareholders, provided that arrangements in the form of Shares or rights to subscribe for\nShares are subject to the approval of the General Meeting of Shareholders. Such a proposal must include the\nnumber of Shares or rights to subscribe for Shares that may be granted to the members of the Executive Board\nand which criteria apply to a grant or modification. The remuneration of the members of the Supervisory Board\nconsists of a fixed cash remuneration, which is determined by the General Meeting of Shareholders.\n", "page_number": 90, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.6397090286692341, "lower_right_x": 0.8711433756805808, "lower_right_y": 0.7496790757381258, "height": 0.10997004706889169, "width": 0.7507562008469449}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-90-12", "text": "  The objective of our remuneration policy is to ensure a high direct involvement and to encourage high\nperformance by our personnel (including members of the Executive Board and Senior Management). The\nremuneration system is based on achieving performance criteria that are determined on a yearly basis.\n", "page_number": 90, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.762943945228926, "lower_right_x": 0.8324258923169994, "lower_right_y": 0.8044501497646556, "height": 0.04150620453572962, "width": 0.7120387174833636}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-90-13", "text": "Executive Board and Senior Management\n", "page_number": 90, "bounding_box": {"top_left_x": 0.1161524500907441, "top_left_y": 0.8177150192554558, "lower_right_x": 0.4162129461584997, "lower_right_y": 0.8318356867779204, "height": 0.014120667522464658, "width": 0.3000604960677556}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-90-14", "text": "  The total remuneration we paid to or for the benefit of members of our Executive Board and our Senior\nManagement in 2006 amounted to approximately \u20ac501,000 and \u20ac600,000, respectively. The following table\ndenotes the breakdown in remuneration of members of the Executive Board and Senior Management in 2006.\n", "page_number": 90, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.8451005562687206, "lower_right_x": 0.8614640048396854, "lower_right_y": 0.8866067608044501, "height": 0.04150620453572951, "width": 0.7410768300060496}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-90-15", "text": "88\n", "page_number": 90, "bounding_box": {"top_left_x": 0.8614640048396854, "top_left_y": 0.9477963200684638, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9572100984167736, "height": 0.00941377834830981, "width": 0.019358741681790637}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-91-0", "text": "                                                             Medical and\n                                               Pension         other        Other        Total\nName                Base Salary   Bonus      Contributions    Benefits     Payments   Remuneration\nJoost Holthuis       \u20ac197,000      \u20ac53,000        \u20ac20,000        \u20ac2,000     \u20ac19,000      \u20ac291,000\nHans Pauli            169,000       29,000         10,000         2,000          -        210,000\nSenior Management     506,000       46,000         25,000         8,000      15,000       600,000\n\nTotal                \u20ac872,000     \u20ac128,000        \u20ac55,000      \u20ac12,000      \u20ac34,000    \u20ac1,101,000\n", "page_number": 91, "bounding_box": {"top_left_x": 0.11857229280096794, "top_left_y": 0.08515190415062045, "lower_right_x": 0.9140955837870538, "lower_right_y": 0.1904150620453573, "height": 0.10526315789473685, "width": 0.7955232909860859}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-91-1", "text": "  Remuneration totals for members of our Executive Board and Senior Management in 2006 do not include the\nvalue of share options.\n", "page_number": 91, "bounding_box": {"top_left_x": 0.12159709618874773, "top_left_y": 0.20838682071031236, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.23491655969191272, "height": 0.026529738981600354, "width": 0.7543859649122807}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-91-2", "text": "   The number of Shares currently owned by members of our Executive Board and Senior Management are as\nfollows:\n", "page_number": 91, "bounding_box": {"top_left_x": 0.12099213551119177, "top_left_y": 0.24946512623020967, "lower_right_x": 0.8614640048396854, "lower_right_y": 0.2738553701326487, "height": 0.024390243902439046, "width": 0.7404718693284936}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-91-3", "text": "                                                                                                                                    Number of Shares\n                                                                                                                                       Owned\nJoost Holthuis1 ...........................................................................................................                3,091,900\nHans Pauli ..................................................................................................................                 56,500\nLeo de Leede..............................................................................................................                    48,000\nGerben Moolhuizen ...................................................................................................                         22,500\nAlexander Willemse ..................................................................................................                         15,000\n\nTotal ...........................................................................................................................          3,233,900\n\n1.     Mr. Holthuis holds part of his Shares through his personal holding company, Sodoro B.V.\n", "page_number": 91, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.28027385537013266, "lower_right_x": 0.8082274652147611, "lower_right_y": 0.4278990158322636, "height": 0.14762516046213092, "width": 0.6878402903811253}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-91-4", "text": " The numbers of options and warrants currently owned by members of our Executive Board and Senior\nManagement are described below.\n", "page_number": 91, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.4411638853230638, "lower_right_x": 0.8318209316394435, "lower_right_y": 0.4689773213521609, "height": 0.02781343602909714, "width": 0.7114337568058077}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-91-5", "text": "Supervisory Board\n", "page_number": 91, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.4856653829696192, "lower_right_x": 0.25105868118572294, "lower_right_y": 0.4985023534445871, "height": 0.012836970474967901, "width": 0.13067150635208713}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-91-6", "text": "   The remuneration of the members of the Supervisory Board is determined by the General Meeting of\nShareholders. The chairperson of the Supervisory Board receives an annual remuneration of \u20ac31,250 and the\nother members of the Supervisory Board receive an annual remuneration of \u20ac25,000 each. In addition, each\nmember of the Supervisory Board who serves in one of its committees receives \u20ac5,000 per membership.\n", "page_number": 91, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.513050919982884, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.5673940949935815, "height": 0.05434317501069752, "width": 0.7313974591651543}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-91-7", "text": "None of the members of the Supervisory Board owns Shares or options to acquire Shares.\n", "page_number": 91, "bounding_box": {"top_left_x": 0.13490623109497882, "top_left_y": 0.5815147625160462, "lower_right_x": 0.7447065940713854, "lower_right_y": 0.5956354300385109, "height": 0.01412066752246477, "width": 0.6098003629764066}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-91-8", "text": "Other Information\n", "page_number": 91, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.6089002995293111, "lower_right_x": 0.25650332728372655, "lower_right_y": 0.6195977749251177, "height": 0.010697475395806566, "width": 0.13611615245009073}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-91-9", "text": "   Except as indicated below, none of the members of the Executive Board, Supervisory Board and Senior\nManagement is, or has been, subject to (i) any convictions in relation to fraudulent offences in the last five\nyears, (ii) any bankruptcies, receiverships or liquidations of any entities in which such members held any office,\ndirectorships or senior management positions in the last five years, or (iii) any official public incrimination\nand/or sanctions of such person by statutory or regulatory authorities (including designated professional bodies),\nor disqualification by a court from acting as a member of the administrative, management or supervisory bodies\nof an issuer or from acting in the management or conduct of the affairs of any issuer for at least the previous five\nyears.\n", "page_number": 91, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.636285836542576, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.7449721865639709, "height": 0.10868635002139493, "width": 0.7604355716878403}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-91-10", "text": "  Hans Pauli served as chairman of the Supervisory Board of Henzo International Holding B.V. One of the\nsubsidiaries of Henzo International Group B.V. filed for bankruptcy as part of a corporate restructuring in April\n2006.\n", "page_number": 91, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.7595207531022679, "lower_right_x": 0.8699334543254689, "lower_right_y": 0.8010269576379975, "height": 0.04150620453572962, "width": 0.7495462794918331}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-91-11", "text": "Administrative, Management and Supervisory Bodies Conflicts of Interest\n", "page_number": 91, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.8177150192554558, "lower_right_x": 0.6527525710828797, "lower_right_y": 0.8305519897304237, "height": 0.012836970474967901, "width": 0.5323653962492438}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-91-12", "text": "   Other than the fact that two of the members of our Supervisory Board may not be independent for the\npurposes of the Dutch Corporate Governance Code as described in \u201cDescription of Share Capital and Corporate\nGovernance \u2013 Dutch Corporate Governance Code\u201d and except as disclosed in \u201cRelated Party Transactions\u201d, we\nare not aware of any potential conflict of interest between the private interests or other duties of the members of\nour Executive Board, Supervisory Board or Senior Management and their duties and responsibilities to us.\n", "page_number": 91, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.8451005562687206, "lower_right_x": 0.8753781004234725, "lower_right_y": 0.9127086007702182, "height": 0.0676080445014976, "width": 0.7549909255898367}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-91-13", "text": "89\n", "page_number": 91, "bounding_box": {"top_left_x": 0.8614640048396854, "top_left_y": 0.9477963200684638, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9572100984167736, "height": 0.00941377834830981, "width": 0.019358741681790637}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-92-0", "text": " No family ties exist among the members of our Executive Board, Supervisory Board and Senior\nManagement.\n\nOption Plans\n\n2003 Option Plan\n", "page_number": 92, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.08515190415062045, "lower_right_x": 0.7888687235329703, "lower_right_y": 0.16773641420624733, "height": 0.08258451005562688, "width": 0.6684815486993345}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-92-1", "text": "   In 2003, we adopted our share option plan as one of the elements of our remuneration policy for senior\npersonnel (see \u201cManagement and Employees \u2013 Remuneration Policy\u201d). In 2003, 2004 and 2006, we granted\noptions pursuant to a standard share option agreement. The terms and conditions of these options are similar,\nexcept for the exercise period and exercise price of the options granted. The exercise period of the options\ngranted prior to August 2004 was 37 months. These options have been exercised or lapsed. The exercise period\nof the options granted thereafter is 60 months. The exercise prices of the options granted by us in the respective\nyears are: \u20ac3.58 (2003), between \u20ac3.43 and \u20ac4.34 (2004) and between \u20ac2.70 and \u20ac4.55 (2006), subject to\ncustomary adjustment provisions. In addition, the exercise prices of the options will be adjusted if we issue\nshares below the applicable exercise price of the options, subject to certain conditions.\n", "page_number": 92, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.1810012836970475, "lower_right_x": 0.8711433756805808, "lower_right_y": 0.30466409927257165, "height": 0.12366281557552417, "width": 0.7507562008469449}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-92-2", "text": "2006 Option Plan\n", "page_number": 92, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.32135216089002994, "lower_right_x": 0.24621899576527526, "lower_right_y": 0.33418913136499784, "height": 0.012836970474967901, "width": 0.12583182093163944}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-92-3", "text": "   With a view to the listing of our Shares in October 2006, we adopted a new share option plan which entered\ninto force following our listing. The share option agreements entered into prior to that date remain in place.\n", "page_number": 92, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.34873769790329484, "lower_right_x": 0.8663036902601331, "lower_right_y": 0.3756953359007274, "height": 0.02695763799743256, "width": 0.7459165154264973}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-92-4", "text": "   Under the 2006 Option Plan, the Supervisory Board has a discretionary power to grant options to our\nemployees. The criteria for the granting of options, as well as the exercise price, will be determined by the\nSupervisory Board. The exercise period of the options shall be 60 months following the date of grant. Options\ncan only be granted to members of the Executive Board following approval from the General Meeting of\nShareholders. Options granted to members of the Executive Board or Senior Management can be exercised after\nsatisfaction of conditions precedent set out in the grant letter pertaining to those options and in any event, at\nleast five years after their grant. We will not issue options which, if exercised, would represent more than 7.5%\nof our issued share capital, unless the General Meeting of Shareholders approves otherwise.\n", "page_number": 92, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.3898160034231921, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.4993581514762516, "height": 0.10954214805305951, "width": 0.7555958862673926}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-92-5", "text": "  All unexercised options held by an employee will lapse if we terminate that person\u2019s employment or that\nperson resigns, except in cases of death, permanent disability or retirement. In the event that the option holder\nceases to be an employee for any reason other than death, permanent disability or retirement, we may force that\nemployee to disgorge a specified portion of any profits realized from the exercise of those options.\n", "page_number": 92, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.513050919982884, "lower_right_x": 0.8705384150030248, "lower_right_y": 0.5682498930252461, "height": 0.0551989730423621, "width": 0.7501512401693889}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-92-6", "text": "Options Granted to the Executive Board, Senior Management and Other Parties\n", "page_number": 92, "bounding_box": {"top_left_x": 0.12099213551119177, "top_left_y": 0.5815147625160462, "lower_right_x": 0.677555958862674, "lower_right_y": 0.5956354300385109, "height": 0.01412066752246477, "width": 0.5565638233514821}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-92-7", "text": " The options indicated in the table below were granted to members of the Executive Board, Senior\nManagement and other employees and consultants for the periods indicated.\n", "page_number": 92, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.6089002995293111, "lower_right_x": 0.7985480943738656, "lower_right_y": 0.636285836542576, "height": 0.02738553701326485, "width": 0.6781609195402298}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-92-8", "text": "Management and other employees and consultants for the periods indicated.\n                                                                                                                 Average\n                                        Currently    Options   Options   End of Exercise   End of Exercise   Exercise Price of\n                                       Outstanding   Granted   Granted   Period of 2004    Period of 2006    All Outstanding\n                      Name               Options     in 2004   in 2006      Options           Options            Options\nJoost Holthuis................           150,370      73,500   76,870        2009             2011                \u20ac3.05\nHans Pauli .....................          92,514      37,100   55,414        2009             2011                 2.99\nLeo de Leede.................             89,558      63,100   26,458        2009             2011                 3.21\nGerben Moolhuizen ......                  61,411      10,000   51,411        2009             2011                 2.82\nAlexander Willemse .....                  41,268      14,000   27,268        2009             2011                 2.95\nEwoud van Hoogdalem                       46,994           0   46,994         n.a.          2010/2011              2.70\nOther employees ...........               72,500           0   72,500         n.a.            2011                 4.00\nConsultants....................           40,200      24,500   15,700        2009             2011                 3.14\n\nTotal ..............................     594,815     222,200   372,615                                            \u20ac3.13\n", "page_number": 92, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.6367137355584083, "lower_right_x": 0.8898971566848155, "lower_right_y": 0.8232777064612752, "height": 0.18656397090286692, "width": 0.7695099818511797}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-92-9", "text": "    The members of our Executive Board and our Senior Management are entitled to receive options by the end\nof 2007 at an exercise price of \u20ac4.55, which is identical to the closing price of our Shares on 31 December 2006,\nif they meet their pre-determined performance criteria. The maximum number of options to be granted is 40,855\nfor Joost Holthuis, 26,820 for Hans Pauli and in total 68,096 for our Senior Management.\n", "page_number": 92, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.8382541720154044, "lower_right_x": 0.8777979431336963, "lower_right_y": 0.8934531450577664, "height": 0.05519897304236199, "width": 0.7574107683000605}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-92-10", "text": "90\n", "page_number": 92, "bounding_box": {"top_left_x": 0.8608590441621294, "top_left_y": 0.9477963200684638, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9572100984167736, "height": 0.00941377834830981, "width": 0.019963702359346636}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-93-0", "text": "   Immediately prior to the Offer, our Executive Board, Senior Management and other employees and\nconsultants held options to acquire a total of 594,815 Shares, which would, if exercised, represent approximately\n2.6% of our total issued share capital immediately after the Offer, assuming we raise \u20ac25 million in the Offer, an\nOffer Price of \u20ac3.95, and no exercise of the Overallotment Option.\n", "page_number": 93, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.08515190415062045, "lower_right_x": 0.8796128251663642, "lower_right_y": 0.14035087719298245, "height": 0.055198973042362, "width": 0.7592256503327284}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-93-1", "text": "Warrants\n", "page_number": 93, "bounding_box": {"top_left_x": 0.12159709618874773, "top_left_y": 0.1540436456996149, "lower_right_x": 0.19358741681790684, "lower_right_y": 0.16773641420624733, "height": 0.013692768506632425, "width": 0.07199032062915911}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-93-2", "text": "   In 2003 and 2004, we granted warrants to Hans Pauli (1,260 warrants), Ton Holthuis (840 warrants), Henrik\nLuessen (560 warrants) and 7X Life Sciences B.V. (1,260 warrants) in connection with loans provided by them\nto us in 2003 and 2004 (see \u201cRelated Party Transactions\u201d). These warrants entitle the holders thereof to acquire\n100 Shares for each warrant during the period from 1 June 2004 to 30 November 2008 at an exercise price of\n\u20ac5.50 per Share, subject to customary adjustment provisions. To date, no warrants to purchase our Shares have\nbeen exercised.\n", "page_number": 93, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.18314077877620882, "lower_right_x": 0.8711433756805808, "lower_right_y": 0.2635857937526744, "height": 0.08044501497646556, "width": 0.7507562008469449}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-93-3", "text": "Employment Agreements\n", "page_number": 93, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.28027385537013266, "lower_right_x": 0.30490018148820325, "lower_right_y": 0.2935387248609328, "height": 0.013264869490800135, "width": 0.18451300665456744}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-93-4", "text": "   We have employment agreements with each of the members of the Executive Board and Senior Management.\nThese employment agreements have an indefinite term and can be terminated, subject to the statutory notice\nperiod, which is one month for the employee and one to four months for us, dependent on the number of years\nof service. In the employment agreement with Mr. Willemse, the notice period is two months for both parties.\n", "page_number": 93, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.3076593923833975, "lower_right_x": 0.8753781004234725, "lower_right_y": 0.362002567394095, "height": 0.054343175010697464, "width": 0.7549909255898367}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-93-5", "text": "Our employment agreements do not provide for severance payments in the event of termination.\n", "page_number": 93, "bounding_box": {"top_left_x": 0.13793103448275862, "top_left_y": 0.3761232349165597, "lower_right_x": 0.7876588021778584, "lower_right_y": 0.3898160034231921, "height": 0.013692768506632425, "width": 0.6497277676950999}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-93-6", "text": "Directors Indemnification and Insurance\n", "page_number": 93, "bounding_box": {"top_left_x": 0.12099213551119177, "top_left_y": 0.40350877192982454, "lower_right_x": 0.41560798548094374, "lower_right_y": 0.4154899443731279, "height": 0.011981172443303378, "width": 0.294615849969752}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-93-7", "text": "  In order to attract and retain qualified and talented persons to serve as members of the Executive Board or the\nSupervisory Board, in respect of a sector, region, product group or other internal company structure or segment,\nwe provide such persons with protection through a directors\u2019 and officers\u2019 insurance policy.\n", "page_number": 93, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.43089430894308944, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.472400513478819, "height": 0.04150620453572956, "width": 0.7555958862673926}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-93-8", "text": "    Furthermore, we provide indemnification for members of our Executive Board and Supervisory Board against\n(i) substantiated costs made within the bounds of reasonableness with respect to conducting a defense (including\nlawyers fees), at law and otherwise, against third party claims for reimbursement of damages, or payment of\nfines, (judicially imposed) penalty payments and the like; and (ii) financial consequences of court rulings and\nresolutions of governmental authorities and amounts due relating to settlements that actually and in\nreasonableness have been paid by such member to third parties, due to an act or failing to act in the performance\nof his duties as member of the Executive Board or Supervisory Board or any other function he performs at our\nrequest, save where such act or the failing to act could be characterized as seriously culpable, or to the extent the\nloss of capital is covered by an insurance.\n", "page_number": 93, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.4856653829696192, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.6093281985451433, "height": 0.12366281557552411, "width": 0.7604355716878403}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-93-9", "text": "Pension Plan and Other Benefits\n", "page_number": 93, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.6260162601626016, "lower_right_x": 0.35329703569267995, "lower_right_y": 0.6367137355584083, "height": 0.010697475395806677, "width": 0.23290986085904414}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-93-10", "text": "   We provide our employees with a collective pension plan. In the past, we have operated a defined benefit\nplan pursuant to which we made specified contributions to a large pension insurance company in the\nNetherlands in return for such company assuming the responsibility to make payments under the plan. This plan\nwas closed on 31 January 2005. From 1 February 2006, we have had a defined contribution plan, which replaced\nour defined benefit plan.\n", "page_number": 93, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.6534017971758665, "lower_right_x": 0.8802177858439202, "lower_right_y": 0.7210098416773641, "height": 0.0676080445014976, "width": 0.7598306110102844}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-93-11", "text": "  For some of our employees, including the members of the Executive Board, individual defined contribution\npension plans apply.\n", "page_number": 93, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.7355584082156611, "lower_right_x": 0.8656987295825771, "lower_right_y": 0.7633718442447582, "height": 0.02781343602909714, "width": 0.7453115547489413}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-93-12", "text": "   We provide our employees with collectively negotiated health and retirement benefits in line with market\npractices in the Netherlands.\n", "page_number": 93, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.7766367137355584, "lower_right_x": 0.8511796733212341, "lower_right_y": 0.8040222507488233, "height": 0.02738553701326485, "width": 0.7307924984875983}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-93-13", "text": "Works Council\n", "page_number": 93, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.8177150192554558, "lower_right_x": 0.2323049001814882, "lower_right_y": 0.8296961916987591, "height": 0.011981172443303323, "width": 0.11191772534785238}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-93-14", "text": "   As required by Dutch law, we have established a works council. Works councils in the Netherlands have the\nauthority to advise on certain company decisions proposed by the General Meeting of Shareholders or the\nExecutive Board, including but not limited to a change of control. Employers are also required to submit certain\nstatutory defined matters that are viewed as \u2018social policy\u2019 (affecting employment terms and conditions) to the\nworks council for prior approval. Our works council has given positive advice with respect to the Offer.\n", "page_number": 93, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.8451005562687206, "lower_right_x": 0.8753781004234725, "lower_right_y": 0.9139922978177151, "height": 0.06889174154899447, "width": 0.7549909255898367}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-93-15", "text": "91\n", "page_number": 93, "bounding_box": {"top_left_x": 0.8608590441621294, "top_left_y": 0.9477963200684638, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9572100984167736, "height": 0.00941377834830981, "width": 0.019963702359346636}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-94-0", "text": "Major Shareholders\n", "page_number": 94, "bounding_box": {"top_left_x": 0.39624924379915305, "top_left_y": 0.10269576379974327, "lower_right_x": 0.6001209921355112, "lower_right_y": 0.11895592640136927, "height": 0.016260162601626008, "width": 0.20387174833635813}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-94-1", "text": "Holdings Prior to and After the Offer\n", "page_number": 94, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.1364997860504921, "lower_right_x": 0.38898971566848156, "lower_right_y": 0.15019255455712452, "height": 0.013692768506632425, "width": 0.26860254083484575}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-94-2", "text": "   The following table presents information about the ownership of our Shares as of the date of this Prospectus\nfor each existing shareholder we know to beneficially own 5% or more of our Shares, our management and\nemployees as a group, and the aggregate number and percentage of Shares owned by others.\n", "page_number": 94, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.16388532306375694, "lower_right_x": 0.8663036902601331, "lower_right_y": 0.20539152759948653, "height": 0.04150620453572959, "width": 0.7459165154264973}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-94-3", "text": "                      Shares owned prior to                  Shares owned immediately after\n                                                                                         1\n                      the closing of the Offer                  the closing of the Offer\n    Shareholder                                   Without exercise of the      With full exercise of the\n                                                  Overallotment Option         Overallotment Option\n                         Total           %         Total            %            Total            %\nJoost Holthuis /       3,091,900          19.1   3,091,900         13.7        3,091,900         13.2\nSodoro B.V.2\nInnoven Partenaires    1,996,394          12.3   1,996,394          8.9        1,996,394          8.5\nS.A.\nS.R. One, Limited      1,981,834          12.2   1,981,834          8.8        1,981,834          8.4\nLife Sciences          2,080,207          12.8   2,080,207          9.2        2,080,207          8.9\nPartners III B.V. /\nC.V. 3\nSurModics, Inc.        1,482,981           9.2   1,482,981          6.6        1,482,981          6.3\nFagus N.V.             1,160,400           7.2   1,160,400          5.1        1,160,400          4.9\nOthers4                4,413,360          27.2   4,413,360         19.6        4,413,360         18.8\n\n\n\nTotals                16,207,076        100.0    16,207,076        71.9       16,207,076         69.0\n", "page_number": 94, "bounding_box": {"top_left_x": 0.15970961887477314, "top_left_y": 0.23234916559691912, "lower_right_x": 0.809437386569873, "lower_right_y": 0.5036371416345743, "height": 0.2712879760376552, "width": 0.6497277676950999}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-94-4", "text": "1.   Based on an offer of 6,329,114 Offer Shares, assuming we raise \u20ac25 million in the Offer and an Offer Price of \u20ac3.95, and excluding\n     any Offer Shares acquired by any of the existing shareholders pursuant to the Offer.\n\n2.   All shares in Sodoro B.V. are held by Joost Holthuis, our Chief Executive Officer.\n\n3.   Life Sciences Partners III B.V. and Life Science Partners III C.V. operate as one joint investment fund.\n\n4.   Others include, inter alia, FormFarm Holding B.V. (the investment company of our co-founder, Daan Crommelin), NPM Capital B.V.,\n     7X Life Sciences B.V. and Hans Pauli, our Chief Financial Officer.\n", "page_number": 94, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.5233204963628584, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.6332905434317501, "height": 0.10997004706889169, "width": 0.7604355716878403}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-94-5", "text": "  Certain members of our Executive Board and Senior Management hold warrants and options to purchase\nShares. We describe these options and warrants in more detail in \u201cManagement and Employees \u2013 Option Plans\u201d\nand \u201cManagement and Employees \u2013 Warrants\u201d.\n", "page_number": 94, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.6465554129225503, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.6880616174582799, "height": 0.04150620453572962, "width": 0.7555958862673926}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-94-6", "text": "   Except as disclosed above, we are not aware of any person who, as of the date of this Prospectus, directly or\nindirectly, has a beneficial interest in 5% or more of our Shares. Our Major Shareholders have the same voting\nrights as other holders of the Shares.\n", "page_number": 94, "bounding_box": {"top_left_x": 0.12099213551119177, "top_left_y": 0.7013264869490801, "lower_right_x": 0.8663036902601331, "lower_right_y": 0.7428326914848096, "height": 0.04150620453572951, "width": 0.7453115547489413}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-94-7", "text": "Restricted Sales Agreement\n", "page_number": 94, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.7560975609756098, "lower_right_x": 0.3194192377495463, "lower_right_y": 0.7702182284980744, "height": 0.014120667522464658, "width": 0.19903206291591047}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-94-8", "text": "   Our Major Shareholders (excluding Joost Holthuis/Sodoro B.V.) as well as FormFarm Holding B.V., NPM\nCapital B.V. and 7X Life Sciences B.V. (the \u201cShareholders\u201d) and us have entered into a \u201crestricted sales\u201d\nagreement, pursuant to which the Shareholders have agreed, subject to limited exceptions described below, (i)\nfor a period of 60 days following the Listing Date (\u201clock-up period\u201d), without the prior written consent of\nCowen, not to offer, sell, assign, pledge, or grant any options, convertible securities or other rights to subscribe\nfor, any of the Shares they currently hold in us, or otherwise transfer or dispose of, or enter into any swap or any\nother agreement that transfers, in whole or in part, the economic consequence of ownership of any of their\nShares nor to announce any of these, and (ii) for a period of 120 days following the lock-up period, not to effect\n", "page_number": 94, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.7834830979888746, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.8934531450577664, "height": 0.1099700470688918, "width": 0.7604355716878403}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-94-9", "text": "92\n", "page_number": 94, "bounding_box": {"top_left_x": 0.8608590441621294, "top_left_y": 0.9477963200684638, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9572100984167736, "height": 0.00941377834830981, "width": 0.019963702359346636}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-95-0", "text": "any of these transactions without the prior approval of us and Shareholders holding at least 50% plus one of the\naggregate number of Shares held by such Shareholders at the date hereof.\n", "page_number": 95, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.08515190415062045, "lower_right_x": 0.8711433756805808, "lower_right_y": 0.11296534017971759, "height": 0.02781343602909714, "width": 0.7507562008469449}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-95-1", "text": "   This restriction shall not apply to the transfer of Shares to the legal successor of a Shareholder as a result of\nthe death of such holder or a merger, liquidation or de-merger of such Shareholder, provided that the legal\nsuccessor adheres to the restricted sales agreement and assumes all rights and obligations thereunder. This\nrestriction also shall not apply to a sale or other transfer to a related party (i.e. a family member of, or a fund\nmanaged by managers of, a Shareholder), provided that the purchaser or transferee adheres to the restricted sales\nagreement and assumes all rights and obligations thereunder.\n", "page_number": 95, "bounding_box": {"top_left_x": 0.12099213551119177, "top_left_y": 0.12623020967051776, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.20881471972614463, "height": 0.08258451005562686, "width": 0.7598306110102843}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-95-2", "text": "   The restricted sales agreement may be terminated with the agreement of us and the holders of at least 75% of\nthe aggregate number of Shares held by such Shareholders at the date hereof.\n", "page_number": 95, "bounding_box": {"top_left_x": 0.12099213551119177, "top_left_y": 0.2220795892169448, "lower_right_x": 0.8741681790683605, "lower_right_y": 0.24989302524604193, "height": 0.02781343602909714, "width": 0.7531760435571687}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-95-3", "text": "93\n", "page_number": 95, "bounding_box": {"top_left_x": 0.8608590441621294, "top_left_y": 0.9477963200684638, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9572100984167736, "height": 0.00941377834830981, "width": 0.019963702359346636}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-96-0", "text": "Related Party Transactions\n", "page_number": 96, "bounding_box": {"top_left_x": 0.3623714458560194, "top_left_y": 0.10226786478391099, "lower_right_x": 0.6388384754990926, "lower_right_y": 0.11895592640136927, "height": 0.016688061617458283, "width": 0.2764670296430732}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-96-1", "text": "   Except as disclosed below, the members of the Executive Board and the Supervisory Board, Senior\nManagement and the Major Shareholders have had no interest in any transactions to which we were a party\nsince 1 January 2004 or which were entered into by us prior thereto and under which we or the other parties still\nhave ongoing obligations.\n", "page_number": 96, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.1364997860504921, "lower_right_x": 0.8753781004234725, "lower_right_y": 0.19127086007702182, "height": 0.054771074026529726, "width": 0.7549909255898367}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-96-2", "text": "   We entered into a shareholders agreement with all our shareholders in January 2005 in connection with our\nsecond private equity round (see \u201cOperating and Financial Review \u2013 Material Factors Affecting our Results of\nOperations and Financial Condition \u2013 Liquidity and Capital Resources\u201d). This agreement has been terminated\nupon completion of our IPO in October 2006.\n", "page_number": 96, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.20496362858365424, "lower_right_x": 0.8663036902601331, "lower_right_y": 0.2601626016260163, "height": 0.05519897304236204, "width": 0.7459165154264973}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-96-3", "text": "   Fagus N.V., a joint venture between the European Investment Fund and Fortis Private Equity Belgium NV,\npurchased Shares in January 2005 as part of this private placement. Fortis, an affiliate of Fortis Private Equity\nBelgium NV, acted as placement agent in connection with this private placement. As part of its compensation\nfor these services, Fortis received 20,400 Shares. Fortis also acted as one of the Underwriters and as Listing\nAgent in our IPO.\n", "page_number": 96, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.2734274711168164, "lower_right_x": 0.8614640048396854, "lower_right_y": 0.3423192126658109, "height": 0.06889174154899447, "width": 0.7410768300060496}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-96-4", "text": "   In January 2005, in conjunction with our second private equity round of financing, funds associated with\nInnoven Partenaires extended a number of subordinated loans to OctoPlus Technologies B.V. with an aggregate\nprincipal amount of approximately \u20ac4.0 million. These loans were replaced by subordinated convertible bonds\nin June 2005. These convertible bonds were redeemed on a non-cash basis at the time of our IPO and their value\nwas added to the share premium reserve.\n", "page_number": 96, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.355584082156611, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.4244758237056055, "height": 0.06889174154899447, "width": 0.7555958862673926}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-96-5", "text": "   Prior to April 2004, we rented our operating facilities at market rates from OctoShed B.V., then a wholly-\nowned subsidiary of Sodoro B.V., the personal holding company of our Chief Executive Officer. In April 2004,\nwe acquired OctoShed and in the context of that transaction our facilities were valued at \u20ac3.7 million. In May\n2004, we entered into a sale and leaseback arrangement with Fortress B.V., a real estate developer. Pursuant to\nthis arrangement, we sold our facilities for \u20ac3.7 million to Fortress and a special purpose vehicle controlled by\npersons affiliated with Fortress. We hold a small beneficial interest in this special purpose vehicle. We entered\ninto this arrangement as Fortess was in a position to finance an expansion of our facilities.\n", "page_number": 96, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.43774069319640563, "lower_right_x": 0.8741681790683605, "lower_right_y": 0.5340179717586649, "height": 0.09627727856225932, "width": 0.7537810042347247}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-96-6", "text": "   Prior to 2005, Sodoro B.V. and Joost Holthuis provided various loans to us at market rates. In January 2005,\nthe outstanding balance of these loans was converted into equity at the valuation applicable to our second\nprivate equity round of financing. In addition, in consideration for providing these loans to us, Mr. Holthuis\nreceived 73,500 options with an exercise price of \u20ac3.43. All of these options are currently still outstanding.\n\n   In November 2003, our Chief Financial Officer, Hans Pauli, provided a \u20ac150,000 guarantee to ING Bank in\nsupport of an increase of our credit facility. The guarantee expired in August 2004. In addition to receiving a\nmonthly fee of 0.5% of the guaranteed amount, Mr. Pauli also received 1,260 warrants entitling to acquire\n126,000 Shares at an exercise price of \u20ac5.50 per Share. The warrants mature on 30 November 2008.\nFurthermore, in August 2004, Mr. Pauli provided us with a loan of \u20ac75,000. In addition to receiving monthly\ninterest of 0.5%, Mr. Pauli also received 23,600 options with an exercise price of \u20ac3.43. This loan was paid back\nin December 2004. The 23,600 options are currently outstanding.\n", "page_number": 96, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.5507060333761232, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.7154471544715447, "height": 0.1647411210954215, "width": 0.7604355716878403}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-96-7", "text": "   In November 2003, Hans Stellingsma, the chairperson of our Supervisory Board, provided a \u20ac150,000\nguarantee to ING Bank in support of an increase of our credit facility. The guarantee expired in June 2004. Mr.\nStellingsma received a monthly fee of 1.0% of the guaranteed amount.\n", "page_number": 96, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.7287120239623449, "lower_right_x": 0.8663036902601331, "lower_right_y": 0.7697903294822422, "height": 0.04107830551989733, "width": 0.7459165154264973}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-96-8", "text": "   In November 2003, Ton Holthuis, a brother of our Chief Executive Officer, Joost Holthuis, provided a\nsubordinated loan of \u20ac100,000, which was paid back in May 2004. In addition to receiving monthly interest of\n0.5%, Mr. Holthuis also received 840 warrants entitling to acquire 84,000 Shares at an exercise price of \u20ac5.50\nper Share. The warrants mature on 30 November 2008.\n", "page_number": 96, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.7834830979888746, "lower_right_x": 0.8663036902601331, "lower_right_y": 0.8382541720154044, "height": 0.05477107402652981, "width": 0.7459165154264973}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-96-9", "text": "94\n", "page_number": 96, "bounding_box": {"top_left_x": 0.8608590441621294, "top_left_y": 0.9477963200684638, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9572100984167736, "height": 0.00941377834830981, "width": 0.019963702359346636}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-97-0", "text": "Description of Share Capital and Corporate Governance\n", "page_number": 97, "bounding_box": {"top_left_x": 0.2159709618874773, "top_left_y": 0.10226786478391099, "lower_right_x": 0.7840290381125227, "lower_right_y": 0.11938382541720154, "height": 0.017115960633290545, "width": 0.5680580762250453}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-97-1", "text": "General\n", "page_number": 97, "bounding_box": {"top_left_x": 0.12159709618874773, "top_left_y": 0.1364997860504921, "lower_right_x": 0.17785843920145192, "lower_right_y": 0.14719726144629866, "height": 0.010697475395806566, "width": 0.05626134301270419}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-97-2", "text": "   Our business was commenced by a company incorporated under Dutch law as a private company with limited\nliability (besloten vennootschap met beperkte aansprakelijkheid), by deed executed on 20 July 1995 under the\nname OctoPlus B.V., which is currently named OctoPlus Development B.V. and is one of our 100%\nsubsidiaries. We were incorporated on 29 May 1997 under Dutch law, under the name Octoplus B.V. On 4\nOctober 2006, we converted Octoplus B.V. into Octoplus N.V. a limited liability company under Dutch law. We\ntrade under the name OctoPlus. We are registered with the Trade Register of the Chamber of Commerce for\nRijnland, the Netherlands under number 28075073. Our corporate seat is in Leiden, the Netherlands and our\noffice address is Zernikedreef 12, 2333 CL Leiden, the Netherlands. We can be contacted by telephone on + 31\n(0)71 5244044, by fax on +31 (0)71 5244048, by email at octoplus@octoplus.nl, or through our website which\nis www.octoplus.nl. The contents of our website are expressly not incorporated by reference into this\nProspectus.\n", "page_number": 97, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.16388532306375694, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.31407787762088146, "height": 0.15019255455712452, "width": 0.7604355716878403}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-97-3", "text": "  Our articles of association were last amended by deed of amendment, executed on 4 October 2006, before\nMr. D.F.M.M. Zaman, civil law notary in Rotterdam, the Netherlands. The certificate of no objection of the\nMinistry of Justice for that amendment was granted on 13 September 2006, under number B.V. 597.465.\n", "page_number": 97, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.3281985451433462, "lower_right_x": 0.8511796733212341, "lower_right_y": 0.36970474967907574, "height": 0.04150620453572956, "width": 0.7307924984875983}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-97-4", "text": "  Set out below is a summary of certain relevant information concerning our share capital, certain significant\nprovisions of Dutch corporate law and a brief summary of certain provisions of our articles of association (the\n\u201cArticles of Association\u201d).\n", "page_number": 97, "bounding_box": {"top_left_x": 0.12099213551119177, "top_left_y": 0.38296961916987593, "lower_right_x": 0.8614640048396854, "lower_right_y": 0.4244758237056055, "height": 0.04150620453572956, "width": 0.7404718693284936}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-97-5", "text": "   This summary does not purport to give a complete overview and should be read in conjunction with the\nArticles of Association, together with relevant provisions of Dutch law, and does not constitute legal advice\nregarding these matters and should not be considered as such.\n", "page_number": 97, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.43774069319640563, "lower_right_x": 0.8469449485783425, "lower_right_y": 0.4809584937954643, "height": 0.043217800599058664, "width": 0.7265577737447066}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-97-6", "text": "Corporate Objects\n", "page_number": 97, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.4959349593495935, "lower_right_x": 0.2558983666061706, "lower_right_y": 0.5091998288403937, "height": 0.013264869490800246, "width": 0.1355111917725348}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-97-7", "text": "Pursuant to Article 3 of our Articles of Association, our corporate objects are:\n", "page_number": 97, "bounding_box": {"top_left_x": 0.1367211131276467, "top_left_y": 0.5233204963628584, "lower_right_x": 0.663036902601331, "lower_right_y": 0.537441163885323, "height": 0.014120667522464658, "width": 0.5263157894736843}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-97-8", "text": "to incorporate, to participate in any way whatsoever in, to manage and to supervise businesses and\ncompanies, in particular, but not limited to those involved in the pharmaceutical and (bio)medical\nindustries, and, more in particular, those involved in the development and exploitation of pharmaceutical\nand biomedical processes and products and the rendering of research and development services;\n\nto develop and trade in patents, trade marks, licenses, know-how and other intellectual property rights;\n\nto render advice and services to businesses and companies with which we form a group and to third\nparties;\n\nto borrow, to lend and to raise funds, including the issue of bonds, promissory notes or other securities or\nevidence of indebtedness, as well as to enter into agreements in connection with the aforementioned\nactivities;\n\nto grant guarantees, to bind ourselves and to pledge our assets for obligations of businesses and\ncompanies with which we form a group and on behalf of third parties;\n\nto acquire, dispose of, manage and exploit registered property and items of property in general; and\n\nto do all that is connected therewith or may be conducive thereto, all to be interpreted in the broadest\nsense.\n", "page_number": 97, "bounding_box": {"top_left_x": 0.16878402903811252, "top_left_y": 0.5507060333761232, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.8386820710312366, "height": 0.28797603765511337, "width": 0.7120387174833636}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-97-9", "text": "\u00b7\n", "page_number": 97, "bounding_box": {"top_left_x": 0.1367211131276467, "top_left_y": 0.5545571245186136, "lower_right_x": 0.14519056261343014, "lower_right_y": 0.5609756097560976, "height": 0.006418485237484006, "width": 0.008469449485783431}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-97-10", "text": "\u00b7\n", "page_number": 97, "bounding_box": {"top_left_x": 0.1355111917725348, "top_left_y": 0.6234488660676081, "lower_right_x": 0.14519056261343014, "lower_right_y": 0.629867351305092, "height": 0.006418485237483895, "width": 0.009679370840895346}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-97-11", "text": "\u00b7\n", "page_number": 97, "bounding_box": {"top_left_x": 0.1355111917725348, "top_left_y": 0.6512623020967052, "lower_right_x": 0.14458560193587416, "lower_right_y": 0.6572528883183568, "height": 0.005990586221651606, "width": 0.009074410163339375}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-97-12", "text": "", "page_number": 97, "bounding_box": {"top_left_x": 0.1367211131276467, "top_left_y": 0.6949080017115961, "lower_right_x": 0.14277071990320628, "lower_right_y": 0.6979032948224219, "height": 0.002995293110825803, "width": 0.006049606775559574}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-97-13", "text": "\u00b7\n", "page_number": 97, "bounding_box": {"top_left_x": 0.1355111917725348, "top_left_y": 0.7492511767222936, "lower_right_x": 0.14519056261343014, "lower_right_y": 0.7556696619597775, "height": 0.006418485237483895, "width": 0.009679370840895346}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-97-14", "text": "\u00b7\n", "page_number": 97, "bounding_box": {"top_left_x": 0.1355111917725348, "top_left_y": 0.7903294822421908, "lower_right_x": 0.14519056261343014, "lower_right_y": 0.7971758664955071, "height": 0.0068463842533162955, "width": 0.009679370840895346}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-97-15", "text": "\u00b7\n", "page_number": 97, "bounding_box": {"top_left_x": 0.1355111917725348, "top_left_y": 0.8177150192554558, "lower_right_x": 0.14519056261343014, "lower_right_y": 0.8245614035087719, "height": 0.0068463842533161845, "width": 0.009679370840895346}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 16, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-97-16", "text": "95\n", "page_number": 97, "bounding_box": {"top_left_x": 0.8608590441621294, "top_left_y": 0.9477963200684638, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9572100984167736, "height": 0.00941377834830981, "width": 0.019963702359346636}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-98-0", "text": "Share Capital\n", "page_number": 98, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.08515190415062045, "lower_right_x": 0.22262552934059285, "lower_right_y": 0.09927257167308515, "height": 0.0141206675224647, "width": 0.10223835450695704}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-98-1", "text": "Authorized and Issued Share Capital\n", "page_number": 98, "bounding_box": {"top_left_x": 0.1161524500907441, "top_left_y": 0.11253744116388532, "lower_right_x": 0.37689050211736236, "lower_right_y": 0.12665810868635002, "height": 0.0141206675224647, "width": 0.26073805202661826}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-98-2", "text": "   At the date of this Prospectus, our authorized share capital amounts to \u20ac8,640,000, divided into 36,000,000\nordinary shares and 36,000,000 preference shares, each with a nominal value of \u20ac0.12. Immediately prior to the\nOffer, we will have 16,207,076 ordinary shares issued and outstanding. In connection with the Offer we intend\nto issue 6,329,114 ordinary shares and expect to raise \u20ac25 million, based on the assumptions expressed below.\n", "page_number": 98, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.1399229781771502, "lower_right_x": 0.8711433756805808, "lower_right_y": 0.1951219512195122, "height": 0.055198973042362015, "width": 0.7507562008469449}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-98-3", "text": "   The following table sets forth information about our issued share capital as of the date of this Prospectus,\nafter the, and following completion of the Offer.\n", "page_number": 98, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.20838682071031236, "lower_right_x": 0.8469449485783425, "lower_right_y": 0.2362002567394095, "height": 0.02781343602909714, "width": 0.7265577737447066}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-98-4", "text": "                                                           Following\n                                  As of the date of     completion of the\n                                  this Prospectus           Offer1\nOrdinary shares                        16,207,076           22,536,190\nPreference shares                               -                    -\nWarrants                                  392,000              392,000\nOptions2                                  794,815              794,815\nTotal                                  17,393,891           23,723,005\n\n    1.   Based on an offer of 6,329,114 Offer Shares, assuming we raise \u20ac25 million in the Offer and an Offer Price of \u20ac3.95.\n\n    2.   594,815 options issued under our share option plans and 200,000 options issued under our agreement with Theratechnologies\n         (see \u201cOutstanding Warrants and Options\u201d below).\n", "page_number": 98, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.24946512623020967, "lower_right_x": 0.8566243194192378, "lower_right_y": 0.41762943945228925, "height": 0.1681643132220796, "width": 0.736237144585602}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-98-5", "text": "   Currently, neither we nor any of our subsidiaries hold any of our shares. All shares that are outstanding as of\nthe date of this Prospectus are fully paid up. As of the date of this prospectus there are 3,920 Warrants\noutstanding, entitling the purchase of 392,000 Shares (see \u201cOutstanding Warrants and Options\u201d below).\n", "page_number": 98, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.43089430894308944, "lower_right_x": 0.8711433756805808, "lower_right_y": 0.472400513478819, "height": 0.04150620453572956, "width": 0.7507562008469449}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-98-6", "text": "   Immediately following completion of the Offer, based on an offer of 6,329,114 Offer Shares, assuming we\nraise \u20ac25 million in the Offer and an Offer Price of \u20ac3.95, and no exercise of the Overallotment Option, we\nexpect to have 22,536,190 ordinary shares issued and outstanding. The percentage of immediate dilution\nresulting from the Offer is 28.1% and amounts to \u20ac25 million.\n", "page_number": 98, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.4856653829696192, "lower_right_x": 0.8560193587416818, "lower_right_y": 0.5430038510911425, "height": 0.05733846812152327, "width": 0.735632183908046}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-98-7", "text": "Form and Trading of Shares\n", "page_number": 98, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.5575524176294394, "lower_right_x": 0.32304900181488205, "lower_right_y": 0.5712451861360719, "height": 0.01369276850663248, "width": 0.20266182698124624}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-98-8", "text": "   Our ordinary shares are in registered form (aandelen op naam) and are traded through the book-entry\nfacilities of Euroclear Netherlands. No share certificates will be issued. We are responsible for keeping a\nshareholders\u2019 register.\n", "page_number": 98, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.5849379546427044, "lower_right_x": 0.8275862068965517, "lower_right_y": 0.6260162601626016, "height": 0.04107830551989722, "width": 0.7071990320629159}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-98-9", "text": "Outstanding Warrants and Options\n", "page_number": 98, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.6397090286692341, "lower_right_x": 0.367816091954023, "lower_right_y": 0.6538296961916987, "height": 0.014120667522464658, "width": 0.24742891712038717}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-98-10", "text": "   In 2003 and 2004, we entered into warrant agreements with Hans Pauli, our Chief Financial Officer, and three\nother parties. Pursuant to these warrant agreements, a total of 3,920 warrants are currently outstanding. Each\nwarrant entitles its holder to acquire 100 ordinary shares at an exercise price of \u20ac5.50.\n", "page_number": 98, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.6670945656824989, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.7086007702182285, "height": 0.04150620453572962, "width": 0.7604355716878403}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-98-11", "text": "   On various occasions in 2003, 2004 and 2006, we entered into share option agreements with employees.\nPursuant to these option agreements, a total of 594,815 options are currently outstanding. Each option entitles its\nholder to acquire an ordinary share for an exercise price, depending on the calendar year in which the option\nwas granted, of \u20ac3.58 (2003), between \u20ac3.43 and \u20ac4.34 (2004) and between \u20ac2.70 and \u20ac4.55 (2006). Except for\nthe exercise price and the exercise period, all option agreements have identical terms (see \u201cManagement and\nEmployees \u2013 Option Plans \u2013 2003 Option Plans\u201d).\n", "page_number": 98, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.7218656397090286, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.8044501497646556, "height": 0.08258451005562695, "width": 0.7604355716878403}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-98-12", "text": "   On 26 September 2007, we granted options to Theratechnologies to acquire 200,000 Shares at an exercise\nprice of \u20ac3.95 per Share, equal to the average closing price of the Shares for the ten trading days immediately\nprior to the date of our license agreement with Theratechnologies. These options are exercisable at any time\nuntil the earlier of ten years following date of execution or the fifth anniversary of the date of termination of the\nagreement with Theratechnologies.\n", "page_number": 98, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.8177150192554558, "lower_right_x": 0.8729582577132486, "lower_right_y": 0.8883183568677792, "height": 0.0706033376123234, "width": 0.7525710828796128}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-98-13", "text": "96\n", "page_number": 98, "bounding_box": {"top_left_x": 0.8608590441621294, "top_left_y": 0.9477963200684638, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9572100984167736, "height": 0.00941377834830981, "width": 0.019963702359346636}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-99-0", "text": "Issue of Shares and Pre-emptive Rights\n", "page_number": 99, "bounding_box": {"top_left_x": 0.1161524500907441, "top_left_y": 0.08515190415062045, "lower_right_x": 0.396854204476709, "lower_right_y": 0.09927257167308515, "height": 0.0141206675224647, "width": 0.2807017543859649}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-99-1", "text": "   In general, each holder of our ordinary shares shall have a pre-emptive right to subscribe for newly issued\nordinary shares, pro rata to the aggregate amount of that holder\u2019s ordinary shares. Such pre-emptive rights do\nnot apply, however, in respect of (i) ordinary shares issued for a non-cash contribution, and (ii) ordinary shares\nissued to our employees. Holders of ordinary shares do not have pre-emptive rights to subscribe for an issue of\npreference shares.\n", "page_number": 99, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.11253744116388532, "lower_right_x": 0.8663036902601331, "lower_right_y": 0.18142918271287975, "height": 0.06889174154899443, "width": 0.7459165154264973}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-99-2", "text": "   Our Articles of Association delegate the authority to issue ordinary shares and preference shares, and/or to\nlimit or exclude pre-emptive rights in relation to an issuance of shares, to the Executive Board, with the prior\napproval of our Supervisory Board, for a period of five years from 4 October 2006, the date on which our\narticles of association were last amended. This delegation may be extended, either by an amendment to the\nArticles of Association, or by a resolution of the General Meeting of Shareholders, for a period not exceeding\nfive years in each case. A delegation pursuant to a resolution of the General Meeting of Shareholders shall\nrequire the proposal of the Executive Board, which is subject to the prior approval of the Supervisory Board.\n", "page_number": 99, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.19469405220367994, "lower_right_x": 0.8614640048396854, "lower_right_y": 0.29097133076593923, "height": 0.09627727856225929, "width": 0.7410768300060496}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-99-3", "text": "  Designation of the Executive Board as the corporate body with these authorities by the Articles of\nAssociation may be revoked by an amendment of the Articles of Association. Designation of the Executive\nBoard as the corporate body with these authorities by the General Meeting of Shareholders cannot be revoked,\nunless determined otherwise at the time of designation.\n", "page_number": 99, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.3042362002567394, "lower_right_x": 0.8663036902601331, "lower_right_y": 0.3594351732991014, "height": 0.05519897304236199, "width": 0.7459165154264973}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-99-4", "text": "  Following termination of the Executive Board\u2019s authority to issue ordinary shares and preference shares\nand/or to limit or exclude pre-emptive rights in relation to an issue of shares, the General Meeting of\nShareholders shall be authorized to do so, unless it has delegated these authorities to another corporate body.\n", "page_number": 99, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.3761232349165597, "lower_right_x": 0.8499697519661222, "lower_right_y": 0.4159178433889602, "height": 0.03979460847240052, "width": 0.7295825771324864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-99-5", "text": "  No resolution of the General Meeting of Shareholders or the Supervisory Board is required for an issue of\nshares pursuant to the exercise of a previously granted right to subscribe for shares.\n", "page_number": 99, "bounding_box": {"top_left_x": 0.12099213551119177, "top_left_y": 0.43089430894308944, "lower_right_x": 0.8566243194192378, "lower_right_y": 0.45742404792468977, "height": 0.026529738981600326, "width": 0.735632183908046}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-99-6", "text": "The preference shares are further discussed below.\n", "page_number": 99, "bounding_box": {"top_left_x": 0.13732607380520268, "top_left_y": 0.4719726144629867, "lower_right_x": 0.47731397459165154, "lower_right_y": 0.4856653829696192, "height": 0.01369276850663248, "width": 0.33998790078644886}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-99-7", "text": "Granting of Rights to Subscribe for Shares\n", "page_number": 99, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.4993581514762516, "lower_right_x": 0.42105263157894735, "lower_right_y": 0.5134788189987163, "height": 0.014120667522464658, "width": 0.30066545674531153}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-99-8", "text": "   Our Articles of Association delegate the authority to grant rights to subscribe for shares to the Executive\nBoard, with the prior approval of our Supervisory Board, for a period of five years starting 4 October 2006 after\nthe meeting of shareholders held on 1 September 2006. This delegation may be extended, either by an\namendment to the Articles of Association, or by a resolution of the General Meeting of Shareholders, for a\nperiod not exceeding five years in each case. A delegation pursuant to a resolution of the General Meeting of\nShareholders shall require a proposal by the Executive Board, which is subject to prior approval of the\nSupervisory Board.\n", "page_number": 99, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.5267436884895165, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.6230209670517758, "height": 0.09627727856225932, "width": 0.7555958862673926}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-99-9", "text": "  Designation of the Executive Board as the corporate body with the authority to grant rights to subscribe for\nshares by the Articles of Association may be revoked by an amendment of the Articles of Association.\nDesignation of the Executive Board as the corporate body with the authority to grant rights to subscribe for\nshares by the General Meeting of Shareholders cannot be revoked, unless determined otherwise at the time of\ndesignation.\n", "page_number": 99, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.636285836542576, "lower_right_x": 0.8614640048396854, "lower_right_y": 0.7051775780915703, "height": 0.06889174154899436, "width": 0.7410768300060496}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-99-10", "text": "   Following termination of the Executive Board\u2019s authority to grant rights to subscribe for ordinary shares and\npreference shares, the General Meeting of Shareholders shall be authorized to do so, unless it has delegated\nthese authorities to another corporate body.\n", "page_number": 99, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.7184424475823705, "lower_right_x": 0.8711433756805808, "lower_right_y": 0.7599486521181001, "height": 0.04150620453572962, "width": 0.7507562008469449}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-99-11", "text": "Acquisition of Shares in Our Capital\n", "page_number": 99, "bounding_box": {"top_left_x": 0.11675741076830005, "top_left_y": 0.7766367137355584, "lower_right_x": 0.37749546279491836, "lower_right_y": 0.7894736842105263, "height": 0.012836970474967901, "width": 0.2607380520266183}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-99-12", "text": "   We may acquire our own fully paid shares at any time for no consideration (om niet). Furthermore, subject to\ncertain provisions of Dutch law and our Articles of Association, we may acquire fully paid shares in our own\ncapital if (i) our shareholders\u2019 equity less the payment required to make the acquisition, does not fall below the\nsum of the paid-in and called-up share capital plus the reserves as required to be maintained by Dutch law or by\nour Articles of Association (such excess, the \u201cDistributable Equity\u201d) and (ii) we and our subsidiaries would\nthereafter not hold shares or hold a pledge over our shares with an aggregate nominal value exceeding 10% of\nour issued share capital.\n", "page_number": 99, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.8040222507488233, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.8990158322635858, "height": 0.09499358151476256, "width": 0.7555958862673926}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-99-13", "text": "97\n", "page_number": 99, "bounding_box": {"top_left_x": 0.8608590441621294, "top_left_y": 0.9477963200684638, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9572100984167736, "height": 0.00941377834830981, "width": 0.019963702359346636}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-100-0", "text": "   Other than those shares acquired for no consideration, shares may only be acquired subject to a resolution of\nthe Executive Board, which is approved by the Supervisory Board, and authorized by the General Meeting of\nShareholders. Such authorization from the General Meeting of Shareholders for the acquisition of our shares\nshall specify the number and class of these shares that may be acquired, the manner in which these shares may\nbe acquired and the price range within which shares may be acquired. Such authorization may be valid for no\nmore than 18 months.\n", "page_number": 100, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.08515190415062045, "lower_right_x": 0.8711433756805808, "lower_right_y": 0.16388532306375694, "height": 0.0787334189131365, "width": 0.7507562008469449}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-100-1", "text": "  The General Meeting of Shareholders has authorized the Executive Board to acquire a maximum of 10% of\nour issued ordinary shares for a period of 18 months from the meeting of shareholders which was held on 24\nApril 2007, at a purchase price between the nominal value of the shares and 110% of the average price of our\nordinary shares during five trading days before the repurchase.\n", "page_number": 100, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.1810012836970475, "lower_right_x": 0.8663036902601331, "lower_right_y": 0.2362002567394095, "height": 0.055198973042362015, "width": 0.7459165154264973}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-100-2", "text": "   No authorization from the General Meeting of Shareholders is required for the acquisition of fully paid shares\nfor the purpose of transferring these shares to employees pursuant to our share option plan. Any shares we hold\nin our own capital may not be voted or counted for voting quorum purposes.\n", "page_number": 100, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.24946512623020967, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.29097133076593923, "height": 0.04150620453572956, "width": 0.7604355716878403}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-100-3", "text": "Reduction of Share Capital\n", "page_number": 100, "bounding_box": {"top_left_x": 0.1161524500907441, "top_left_y": 0.3076593923833975, "lower_right_x": 0.3103448275862069, "lower_right_y": 0.3200684638425332, "height": 0.012409071459135668, "width": 0.1941923774954628}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-100-4", "text": "   The General Meeting of Shareholders may, at the proposal of the Executive Board, which proposal is subject\nto the approval of the Supervisory Board, resolve to reduce our issued and outstanding share capital by\ncancelling our shares, or by amending our Articles of Association to reduce the nominal value of our shares.\n", "page_number": 100, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.33504492939666236, "lower_right_x": 0.8747731397459165, "lower_right_y": 0.37526743688489517, "height": 0.040222507488232806, "width": 0.7543859649122807}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-100-5", "text": "Dividends and Other Distributions\n", "page_number": 100, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.3898160034231921, "lower_right_x": 0.37265577737447064, "lower_right_y": 0.40051347881899874, "height": 0.010697475395806622, "width": 0.25226860254083483}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-100-6", "text": "  We may only make distributions to our shareholders in so far as our shareholders\u2019 equity exceeds the\nDistributable Equity.\n", "page_number": 100, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.417201540436457, "lower_right_x": 0.8173018753781004, "lower_right_y": 0.44458707744972187, "height": 0.02738553701326485, "width": 0.6969147005444646}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-100-7", "text": "   Under our Articles of Association, a dividend shall first, if possible, be paid on the preference shares out of\nthe profits (the positive balance of the profit and loss accounts) made in the most recently elapsed financial year.\nThe dividend payable on the preference shares shall, if possible, be equal to the average twelve month\nEURIBOR (Euro Interbank Offered Rate), weighted for the number of days to which the distribution pertains,\nincreased by 1%, calculated over the paid up part of the nominal value of those shares. The dividend on the\npreference shares shall, if the respective shares have been issued in the course of the financial year, be\ncalculated pro rata, to the period of the year they have been outstanding.\n", "page_number": 100, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.4582798459563543, "lower_right_x": 0.8753781004234725, "lower_right_y": 0.5545571245186136, "height": 0.09627727856225932, "width": 0.7549909255898367}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-100-8", "text": "  If twelve month EURIBOR shall no longer be published at any time, the dividend payable on the preference\nshares shall be equal to the mathematical average of the average effective return on the five Dutch government\nbonds with the longest maturity, as drawn up by the Central Bureau of Statistics and published in the Daily\nOfficial List, over the 20 trading days preceding the issue, increased by a surcharge to be determined by the\nExecutive Board, subject to the approval of the Supervisory Board, such surcharge to be between 0.25% and\n1%, calculated over the paid up part of the nominal value of those shares.\n", "page_number": 100, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.5678219940094138, "lower_right_x": 0.8663036902601331, "lower_right_y": 0.6504065040650406, "height": 0.08258451005562684, "width": 0.7459165154264973}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-100-9", "text": "   The resolution to issue the preference shares may specify that if the profits of any financial year do not permit\na distribution of dividends on the preference shares, the deficit shall be distributed from our Distributable Equity\nand, if this is also insufficient, from the profits of any subsequent years (i.e. cumulative preference shares).\n", "page_number": 100, "bounding_box": {"top_left_x": 0.12099213551119177, "top_left_y": 0.6636713735558408, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.7051775780915703, "height": 0.04150620453572951, "width": 0.7598306110102843}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-100-10", "text": "   After distribution of dividends on the preference shares (including any outstanding distribution on cumulative\npreference shares), the Executive Board may, subject to the approval of the Supervisory Board, determine which\npart of the profits shall be reserved. The part of the profit remaining after reservation shall be distributed as a\ndividend on the ordinary shares.\n", "page_number": 100, "bounding_box": {"top_left_x": 0.12099213551119177, "top_left_y": 0.7184424475823705, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.7736414206247325, "height": 0.05519897304236199, "width": 0.7598306110102843}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-100-11", "text": "   Under our Articles of Association, we may only make a distribution of dividends to our shareholders if our\nstatutory annual accounts demonstrate that such distribution is legally permitted. The Executive Board may,\nhowever, subject to the prior approval of the Supervisory Board, declare an interim dividend. The General\nMeeting of Shareholders may, furthermore, upon the proposal by the Executive Board, with the prior approval\nof the Supervisory Board, resolve that a distribution is made from the Distributable Equity and that a\ndistribution of dividends on the ordinary shares shall not be paid in whole or in part in cash, but in shares.\n", "page_number": 100, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.7903294822421908, "lower_right_x": 0.8614640048396854, "lower_right_y": 0.8712023962344887, "height": 0.0808729139922979, "width": 0.7410768300060496}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-100-12", "text": "98\n", "page_number": 100, "bounding_box": {"top_left_x": 0.8608590441621294, "top_left_y": 0.9477963200684638, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9572100984167736, "height": 0.00941377834830981, "width": 0.019963702359346636}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-101-0", "text": "   Claims to dividends and other distributions not made within five years from the date that such dividends or\ndistributions became payable, will lapse and any such amounts will be considered to have been forfeited to us\n(verjaring).\n", "page_number": 101, "bounding_box": {"top_left_x": 0.12099213551119177, "top_left_y": 0.08515190415062045, "lower_right_x": 0.8614640048396854, "lower_right_y": 0.12665810868635002, "height": 0.04150620453572958, "width": 0.7404718693284936}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-101-1", "text": "Preference Shares and Stichting Continu\u00efteit OctoPlus\n", "page_number": 101, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.1399229781771502, "lower_right_x": 0.5130066545674531, "lower_right_y": 0.1540436456996149, "height": 0.014120667522464714, "width": 0.3926194797338173}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-101-2", "text": "  On 29 March 2007 we incorporated Stichting Continu\u00efteit OctoPlus (the \u201cFoundation\u201d). The purpose of the\nFoundation will be to safeguard our interests and those of our enterprise and to protect, insofar as possible, our\ncontinuity, our independence and our corporate identity. The board of the Foundation consists of two A board\nmembers and one B board member. Emile Bakker and Ruut van Dam are serving as A board members and Jan\nWillem Termeijtelen is serving as B board member. The A board members will be appointed by the board of the\nFoundation, whilst the B board member will be appointed by the Supervisory Board upon proposal of the\nExecutive Board. All board members are independent within the meaning of Appendix X of the Euronext Rule\nBook, Book II.\n", "page_number": 101, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.16730851519041506, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.2772785622593068, "height": 0.10997004706889174, "width": 0.7555958862673926}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-101-3", "text": "   Our preference shares will be an instrument of protection against hostile takeovers. In line with guidance\nfrom the Dutch Corporate Governance Code, we believe that the issuance of preference shares may help us to\ndetermine our position in relation to a bidder and its plans, and to seek alternatives. The issue of preference\nshares is intended to be temporary. Unless the preference shares have been issued by a vote of the General\nMeeting of Shareholders, our Articles of Association require that a General Meeting of Shareholders be held no\nlater than two years after the issue of preference shares to consider their redemption or cancellation. If the\nGeneral Meeting of Shareholders does not resolve to redeem or cancel the preference shares, another General\nMeeting of Shareholders will be held within two years. Until the preference shares have been redeemed or\ncancelled, a General Meeting of Shareholders to consider a redemption or cancellation of the preference shares\nwill be held within two years of the previous meeting.\n", "page_number": 101, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.290543431750107, "lower_right_x": 0.8705384150030248, "lower_right_y": 0.4278990158322636, "height": 0.1373555840821566, "width": 0.7501512401693889}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-101-4", "text": "   Under the terms of an agreement with the Foundation, we have granted the Foundation a call option (the\n\u201cCall Option\u201d) entitling it, in certain circumstances, to acquire from us preference shares up to a maximum of\n100% of our total issued and outstanding share capital (excluding issued and outstanding preference shares) at\nthe time the Foundation exercises the Call Option. Under the terms of another agreement, the Foundation has\ngranted us a put option (the \u201cPut Option\u201d) entitling us, in certain circumstances, to issue preference shares to the\nFoundation up to a maximum of 100% of our total issued and outstanding share capital (excluding issued and\noutstanding preference shares) at the time we exercise the Put Option. The Call Option as well as the Put Option\ncan be exercised in one or more tranches.\n", "page_number": 101, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.441591784338896, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.5507060333761232, "height": 0.10911424903722722, "width": 0.7555958862673926}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-101-5", "text": "   No resolution of the General Meeting of Shareholders or the Executive Board is required for an issue of\npreference shares pursuant to the exercise of the Call Option or the Put Option. However, an issue of preference\nshares pursuant to a resolution of a corporate body other than the General Meeting of Shareholders, through\nwhich an amount of preference shares shall be issued that exceeds 100% of the outstanding amount of ordinary\nshares, is only permitted with prior approval of the General Meeting of Shareholders given for that specific\ninstance. In the event of an issue of preference shares pursuant to a resolution of a corporate body other than the\nGeneral Meeting of Shareholders, through which an amount of preference shares shall be issued that does not\nexceed 100% of the outstanding amount of ordinary shares, a General Meeting of Shareholders shall be\nconvened and held within four weeks after the issue, at which meeting the reasons for the issue shall be\nexplained.\n", "page_number": 101, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.5678219940094138, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.7051775780915703, "height": 0.13735558408215653, "width": 0.7555958862673926}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-101-6", "text": "  Upon the issue of preference shares to the Foundation, the Foundation must pay at least 25% of the nominal\nvalue of the preference shares. The Foundation intends to enter into a credit facility agreement with a bank in\norder to finance such payment.\n", "page_number": 101, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.7184424475823705, "lower_right_x": 0.8663036902601331, "lower_right_y": 0.7590928540864356, "height": 0.04065040650406504, "width": 0.7459165154264973}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-101-7", "text": "   A transfer of preference shares (save for a transfer of preference shares to us) requires the prior approval of\nthe Executive Board.\n", "page_number": 101, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.7732135216089003, "lower_right_x": 0.8614640048396854, "lower_right_y": 0.7976037655113393, "height": 0.024390243902438935, "width": 0.7410768300060496}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-101-8", "text": "General Meetings of Shareholders and Voting Rights\n", "page_number": 101, "bounding_box": {"top_left_x": 0.12159709618874773, "top_left_y": 0.8142918271287976, "lower_right_x": 0.5033272837265578, "lower_right_y": 0.8284124946512623, "height": 0.01412066752246477, "width": 0.3817301875378101}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-101-9", "text": "  The annual General Meeting of Shareholders shall be held within six months after the end of each financial\nyear. Our financial year is equal to a calendar year.\n", "page_number": 101, "bounding_box": {"top_left_x": 0.12159709618874773, "top_left_y": 0.8416773641420625, "lower_right_x": 0.8614640048396854, "lower_right_y": 0.8694908001711597, "height": 0.02781343602909714, "width": 0.7398669086509377}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-101-10", "text": "   An Extraordinary General Meeting of Shareholders may be convened, whenever our interests so require, by\nthe Executive Board or the Supervisory Board. Shareholders representing alone or in aggregate at least one-\n", "page_number": 101, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.8827556696619597, "lower_right_x": 0.8663036902601331, "lower_right_y": 0.9105691056910569, "height": 0.02781343602909714, "width": 0.7459165154264973}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-101-11", "text": "99\n", "page_number": 101, "bounding_box": {"top_left_x": 0.8608590441621294, "top_left_y": 0.9477963200684638, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9572100984167736, "height": 0.00941377834830981, "width": 0.019963702359346636}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-102-0", "text": "tenth of our issued and outstanding share capital may, pursuant to the Dutch Civil Code and our Articles of\nAssociation, request the district court to authorize such shareholder to convene a General Meeting of\nShareholders.\n", "page_number": 102, "bounding_box": {"top_left_x": 0.12099213551119177, "top_left_y": 0.08515190415062045, "lower_right_x": 0.8415003024803388, "lower_right_y": 0.12323491655969192, "height": 0.03808301240907147, "width": 0.720508166969147}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-102-1", "text": "   The notice convening any General Meeting of Shareholders shall be sent no later than the 15th day prior to\nthe meeting and shall include an agenda stating the items to be dealt with. Holders of shares (including holders\nof the rights conferred by law upon holders of depositary receipts issued with a company\u2019s cooperation for\nshares in its capital) who, alone or in the aggregate, own shares representing at least 1% of our issued and\noutstanding capital have the right to request the Supervisory Board or the Executive Board to place items on the\nagenda of the General Meeting of Shareholders. If such proposals are submitted to the Executive Board or the\nSupervisory Board in time for the Executive Board to put these proposals on the agenda for the next meeting, or\nannounce them prior to the meeting by means of a supplementary notice with due observance of the\naforementioned notice period, the Executive Board or the Supervisory Board shall be obliged to do so, provided\nthat no important interest (zwaarwichtig belang) we have dictates otherwise.\n", "page_number": 102, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.1399229781771502, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.2772785622593068, "height": 0.13735558408215662, "width": 0.7555958862673926}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-102-2", "text": "   All notices of General Meetings of Shareholders, all announcements concerning dividend and other\ndistributions, and all other announcements to holders of shares (including holders of rights conferred by law\nupon holders of depositary receipts issued with a company\u2019s cooperation for shares in its capital), shall be\neffected by means of a publication in a nationally distributed daily newspaper, in the Daily Official List and on\nour website.\n", "page_number": 102, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.290543431750107, "lower_right_x": 0.8711433756805808, "lower_right_y": 0.35772357723577236, "height": 0.06718014548566537, "width": 0.7507562008469449}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-102-3", "text": "   The Executive Board shall be authorized to determine a record date to establish which shareholders are\nentitled to attend and vote in the General Meeting of Shareholders. Such record date may not be set for a date\nprior to the seventh day before that of the meeting.\n", "page_number": 102, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.3727000427899016, "lower_right_x": 0.8566243194192378, "lower_right_y": 0.41420624732563116, "height": 0.04150620453572956, "width": 0.736237144585602}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-102-4", "text": "  Each of our preference shares and ordinary shares is entitled to one vote. Shareholders may vote by proxy.\nThe voting rights attached to any of our shares held by us are suspended as long as they are held in treasury.\n", "page_number": 102, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.4274711168164313, "lower_right_x": 0.8554143980641258, "lower_right_y": 0.45699614890885754, "height": 0.02952503209242624, "width": 0.73502722323049}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-102-5", "text": "  Decisions of the General Meeting of Shareholders are taken by an absolute majority of votes cast, except\nwhere Dutch law provides for a qualified majority.\n", "page_number": 102, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.4719726144629867, "lower_right_x": 0.8463399879007865, "lower_right_y": 0.4985023534445871, "height": 0.02652973898160038, "width": 0.7259528130671506}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-102-6", "text": "Amendment of Our Articles of Association and Change of Our Corporate Form\n", "page_number": 102, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.513050919982884, "lower_right_x": 0.6938898971566848, "lower_right_y": 0.5267436884895165, "height": 0.01369276850663248, "width": 0.573502722323049}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-102-7", "text": "  The General Meeting of Shareholders may resolve to amend our Articles of Association, subject to a proposal\nby the Executive Board, which requires the approval of the Supervisory Board.\n", "page_number": 102, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.540436456996149, "lower_right_x": 0.8802177858439202, "lower_right_y": 0.5682498930252461, "height": 0.02781343602909714, "width": 0.7598306110102844}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-102-8", "text": "  The General Meeting of Shareholders may furthermore resolve to change our corporate form. A change of\nour corporate form shall require a resolution to amend our Articles of Association, subject to a proposal by the\nExecutive Board, which requires the approval of the Supervisory Board.\n", "page_number": 102, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.5815147625160462, "lower_right_x": 0.8663036902601331, "lower_right_y": 0.6230209670517758, "height": 0.04150620453572962, "width": 0.7459165154264973}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-102-9", "text": "Statutory Merger and Statutory Demerger\n", "page_number": 102, "bounding_box": {"top_left_x": 0.12099213551119177, "top_left_y": 0.636285836542576, "lower_right_x": 0.4307320024198427, "lower_right_y": 0.6504065040650406, "height": 0.014120667522464658, "width": 0.30973986690865096}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-102-10", "text": "   The General Meeting of Shareholders may resolve that we enter into a statutory merger or demerger (which\nterm includes both a split-up and a spin-off), subject to a proposal by the Executive Board, which requires the\napproval of the Supervisory Board. In the event we are the acquiring company, the Executive Board may resolve\nto enter into a statutory merger or demerger, unless one or more shareholders representing at least 5% of our\nissued share capital request the Executive Board within one month of the announcement of the merger or\ndemerger, to convene a General Meeting of Shareholders.\n", "page_number": 102, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.6640992725716731, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.7462558836114677, "height": 0.08215661103979455, "width": 0.7604355716878403}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-102-11", "text": "Dissolution and Liquidation\n", "page_number": 102, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.762943945228926, "lower_right_x": 0.32425892316999394, "lower_right_y": 0.7757809157038938, "height": 0.012836970474967901, "width": 0.20387174833635813}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-102-12", "text": "   We may only be dissolved by a resolution of the General Meeting of Shareholders subject to a proposal by\nthe Executive Board, which requires the approval of the Supervisory Board.\n", "page_number": 102, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.7903294822421908, "lower_right_x": 0.8566243194192378, "lower_right_y": 0.8172871202396235, "height": 0.02695763799743267, "width": 0.736237144585602}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-102-13", "text": "   In the event of a dissolution, our business will be liquidated in accordance with Dutch law and our Articles of\nAssociation, and the members of the Executive Board will (unless otherwise determined by the General Meeting\nof Shareholders) become liquidators, acting under supervision of the Supervisory Board. During liquidation, the\nprovisions of our Articles of Association will remain in force to the extent possible.\n", "page_number": 102, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.8314077877620881, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.8861788617886179, "height": 0.05477107402652981, "width": 0.7604355716878403}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-102-14", "text": "100\n", "page_number": 102, "bounding_box": {"top_left_x": 0.8560193587416818, "top_left_y": 0.9477963200684638, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9572100984167736, "height": 0.00941377834830981, "width": 0.024803387779794295}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-103-0", "text": "   The balance remaining after settlement of debts shall firstly be distributed to the holders of preference shares\nup to the amount of the outstanding dividends payable on the preference shares. Thereafter, an amount equal to\nthe nominal paid-up amount of the preference shares shall be paid on each preference share. Any balance\nremaining after such payments shall be transferred to the holders of ordinary shares, in proportion to the\naggregate nominal amount of their ordinary shares.\n", "page_number": 103, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.08515190415062045, "lower_right_x": 0.8711433756805808, "lower_right_y": 0.1540436456996149, "height": 0.06889174154899445, "width": 0.7507562008469449}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-103-1", "text": "Dutch Corporate Governance Code\n", "page_number": 103, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.16730851519041506, "lower_right_x": 0.37749546279491836, "lower_right_y": 0.18142918271287975, "height": 0.014120667522464686, "width": 0.25710828796128254}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-103-2", "text": "   On 9 December 2003, the Dutch Corporate Governance Committee, also known as the Tabaksblat\nCommittee, released the Dutch Corporate Governance Code. The Dutch Corporate Governance Code contains\n21 principles and 113 best practice provisions for executive boards, supervisory boards, shareholders and\ngeneral meetings of shareholders, financial reporting, auditors, disclosure, compliance and enforcement\nstandards.\n", "page_number": 103, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.19469405220367994, "lower_right_x": 0.8614640048396854, "lower_right_y": 0.26187419768934533, "height": 0.0671801454856654, "width": 0.7410768300060496}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-103-3", "text": "    Dutch companies listed on a government-recognized stock exchange, whether in the Netherlands or\nelsewhere, are required under Dutch law to disclose in their annual reports whether or not they apply the\nprovisions of the Dutch Corporate Governance Code that relate to the executive board or supervisory board and,\nif they do not apply, to explain the reasons why. The Dutch Corporate Governance Code provides that if a\ncompany\u2019s general meeting of shareholders explicitly approves the corporate governance structure and policy\nand endorses the explanation for any deviation from the best practice provisions, such company will be deemed\nto have applied the Dutch Corporate Governance Code.\n", "page_number": 103, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.2768506632434745, "lower_right_x": 0.8753781004234725, "lower_right_y": 0.37312794180573383, "height": 0.09627727856225932, "width": 0.7549909255898367}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-103-4", "text": "  We acknowledge the importance of good corporate governance. The Executive Board and Supervisory Board\nhave reviewed the Dutch Corporate Governance Code, generally agree with its basic provisions, and have taken\nand will take any further steps they consider appropriate to implement the Dutch Corporate Governance Code.\n", "page_number": 103, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.386392811296534, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.42961061189559263, "height": 0.04321780059905861, "width": 0.7555958862673926}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-103-5", "text": "   We support the Dutch Corporate Governance Code and will apply with the relevant best practice provisions\nof the Dutch Corporate Governance Code, subject to the exceptions set out below.\n", "page_number": 103, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.44458707744972187, "lower_right_x": 0.8663036902601331, "lower_right_y": 0.4711168164313222, "height": 0.026529738981600326, "width": 0.7459165154264973}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-103-6", "text": "Non-Compliance with the Dutch Corporate Governance Code\n", "page_number": 103, "bounding_box": {"top_left_x": 0.1161524500907441, "top_left_y": 0.4856653829696192, "lower_right_x": 0.5517241379310345, "lower_right_y": 0.4993581514762516, "height": 0.013692768506632425, "width": 0.4355716878402904}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-103-7", "text": "II.1.1   An Executive Board member is appointed for a maximum period of four years. A member may be\n         reappointed for a term not more than four years at a time.\n", "page_number": 103, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.513050919982884, "lower_right_x": 0.8415003024803388, "lower_right_y": 0.5408643560119811, "height": 0.02781343602909714, "width": 0.721113127646703}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-103-8", "text": "   The current members of the Executive Board have been appointed for an unlimited period and we do not\nconsider it appropriate to renegotiate the existing agreements, in so far as this would be possible given the\nmandatory provisions of Dutch labor law. Any future appointments of members of the Executive Board will be\nin compliance with this provision.\n", "page_number": 103, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.5541292255027813, "lower_right_x": 0.8711433756805808, "lower_right_y": 0.6093281985451433, "height": 0.05519897304236199, "width": 0.7507562008469449}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-103-9", "text": "II.2.1   Options to acquire shares are a conditional remuneration component, and become unconditional only\n         when the Executive Board members have fulfilled predetermined performance criteria after a period of\n         at least three years from the grant date.\n", "page_number": 103, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.6225930680359435, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.6640992725716731, "height": 0.04150620453572962, "width": 0.7555958862673926}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-103-10", "text": "  A part of the currently outstanding warrants and options have been granted unconditionally. We shall not\namend these existing agreements. Considering that we are still in a relatively early stage of development of our\nproducts and that the setting of credible predetermined performance criteria at a term of at least three years is\nnot practical at this stage, we shall not fully apply this provision.\n", "page_number": 103, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.6773641420624733, "lower_right_x": 0.8669086509376891, "lower_right_y": 0.7325631151048353, "height": 0.05519897304236199, "width": 0.7465214761040533}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-103-11", "text": "II.2.6   The supervisory board shall draw up regulations concerning ownership of and transactions in securities\n         by Executive Board members, other than securities issued by their \u2018own\u2019 company. The regulations\n         shall be posted on the website. An Executive Board member shall give periodic notice, but in any event\n         at least once a quarter, of any changes in his holding of securities in Dutch listed companies to the\n         compliance officer or, if the company has not appointed a compliance officer, to the chairman of the\n         supervisory board. An Executive Board member who invests exclusively in listed investment funds or\n         who has transferred the discretionary management of his securities portfolio to an independent third\n         party by means of a written mandate agreement is exempted from compliance with this last provision.\n", "page_number": 103, "bounding_box": {"top_left_x": 0.12099213551119177, "top_left_y": 0.7492511767222936, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.8575096277278562, "height": 0.10825845100556264, "width": 0.7549909255898366}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-103-12", "text": "   We believe that the restrictions under Dutch securities law are sufficient to govern the ownership of and\ntransactions in securities by members of the Executive Board. Implementing additional restrictions would\n", "page_number": 103, "bounding_box": {"top_left_x": 0.12159709618874773, "top_left_y": 0.8724860932819855, "lower_right_x": 0.837265577737447, "lower_right_y": 0.8990158322635858, "height": 0.02652973898160038, "width": 0.7156684815486993}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-103-13", "text": "101\n", "page_number": 103, "bounding_box": {"top_left_x": 0.8560193587416818, "top_left_y": 0.9477963200684638, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9572100984167736, "height": 0.00941377834830981, "width": 0.024803387779794295}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-104-0", "text": "potentially harm our ability to attract and ensure the continued services of the members of the Executive Board\nand we therefore believe that applying this best practice provision is not in our best interest.\n", "page_number": 104, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.08515190415062045, "lower_right_x": 0.868723532970357, "lower_right_y": 0.11296534017971759, "height": 0.02781343602909714, "width": 0.7483363581367212}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-104-1", "text": "III.2.1 The supervisory board members, with the exception of not more than one person, shall be independent\n        within the meaning of best practice provision III.2.2.\n", "page_number": 104, "bounding_box": {"top_left_x": 0.12099213551119177, "top_left_y": 0.12623020967051776, "lower_right_x": 0.8711433756805808, "lower_right_y": 0.1540436456996149, "height": 0.02781343602909714, "width": 0.7501512401693889}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-104-2", "text": "   Our Supervisory Board consists of four members, of which three were appointed by our General Meeting of\nShareholders upon nomination by Life Sciences Partners, S.R. One and Innoven Partenaires. At our General\nMeeting of Shareholders, which is scheduled to take place on 18 December 2007, we will propose to appoint\nMessrs. Eelkman Rooda, Sturge and Jacquesson and grant discharge to Messrs. Kuijten and Toon who will\nresign on the same date. Following these appointments and resignations, our Supervisory Board will only have\none member who is not independent and in consequence, we will be in compliance with this best practice\nprovision of the Code.\n", "page_number": 104, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.16730851519041506, "lower_right_x": 0.8663036902601331, "lower_right_y": 0.2635857937526744, "height": 0.09627727856225932, "width": 0.7459165154264973}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-104-3", "text": "III.7.3 The supervisory board shall adopt a set of regulations containing rules governing ownership of and\n        transactions in securities by supervisory board members, other than securities issued by their \u2018own\u2019\n        company. The regulations shall be posted on the website. A supervisory board member shall give\n        periodic notice, but in any event at least once a quarter, of any changes in his holding of securities in\n        Dutch listed companies to the compliance officer or, if the company has not appointed a compliance\n        officer, to the chairman of the supervisory board. A supervisory board member who invests exclusively\n        in listed investment funds or who has transferred the discretionary management of his securities\n        portfolio to an independent third party by means of a written mandate agreement is exempted from\n        compliance with this last provision.\n", "page_number": 104, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.2768506632434745, "lower_right_x": 0.8753781004234725, "lower_right_y": 0.40051347881899874, "height": 0.12366281557552422, "width": 0.7549909255898367}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-104-4", "text": "   We believe that the restrictions under Dutch securities law are sufficient to govern the ownership of and\ntransactions in securities by Supervisory Board members. Implementing additional restrictions would potentially\nharm our ability to attract and ensure the continued services of Supervisory Board members and we therefore\nbelieve that applying this best practice provision is not in our best interest.\n", "page_number": 104, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.41377834830979887, "lower_right_x": 0.8802177858439202, "lower_right_y": 0.47068891741548996, "height": 0.05691056910569109, "width": 0.7598306110102844}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-104-5", "text": "IV.3.1 Meetings with analysts, presentations to analysts, presentations to investors and institutional investors\n       and press conferences shall be announced in advance on the website and by means of press releases.\n       Provision shall be made for all shareholders to follow these meetings and presentations in real time, for\n       example by means of web casting or telephone lines. After the meetings, the presentations shall be\n       posted on the company\u2019s website.\n", "page_number": 104, "bounding_box": {"top_left_x": 0.12099213551119177, "top_left_y": 0.4856653829696192, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.5532734274711169, "height": 0.06760804450149765, "width": 0.7549909255898366}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-104-6", "text": "   Considering our size, it would create an excessive burden to issue a press release when meeting with analysts\nor investors, however, announcements of such meetings will be posted on our website prior to such meetings\ntaking place. Furthermore, it would create an excessive burden too if we were to provide facilities which enable\nshareholders to follow in real time the meetings and presentations referred to in the best practice provision. We\nwill, however, ensure that presentations are posted on our website immediately after the meetings.\n", "page_number": 104, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.5678219940094138, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.636285836542576, "height": 0.06846384253316218, "width": 0.7555958862673926}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-104-7", "text": "V.3.1   The external auditor and the audit committee shall be involved in drawing up the work schedule of the\n        internal auditor. They shall also take cognizance of the findings of the internal auditor.\n", "page_number": 104, "bounding_box": {"top_left_x": 0.12159709618874773, "top_left_y": 0.6499786050492083, "lower_right_x": 0.8705384150030248, "lower_right_y": 0.6773641420624733, "height": 0.02738553701326496, "width": 0.7489413188142771}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-104-8", "text": "  We feel that our financial reporting will be sufficiently monitored by our audit committee and will initially\nnot appoint an internal auditor.\n", "page_number": 104, "bounding_box": {"top_left_x": 0.12159709618874773, "top_left_y": 0.6910569105691057, "lower_right_x": 0.8554143980641258, "lower_right_y": 0.7188703465982028, "height": 0.02781343602909714, "width": 0.7338173018753781}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-104-9", "text": "Disclosure of Information\n", "page_number": 104, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.7329910141206675, "lower_right_x": 0.30973986690865096, "lower_right_y": 0.7462558836114677, "height": 0.01326486949080019, "width": 0.18935269207501515}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-104-10", "text": "   As a Dutch company listed on Euronext Amsterdam, we will be required to make our annual accounts\n(including the annual report) and our semi-annual report available to the public within five months and four\nmonths, respectively, of the end of the period to which the information relates. We will be required to publish\nour annual accounts within four months after the end of each financial year and our half-yearly figures within\ntwo months after the end of the first six months of each financial year following the implementation of\nEuropean Union Directive 2004/109/EC, which is expected to be 1 January 2008. In addition, the Company will\nalso become obliged to publish interim management statements following the implementation of the Directive.\n", "page_number": 104, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.7595207531022679, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.8557980316645272, "height": 0.09627727856225932, "width": 0.7555958862673926}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-104-11", "text": "   We must also make public certain inside information by means of a press release. Pursuant to the Financial\nSupervision Act, inside information is knowledge of concrete information directly or indirectly relating to the\nissuer or the trade in its securities which has not been made public and publication of which could significantly\n", "page_number": 104, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.8690629011553274, "lower_right_x": 0.8669086509376891, "lower_right_y": 0.9122807017543859, "height": 0.04321780059905855, "width": 0.7465214761040533}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-104-12", "text": "102\n", "page_number": 104, "bounding_box": {"top_left_x": 0.8560193587416818, "top_left_y": 0.9477963200684638, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9572100984167736, "height": 0.00941377834830981, "width": 0.024803387779794295}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-105-0", "text": "affect the trading price of the securities. The Financial Supervision Act contains specific rules intended to\nprevent insider trading.\n", "page_number": 105, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.08515190415062045, "lower_right_x": 0.8324258923169994, "lower_right_y": 0.11296534017971759, "height": 0.02781343602909714, "width": 0.7120387174833636}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-105-1", "text": "Obligations of Shareholders to Make a Public Offer\n", "page_number": 105, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.12623020967051776, "lower_right_x": 0.49364791288566245, "lower_right_y": 0.14035087719298245, "height": 0.014120667522464686, "width": 0.37326073805202664}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-105-2", "text": "   The European Directive on Takeover Bids (2004/25/EC) was implemented in Dutch legislation in June 2007\nin the Act on Takeover Bids (Wet openbaar overnamebod). This Act entered into force on 28 October 2007.\nPursuant to this Act, a shareholder who has acquired 30% of our shares or of our voting rights has the obligation\nto launch a public offer for all shares and depositary receipts issued for shares. The legislation also applies to\nshareholders acting in concert.\n", "page_number": 105, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.15361574668378264, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.22250748823277705, "height": 0.06889174154899441, "width": 0.7555958862673926}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-105-3", "text": "Squeeze Out Procedures\n", "page_number": 105, "bounding_box": {"top_left_x": 0.12099213551119177, "top_left_y": 0.23919554985023533, "lower_right_x": 0.3000604960677556, "lower_right_y": 0.251604621309371, "height": 0.012409071459135668, "width": 0.17906836055656383}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-105-4", "text": "   Pursuant to section 2:92a of the Dutch Civil Code, a shareholder who for his own account contributes at least\n95% of our issued capital may institute proceedings against our other shareholders jointly for the transfer of\ntheir shares to the claimant. The proceedings are held before the Enterprise Chamber of the Amsterdam Court of\nAppeal (Ondernemingskamer van het Gerechtshof te Amsterdam, the \u201cEnterprise Chamber\u201d) and can be\ninstituted by means of a writ of summons served upon each of the minority shareholders in accordance with the\nprovisions of the Dutch Code of Civil Procedure (Wetboek van Burgerlijke Rechtsvordering). The Enterprise\nChamber may grant the claim for squeeze out in relation to all minority shareholders and will determine the\nprice to be paid for the shares, if necessary upon advice of one or three experts. Once the order to transfer\nbecomes final before the Enterprise Chamber, the person acquiring the shares shall give written notice of the\ndate and place of payment and the price to the holders of the shares to be acquired whose addresses are known\nto him. Unless the addresses of all of them are known to him, he shall also publish the same in a newspaper with\na national circulation.\n", "page_number": 105, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.26658108686350024, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.4274711168164313, "height": 0.16089002995293106, "width": 0.7604355716878403}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-105-5", "text": "   With the implementation of the Takeover Directive into the Act on Takeover Bids, the rules for squeeze out\nprocedures have been supplemented. This legislation explicitly confirms that the offeror under a public offer is\nalso entitled to start a squeeze out procedure, within three months after the public offer, if following the public\noffer he contributes at least 95% of the class of shares and represents at least 95% of the total voting rights\nattached to these shares. A mandatory offer price is in principal deemed to be a reasonable price, which has to\nbe accepted by minority shareholders. In the event of a voluntary public offer, the offered price is considered\nreasonable as long as 90% of the shares have been acquired. Should the offeror's offer of a squeeze out not be\nforthcoming, then the minority shareholders that have not previously tendered their shares are also entitled to the\nright of a squeeze out, if the offeror has acquired at least 95% of the class of shares and at least 95% of the\nvoting rights attached thereto. With regard to price, the same procedure as for squeeze out proceedings applies.\n", "page_number": 105, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.44458707744972187, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.581086863500214, "height": 0.13649978605049212, "width": 0.7604355716878403}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-105-6", "text": "Notification of Holdings of Voting Rights and Capital Interest\n", "page_number": 105, "bounding_box": {"top_left_x": 0.12099213551119177, "top_left_y": 0.5952075310226786, "lower_right_x": 0.5656382335148216, "lower_right_y": 0.6089002995293111, "height": 0.01369276850663248, "width": 0.4446460980036298}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-105-7", "text": "   Pursuant to the Financial Supervision Act, certain notification requirements apply to us as well as to holders\nof our shares due to the fact that we are a listed company. The notification requirements are summarized below.\n", "page_number": 105, "bounding_box": {"top_left_x": 0.12159709618874773, "top_left_y": 0.6225930680359435, "lower_right_x": 0.8711433756805808, "lower_right_y": 0.6499786050492083, "height": 0.02738553701326485, "width": 0.7495462794918331}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-105-8", "text": "   Pursuant to the Financial Supervision Act, each person whose holding of voting rights and/or capital interest,\ndirectly or indirectly, amounts to 5% or more must notify the AFM without delay by means of a standard form\nor through the automated notification system of the AFM. Any person who, directly or indirectly, acquires or\ndisposes of an interest in our share capital or voting rights must without delay give written notice to the AFM, if,\nas a result of such acquisition or disposal, the percentage of capital interest or voting rights held by such person,\ndirectly or indirectly, reaches, exceeds or falls below the following thresholds: 5%, 10%, 15%, 20%, 25%, 30%,\n40%, 50%, 60%, 75% and 95%.\n", "page_number": 105, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.6636713735558408, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.7599486521181001, "height": 0.09627727856225932, "width": 0.7604355716878403}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-105-9", "text": "   We are required to notify the AFM of any changes in our share capital and voting rights. More specifically,\nwe are required to notify the AFM without delay of any changes in our share capital if our share capital has\nchanged by 1% or more compared to the previous disclosure in respect of our share capital. We are also required\nto notify the AFM without delay of any changes in the voting rights, insofar as it has not already been notified at\nthe same time as a related change in our share capital. Changes in our share capital and voting rights of less than\n1% must also be notified; these changes can be notified at any time but at the latest within eight days after the\nend of each calendar quarter. The AFM will publish such notifications in a public register. If, as a result of such\nchange, a person\u2019s direct or indirect interest in our share capital or voting rights passively reaches, exceeds or\nfalls below the abovementioned thresholds, the person in question must give notice to the AFM no later than the\n", "page_number": 105, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.7732135216089003, "lower_right_x": 0.8802177858439202, "lower_right_y": 0.8968763371844245, "height": 0.12366281557552417, "width": 0.7598306110102844}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-105-10", "text": "103\n", "page_number": 105, "bounding_box": {"top_left_x": 0.8560193587416818, "top_left_y": 0.9477963200684638, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9572100984167736, "height": 0.00941377834830981, "width": 0.024803387779794295}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-106-0", "text": "fourth trading day after the AFM has published the change in our share capital and/or voting rights in the public\nregister.\n", "page_number": 106, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.08515190415062045, "lower_right_x": 0.8753781004234725, "lower_right_y": 0.11296534017971759, "height": 0.02781343602909714, "width": 0.7549909255898367}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-106-1", "text": "   In addition, annually within four weeks after the end of the calendar year, every holder of 5% or more of our\nshares or voting rights whose interest has changed in the period after his most recent notification to the AFM,\nwhich change relates to the composition of the notification as a result of certain acts (e.g., the exchange of\nshares (an actual interest) for depositary receipts for shares (which is a potential interest) or the exercise of a\nright to acquire shares (pursuant to which the potential interest becomes an actual interest)) must notify the\nAFM of such changes.\n", "page_number": 106, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.12623020967051776, "lower_right_x": 0.8705384150030248, "lower_right_y": 0.20881471972614463, "height": 0.08258451005562686, "width": 0.7501512401693889}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-106-2", "text": "   A person is deemed to hold the interest in our share capital or voting rights that is held by its subsidiaries as\ndefined in the Financial Supervision Act. The subsidiary does not have a duty to notify the AFM because the\ninterest is attributed to the (ultimate) parent, which as a result has to notify the interest as an indirect interest.\nAny person, including an individual, may qualify as a parent for the purposes of the Financial Supervision Act.\nA person who has a 5% or larger interest in our share capital or voting rights and who ceases to be a subsidiary\nfor purposes of the Financial Supervision Act must without delay notify the AFM. As of that moment, all\nnotification obligations under the Financial Supervision Act will become applicable to the former subsidiary.\n", "page_number": 106, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.2220795892169448, "lower_right_x": 0.8711433756805808, "lower_right_y": 0.31835686777920413, "height": 0.09627727856225934, "width": 0.7507562008469449}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-106-3", "text": "   For the purpose of calculating the percentage of capital interest or voting rights, amongst others, the following\ninterests must be taken into account: (i) shares or depositary receipts for shares or voting rights directly held (or\nacquired or disposed of) by any person, (ii) shares or depositary receipts for shares or voting rights held (or\nacquired or disposed of) by such person\u2019s subsidiaries or by a third party for such person\u2019s account or by a third\nparty with whom such person has concluded an oral or written voting agreement (including a discretionary\npower of attorney), and (iii) shares or depositary receipts for shares or voting rights which such person, or any\nsubsidiary or third party referred to above, may acquire pursuant to any option or other right held by such person\n(including, but not limited to, on the basis of convertible bonds). As a consequence, the notification should\nindicate whether the interest is held directly or indirectly, and whether the interest is an actual or a potential\ninterest.\n", "page_number": 106, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.33162173727000427, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.4689773213521609, "height": 0.13735558408215665, "width": 0.7604355716878403}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-106-4", "text": "   A holder of a pledge or right of usufruct in respect of shares or depositary receipts for shares can also be\nsubject to the reporting obligations of the Financial Supervision Act, if such person has, or can acquire, the right\nto vote on the shares or, in the case of depositary receipts for shares, the underlying shares. If a pledgee or\nusufructuary acquires the voting rights on the shares or depositary receipts for shares, this may trigger a\ncorresponding reporting obligation for the holder of the shares or depositary receipts for shares. Special rules\napply with respect to the attribution of shares or depositary receipts for shares or voting rights which are part of\nthe property of a partnership or other community of property.\n", "page_number": 106, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.48224219084296105, "lower_right_x": 0.8753781004234725, "lower_right_y": 0.5785194694052204, "height": 0.09627727856225932, "width": 0.7549909255898367}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-106-5", "text": "  The Financial Supervision Act contains detailed rules that set out how its requirements apply to certain\ncategories of holders, including but not limited to (managers of) investment funds, investment managers,\ncustodians, market makers, clearing and settlement institutions, brokers and credit institutions.\n", "page_number": 106, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.5952075310226786, "lower_right_x": 0.8324258923169994, "lower_right_y": 0.6358579375267437, "height": 0.04065040650406504, "width": 0.7120387174833636}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-106-6", "text": "  Pursuant to the Financial Supervision Act, members of our Executive Board and Supervisory Board must\nnotify the AFM of their interest in our share capital and voting rights within two weeks of their appointment as a\nmember of our Executive Board or our Supervisory Board. Any subsequent change of their interest in our share\ncapital and voting rights must be notified to the AFM without delay.\n", "page_number": 106, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.6499786050492083, "lower_right_x": 0.8802177858439202, "lower_right_y": 0.7043217800599059, "height": 0.05434317501069752, "width": 0.7598306110102844}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-106-7", "text": "   The notifications referred to in this paragraph should be made in writing by means of a standard form or\nelectronically through the notification system of the AFM.\n", "page_number": 106, "bounding_box": {"top_left_x": 0.12159709618874773, "top_left_y": 0.7184424475823705, "lower_right_x": 0.837265577737447, "lower_right_y": 0.7462558836114677, "height": 0.02781343602909714, "width": 0.7156684815486993}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-106-8", "text": "Market Abuse Regime\n", "page_number": 106, "bounding_box": {"top_left_x": 0.12099213551119177, "top_left_y": 0.7595207531022679, "lower_right_x": 0.28554143980641256, "lower_right_y": 0.7732135216089003, "height": 0.01369276850663248, "width": 0.1645493042952208}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-106-9", "text": "   The rules on preventing market abuse set out in the Financial Supervision Act are applicable to us, the\nmembers of our Executive Board and Supervisory Board, other insiders and persons performing or conducting\ntransactions in our securities. Certain important market abuse rules set out in the Financial Supervision Act that\nare relevant for investors are described hereunder.\n", "page_number": 106, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.7869062901155327, "lower_right_x": 0.8705384150030248, "lower_right_y": 0.8399657680787335, "height": 0.05305947796320076, "width": 0.7501512401693889}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-106-10", "text": "  We are required to make inside information public. Inside information is information that is specific and\npertains directly or indirectly to us or our shares or the trading thereof: (a) which information has not been made\npublic and (b) where disclosure of such information could have a significant effect on the price of our shares or\nderivatives of our shares. We must also provide the AFM with this inside information at the time of publication.\n", "page_number": 106, "bounding_box": {"top_left_x": 0.12099213551119177, "top_left_y": 0.8553701326486949, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.9105691056910569, "height": 0.05519897304236199, "width": 0.7549909255898366}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-106-11", "text": "104\n", "page_number": 106, "bounding_box": {"top_left_x": 0.8560193587416818, "top_left_y": 0.9477963200684638, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9572100984167736, "height": 0.00941377834830981, "width": 0.024803387779794295}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-107-0", "text": "Furthermore, we must without delay publish the inside information on our website and keep it available on our\nwebsite for at least one year.\n", "page_number": 107, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.08515190415062045, "lower_right_x": 0.8663036902601331, "lower_right_y": 0.11253744116388532, "height": 0.027385537013264877, "width": 0.7459165154264973}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-107-1", "text": "   It is prohibited for any person to make use of inside information within or from the Netherlands or a non-\nEuropean Union member state by conducting or effecting a transaction in our shares. In addition, it is prohibited\nfor any person to pass on inside information to a third party or to recommend or induce, on the basis of inside\ninformation, any person to conduct a transaction. Furthermore, it is prohibited for any person to manipulate the\nmarket, for instance by conducting transactions which could lead to an incorrect or misleading signal of the\nsupply of, the demand for or the price of the securities.\n", "page_number": 107, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.12623020967051776, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.20838682071031236, "height": 0.0821566110397946, "width": 0.7555958862673926}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-107-2", "text": "   Our insiders within the meaning of the Financial Supervision Act are obliged to notify the AFM when they\ncarry out or cause to be carried out, for their own account, a transaction in our shares or in securities the value of\nwhich is at least in part determined by the value of our shares. Insiders within the meaning of the Financial\nSupervision Act in this respect are: (i) members of our Executive Board and our Supervisory Board, (ii) other\npersons who have a managerial position and in that capacity are authorized to make decisions which have\nconsequences for our future development and business prospects and who, on a regular basis, can have access to\ninside information relating, directly or indirectly, to us, and (iii) certain persons closely associated with the\npersons mentioned under (i) and (ii) designated by the Dutch Market Abuse Decree (Besluit marktmisbruik Wft).\n", "page_number": 107, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.2220795892169448, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.33204963628583656, "height": 0.10997004706889177, "width": 0.7604355716878403}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-107-3", "text": "   This notification must be made no later than the fifth business day after the transaction date on a standard\nform drawn up by the AFM. This notification obligation does not apply to transactions based on a discretionary\nmanagement agreement as described in section 8 of the Dutch Market Abuse Decree. Under certain\ncircumstances, the notification may be delayed until the date on which the value of the transactions amounts to\n\u20ac5,000 or more in the calendar year in question.\n", "page_number": 107, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.3453145057766367, "lower_right_x": 0.8711433756805808, "lower_right_y": 0.41420624732563116, "height": 0.06889174154899447, "width": 0.7507562008469449}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-107-4", "text": "   If a member of our Executive Board or Supervisory Board has notified a transaction to the AFM under the\nFinancial Supervision Act as described above under \u201cNotification of Holdings of Voting Rights and Capital\nInterest\u201d, such notification is sufficient for purposes of the Financial Supervision Act as described in this\nparagraph.\n", "page_number": 107, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.4274711168164313, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.4839537869062901, "height": 0.0564826700898588, "width": 0.7313974591651543}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-107-5", "text": "   We have adopted an internal code on inside information in respect of the holding of and carrying out of\ntransactions in our shares by the members of our Executive Board and Supervisory Board and our employees.\nFurther, we have drawn up a list of those persons working for the Company who could have access to inside\ninformation on a regular or incidental basis and we have informed the persons concerned of the rules on insider\ntrading and market manipulation including the sanctions which can be imposed in the event of a violation of\nthose rules.\n", "page_number": 107, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.4993581514762516, "lower_right_x": 0.8711433756805808, "lower_right_y": 0.5785194694052204, "height": 0.07916131792896874, "width": 0.7507562008469449}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-107-6", "text": "105\n", "page_number": 107, "bounding_box": {"top_left_x": 0.8560193587416818, "top_left_y": 0.9477963200684638, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9572100984167736, "height": 0.00941377834830981, "width": 0.024803387779794295}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-108-0", "text": "Market Information\n", "page_number": 108, "bounding_box": {"top_left_x": 0.39624924379915305, "top_left_y": 0.10226786478391099, "lower_right_x": 0.6049606775559588, "lower_right_y": 0.11596063329054343, "height": 0.013692768506632438, "width": 0.2087114337568058}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-108-1", "text": "Euronext Amsterdam\n", "page_number": 108, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.1364997860504921, "lower_right_x": 0.2807017543859649, "lower_right_y": 0.14848095849379547, "height": 0.011981172443303378, "width": 0.16031457955232908}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-108-2", "text": "  Our Shares are listed and traded on Euronext Amsterdam. We are subject to Dutch securities regulations and\nsupervision by the relevant Netherlands authorities.\n", "page_number": 108, "bounding_box": {"top_left_x": 0.12099213551119177, "top_left_y": 0.16388532306375694, "lower_right_x": 0.8705384150030248, "lower_right_y": 0.19169875909285408, "height": 0.02781343602909714, "width": 0.749546279491833}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-108-3", "text": "Market Regulation\n", "page_number": 108, "bounding_box": {"top_left_x": 0.12099213551119177, "top_left_y": 0.20624732563115106, "lower_right_x": 0.2613430127041742, "lower_right_y": 0.21908429610611896, "height": 0.012836970474967901, "width": 0.14035087719298245}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-108-4", "text": "   The AFM is the market regulator in the Netherlands and supervises market conduct of the parties active on\nthe securities markets. The AFM has supervisory powers with respect to the application of takeover regulations\nand compliance with financial reporting requirements. It also supervises financial intermediaries and investment\nadvisers. Since the implementation of the Prospectus Directive on 1 July 2005, the AFM is furthermore the\ncompetent authority for approving all prospectuses published for admission of securities to trading on Euronext\nAmsterdam, except for prospectuses approved in other European Economic Area states that are used in the\nNetherlands in accordance with applicable passporting rules. Due to the implementation of the Market Abuse\nDirective and related Commission Directives on 1 October 2005, the AFM has taken over from Euronext\nAmsterdam its supervisory powers with respect to publication of inside information by listed companies. The\nsurveillance unit of Euronext Amsterdam continues to monitor and supervise all trading operations.\n", "page_number": 108, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.23234916559691912, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.36970474967907574, "height": 0.13735558408215662, "width": 0.7555958862673926}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-108-5", "text": "106\n", "page_number": 108, "bounding_box": {"top_left_x": 0.8560193587416818, "top_left_y": 0.9477963200684638, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9572100984167736, "height": 0.00941377834830981, "width": 0.024803387779794295}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-109-0", "text": "Taxation\n", "page_number": 109, "bounding_box": {"top_left_x": 0.455535390199637, "top_left_y": 0.10226786478391099, "lower_right_x": 0.5462794918330308, "lower_right_y": 0.11596063329054343, "height": 0.013692768506632438, "width": 0.0907441016333938}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-109-1", "text": "This is a general summary and the tax consequences as described here may not apply to a holder of Shares. Any\npotential investor should consult his own tax adviser for more information about the tax consequences of\nacquiring, owning and disposing of Shares in his particular circumstances.\n", "page_number": 109, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.1364997860504921, "lower_right_x": 0.8765880217785844, "lower_right_y": 0.1775780915703894, "height": 0.0410783055198973, "width": 0.7610405323653963}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-109-2", "text": "Taxation in the Netherlands\n", "page_number": 109, "bounding_box": {"top_left_x": 0.12099213551119177, "top_left_y": 0.19127086007702182, "lower_right_x": 0.32425892316999394, "lower_right_y": 0.2032520325203252, "height": 0.011981172443303378, "width": 0.20326678765880218}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-109-3", "text": "   This taxation summary solely addresses the principal Dutch tax consequences of the acquisition, the\nownership and disposition of Shares. It does not consider every aspect of taxation that may be relevant to a\nparticular holder of Shares under special circumstances or who is subject to special treatment under applicable\nlaw. Where in this summary English terms and expressions are used to refer to Dutch concepts, the meaning to\nbe attributed to such terms and expressions shall be the meaning to be attributed to the equivalent Dutch\nconcepts under Dutch tax law. This summary also assumes that we are organised, and that our business will be\nconducted, in the manner outlined in this Prospectus. A change to such organizational structure or to the manner\nin which we conduct our business may invalidate the contents of this summary, which will not be updated to\nreflect any such change.\n", "page_number": 109, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.2186563970902867, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.3423192126658109, "height": 0.1236628155755242, "width": 0.7555958862673926}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-109-4", "text": "   This summary is based on the tax law of the Netherlands (unpublished case law not included) as it stands on\nthe date of this Prospectus. The law upon which this summary is based is subject to change, perhaps with\nretroactive effect. Any such change may invalidate the contents of this summary, which will not be updated to\nreflect such change.\n", "page_number": 109, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.355584082156611, "lower_right_x": 0.8663036902601331, "lower_right_y": 0.41078305519897307, "height": 0.05519897304236204, "width": 0.7459165154264973}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-109-5", "text": "Dutch Taxation \u2013 Taxes on Income and Capital Gains\n", "page_number": 109, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.4274711168164313, "lower_right_x": 0.5081669691470054, "lower_right_y": 0.44030808729139925, "height": 0.012836970474967957, "width": 0.3877797943133696}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-109-6", "text": "Resident Holders of Shares\n", "page_number": 109, "bounding_box": {"top_left_x": 0.11796733212341198, "top_left_y": 0.4548566538296962, "lower_right_x": 0.30973986690865096, "lower_right_y": 0.4685494223363286, "height": 0.013692768506632425, "width": 0.19177253478523898}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-109-7", "text": "General\n", "page_number": 109, "bounding_box": {"top_left_x": 0.1397459165154265, "top_left_y": 0.48224219084296105, "lower_right_x": 0.1984271022383545, "lower_right_y": 0.49293966623876767, "height": 0.010697475395806622, "width": 0.05868118572292799}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-109-8", "text": "  The summary set out in this section \u201cDutch Taxation \u2013 Taxes on Income and Capital Gains \u2013 Resident\nHolders of Shares\u201d only applies to a holder of Shares who is a \u201cDutch Individual\u201d or a \u201cDutch Corporate\nEntity\u201d.\n", "page_number": 109, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.5096277278562259, "lower_right_x": 0.8275862068965517, "lower_right_y": 0.5511339323919555, "height": 0.04150620453572962, "width": 0.7071990320629159}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-109-9", "text": "For the purposes of this section you are a \u201cDutch Individual\u201d if you satisfy the following tests:\n", "page_number": 109, "bounding_box": {"top_left_x": 0.13914095583787053, "top_left_y": 0.5643988018827557, "lower_right_x": 0.7743496672716274, "lower_right_y": 0.5785194694052204, "height": 0.014120667522464658, "width": 0.6352087114337568}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-109-10", "text": "a. you are an individual;\n\nb. you are resident, or deemed to be resident, in the Netherlands for Dutch income tax purposes, or you have\n   elected to be treated as a resident of the Netherlands for Dutch income tax purposes;\n\nc. your Shares and any benefits derived or deemed to be derived therefrom have no connection with your\n   past, present or future employment, if any; and\n\nd. your Shares do not form part of a substantial interest (aanmerkelijk belang) or a deemed substantial\n   interest in us within the meaning of Chapter 4 of the Dutch Income Tax Act 2001 (Wet\n   inkomstenbelasting 2001).\n", "page_number": 109, "bounding_box": {"top_left_x": 0.13490623109497882, "top_left_y": 0.5917843388960206, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.7454000855798032, "height": 0.15361574668378264, "width": 0.7410768300060496}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-109-11", "text": "  Generally, if a person holds an interest in us, such interest forms part of a substantial interest, or a deemed\nsubstantial interest, in us if any one or more of the following circumstances is present:\n", "page_number": 109, "bounding_box": {"top_left_x": 0.12159709618874773, "top_left_y": 0.7595207531022679, "lower_right_x": 0.8511796733212341, "lower_right_y": 0.7869062901155327, "height": 0.02738553701326485, "width": 0.7295825771324864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-109-12", "text": "1. Such person alone or, if he is an individual, together with his partner (partner, as defined in Article 1.2 of\n   the Dutch Income Tax Act 2001), if any, owns, directly or indirectly, a number of shares in us\n   representing 5% or more of our total issued and outstanding capital (or the issued and outstanding capital\n   of any class of our shares), or rights to acquire, directly or indirectly, shares, whether or not already\n   issued, representing 5% or more of our total issued and outstanding capital (or the issued and outstanding\n   capital of any class of our shares), or profit participating certificates (winstbewijzen) relating to 5% or\n   more of our annual profit or to 5% or more of our liquidation proceeds.\n", "page_number": 109, "bounding_box": {"top_left_x": 0.14035087719298245, "top_left_y": 0.8005990586221652, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.8964484381685922, "height": 0.09584937954642703, "width": 0.735632183908046}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-109-13", "text": "107\n", "page_number": 109, "bounding_box": {"top_left_x": 0.8560193587416818, "top_left_y": 0.9477963200684638, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9572100984167736, "height": 0.00941377834830981, "width": 0.024803387779794295}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-110-0", "text": "2. Such person's shares, profit participating certificates or rights to acquire shares or profit participating\n   certificates in us have been acquired by him or are deemed to have been acquired by him under a non-\n   recognition provision.\n\n3. Such person's partner or any of his relatives by blood or by marriage in the direct line (including foster-\n   children) or of those of his partner has a substantial interest (as described under 1. and 2. above) in us.\n", "page_number": 110, "bounding_box": {"top_left_x": 0.13490623109497882, "top_left_y": 0.08515190415062045, "lower_right_x": 0.8566243194192378, "lower_right_y": 0.16773641420624733, "height": 0.08258451005562688, "width": 0.721718088324259}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-110-1", "text": "   A person who is entitled to the benefits from shares or profit participating certificates (for instance a holder of\na right of usufruct) is deemed to be a holder of shares or profit participating certificates, as the case may be, and\nhis entitlement to benefits is considered a share or profit participating certificate, as the case may be.\n", "page_number": 110, "bounding_box": {"top_left_x": 0.12099213551119177, "top_left_y": 0.1810012836970475, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.22250748823277705, "height": 0.04150620453572956, "width": 0.7598306110102843}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-110-2", "text": "   If you are an individual and a holder of Shares and if you satisfy test b., but do not satisfy test c. and/or test\nd., your Dutch income tax position is not discussed in this Prospectus. If you are an individual and a holder of\nShares who does not satisfy test b., please refer to the section \u201cDutch Taxation \u2013 Taxes on Income and Capital\nGains \u2013 Non-Resident Holders of Shares\u201d.\n", "page_number": 110, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.23577235772357724, "lower_right_x": 0.8614640048396854, "lower_right_y": 0.29097133076593923, "height": 0.05519897304236199, "width": 0.7410768300060496}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-110-3", "text": "For the purposes of this section you are a \u201cDutch Corporate Entity\u201d if you satisfy the following tests:\n", "page_number": 110, "bounding_box": {"top_left_x": 0.13490623109497882, "top_left_y": 0.3076593923833975, "lower_right_x": 0.8179068360556564, "lower_right_y": 0.3209242618741977, "height": 0.01326486949080019, "width": 0.6830006049606776}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-110-4", "text": "i. you are a corporate entity (lichaam), including an association that is taxable as a corporate entity, that is\n   subject to Dutch corporation tax in respect of benefits derived from its Shares;\n\nii. you are resident, or deemed to be resident, in the Netherlands for Dutch corporation tax purposes;\n\niii. you are not an entity that, although in principle subject to Dutch corporation tax, is, in whole or in part,\n     specifically exempt from that tax; and\n\niv. you are not an investment institution (beleggingsinstelling) as defined in the Dutch Corporation Tax Act\n    1969 (Wet op de vennootschapsbelasting 1969).\n", "page_number": 110, "bounding_box": {"top_left_x": 0.13490623109497882, "top_left_y": 0.32135216089002994, "lower_right_x": 0.8656987295825771, "lower_right_y": 0.472400513478819, "height": 0.15104835258878907, "width": 0.7307924984875983}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-110-5", "text": "   If you are not an individual and a holder of Shares and if you do not satisfy any one or more of these tests,\nwith the exception of test ii., your Dutch corporation tax position is not discussed in this Prospectus. If you are\nnot an individual and a holder of Shares that does not satisfy test ii., please refer to the section \u201cDutch Taxation\n\u2013 Taxes on Income and Capital Gains \u2013 Non-Resident Holders of Shares\u201d.\n", "page_number": 110, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.4856653829696192, "lower_right_x": 0.8705384150030248, "lower_right_y": 0.5408643560119811, "height": 0.05519897304236193, "width": 0.7501512401693889}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-110-6", "text": "Dutch Individuals Deriving Profits or Deemed To Be Deriving Profits from an Enterprise\n", "page_number": 110, "bounding_box": {"top_left_x": 0.1355111917725348, "top_left_y": 0.5545571245186136, "lower_right_x": 0.7447065940713854, "lower_right_y": 0.5699614890885751, "height": 0.015404364569961526, "width": 0.6091954022988506}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-110-7", "text": "   If you are a Dutch Individual and if you derive or are deemed to derive any benefits from Shares, including\nany capital gain realised on the disposal thereof, that are attributable to an enterprise from which you derive\nprofits, whether as an entrepreneur (ondernemer) or pursuant to a co-entitlement to the net value of an\nenterprise, other than as a shareholder, such benefits are generally subject to Dutch income tax at progressive\nrates.\n", "page_number": 110, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.5849379546427044, "lower_right_x": 0.8614640048396854, "lower_right_y": 0.6499786050492083, "height": 0.06504065040650397, "width": 0.7410768300060496}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-110-8", "text": "Dutch Individuals Deriving Benefits from Miscellaneous Activities\n", "page_number": 110, "bounding_box": {"top_left_x": 0.13490623109497882, "top_left_y": 0.6670945656824989, "lower_right_x": 0.5856019358741682, "lower_right_y": 0.6803594351732991, "height": 0.01326486949080019, "width": 0.4506957047791894}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-110-9", "text": "  If you are a Dutch Individual and if you derive or are deemed to derive any benefits from Shares, including\nany gain realised on the disposal thereof, that constitute benefits from miscellaneous activities (resultaat uit\noverige werkzaamheden), such benefits are generally subject to Dutch income tax at progressive rates.\n", "page_number": 110, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.6944801026957638, "lower_right_x": 0.8614640048396854, "lower_right_y": 0.7355584082156611, "height": 0.04107830551989733, "width": 0.7410768300060496}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-110-10", "text": "   If you are a Dutch Individual you may, inter alia, derive benefits from Shares that are taxable as benefits from\nmiscellaneous activities if your investment activities go beyond the activities of an active portfolio investor, for\ninstance in the case of the use of insider knowledge (voorkennis) or comparable forms of special knowledge.\n", "page_number": 110, "bounding_box": {"top_left_x": 0.12159709618874773, "top_left_y": 0.7492511767222936, "lower_right_x": 0.8765880217785844, "lower_right_y": 0.7907573812580231, "height": 0.04150620453572951, "width": 0.7549909255898367}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-110-11", "text": "Other Dutch Individuals\n", "page_number": 110, "bounding_box": {"top_left_x": 0.1355111917725348, "top_left_y": 0.8040222507488233, "lower_right_x": 0.30490018148820325, "lower_right_y": 0.8164313222079589, "height": 0.012409071459135612, "width": 0.16938898971566846}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-110-12", "text": "   If you are a Dutch Individual and your situation has not been discussed before in this section \u201cDutch Taxation\n\u2013 Taxes on Income and Capital Gains \u2013 Resident Holders of Shares\u201d, benefits from your Shares are taxed as a\nbenefit from savings and investments (voordeel uit sparen en beleggen). Such benefit is deemed to be 4% per\nannum of the average of your \u201cyield basis\u201d (rendementsgrondslag) at the beginning and at the end of the year,\ninsofar as that average exceeds the \u201cexempt net asset amount\u201d (heffingvrij vermogen). The benefit is taxed at the\n", "page_number": 110, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.8314077877620881, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9002995293110826, "height": 0.06889174154899447, "width": 0.7604355716878403}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-110-13", "text": "108\n", "page_number": 110, "bounding_box": {"top_left_x": 0.8560193587416818, "top_left_y": 0.9477963200684638, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9572100984167736, "height": 0.00941377834830981, "width": 0.024803387779794295}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-111-0", "text": "rate of 30%. The value of your Shares forms part of your yield basis. Actual benefits derived from your Shares,\nincluding any gain realised on the disposal thereof, are not as such subject to Dutch income tax.\n", "page_number": 111, "bounding_box": {"top_left_x": 0.12159709618874773, "top_left_y": 0.08515190415062045, "lower_right_x": 0.8711433756805808, "lower_right_y": 0.11296534017971759, "height": 0.02781343602909714, "width": 0.7495462794918331}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-111-1", "text": "Dutch Corporate Entities\n", "page_number": 111, "bounding_box": {"top_left_x": 0.1355111917725348, "top_left_y": 0.12623020967051776, "lower_right_x": 0.30973986690865096, "lower_right_y": 0.14035087719298245, "height": 0.014120667522464686, "width": 0.17422867513611617}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-111-2", "text": "   If you are a Dutch Corporate Entity, any benefits derived or deemed to be derived by you from Shares,\nincluding any gain realised on the disposal thereof, are generally subject to Dutch corporation tax, except to the\nextent that the benefits are exempt under the participation exemption as laid down in the Dutch Corporation Tax\nAct 1969.\n", "page_number": 111, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.15361574668378264, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.20710312366281558, "height": 0.05348737697903294, "width": 0.7555958862673926}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-111-3", "text": "Non-Resident Holders of Shares\n", "page_number": 111, "bounding_box": {"top_left_x": 0.1161524500907441, "top_left_y": 0.2255027813436029, "lower_right_x": 0.3484573502722323, "lower_right_y": 0.23791185280273855, "height": 0.01240907145913564, "width": 0.2323049001814882}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-111-4", "text": "  The summary set out in this section \u201cDutch Taxation \u2013 Taxes on Income and Capital Gains \u2013 Non-Resident\nHolders of Shares\u201d only applies to a holder of Shares who is a Non-resident holder of Shares.\n", "page_number": 111, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.25288831835686776, "lower_right_x": 0.8644888082274652, "lower_right_y": 0.27941805733846814, "height": 0.02652973898160038, "width": 0.7441016333938294}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-111-5", "text": "For the purposes of this section, you are a \u201cNon-resident holder of Shares\u201d if you satisfy the following tests:\n", "page_number": 111, "bounding_box": {"top_left_x": 0.13611615245009073, "top_left_y": 0.2939666238767651, "lower_right_x": 0.8663036902601331, "lower_right_y": 0.3072314933675653, "height": 0.01326486949080019, "width": 0.7301875378100424}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-111-6", "text": "a. you are neither resident, nor deemed to be resident, in the Netherlands for purposes of Dutch income tax\n   or corporation tax, as the case may be, and, if you are an individual, you have not elected to be treated as a\n   resident of the Netherlands for Dutch income tax purposes;\n\nb. your Shares and any benefits derived or deemed to be derived therefrom have no connection with your\n   past, present or future employment or membership of an Executive Board (bestuurder) or a supervisory\n   board (commissaris);\n\nc. your Shares do not form part of a substantial interest or a deemed substantial interest in us within the\n   meaning of Chapter 4 of the Dutch Income Tax Act 2001, unless such interest forms part of the assets of\n   an enterprise;\n\nd. if you are not an individual, no part of the benefits derived from your Shares is exempt from Dutch\n   corporation tax under the participation exemption as laid down in the Dutch Corporation Tax Act 1969;\n   and\n\ne. you are not an entity that is resident in a Member State of the European Union and that is not subject to a\n   tax on profits levied there.\n", "page_number": 111, "bounding_box": {"top_left_x": 0.13490623109497882, "top_left_y": 0.32135216089002994, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.5699614890885751, "height": 0.2486093281985452, "width": 0.7459165154264973}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-111-7", "text": "   See the section \u201cDutch Taxation \u2013 Taxes on Income and Capital Gains \u2013 Resident Holders of Shares\u201d for a\ndescription of the circumstances under which Shares form part of a substantial interest or a deemed substantial\ninterest in us.\n", "page_number": 111, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.5849379546427044, "lower_right_x": 0.8663036902601331, "lower_right_y": 0.6230209670517758, "height": 0.038083012409071415, "width": 0.7459165154264973}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-111-8", "text": "  If you are a holder of Shares and you satisfy test a., but do not satisfy any one or more of tests b., c., d. and e.,\nyour Dutch income tax position or corporation tax position, as the case may be, is not discussed in this\nProspectus.\n", "page_number": 111, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.6397090286692341, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.6790757381258024, "height": 0.03936670945656828, "width": 0.7555958862673926}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-111-9", "text": "   If you are a Non-resident holder of Shares you will not be subject to any Dutch taxes on income or capital\ngains (other than the dividend withholding tax described below) in respect of any benefits derived or deemed to\nbe derived by you from Shares, including any capital gain realised on the disposal thereof, except if:\n\n  1. (i) you derive profits from an enterprise, as an entrepreneur (ondernemer) or pursuant to a co-entitlement\n     to the net value of such enterprise, other than as a shareholder, if you are an individual, or other than as a\n     holder of securities, if you are not an individual and (ii) such enterprise is either managed in the\n     Netherlands or carried on, in whole or in part, through a permanent establishment or a permanent\n     representative in the Netherlands and (iii) your Shares are attributable to such enterprise; or\n\n  2. you are an individual and you derive benefits from Shares that are taxable as benefits from miscellaneous\n     activities in the Netherlands.\n\n  See the section \u201cDutch Taxation \u2013 Taxes on Income and Capital Gains \u2013 Resident Holders of Shares\u201d for a\ndescription of the circumstances under which the benefits derived from Shares may be taxable as benefits from\n", "page_number": 111, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.6944801026957638, "lower_right_x": 0.8711433756805808, "lower_right_y": 0.9002995293110826, "height": 0.20581942661531882, "width": 0.7507562008469449}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-111-10", "text": "109\n", "page_number": 111, "bounding_box": {"top_left_x": 0.8560193587416818, "top_left_y": 0.9477963200684638, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9572100984167736, "height": 0.00941377834830981, "width": 0.024803387779794295}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-112-0", "text": "miscellaneous activities, on the understanding that such benefits will be taxable in the Netherlands only if such\nactivities are performed or deemed to be performed in the Netherlands.\n", "page_number": 112, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.08515190415062045, "lower_right_x": 0.8650937689050212, "lower_right_y": 0.11296534017971759, "height": 0.02781343602909714, "width": 0.7447065940713854}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-112-1", "text": "Dutch Taxation \u2013 Dividend Withholding Tax\n", "page_number": 112, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.12623020967051776, "lower_right_x": 0.4452510586811857, "lower_right_y": 0.14035087719298245, "height": 0.014120667522464686, "width": 0.3248638838475499}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-112-2", "text": "General\n", "page_number": 112, "bounding_box": {"top_left_x": 0.12099213551119177, "top_left_y": 0.15361574668378264, "lower_right_x": 0.17906836055656383, "lower_right_y": 0.1668806161745828, "height": 0.013264869490800163, "width": 0.05807622504537206}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-112-3", "text": "   We are generally required to withhold Dutch dividend withholding tax at a rate of 15% from dividends\ndistributed by us.\n", "page_number": 112, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.1810012836970475, "lower_right_x": 0.8324258923169994, "lower_right_y": 0.21052631578947367, "height": 0.029525032092426184, "width": 0.7120387174833636}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-112-4", "text": "  The concept \u201cdividends distributed by us\u2019 as used in this section \u201cDutch Taxation \u2013 Dividend Withholding\nTax\u201d includes, but is not limited to, the following:\n", "page_number": 112, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.2255027813436029, "lower_right_x": 0.8566243194192378, "lower_right_y": 0.25203252032520324, "height": 0.026529738981600326, "width": 0.736237144585602}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-112-5", "text": "distributions in cash or in kind, deemed and constructive distributions and repayments of capital not\nrecognised as paid-in for Dutch dividend withholding tax purposes;\n\nliquidation proceeds and proceeds of repurchase or redemption of shares in excess of the average capital\nrecognised as paid-in for Dutch dividend withholding tax purposes;\n\nthe par value of shares issued by us to a holder of Shares or an increase of the par value of shares, as the\ncase may be, to the extent that it does not appear that a contribution, recognised for Dutch dividend\nwithholding tax purposes, has been made or will be made; and\n\npartial repayment of capital, recognised as paid-in for Dutch dividend withholding tax purposes, if and to\nthe extent that there are net profits (zuivere winst), unless (a) the general meeting of our shareholders has\nresolved in advance to make such repayment and (b) the par value of the shares concerned has been\nreduced by an equal amount by way of an amendment to our articles of association.\n", "page_number": 112, "bounding_box": {"top_left_x": 0.16878402903811252, "top_left_y": 0.26658108686350024, "lower_right_x": 0.8802177858439202, "lower_right_y": 0.4587077449721866, "height": 0.19212665810868634, "width": 0.7114337568058077}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-112-6", "text": "\u00b7\n", "page_number": 112, "bounding_box": {"top_left_x": 0.1355111917725348, "top_left_y": 0.27000427899015833, "lower_right_x": 0.14519056261343014, "lower_right_y": 0.2768506632434745, "height": 0.0068463842533161845, "width": 0.009679370840895346}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-112-7", "text": "\u00b7\n", "page_number": 112, "bounding_box": {"top_left_x": 0.1355111917725348, "top_left_y": 0.3110825845100556, "lower_right_x": 0.14519056261343014, "lower_right_y": 0.31792896876337184, "height": 0.00684638425331624, "width": 0.009679370840895346}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-112-8", "text": "\u00b7\n", "page_number": 112, "bounding_box": {"top_left_x": 0.1355111917725348, "top_left_y": 0.35301668806161746, "lower_right_x": 0.14519056261343014, "lower_right_y": 0.3594351732991014, "height": 0.006418485237483951, "width": 0.009679370840895346}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-112-9", "text": "\u00b7\n", "page_number": 112, "bounding_box": {"top_left_x": 0.1355111917725348, "top_left_y": 0.40821566110397944, "lower_right_x": 0.14458560193587416, "lower_right_y": 0.41420624732563116, "height": 0.005990586221651717, "width": 0.009074410163339375}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-112-10", "text": "Dutch Individuals and Dutch Corporate Entities\n", "page_number": 112, "bounding_box": {"top_left_x": 0.1161524500907441, "top_left_y": 0.4719726144629867, "lower_right_x": 0.45795523290986084, "lower_right_y": 0.48609328198545143, "height": 0.014120667522464714, "width": 0.34180278281911675}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-112-11", "text": "   A Dutch Individual (other than an individual who is not resident or deemed to be resident in the Netherlands,\nbut who has elected to be treated as a resident of the Netherlands for Dutch income tax purposes) or a Dutch\nCorporate Entity generally can credit Dutch dividend withholding tax against his Dutch income tax or its Dutch\ncorporation tax liability, as the case may be, and generally is entitled to a refund in the form of a negative\nassessment of Dutch dividend withholding tax insofar as such tax, together with any other creditable domestic\nand/or foreign taxes, exceeds his aggregate Dutch income tax or its aggregate Dutch corporation tax liability, as\nthe case may be, provided that, in the case of a Dutch Corporate Entity, (i) the dividends distributed by us in\nrespect of which such dividend withholding tax is withheld are included in its taxable profits and (ii) it has\ntimely and duly filed a corporation tax return. In the case of a Dutch Corporate Entity for which dividends\ndistributed by us are not included in its taxable profits, the dividend withholding tax withheld thereon is\nrefunded upon a timely and duly filed request.\n", "page_number": 112, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.4993581514762516, "lower_right_x": 0.8711433756805808, "lower_right_y": 0.6504065040650406, "height": 0.15104835258878901, "width": 0.7507562008469449}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-112-12", "text": "   Pursuant to domestic rules to avoid dividend stripping, Dutch dividend withholding tax will only be\ncreditable by or refundable to the beneficial owner (uiteindelijk gerechtigde) of dividends distributed by us. A\nholder of Shares who receives proceeds therefrom shall not be recognised as the beneficial owner of such\nproceeds if, in connection with the receipt of the proceeds, it has given a consideration, in the framework of a\ncomposite transaction including, without limitation, the mere acquisition of one or more dividend coupons or the\ncreation of short-term rights of enjoyment of shares (kortlopende genotsrechten op aandelen), whereas it may be\npresumed that (i) such proceeds in whole or in part, directly or indirectly, inure to a person who would not have\nbeen entitled to an exemption from, reduction or refund of, or credit for, dividend withholding tax, or who\nwould have been entitled to a smaller reduction or refund of, or credit for, dividend withholding tax than the\nactual recipient of the proceeds; and (ii) such person acquires or retains, directly or indirectly, an interest in\nShares or similar instruments, comparable to its interest in Shares prior to the time the composite transaction\nwas first initiated.\n", "page_number": 112, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.6670945656824989, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.8275566966195977, "height": 0.16046213093709882, "width": 0.7604355716878403}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-112-13", "text": "   An individual who is not resident or deemed to be resident in the Netherlands, but who has elected to be\ntreated as a resident of the Netherlands for Dutch income tax purposes, may be eligible for relief from Dutch\ndividend withholding tax on the same conditions as an individual who is a Non-resident holder of Shares, as\ndiscussed below.\n", "page_number": 112, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.8451005562687206, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.8968763371844245, "height": 0.051775780915703895, "width": 0.7313974591651543}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-112-14", "text": "110\n", "page_number": 112, "bounding_box": {"top_left_x": 0.8560193587416818, "top_left_y": 0.9477963200684638, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9572100984167736, "height": 0.00941377834830981, "width": 0.024803387779794295}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-113-0", "text": "   See the section \u201cDutch Taxation \u2013 Dividend Withholding Tax \u2013 General\u201d for a description of the concept\n\u201cdividends distributed by us\u201d.\n", "page_number": 113, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.08515190415062045, "lower_right_x": 0.8463399879007865, "lower_right_y": 0.11296534017971759, "height": 0.02781343602909714, "width": 0.7259528130671506}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-113-1", "text": "  See the section \u201cDutch Taxation \u2013 Taxes on Income and Capital Gains \u2013 Resident Holders of Shares\u201d for a\ndescription of the terms Dutch Individual and Dutch Corporate Entity.\n", "page_number": 113, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.12623020967051776, "lower_right_x": 0.8560193587416818, "lower_right_y": 0.1540436456996149, "height": 0.02781343602909714, "width": 0.735632183908046}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-113-2", "text": "Non-Resident Holders of Shares\n", "page_number": 113, "bounding_box": {"top_left_x": 0.11796733212341198, "top_left_y": 0.16730851519041506, "lower_right_x": 0.3484573502722323, "lower_right_y": 0.18142918271287975, "height": 0.014120667522464686, "width": 0.2304900181488203}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-113-3", "text": "   If a Non-resident holder of Shares is resident in the Netherlands Antilles or Aruba or in a country that has\nconcluded a double taxation treaty with the Netherlands, such holder may be eligible for a full or partial relief\nfrom the dividend withholding tax, provided such relief is timely and duly claimed. Pursuant to domestic rules\nto avoid dividend stripping, dividend withholding tax relief will only be available to the beneficial owner of\ndividends distributed by us. The Dutch tax authorities have taken the position that this beneficial-ownership test\ncan also be applied to deny relief from dividend withholding tax under double tax treaties and the Tax\nArrangement for the Kingdom (Belastingregeling voor het Koninkrijk).\n", "page_number": 113, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.19469405220367994, "lower_right_x": 0.8753781004234725, "lower_right_y": 0.29097133076593923, "height": 0.09627727856225929, "width": 0.7549909255898367}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-113-4", "text": "   In addition, a Non-resident holder of Shares that is not an individual and that is resident in a Member State of\nthe European Union is entitled to an exemption from dividend withholding tax, provided that the following tests\nare satisfied:\n  1. it takes one of the legal forms listed in the Annex to the European Union Parent Subsidiary Directive\n       (Directive 90/435/EEC, as amended), or a legal form designated by ministerial decree;\n  2. any one or more of the following threshold conditions are satisfied:\n       a. at the time the dividend is distributed by us, it holds shares representing at least 5% of our nominal\n           paid up capital; or\n       b. it has held shares representing at least 5% of our nominal paid up capital for a continuous period of\n           more than one year at any time during the four years preceding the time the dividend is distributed by\n           us, provided that such period ended after 31 December 2006; or\n       c. it is connected with us within the meaning of article 10a, paragraph 4, of the Dutch Corporation Tax\n           Act; or\n       d. an entity connected with it within the meaning of article 10a, paragraph 4, of the Dutch Corporation\n           Tax Act holds at the time the dividend is distributed by us, shares representing at least 5% of our\n           nominal paid up capital;\n  3. it is subject to the tax levied in its country of residence as meant in article 2, paragraph 1, letter c, of the\n       European Union Parent Subsidiary Directive (Directive 90/435/EEC, as amended) without the possibility\n       of an option or of being exempt; and\n  4. it is not considered to be resident outside the Member States of the European Union under the terms of a\n       double taxation treaty concluded with a third State.\n", "page_number": 113, "bounding_box": {"top_left_x": 0.12159709618874773, "top_left_y": 0.3076593923833975, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.5922122379118528, "height": 0.28455284552845533, "width": 0.7543859649122807}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-113-5", "text": "   The exemption from dividend withholding tax is not available if pursuant to a provision for the prevention of\nfraud or abuse included in a double taxation treaty between the Netherlands and the country of residence of the\nNon-resident holder of Shares, such holder would not be entitled to the reduction of tax on dividends provided\nfor by such treaty. Furthermore, the exemption from dividend withholding tax will only be available to the\nbeneficial owner of dividends distributed by us. If a Non-resident holder of Shares is resident in a Member State\nof the European Union with which the Netherlands has concluded a double taxation treaty that provides for a\nreduction of tax on dividends based on the ownership of the number of voting rights, the test under 2.a. above is\nalso satisfied if such holder owns 5% of the voting rights in us.\n", "page_number": 113, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.6089002995293111, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.7175866495507061, "height": 0.10868635002139493, "width": 0.7555958862673926}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-113-6", "text": "  See the section \u201cDutch Taxation \u2013 Dividend Withholding Tax \u2013 Dutch Individuals and Dutch Corporate\nEntities\u201d for a description of the term beneficial owner.\n", "page_number": 113, "bounding_box": {"top_left_x": 0.12099213551119177, "top_left_y": 0.732135216089003, "lower_right_x": 0.837265577737447, "lower_right_y": 0.7586649550706034, "height": 0.02652973898160038, "width": 0.7162734422262552}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-113-7", "text": "   See the section\u201dDutch Taxation \u2013 Dividend Withholding Tax \u2013 General\u201d for a description of the concept\n\u201cdividends distributed by us\u201d.\n", "page_number": 113, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.7732135216089003, "lower_right_x": 0.8421052631578947, "lower_right_y": 0.8010269576379975, "height": 0.02781343602909714, "width": 0.7217180883242589}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-113-8", "text": "   See the section \u201cDutch Taxation \u2013 Taxes on Income and Capital Gains \u2013 Non-Resident Holders of Shares\u201d\nfor a description of the term Non-resident holder of Shares.\n", "page_number": 113, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.8142918271287976, "lower_right_x": 0.8566243194192378, "lower_right_y": 0.8421052631578947, "height": 0.02781343602909714, "width": 0.736237144585602}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-113-9", "text": "111\n", "page_number": 113, "bounding_box": {"top_left_x": 0.8560193587416818, "top_left_y": 0.9477963200684638, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9572100984167736, "height": 0.00941377834830981, "width": 0.024803387779794295}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-114-0", "text": "Dutch Taxation \u2013 Gift and Inheritance Taxes\n", "page_number": 114, "bounding_box": {"top_left_x": 0.12099213551119177, "top_left_y": 0.08515190415062045, "lower_right_x": 0.4452510586811857, "lower_right_y": 0.09713307659392384, "height": 0.011981172443303392, "width": 0.32425892316999394}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-114-1", "text": "   If you acquire Shares as a gift (in form or in substance) or if you acquire or are deemed to acquire Shares on\nthe death of an individual, you will not be subject to Dutch gift tax or to Dutch inheritance tax, as the case may\nbe, unless:\n", "page_number": 114, "bounding_box": {"top_left_x": 0.12159709618874773, "top_left_y": 0.11253744116388532, "lower_right_x": 0.8663036902601331, "lower_right_y": 0.15233204963628583, "height": 0.0397946084724005, "width": 0.7447065940713854}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-114-2", "text": "\u00b7   the donor is, or the deceased was, resident or deemed to be resident in the Netherlands for purposes of\n    gift or inheritance tax (as the case may be); or\n\n\u00b7   the Shares are or were attributable to an enterprise or part of an enterprise that the donor or deceased\n    carried on through a permanent establishment or a permanent representative in the Netherlands at the\n    time of the gift or of the death of the deceased; or\n\n\u00b7   the donor made a gift of Shares, then became a resident or deemed resident of the Netherlands, and died\n    as a resident or deemed resident of the Netherlands within 180 days of the date of the gift.\n", "page_number": 114, "bounding_box": {"top_left_x": 0.14035087719298245, "top_left_y": 0.16730851519041506, "lower_right_x": 0.8711433756805808, "lower_right_y": 0.2939666238767651, "height": 0.12665810868635002, "width": 0.7307924984875983}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-114-3", "text": "", "page_number": 114, "bounding_box": {"top_left_x": 0.1367211131276467, "top_left_y": 0.17458279845956354, "lower_right_x": 0.1397459165154265, "lower_right_y": 0.1775780915703894, "height": 0.0029952931108258585, "width": 0.003024803387779801}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-114-4", "text": "", "page_number": 114, "bounding_box": {"top_left_x": 0.1367211131276467, "top_left_y": 0.21566110397946084, "lower_right_x": 0.1397459165154265, "lower_right_y": 0.2186563970902867, "height": 0.0029952931108258585, "width": 0.003024803387779801}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-114-5", "text": "\u00b7\n", "page_number": 114, "bounding_box": {"top_left_x": 0.1355111917725348, "top_left_y": 0.27000427899015833, "lower_right_x": 0.1397459165154265, "lower_right_y": 0.27556696619597776, "height": 0.005562687205819428, "width": 0.004234724742891716}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-114-6", "text": "Dutch Taxation \u2013 Other Taxes and Duties\n", "page_number": 114, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.3076593923833975, "lower_right_x": 0.41984271022383546, "lower_right_y": 0.31835686777920413, "height": 0.010697475395806622, "width": 0.29945553539019965}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-114-7", "text": "   No Dutch registration tax, transfer tax, stamp duty or any other similar documentary tax or duty, other than\ncourt fees, is payable in the Netherlands by the holder of Shares in respect of or in connection with the\nsubscription, issue, placement, allotment, delivery of Shares, the delivery and/or enforcement by way of legal\nproceedings (including the enforcement of any foreign judgment in the courts of the Netherlands) of the\ndocuments relating to the issue of Shares or the performance by us of our obligations thereunder, or in respect of\nor in connection with the transfer of Shares.\n", "page_number": 114, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.33504492939666236, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.41420624732563116, "height": 0.0791613179289688, "width": 0.7604355716878403}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-114-8", "text": "Taxation in the United States\n", "page_number": 114, "bounding_box": {"top_left_x": 0.12099213551119177, "top_left_y": 0.43089430894308944, "lower_right_x": 0.33272837265577737, "lower_right_y": 0.441591784338896, "height": 0.010697475395806566, "width": 0.21173623714458562}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-114-9", "text": "   US Internal Revenue Service Circular 230 Notice: To ensure compliance with Internal Revenue Service\nCircular 230, prospective investors are hereby notified that: (a) any discussion of US federal tax issues\ncontained or referred to in this Prospectus or any document referred to herein is not intended or written to be\nused, and cannot be used by prospective investors for the purpose of avoiding penalties that may be imposed on\nthem under the US Internal Revenue Code; (b) such discussion is written for use in connection with the\npromotion or marketing of the transactions or matters addressed herein; and (c) prospective investors should\nseek advice based on their particular circumstances from an independent tax advisor.\n", "page_number": 114, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.4582798459563543, "lower_right_x": 0.8711433756805808, "lower_right_y": 0.5545571245186136, "height": 0.09627727856225932, "width": 0.7507562008469449}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-114-10", "text": "  The following summary describes the material US federal income tax consequences of the purchase,\nownership and disposition of our Shares as of the date of this prospectus.\n", "page_number": 114, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.5678219940094138, "lower_right_x": 0.8179068360556564, "lower_right_y": 0.5956354300385109, "height": 0.02781343602909714, "width": 0.6975196612220206}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-114-11", "text": "   Except where otherwise stated, this summary deals only with Shares held as a capital asset by a holder who is\na US holder (as defined below), purchases the Shares in the Offer, and does not own (directly or by attribution)\n10% or more of the voting power of all our outstanding Shares).\n", "page_number": 114, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.6089002995293111, "lower_right_x": 0.8753781004234725, "lower_right_y": 0.6504065040650406, "height": 0.04150620453572951, "width": 0.7549909255898367}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-114-12", "text": "A \u201cUS holder\u201d is a beneficial owner of our Shares that is for US Federal income tax purposes:\n", "page_number": 114, "bounding_box": {"top_left_x": 0.13793103448275862, "top_left_y": 0.6670945656824989, "lower_right_x": 0.7743496672716274, "lower_right_y": 0.6812152332049636, "height": 0.014120667522464658, "width": 0.6364186327888688}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-114-13", "text": "a citizen or resident of the United States;\n\na corporation or other entity treated as a corporation for US federal income tax purposes created or\norganized in or under the laws of the United States or any states within the United States or the District\nof Columbia;\n\nan estate the income of which is subject to US federal income taxation regardless of its source; or\n\na trust if it is subject to the primary supervision of a court within the United States and one or more US\npersons have the authority to control all substantial decisions of the trust, or has a valid election in effect\nunder applicable US Treasury regulations to be treated as a US person.\n", "page_number": 114, "bounding_box": {"top_left_x": 0.16878402903811252, "top_left_y": 0.6944801026957638, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.8455284552845529, "height": 0.15104835258878913, "width": 0.7071990320629159}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-114-14", "text": "\u00b7\n", "page_number": 114, "bounding_box": {"top_left_x": 0.1355111917725348, "top_left_y": 0.6979032948224219, "lower_right_x": 0.14519056261343014, "lower_right_y": 0.7047496790757382, "height": 0.0068463842533162955, "width": 0.009679370840895346}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-114-15", "text": "\u00b7\n", "page_number": 114, "bounding_box": {"top_left_x": 0.1355111917725348, "top_left_y": 0.7252888318356868, "lower_right_x": 0.14519056261343014, "lower_right_y": 0.732135216089003, "height": 0.0068463842533161845, "width": 0.009679370840895346}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 16, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-114-16", "text": "\u00b7\n", "page_number": 114, "bounding_box": {"top_left_x": 0.1355111917725348, "top_left_y": 0.7809157038938811, "lower_right_x": 0.14519056261343014, "lower_right_y": 0.787334189131365, "height": 0.006418485237483895, "width": 0.009679370840895346}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 17, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-114-17", "text": "\u00b7\n", "page_number": 114, "bounding_box": {"top_left_x": 0.1355111917725348, "top_left_y": 0.8087291399229781, "lower_right_x": 0.14458560193587416, "lower_right_y": 0.8147197261446298, "height": 0.005990586221651717, "width": 0.009074410163339375}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 18, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-114-18", "text": "   If a partnership (or other entity treated as a partnership for US federal income tax purposes) holds Shares, the\ntax treatment of a partner will generally depend upon the status of the partner and the activities of the\npartnership. If you are a partner of a partnership that acquires the Shares, you should consult your tax advisor.\n", "page_number": 114, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.858793324775353, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.9002995293110826, "height": 0.04150620453572962, "width": 0.7555958862673926}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 19, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-114-19", "text": "112\n", "page_number": 114, "bounding_box": {"top_left_x": 0.8560193587416818, "top_left_y": 0.9477963200684638, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9572100984167736, "height": 0.00941377834830981, "width": 0.024803387779794295}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-115-0", "text": "   US taxation is often dependent on the taxpayer\u2019s particular situation, and each US holder is encouraged to\nconsult his or her own tax advisor. This summary does not address all the tax consequences that may be relevant\nto holders that are subject to special tax treatment, such as:\n", "page_number": 115, "bounding_box": {"top_left_x": 0.12159709618874773, "top_left_y": 0.08515190415062045, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.12665810868635002, "height": 0.04150620453572958, "width": 0.7592256503327284}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-115-1", "text": "\u00b7   dealers in securities or currencies;\n\n\u00b7   financial institutions;\n\n\u00b7   tax-exempt investors;\n\n\u00b7   traders in securities that elect to use a mark-to-market method of accounting for their securities holdings;\n\n\u00b7   persons liable for alternative minimum tax;\n\n\u00b7   insurance companies;\n\n\u00b7   real estate investment trusts;\n\n\u00b7   regulated investment companies;\n\n\u00b7   persons holding Shares as part of a hedging, conversion, integrated or constructive sale transaction;\n\n\u00b7   persons holding ordinary shares as part of a straddle; or\n\n\u00b7   US holders whose functional currency is not the US dollar.\n", "page_number": 115, "bounding_box": {"top_left_x": 0.13490623109497882, "top_left_y": 0.1399229781771502, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.4338896020539153, "height": 0.2939666238767651, "width": 0.7410768300060496}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-115-2", "text": "   This summary is based on the Internal Revenue Code of 1986, as amended (the \u201cInternal Revenue Code\u201d),\nthe Treasury Regulations promulgated under the Internal Revenue Code and administrative and judicial\ninterpretations. These income tax laws, regulations and interpretations, however, may change at any time,\npossibly with retroactive effect.\n", "page_number": 115, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.44801026957637996, "lower_right_x": 0.8566243194192378, "lower_right_y": 0.5027813436029097, "height": 0.054771074026529754, "width": 0.736237144585602}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-115-3", "text": "   This summary does not address state, local, foreign or other tax laws. This summary is not intended to be, nor\nshould it be construed to be, legal, business or tax advice to any particular shareholder. Accordingly, US holders\nshould consult their own tax advisors with respect to the US federal, state, and local tax consequences and the\nforeign tax consequences to them of the ownership of Shares.\n", "page_number": 115, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.5164741121095422, "lower_right_x": 0.8765880217785844, "lower_right_y": 0.5716730851519042, "height": 0.05519897304236199, "width": 0.7562008469449486}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-115-4", "text": "Disposition of Shares\n", "page_number": 115, "bounding_box": {"top_left_x": 0.1161524500907441, "top_left_y": 0.5849379546427044, "lower_right_x": 0.2710223835450696, "lower_right_y": 0.599058622165169, "height": 0.014120667522464658, "width": 0.15486993345432548}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-115-5", "text": "    In general, subject to the \u201cPassive Foreign Investment Company Considerations\u201d discussed below and unless\nan exception set forth in the Internal Revenue Code applies, a sale or exchange of our Shares will give rise to\ntaxable capital gain or loss equal to the amount by which the adjusted tax basis of the Shares sold or exchanged\nis less or more than the amount realized by the US holder on the disposition. Capital gains of non-corporate\ntaxpayers on dispositions of Shares held for more than one year generally will be subject to tax at a maximum\nrate of 15% if such gain is recognized prior to 1 January 2011. Any gain or loss on Shares held by a US holder\nfor less than one year will be treated as short-term capital gain or loss, with gain generally taxed at ordinary\nincome rates. The tax basis of the Shares will be the amount of cash paid to acquire them. The deductibility of\ncapital losses is subject to limitations.\n", "page_number": 115, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.6123234916559692, "lower_right_x": 0.8753781004234725, "lower_right_y": 0.7359863072314934, "height": 0.12366281557552417, "width": 0.7549909255898367}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-115-6", "text": "Dividends on Shares\n", "page_number": 115, "bounding_box": {"top_left_x": 0.1161524500907441, "top_left_y": 0.7526743688489517, "lower_right_x": 0.2661826981246219, "lower_right_y": 0.7633718442447582, "height": 0.010697475395806566, "width": 0.15003024803387782}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-115-7", "text": "   Dividends from a \u201cqualified foreign corporation\u201d are currently taxable in the United States at the maximum\nrate of 15% for non-corporate taxpayers if certain conditions are satisfied (including certain holding period\nrequirements and that the corporation does not qualify as a PFIC). That rate is scheduled to expire at the end of\n2010, after which dividends will be taxed at the same rate as ordinary income. We believe that we are a\nqualified foreign corporation; however, we have not sought or received an opinion of counsel or a ruling from\nthe IRS to that effect. No assurance can be given that a court would not ultimately determine that we are not a\nqualified foreign corporation. If we were not a qualified foreign corporation, our dividends would be taxable as\nordinary income at rates up to 35%.\n", "page_number": 115, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.7800599058622165, "lower_right_x": 0.8711433756805808, "lower_right_y": 0.8887462558836114, "height": 0.10868635002139493, "width": 0.7507562008469449}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-115-8", "text": "113\n", "page_number": 115, "bounding_box": {"top_left_x": 0.8560193587416818, "top_left_y": 0.9477963200684638, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9572100984167736, "height": 0.00941377834830981, "width": 0.024803387779794295}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-116-0", "text": "    Subject to the \u201cPassive Foreign Investment Company Considerations\u201d below, for US federal income tax\npurposes, distributions paid by us will be taxable as dividends to the extent of our current and accumulated\nearnings and profits. Such dividends generally will be foreign source income. Any further distributions are first\ntreated as tax-free return of basis and then as capital gain. If the dividend has been subject to withholding taxes\nin the country of origin, the US holder may be able to claim a credit for such taxes or may be able to claim a\ndeduction in lieu of such credit. Special rules apply in determining the foreign tax credit limitation with respect\nto dividends that are subject to the maximum 15% tax rate. The US holder will be required to include in income\nits amount of foreign taxes withheld. The dividend will not be eligible for the dividends received deduction\ngenerally allowed to US corporations in respect of dividends received from other US corporations. US holders\nshould consult their own tax advisers with respect to the appropriate US federal income tax treatment of any\ndistribution received from us.\n", "page_number": 116, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.08515190415062045, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.23277706461275138, "height": 0.14762516046213092, "width": 0.7555958862673926}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-116-1", "text": "Passive Foreign Investment Company Considerations\n", "page_number": 116, "bounding_box": {"top_left_x": 0.11857229280096794, "top_left_y": 0.24946512623020967, "lower_right_x": 0.49304295220810646, "lower_right_y": 0.2635857937526744, "height": 0.014120667522464714, "width": 0.37447065940713853}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-116-2", "text": "   A corporation organized outside the United States generally will be classified as a \u201cpassive foreign\ninvestment company\u201d (\u201cPFIC\u201d), for US federal income tax purposes in any taxable year in which, after applying\ncertain look-through rules, either: (i) at least 75% of its gross income is \u201cpassive income\u201d, or (ii) on average, at\nleast 50% of the gross value of its assets is attributable to assets that produce \u201cpassive income\u201d or are held for\nthe production of passive income. Passive income for this purpose generally includes dividends, interest,\nroyalties, rents, annuities, the excess of gains over losses from commodities and securities transactions, and the\nexcess of gains over losses from the disposition of assets which produce passive income. For purposes of\napplying the foregoing tests, the assets and gross income of a company\u2019s significant direct, and indirect,\nsubsidiaries are attributed to the company. We do not believe that we are now, nor do we expect to become, a\nPFIC, but this conclusion is a factual determination that generally cannot be determined until the close of the\ntaxable year in question and is made annually (based in part upon the value of our assets and ordinary shares)\nand thus may be subject to change. We have not sought or obtained an independent appraisal of our assets and\nbusiness. No assurance can be offered that our conclusions as to the values of our assets will not be challenged\nby the US Internal Revenue Service (\u201cIRS\u201d) or that a court might not ultimately sustain such a challenge. We\nhave neither sought nor obtained any advance ruling from the IRS regarding the US federal income tax\nconsequences of any of the transactions described in this prospectus. If we were to be a PFIC in any year,\nmaterially adverse consequences as described below could result for US holders. US holders are urged to\nconsult their own tax advisers regarding the possibility of us being classified as a PFIC and the potential tax\nconsequences arising from the ownership and disposition of an interest in a PFIC.\n", "page_number": 116, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.2768506632434745, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.537441163885323, "height": 0.2605905006418485, "width": 0.7555958862673926}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-116-3", "text": "   If we were a PFIC in any year during which a US holder owned Shares and the US holder did not make, or\nhave in effect, one of the elections described below, the US holder would generally be subject to special rules\n(regardless of whether we continued to be a PFIC) with respect to (i) any \u201cexcess distribution\u201d (generally,\ndistributions received by the US holder in a taxable year in excess of 125% of the average annual distributions\nreceived by that US holder in the three preceding taxable years, or, if shorter, the US holder\u2019s holding period),\nand (ii) any gain realized on the sale, retirement or other disposition of Shares. Under these rules, (a) the excess\ndistribution or gain would be allocated ratably over the US holder\u2019s holding period, (b) the amount allocated to\nthe current taxable year and any taxable year prior to the first taxable year in which we were a PFIC would be\ntaxed as ordinary income, and (c) the amount allocated to each of the prior taxable years would be subject to US\nfederal income tax at the highest rate of tax in effect for the taxpayer for that year plus an interest charge on the\namount of tax deemed to be deferred.\n", "page_number": 116, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.5507060333761232, "lower_right_x": 0.8741681790683605, "lower_right_y": 0.699614890885751, "height": 0.1489088575096278, "width": 0.7537810042347247}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-116-4", "text": "    Certain elections enable the Shareholder in a PFIC to avoid these consequences. A US holder makes a\nQualified Electing Fund (\u201cQEF\u201d) election for a taxable year by properly filing and completing a Form 8621 with\nits tax return for such year. The effect of such election is that the US holder generally will be currently taxable\non its pro rata share of a company\u2019s ordinary earnings and net capital gains (at ordinary income and capital gains\nrates, respectively) for each taxable year of such company in which it is classified as a PFIC, even if no dividend\ndistributions are received by such US holder, unless such US holder makes an election to defer such taxes.\n", "page_number": 116, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.7150192554557124, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.7976037655113393, "height": 0.08258451005562684, "width": 0.7604355716878403}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-116-5", "text": "   A QEF election may only be made by US holders of Shares if we provide such holders with certain\ninformation that allows such holders to report and pay any current or deferred taxes due with respect to their pro\nrata shares of our net ordinary earnings and net capital gains for such taxable year. If we determine that we are a\nPFIC for a taxable year, we may or may not provide such information. US holders should consult their tax\nadvisors concerning the merits and mechanics of making a QEF election and other relevant tax considerations if\nwe are a PFIC for any taxable year.\n", "page_number": 116, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.8108686350021395, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.8934531450577664, "height": 0.08258451005562695, "width": 0.7555958862673926}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-116-6", "text": "114\n", "page_number": 116, "bounding_box": {"top_left_x": 0.8560193587416818, "top_left_y": 0.9477963200684638, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9572100984167736, "height": 0.00941377834830981, "width": 0.024803387779794295}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-117-0", "text": "   If a US holder does not make a QEF election for the first year that a company is a PFIC, the US holder may\nlater elect QEF status, as described above, and if it does so, may also elect to \u201cpurge\u201d such company\u2019s PFIC\ntaint. A US taxpayer\u2019s \u201cpurge election\u201d must be made as to its PFIC shares held as of the qualification date (see\nbelow) by also attaching a Form 8621 to the tax return for the US holder\u2019s taxable year that includes the\nqualification date. The qualification date is the first day of the US holder\u2019s taxable year for which it elects to\ntreat the PFIC as a QEF. The election may cause the US holder to recognize taxable gain as if the ordinary\nshares had been sold.\n", "page_number": 117, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.08515190415062045, "lower_right_x": 0.8705384150030248, "lower_right_y": 0.17800599058622166, "height": 0.09285408643560121, "width": 0.7501512401693889}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-117-1", "text": "   If we were a PFIC, a US holder who does not make a QEF election may be able to avoid taxation and interest\ncharges under the PFIC regime by making a mark-to-market election with respect to their Shares, provided that\nthe Shares are regularly traded on a qualifying securities exchange within the meaning of the applicable\nTreasury Regulations. The mark-to-market election requires a US holder to include as ordinary income each\ntaxable year an amount equal to the excess, if any, of the fair market value of the ordinary shares at the close of\nthe tax year over the shareholder\u2019s adjusted basis in the ordinary shares. Similarly, an electing US holder may\ndeduct the excess, if any, of the US holder\u2019s adjusted basis in the ordinary shares over their fair market value at\nthe close of each tax year. However, the US holder\u2019s deduction is limited to the net mark-to-market gains\n(reduced by any prior deductions) that the US holder has included in income from the ordinary shares in\nprevious tax years. US holders should consult their tax advisers regarding the availability and consequences of a\nmark-to-market election.\n", "page_number": 117, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.19469405220367994, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.3427471116816431, "height": 0.14805305947796318, "width": 0.7555958862673926}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-117-2", "text": "Information Reporting and Backup Withholding\n", "page_number": 117, "bounding_box": {"top_left_x": 0.1161524500907441, "top_left_y": 0.3590072742832692, "lower_right_x": 0.45977011494252873, "lower_right_y": 0.37312794180573383, "height": 0.014120667522464658, "width": 0.34361766485178463}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-117-3", "text": "For a non-corporate US holder, information reporting requirements, on IRS Form 1099, generally will apply\n", "page_number": 117, "bounding_box": {"top_left_x": 0.13914095583787053, "top_left_y": 0.386392811296534, "lower_right_x": 0.868723532970357, "lower_right_y": 0.40051347881899874, "height": 0.014120667522464714, "width": 0.7295825771324864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-117-4", "text": "to:\n\n  \u00b7   payments of dividends or other taxable distributions made within the United States; and\n\n  \u00b7   the payment of proceeds from the sale of Shares effected at a US office of a broker.\n", "page_number": 117, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.40350877192982454, "lower_right_x": 0.7622504537205081, "lower_right_y": 0.4711168164313222, "height": 0.06760804450149765, "width": 0.6418632788868723}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-117-5", "text": "  Additionally, backup withholding may apply to these payments if the non-corporate US holder fails to\nprovide an accurate taxpayer identification number or certification of exempt status or fails to report all interest\nand dividends required to be shown on its US federal income tax returns.\n", "page_number": 117, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.4856653829696192, "lower_right_x": 0.8711433756805808, "lower_right_y": 0.5267436884895165, "height": 0.041078305519897274, "width": 0.7507562008469449}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-117-6", "text": "   Payment of the proceeds from the sale of Shares effected at a foreign office of a broker generally will not be\nsubject to information reporting or backup withholding. However, a sale of Shares that is effected at a foreign\noffice of a broker will be subject to information reporting and backup withholding if:\n", "page_number": 117, "bounding_box": {"top_left_x": 0.12099213551119177, "top_left_y": 0.540436456996149, "lower_right_x": 0.8663036902601331, "lower_right_y": 0.5819426615318785, "height": 0.04150620453572951, "width": 0.7453115547489413}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-117-7", "text": "\u00b7   the proceeds are transferred to an account maintained by the holder in the United States;\n\n\u00b7   the payment of proceeds or the confirmation of the sale is mailed to the holder at a US address; or\n\n\u00b7   the sale has some other specified connection with the United States as provided in Treasury Regulations;\n", "page_number": 117, "bounding_box": {"top_left_x": 0.13490623109497882, "top_left_y": 0.5952075310226786, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.6640992725716731, "height": 0.06889174154899447, "width": 0.7410768300060496}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-117-8", "text": "  unless the broker does not have actual knowledge or reason to know that the holder is a US person and the\ndocumentation requirements described above are met or the holder otherwise establishes an exemption.\n", "page_number": 117, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.6807873341891314, "lower_right_x": 0.8566243194192378, "lower_right_y": 0.7086007702182285, "height": 0.02781343602909714, "width": 0.736237144585602}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-117-9", "text": "   In addition, a sale of Shares effected at a foreign office of a broker will be subject to information reporting if\nthe broker is:\n", "page_number": 117, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.7218656397090286, "lower_right_x": 0.8711433756805808, "lower_right_y": 0.7462558836114677, "height": 0.024390243902439046, "width": 0.7507562008469449}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-117-10", "text": "\u00b7   a US person;\n\n\u00b7   a controlled foreign corporation for US tax purposes;\n\n\u00b7   a foreign person 50% or more of whose gross income is effectively connected with the conduct of a US\n    trade or business for a specified three-year period; or\n\n\u00b7   a foreign partnership, if at any time during its tax year, one or more of its partners are \u201cUS persons\u201d, as\n    defined in Treasury Regulations, who in the aggregate hold more than 50% of the income or capital\n    interest in the partnership; or such foreign partnership is engaged in the conduct of a US trade or\n    business;\n", "page_number": 117, "bounding_box": {"top_left_x": 0.13490623109497882, "top_left_y": 0.762943945228926, "lower_right_x": 0.8663036902601331, "lower_right_y": 0.9139922978177151, "height": 0.15104835258878913, "width": 0.7313974591651543}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-117-11", "text": "115\n", "page_number": 117, "bounding_box": {"top_left_x": 0.8560193587416818, "top_left_y": 0.9477963200684638, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9572100984167736, "height": 0.00941377834830981, "width": 0.024803387779794295}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-118-0", "text": "unless the broker does not have actual knowledge or reason to know that the holder is a US person and the\ndocumentation requirements described above are met or the holder otherwise establishes an exemption. Backup\nwithholding will apply if the sale is subject to information reporting and the broker has actual knowledge or\nreason to know that the holder is a US person.\n", "page_number": 118, "bounding_box": {"top_left_x": 0.12099213551119177, "top_left_y": 0.08515190415062045, "lower_right_x": 0.8705384150030248, "lower_right_y": 0.14035087719298245, "height": 0.055198973042362, "width": 0.749546279491833}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-118-1", "text": "   The backup withholding tax is imposed at a rate of 28%. Backup withholding is not an additional tax and will\nbe credited against the US holder\u2019s US federal income tax liability or refunded to the US holder, provided that\nthe required information is furnished to the IRS.\n", "page_number": 118, "bounding_box": {"top_left_x": 0.12159709618874773, "top_left_y": 0.15361574668378264, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.19426615318784768, "height": 0.04065040650406504, "width": 0.7543859649122807}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-118-2", "text": "   The above summary of US federal income tax consequences is for general information only and is not\nintended to constitute a complete analysis of all US income tax consequences relating to US holders of\ntheir acquisition, ownership and disposition of the Shares. All prospective purchasers should consult their\ntax advisers as to the particular tax consequences to them of owning the Shares, including the\napplicability and effect of state, local, foreign and other tax laws and possible changes in tax law.\n", "page_number": 118, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.20838682071031236, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.2772785622593068, "height": 0.06889174154899444, "width": 0.7604355716878403}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-118-3", "text": "116\n", "page_number": 118, "bounding_box": {"top_left_x": 0.8560193587416818, "top_left_y": 0.9477963200684638, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9572100984167736, "height": 0.00941377834830981, "width": 0.024803387779794295}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-119-0", "text": "The Offer\n", "page_number": 119, "bounding_box": {"top_left_x": 0.4500907441016334, "top_left_y": 0.10226786478391099, "lower_right_x": 0.5517241379310345, "lower_right_y": 0.11596063329054343, "height": 0.013692768506632438, "width": 0.10163339382940106}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-119-1", "text": "Introduction\n", "page_number": 119, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.1364997860504921, "lower_right_x": 0.21294615849969753, "lower_right_y": 0.14890885750962773, "height": 0.01240907145913564, "width": 0.09255898366606172}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-119-2", "text": "   The Offer consists of an offering of up to \u20ac25 million in Offer Shares by us. The Offer consists of a public\noffering in the Netherlands and an international offering to institutional investors in certain other jurisdictions.\n", "page_number": 119, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.16388532306375694, "lower_right_x": 0.8614640048396854, "lower_right_y": 0.19169875909285408, "height": 0.02781343602909714, "width": 0.7410768300060496}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-119-3", "text": "  The Offer Price will be determined on the basis of a book-building process, as further described below under\n\u201cOffer Price and Number of Offer Shares\u201d. Existing shareholders will not have pre-emptive rights.\n", "page_number": 119, "bounding_box": {"top_left_x": 0.12099213551119177, "top_left_y": 0.20496362858365424, "lower_right_x": 0.8705384150030248, "lower_right_y": 0.23277706461275138, "height": 0.02781343602909714, "width": 0.749546279491833}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-119-4", "text": "The Offer Shares offered in the Offer will be issued on the Settlement Date.\n", "page_number": 119, "bounding_box": {"top_left_x": 0.13490623109497882, "top_left_y": 0.24604193410355157, "lower_right_x": 0.6485178463399879, "lower_right_y": 0.2593068035943517, "height": 0.013264869490800135, "width": 0.5136116152450091}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-119-5", "text": "The rights of holders of Shares (including the Offer Shares) will rank pari passu with each other.\n", "page_number": 119, "bounding_box": {"top_left_x": 0.13914095583787053, "top_left_y": 0.2768506632434745, "lower_right_x": 0.793708408953418, "lower_right_y": 0.28968763371844247, "height": 0.012836970474967957, "width": 0.6545674531155474}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-119-6", "text": "  We have granted to the Underwriters an option, exercisable within 30 calendar days after the Listing Date,\npursuant to which the Underwriters may require us to issue additional Offer Shares at the Offer Price for an\namount up to 15% of the amount of the Offer. For more information on the Overallotment Option, see\n\u201cUnderwriting \u2013 Overallotment Option\u201d.\n", "page_number": 119, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.3042362002567394, "lower_right_x": 0.8566243194192378, "lower_right_y": 0.3585793752674369, "height": 0.054343175010697464, "width": 0.736237144585602}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-119-7", "text": "  Our Shares are listed and traded on Euronext Amsterdam under the symbol \u201cOCTO\u201d and ISIN Code\nNL0000345718. We shall apply for admission of the Offer Shares to listing and trading on Euronext\nAmsterdam.\n", "page_number": 119, "bounding_box": {"top_left_x": 0.1161524500907441, "top_left_y": 0.37056054771074026, "lower_right_x": 0.8179068360556564, "lower_right_y": 0.41078305519897307, "height": 0.040222507488232806, "width": 0.7017543859649122}, "blob_type": "paragraph", "predictions": {}, "annotations": {"isin": ["NL0000345718"], "ticker": ["OCTO"]}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-119-8", "text": "Timetable\n", "page_number": 119, "bounding_box": {"top_left_x": 0.12099213551119177, "top_left_y": 0.4274711168164313, "lower_right_x": 0.19358741681790684, "lower_right_y": 0.4381685922122379, "height": 0.010697475395806622, "width": 0.07259528130671507}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-119-9", "text": "The timetable below lists certain expected key dates for the Offer.\n", "page_number": 119, "bounding_box": {"top_left_x": 0.1355111917725348, "top_left_y": 0.4548566538296962, "lower_right_x": 0.5831820931639443, "lower_right_y": 0.4689773213521609, "height": 0.014120667522464714, "width": 0.4476709013914095}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-119-10", "text": "Time and Date\n12 November 2007 09:00 (Amsterdam time)\n27 November 2007 16:00 (Amsterdam time)\n27 November 2007\n3 December 2007\n3 December 2007\n", "page_number": 119, "bounding_box": {"top_left_x": 0.5753176043557169, "top_left_y": 0.4856653829696192, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.5626872058194267, "height": 0.07702182284980746, "width": 0.30066545674531153}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-119-11", "text": "", "page_number": 119, "bounding_box": {"top_left_x": 0.12220205686630368, "top_left_y": 0.4856653829696192, "lower_right_x": 0.1542649727767695, "lower_right_y": 0.4895164741121095, "height": 0.003851091142490326, "width": 0.032062915910465825}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-119-12", "text": "Event\nBeginning of subscription period in the Netherlands\nEnd of subscription period in the Netherlands\nExpected allotment of Offer Shares\nListing Date\nSettlement Date\n", "page_number": 119, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.4899443731279418, "lower_right_x": 0.4694494857834241, "lower_right_y": 0.5639709028669234, "height": 0.0740265297389816, "width": 0.3490623109497883}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-119-13", "text": "The timetable for the Offer is subject to acceleration or extension.\n", "page_number": 119, "bounding_box": {"top_left_x": 0.13490623109497882, "top_left_y": 0.5780915703893881, "lower_right_x": 0.5807622504537205, "lower_right_y": 0.5922122379118528, "height": 0.01412066752246477, "width": 0.44585601935874175}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-119-14", "text": "   Any acceleration or extension of the timetable for the Offer will be announced in a press release (together\nwith any related revision of the expected dates of pricing, allocation and closing), in the event of an accelerated\ntimetable for the Offer, at least three hours before the proposed expiration of the accelerated timetable for the\nOffer or, in the event of an extended timetable for the Offer, at least three hours before the expiration of the\noriginal timetable for the Offer. Any extension of the timetable for the Offer will be for a minimum of one full\ntrading day.\n", "page_number": 119, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.6054771074026529, "lower_right_x": 0.8711433756805808, "lower_right_y": 0.6902011125374412, "height": 0.08472400513478828, "width": 0.7507562008469449}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-119-15", "text": "Offer Price and Number of Offer Shares\n", "page_number": 119, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.7047496790757382, "lower_right_x": 0.4101633393829401, "lower_right_y": 0.7154471544715447, "height": 0.010697475395806566, "width": 0.28977616454930427}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 16, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-119-16", "text": "   The Offer Price will be determined on the basis of a book-building process and on the basis of the quoted\nshare price as well as the demand in the Offer. The definitive Offer Price and the actual number of Offer Shares\noffered in the Offer will be determined by negotiations between us and the Underwriters, taking into account\nmarket conditions, a qualitative assessment of demand for the Offer Shares and any other factors deemed\nappropriate.\n", "page_number": 119, "bounding_box": {"top_left_x": 0.12099213551119177, "top_left_y": 0.732135216089003, "lower_right_x": 0.8705384150030248, "lower_right_y": 0.8001711596063329, "height": 0.06803594351732989, "width": 0.749546279491833}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 17, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-119-17", "text": "   The Offer Price, the actual number of Offer Shares and the Offer proceeds will be published in a pricing\nstatement on or about 28 November 2007 which will be deposited with the AFM and be published in the Daily\nOfficial List and in a national newspaper distributed daily in the Netherlands. The pricing statement will also be\nplaced on our website at www.octoplus.nl and you should access this information as soon as it is available.\n", "page_number": 119, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.8142918271287976, "lower_right_x": 0.8753781004234725, "lower_right_y": 0.8690629011553274, "height": 0.05477107402652981, "width": 0.7549909255898367}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 18, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-119-18", "text": "117\n", "page_number": 119, "bounding_box": {"top_left_x": 0.8560193587416818, "top_left_y": 0.9477963200684638, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9572100984167736, "height": 0.00941377834830981, "width": 0.024803387779794295}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-120-0", "text": "Subscription\n", "page_number": 120, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.08515190415062045, "lower_right_x": 0.21294615849969753, "lower_right_y": 0.09841677364142062, "height": 0.013264869490800177, "width": 0.09255898366606172}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-120-1", "text": " The subscription period for prospective investors is expected to begin on 12 November 2007 at 09:00\nAmsterdam time and end on 27 November 2007 at 16:00 Amsterdam time.\n", "page_number": 120, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.11253744116388532, "lower_right_x": 0.822746521476104, "lower_right_y": 0.13821138211382114, "height": 0.025673940949935817, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-120-2", "text": "   Subscriptions can be submitted at the branches of the Underwriters, as described in more detail below, at no\ncost to the investor. Subscriptions are not binding upon us if they are not accepted, as discussed in more detail\nunder \u201cAllotment\u201d below. Investors wishing to subscribe through intermediaries other than the Underwriters\nshould request details of the costs which these intermediaries may charge and which they will have to pay\nthemselves.\n", "page_number": 120, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.15361574668378264, "lower_right_x": 0.8663036902601331, "lower_right_y": 0.22122379118528027, "height": 0.06760804450149763, "width": 0.7459165154264973}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-120-3", "text": "   Only one application form per investor will be accepted. If Cowen, Kempen & Co or SNS Securities\ndetermines, or has reason to believe, that a single investor has submitted several orders, through one or more\ninstitutions, it may disregard such orders.\n", "page_number": 120, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.23577235772357724, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.2772785622593068, "height": 0.04150620453572956, "width": 0.7313974591651543}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-120-4", "text": "  Investors are invited to introduce their orders as soon as possible with the Underwriters. Except in the event\nwhere an amendment to this Prospectus were to be published prior to the closing of the Offer, subscriptions\ncannot be reduced or withdrawn.\n", "page_number": 120, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.2939666238767651, "lower_right_x": 0.8663036902601331, "lower_right_y": 0.33162173727000427, "height": 0.03765511339323918, "width": 0.7459165154264973}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-120-5", "text": "Retail Investors\n", "page_number": 120, "bounding_box": {"top_left_x": 0.13490623109497882, "top_left_y": 0.34873769790329484, "lower_right_x": 0.24742891712038717, "lower_right_y": 0.3594351732991014, "height": 0.010697475395806566, "width": 0.11252268602540835}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-120-6", "text": "   Retail investors must indicate in their orders the number of Offer Shares they commit to subscribe to. Retail\ninvestors can only subscribe for the Offer Shares at the Offer Price, see \u201cThe Offer \u2013 Offer Price and Number of\nOffer Shares\u201d. Retail investors can submit their subscriptions to Kempen & Co through their own admitted\ninstitution.\n", "page_number": 120, "bounding_box": {"top_left_x": 0.12099213551119177, "top_left_y": 0.3761232349165597, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.4278990158322636, "height": 0.051775780915703895, "width": 0.7598306110102843}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-120-7", "text": "Institutional Investors\n", "page_number": 120, "bounding_box": {"top_left_x": 0.13732607380520268, "top_left_y": 0.44458707744972187, "lower_right_x": 0.294615849969752, "lower_right_y": 0.45656824989302525, "height": 0.011981172443303378, "width": 0.1572897761645493}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-120-8", "text": "   Institutional investors must indicate in their orders the number of Offer Shares they commit to subscribe for,\nand the price (within the Price Range) at which they are making such orders. Institutional investors can submit\ntheir subscriptions to the Underwriters.\n", "page_number": 120, "bounding_box": {"top_left_x": 0.12159709618874773, "top_left_y": 0.4719726144629867, "lower_right_x": 0.8693284936479129, "lower_right_y": 0.5126230209670518, "height": 0.040650406504065095, "width": 0.7477313974591652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-120-9", "text": "Allotment\n", "page_number": 120, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.5267436884895165, "lower_right_x": 0.19358741681790684, "lower_right_y": 0.5395806589644844, "height": 0.012836970474967901, "width": 0.07320024198427103}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-120-10", "text": "   The allotment is expected to take place on the Allotment Date, which is expected to be on or about 27\nNovember 2007, subject to acceleration or extension of the timetable for the Offer. Other investors may receive\na smaller number of Offer Shares than subscribed for, or none at all. The Underwriters may, at their own\ndiscretion and without stating the grounds, reject any subscriptions of investors wholly or partly. In the event\nthat the Offer Shares are oversubscribed, preferential treatment may be given to orders submitted by investors at\nthe branches of the Underwriters rather than through other financial intermediaries.\n", "page_number": 120, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.5541292255027813, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.6367137355584083, "height": 0.08258451005562695, "width": 0.7555958862673926}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-120-11", "text": "   We expect to announce the Offer Price, the Offer proceeds and the numbers of Offer Shares allocated to\ninvestors under the Offer on or about 28 November 2007. Concurrently with such announcement, we will\npublish a pricing statement which will state the Offer Price and the aggregate number of Offer Shares and to be\nissued by us in the Daily Official List and in a national newspaper distributed daily in the Netherlands. The\npricing statement will also be placed on our website at www.octoplus.nl and you should access this information\nas soon as it is available.\n", "page_number": 120, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.6534017971758665, "lower_right_x": 0.8711433756805808, "lower_right_y": 0.7325631151048353, "height": 0.07916131792896874, "width": 0.7507562008469449}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-120-12", "text": "   Investors will be informed by their intermediaries of the number of Offer Shares allotted to them shortly after\nthe Listing Date.\n", "page_number": 120, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.7492511767222936, "lower_right_x": 0.8753781004234725, "lower_right_y": 0.7762088147197261, "height": 0.02695763799743256, "width": 0.7549909255898367}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-120-13", "text": "Joint Global Coordinators and Joint Bookrunners\n", "page_number": 120, "bounding_box": {"top_left_x": 0.12099213551119177, "top_left_y": 0.7903294822421908, "lower_right_x": 0.4839685420447671, "lower_right_y": 0.8010269576379975, "height": 0.010697475395806677, "width": 0.3629764065335753}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-120-14", "text": "   Cowen and Kempen & Co are acting as Joint Global Coordinators and Joint Bookrunners in connection with\nthe Offer.\n", "page_number": 120, "bounding_box": {"top_left_x": 0.12099213551119177, "top_left_y": 0.8177150192554558, "lower_right_x": 0.8711433756805808, "lower_right_y": 0.842533162173727, "height": 0.024818142918271224, "width": 0.7501512401693889}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-120-15", "text": "118\n", "page_number": 120, "bounding_box": {"top_left_x": 0.8560193587416818, "top_left_y": 0.9477963200684638, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9572100984167736, "height": 0.00941377834830981, "width": 0.024803387779794295}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-121-0", "text": "Listing Agent and Paying Agent\n", "page_number": 121, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.08515190415062045, "lower_right_x": 0.35329703569267995, "lower_right_y": 0.09927257167308515, "height": 0.0141206675224647, "width": 0.23290986085904414}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-121-1", "text": "   Kempen & Co N.V. is the Listing Agent and Fortis Bank (Nederland) N.V. is the Paying Agent with respect\nto the listing and trading of our Shares on Euronext Amsterdam. The addresses of the Listing and the Paying\nAgent are:\n", "page_number": 121, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.11253744116388532, "lower_right_x": 0.8663036902601331, "lower_right_y": 0.15361574668378264, "height": 0.041078305519897315, "width": 0.7459165154264973}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-121-2", "text": "Kempen & Co N.V.\n", "page_number": 121, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.16859221223791185, "lower_right_x": 0.25468844525105866, "lower_right_y": 0.181857081728712, "height": 0.013264869490800163, "width": 0.13430127041742285}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-121-3", "text": "Beethovenstraat 300\n", "page_number": 121, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.1822849807445443, "lower_right_x": 0.2577132486388385, "lower_right_y": 0.19426615318784768, "height": 0.011981172443303378, "width": 0.13732607380520268}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-121-4", "text": "Beethovenstraat 300\n1077 WZ Amsterdam\n", "page_number": 121, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.19554985023534446, "lower_right_x": 0.26678765880217786, "lower_right_y": 0.2079589216944801, "height": 0.01240907145913564, "width": 0.14640048396854205}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-121-5", "text": "1077 WZ Amster\nThe Netherlands\n", "page_number": 121, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.2092426187419769, "lower_right_x": 0.23169993950393225, "lower_right_y": 0.22122379118528027, "height": 0.011981172443303378, "width": 0.11131276467029644}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-121-6", "text": "Fortis Bank (Nederland) N.V.\n", "page_number": 121, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.24261874197689345, "lower_right_x": 0.323653962492438, "lower_right_y": 0.25673940949935814, "height": 0.014120667522464686, "width": 0.20326678765880218}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-121-7", "text": "Rokin 55\n", "page_number": 121, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.259734702610184, "lower_right_x": 0.1839080459770115, "lower_right_y": 0.27043217800599056, "height": 0.010697475395806566, "width": 0.06352087114337568}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-121-8", "text": "1012 KK Amsterdam\n", "page_number": 121, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.2768506632434745, "lower_right_x": 0.2661826981246219, "lower_right_y": 0.28754813863928114, "height": 0.010697475395806622, "width": 0.1457955232909861}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-121-9", "text": "The Netherlands\n", "page_number": 121, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.2939666238767651, "lower_right_x": 0.23169993950393225, "lower_right_y": 0.30466409927257165, "height": 0.010697475395806566, "width": 0.11131276467029644}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-121-10", "text": "Payment, Delivery, Clearing and Settlement\n", "page_number": 121, "bounding_box": {"top_left_x": 0.12099213551119177, "top_left_y": 0.32135216089002994, "lower_right_x": 0.4398064125831821, "lower_right_y": 0.33504492939666236, "height": 0.013692768506632425, "width": 0.31881427707199034}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-121-11", "text": "  Payment for the Offer Shares, and payment for any Offer Shares subject to the Overallotment Option\nprovided this option has been exercised prior to the Settlement Date, will take place on the Settlement Date.\n", "page_number": 121, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.34873769790329484, "lower_right_x": 0.8469449485783425, "lower_right_y": 0.3761232349165597, "height": 0.02738553701326485, "width": 0.7265577737447066}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-121-12", "text": "  The Shares will be ordinary shares in registered form (aandelen op naam) which are entered into the\ncollection deposit (verzameldepot) and/or giro deposit (girodepot) on the basis of the Securities Giro Act (Wet\nGiraal Effectenverkeer). Application has been made for the Shares to be accepted for clearance through the\nbook-entry facilities of Euroclear Netherlands.\n", "page_number": 121, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.3898160034231921, "lower_right_x": 0.8644888082274652, "lower_right_y": 0.4450149764655541, "height": 0.05519897304236199, "width": 0.7441016333938294}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-121-13", "text": "   Delivery of the Offer Shares is expected to take place on or about 3 December 2007 (the Settlement Date)\nthrough the book-entry facilities of Euroclear Netherlands only, in accordance with its normal settlement\nprocedures applicable to equity securities and against payment for the Offer Shares in immediately available\nfunds.\n", "page_number": 121, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.4582798459563543, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.5109114249037228, "height": 0.052631578947368474, "width": 0.7313974591651543}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-121-14", "text": "  There are certain restrictions on the transfer of our registered book-entry shares, as detailed in \u201cSelling\nRestrictions\u201d and \u201cTransfer Restrictions\u201d.\n", "page_number": 121, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.5267436884895165, "lower_right_x": 0.8324258923169994, "lower_right_y": 0.5545571245186136, "height": 0.02781343602909714, "width": 0.7120387174833636}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-121-15", "text": "Ranking and Dividends\n", "page_number": 121, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.5712451861360719, "lower_right_x": 0.29038112522686027, "lower_right_y": 0.5840821566110398, "height": 0.012836970474967901, "width": 0.16999395039322446}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 16, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-121-16", "text": "   Should the Executive Board decide in the future to grant a dividend, the rights of holders of the Shares will\nrank pari passu with each other. See \u201cDividend Policy\u201d.\n", "page_number": 121, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.5986307231493367, "lower_right_x": 0.8614640048396854, "lower_right_y": 0.6260162601626016, "height": 0.02738553701326485, "width": 0.7410768300060496}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 17, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-121-17", "text": "Listing and Trading of Offer Shares\n", "page_number": 121, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.6397090286692341, "lower_right_x": 0.382335148215366, "lower_right_y": 0.6534017971758665, "height": 0.01369276850663248, "width": 0.2619479733817302}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 18, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-121-18", "text": "  We expect that listing and trading in our Offer Shares offered in the Offer on Euronext Amsterdam will\ncommence on the Settlement Date on which the closing of the Offer and delivery of the Offer Shares is\nscheduled to take place, which is expected to be on or about 3 December 2007.\n", "page_number": 121, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.6670945656824989, "lower_right_x": 0.837265577737447, "lower_right_y": 0.7081728712023962, "height": 0.04107830551989733, "width": 0.7168784029038112}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 19, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-121-19", "text": "   The closing of the Offer may not take place on the Settlement Date or at all if certain conditions or events\nreferred to in the Underwriting Agreement (see \u201cUnderwriting\u201d) are not satisfied or waived or occur on or prior\nto such date. Such conditions include the receipt of officers\u2019 certificates and legal opinions and such events\ninclude the suspension of trading on Euronext Amsterdam or other international market or a material adverse\nchange in our financial condition or business affairs or in the financial markets. If closing of the Offer does not\ntake place on the Settlement Date or at all, the Offer will be withdrawn, all subscriptions for the Offer Shares\nwill be disregarded, any allotments made will be deemed not to have been made and any subscription payments\nmade will be returned without interest or other compensation.\n", "page_number": 121, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.7218656397090286, "lower_right_x": 0.8711433756805808, "lower_right_y": 0.8314077877620881, "height": 0.10954214805305951, "width": 0.7507562008469449}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 20, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-121-20", "text": "119\n", "page_number": 121, "bounding_box": {"top_left_x": 0.8560193587416818, "top_left_y": 0.9477963200684638, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9572100984167736, "height": 0.00941377834830981, "width": 0.024803387779794295}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-122-0", "text": "Underwriting\n", "page_number": 122, "bounding_box": {"top_left_x": 0.4307320024198427, "top_left_y": 0.10226786478391099, "lower_right_x": 0.5710828796128251, "lower_right_y": 0.11895592640136927, "height": 0.016688061617458283, "width": 0.1403508771929824}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-122-1", "text": "Underwriting Agreement\n", "page_number": 122, "bounding_box": {"top_left_x": 0.12099213551119177, "top_left_y": 0.1364997860504921, "lower_right_x": 0.3024803387779794, "lower_right_y": 0.15062045357295678, "height": 0.014120667522464686, "width": 0.18148820326678766}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-122-2", "text": "   We and the Underwriters are expected to enter into an underwriting agreement no later than at the Pricing\nDate, which is expected to take place on 27 November 2007 with respect to the Offer Shares being offered.\nSubject to the terms and conditions of the underwriting agreement, each Underwriter is expected to severally\nagree to purchase from us the percentage of Offer Shares set forth opposite its name below. Cowen International\nLimited and Kempen & Co are Joint Global Coordinators and Joint Bookrunners and acting as the\nrepresentatives of the Underwriters.\n", "page_number": 122, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.16388532306375694, "lower_right_x": 0.8765880217785844, "lower_right_y": 0.2468977321352161, "height": 0.08301240907145915, "width": 0.7562008469449486}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-122-3", "text": "                 Percentage of\nUnderwriter        the Offer\nCowen                50%\nKempen & Co          35%\nSNS Securities       15%\nTotal                100%\n", "page_number": 122, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.24732563115104836, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.3303380402225075, "height": 0.08301240907145915, "width": 0.7652752571082879}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-122-4", "text": "   The Offer consists of a public offering in the Netherlands and an international offering to institutional\ninvestors in certain other jurisdictions. Cowen International Limited and Kempen & Co N.V., through their\nrespective selling agents, Cowen and Company, LLC and Kempen & Co USA Inc., propose to resell Offer\nShares in the United States to QIBs in reliance on Rule 144A. Any offers or sales of Offer Shares in reliance on\nRule 144A will be made by broker-dealers registered as such under the US Securities and Exchange Act of\n1934, as amended (the \u201cExchange Act\u201d).\n", "page_number": 122, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.34873769790329484, "lower_right_x": 0.8699334543254689, "lower_right_y": 0.4313222079589217, "height": 0.08258451005562684, "width": 0.7495462794918331}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-122-5", "text": "  The underwriting agreement provides that, upon the occurrence of certain events, such as a suspension or\nmaterial limitation in trading in securities generally on the New York Stock Exchange, the Nasdaq Global\nMarket, the London Stock Exchange or Euronext Amsterdam, a material loss or interference with our business,\nany change or development in or affecting our condition (financial or otherwise), the results of our operations,\nour assets, our management or our business in a material adverse way, or certain other conditions, the\nUnderwriters have the right, collectively but not individually, not to proceed with the consummation of the\nOffer.\n", "page_number": 122, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.44458707744972187, "lower_right_x": 0.868723532970357, "lower_right_y": 0.537441163885323, "height": 0.09285408643560117, "width": 0.7483363581367212}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-122-6", "text": "   The Underwriters have agreed, severally and not jointly, to purchase all of the Offer Shares sold under the\nunderwriting agreement if any of these Offer Shares are purchased, other than those Offer Shares covered by the\nOverallotment Option described below. If an Underwriter defaults, the underwriting agreement provides that the\npurchase commitments of the non-defaulting Underwriters may be increased or the underwriting agreement may\nbe terminated.\n", "page_number": 122, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.5541292255027813, "lower_right_x": 0.8784029038112523, "lower_right_y": 0.621737270004279, "height": 0.06760804450149771, "width": 0.7580157289776165}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-122-7", "text": "   We have agreed that we shall indemnify and hold harmless each Underwriter, its directors, officers,\nmanagers, members, employees, representatives, agents, controlling persons and affiliates, against any loss,\nclaim, damage, expense or liability whatsoever (or any action, investigation or proceeding in respect thereof),\njoint or several, to which such person may become subject under applicable securities laws or otherwise insofar\nas such loss, claim, damage, expense, liability, action, investigation or proceeding arises out of or is based upon,\namongst others, an untrue statement or omission, or alleged untrue statement or omission, of a material fact in\nthis Prospectus.\n", "page_number": 122, "bounding_box": {"top_left_x": 0.11736237144585603, "top_left_y": 0.6367137355584083, "lower_right_x": 0.8753781004234725, "lower_right_y": 0.7325631151048353, "height": 0.09584937954642703, "width": 0.7580157289776165}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-122-8", "text": "  The Underwriters are offering the Offer Shares, subject to prior sale, when, as and if issued to and accepted\nby them, subject to approval of legal matters by their counsel and other conditions specified in the underwriting\nagreement. The Underwriters reserve the right to withdraw, cancel or modify offers to the public and to reject\norders in whole or in part.\n", "page_number": 122, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.7492511767222936, "lower_right_x": 0.8711433756805808, "lower_right_y": 0.8031664527171587, "height": 0.05391527599486512, "width": 0.7507562008469449}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-122-9", "text": "Overallotment Option\n", "page_number": 122, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.8177150192554558, "lower_right_x": 0.2807017543859649, "lower_right_y": 0.8314077877620881, "height": 0.013692768506632369, "width": 0.16031457955232908}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-122-10", "text": "   The Underwriters may require us to issue additional Offer Shares at the Offer Price for an amount up to 15%\nof the amount of the Offer. This option is exercisable for a period of 30 days after the Listing Date. The\nUnderwriters may exercise this option for any purpose in accordance with applicable law, including for\npurposes of covering overallotments, if any, made in connection with the sale of Offer Shares offered hereby or\n", "page_number": 122, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.8451005562687206, "lower_right_x": 0.8711433756805808, "lower_right_y": 0.8998716302952503, "height": 0.0547710740265297, "width": 0.7507562008469449}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-122-11", "text": "120\n", "page_number": 122, "bounding_box": {"top_left_x": 0.8560193587416818, "top_left_y": 0.9477963200684638, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9572100984167736, "height": 0.00941377834830981, "width": 0.024803387779794295}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-123-0", "text": "in subsequent transactions. To the extent that the Underwriters exercise this option, the Underwriters will\npurchase additional Offer Shares from us in approximately the same proportion as shown in the table above.\n", "page_number": 123, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.08515190415062045, "lower_right_x": 0.8511796733212341, "lower_right_y": 0.11296534017971759, "height": 0.02781343602909714, "width": 0.7307924984875983}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-123-1", "text": "Fees and Commissions\n", "page_number": 123, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.12623020967051776, "lower_right_x": 0.28554143980641256, "lower_right_y": 0.14035087719298245, "height": 0.014120667522464686, "width": 0.16515426497277674}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-123-2", "text": "   The Underwriting Agreement provides that we shall pay to the Underwriters a fixed commission of 4.25% of\nthe gross proceeds of the Offer. In addition, we shall pay to the Underwriters an incentive fee of 0.25% of the\ngross proceeds of the Offer, which we will allocate among the Underwriters at our discretion, within 10 business\ndays following the Listing Date.\n", "page_number": 123, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.15361574668378264, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.20881471972614463, "height": 0.05519897304236199, "width": 0.7604355716878403}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-123-3", "text": "  We estimate that the total expenses of the Offer, excluding underwriting fees and commissions, will be\napproximately \u20ac1.0 million and are payable by us.\n", "page_number": 123, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.2220795892169448, "lower_right_x": 0.8324258923169994, "lower_right_y": 0.24989302524604193, "height": 0.02781343602909714, "width": 0.7120387174833636}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-123-4", "text": "The Underwriters propose to offer the Offer Shares at the Offer Price.\n", "page_number": 123, "bounding_box": {"top_left_x": 0.13914095583787053, "top_left_y": 0.26658108686350024, "lower_right_x": 0.6091954022988506, "lower_right_y": 0.27941805733846814, "height": 0.012836970474967901, "width": 0.47005444646098005}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-123-5", "text": "Stabilization\n", "page_number": 123, "bounding_box": {"top_left_x": 0.12099213551119177, "top_left_y": 0.2939666238767651, "lower_right_x": 0.21294615849969753, "lower_right_y": 0.30466409927257165, "height": 0.010697475395806566, "width": 0.09195402298850576}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-123-6", "text": "   In connection with the Offer, the Underwriters, through Kempen & Co acting as stabilization manager or its\naffiliates or agents, may engage in stabilizing transactions, Overallotment transactions, syndicate covering\ntransactions, penalty bids and purchases to cover positions created by short sales.\n", "page_number": 123, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.32135216089002994, "lower_right_x": 0.8663036902601331, "lower_right_y": 0.36243046640992727, "height": 0.04107830551989733, "width": 0.7459165154264973}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-123-7", "text": "\u00b7   Stabilizing transactions consist of various bids for any purchases of Shares made by the Underwriters in\n    the open market during the stabilization period, and are engaged in for the purpose of preventing or\n    retarding a decline in the market price of the Shares while the Offer is in progress.\n\n\u00b7   Overallotment transactions involve sales by the Underwriters of Shares in excess of the number of\n    Shares the Underwriters are obligated to purchase. This creates a syndicate short position which may be\n    either a covered short position or a naked short position. In a covered short position, the number of\n    Shares over-allotted by the Underwriters is not greater than the number of Shares that they may purchase\n    in the Overallotment Option. In a naked short position, the number of Shares involved is greater than the\n    number of Shares in the Overallotment Option. The Underwriters may sell Shares in excess of the\n    Overallotment Option as discussed above up to a maximum of 5% of the number of Shares initially\n    purchased in the Offer, creating a naked short position. The Underwriters may close out any short\n    position by exercising their Overallotment Option and/or purchasing Shares in the open market.\n\n\u00b7   Syndicate covering transactions involve purchases of Shares in the open market after the distribution has\n    been completed in order to cover syndicate short positions. In determining the source of Shares to close\n    out the short position, the Underwriters will consider, among other things, the price of Shares available\n    for purchase in the open market as compared with the price at which they may purchase Shares through\n    exercise of the Overallotment Option. If the Underwriters sell more Shares than could be covered by\n    exercise of the Overallotment Option and, therefore, have a naked short position, the position can be\n    closed out only by buying Shares in the open market. A naked short position is more likely to be created\n    if the Underwriters are concerned that after pricing there could be downward pressure on the price of the\n    Shares in the open market that could adversely affect investors who purchase in the Offer.\n\n\u00b7   Penalty bids permit the representative to reclaim a selling concession from a syndicate member when the\n    Shares originally sold by that syndicate member are purchased in stabilizing or syndicate covering\n    transactions to cover syndicate short positions.\n", "page_number": 123, "bounding_box": {"top_left_x": 0.1355111917725348, "top_left_y": 0.3761232349165597, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.7462558836114677, "height": 0.370132648694908, "width": 0.7404718693284936}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-123-8", "text": "   These stabilizing transactions, syndicate covering transactions and penalty bids may have the effect of raising\nor maintaining the market price of our Shares or preventing or retarding a decline in the market price of our\nShares. As a result, the price of our Shares in the open market may be higher than it would otherwise be in the\nabsence of these transactions. Neither we nor the Underwriters make any representation or prediction as to the\neffect that the transactions described above may have on the price of our Shares. These transactions may be\neffected on the Euronext Amsterdam, in the over-the-counter market or otherwise and, if commenced, may be\ndiscontinued at any time.\n", "page_number": 123, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.762943945228926, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.8575096277278562, "height": 0.09456568249893027, "width": 0.7555958862673926}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-123-9", "text": "121\n", "page_number": 123, "bounding_box": {"top_left_x": 0.8560193587416818, "top_left_y": 0.9477963200684638, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9572100984167736, "height": 0.00941377834830981, "width": 0.024803387779794295}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-124-0", "text": "Lock-Up Arrangements\n", "page_number": 124, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.08515190415062045, "lower_right_x": 0.294615849969752, "lower_right_y": 0.09927257167308515, "height": 0.0141206675224647, "width": 0.17422867513611617}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-124-1", "text": "   Pursuant to certain \u201clock-up\u201d agreements, we and the members of our Executive Board and our Senior\nManagement have agreed, for a period of 180 days from the date of the underwriting agreement (\u201clock-up\nperiod\u201d), subject to certain exceptions listed below, not to directly or indirectly offer, sell, assign, transfer,\npledge, contract to sell or otherwise dispose of, or announce any intention to sell or otherwise dispose of, or\nenter into any swap or other agreement that transfers, in whole or in part, the economic consequence of\nownership of, directly or indirectly, any Shares or securities convertible into or exchangeable or exercisable for\nor repayable with any Shares currently owned or held by those shareholders at the date of the relevant lock-up\nagreement, without the prior written consent of Cowen. The lock-up period will be automatically extended if (i)\nduring the last 17 days of the lock-up period we issue an earnings release or material news or a material event\nrelating to us occurs or (ii) prior to the expiration of the lock-up period, we announce that we will release\nearnings results or become aware that material news or a material event will occur during the 16-day period\nbeginning on the last day of the lock-up period, in either of which case the restrictions described above will\ncontinue to apply until the expiration of the 18-day period beginning on the issuance of the earnings release or\nthe occurrence of the material news or material event.\n", "page_number": 124, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.11253744116388532, "lower_right_x": 0.8711433756805808, "lower_right_y": 0.3020967051775781, "height": 0.18955926401369277, "width": 0.7507562008469449}, "blob_type": "paragraph", "predictions": {}, "annotations": {"lock-up_period": ["180 days "]}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-124-2", "text": "   The exceptions to the lock-up provision permit us, among other things and subject to restrictions, to: (a) issue\nShares or options pursuant to employee benefit plans, (b) issue Shares upon exercise of outstanding options or\nwarrants, or (c) issue securities in connection with acquisitions or similar transactions. The exceptions permit\nparties to the \u201clock-up\u201d agreements, among other things and subject to restrictions, to: (a) participate in tenders\ninvolving the acquisition of a majority of our Shares, (b) participate in transfers or exchanges involving Shares\nor securities convertible into Shares or (c) make certain gifts. In addition, the lock-up provision will not restrict\nbroker-dealers from engaging in market making and similar activities conducted in the ordinary course of their\nbusiness.\n", "page_number": 124, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.31792896876337184, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.4249037227214377, "height": 0.10697475395806588, "width": 0.7555958862673926}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-124-3", "text": "  The exceptions to the lock-up provision which apply to the members of our Executive Board and our Senior\nManagement, permit them, among other things and subject to restrictions, to: (a) make transfers in respect of the\nacceptance of a general tender offer for no less than a majority of our Shares and (b) make certain transfers for\nno consideration, including gifts to family members in the case of an individual, or distributions to equity\nowners or transfers to affiliates in the case of a legal entity.\n", "page_number": 124, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.4411638853230638, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.5100556268720582, "height": 0.06889174154899441, "width": 0.7555958862673926}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-124-4", "text": "Other Relationships\n", "page_number": 124, "bounding_box": {"top_left_x": 0.12099213551119177, "top_left_y": 0.5267436884895165, "lower_right_x": 0.2661826981246219, "lower_right_y": 0.5395806589644844, "height": 0.012836970474967901, "width": 0.14519056261343016}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-124-5", "text": "   Certain of the Underwriters and their affiliates have provided, and may in the future provide, various\ninvestment banking, commercial banking and other financial services for us and our affiliates for which they\nreceived, and may in the future receive, customary fees.\n", "page_number": 124, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.5541292255027813, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.5956354300385109, "height": 0.04150620453572962, "width": 0.7313974591651543}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-124-6", "text": "   In July 2006, we retained Kempen & Co as our advisor to perform a strategic study with the goal of\nidentifying possible acquisition candidates. As part of this mandate, Kempen & Co would be entitled to a\nfinder\u2019s fee if a particular acquisition is consummated. We are currently not in discussions with possible\nacquisition candidates and have no present intention to complete an acquisition.\n", "page_number": 124, "bounding_box": {"top_left_x": 0.12099213551119177, "top_left_y": 0.6089002995293111, "lower_right_x": 0.8324258923169994, "lower_right_y": 0.6632434745400085, "height": 0.05434317501069741, "width": 0.7114337568058076}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-124-7", "text": "    Electronic Offer, Sale and Distribution of Shares. A Prospectus in electronic format may be made available\non restricted portions of the websites maintained by one or more of the Underwriters or selling group members,\nif any, participating in the Offer, and one or more of the Underwriters participating in the Offer may distribute\nProspectuses electronically. The Representative may agree to allocate a number of Shares to Underwriters and\nselling group members for sale to their online brokerage account holders. Internet distributions will be allocated\nby the Underwriters and selling group members that will make internet distributions on the same basis as other\nallocations. Other than the Prospectus in electronic format, the information on these websites is not part of this\nProspectus, has not been approved or endorsed by us or any Underwriter in its capacity as underwriter, and\nshould not be relied upon by investors.\n", "page_number": 124, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.6773641420624733, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.8005990586221652, "height": 0.12323491655969188, "width": 0.7555958862673926}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-124-8", "text": "No Public Offering Outside The Netherlands\n", "page_number": 124, "bounding_box": {"top_left_x": 0.12099213551119177, "top_left_y": 0.8142918271287976, "lower_right_x": 0.4452510586811857, "lower_right_y": 0.8284124946512623, "height": 0.01412066752246477, "width": 0.32425892316999394}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-124-9", "text": "   No action has been or will be taken in any jurisdiction other than the Netherlands that would permit a public\noffering of the Offer Shares, or the possession, circulation or distribution of this Prospectus or any other material\nrelating to us or the Offer Shares in any jurisdiction where action for that purpose is required. Accordingly, the\nOffer Shares may not be offered or sold, directly or indirectly, and neither this Prospectus nor any other offering\nmaterial or advertisements in connection with the Offer Shares may be distributed or published, in or from any\n", "page_number": 124, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.8416773641420625, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9101412066752247, "height": 0.06846384253316218, "width": 0.7604355716878403}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-124-10", "text": "122\n", "page_number": 124, "bounding_box": {"top_left_x": 0.8560193587416818, "top_left_y": 0.9477963200684638, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9572100984167736, "height": 0.00941377834830981, "width": 0.024803387779794295}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-125-0", "text": "country or jurisdiction except in compliance with any applicable rules and regulations of any such country or\njurisdiction.\n", "page_number": 125, "bounding_box": {"top_left_x": 0.11675741076830005, "top_left_y": 0.08515190415062045, "lower_right_x": 0.8548094373865699, "lower_right_y": 0.11296534017971759, "height": 0.02781343602909714, "width": 0.7380520266182699}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-125-1", "text": "  Purchasers of the Offer Shares may be required to pay stamp taxes and other charges in accordance with the\nlaws and practices of the country of purchase in addition to the Offer Price.\n", "page_number": 125, "bounding_box": {"top_left_x": 0.12220205686630368, "top_left_y": 0.12623020967051776, "lower_right_x": 0.8663036902601331, "lower_right_y": 0.1540436456996149, "height": 0.02781343602909714, "width": 0.7441016333938294}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-125-2", "text": "123\n", "page_number": 125, "bounding_box": {"top_left_x": 0.8560193587416818, "top_left_y": 0.9477963200684638, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9572100984167736, "height": 0.00941377834830981, "width": 0.024803387779794295}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-126-0", "text": "Selling Restrictions\n", "page_number": 126, "bounding_box": {"top_left_x": 0.4010889292196007, "top_left_y": 0.10226786478391099, "lower_right_x": 0.5995160314579552, "lower_right_y": 0.11895592640136927, "height": 0.016688061617458283, "width": 0.19842710223835447}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-126-1", "text": "European Economic Area\n", "page_number": 126, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.1364997860504921, "lower_right_x": 0.30913490623109496, "lower_right_y": 0.15062045357295678, "height": 0.014120667522464686, "width": 0.18874773139745915}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-126-2", "text": "   In relation to each member state of the European Economic Area which has implemented the Prospectus\nDirective (each, a \u201cRelevant Member State\u201d), with effect from and including the date on which the Prospectus\nDirective was implemented in that Relevant Member State (the \u201cRelevant Implementation Date\u201d) no Offer\nShares have been offered or will be offered pursuant to the Offer to the public in that Relevant Member State\nprior to the publication of a prospectus in relation to the Offer Shares which has been approved by the\ncompetent authority in that Relevant Member State or, where appropriate, approved in another Relevant\nMember State and notified to the competent authority in the Relevant Member State, all in accordance with the\nProspectus Directive, except that with effect from and including the Relevant Implementation Date, offers of\nOffer Shares may be made to the public in that Relevant Member State at any time:\n", "page_number": 126, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.16388532306375694, "lower_right_x": 0.8699334543254689, "lower_right_y": 0.28754813863928114, "height": 0.1236628155755242, "width": 0.7495462794918331}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-126-3", "text": "\u00b7   to legal entities which are authorized or regulated to operate in the financial markets or, if not so\n    authorized or regulated, whose corporate purpose is solely to invest in securities;\n\n\u00b7   to any legal entity which has two or more of (i) an average of at least 250 employees during the last\n    financial year; (ii) a total balance sheet of more than \u20ac43 million; and (iii) an annual turnover of more\n    than \u20ac50 million as shown in its last annual or consolidated accounts;\n\n\u00b7   to fewer than 100 natural or legal persons (other than qualified investors as defined in the Prospectus\n    Directive) subject to obtaining the prior consent of the Underwriters; or\n\n\u00b7   in any other circumstances that do not require the publication by us of a prospectus pursuant to Article 3\n    of the Prospectus Directive,\n", "page_number": 126, "bounding_box": {"top_left_x": 0.14035087719298245, "top_left_y": 0.30124090714591356, "lower_right_x": 0.8705384150030248, "lower_right_y": 0.4689773213521609, "height": 0.16773641420624735, "width": 0.7301875378100423}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-126-4", "text": "\u00b7\n", "page_number": 126, "bounding_box": {"top_left_x": 0.1355111917725348, "top_left_y": 0.3055198973042362, "lower_right_x": 0.1397459165154265, "lower_right_y": 0.3115104835258879, "height": 0.005990586221651717, "width": 0.004234724742891716}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-126-5", "text": "", "page_number": 126, "bounding_box": {"top_left_x": 0.1367211131276467, "top_left_y": 0.3491655969191271, "lower_right_x": 0.1397459165154265, "lower_right_y": 0.35216089002995293, "height": 0.0029952931108258585, "width": 0.003024803387779801}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-126-6", "text": "\u00b7\n", "page_number": 126, "bounding_box": {"top_left_x": 0.1355111917725348, "top_left_y": 0.40350877192982454, "lower_right_x": 0.1397459165154265, "lower_right_y": 0.40907145913564397, "height": 0.005562687205819428, "width": 0.004234724742891716}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-126-7", "text": "\u00b7\n", "page_number": 126, "bounding_box": {"top_left_x": 0.1355111917725348, "top_left_y": 0.44458707744972187, "lower_right_x": 0.1397459165154265, "lower_right_y": 0.4501497646555413, "height": 0.005562687205819428, "width": 0.004234724742891716}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-126-8", "text": "  and each person who initially acquires any Offer Shares or to whom any offer is made under the Offer will,\nunless under bullet point three above, be deemed to have represented, acknowledged and agreed that it is a\n\u201cqualified investor\u201d, within the meaning of Article 2(1)(e) of the Prospectus Directive.\n", "page_number": 126, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.48224219084296105, "lower_right_x": 0.8608590441621294, "lower_right_y": 0.5233204963628584, "height": 0.04107830551989733, "width": 0.7404718693284936}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-126-9", "text": "   For the purpose of the expression an \u201coffer of any Offer Shares to the public\u201d in relation to any Offer Shares\nin any Relevant Member State means the communication in any form and by any means of sufficient\ninformation on the terms of the offer of any Offer Shares to be offered so as to enable an investor to decide to\npurchase any Offer Shares, as the same may be varied in that Relevant Member State by any measure\nimplementing the Prospectus Directive in that Relevant Member State.\n", "page_number": 126, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.5370132648694907, "lower_right_x": 0.8669086509376891, "lower_right_y": 0.6054771074026529, "height": 0.06846384253316218, "width": 0.7465214761040533}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-126-10", "text": "   In the case of any Offer Shares being offered to a financial intermediary as that term is used in Article 3(2) of\nthe Prospectus Directive, such financial intermediary will also be deemed to have represented, acknowledged\nand agreed that the Offer Shares acquired by it in the Offer have not been acquired on a non-discretionary basis\non behalf of, nor have they been acquired with a view to their offer or resale to persons in circumstances which\nmay give rise to an offer of any Offer Shares to the public other than their offer or resale in a Relevant Member\nState to qualified investors as so defined or in circumstances in which the prior consent of the Underwriters has\nbeen obtained to each such proposed offer or resale. We, the Underwriters and their affiliates, and others will\nrely upon the truth and accuracy of the foregoing representation, acknowledgement and agreement.\nNotwithstanding the above, a person who is not a qualified investor and who has notified the Underwriters of\nsuch fact in writing may, with the consent of the Underwriters, be permitted to subscribe for or purchase Offer\nShares in the Offer.\n", "page_number": 126, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.6191698759092854, "lower_right_x": 0.8765880217785844, "lower_right_y": 0.7667950363714163, "height": 0.14762516046213092, "width": 0.7562008469449486}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-126-11", "text": "United Kingdom\n", "page_number": 126, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.7834830979888746, "lower_right_x": 0.24198427102238354, "lower_right_y": 0.7976037655113393, "height": 0.014120667522464658, "width": 0.12159709618874773}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-126-12", "text": "   This Prospectus is for distribution only to persons who (i) have professional experience in matters relating to\ninvestments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion)\nOrder 2005 (as amended, the \u201cFinancial Promotion Order\u201d), (ii) are persons falling within Article 49(2)(a) to (d)\n(\u201chigh net worth companies, unincorporated associations etc\u201d) of the Financial Promotion Order, (iii) are\noutside the United Kingdom, or (iv) are persons to whom an invitation or inducement to engage in investment\nactivity (within the meaning of section 21 of the Financial Services and Markets Act 2000) in connection with\nthe issue or sale of any Offer Shares may otherwise lawfully be communicated or caused to be communicated\n", "page_number": 126, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.8108686350021395, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.9071459135643988, "height": 0.09627727856225932, "width": 0.7555958862673926}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-126-13", "text": "124\n", "page_number": 126, "bounding_box": {"top_left_x": 0.8560193587416818, "top_left_y": 0.9477963200684638, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9572100984167736, "height": 0.00941377834830981, "width": 0.024803387779794295}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-127-0", "text": "(for the purpose of this paragraph, all such persons together \u201crelevant persons\u201d). This document is directed only\nat relevant persons and must not be acted on or relied on by persons who are not relevant persons. Any\ninvestment or investment activity to which this document relates is available only to relevant persons and will be\nengaged in only with relevant persons.\n", "page_number": 127, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.08515190415062045, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.14035087719298245, "height": 0.055198973042362, "width": 0.7604355716878403}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-127-1", "text": "Italy\n", "page_number": 127, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.15361574668378264, "lower_right_x": 0.1542649727767695, "lower_right_y": 0.16773641420624733, "height": 0.014120667522464686, "width": 0.0338777979431337}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-127-2", "text": "  The contents of this Prospectus have not been approved by the Commissione Nazionale Per La Societ\u00e0 E La\nBorsa (\u201cConsob\u201d) nor any other authority in Italy. The offering of the Offer Shares is exempt from registration\nwith the Consob pursuant to section 100, first paragraph, letter (a) of legislative decree no. 58 of 24 February\n1998 .\n", "page_number": 127, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.1810012836970475, "lower_right_x": 0.8663036902601331, "lower_right_y": 0.23491655969191272, "height": 0.05391527599486523, "width": 0.7459165154264973}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-127-3", "text": "   The offer, sale or delivery of the Offer Shares or distribution of copies of this Prospectus in the republic of\nItaly may only be made (a) by an investment firm, bank or financial intermediary permitted to conduct such\nactivities in the republic of Italy in accordance with legislative decree no. 385 of 1 September 1993 (\u201cdecree no.\n385\u201d), legislative decree no. 58 of 24 February 1998, Consob regulation no. 11971 of 14 May 1999 and any\nother applicable laws and regulation; (b) exclusively to professional investors as defined in section 30, second\nparagraph of legislative decree no. 58 of 24 February 1998 and section 31, 2nd paragraph of Consob regulation\nno. 11522 of 1 July 1998 and subsequent amendments; (c) in compliance with any other applicable notification\nrequirement or limitation which may be imposed by Consob or any other Italian regulatory authority.\n", "page_number": 127, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.24946512623020967, "lower_right_x": 0.8753781004234725, "lower_right_y": 0.3594351732991014, "height": 0.10997004706889174, "width": 0.7549909255898367}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-127-4", "text": "United Arab Emirates\n", "page_number": 127, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.3761232349165597, "lower_right_x": 0.2807017543859649, "lower_right_y": 0.38682071031236626, "height": 0.010697475395806566, "width": 0.16031457955232908}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-127-5", "text": "   This Prospectus does not constitute a public offer or a solicitation of securities within the territory of the\nUnited Arab Emirates and accordingly should not be construed as such. This Prospectus is not for circulation to\nthe general public in the United Arab Emirates, nor will Offer Shares be offered to the general public in the\nUnited Arab Emirates. To the extent that this Prospectus is circulated within the territory of the United Arab\nEmirates, it is being done so in relation to a private placement (i.e. a limited circle of investors) only.\nAccordingly, the Offer and this Prospectus have not been filed with, reviewed by or approved by the United\nArab Emirates Central Bank, the Emirates Securities and Commodities Authority, or any other United Arab\nEmirates governmental regulatory body or securities exchange. This Prospectus must not be copied or otherwise\ndistributed by the recipient to others.\n", "page_number": 127, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.40350877192982454, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.5258878904578519, "height": 0.12237911852802735, "width": 0.7555958862673926}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-127-6", "text": "Kuwait\n", "page_number": 127, "bounding_box": {"top_left_x": 0.12099213551119177, "top_left_y": 0.540436456996149, "lower_right_x": 0.17422867513611615, "lower_right_y": 0.5511339323919555, "height": 0.010697475395806566, "width": 0.053236539624924376}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-127-7", "text": "   By receiving this Prospectus, the person or entity to whom it has been issued or provided understands,\nacknowledges and agrees that this Prospectus has not been approved by the Central Bank of Kuwait or the\nKuwait Ministry of Commerce and Industry or any authorities in Kuwait, nor have we or any of our\nrepresentatives received authorization or licensing from the Central Bank of Kuwait or the Kuwait Ministry of\nCommerce and Industry or any authorities in Kuwait to market or sell the Offer Shares within Kuwait.\nTherefore, the Offer Shares will not be marketed or sold from within Kuwait and no services relating to an\noffering, including the receipt of applications or this Prospectus or both, will be rendered within Kuwait by us or\nany of our representatives. The Offer Shares are being offered for sale only to qualified institutional investors\nand sophisticated, high-net-worth individuals. Neither the Offer Shares nor the private offering have been\nlicensed by the Central Bank of Kuwait, the Kuwait Ministry of Commerce and Industry or any other relevant\nKuwaiti government agency. No Underwriter or any other party involved in the Offer is licensed in Kuwait.\n", "page_number": 127, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.5678219940094138, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.7188703465982028, "height": 0.15104835258878901, "width": 0.7604355716878403}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-127-8", "text": "Bahrain", "page_number": 127, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.732135216089003, "lower_right_x": 0.1839080459770115, "lower_right_y": 0.7428326914848096, "height": 0.010697475395806566, "width": 0.06352087114337568}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-127-9", "text": "   Any marketing of Offer Shares to investors in Bahrain is done by way of private placement only. It is not\nsubject to the regulations of the Central Bank of Bahrain that apply to public offerings of securities and the\nextensive disclosure requirements and other protections that these regulations contain. This Prospectus is\ntherefore intended only for \u201cprofessional clients\u201d or \u201cmarket counterparties\u201d as defined by the Central Bank of\nBahrain.\n", "page_number": 127, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.7595207531022679, "lower_right_x": 0.8663036902601331, "lower_right_y": 0.8249893025246042, "height": 0.06546854942233638, "width": 0.7459165154264973}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-127-10", "text": "  The Offer Shares offered pursuant to this Prospectus, may only be offered in minimum subscriptions of\n$250,000 (or equivalent in other currencies).\n", "page_number": 127, "bounding_box": {"top_left_x": 0.12099213551119177, "top_left_y": 0.8416773641420625, "lower_right_x": 0.837265577737447, "lower_right_y": 0.8694908001711597, "height": 0.02781343602909714, "width": 0.7162734422262552}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-127-11", "text": "125\n", "page_number": 127, "bounding_box": {"top_left_x": 0.8560193587416818, "top_left_y": 0.9477963200684638, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9572100984167736, "height": 0.00941377834830981, "width": 0.024803387779794295}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-128-0", "text": "  The Central Bank of Bahrain assumes no responsibility for the accuracy and completeness of the statements\nand information contained in this Prospectus and expressly disclaims any liability whatsoever for any loss\nhowsoever arising from reliance upon the whole or any part of the contents of this Prospectus.\n", "page_number": 128, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.08515190415062045, "lower_right_x": 0.8663036902601331, "lower_right_y": 0.12665810868635002, "height": 0.04150620453572958, "width": 0.7459165154264973}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-128-1", "text": "Qatar\n", "page_number": 128, "bounding_box": {"top_left_x": 0.12099213551119177, "top_left_y": 0.1407787762088147, "lower_right_x": 0.1645493042952208, "lower_right_y": 0.1540436456996149, "height": 0.01326486949080019, "width": 0.04355716878402903}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-128-2", "text": "   No general offering of the Offer Shares will be made in Qatar, and any Offer Shares may only be placed with\na limited number of targeted investors in Qatar.\n", "page_number": 128, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.16730851519041506, "lower_right_x": 0.8753781004234725, "lower_right_y": 0.1951219512195122, "height": 0.02781343602909714, "width": 0.7549909255898367}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-128-3", "text": "Lebanon\n", "page_number": 128, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.21181001283697048, "lower_right_x": 0.18330308529945555, "lower_right_y": 0.2220795892169448, "height": 0.010269576379974305, "width": 0.06291591046581974}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-128-4", "text": "   All prospective investors in Lebanon whose investment authority is subject to legal restriction should consult\ntheir legal advisors to determine whether and to what extent the Offer Shares constitute legal investments under\nthose restrictions. The Offer Shares are suitable only as an investment for, and are being offered only to, persons\nwho have, directly or through qualified representatives, the ability to evaluate the merits and risks of an\ninvestment in the Offer Shares and the ability to assume all the risks involved in such an investment. In addition,\ninvestment in the Offer Shares requires the financial ability and willingness to accept the risks inherent in an\ninvestment in the Offer Shares, the knowledge and experience in financial and business matters to be capable of\nevaluating a prospective investment in the Offer Shares, and the financial ability to bear the risks of such an\ninvestment.\n", "page_number": 128, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.23919554985023533, "lower_right_x": 0.8802177858439202, "lower_right_y": 0.3590072742832692, "height": 0.11981172443303384, "width": 0.7598306110102844}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-128-5", "text": "   The acceptance of this Prospectus shall constitute the agreement of the recipient that: (a) it will hold this\nProspectus and all related enclosures, documents and information in the strictest confidence; (b) it will not\nreproduce or use this Prospectus for any purpose other than in connection with a decision to purchase Offer\nShares; (c) it will not transmit to or discuss this Prospectus with persons other than its authorized representatives\nand advisors who agree to hold the same subject to the provisions of this paragraph; (d) it will not utilize the\ncontents of this Prospectus in any manner detrimental to the interests of the selling agents; and (e) it will return\nthis Prospectus to the Underwriters or their selling agents immediately upon request.\n", "page_number": 128, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.3761232349165597, "lower_right_x": 0.8802177858439202, "lower_right_y": 0.4711168164313222, "height": 0.0949935815147625, "width": 0.7598306110102844}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-128-6", "text": "Jordan\n", "page_number": 128, "bounding_box": {"top_left_x": 0.12099213551119177, "top_left_y": 0.4856653829696192, "lower_right_x": 0.17422867513611615, "lower_right_y": 0.49636285836542576, "height": 0.010697475395806566, "width": 0.053236539624924376}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-128-7", "text": "  Any marketing of Offer Shares to Jordanian investors is done by way of private placement only. The Offer\nShares are being offered in Jordan on a cross border basis based on one-on-one contacts to no more than 30\npotential investors and accordingly the Offer Shares will not be registered with the Jordanian Securities\nCommission and a local prospectus is not required.\n", "page_number": 128, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.513050919982884, "lower_right_x": 0.8566243194192378, "lower_right_y": 0.5678219940094138, "height": 0.05477107402652981, "width": 0.736237144585602}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-128-8", "text": "Israel\n", "page_number": 128, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.5815147625160462, "lower_right_x": 0.1645493042952208, "lower_right_y": 0.5939238339751819, "height": 0.012409071459135723, "width": 0.04416212946158499}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-128-9", "text": "   This Prospectus may not be distributed to any individual (for the purpose of this paragraph, the \u201cIsrael\nPublic\u201d) in Israel or used, or considered by any member of the Israel Public as, an offer to the Israel Public to\nsell the Offer Shares, or a solicitation of an offer from any person to the Israel Public, to buy or subscribe for the\nOffer Shares. Any such offer or solicitation to the Israel Public may only be made in a prospectus published in\nIsrael in accordance with a permit granted by the Israel Securities Authority (for the purpose of this paragraph,\nthe \u201cSecurities Authority\u201d) pursuant to the provisions of the Securities Law, 5728-1968, of Israel (the \u201cIsrael\nSecurities Law\u201d), after examination and approval of this Prospectus by the Securities Authority. This Prospectus\nand the Offer Shares hereby offered have not been submitted to, approved by or registered with the Securities\nAuthority, nor has a permit been requested or granted, pursuant to the provisions of the Israel Securities Law.\n", "page_number": 128, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.6089002995293111, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.7325631151048353, "height": 0.12366281557552417, "width": 0.7555958862673926}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-128-10", "text": "126\n", "page_number": 128, "bounding_box": {"top_left_x": 0.8560193587416818, "top_left_y": 0.9477963200684638, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9572100984167736, "height": 0.00941377834830981, "width": 0.024803387779794295}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-129-0", "text": "Transfer Restrictions\n", "page_number": 129, "bounding_box": {"top_left_x": 0.3932244404113733, "top_left_y": 0.10226786478391099, "lower_right_x": 0.6098003629764065, "lower_right_y": 0.11638853230637569, "height": 0.0141206675224647, "width": 0.21657592256503322}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-129-1", "text": "Rule 144A Shares\n", "page_number": 129, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.1364997860504921, "lower_right_x": 0.25105868118572294, "lower_right_y": 0.14890885750962773, "height": 0.01240907145913564, "width": 0.13067150635208713}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-129-2", "text": "  Each purchaser of Offer Shares within the United States pursuant to Rule 144A, by accepting delivery of this\nProspectus will be deemed to have represented, agreed and acknowledged that:\n", "page_number": 129, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.16388532306375694, "lower_right_x": 0.8717483363581368, "lower_right_y": 0.19169875909285408, "height": 0.02781343602909714, "width": 0.7513611615245009}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-129-3", "text": "  \u00b7   It is (a) a qualified institutional buyer within the meaning of Rule 144A (\u201cQIB\u201d), (b) acquiring such\n      Offer Shares for its own account or for the account of another QIB and (c) aware, and each beneficial\n      owner of such Offer Shares has been advised, that the sale of such Offer Shares to it is being made in\n      reliance on Rule 144A.\n\n  \u00b7   It understands that such Offer Shares have not been and will not be registered under the Securities Act\n      and may not be offered, sold, pledged or otherwise transferred except (a) in accordance with Rule 144A\n      to a person that it and any person acting on its behalf reasonably believe is a QIB purchasing for its own\n      account or for the account of another QIB, (b) in an offshore transaction in accordance with Rule 903 or\n      Rule 904 of Regulation S or (c) pursuant to an exemption from registration under the Securities Act\n      provided by Rule 144 thereunder (if available), in each case in accordance with any applicable securities\n      laws of any State of the United States.\n\n  \u00b7   It understands that such Offer Shares, if certificated, will bear a legend substantially to the following\n      effect unless otherwise determined by us in accordance with applicable law:\n\n      THIS SHARE HAS NOT BEEN AND WILL NOT BE REGISTERED UNDER THE UNITED\n      STATES SECURITIES ACT OF 1933 (THE \u201cSECURITIES ACT\u201d) OR WITH ANY SECURITIES\n      REGULATORY AUTHORITY OR ANY STATE OR OTHER JURISDICTION OF THE UNITED\n      STATES AND MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED\n      EXCEPT (1) IN ACCORDANCE WITH RULE 144A UNDER THE SECURITIES ACT TO A\n      PERSON THAT THE HOLDER AND ANY PERSON ACTING ON ITS BEHALF REASONABLY\n      BELIEVE IS A QUALIFIED INSTITUTIONAL BUYER WITHIN THE MEANING OF RULE 144A\n      PURCHASING FOR ITS OWN ACCOUNT OR FOR THE ACCOUNT OF ANOTHER QUALIFIED\n      INSTITUTIONAL BUYER, (2) IN AN OFFSHORE TRANSACTION IN ACCORDANCE WITH\n      RULE 903 OR RULE 904 OF REGULATION S UNDER THE SECURITIES ACT OR (3)\n      PURSUANT TO AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT\n      PROVIDED BY RULE 144 THEREUNDER (IF AVAILABLE). IN EACH CASE IN ACCORDANCE\n      WITH ANY APPLICABLE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES. NO\n      REPRESENTATION CAN BE MADE AS TO THE AVAILABILITY OF THE EXEMPTION\n      PROVIDED BY RULE 144 UNDER THE SECURITIES ACT FOR RESALES OF THIS SHARE.\n\n  \u00b7   We, the Underwriters and their affiliates, and others will rely upon the truth and accuracy of the\n      foregoing acknowledgements, representations and agreements. If it is acquiring any Offer Shares for the\n      account of one or more QIBs, it represents that it has sole investment discretion with respect to each such\n      account and that it has full power to make the foregoing acknowledgements, representations and\n      agreements on behalf of each such account.\n\n  You are hereby notified that sellers of the Offer Shares may be relying on the exemption from the\nprovisions of Section 5 of the Securities Act provided by Rule 144A.\n", "page_number": 129, "bounding_box": {"top_left_x": 0.12099213551119177, "top_left_y": 0.20496362858365424, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.7560975609756098, "height": 0.5511339323919555, "width": 0.7598306110102843}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-129-4", "text": "127\n", "page_number": 129, "bounding_box": {"top_left_x": 0.8560193587416818, "top_left_y": 0.9477963200684638, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9572100984167736, "height": 0.00941377834830981, "width": 0.024803387779794295}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-130-0", "text": "General Information\n", "page_number": 130, "bounding_box": {"top_left_x": 0.3926194797338173, "top_left_y": 0.10226786478391099, "lower_right_x": 0.603145795523291, "lower_right_y": 0.11596063329054343, "height": 0.013692768506632438, "width": 0.21052631578947367}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-130-1", "text": "Available Information\n", "page_number": 130, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.1364997860504921, "lower_right_x": 0.28009679370840895, "lower_right_y": 0.14848095849379547, "height": 0.011981172443303378, "width": 0.15970961887477314}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-130-2", "text": "   Annually, within five months of the end of our fiscal year, unless the General Meeting of Shareholders has\nextended this period (which it may do for up to a maximum of six months due to special circumstances), the\nExecutive Board is required to prepare annual accounts, accompanied by an annual report and an accountants\u2019\ncertificate. We will be required to publish our annual accounts within four months after the end of each financial\nyear and our half-yearly figures within two months after the end of the first six months of each financial year\nfollowing the implementation of European Union Directive 2004/109/EC, which is expected to be 1 January\n2008. In addition, we will also become obliged to publish interim management statements following the\nimplementation of the Directive.\n", "page_number": 130, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.16388532306375694, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.2738553701326487, "height": 0.10997004706889177, "width": 0.7555958862673926}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-130-3", "text": "   The annual accounts must be signed by all members of the Executive Board and the Supervisory Board. The\nannual accounts, annual report and accountant\u2019s certificate and the half-yearly figures and interim management\nstatements upon their publication can be inspected by our shareholders without charge at our head office in\nLeiden during regular business hours from the day of notice convening the annual General Meeting of\nShareholders. Our annual accounts and annual report as well as the half-yearly figures and interim management\nstatements upon their publication will also be available from our website: www.octoplus.nl.\n", "page_number": 130, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.28712023962344885, "lower_right_x": 0.8711433756805808, "lower_right_y": 0.36970474967907574, "height": 0.08258451005562689, "width": 0.7507562008469449}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-130-4", "text": "   Copies of our annual accounts for the years ended 31 December 2004, 2005 and 2006, our deed of\nincorporation and our Articles of Association may be obtained free of charge for the life of this Prospectus by\nsending a request in writing to us at our business address: Zernikedreef 12, 2333 CL Leiden, the Netherlands.\n", "page_number": 130, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.38296961916987593, "lower_right_x": 0.8614640048396854, "lower_right_y": 0.4244758237056055, "height": 0.04150620453572956, "width": 0.7410768300060496}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-130-5", "text": "   This Prospectus will be available to investors at no cost upon simple request from Kempen & Co,\nBeethovenstraat 300, 1077 WZ Amsterdam, the Netherlands at documents@kempen.nl or telephone number\n+31 (0)20-348 85 29 and Fortis Bank (Nederland) N.V., Rokin 55, 1012 KK Amsterdam, the Netherlands, at\nprospectus@nl.fortis.com or telephone number +31 (0)20-527 24 67. Alternatively, the Prospectus is also\navailable for Dutch residents, for information purposes only, through our website at www.octoplus.nl and\nthrough the NYSE Euronext website at www.euronext.com.\n", "page_number": 130, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.43945228925973473, "lower_right_x": 0.8560193587416818, "lower_right_y": 0.5220367993153616, "height": 0.08258451005562689, "width": 0.735632183908046}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-130-6", "text": "Provision of Information\n", "page_number": 130, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.5370132648694907, "lower_right_x": 0.3000604960677556, "lower_right_y": 0.5477107402652974, "height": 0.010697475395806677, "width": 0.17967332123411978}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-130-7", "text": "   We have agreed that, for so long as any of the Shares are outstanding and are \u201crestricted securities\u201d within the\nmeaning of Rule 144(a)(3) under the Securities Act, we will, during any period in which we are neither subject\nto Section 13 or 15(d) of the Exchange Act nor exempt from reporting pursuant to Rule 12g3-2(b) thereunder,\nprovide to any holder or beneficial owner of such restricted Shares or to any prospective purchaser of such\nrestricted Shares designated by such holder or beneficial owner, upon the request of such holder, beneficial\nowner or prospective purchaser, the information required to be provided by Rule 144A(d)(4) under the\nSecurities Act.\n", "page_number": 130, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.5643988018827557, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.6572528883183568, "height": 0.09285408643560111, "width": 0.7604355716878403}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-130-8", "text": "  We are not currently subject to the periodic reporting and other informational requirements of the Exchange\nAct.\n", "page_number": 130, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.6739409499358151, "lower_right_x": 0.8663036902601331, "lower_right_y": 0.6983311938382541, "height": 0.024390243902439046, "width": 0.7459165154264973}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-130-9", "text": "Share Trading Information\n", "page_number": 130, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.7150192554557124, "lower_right_x": 0.3194192377495463, "lower_right_y": 0.7282841249465126, "height": 0.01326486949080019, "width": 0.19903206291591047}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-130-10", "text": "  The Shares are traded through the book-entry facilities of Euroclear Netherlands, only. The address of\nEuroclear Netherlands is: Damrak 70, 1012 LM Amsterdam.\n", "page_number": 130, "bounding_box": {"top_left_x": 0.12099213551119177, "top_left_y": 0.7424047924689773, "lower_right_x": 0.8275862068965517, "lower_right_y": 0.7697903294822422, "height": 0.02738553701326496, "width": 0.7065940713853599}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-130-11", "text": "The Shares are traded under the following characteristics:\n", "page_number": 130, "bounding_box": {"top_left_x": 0.13611615245009073, "top_left_y": 0.7843388960205392, "lower_right_x": 0.5275257108287962, "lower_right_y": 0.7976037655113393, "height": 0.01326486949080008, "width": 0.39140955837870545}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-130-12", "text": "ISIN Code: NL0000345718\nCommon Code: 026668441\nAmsterdam Security Code: 34571\nEuronext Amsterdam Symbol: OCTO\n", "page_number": 130, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.810012836970475, "lower_right_x": 0.3799153055051422, "lower_right_y": 0.866923406076166, "height": 0.05691056910569103, "width": 0.2595281306715064}, "blob_type": "paragraph", "predictions": {}, "annotations": {"isin": ["NL0000345718"], "ticker": ["OCTO"]}}, {"blob_number_in_page": 13, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-130-13", "text": "128\n", "page_number": 130, "bounding_box": {"top_left_x": 0.8560193587416818, "top_left_y": 0.9477963200684638, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9572100984167736, "height": 0.00941377834830981, "width": 0.024803387779794295}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-131-0", "text": "Corporate Resolutions\n", "page_number": 131, "bounding_box": {"top_left_x": 0.12159709618874773, "top_left_y": 0.08515190415062045, "lower_right_x": 0.2849364791288566, "lower_right_y": 0.09927257167308515, "height": 0.0141206675224647, "width": 0.16333938294010888}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-131-1", "text": "   Prior to the Listing Date, our Executive Board shall resolve to issue the Offer Shares and to exclude the\nrelated pre-emptive rights of the existing holders of Shares, which resolution shall be approved by our\nSupervisory Board..\n", "page_number": 131, "bounding_box": {"top_left_x": 0.12099213551119177, "top_left_y": 0.11253744116388532, "lower_right_x": 0.837265577737447, "lower_right_y": 0.1540436456996149, "height": 0.04150620453572958, "width": 0.7162734422262552}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-131-2", "text": "Organizational Structure\n", "page_number": 131, "bounding_box": {"top_left_x": 0.12159709618874773, "top_left_y": 0.16730851519041506, "lower_right_x": 0.30490018148820325, "lower_right_y": 0.18142918271287975, "height": 0.014120667522464686, "width": 0.18330308529945552}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-131-3", "text": "   We are a holding company of a number of directly held operating companies. Our subsidiaries and holdings\nare:\n", "page_number": 131, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.1951219512195122, "lower_right_x": 0.8663036902601331, "lower_right_y": 0.22250748823277705, "height": 0.02738553701326485, "width": 0.7459165154264973}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-131-4", "text": "Name                              Percentage   Country of Incorporation\nOctoPlus Development B.V.         100%         The Netherlands\nOctoPlus Technologies B.V.        100%         The Netherlands\nChienna B.V.                      100%         The Netherlands\nOctoPlus Sciences B.V.            100%         The Netherlands\nOctoShare B.V.                    100%         The Netherlands\nOctoPlus Inc.                     100%         United States (Delaware)\nZernike Investment Beheer B.V.1   90%          The Netherlands\n", "page_number": 131, "bounding_box": {"top_left_x": 0.11857229280096794, "top_left_y": 0.23577235772357724, "lower_right_x": 0.7749546279491834, "lower_right_y": 0.34403080872913994, "height": 0.1082584510055627, "width": 0.6563823351482154}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-131-5", "text": "Pursuant to voting restrictions in the articles of association of Zernike, we can only exercise 33% of the voting rights on the entire\nissued share capital and therefore disclaim control of this company.\n", "page_number": 131, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.3590072742832692, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.38339751818570816, "height": 0.02439024390243899, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-131-6", "text": "1.\n", "page_number": 131, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.36157466837826274, "lower_right_x": 0.13006654567453116, "lower_right_y": 0.36970474967907574, "height": 0.008130081300812997, "width": 0.009679370840895346}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-131-7", "text": "Advisors\n", "page_number": 131, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.39666238767650835, "lower_right_x": 0.18330308529945555, "lower_right_y": 0.4073598630723149, "height": 0.010697475395806566, "width": 0.06291591046581974}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-131-8", "text": "  Loyens & Loeff N.V. acts as our Dutch counsel in connection with the Offer and this Prospectus. Our US\ncounsel is Hughes Hubbard & Reed LLP. The Underwriters are being represented by Houthoff Buruma N.V.\nwith respect to matters of Dutch law and Ashurst LLP with respect to matters of US law.\n", "page_number": 131, "bounding_box": {"top_left_x": 0.12099213551119177, "top_left_y": 0.4240479246897732, "lower_right_x": 0.8566243194192378, "lower_right_y": 0.46512623020967053, "height": 0.04107830551989733, "width": 0.735632183908046}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-131-9", "text": "Independent Auditors\n", "page_number": 131, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.47881899871630296, "lower_right_x": 0.2807017543859649, "lower_right_y": 0.49293966623876767, "height": 0.014120667522464714, "width": 0.16031457955232908}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-131-10", "text": "   Our audited consolidated financial statements as of and for each of the years in the three-year period ended 31\nDecember 2004, 2005 and 2006, appearing in this Prospectus have been audited by Deloitte Accountants B.V.,\nindependent auditors, as stated in their report thereon appearing elsewhere herein. Deloitte Accountants B.V. is\na member of the Royal Netherlands Institute of Chartered Accountants (Koninklijk Nederlands Instituut voor\nRegisteraccountants). Our consolidated interim financial statements as of and for the six month period ended 30\nJune 2006 and 30 June 2007 have not been audited, but have been reviewed by Deloitte Accountants B.V. as\nstated in their report appearing elsewhere herein (see \u201cIndex to Financial Statements \u2013 Condensed Consolidated\nInterim Financial Statements 30 June 2007 and 2006 \u2013 Review Report\u201d).\n", "page_number": 131, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.5040650406504065, "lower_right_x": 0.8838475499092558, "lower_right_y": 0.6161745827984596, "height": 0.11210954214805313, "width": 0.7683000604960677}, "blob_type": "paragraph", "predictions": {}, "annotations": {"audited_financial_statements": ["audited consolidated financial statements as of and for each of the years in the three-year period ended 31December 2004, 2005 and 2006,", "audited consolidated financial statements as of and for each of the years in the three-year period ended 31December 2004, 2005 and 2006,"], "periods_of_audited_financial_statements": ["31December 2004, 2005 and 2006"]}}, {"blob_number_in_page": 11, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-131-11", "text": "Legal Proceedings\n", "page_number": 131, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.6328626444159179, "lower_right_x": 0.2534785238959468, "lower_right_y": 0.646127513906718, "height": 0.01326486949080008, "width": 0.13309134906231096}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-131-12", "text": "  Except as described in the section \u201cBusiness \u2013 Legal Proceedings\u201d, there are no governmental, legal or\narbitration proceedings, including any such proceedings pending or threatened of which we are aware, during a\nperiod covering at least the past 12 months which may have, or have had in the recent past, significant effects on\nour financial position or profitability.\n", "page_number": 131, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.6602481814291827, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.7137355584082157, "height": 0.05348737697903294, "width": 0.7604355716878403}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-131-13", "text": "Financial and Trading Position\n", "page_number": 131, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.7287120239623449, "lower_right_x": 0.34603750756200846, "lower_right_y": 0.7428326914848096, "height": 0.014120667522464658, "width": 0.22565033272837265}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-131-14", "text": "Since 30 June 2007, no significant changes in our financial or trading position have occurred.\n", "page_number": 131, "bounding_box": {"top_left_x": 0.13732607380520268, "top_left_y": 0.7560975609756098, "lower_right_x": 0.7695099818511797, "lower_right_y": 0.7697903294822422, "height": 0.01369276850663248, "width": 0.632183908045977}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-131-15", "text": "129\n", "page_number": 131, "bounding_box": {"top_left_x": 0.8560193587416818, "top_left_y": 0.9477963200684638, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9572100984167736, "height": 0.00941377834830981, "width": 0.024803387779794295}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-132-0", "text": "Summary of Significant Differences between IFRS and US GAAP\n", "page_number": 132, "bounding_box": {"top_left_x": 0.16878402903811252, "top_left_y": 0.10226786478391099, "lower_right_x": 0.8275862068965517, "lower_right_y": 0.11895592640136927, "height": 0.016688061617458283, "width": 0.6588021778584392}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-132-1", "text": "   Our consolidated financial statements as of 31 December 2006, 2005 and 2004 and for the years then ended\nhave been prepared in accordance with the International Financial Reporting Standards as adopted by the\nEuropean Union (\u201cIFRS\u201d), which differ in certain significant respects from accounting principles generally\naccepted in the United States of America (\u201cUS GAAP\u201d). We have not prepared the financial statements included\nin this Prospectus in accordance with US GAAP. A brief description of principal differences between our stated\naccounting policies in Note 2 to our consolidated financial statements and US GAAP is outlined below. These\ndifferences have not been quantified. In making an investment decision, you must rely upon your own\nexamination of us, the terms of this Prospectus and the financial and other information contained in this\nProspectus. You should consult your own advisors for an understanding of the differences between IFRS and\nUS GAAP and how those differences could affect the financial information contained herein.\n", "page_number": 132, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.1364997860504921, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.27043217800599056, "height": 0.13393239195549847, "width": 0.7604355716878403}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-132-2", "text": "   The following is a summary of certain differences between IFRS and US GAAP as of the dates of our\nfinancial statements included in this Prospectus. We are responsible for preparing the summary below. You\nshould not take this summary to be an exhaustive list of all differences between IFRS and US GAAP. The\nfollowing discussion does not purport to identify all disclosure, presentation or classification differences that\nwould affect the manner in which transactions, events, or results are presented in our consolidated financial\nstatements or the notes thereto. We have not prepared a complete reconciliation of our financial statements and\nrelated footnotes disclosures between IFRS and US GAAP and have not quantified such differences. Had we\nundertaken any such quantification or preparation or reconciliation, other potentially significant accounting and\ndisclosure differences may have come to our attention which are not identified below. Accordingly, we can\nprovide no assurance that the identified differences in the summary below represent all of the principal\ndifferences relating to our financial position, operations and cash flows. Furthermore, no attempt has been made\nto identify future differences between IFRS and US GAAP as the result of prescribed changes in accounting\nstandards, transactions or events that may occur in the future. Regulatory bodies that promulgate IFRS and US\nGAAP have significant projects ongoing that could affect future comparisons such as this one. Future\ndevelopments or changes in either IFRS or US GAAP may give rise to additional differences between IFRS and\nUS GAAP, which could have a significant impact on us.\n", "page_number": 132, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.28712023962344885, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.5062045357295678, "height": 0.21908429610611896, "width": 0.7555958862673926}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-132-3", "text": "Business Combinations\n", "page_number": 132, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.5198973042362003, "lower_right_x": 0.28977616454930427, "lower_right_y": 0.5310226786478391, "height": 0.011125374411638855, "width": 0.16938898971566846}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-132-4", "text": "Earn Out\n", "page_number": 132, "bounding_box": {"top_left_x": 0.1161524500907441, "top_left_y": 0.5477107402652974, "lower_right_x": 0.18874773139745918, "lower_right_y": 0.5614035087719298, "height": 0.013692768506632369, "width": 0.07259528130671508}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-132-5", "text": "   Under IFRS, if part of the purchase consideration is contingent on a future event, an estimate of the amount\nmust be included as part of the cost at the date of the acquisition where it is probable that it will be paid and it\ncan be reliably measured. Any revision to the estimate is subsequently adjusted against goodwill. Under US\nGAAP, contingent purchase considerations are generally excluded from the initial purchase price. The\nadditional cost is not recognized until the contingency is resolved or the amount is determinable beyond a\nreasonable doubt. Any additional revision to the estimate is recognized as an adjustment to goodwill.\n", "page_number": 132, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.57466837826273, "lower_right_x": 0.8614640048396854, "lower_right_y": 0.6572528883183568, "height": 0.08258451005562684, "width": 0.7410768300060496}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-132-6", "text": "Liabilities for Termination or Reducing of Activities\n", "page_number": 132, "bounding_box": {"top_left_x": 0.11796733212341198, "top_left_y": 0.6739409499358151, "lower_right_x": 0.4839685420447671, "lower_right_y": 0.6880616174582799, "height": 0.01412066752246477, "width": 0.3660012099213551}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-132-7", "text": "   Under IFRS, liabilities for termination or reducing the activities of the acquiree are only recognized as\nliabilities on acquisition when the acquiree has, at the acquisition date, an existing liability for restructuring\nrecognized. Any liabilities arising as a result of decisions made by the acquirer are dealt with as post-acquisition\ncosts. Under US GAAP, such liabilities related to restructuring of the acquiree are recognized as a liability in the\npurchase price allocation of the acquirer, if as of the acquisition date, management, having the appropriate level\nof authority, has begun assessing and formulating a plan to exit an activity of the acquiring entity. The plan must\nbe completed in detail as soon as possible, but no more than one year after the consummation date and\nmanagement must communicate the termination or relocation arrangements to the employees of the acquired\ncompany.\n", "page_number": 132, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.7013264869490801, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.8249893025246042, "height": 0.12366281557552417, "width": 0.7604355716878403}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-132-8", "text": "Acquired in Process Research and Development\n", "page_number": 132, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.8382541720154044, "lower_right_x": 0.4543254688445251, "lower_right_y": 0.8519469405220368, "height": 0.013692768506632369, "width": 0.3339382940108893}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-132-9", "text": "   Under IFRS, acquired in-process research and development (R&D) is recognized as a separate intangible\nasset if it meets the definition of an intangible asset and its fair value can be measured reliably. Non-identifiable\nintangible assets are subsumed within goodwill. US GAAP similarly requires acquired in-process R&D to be\n", "page_number": 132, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.8656397090286693, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.9067180145485665, "height": 0.04107830551989722, "width": 0.7555958862673926}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-132-10", "text": "130\n", "page_number": 132, "bounding_box": {"top_left_x": 0.8560193587416818, "top_left_y": 0.9477963200684638, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9572100984167736, "height": 0.00941377834830981, "width": 0.024803387779794295}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-133-0", "text": "valued at fair value. However, the acquired in-process R&D is expensed immediately unless it has an alternative\nfuture use.\n", "page_number": 133, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.08515190415062045, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.10954214805305948, "height": 0.024390243902439032, "width": 0.7555958862673926}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-133-1", "text": "Negative Goodwill\n", "page_number": 133, "bounding_box": {"top_left_x": 0.1161524500907441, "top_left_y": 0.12623020967051776, "lower_right_x": 0.25105868118572294, "lower_right_y": 0.14035087719298245, "height": 0.014120667522464686, "width": 0.13490623109497885}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-133-2", "text": "   Prior to issuance of IFRS 3, \u201cBusiness Combinations\u201d, IFRS required that the excess of fair value of net\nassets acquired over the acquisition costs be recognized as negative goodwill. This negative goodwill was\nsubsequently taken into income either (1) in the periods when future losses occurred to the extent that the\nnegative goodwill related to expectations of future losses or (2) on a systematic basis over the remaining\nweighted-average useful life of the acquired assets for amounts of negative goodwill that did not exceed the fair\nvalues of acquired identifiable non-monetary assets or (3) immediately for amounts of negative goodwill that\nexceeded the fair values of acquired non-monetary assets. From 1 January 2003, upon adoption of IFRS 3,\n\u201cBusiness Combinations,\u201d negative goodwill resulting from business combinations is to be immediately\nrecognized in income. Furthermore, according to the standards transition rules, any existing negative goodwill\nwas to be derecognized with a corresponding adjustment to the opening balance of retained earnings. Under US\nGAAP, the excess of fair value of net assets over the acquisition costs is allocated on a pro-rata basis to reduce\nthe carrying amounts of certain acquired non-financial assets, with any excess recognized as an extraordinary\ngain.\n", "page_number": 133, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.15361574668378264, "lower_right_x": 0.8753781004234725, "lower_right_y": 0.33204963628583656, "height": 0.17843388960205392, "width": 0.7549909255898367}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-133-3", "text": "Impairment of Goodwill\n", "page_number": 133, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.34873769790329484, "lower_right_x": 0.29522081064730793, "lower_right_y": 0.36114676936243045, "height": 0.012409071459135612, "width": 0.17483363581367212}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-133-4", "text": "   Under IFRS, when events or changes in circumstances indicate possible impairment, the sum of expected\ndiscounted future cash flows is compared to the carrying amount of the goodwill. If the carrying amount of the\ngoodwill exceeds the sum of the discounted future cash flows, an impairment loss exists and a write-down is\nnecessary. The impairment loss is based on the recoverable amount. Subsequent reversal of impairment losses is\nnot permitted.\n", "page_number": 133, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.3761232349165597, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.44244758237056053, "height": 0.06632434745400084, "width": 0.7555958862673926}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-133-5", "text": "   Under US GAAP, a goodwill impairment test involves a two-step approach. Under US GAAP, in step one,\nwhen events or changes in circumstances indicate possible impairment, the sum of expected undiscounted future\ncash flows, related to the fixed asset (or group of assets) being measured, is compared to the carrying amount of\nthe respective assets. Estimates of future cash flows to test the recoverability of a long-lived asset group should\ninclude only the future cash flows that are directly associated with and are expected to arise as a direct result of\nthe use and eventual disposition of that asset group. If the sum of expected undiscounted future cash flows of the\nreporting unit is less than its book value, goodwill is considered to be impaired.\n", "page_number": 133, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.4582798459563543, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.5532734274711169, "height": 0.09499358151476256, "width": 0.7604355716878403}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-133-6", "text": "   In step two, the goodwill impairment charge is measured as the excess of its carrying amount over its implied\nfair value (i.e., fair value of the reporting unit minus fair value of individual identifiable assets and liabilities).\nFair value may be measured using quoted market prices in active markets, if available or using discounted future\ncash flows. Subsequent reversal of impairment losses is not permitted.\n", "page_number": 133, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.5678219940094138, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.6221651690201112, "height": 0.05434317501069741, "width": 0.7604355716878403}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-133-7", "text": "Impairment of Long Lived Assets\n", "page_number": 133, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.636285836542576, "lower_right_x": 0.3629764065335753, "lower_right_y": 0.6504065040650406, "height": 0.014120667522464658, "width": 0.2425892316999395}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-133-8", "text": "   Under IFRS, when events or changes in circumstances indicate possible impairment, the sum of expected\ndiscounted future cash flows is compared to the carrying amount of the respective assets. If the carrying amount\nof the asset exceeds the sum of the discounted future cash flows, an impairment loss exists and a write-down is\nnecessary. The impairment loss is based on the recoverable amount (the higher of the asset\u2019s value-in-use and\nnet selling price). Subsequent reversal of an impairment loss is required if certain criteria are met.\n", "page_number": 133, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.6636713735558408, "lower_right_x": 0.8753781004234725, "lower_right_y": 0.7325631151048353, "height": 0.06889174154899447, "width": 0.7549909255898367}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-133-9", "text": "  Under US GAAP, the goodwill impairment loss is based on the fair value compared to the carrying amount.\nSubsequent reversal of an impairment loss is prohibited.\n", "page_number": 133, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.7458279845956355, "lower_right_x": 0.8626739261947973, "lower_right_y": 0.7736414206247325, "height": 0.027813436029097027, "width": 0.7422867513611615}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-133-10", "text": "Revenue Recognition\n", "page_number": 133, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.7869062901155327, "lower_right_x": 0.27586206896551724, "lower_right_y": 0.8010269576379975, "height": 0.01412066752246477, "width": 0.15547489413188142}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-133-11", "text": "   IFRS focuses on the transfer of significant risk and rewards and the probability that the economic benefits\nassociated with the transaction will flow to the entity and that the revenue and costs can be measured reliably.\nUnder US GAAP, revenue recognition is, in principle, similar to IFRS. However there are four key criteria that\nmust be present in order to recognize revenue under US GAAP. These four criteria are (a) the seller\u2019s price to\nthe buyer is fixed or determinable, (b) collectibility of payment is reasonably assured, (c) there must be\npersuasive evidence that an arrangement exists and (d) delivery must have occurred or services must have been\nrendered.\n", "page_number": 133, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.8142918271287976, "lower_right_x": 0.8711433756805808, "lower_right_y": 0.9101412066752247, "height": 0.09584937954642714, "width": 0.7507562008469449}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-133-12", "text": "131\n", "page_number": 133, "bounding_box": {"top_left_x": 0.8560193587416818, "top_left_y": 0.9477963200684638, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9572100984167736, "height": 0.00941377834830981, "width": 0.024803387779794295}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-134-0", "text": "   Under IFRS, revenue for rendering of services is usually recognized by reference to the stage of completion.\nWhen the percentage of completion cannot be estimated reliably and, when services are performed by an\nindeterminate number of acts over a specified period of time, revenue under IFRS can be recognized, for\npractical purposes, on a straight line basis over the specified period unless there is evidence that some other\nmethod better represents the stage of completion. When the percentage of completion cannot be estimated\nreliably, revenue under IRFS can also be recognized based on the cost recovery method. When a specific act is\nmuch more significant than any other acts, the recognition of revenue is postponed until the significant act is\nexecuted. Under US GAAP, revenue for services where percentage of completion cannot be recognized reliably\nwould be recognized based on a completed contract method.\n", "page_number": 134, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.08515190415062045, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.20838682071031236, "height": 0.12323491655969192, "width": 0.7555958862673926}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-134-1", "text": "Leases", "page_number": 134, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.2233632862644416, "lower_right_x": 0.1693889897156685, "lower_right_y": 0.23277706461275138, "height": 0.009413778348309781, "width": 0.049001814882032674}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-134-2", "text": "   Under IFRS, a lease is classified as a finance lease if the risks and rewards incident to ownership lie with the\nlessee. There are only narrative thresholds for useful life (described as major part) and present value test\n(described as substantially all of). Classifying a lease depends upon the substance of transaction rather than the\nform of the contract. Under US GAAP, if any one of the following four criteria applies to a lease agreement,\nthen the lessee must clarify the lease as a finance (or capital) lease:\n", "page_number": 134, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.24946512623020967, "lower_right_x": 0.8711433756805808, "lower_right_y": 0.31835686777920413, "height": 0.06889174154899447, "width": 0.7507562008469449}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-134-3", "text": "The lease transfers ownership of the leased assets to the lessee at the end of the lease term.\n\nThe lease contains a bargain purchase option.\n\nThe lease term is greater than or equal to 75% of the economic useful life of the leased asset.\n\nThe present value of the minimum lease payments is greater than or equal to 90% of the fair value of the\nleased asset.\n", "page_number": 134, "bounding_box": {"top_left_x": 0.16878402903811252, "top_left_y": 0.33162173727000427, "lower_right_x": 0.8753781004234725, "lower_right_y": 0.441591784338896, "height": 0.10997004706889174, "width": 0.70659407138536}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-134-4", "text": "\u00b7\n", "page_number": 134, "bounding_box": {"top_left_x": 0.1367211131276467, "top_left_y": 0.33889602053915274, "lower_right_x": 0.14277071990320628, "lower_right_y": 0.3418913136499786, "height": 0.0029952931108258585, "width": 0.006049606775559574}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-134-5", "text": "\u00b7\n", "page_number": 134, "bounding_box": {"top_left_x": 0.1355111917725348, "top_left_y": 0.36585365853658536, "lower_right_x": 0.14519056261343014, "lower_right_y": 0.3722721437740693, "height": 0.006418485237483951, "width": 0.009679370840895346}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-134-6", "text": "\u00b7\n", "page_number": 134, "bounding_box": {"top_left_x": 0.1355111917725348, "top_left_y": 0.39323919554985026, "lower_right_x": 0.14519056261343014, "lower_right_y": 0.40008557980316645, "height": 0.0068463842533161845, "width": 0.009679370840895346}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-134-7", "text": "\u00b7\n", "page_number": 134, "bounding_box": {"top_left_x": 0.1355111917725348, "top_left_y": 0.4206247325631151, "lower_right_x": 0.14519056261343014, "lower_right_y": 0.4274711168164313, "height": 0.0068463842533161845, "width": 0.009679370840895346}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-134-8", "text": "   Another difference between IFRS and US GAAP relates to build to suit leases. These situations arise when a\nparty enters into a lease agreement with a lessor while the asset that is the subject of the lease is still under\nconstruction. Under IFRS capitalization occurs upon commencement of the lease. Under US GAAP, the\napplicable guidance may require the capitalization of the asset under construction on the books of the future\nlessee prior to the lease commencement date.\n", "page_number": 134, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.4582798459563543, "lower_right_x": 0.8711433756805808, "lower_right_y": 0.5271715875053488, "height": 0.06889174154899447, "width": 0.7507562008469449}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-134-9", "text": "   Under IFRS, leases of land and buildings are considered separately unless the land element is not material.\nUnder US GAAP, land and building elements are generally accounted for as a single unit, unless land represents\nmore than 25% of the total fair value of the leased property or it contains a bargain purchase option or the lease\ntransfers ownership at the end of the lease.\n", "page_number": 134, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.540436456996149, "lower_right_x": 0.8753781004234725, "lower_right_y": 0.5956354300385109, "height": 0.05519897304236199, "width": 0.7549909255898367}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-134-10", "text": "Sale and Leaseback Transactions\n", "page_number": 134, "bounding_box": {"top_left_x": 0.12099213551119177, "top_left_y": 0.6089002995293111, "lower_right_x": 0.3605565638233515, "lower_right_y": 0.6230209670517758, "height": 0.014120667522464658, "width": 0.23956442831215974}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-134-11", "text": "   IFRS and US GAAP generally require that any gain or loss on a sale and leaseback transaction be deferred\nand amortized over future periods if the resulting lease is a capital or finance lease. However, IFRS require that\nthe deferred amount be amortized over the lease term, while US GAAP requires that the deferred amount be\namortized in proportion to the amortization of the leased asset.\n", "page_number": 134, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.636285836542576, "lower_right_x": 0.8711433756805808, "lower_right_y": 0.691484809584938, "height": 0.05519897304236199, "width": 0.7507562008469449}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-134-12", "text": "   IFRS require immediate profit or loss recognition for a sale and leaseback transaction classified as an\noperating lease if the sale transaction is established at fair value because, in those situations, the sale transaction\nis deemed to be a normal sale transaction that would typically result in profit or loss being recognized\nimmediately. If the sale price is less than the property\u2019s fair value, IFRS require immediate loss recognition\nunless the loss is compensated by future rentals at a below-market price, in which case the loss is deferred and\namortized in relation to the rental payments over the period that the asset is expected to be used. If the sale price\nis above fair value, IFRS require that the excess over fair value be deferred and amortized over the period for\nwhich the asset is expected to be used. US GAAP generally require deferral of profit or loss on a sale and\nleaseback transaction that is classified as an operating lease, whereby such profit or loss would be recognized\nover the lease term.\n", "page_number": 134, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.7081728712023962, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.8421052631578947, "height": 0.13393239195549844, "width": 0.7555958862673926}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-134-13", "text": "   Under US GAAP specific strict criteria are considered if the sale and leaseback transaction involves real\nestate. Furthermore, under US GAAP specific rules apply for sale and leaseback transactions relating to\ncontinuing involvement and transfer of risks and rewards of ownership.\n", "page_number": 134, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.858793324775353, "lower_right_x": 0.8415003024803388, "lower_right_y": 0.8990158322635858, "height": 0.04022250748823286, "width": 0.721113127646703}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-134-14", "text": "132\n", "page_number": 134, "bounding_box": {"top_left_x": 0.8560193587416818, "top_left_y": 0.9477963200684638, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9572100984167736, "height": 0.00941377834830981, "width": 0.024803387779794295}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-135-0", "text": "   Under US GAAP, sale and leaseback transactions with continuing involvement in sold properties are\naccounted for as a financing. Accordingly, the seller-lessee continues to depreciate the asset as if the transaction\nhad not occurred and the sales proceeds are recognized as a financing obligation which is amortized via the\neffective interest method based upon lease payments due under the \u201clease\u201d. When the prohibited form of\ncontinuing involvement no longer exists, the sale is recognized and the related asset and obligation are removed\nwith any difference recognized as a gain. Gains of the seller-lessee are generally deferred and amortized over\nthe lease term if the leaseback is classified as an operating lease, or in proportion to the amortization of leased\nasset if leaseback is classified as a finance (or capital) lease. Losses of the seller lessee are recognized\nimmediately when the fair value of the asset is less than its carrying amount.\n", "page_number": 135, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.08515190415062045, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.20838682071031236, "height": 0.12323491655969192, "width": 0.7555958862673926}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-135-1", "text": "Stock-Based Compensation\n", "page_number": 135, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.2220795892169448, "lower_right_x": 0.3194192377495463, "lower_right_y": 0.23534445870774498, "height": 0.01326486949080019, "width": 0.19903206291591047}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-135-2", "text": "   IFRS 2, which was effective as of January 1, 2005, requires an entity to measure the goods or services\nreceived, and the corresponding increase in equity, directly, at the fair value of the goods or services received,\nunless that fair value cannot be estimated reliably. If the entity cannot estimate reliably the fair value of the\ngoods or services received, the entity is required to measure their value, and the corresponding increase in\nequity, indirectly, by reference to the fair value of the equity instruments granted. Fair value is estimated using a\nvaluation technique to estimate what the price of those equity instruments would have been on the measurement\ndate. For employees and others providing similar services, the fair value of the equity instruments granted is\nmeasured at grant date. For transactions with parties other than employees, the fair value is measured at the date\nthe entity obtains the goods or the counterparty renders service. The Company early adopted IFRS 2 effective\nJanuary 1, 2003.\n", "page_number": 135, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.24946512623020967, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.38596491228070173, "height": 0.13649978605049207, "width": 0.7604355716878403}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-135-3", "text": "   Under US GAAP, prior to the effective date of FAS 123(R), the Company can elect to follow the accounting\nprescribed by either Accounting Principles Board Opinion 25, \u201cAccounting for Stock Issued to Employees\u201d,\n(APB 25) or SFAS No 123, \u201cAccounting for Stock-Based Compensation\u201d (SFAS 123).\n", "page_number": 135, "bounding_box": {"top_left_x": 0.12099213551119177, "top_left_y": 0.40008557980316645, "lower_right_x": 0.8711433756805808, "lower_right_y": 0.441591784338896, "height": 0.04150620453572956, "width": 0.7501512401693889}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-135-4", "text": "    Under US GAAP, compensation is recorded for the cost of providing the warrants and options to the\nemployee over the relevant service period. The costs can be determined based on either the intrinsic value\nmethod (APB 25) or the fair value method (SFAS 123). Under the intrinsic value method, the compensation cost\nis the difference between the market price of the stock at the measurement date and the price to be contributed\nby the employee (exercise price). Under the intrinsic method, the measurement date is the first date on which the\nemployee knows the number of shares that such employee is entitled to receive and the exercise price. The\nmeasurement date is often the grant date; however, it may be later than the grant date in plans with variable\nterms that depend on events which occur after the grant date. These terms may be variable by design, may\nbecome variable due to their modification after the date of grant, or may be considered variable due to their\nrelationship to other stock option features. In such cases, compensation is measured at the end of each reporting\nperiod until the measurement date or, in some cases, until the stock option\u2019s exercise, forfeiture, or expiry.\n", "page_number": 135, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.4548566538296962, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.6059050064184852, "height": 0.15104835258878901, "width": 0.7604355716878403}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-135-5", "text": "  Under the fair value method, the cost associated with warrants and options is based on the fair value at the\ndate of grant. Cost is estimated using an option-pricing model. If an entity chooses to follow the intrinsic value\nmethod, it must make pro-forma disclosures of net income and earnings per share as if the fair value method had\nbeen applied.\n", "page_number": 135, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.6225930680359435, "lower_right_x": 0.8802177858439202, "lower_right_y": 0.6765083440308087, "height": 0.05391527599486523, "width": 0.7598306110102844}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-135-6", "text": "   Under US GAAP, warrants and options granted to non-employees for services performed are accounted for at\nfair value. The fair value is measured at the earlier of the completion of the services or the date when the\ncompany receives a commitment of performance.\n", "page_number": 135, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.6910569105691057, "lower_right_x": 0.8802177858439202, "lower_right_y": 0.7317073170731707, "height": 0.04065040650406504, "width": 0.7598306110102844}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-135-7", "text": "   In December 2004, the FASB issued FASB Statement No. 123(R), Share-Based Payment (FAS 123(R)). FAS\n123(R) requires companies to (i) use fair value to measure stock-based compensation awards and (ii) cease\nusing the \u201cintrinsic value\u201d method of accounting, which APB 25 allowed and resulted in no expense for many\nawards of stock options for which the exercise price of the option equalled the price of the underlying stock at\nthe grant date. FAS 123(R) is effective for non-public companies as of 1 November 2006.\n", "page_number": 135, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.7458279845956355, "lower_right_x": 0.8796128251663642, "lower_right_y": 0.8142918271287976, "height": 0.06846384253316207, "width": 0.7592256503327284}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-135-8", "text": "Research and Development Costs\n", "page_number": 135, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.82798459563543, "lower_right_x": 0.3623714458560194, "lower_right_y": 0.8412494651262302, "height": 0.01326486949080019, "width": 0.24198427102238357}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-135-9", "text": "   Under IFRS, research costs should be expensed as incurred. An intangible asset arising from development (or\nfrom the development phase of an internal project) should be recognized as an intangible if, and only if, an\nenterprise can demonstrate all of the following:\n", "page_number": 135, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.8553701326486949, "lower_right_x": 0.8777979431336963, "lower_right_y": 0.8968763371844245, "height": 0.04150620453572962, "width": 0.7574107683000605}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-135-10", "text": "133\n", "page_number": 135, "bounding_box": {"top_left_x": 0.8560193587416818, "top_left_y": 0.9477963200684638, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9572100984167736, "height": 0.00941377834830981, "width": 0.024803387779794295}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-136-0", "text": "  \u00b7    The technical feasibility of completing the intangible asset so that it will be available for use or sale;\n\n  \u00b7    Its intention to complete the intangible asset and use or sell it;\n\n  \u00b7    Its ability to use or sell the intangible asset;\n\n  \u00b7    How the intangible asset will generate probable future economic benefits. Among other things, the\n       enterprise should demonstrate the existence of a market for the output of the intangible asset or the\n       intangible asset itself or, if it is to be used internally, the usefulness of the intangible asset;\n\n  \u00b7    The availability of adequate technical, financial and other resources to complete the development and to\n       use or sell the intangible asset; and\n\n  \u00b7    Its ability to reliably measure the expenditure attributable to the intangible asset during its development.\n\n  The ability to use the intangible asset is assessed primarily on the probability of obtaining regulatory\napproval.\n", "page_number": 136, "bounding_box": {"top_left_x": 0.12099213551119177, "top_left_y": 0.08515190415062045, "lower_right_x": 0.8711433756805808, "lower_right_y": 0.32135216089002994, "height": 0.23620025673940948, "width": 0.7501512401693889}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-136-1", "text": "Under US GAAP, all research and development costs are expensed as incurred.\n", "page_number": 136, "bounding_box": {"top_left_x": 0.1385359951603146, "top_left_y": 0.33504492939666236, "lower_right_x": 0.6715063520871143, "lower_right_y": 0.3491655969191271, "height": 0.014120667522464714, "width": 0.5329703569267997}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-136-2", "text": "Pension Liabilities\n", "page_number": 136, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.36243046640992727, "lower_right_x": 0.25650332728372655, "lower_right_y": 0.37526743688489517, "height": 0.012836970474967901, "width": 0.13611615245009073}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-136-3", "text": "   IFRS and US GAAP have similar fundamental approaches to accounting for employee benefit plans. The net\nobligation in respect of defined benefit pension plans and similar obligations is calculated using the projected\nunit credit method. Differences, however, can arise due to a number of differences in the details of the relevant\nstandards, especially in respect of the additional minimum liability, the recognition of prior service costs and the\namortization of actuarial gains and losses.\n", "page_number": 136, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.3898160034231921, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.4587077449721866, "height": 0.06889174154899447, "width": 0.7555958862673926}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-136-4", "text": "   Under US GAAP, if the accumulated benefit obligation exceeds the fair value of plan assets, an additional\nminimum liability that is at least equal to the unfunded accumulated benefit obligation, is recorded. Also, under\nUS GAAP, an equal amount is capitalized as an intangible asset up to the amount of any unrecognized net\ntransition obligation plus the unrecognized prior service costs, with the remainder charged against shareholders\u2019\nequity as a component of other comprehensive income. Under IFRS, there are no such requirements for the\nimmediate recognition of an additional minimum pension liability.\n", "page_number": 136, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.4719726144629867, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.5562687205819427, "height": 0.08429610611895594, "width": 0.7555958862673926}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-136-5", "text": "  Under IFRS, the vested portion of past service cost, which is the increase in the present value of the\nobligation due to changes in the benefit entitlement that is allocated to prior period\u2019s service, is recognized\nimmediately in full. Under US GAAP, both the vested and the unvested portions are amortized on a straight-line\nbasis over the average future service lives of the active participants.\n", "page_number": 136, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.5712451861360719, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.6251604621309371, "height": 0.05391527599486523, "width": 0.7555958862673926}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-136-6", "text": "   Under US GAAP, actuarial gains and losses are recognized as income or expense if the net cumulative\nunrecognized actuarial gains and losses at the end of the previous reporting period exceeded the greater of 10%\nof the present value of the projected benefit obligation at that date (before deducting plan assets) or 10% of the\nfair value of any plan assets at that date. In accordance with IFRS actuarial gains and losses may be recognized\neven if they fall within the aforementioned limits.\n", "page_number": 136, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.6397090286692341, "lower_right_x": 0.8711433756805808, "lower_right_y": 0.707744972186564, "height": 0.06803594351732989, "width": 0.7507562008469449}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-136-7", "text": "  Under IFRS, net pension assets are limited to the lower of (a) the asset resulting from applying the standard,\nand (b) the net total of any unrecognized actuarial losses and past service costs and the present value of any\navailable funds from the plan or reduction in future contributions to the plan. This concept of an asset limitation\ndoes not exist under US GAAP.\n", "page_number": 136, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.7218656397090286, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.7736414206247325, "height": 0.051775780915703895, "width": 0.7555958862673926}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-136-8", "text": "   As our defined benefit plan was terminated in 2006, the application of FAS 158 does not impact our financial\nstatements.\n", "page_number": 136, "bounding_box": {"top_left_x": 0.12099213551119177, "top_left_y": 0.7903294822421908, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.8151476251604621, "height": 0.024818142918271335, "width": 0.7549909255898366}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-136-9", "text": "Other Comprehensive Income\n", "page_number": 136, "bounding_box": {"top_left_x": 0.12159709618874773, "top_left_y": 0.8314077877620881, "lower_right_x": 0.338777979431337, "lower_right_y": 0.8455284552845529, "height": 0.01412066752246477, "width": 0.21718088324258925}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-136-10", "text": "  Generally under IFRS, items such as cumulative translation adjustments and revaluations of available-for-sale\nmarketable securities are recorded directly in equity.\n", "page_number": 136, "bounding_box": {"top_left_x": 0.12159709618874773, "top_left_y": 0.858793324775353, "lower_right_x": 0.8790078644888082, "lower_right_y": 0.8866067608044501, "height": 0.02781343602909714, "width": 0.7574107683000605}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-136-11", "text": "134\n", "page_number": 136, "bounding_box": {"top_left_x": 0.8560193587416818, "top_left_y": 0.9477963200684638, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9572100984167736, "height": 0.00941377834830981, "width": 0.024803387779794295}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-137-0", "text": "  Under US GAAP, such items are recorded in Other Comprehensive Income, which must be disclosed as a\nseparate primary statement or as a category highlighted within the primary statement of change in Shareholders\u2019\nequity.\n", "page_number": 137, "bounding_box": {"top_left_x": 0.12099213551119177, "top_left_y": 0.08515190415062045, "lower_right_x": 0.8753781004234725, "lower_right_y": 0.12623020967051776, "height": 0.041078305519897315, "width": 0.7543859649122807}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-137-1", "text": "Disclosure Differences between IFRS and US GAAP\n", "page_number": 137, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.1399229781771502, "lower_right_x": 0.49788263762855417, "lower_right_y": 0.1527599486521181, "height": 0.012836970474967901, "width": 0.37749546279491836}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-137-2", "text": "  In addition to the summary of certain differences between IFRS and US GAAP, which may affect\nconsolidated income and total shareholders\u2019 equity, there are a number of significant disclosure differences.\n", "page_number": 137, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.16730851519041506, "lower_right_x": 0.8463399879007865, "lower_right_y": 0.1951219512195122, "height": 0.02781343602909714, "width": 0.7259528130671506}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-137-3", "text": "   Compared to IFRS, the financial statement disclosures required under US GAAP can be more comprehensive\nin many areas including taxes, retirement and other post-retirement benefits, leasing, segment information,\nexecutive and director compensation and related party disclosures. No attempt has been made to identify all\ndisclosure differences or future disclosure differences as the result of prescribed changes in accounting\nstandards. In addition, this description is not intended to address all differences in presentation, including\nclassification, disclosure and display of financial information contained therein.\n", "page_number": 137, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.20838682071031236, "lower_right_x": 0.8753781004234725, "lower_right_y": 0.29097133076593923, "height": 0.08258451005562686, "width": 0.7549909255898367}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-137-4", "text": "135\n", "page_number": 137, "bounding_box": {"top_left_x": 0.8560193587416818, "top_left_y": 0.9477963200684638, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9572100984167736, "height": 0.00941377834830981, "width": 0.024803387779794295}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-138-0", "text": "Glossary of Selected Terms\n", "page_number": 138, "bounding_box": {"top_left_x": 0.3623714458560194, "top_left_y": 0.10226786478391099, "lower_right_x": 0.6388384754990926, "lower_right_y": 0.11895592640136927, "height": 0.016688061617458283, "width": 0.2764670296430732}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-138-1", "text": "Biomarkers: Biomarkers are anatomic, physiologic, biochemical, or molecular parameters associated with the\npresence and severity of specific disease states. Biomarkers are detectable and measurable by a variety of\nmethods including physical examination, laboratory assays and medical imaging.\n", "page_number": 138, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.1364997860504921, "lower_right_x": 0.8663036902601331, "lower_right_y": 0.1775780915703894, "height": 0.0410783055198973, "width": 0.7459165154264973}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-138-2", "text": "Biopharmaceutical/biologic: A biological molecule used as a drug, usually a protein.\n", "page_number": 138, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.19127086007702182, "lower_right_x": 0.6999395039322444, "lower_right_y": 0.20539152759948653, "height": 0.014120667522464714, "width": 0.5795523290986085}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-138-3", "text": "cGMP: Formal standards of a manufacturing facility\u2019s cleanliness, process, quality controls and documentation\nset out and periodically monitored by the main medicines control agencies to which a company has to conform\nin order to manufacture quantities of a medicinal product for clinical-phase testing.\n", "page_number": 138, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.2186563970902867, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.2601626016260163, "height": 0.04150620453572959, "width": 0.7555958862673926}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-138-4", "text": "Clinical trials: Trials of a new drug, device or drug indication in humans, divided into phases that examine\nsafety and efficacy. Subject to the scrutiny of the results from such trials, the governing body may give approval\nfor marketing.\n", "page_number": 138, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.2734274711168164, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.314933675652546, "height": 0.04150620453572956, "width": 0.7555958862673926}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-138-5", "text": "Controlled release: A way of formulating a medicine so that it is released into the body steadily, over a long\nperiod of time, thus reducing the dosing frequency.\n", "page_number": 138, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.33162173727000427, "lower_right_x": 0.8614640048396854, "lower_right_y": 0.3581514762516046, "height": 0.026529738981600326, "width": 0.7410768300060496}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-138-6", "text": "EMEA: The European Medicines Evaluation Agency, which oversees the approval process for a new drug or\ndevice to be marketed.\n", "page_number": 138, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.3727000427899016, "lower_right_x": 0.8602540834845736, "lower_right_y": 0.3970902866923406, "height": 0.02439024390243899, "width": 0.7398669086509377}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-138-7", "text": "Epitope: A unique shape or the part of an antigen molecule which contacts the antigen binding site of an\nantibody or T-cell receptor, carried on an antigen's surface that triggers a corresponding antibody response.\n", "page_number": 138, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.41377834830979887, "lower_right_x": 0.8415003024803388, "lower_right_y": 0.441591784338896, "height": 0.02781343602909714, "width": 0.721113127646703}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-138-8", "text": "EVR (early viral response):\n", "page_number": 138, "bounding_box": {"top_left_x": 0.12099213551119177, "top_left_y": 0.4548566538296962, "lower_right_x": 0.308529945553539, "lower_right_y": 0.4689773213521609, "height": 0.014120667522464714, "width": 0.18753781004234726}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-138-9", "text": ": A reduction of at least two logs of plasma HCV virus levels at week 12 of therapy.\n", "page_number": 138, "bounding_box": {"top_left_x": 0.30913490623109496, "top_left_y": 0.4548566538296962, "lower_right_x": 0.8663036902601331, "lower_right_y": 0.4689773213521609, "height": 0.014120667522464714, "width": 0.5571687840290381}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-138-10", "text": "FDA: The US Food and Drug Administration, responsible for overseeing the approval process for a new drug or\n", "page_number": 138, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.48267008985879334, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.49636285836542576, "height": 0.013692768506632425, "width": 0.7604355716878403}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-138-11", "text": "FDA: The US Food and\ndevice to be marketed.\n", "page_number": 138, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.49636285836542576, "lower_right_x": 0.2752571082879613, "lower_right_y": 0.5083440308087291, "height": 0.011981172443303378, "width": 0.15486993345432548}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-138-12", "text": "Genotype: The genotype is the specific genetic makeup (genome) of an individual, in the form of DNA.\nTogether with the environmental variation that influences the individual, it codes for the phenotype of that\nindividual.\n", "page_number": 138, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.5233204963628584, "lower_right_x": 0.837265577737447, "lower_right_y": 0.5648267008985879, "height": 0.04150620453572951, "width": 0.7168784029038112}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-138-13", "text": "GLP-1: An abbreviation for glucagon-like peptide-1, an endogenous peptide secreted by intestinal cells and\nregulating insulin and glucagon action, and mediating satiety.\n", "page_number": 138, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.5780915703893881, "lower_right_x": 0.8487598306110102, "lower_right_y": 0.6084724005134788, "height": 0.030380830124090763, "width": 0.7283726557773744}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-138-14", "text": "Hepatitis C Virus (HCV): A contagious virus that causes inflammation of the liver. A chronic carrier state\noccurs in some individuals and may result in life-threatening liver damage, cirrhosis and/or liver cancer. HCV is\nspread mainly via contaminated blood products or shared needles. There is no standard treatment or vaccine.\n", "page_number": 138, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.6225930680359435, "lower_right_x": 0.8753781004234725, "lower_right_y": 0.6632434745400085, "height": 0.04065040650406504, "width": 0.7549909255898367}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-138-15", "text": "IFN: An abbreviation for Interferon. Interferons are cytokines that can induce cells to resist viral replication.\nInterferon-a and interferon-b are produced by leukocytes and fibroblasts respectively as well as by other cells.\n", "page_number": 138, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.6773641420624733, "lower_right_x": 0.8584392014519057, "lower_right_y": 0.7051775780915703, "height": 0.027813436029097027, "width": 0.7380520266182699}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 16, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-138-16", "text": "In vitro: Pertaining to experiments or reactions occurring in the artificial environment of a laboratory test tube.\nLiterally meaning \u201cin glass\u201d.\n", "page_number": 138, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.7184424475823705, "lower_right_x": 0.8711433756805808, "lower_right_y": 0.7462558836114677, "height": 0.02781343602909714, "width": 0.7507562008469449}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 17, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-138-17", "text": "IND/pre-IND: Investigational New Drug (IND) is the status of an experimental drug after the FDA agrees that\nit can be tested in people. After completing pre-clinical testing, a company files an IND with the FDA to begin\nto test the drug in humans. The IND becomes effective if the FDA does not disapprove it within 30 days. Pre-\nIND is the status prior to this agreement.\n", "page_number": 138, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.7595207531022679, "lower_right_x": 0.8711433756805808, "lower_right_y": 0.8147197261446298, "height": 0.05519897304236199, "width": 0.7507562008469449}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 18, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-138-18", "text": "Interferon alfa: Interferons are any of a group of glycoproteins that are produced by different cell types in\nresponse to various stimuli, such as exposure to a virus, bacterium, parasite, or other antigen, and that prevent\nviral replication in newly infected cells and, in some cases, modulate specific cellular functions. There are three\ntypes of Interferons. Alfa and beta Interferons are produced by white blood cells and a type of connective tissue\ncell called a fibroblast.\n", "page_number": 138, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.82798459563543, "lower_right_x": 0.8735632183908046, "lower_right_y": 0.8947368421052632, "height": 0.06675224646983313, "width": 0.7531760435571688}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 19, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-138-19", "text": "136\n", "page_number": 138, "bounding_box": {"top_left_x": 0.8560193587416818, "top_left_y": 0.9477963200684638, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9572100984167736, "height": 0.00941377834830981, "width": 0.024803387779794295}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-139-0", "text": "Japanese encephalitis: Japanese encephalitis is a disease that is spread to humans by infected mosquitoes in\nAsia. It is one of a group of mosquito-borne virus diseases that can affect the central nervous system and cause\nsevere complications and even death.\n", "page_number": 139, "bounding_box": {"top_left_x": 0.12099213551119177, "top_left_y": 0.08515190415062045, "lower_right_x": 0.8663036902601331, "lower_right_y": 0.12665810868635002, "height": 0.04150620453572958, "width": 0.7453115547489413}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-139-1", "text": "Neutrophil: The most common type of white blood cell and an essential part of the immune system.\n", "page_number": 139, "bounding_box": {"top_left_x": 0.12099213551119177, "top_left_y": 0.1399229781771502, "lower_right_x": 0.7979431336963098, "lower_right_y": 0.1540436456996149, "height": 0.014120667522464714, "width": 0.676950998185118}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-139-2", "text": "New Drug Application (NDA): An application submitted by the manufacturer of a drug to the FDA, after\nclinical trials have been completed, for license to market the drug for a specified indication.\n", "page_number": 139, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.16730851519041506, "lower_right_x": 0.837265577737447, "lower_right_y": 0.1951219512195122, "height": 0.02781343602909714, "width": 0.7168784029038112}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-139-3", "text": "OAS: An enzyme known as 2\u20195\u2019-oligoadenylate synthetase. This enzyme is a biological marker for the activity\nin interferon alfa.\n", "page_number": 139, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.20838682071031236, "lower_right_x": 0.8711433756805808, "lower_right_y": 0.2362002567394095, "height": 0.02781343602909714, "width": 0.7507562008469449}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-139-4", "text": "Otitis Media: Middle ear infection (otitis media) is an infection of the part of the ear inside the ear drum. It\ncauses ear pain and fever, is most common in children, and often follows a cold.\n", "page_number": 139, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.25288831835686776, "lower_right_x": 0.8469449485783425, "lower_right_y": 0.27941805733846814, "height": 0.02652973898160038, "width": 0.7265577737447066}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-139-5", "text": "OctoDEX\u2122: Our proprietary delivery system for the controlled release of therapeutic proteins. The technology\nis based on cross-linked dextran microspheres, prepared without organic solvents. OctoDEX based products can\nbe used for both subcutaneous and intramuscular administration.\n", "page_number": 139, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.2939666238767651, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.33204963628583656, "height": 0.03808301240907147, "width": 0.7555958862673926}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-139-6", "text": "Parenteral: Delivery of a drug not through the alimentary canal, but by injection through some other route such\nas subcutaneous, intravenous, or intramuscular.\n", "page_number": 139, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.355584082156611, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.3816859221223791, "height": 0.026101839965768092, "width": 0.7555958862673926}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-139-7", "text": "Pegylated interferon: The chemical addition of polyethylene glycol (PEG) to interferon. This acts as a\nprolonged release formulation since the long chain PEG molecules degrade slowly giving a prolonged\ncirculation of interferon.\n", "page_number": 139, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.39666238767650835, "lower_right_x": 0.8179068360556564, "lower_right_y": 0.4347454000855798, "height": 0.03808301240907147, "width": 0.6975196612220206}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-139-8", "text": "Peptide: A substance which consists of a chain of two ore more amino acids. A functional peptide is commonly\nreferred to as a protein.\n", "page_number": 139, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.4582798459563543, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.4856653829696192, "height": 0.027385537013264905, "width": 0.7555958862673926}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-139-9", "text": "Pharmacodynamics: The study of a drugs action in the body over time, this includes absorption, distribution,\nlocalization, transformation, and excretion (in simple terms, what the drug does in the body).\n", "page_number": 139, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.5062045357295678, "lower_right_x": 0.8608590441621294, "lower_right_y": 0.5335900727428327, "height": 0.02738553701326485, "width": 0.7404718693284936}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-139-10", "text": "Pharmacokinetics (PK): The study of absorption, distribution, metabolism, and excretion of drugs (what the\nbody does to the drug).\n", "page_number": 139, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.5507060333761232, "lower_right_x": 0.8566243194192378, "lower_right_y": 0.5785194694052204, "height": 0.02781343602909714, "width": 0.736237144585602}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-139-11", "text": "Phenotype: The observable character of a cell or an organism, the physical manifestation of the genotype.\n", "page_number": 139, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.5952075310226786, "lower_right_x": 0.8366606170598911, "lower_right_y": 0.6093281985451433, "height": 0.014120667522464658, "width": 0.7162734422262553}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-139-12", "text": "PolyActive\u2122: A biodegradable polymeric drug delivery system. It controls the release of proteins and\nlipophilic small molecules. Products based on PolyActive can be used for both local and systemic\nadministration, and have applications in pharmaceutics and medical technology.\n", "page_number": 139, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.6225930680359435, "lower_right_x": 0.8130671506352087, "lower_right_y": 0.6632434745400085, "height": 0.04065040650406504, "width": 0.6926799758015729}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-139-13", "text": "Prophylactic vaccine: A vaccine for the prevention of, or protective treatment for a disease. This vaccine\ncreates an immunological barrier at the portal of entry.\n", "page_number": 139, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.6842105263157895, "lower_right_x": 0.837265577737447, "lower_right_y": 0.7107402652973898, "height": 0.02652973898160027, "width": 0.7168784029038112}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-139-14", "text": "Recombinant: A microbe, or strain, that has received chromosomal parts from different parental strains. Often\nused to denote the insertions of a sequence of DNA, by chemical or biological means, into the DNA of a\nrecipient organism with the objective of producing therapeutically useful products.\n", "page_number": 139, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.7252888318356868, "lower_right_x": 0.8711433756805808, "lower_right_y": 0.7659392383397519, "height": 0.04065040650406504, "width": 0.7507562008469449}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-139-15", "text": "137\n", "page_number": 139, "bounding_box": {"top_left_x": 0.8560193587416818, "top_left_y": 0.9477963200684638, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.9572100984167736, "height": 0.00941377834830981, "width": 0.024803387779794295}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-140-0", "text": "Index to Financial Statements\n", "page_number": 140, "bounding_box": {"top_left_x": 0.34785238959467635, "top_left_y": 0.11253744116388532, "lower_right_x": 0.6485178463399879, "lower_right_y": 0.12665810868635002, "height": 0.0141206675224647, "width": 0.30066545674531153}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-140-1", "text": "                                                                                         Page\nCondensed Consolidated Interim Financial Statements 30 June 2007 and 2006                F-2\nReview Report                                                                            F-3\nCondensed consolidated balance sheet                                                     F-5\nCondensed consolidated income statement                                                  F-6\nCondensed consolidated statement of changes in equity                                    F-7\nCondensed consolidated cash flow statement                                               F-9\nNotes to the condensed consolidated interim financial statements 30 June 2007 and 2006   F-10\n\nConsolidated Financial Statements 31 December 2006                                       F-15\nAuditor\u2019s Report                                                                         F-16\nConsolidated balance sheet                                                               F-18\nConsolidated income statement                                                            F-19\nConsolidated statement of changes in equity                                              F-20\nConsolidated cash flow statement                                                         F-21\nNotes to the consolidated financial statements 31 December 2006                          F-22\n\nConsolidated Financial Statements 31 December 2005, 2004 and 2003                        F-57\nAuditor\u2019s Report                                                                         F-58\nConsolidated balance sheet                                                               F-59\nConsolidated income statement                                                            F-61\nConsolidated statement of changes in equity                                              F-62\nConsolidated cash flow statement                                                         F-63\nNotes to the consolidated financial statements 31 December 2005, 2004 and 2003           F-64\n", "page_number": 140, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.1647411210954215, "lower_right_x": 0.8082274652147611, "lower_right_y": 0.5609756097560976, "height": 0.3962344886606761, "width": 0.6588021778584392}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-140-2", "text": "F-1 -\n", "page_number": 140, "bounding_box": {"top_left_x": 0.48336358136721114, "top_left_y": 0.9477963200684638, "lower_right_x": 0.5117967332123412, "lower_right_y": 0.9572100984167736, "height": 0.00941377834830981, "width": 0.028433151845130067}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-141-0", "text": "OctoPlus N.V.\n", "page_number": 141, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.12280701754385964, "lower_right_x": 0.3484573502722323, "lower_right_y": 0.14035087719298245, "height": 0.017543859649122806, "width": 0.19903206291591044}, "blob_type": "image", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-141-1", "text": "Condensed      Consolidated    Interim   Financial\nStatements 30 June 2007 and 2006\n", "page_number": 141, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.17415489944373128, "lower_right_x": 0.8511796733212341, "lower_right_y": 0.21566110397946084, "height": 0.04150620453572956, "width": 0.7017543859649122}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-141-2", "text": "F-2\n", "page_number": 141, "bounding_box": {"top_left_x": 0.48941318814277074, "top_left_y": 0.9238339751818571, "lower_right_x": 0.5075620084694494, "lower_right_y": 0.9341035515618314, "height": 0.010269576379974388, "width": 0.018148820326678694}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-142-0", "text": "", "page_number": 142, "bounding_box": {"top_left_x": 0.1500302480338778, "top_left_y": 0.0646127513906718, "lower_right_x": 0.8469449485783425, "lower_right_y": 0.07274283269148481, "height": 0.00813008130081301, "width": 0.6969147005444647}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-142-1", "text": "Deloitte.\n\nDeloltteAceauatancs BY.\nKangaloorh 43\n\n2424 Leiden\na6\n\noe\n230 Ak -aoen\nNethe: ands\n\n    \n\nville.\nHscantnm ber 2094S\n\nTo the Board of Supervisery Directors and Board ot Directors of\nOrtoPlus NV.\n\nP.Q), Box 722\n\n1300 AS Leiden\n\nThe Nethedlandy\n\ncor Frem Os refwence\n3100101130 92)\n\nSi beet You rfernn:\n\nLodepeadent Auditot's Repurt\n\nReview report\n\nIntroduction\n\nWe luive reviewed the conadcnscd consulidatert balauve sheets of OctoPlus N.\u00a5. az of 39 June\n2007 und 31 December 2006, and the relaled condensed consolidated incame statement fur the\nsix-month periads coded 30 June 20? and 2U06, the coudeused stulemenr. of changes in cynity\nand the condensed cash flow statement and the notes chetwon fur the sis-mouth periods ended 30\nJunc 2007 and 2006, together the itdcrim tinancial statements. \u2018I'he Company\u2019s drauayement is\nTespousible for the peepuration and prosentation of the interim financial statenenty in accordance\nwith Liemational Financial Reporting Standard 34 \u201cInterim Minancial Stalenuenty\" as adopted by\nthe European Uniun. Our responsibility is te ivsne a tepart on these Alezim fmancial statements\nbased on our review.\n\nSenpe\n\nWe conducted our review of the interim financial statenuenta in accordance with Dutch law,\nincluding Standard 2410 \u201cReview of interim financial information pertocmed by the independent\nauditor of the enity\u201d. A revicw af interim finuncial itiformarion consisls of enguirics with\nCompany persoumel responsible for finuneing and reporting, and applying analytical procedures\nWw the financial information and underlying financial data, and, bused thercan, assessing whether\nthe accounting poticies atl presentation have been consistently applicd unless otherwise\ndisclosed A rovicw excludes sudit procedures such as tests of controls and veti Geution of assets.\nliabilities and trarisuctiions, [tis substantially fexs in soupy than an audit perfarmed in contottuily\nwith Dutch Law including Auditing Sundsrds, and omecquently does not enable 03 to chluin\nAsamauee thu we would beconle awure of all significant mauers (hal might be Kdentified in an\naudit. Accordingly, we da nel express au audil opinion.\n\nBein Azcoutitanta By, Is reclsiered WHE the Trade Begs or Ihe Cre nibar af Conerecce and kdugiy'lt Messer of\nPatten number 143083053 Osloltts Tewehc Totenatce", "page_number": 142, "bounding_box": {"top_left_x": 0.21355111917725347, "top_left_y": 0.0928540864356012, "lower_right_x": 0.8892921960072595, "lower_right_y": 0.8040222507488233, "height": 0.711168164313222, "width": 0.6757410768300061}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-142-2", "text": "F-3\n", "page_number": 142, "bounding_box": {"top_left_x": 0.48941318814277074, "top_left_y": 0.9238339751818571, "lower_right_x": 0.5081669691470054, "lower_right_y": 0.9341035515618314, "height": 0.010269576379974388, "width": 0.018753781004234693}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-143-0", "text": "Deloitte. 4\n\n2\nJIGLOL 130-12),\n\nConclusion\n\nBased un worrevicw, acthing bas cume ti our attedtion jhul causes us to helieve that the\naccompanying interim financial statements, jn all marcrial respects, du cot comply with IAS 34\n\u201cInterim Kismaicial Reporting\u201d a3 adopted by the Kuropess Caiou,\n\nLeiden, 6 August. 2007\n\nDeluitly Acoountaina BY,\n\n  \n\ni\ni\nI. Verloop a", "page_number": 143, "bounding_box": {"top_left_x": -0.024954627949183288, "top_left_y": 0.0680359435173299, "lower_right_x": 1.0461282516636419, "lower_right_y": 0.44501497646555416, "height": 0.37697903294822427, "width": 1.0710828796128251}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-143-1", "text": "", "page_number": 143, "bounding_box": {"top_left_x": 0.8039927404718693, "top_left_y": 0.5725288831835686, "lower_right_x": 0.8064125831820932, "lower_right_y": 0.6046213093709885, "height": 0.03209242618741981, "width": 0.002419842710223885}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-143-2", "text": "F-4\n", "page_number": 143, "bounding_box": {"top_left_x": 0.48941318814277074, "top_left_y": 0.9238339751818571, "lower_right_x": 0.5081669691470054, "lower_right_y": 0.9328198545143346, "height": 0.00898587933247752, "width": 0.018753781004234693}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-144-0", "text": "Condensed consolidated balance sheet\nat 30 June 2007 and 31 December 2006\n\n                                       (In Euro x 1,000)\n", "page_number": 144, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.09542148053059478, "lower_right_x": 0.8911070780399274, "lower_right_y": 0.16859221223791185, "height": 0.07317073170731707, "width": 0.7416817906836055}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-144-1", "text": "                                Note   At 30 June 2007 At 31 December 2006\n\n\n\n\nIntangible fixed assets          4              3,018                1,766\nProperty, plant and equipment    5              6,622                6,350\nFinancial fixed assets           6                 16                1,016\n                                                9,656                9,132\n\nOther current assets             6              9,898               14,599\nCash and cash equivalents        6              5,711                8,535\n                                               15,609               23,134\nTotal assets                                   25,265               32,266\n\nEquity                           7             15,317               21,142\nNon-current liabilities                         3,583                3,618\nCurrent liabilities              6              6,365                7,506\nTotal equity and liabilities                   25,265               32,266\n", "page_number": 144, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.2092426187419769, "lower_right_x": 0.8953418027828192, "lower_right_y": 0.4890885750962773, "height": 0.27984595635430043, "width": 0.7459165154264973}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-144-2", "text": "F-5\n", "page_number": 144, "bounding_box": {"top_left_x": 0.48941318814277074, "top_left_y": 0.9238339751818571, "lower_right_x": 0.5075620084694494, "lower_right_y": 0.9332477535301669, "height": 0.00941377834830981, "width": 0.018148820326678694}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-145-0", "text": "Condensed consolidated income statement for the period ended 30 June\n2007 and 2006\n", "page_number": 145, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.08515190415062045, "lower_right_x": 0.8953418027828192, "lower_right_y": 0.11895592640136927, "height": 0.03380402225074883, "width": 0.7459165154264973}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-145-1", "text": "(In Euro x 1,000)\n", "page_number": 145, "bounding_box": {"top_left_x": 0.7985480943738656, "top_left_y": 0.1467693624304664, "lower_right_x": 0.8905021173623714, "lower_right_y": 0.157466837826273, "height": 0.010697475395806594, "width": 0.09195402298850575}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-145-2", "text": "                                                                           Six months ending 30 June\n\n                                                                    Note             2007              2006\n\nService revenues                                                                     2,543             3,157\nRoyalty and license revenues                                                           213                30\nIncome from subsidies                                                                  118                92\nTotal revenues                                                                       2,874             3,279\n\nRaw materials and auxiliaries                                                          191               100\nCost of contracted work and other external charges                   8               1,403             1,147\nEmployee benefits                                                    9               3,993             2,920\nDepreciation and amortisation                                                          541               512\nOther costs                                                          9               2,930             2,597\nTotal operating costs                                                                9,058             7,276\n\nOperating loss                                                                     (6,184)         (3,997)\n\nInterest                                                             10                63              (104)\nResult before corporate income taxes                                               (6,121)         (4,101)\n\nCorporate income taxes                                                                   -               -\nResult for the period                                                              (6,121)         (4,101)\n\nAttributable to:\nEquity holders of the Company                                                      (6,121)         (4,101)\n\nResult per share for result attributable to the equity holders of\nthe Company during the six month period (expressed in Euro\nper share)\n\u2013 basic                                                                             (0.38)             (0.35)\n\u2013 diluted                                                                           (0.38)             (0.35)\n", "page_number": 145, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.20496362858365424, "lower_right_x": 0.8953418027828192, "lower_right_y": 0.7167308515190415, "height": 0.5117672229353872, "width": 0.7459165154264973}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-145-3", "text": "F-6\n", "page_number": 145, "bounding_box": {"top_left_x": 0.48941318814277074, "top_left_y": 0.9238339751818571, "lower_right_x": 0.5081669691470054, "lower_right_y": 0.9332477535301669, "height": 0.00941377834830981, "width": 0.018753781004234693}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-146-0", "text": "Condensed consolidated statement of changes in equity\nfor the period ended 30 June 2007 and 2006\n", "page_number": 146, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.08515190415062045, "lower_right_x": 0.7017543859649122, "lower_right_y": 0.12280701754385964, "height": 0.037655113393239195, "width": 0.5523290986085904}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-146-1", "text": "(In Euro x\n", "page_number": 146, "bounding_box": {"top_left_x": 0.8124621899576527, "top_left_y": 0.12665810868635002, "lower_right_x": 0.8656987295825771, "lower_right_y": 0.13692768506632436, "height": 0.010269576379974332, "width": 0.05323653962492436}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-146-2", "text": "x 1,000)\n", "page_number": 146, "bounding_box": {"top_left_x": 0.8663036902601331, "top_left_y": 0.12665810868635002, "lower_right_x": 0.9086509376890503, "lower_right_y": 0.13692768506632436, "height": 0.010269576379974332, "width": 0.042347247428917156}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-146-3", "text": "                                           Note             Attributable to equity holders of the Company\n\n\n                                                  Share         Share      Other Accumulated       Convertible     Total\n                                                  capital     premium    reserves      deficit            loan    equity\n                                                               reserve\nBalance at 1 January 2006                           116        17,876        160    (10,386)            3,985    11,751\nResult for 6 month period ending 30 June\n                                                        -            -          -     (4,101)                -   (4,101)\n2006\nTotal recognised loss for 6 month period\n                                                        -            -          -     (4,101)                -   (4,101)\nending 30 June 2006\n\n\nEmployee share option scheme:\n\u2013 value of employee services                            -            -        33               -             -       33\n\n\nIssue of share capital                      7          2          607           -              -          164       773\n                                                       2          607         33               -          164       806\nBalance at 30 June 2006                             118        18,483        193    (14,487)            4,149     8,456\n\n\nBalance at 1 July 2006                              118        18,483        193    (14,487)            4,149     8,456\nResult for 6 month period ending 31\n                                                        -            -          -     (4,564)                -   (4,564)\nDecember 2006\nTotal recognised loss for 6 month period\n                                                        -            -          -     (4,564)                -   (4,564)\nending 31 December 2006\n\n\nEmployee share option scheme:\n\u2013 value of employee services                            -            -        57               -             -       57\n\u2013 options exercised, lapsed & forfeited                 -            -      (47)          47                 -         -\n\n\nIssue of share capital (pre-IPO)            7          1           80           -              -             -       81\nShare split                                 7     1,305       (1,305)           -              -             -         -\nConvertible subordinated loan               7           -       4,149           -              -      (4,149)          -\nIssue of share capital (IPO)                7       516        16,596           -              -             -   17,112\n                                                  1,822        19,520         10          47          (4,149)    17,250\nBalance at 31 December 2006                       1,940        38,003        203    (19,004)                 -   21,142\n\n\nBalance at 1 January 2007                         1,940        38,003        203    (19,004)                 -   21,142\nResult for 6 month period ending 30 June\n                                                        -            -          -     (6,121)                -   (6,121)\n2007\nTotal recognised loss for 6 month period\n                                                        -            -          -     (6,121)                    (6,121)\nending 30 June 2007\n\n\nEmployee share option scheme:\n\u2013 value of employee services                            -            -       151               -             -      151\n", "page_number": 146, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.15019255455712452, "lower_right_x": 0.9243799153055051, "lower_right_y": 0.9071459135643988, "height": 0.7569533590072742, "width": 0.7749546279491832}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-146-4", "text": "F-7\n", "page_number": 146, "bounding_box": {"top_left_x": 0.48941318814277074, "top_left_y": 0.9238339751818571, "lower_right_x": 0.5081669691470054, "lower_right_y": 0.9323919554985024, "height": 0.008557980316645342, "width": 0.018753781004234693}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-147-0", "text": "\u2013 options exercised, lapsed & forfeited           -        -   (29)        29    -        -\n\n\nIssue of share capital                    7      4      141       -          -   -     145\n                                                 4      141    122         29    -     296\nBalance at 30 June 2007                       1,944   38,144   325    (25,096)   -   15,317\n", "page_number": 147, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.07145913564398802, "lower_right_x": 0.9286146400483969, "lower_right_y": 0.157466837826273, "height": 0.08600770218228497, "width": 0.779189352692075}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-147-1", "text": "F-8\n", "page_number": 147, "bounding_box": {"top_left_x": 0.48941318814277074, "top_left_y": 0.9238339751818571, "lower_right_x": 0.5075620084694494, "lower_right_y": 0.9332477535301669, "height": 0.00941377834830981, "width": 0.018148820326678694}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-148-0", "text": "Condensed consolidated cash flow statement\nfor the period ended 30 June 2007 and 2006\n", "page_number": 148, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.08515190415062045, "lower_right_x": 0.5995160314579552, "lower_right_y": 0.12280701754385964, "height": 0.037655113393239195, "width": 0.4500907441016333}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-148-1", "text": "(In Euro x 1,000)\n", "page_number": 148, "bounding_box": {"top_left_x": 0.7834240774349668, "top_left_y": 0.12623020967051776, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.1386392811296534, "height": 0.01240907145913564, "width": 0.09255898366606163}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-148-2", "text": "                                                        Six months ending 30 June\n                                                 Note         2007             2006\nCash flows from operating activities\n\nResult before corporate income taxes                          (6,121)         (4,101)\nAdjustments for:\n\u2013 Depreciation and amortisation                                   541             512\n\u2013 Share-based payments                                            151              33\n\u2013 Change in pension provision                                       -              37\n\u2013 Changes in working capital                                    (706)         (1,160)\nNet cash used in operating activities                         (6,135)         (4,679)\n\nCash flows from/(used in) investing activities    6            3,938            (606)\nCash flows from financing activities                              62              29\n\nCash, cash equivalents and bank overdrafts\nNet decrease during the six month period                      (2,135)         (5,256)\nBalance at 1 January                              6             7,053           9,230\nBalance at 30 June                                6             4,918           3,974\n", "page_number": 148, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.15703893881044073, "lower_right_x": 0.8953418027828192, "lower_right_y": 0.4475823705605477, "height": 0.290543431750107, "width": 0.7459165154264973}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-148-3", "text": "F-9\n", "page_number": 148, "bounding_box": {"top_left_x": 0.48941318814277074, "top_left_y": 0.9238339751818571, "lower_right_x": 0.5081669691470054, "lower_right_y": 0.9332477535301669, "height": 0.00941377834830981, "width": 0.018753781004234693}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-149-0", "text": "Notes to the condensed consolidated interim financial statements for\nthe period ended 30 June 2007 and 2006\n", "page_number": 149, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.07145913564398802, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.10569105691056911, "height": 0.03423192126658109, "width": 0.7023593466424682}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-149-1", "text": "1. General information\n", "page_number": 149, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.12623020967051776, "lower_right_x": 0.30913490623109496, "lower_right_y": 0.13692768506632436, "height": 0.010697475395806594, "width": 0.1597096188747731}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-149-2", "text": "On 4 October 2006, immediately prior to OctoPlus\u2019 Initial Public Offering (\u201cIPO\u201d) and as approved by the\nextraordinary meeting of shareholders, all outstanding shares were converted into the same number of\nordinary shares and each ordinary share was split into 100 ordinary shares (see Note 7). The condensed\nconsolidated interim financial statements, including the number of shares and options as well as the per share\ndata, have been retroactively restated to reflect this share split for all periods presented.\n", "page_number": 149, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.16046213093709885, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.2396234488660676, "height": 0.07916131792896874, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-149-3", "text": "2. Summary of significant accounting policies\n", "page_number": 149, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.2563115104835259, "lower_right_x": 0.45977011494252873, "lower_right_y": 0.27043217800599056, "height": 0.014120667522464658, "width": 0.31034482758620685}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-149-4", "text": "The principal accounting policies applied in the preparation of these condensed consolidated interim\nfinancial statements are set out below. These policies have been consistently applied to all periods presented,\nunless otherwise stated.\n", "page_number": 149, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.2939666238767651, "lower_right_x": 0.8324258923169994, "lower_right_y": 0.33204963628583656, "height": 0.03808301240907147, "width": 0.6830006049606775}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-149-5", "text": "2.1 Basis of preparation\n", "page_number": 149, "bounding_box": {"top_left_x": 0.1500302480338778, "top_left_y": 0.3590072742832692, "lower_right_x": 0.3145795523290986, "lower_right_y": 0.36970474967907574, "height": 0.010697475395806566, "width": 0.16454930429522083}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-149-6", "text": "The condensed consolidated interim financial statements have been prepared in accordance with the\nrequirements of International Accounting Standard (IAS) 34, Interim Financial Reporting, as adopted by the\nEU.\n", "page_number": 149, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.39323919554985026, "lower_right_x": 0.8469449485783425, "lower_right_y": 0.4313222079589217, "height": 0.038083012409071415, "width": 0.6975196612220206}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-149-7", "text": "The condensed consolidated interim financial statements have been prepared under the historical cost\nconvention. Furthermore, the condensed consolidated interim financial statements are presented in euros and\nall values are rounded to the nearest thousand except when otherwise indicated.\n", "page_number": 149, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.4582798459563543, "lower_right_x": 0.8463399879007865, "lower_right_y": 0.49893025246041933, "height": 0.04065040650406504, "width": 0.6969147005444646}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-149-8", "text": "The preparation of condensed consolidated interim financial statements in conformity with accounting\npolicies consistent with IFRS requires the use of certain critical accounting estimates. It also requires\nmanagement to exercise its judgement in the process of applying the Groups\u2019 accounting policies. The areas\ninvolving a higher degree of judgement or complexity or areas where assumptions and estimates are\nsignificant to the condensed consolidated financial statements are disclosed in the notes to the annual report\n2006.\n", "page_number": 149, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.5207531022678648, "lower_right_x": 0.8421052631578947, "lower_right_y": 0.6020539152759948, "height": 0.08130081300813008, "width": 0.6926799758015728}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-149-9", "text": "The accounting policies adopted are consistent with those followed in the preparation of the Group\u2019s annual\nfinancial statements for the year ended 31 December 2006.\n", "page_number": 149, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.6294394522892597, "lower_right_x": 0.8421052631578947, "lower_right_y": 0.6568249893025246, "height": 0.02738553701326496, "width": 0.6926799758015728}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-149-10", "text": "The condensed consolidated interim financial statements for the six month period ended 30 June 2007 and\n2006 are unaudited but have been reviewed by the auditors.\n", "page_number": 149, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.6773641420624733, "lower_right_x": 0.8318209316394435, "lower_right_y": 0.7051775780915703, "height": 0.027813436029097027, "width": 0.6823956442831216}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-149-11", "text": "2.2 Consolidation\n", "page_number": 149, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.7287120239623449, "lower_right_x": 0.26860254083484575, "lower_right_y": 0.7394094993581515, "height": 0.010697475395806566, "width": 0.1191772534785239}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-149-12", "text": "The Company is the holding company of a group of companies. The other consolidated group companies\n(\u201csubsidiaries\u201d) are:\n", "page_number": 149, "bounding_box": {"top_left_x": 0.1500302480338778, "top_left_y": 0.762943945228926, "lower_right_x": 0.8209316394434362, "lower_right_y": 0.7907573812580231, "height": 0.02781343602909714, "width": 0.6709013914095584}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-149-13", "text": "-   OctoShare B.V., 100%, having its legal seat in Leiden, the Netherlands\n-   OctoPlus Development B.V., 100%, having its legal seat in Leiden, the Netherlands\n-   OctoPlus Technologies B.V., 100%, having its legal seat in Leiden, the Netherlands\n-   OctoPlus Sciences B.V., 100%, having its legal seat in Leiden, the Netherlands\n-   Chienna B.V., 100%, having its legal seat in Bilthoven, the Netherlands\n-   OctoPlus Inc., 100%, having its legal seat in Delaware, United States of America\n", "page_number": 149, "bounding_box": {"top_left_x": 0.17846339987900786, "top_left_y": 0.7950363714163458, "lower_right_x": 0.7489413188142771, "lower_right_y": 0.8968763371844245, "height": 0.10183996576807874, "width": 0.5704779189352692}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-149-14", "text": "F-10\n", "page_number": 149, "bounding_box": {"top_left_x": 0.48336358136721114, "top_left_y": 0.9238339751818571, "lower_right_x": 0.5130066545674531, "lower_right_y": 0.9345314505776636, "height": 0.010697475395806566, "width": 0.029643073200241954}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-150-0", "text": "3. Segment information\n", "page_number": 150, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.08515190415062045, "lower_right_x": 0.3133696309739867, "lower_right_y": 0.09841677364142062, "height": 0.013264869490800177, "width": 0.16394434361766483}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-150-1", "text": "The segment results for the six month period ending 30 June 2007 are as follows:\n", "page_number": 150, "bounding_box": {"top_left_x": 0.15063520871143377, "top_left_y": 0.11596063329054343, "lower_right_x": 0.6823956442831216, "lower_right_y": 0.1292255027813436, "height": 0.013264869490800163, "width": 0.5317604355716878}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-150-2", "text": "                                        Contract   Products and    Unallocated   Group\n                                     development   drug delivery\nTotal gross segment revenues               4,533            307              -    4,840\nInter-segment revenues                   (2,084)               -             -   (2,084)\nSubsidies and other income                     -            118              -      118\nRevenues                                   2,449            425              -    2,874\n\nOperating result                            276          (6,345)         (115)   (6,184)\nFinance costs \u2013 net                                                                  63\nResult before corporate income tax                                               (6,121)\nCorporate income taxes                                                                 -\nResult for the year                                                              (6,121)\n", "page_number": 150, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.15361574668378264, "lower_right_x": 0.8560193587416818, "lower_right_y": 0.36585365853658536, "height": 0.21223791185280272, "width": 0.7065940713853599}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-150-3", "text": "The segment results for the six month period ending 30 June 2006 are as follows:\n", "page_number": 150, "bounding_box": {"top_left_x": 0.15063520871143377, "top_left_y": 0.38296961916987593, "lower_right_x": 0.6823956442831216, "lower_right_y": 0.39580658964484383, "height": 0.012836970474967901, "width": 0.5317604355716878}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-150-4", "text": "                                        Contract   Products and    Unallocated   Group\n                                     development   drug delivery\nTotal gross segment revenues               4,112             30              -    4,142\nInter-segment revenues                     (955)               -             -    (955)\nSubsidies and other income                     -             92              -       92\nRevenues                                   3,157            122              -    3,279\n\n\nOperating result                            258         (4,217)           (38)   (3,997)\nFinance costs \u2013 net                                                               (104)\nResult before corporate income tax                                               (4,101)\nCorporate income taxes                                                                 -\nResult for the year                                                              (4,101)\n", "page_number": 150, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.417201540436457, "lower_right_x": 0.8560193587416818, "lower_right_y": 0.6268720581942662, "height": 0.20967051775780915, "width": 0.7065940713853599}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-150-5", "text": "4. Intangible fixed assets\n", "page_number": 150, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.6499786050492083, "lower_right_x": 0.3194192377495463, "lower_right_y": 0.6628155755241762, "height": 0.012836970474967901, "width": 0.16999395039322443}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-150-6", "text": "The increase in intangible fixed assets is mainly caused by the acquisition of the full rights to the PolyActive\ntechnology and its intellectual property in certain strategic areas from IsoTis, Inc. in April 2007.\n", "page_number": 150, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.6842105263157895, "lower_right_x": 0.8469449485783425, "lower_right_y": 0.7120239623448866, "height": 0.02781343602909714, "width": 0.6975196612220206}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-150-7", "text": "5. Property, plant and equipment\n", "page_number": 150, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.7355584082156611, "lower_right_x": 0.37749546279491836, "lower_right_y": 0.748395378690629, "height": 0.012836970474967901, "width": 0.2280701754385965}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-150-8", "text": "In 2006, the Company signed a finance lease contract for additional office, laboratory and production\nfacilities in a building adjacent to the Company\u2019s headquarters. Some of the tailor made production and\nlaboratory facilities, as well as the equipment used in these facilities, will be developed and owned by\nOctoPlus. Included under property, plant and equipment is \u20ac 624 of these assets under construction (2006: \u20ac\n211).\n", "page_number": 150, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.7697903294822422, "lower_right_x": 0.8421052631578947, "lower_right_y": 0.8403936670945656, "height": 0.0706033376123234, "width": 0.6926799758015728}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-150-9", "text": "F-11\n", "page_number": 150, "bounding_box": {"top_left_x": 0.48336358136721114, "top_left_y": 0.9238339751818571, "lower_right_x": 0.5117967332123412, "lower_right_y": 0.9332477535301669, "height": 0.00941377834830981, "width": 0.028433151845130067}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-151-0", "text": "6. Cash, cash equivalents & bank overdrafts\n", "page_number": 151, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.06803594351732992, "lower_right_x": 0.4543254688445251, "lower_right_y": 0.0821566110397946, "height": 0.014120667522464686, "width": 0.3049001814882033}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-151-1", "text": "Cash, cash equivalents and bank overdrafts include the following for the purposes of the cash flow\nstatement:\n", "page_number": 151, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.10569105691056911, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.13008130081300814, "height": 0.024390243902439032, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-151-2", "text": "                                                At 30 Jun       At 31 Dec    At 30 Jun\n                                                     2007            2006         2006\nCash and cash equivalents                           5,711           8,535        4,960\nBank overdrafts                                      (793)         (1,482)        (986)\nNet cash and cash equivalents                       4,918           7,053        3,974\n\nShort-term deposits (between 3 and 12 months)       6,545          11,500                -\nLong-term deposits (> 12 months)                            -       1,000                -\nTotal short-term and long-term deposits             6,545          12,500                -\n", "page_number": 151, "bounding_box": {"top_left_x": 0.15910465819721717, "top_left_y": 0.1399229781771502, "lower_right_x": 0.8590441621294616, "lower_right_y": 0.2939666238767651, "height": 0.1540436456996149, "width": 0.6999395039322444}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-151-3", "text": "The movement in short-term and long-term deposits (\u20ac 5,955) over the six month period is included under\ncash flows from investing activities (2006: \u20ac 0).\n", "page_number": 151, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.31450577663671375, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.3418913136499786, "height": 0.02738553701326485, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-151-4", "text": "Long-term deposits are included under financial fixed assets in the balance sheet, short-term deposits are\nincluded under other current assets in the balance sheet and bank overdrafts are included under current\nliabilities in the balance sheet.\n", "page_number": 151, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.36243046640992727, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.40350877192982454, "height": 0.041078305519897274, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-151-5", "text": "7. Equity\n", "page_number": 151, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.4278990158322636, "lower_right_x": 0.21234119782214156, "lower_right_y": 0.441591784338896, "height": 0.013692768506632425, "width": 0.06291591046581971}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-151-6", "text": "The number of outstanding shares per 31 December 2005 was 115,549, comprising of 46,934 ordinary\nshares, 53,752 Class AP preferred shares and 14,863 Class BP preferred shares.\nAs a result of the January 2005 investment agreement, additional shares were issued in June 2006 and a total\nof \u20ac 750 was raised. As a consequence, the number of Class AP preferred shares increased with 2,177 shares\nto 55,929 shares per 30 June 2006 and the number of Class BP preferred shares increased with 609 shares to\n15,472 shares per 30 June 2006. As a result of this transaction, share capital increased with \u20ac 2, share\npremium reserve increased with \u20ac 584 and the subordinated convertible loan increased with \u20ac 164.\nBecause of exercising options in 2006 in the period 1 January up to 30 June 2006, the number of ordinary\nshares increased with 65 shares to 46,999 per 30 June 2006, resulting in an increase of share capital with \u20ac\n0k and an increase of share premium reserve with \u20ac 23.\n", "page_number": 151, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.46512623020967053, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.6127513906718015, "height": 0.14762516046213098, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-151-7", "text": "Because of exercising options in the period 1 July 2006 up to 3 October 2006, the number of ordinary shares\nincreased with 225 shares to 47,224 per 3 October 2006, resulting in an increase of share capital with \u20ac 1 and\nan increase of share premium reserve with \u20ac 80.\n", "page_number": 151, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.636285836542576, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.676936243046641, "height": 0.04065040650406504, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-151-8", "text": "Immediately prior to OctoPlus\u2019 IPO on 4 October 2006, which is discussed in more detail below, a Deed of\nAmendment and Conversion was executed which had the following impact:\n", "page_number": 151, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.6987590928540864, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.725716730851519, "height": 0.02695763799743256, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-151-9", "text": "-   An authorised capital of the Company of \u20ac 8,640, divided into 36,000,000 ordinary shares with a\n    nominal value of \u20ac 0.12 per share and 36,000,000 preference shares with a nominal value of \u20ac 0.12\n    per share.\n-   All Ordinary (\u201cClass C\u201d) shares, all Class AP preferred shares and all Class BP preferred shares,\n    outstanding immediately prior to the IPO were converted into the same number of ordinary shares,\n-   A split of each of these ordinary shares into 100 ordinary shares with a nominal value of \u20ac 0.01 per\n    share,\n-   An increase in the nominal value of these ordinary shares to \u20ac 0.12 per share, resulting in an\n    increase of share capital with \u20ac 1,305 and a corresponding reduction in share premium reserve,\n-   The creation of a new class of preference shares.\n", "page_number": 151, "bounding_box": {"top_left_x": 0.17846339987900786, "top_left_y": 0.732135216089003, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.8866067608044501, "height": 0.1544715447154471, "width": 0.6733212341197823}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-151-10", "text": "F-12\n", "page_number": 151, "bounding_box": {"top_left_x": 0.48336358136721114, "top_left_y": 0.9238339751818571, "lower_right_x": 0.5130066545674531, "lower_right_y": 0.9341035515618314, "height": 0.010269576379974388, "width": 0.029643073200241954}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-152-0", "text": "As a result of this Deed, the total number of issued and outstanding ordinary shares immediately prior to the\nIPO was 11,862,500. With the IPO, the Company issued 4,301,076 new shares at a price of \u20ac 4.65 per share,\nraising a total of \u20ac 20.0 million (gross). As a result, the total number of issued and outstanding ordinary\nshares increased to 16,163,576 at 31 December 2006.\n", "page_number": 152, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.06803594351732992, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.12323491655969192, "height": 0.055198973042362, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-152-1", "text": "Because of exercising options in the first six months of 2007, the number of ordinary shares increased with\n39,000 shares to 16,202,576 per 30 June 2007, resulting in an increase of share capital with \u20ac 4 and an\nincrease of share premium reserve with \u20ac 141.\n", "page_number": 152, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.1467693624304664, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.188275566966196, "height": 0.04150620453572959, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-152-2", "text": "No preference shares were issued and outstanding in the period between 31 December 2006 and 30 June\n2007.\n", "page_number": 152, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.21181001283697048, "lower_right_x": 0.8173018753781004, "lower_right_y": 0.23577235772357724, "height": 0.023962344886606757, "width": 0.6678765880217785}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-152-3", "text": "No shares are held as treasury shares in the period between 31 December 2006 and 30 June 2007.\n", "page_number": 152, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.2601626016260163, "lower_right_x": 0.7743496672716274, "lower_right_y": 0.2738553701326487, "height": 0.013692768506632425, "width": 0.6249243799153055}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-152-4", "text": "8. Cost of contracted work\n", "page_number": 152, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.2973898160034232, "lower_right_x": 0.3339382940108893, "lower_right_y": 0.3080872913992298, "height": 0.010697475395806622, "width": 0.18451300665456746}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-152-5", "text": "Cost of contracted work increased as a result of greater activity involving the development of our clinical\ncandidates. In particular, we incurred greater costs from the contract research organisations that were\nmanaging our clinical and pre-clinical trial activities, largely related to Locteron.\n", "page_number": 152, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.33162173727000427, "lower_right_x": 0.822746521476104, "lower_right_y": 0.37526743688489517, "height": 0.0436456996148909, "width": 0.6733212341197822}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-152-6", "text": "9. Employee benefits and other costs\n", "page_number": 152, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.39666238767650835, "lower_right_x": 0.4016938898971567, "lower_right_y": 0.4099272571673085, "height": 0.013264869490800135, "width": 0.25226860254083483}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-152-7", "text": "The increase in employee benefits and other costs is mainly caused by an increase in staff from 125\nemployees per 30 June 2006 to 153 employees per 30 June 2007.\n", "page_number": 152, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.43431750106974754, "lower_right_x": 0.7876588021778584, "lower_right_y": 0.4621309370988447, "height": 0.02781343602909714, "width": 0.6382335148215366}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-152-8", "text": "10. Interest\n", "page_number": 152, "bounding_box": {"top_left_x": 0.1512401693889897, "top_left_y": 0.48224219084296105, "lower_right_x": 0.2323049001814882, "lower_right_y": 0.49293966623876767, "height": 0.010697475395806622, "width": 0.08106473079249849}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-152-9", "text": "The interest income (net) of \u20ac 63 for the first six months of 2007, compared to the interest expense (net) of\n\u20ac 104 for the first six months of 2006, is caused by higher deposit balances in 2007 as a result of the \u20ac 20\nmillion (gross) raised with the IPO in October 2006.\n", "page_number": 152, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.5198973042362003, "lower_right_x": 0.837265577737447, "lower_right_y": 0.5605477107402653, "height": 0.04065040650406504, "width": 0.6878402903811252}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-152-10", "text": "11. Contingent liabilities\n", "page_number": 152, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.5815147625160462, "lower_right_x": 0.3194192377495463, "lower_right_y": 0.5956354300385109, "height": 0.01412066752246477, "width": 0.16999395039322443}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-152-11", "text": "On 24 April 2007, OctoPlus signed a new contract with IsoTis, Inc. to acquire the full rights to the\nPolyActive technology and its intellectual property in certain areas. As part of this contract, the \u201camended\nand restated license assignment and cross license assignment\u201d (\u201cACLA\u201d), as signed in May 2003, was\nterminated. This ACLA outlines, among others, the commercial development milestone payments and the\nprofit sharing payments from OctoPlus to IsoTis Inc. As per the new contract, OctoPlus is required to make\ncertain royalty payments on the sales of Locteron during the patent terms and the sales on other\npharmaceutical products based on the PolyActive technology during the patents terms. If and when these\nroyalty payments have to be made is uncertain and dependent on the commercial success of Locteron and the\npharmaceutical products developed based upon the PolyActive technology.\n", "page_number": 152, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.6191698759092854, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.7462558836114677, "height": 0.12708600770218226, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-152-12", "text": "F-13\n", "page_number": 152, "bounding_box": {"top_left_x": 0.48336358136721114, "top_left_y": 0.9238339751818571, "lower_right_x": 0.5130066545674531, "lower_right_y": 0.9323919554985024, "height": 0.008557980316645342, "width": 0.029643073200241954}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-153-0", "text": "12. Capital commitments\n", "page_number": 153, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.06803594351732992, "lower_right_x": 0.32425892316999394, "lower_right_y": 0.0821566110397946, "height": 0.014120667522464686, "width": 0.1748336358136721}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-153-1", "text": "As part of the new office, laboratory and production facilities currently being built adjacent to the\nCompany\u2019s headquarters (see Note 5), capital commitments have been made for approximately \u20ac 889 (2006:\n\u20ac 0).\n", "page_number": 153, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.10569105691056911, "lower_right_x": 0.8445251058681186, "lower_right_y": 0.14634146341463414, "height": 0.040650406504065026, "width": 0.6950998185117967}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-153-2", "text": "13. Approval of condensed consolidated interim financial statements\n", "page_number": 153, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.17073170731707318, "lower_right_x": 0.6146400483968542, "lower_right_y": 0.18142918271287975, "height": 0.010697475395806566, "width": 0.4652147610405323}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-153-3", "text": "The condensed consolidated interim financial statements for the six month period ended 30 June 2007 and\n2006 were approved by the Board of Supervisory Directors on 6 August 2007.\n", "page_number": 153, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.20496362858365424, "lower_right_x": 0.8324258923169994, "lower_right_y": 0.23234916559691912, "height": 0.027385537013264877, "width": 0.6830006049606775}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-153-4", "text": "F-14\n", "page_number": 153, "bounding_box": {"top_left_x": 0.48336358136721114, "top_left_y": 0.9238339751818571, "lower_right_x": 0.5130066545674531, "lower_right_y": 0.9341035515618314, "height": 0.010269576379974388, "width": 0.029643073200241954}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-154-0", "text": "Consolidated Financial Statements\n31 December 2006\n", "page_number": 154, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.07145913564398802, "lower_right_x": 0.6001209921355112, "lower_right_y": 0.11296534017971759, "height": 0.04150620453572956, "width": 0.4506957047791893}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-154-1", "text": "F-15\n", "page_number": 154, "bounding_box": {"top_left_x": 0.48336358136721114, "top_left_y": 0.9238339751818571, "lower_right_x": 0.5130066545674531, "lower_right_y": 0.9323919554985024, "height": 0.008557980316645342, "width": 0.029643073200241954}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-155-0", "text": "Deloitte\n\nDeloitte Accountants 8.V,\nKanaalpark 143\n\n2321 JV Leiden\n\nP.0.Box 402\n\n2300 AK Leiden\nNetherlands\n\nTel: +31 (71) 5352352\nFax: +31 (71) 5352370\nwww.deloitte.n!\n\nBeconnumber 200943\n\nTo the Shareholders and the Board of Supervisory Directors of\nOctoPlus N.V.\n\nP.O. Box 722\n\n2300 AS LEIDEN\n\nNetherlands\n\nDate From Our reference\n3100101130-020\n\nSubject Your reference\n\nAuditors\u2019 report\n\nReport on the financial statements\n\nWe have audited the accompanying financial statements 2006 of OctoPlus N.V., Leiden, which\ncomprise the consolidated and company balance sheet as at 31 December 2006, the profit and\nloss account, statement of changes in equity and cash flow statement for the year then ended, and\na summary of significant accounting policies and other explanatory notes.\n\nManagement\u2019s responsibility\n\nManagement is responsible for the preparation and fair presentation of the financial statements in\naccordance with International Financial Reporting Standards as adopted by the European Union\nand with Part 9 of Book 2 of the Netherlands Civil Code, and for the preparation of the\nmanagement board report in accordance with Part 9 of Book 2 of the Netherlands Civil Code.\nThis responsibility includes: designing, implementing and maintaining internal control relevant\nto the preparation and fair presentation of the financial statements that are free from material\nmisstatement, whether due to fraud or error: selecting and applying appropriate accounting\npolicies; and making accounting estimates that are reasonable in the circumstances.\n\nAuditors\u2019 responsibility\n\nOur responsibility is to express an opinion on the financial statements based on our audit. We\nconducted our audit in accordance with Dutch law. This law requires that we comply with ethical\nrequirements and plan and perform the audit to obtain reasonable assurance whether the financial\nstatements are free from material misstatement.", "page_number": 155, "bounding_box": {"top_left_x": 0.1645493042952208, "top_left_y": 0.10569105691056911, "lower_right_x": 0.7979431336963098, "lower_right_y": 0.6949080017115961, "height": 0.5892169448010269, "width": 0.633393829401089}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-155-1", "text": "", "page_number": 155, "bounding_box": {"top_left_x": 0.822141560798548, "top_left_y": 0.3461703038083012, "lower_right_x": 0.8263762855414398, "lower_right_y": 0.3560119811724433, "height": 0.009841677364142098, "width": 0.004234724742891771}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-155-2", "text": "", "page_number": 155, "bounding_box": {"top_left_x": 0.822141560798548, "top_left_y": 0.3594351732991014, "lower_right_x": 0.8269812462189957, "lower_right_y": 0.37098844672657255, "height": 0.011553273427471145, "width": 0.004839685420447659}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-155-3", "text": "", "page_number": 155, "bounding_box": {"top_left_x": 0.822141560798548, "top_left_y": 0.3769790329482242, "lower_right_x": 0.8263762855414398, "lower_right_y": 0.38767650834403083, "height": 0.010697475395806622, "width": 0.004234724742891771}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-155-4", "text": "", "page_number": 155, "bounding_box": {"top_left_x": 0.822141560798548, "top_left_y": 0.4120667522464698, "lower_right_x": 0.8263762855414398, "lower_right_y": 0.41891313649978607, "height": 0.00684638425331624, "width": 0.004234724742891771}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-155-5", "text": "Deloitte Accountants B.V. is registered with the Trade Register of the Chamber of Commerce and Industry in Member of\nRotterdam number 24362853 Deloitte Touche Tohmatsu", "page_number": 155, "bounding_box": {"top_left_x": 0.22807017543859648, "top_left_y": 0.7124518613607189, "lower_right_x": 0.7114337568058077, "lower_right_y": 0.7291399229781772, "height": 0.016688061617458283, "width": 0.4833635813672112}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-155-6", "text": "F-16\n", "page_number": 155, "bounding_box": {"top_left_x": 0.48336358136721114, "top_left_y": 0.9238339751818571, "lower_right_x": 0.5117967332123412, "lower_right_y": 0.9323919554985024, "height": 0.008557980316645342, "width": 0.028433151845130067}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-156-0", "text": "Deloitte.", "page_number": 156, "bounding_box": {"top_left_x": 0.2413793103448276, "top_left_y": 0.11296534017971759, "lower_right_x": 0.38656987295825773, "lower_right_y": 0.13607188703465983, "height": 0.023106546854942248, "width": 0.14519056261343014}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-156-1", "text": "", "page_number": 156, "bounding_box": {"top_left_x": 0.2365396249243799, "top_left_y": 0.1775780915703894, "lower_right_x": 0.24682395644283123, "lower_right_y": 0.18485237483953787, "height": 0.007274283269148474, "width": 0.010284331518451317}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-156-2", "text": "3100101130-020", "page_number": 156, "bounding_box": {"top_left_x": 0.2365396249243799, "top_left_y": 0.1878476679503637, "lower_right_x": 0.3290986085904416, "lower_right_y": 0.19768934531450577, "height": 0.00984167736414207, "width": 0.09255898366606169}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-156-3", "text": "An audit involves performing procedures to obtain audit evidence about the amounts and\ndisclosures in the financial statements. The procedures selected depend on the auditor's\njudgment, including the assessment of the risks of material misstatement of the financial\nstatements, whether due to fraud or error. In making those risk assessments, the auditor considers\ninternal control relevant to the entity\u2019s preparation and fair presentation of the financial\nstatements in order to design audit procedures that are appropriate in the circumstances, but not\nfor the purpose of expressing an opinion on the effectiveness of the entity's internal control. An\naudit also includes evaluating the appropriateness of accounting policies used and the\nreasonableness of accounting estimates made by management, as well as evaluating the overall\npresentation of the financial statements.", "page_number": 156, "bounding_box": {"top_left_x": 0.23169993950393225, "top_left_y": 0.23234916559691912, "lower_right_x": 0.7598306110102844, "lower_right_y": 0.3418913136499786, "height": 0.10954214805305948, "width": 0.5281306715063521}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-156-4", "text": "We believe that the audit evidence we have obtained is sufficient and appropriate to provide a", "page_number": 156, "bounding_box": {"top_left_x": 0.2335148215366001, "top_left_y": 0.3500213949507916, "lower_right_x": 0.7404718693284936, "lower_right_y": 0.3628583654257595, "height": 0.012836970474967901, "width": 0.5069570477918935}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-156-5", "text": "basis for our audit opinion.", "page_number": 156, "bounding_box": {"top_left_x": 0.23169993950393225, "top_left_y": 0.3628583654257595, "lower_right_x": 0.382335148215366, "lower_right_y": 0.37312794180573383, "height": 0.010269576379974332, "width": 0.15063520871143377}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-156-6", "text": "Opinion", "page_number": 156, "bounding_box": {"top_left_x": 0.23472474289171205, "top_left_y": 0.38296961916987593, "lower_right_x": 0.2849364791288566, "lower_right_y": 0.3936670945656825, "height": 0.010697475395806566, "width": 0.05021173623714456}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-156-7", "text": "In our opinion, the financial statements give a true and fair view of the financial position of\nOctoPlus N.V. as at 31 December 2006, and of its result and its cash flow for the year then ended\nin accordance with International Financial Reporting Standards as adopted by the European\nUnion and with Part 9 of Book 2 of the Netherlands Civil Code.", "page_number": 156, "bounding_box": {"top_left_x": 0.23169993950393225, "top_left_y": 0.40350877192982454, "lower_right_x": 0.7592256503327284, "lower_right_y": 0.4450149764655541, "height": 0.04150620453572956, "width": 0.5275257108287961}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-156-8", "text": "Report on other legal and regulatory requirements", "page_number": 156, "bounding_box": {"top_left_x": 0.23169993950393225, "top_left_y": 0.4548566538296962, "lower_right_x": 0.5275257108287962, "lower_right_y": 0.46812152332049634, "height": 0.013264869490800135, "width": 0.29582577132486393}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-156-9", "text": "Pursuant to the legal requirement under 2:393 sub 5 part e of the Netherlands Civil Code, we\nreport, to the extent of our competence, that the management board report is consistent with the\nfinancial statements as required by 2:391 sub 4 of the Netherlands Civil Code.", "page_number": 156, "bounding_box": {"top_left_x": 0.23169993950393225, "top_left_y": 0.47539580658964486, "lower_right_x": 0.7495462794918331, "lower_right_y": 0.5100556268720582, "height": 0.03465982028241332, "width": 0.5178463399879008}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-156-10", "text": "Leiden, 15 March 2007", "page_number": 156, "bounding_box": {"top_left_x": 0.23169993950393225, "top_left_y": 0.5169020111253744, "lower_right_x": 0.3629764065335753, "lower_right_y": 0.5297389816003423, "height": 0.012836970474967901, "width": 0.13127646702964307}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-156-11", "text": "Deloitte Accountants B.V.\n\nJ. Verloop", "page_number": 156, "bounding_box": {"top_left_x": 0.23169993950393225, "top_left_y": 0.5382969619169876, "lower_right_x": 0.39201451905626133, "lower_right_y": 0.6157466837826273, "height": 0.0774497218656397, "width": 0.16031457955232908}, "blob_type": "image", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-156-12", "text": "", "page_number": 156, "bounding_box": {"top_left_x": 0.23472474289171205, "top_left_y": 0.6157466837826273, "lower_right_x": 0.35753176043557167, "lower_right_y": 0.6478391099700471, "height": 0.03209242618741981, "width": 0.12280701754385961}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-156-13", "text": "F-17\n", "page_number": 156, "bounding_box": {"top_left_x": 0.48336358136721114, "top_left_y": 0.9238339751818571, "lower_right_x": 0.5130066545674531, "lower_right_y": 0.9328198545143346, "height": 0.00898587933247752, "width": 0.029643073200241954}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-157-0", "text": "Consolidated balance sheet\n", "page_number": 157, "bounding_box": {"top_left_x": 0.1500302480338778, "top_left_y": 0.08515190415062045, "lower_right_x": 0.42528735632183906, "lower_right_y": 0.10141206675224647, "height": 0.01626016260162602, "width": 0.27525710828796124}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-157-1", "text": "(In \u20ac x 1,000)\n", "page_number": 157, "bounding_box": {"top_left_x": 0.8027828191167574, "top_left_y": 0.08857509627727857, "lower_right_x": 0.8753781004234725, "lower_right_y": 0.10098416773641421, "height": 0.01240907145913564, "width": 0.07259528130671511}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-157-2", "text": "Consolidated balance sheet                                          (In \u20ac x 1,000)\n\n\n                                                           At 31 December\n                                                    Note    2006      2005\nASSETS\nNon-current assets\nIntangible assets\nGoodwill                                              6       243         243\nPatents                                               6     1,217       1,167\nOther intangible assets                               6       306         295\n                                                            1,766       1,705\nProperty, plant and equipment\nLand and buildings                                    7     3,128       3,246\nMachines and installations                            7     2,747       2,499\nOther equipment                                       7       475         528\n                                                            6,350       6,273\nFinancial assets carried at cost                      8        16          16\nLong-term deposits                                    9     1,000           -\n                                                            9,132       7,994\nCurrent assets\nShort-term deposits                                   9    11,500          -\nInventories                                          10       498         15\nTrade receivables                                    11     1,139      1,345\nSocial securities and other taxes                    11       377        255\nOther receivables, prepayments and accrued income    11     1,085      1,165\nCash and cash equivalents                             9     8,535      9,726\n                                                           23,134     12,506\nTotal assets                                               32,266     20,500\n\n\nEQUITY\nShareholders\u2019 equity                                 12    21,142      7,766\nConvertible subordinated loan                        13         -      3,985\nTotal group equity                                         21,142     11,751\n\nLIABILITIES\nNon-current liabilities\nPension liabilities                                  15         -          89\nFinance lease liabilities                            16     3,592       3,649\nOther non-current liabilities                        17        26           -\n                                                            3,618       3,738\nCurrent liabilities\nCurrent portion of non-current liabilities           16       164        142\nBank overdrafts                                      16     1,482        496\nTrade payables                                       17     2,468      1,491\nPayable to related parties                           17        12          -\nSocial securities and other taxes                    17       226        239\nOther current liabilities                            17     3,154      2,643\n                                                            7,506      5,011\nTotal liabilities                                          11,124      8,749\nTotal equity and liabilities                               32,266     20,500\n", "page_number": 157, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.10183996576807873, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.848951647411211, "height": 0.7471116816431322, "width": 0.7313974591651542}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-157-3", "text": "The notes on pages F-22 to F-56 are an integral part of these consolidated financial statements.\n", "page_number": 157, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.8660676080445014, "lower_right_x": 0.7501512401693889, "lower_right_y": 0.8797603765511339, "height": 0.01369276850663248, "width": 0.6007259528130671}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-157-4", "text": "F-18\n", "page_number": 157, "bounding_box": {"top_left_x": 0.48336358136721114, "top_left_y": 0.9238339751818571, "lower_right_x": 0.5130066545674531, "lower_right_y": 0.9332477535301669, "height": 0.00941377834830981, "width": 0.029643073200241954}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-158-0", "text": "Consolidated income statement\n", "page_number": 158, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.08515190415062045, "lower_right_x": 0.4646098003629764, "lower_right_y": 0.09927257167308515, "height": 0.0141206675224647, "width": 0.3151845130066545}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-158-1", "text": "(In \u20ac x 1,000)\n", "page_number": 158, "bounding_box": {"top_left_x": 0.8033877797943134, "top_left_y": 0.08857509627727857, "lower_right_x": 0.8753781004234725, "lower_right_y": 0.09927257167308515, "height": 0.01069747539580658, "width": 0.07199032062915911}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-158-2", "text": "                                                               Year ended\n                                                              31 December\n                                                     Note     2006       2005\n\nService revenues                                             5,587      6,563\nRoyalty and license revenues                                   332         60\nIncome from subsidies                                 18       132        394\nTotal revenues                                               6,051      7,017\n\nRaw materials and auxiliaries                          19      180        237\nCost of contracted work and other external charges     19    1,928      1,390\nEmployee benefits                                      20    6,140      4,758\nDepreciation and amortisation                         6,7    1,060        863\nOther costs                                            21    5,263      4,213\nTotal operating costs                                       14,571     11,461\n\nOperating loss                                              (8,520)   (4,444)\n\nInterest income                                       23        246       287\nInterest costs                                        23      (391)     (405)\nResult before corporate income taxes                        (8,665)   (4,562)\n", "page_number": 158, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.12280701754385964, "lower_right_x": 0.8693284936479129, "lower_right_y": 0.4347454000855798, "height": 0.3119383825417202, "width": 0.719903206291591}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-158-3", "text": "Corporate income taxes                                           24         -       353\nResult for the year                                                   (8,665)   (4,209)\n\n\nAttributable to\nEquity holders of the Company                                         (8,665)   (4,209)\n\nResult per share for result attributable to the equity holders\nof the Company during the year (expressed in \u20ac per share)\n\n\u2013 basic                                                          25    (0.68)    (0.38)\n\u2013 diluted                                                        25    (0.68)    (0.38)\n", "page_number": 158, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.4514334617030381, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.6204535729567822, "height": 0.16902011125374405, "width": 0.7313974591651542}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-158-4", "text": "The notes on pages F-22 to F-56 are an integral part of these consolidated financial statements.\n", "page_number": 158, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.6431322207958922, "lower_right_x": 0.7495462794918331, "lower_right_y": 0.6572528883183568, "height": 0.014120667522464658, "width": 0.6001209921355112}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-158-5", "text": "F-19\n", "page_number": 158, "bounding_box": {"top_left_x": 0.48336358136721114, "top_left_y": 0.9238339751818571, "lower_right_x": 0.5130066545674531, "lower_right_y": 0.9328198545143346, "height": 0.00898587933247752, "width": 0.029643073200241954}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-159-0", "text": "Consolidated statement of changes in equity\n", "page_number": 159, "bounding_box": {"top_left_x": 0.1500302480338778, "top_left_y": 0.08515190415062045, "lower_right_x": 0.5952813067150635, "lower_right_y": 0.10440735986307231, "height": 0.019255455712451866, "width": 0.44525105868118575}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-159-1", "text": "(In \u20ac x 1,000)\n", "page_number": 159, "bounding_box": {"top_left_x": 0.8033877797943134, "top_left_y": 0.08857509627727857, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.10141206675224647, "height": 0.012836970474967901, "width": 0.072595281306715}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-159-2", "text": "                                          Note         Attributable to equity holders of the Company\n\n                                                 Share       Share      Other    Accumu-     Conver-      Total\n                                                 capital   premium    reserves      lated       tible    equity\n                                                            reserve                deficit      loan\nBalance at 1 January 2005                            47      4,746         28    (6,177)           -    (1,356)\nResult for the year                                    -          -          -   (4,209)           -    (4,209)\nTotal recognised loss for 2005                         -          -          -   (4,209)           -    (4,209)\n\nEmployee share option scheme:\n\u2013 value of employee services                12         -          -      132            -          -       132\n\nIssue of share capital                      12      69      13,130         -        -             -     13,199\nConvertible subordinated loan               13       -           -         -        -         3,985      3,985\n                                                    69      13,130       132        -         3,985     17,316\nBalance at 31 December 2005                        116      17,876       160 (10,386)         3,985     11,751\n\n\nBalance at 1 January 2006                          116      17,876       160 (10,386)         3,985     11,751\nResult for the year                                    -          -          -   (8,665)           -    (8,665)\nTotal recognised loss for 2006                         -          -          -   (8,665)           -    (8,665)\n\nEmployee share option scheme:\n\u2013 value of employee services                12         -          -        90          -           -        90\n\u2013 options exercised, lapsed & forfeited                -          -      (47)         47           -         -\n\nIssue of share capital (pre-IPO)            12       3         687         -        -            164       854\nShare split                                 12   1,305     (1,305)         -        -              -         -\nConvertible subordinated loan               13       -       4,149         -        -        (4,149)         -\nIssue of share capital (IPO)                12     516     16,596          -        -              -    17,112\n                                                 1,824     20,127         43       47        (3,985)    18,056\nBalance at 31 December 2006                      1,940     38,003        203 (19,004)              -    21,142\n", "page_number": 159, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.1364997860504921, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.6290115532734275, "height": 0.49251176722293544, "width": 0.7313974591651542}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-159-3", "text": "The notes on pages F-22 to F-56 are an integral part of these consolidated financial statements.\n", "page_number": 159, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.6465554129225503, "lower_right_x": 0.7586206896551724, "lower_right_y": 0.6602481814291827, "height": 0.01369276850663248, "width": 0.6091954022988505}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-159-4", "text": "F-20\n", "page_number": 159, "bounding_box": {"top_left_x": 0.48336358136721114, "top_left_y": 0.9238339751818571, "lower_right_x": 0.5130066545674531, "lower_right_y": 0.9341035515618314, "height": 0.010269576379974388, "width": 0.029643073200241954}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-160-0", "text": "Consolidated cash flow statement\n", "page_number": 160, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.08515190415062045, "lower_right_x": 0.4882032667876588, "lower_right_y": 0.09927257167308515, "height": 0.0141206675224647, "width": 0.3387779794313369}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-160-1", "text": "(In \u20ac x 1,000)\n", "page_number": 160, "bounding_box": {"top_left_x": 0.8045977011494253, "top_left_y": 0.08857509627727857, "lower_right_x": 0.8759830611010284, "lower_right_y": 0.09927257167308515, "height": 0.01069747539580658, "width": 0.07138535995160311}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-160-2", "text": "                                                                        Year ended 31\n                                                                         December\n                                                              Note       2006      2005\n\nCash flows from operating activities\nResult before corporate income taxes                                   (8,665)   (4,562)\nAdjustments for:\n\u2013         Depreciation and amortisation                         6,7     1,060       863\n\u2013         Share-based payments                                   20        90       132\n\u2013         Interest costs                                                  391       405\n\u2013         Interest income                                               (246)     (287)\n\u2013         Change in pension liability                                    (89)      (42)\nChanges in working capital:\n\u2013         Inventories                                                    (483)         -\n\u2013         Trade receivables                                                206     (171)\n\u2013         Payable to related parties                                        12         3\n\u2013         Social securities and other taxes                              (122)     (206)\n\u2013         Other receivables, prepayments and accrued income                 80     (609)\n\u2013         Trade payables                                                   977       412\n\u2013         Other liabilities and accruals                                   498     (556)\nCash used in operations                                                (6,291)   (4,618)\nIncrease in other non-current liabilities                                   26         -\nInterest received                                                          246       287\nInterest paid                                                            (391)     (405)\nNet cash used in operating activities                                  (6,410)   (4,736)\n\nCash flows from investing activities\nPurchases of property, plant and equipment                      27       (916)     (924)\nPurchases of intangible assets                                   6       (172)     (294)\nIncrease in long-term and short-term deposits                    9    (12,500)         -\nNet cash used in investing activities                                 (13,588)   (1,218)\n\nCash flows from financing activities\nProceeds from issuance of shares                              12,27    17,966    13,038\nProceeds from issuance of convertible subordinated loan          13         -     3,985\nRepayment of finance lease liabilities                                  (145)     (163)\nNet cash generated from financing activities                           17,821    16,860\n\nCash, cash equivalents and bank overdrafts\nNet increase/(decrease) during the year                                (2,177)    10,906\nBalance at beginning of the year                                         9,230   (1,676)\nBalance at end of the year                                       9       7,053     9,230\n", "page_number": 160, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.12280701754385964, "lower_right_x": 0.8765880217785844, "lower_right_y": 0.756525459991442, "height": 0.6337184424475824, "width": 0.7271627344222625}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-160-3", "text": "The notes on pages F-22 to F-56 are an integral part of these consolidated financial statements.\n", "page_number": 160, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.7766367137355584, "lower_right_x": 0.7598306110102844, "lower_right_y": 0.7899015832263586, "height": 0.01326486949080019, "width": 0.6104053236539625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-160-4", "text": "F-21\n", "page_number": 160, "bounding_box": {"top_left_x": 0.48336358136721114, "top_left_y": 0.9238339751818571, "lower_right_x": 0.5117967332123412, "lower_right_y": 0.9341035515618314, "height": 0.010269576379974388, "width": 0.028433151845130067}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-161-0", "text": "Notes to the consolidated financial statements 31 December 2006\n", "page_number": 161, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.07145913564398802, "lower_right_x": 0.7985480943738656, "lower_right_y": 0.08557980316645272, "height": 0.0141206675224647, "width": 0.6491228070175438}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-161-1", "text": "1. General information\n", "page_number": 161, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.12280701754385964, "lower_right_x": 0.3484573502722323, "lower_right_y": 0.13692768506632436, "height": 0.014120667522464714, "width": 0.19903206291591044}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-161-2", "text": "OctoPlus N.V. (\"the Company\" or \u201cOctoPlus\u201d) and its subsidiaries (together \u201cthe Group\u201d) are engaged in\nproviding services for life sciences companies in the field of drug formulation. Furthermore, the Group\ndevelops a product portfolio based on its proprietary drug delivery technology. The Company was renamed\non 4 October 2006 from OctoPlus International Holding B.V. to OctoPlus N.V. as part of the Company\u2019s\nDeed of Amendment prior to the Company\u2019s Initial Public Offering (\u201cIPO\u201d; see note 12). The new company\nname is used throughout this document; also for periods prior to 4 October 2006.\n", "page_number": 161, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.1433461703038083, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.2293538724860933, "height": 0.08600770218228498, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-161-3", "text": "The Company is a public limited liability company incorporated and domiciled in the Netherlands. The\naddress of its registered office is Zernikedreef 12, 2333 CL Leiden, the Netherlands.\n", "page_number": 161, "bounding_box": {"top_left_x": 0.1500302480338778, "top_left_y": 0.25288831835686776, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.2798459563543004, "height": 0.026957637997432615, "width": 0.7017543859649124}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-161-4", "text": "These consolidated financial statements are subject to approval by the General Meeting of Shareholders.\n", "page_number": 161, "bounding_box": {"top_left_x": 0.1500302480338778, "top_left_y": 0.3008130081300813, "lower_right_x": 0.8173018753781004, "lower_right_y": 0.314933675652546, "height": 0.014120667522464658, "width": 0.6672716273442226}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-161-5", "text": "On 4 October 2006, immediately prior to OctoPlus\u2019 IPO and as approved by the extraordinary meeting of\nshareholders, all outstanding shares were converted into the same number of ordinary shares and each\nordinary share was split into 100 ordinary shares (see note 12). The Financial statements, including the\nnumber of shares, options and warrants as well as the per share data, have been retroactively restated to\nreflect this share split for all periods presented, with the exception of note 12, section share capital and share\npremium reserve.\n", "page_number": 161, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.3384681215233205, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.42105263157894735, "height": 0.08258451005562684, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-161-6", "text": "2. Summary of significant accounting policies\n", "page_number": 161, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.44458707744972187, "lower_right_x": 0.5420447670901392, "lower_right_y": 0.46041934103551563, "height": 0.01583226358579376, "width": 0.3926194797338173}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-161-7", "text": "The principal accounting policies applied in the preparation of these consolidated financial statements are set\nout below. These policies have been consistently applied to the years presented, unless otherwise stated.\n", "page_number": 161, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.46512623020967053, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.49293966623876767, "height": 0.02781343602909714, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-161-8", "text": "2.1 Basis of preparation\n", "page_number": 161, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.5164741121095422, "lower_right_x": 0.3139745916515426, "lower_right_y": 0.5293110825845101, "height": 0.012836970474967901, "width": 0.16454930429522077}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-161-9", "text": "The consolidated financial statements have been prepared in accordance with International Financial\nReporting Standards (\"IFRS\"), including International Accounting Standards (\"IAS\") and interpretations\nissued by the International Accounting Standards Board (\"IASB\") as adopted by the EU (\"EU-IFRS\"). With\nreference to the company-only income statement of the Company, use has been made of the exemption\npursuant to Section 402 of Book 2 of the Netherlands Civil Code.\n", "page_number": 161, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.5335900727428327, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.6029097133076594, "height": 0.06931964056482676, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-161-10", "text": "The consolidated financial statements have been prepared under the historical cost convention. Furthermore,\nthe consolidated financial statements are presented in Euros and all values are rounded to the nearest\nthousand except when otherwise indicated.\n", "page_number": 161, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.6260162601626016, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.6675224646983312, "height": 0.04150620453572962, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-161-11", "text": "The preparation of financial statements in conformity with IFRS requires the use of certain critical\naccounting estimates. It also requires management to exercise its judgement in the process of applying the\nGroup\u2019s accounting policies. The areas involving a higher degree of judgement or complexity or areas where\nassumptions and estimates are significant to the consolidated financial statements are disclosed in Note 4.\n", "page_number": 161, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.6910569105691057, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.7462558836114677, "height": 0.05519897304236199, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-161-12", "text": "2.2 Consolidation\n", "page_number": 161, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.7697903294822422, "lower_right_x": 0.26860254083484575, "lower_right_y": 0.7804878048780488, "height": 0.010697475395806566, "width": 0.1191772534785239}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-161-13", "text": "The Company is the holding company of a group of companies. The other consolidated group companies\n(\u201csubsidiaries\u201d) are:\n", "page_number": 161, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.7869062901155327, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.8147197261446298, "height": 0.02781343602909714, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-161-14", "text": "-   OctoShare B.V.1 , 100%, having its legal seat in Leiden, the Netherlands\n-   OctoPlus Development B.V., 100%, having its legal seat in Leiden, the Netherlands\n-   OctoPlus Technologies B.V., 100%, having its legal seat in Leiden, the Netherlands\n-   OctoPlus Sciences B.V., 100%, having its legal seat in Leiden, the Netherlands\n-   Chienna B.V., 100%, having its legal seat in Bilthoven, the Netherlands\n-   OctoPlus Inc.2, 100%, having its legal seat in Delaware, United States of America\n", "page_number": 161, "bounding_box": {"top_left_x": 0.17846339987900786, "top_left_y": 0.8284124946512623, "lower_right_x": 0.7501512401693889, "lower_right_y": 0.9139922978177151, "height": 0.08557980316645275, "width": 0.5716878402903811}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-161-15", "text": "F-22\n", "page_number": 161, "bounding_box": {"top_left_x": 0.48336358136721114, "top_left_y": 0.9238339751818571, "lower_right_x": 0.5130066545674531, "lower_right_y": 0.9341035515618314, "height": 0.010269576379974388, "width": 0.029643073200241954}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-162-0", "text": "1\n On 1 September 2006, OctoShare B.V. merged into the Company. Subsequently, OctoShed B.V., another\n100% subsidiary of the Company, changed its name into OctoShare B.V. pursuant to a deed of amendment\nof its articles of association.\n2\n    In accordance with IAS 21.9, the functional currency of OctoPlus Inc. is Euros.\n", "page_number": 162, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.08515190415062045, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.1467693624304664, "height": 0.06161745827984595, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-162-1", "text": "Subsidiaries\n", "page_number": 162, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.17073170731707318, "lower_right_x": 0.2323049001814882, "lower_right_y": 0.1810012836970475, "height": 0.010269576379974305, "width": 0.08287961282516634}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-162-2", "text": "Subsidiaries\nSubsidiaries are all entities over which the Group has the power to govern the financial and operating\npolicies, generally accompanied by a shareholding of more than one half of the voting rights. The existence\nand effect of potential voting rights that are currently exercisable or convertible are considered when\nassessing whether the Group controls another entity. Subsidiaries are fully consolidated from the date on\nwhich control is transferred to the Group. They are de-consolidated from the date that control ceases.\n", "page_number": 162, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.18142918271287975, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.25331621737270005, "height": 0.0718870346598203, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-162-3", "text": "The purchase method of accounting is used to account for the acquisition of subsidiaries by the Group. The\ncost of an acquisition is measured as the fair value of the assets given, equity instruments issued and\nliabilities incurred or assumed at the date of exchange, plus costs directly attributable to the acquisition.\nIdentifiable assets acquired and liabilities and contingent liabilities assumed in a business combination are\nmeasured initially at their fair values at the acquisition date, irrespective of the extent of any minority\ninterest. The excess of the cost of acquisition over the fair value of the Group\u2019s share of the identifiable net\nassets acquired is recorded as goodwill. If the cost of acquisition is less than the fair value of the net assets of\nthe subsidiary acquired (also after re-assessment), the difference is recognised directly in the income\nstatement.\n", "page_number": 162, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.2768506632434745, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.40051347881899874, "height": 0.12366281557552422, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-162-4", "text": "Inter-company transactions, balances and unrealised gains on transactions between group companies are\neliminated. Unrealised losses between group companies are also eliminated, however, these are considered\nto be an impairment indicator of the asset transferred. Accounting policies of subsidiaries have been changed\nwhere necessary to ensure consistency with the policies adopted by the Group.\n", "page_number": 162, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.4240479246897732, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.48224219084296105, "height": 0.058194266153187846, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-162-5", "text": "2.3 Segment reporting\n", "page_number": 162, "bounding_box": {"top_left_x": 0.1500302480338778, "top_left_y": 0.5062045357295678, "lower_right_x": 0.30490018148820325, "lower_right_y": 0.5169020111253744, "height": 0.010697475395806566, "width": 0.15486993345432545}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-162-6", "text": "A business segment is a group of assets and operations engaged in providing products or services that are\nsubject to risks and returns that are different from those of other business segments. A geographical segment\nis engaged in providing products or services within a particular economic environment which are subject to\nrisks and returns that are different from those of segments operating in other economic environments.\n", "page_number": 162, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.5233204963628584, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.5780915703893881, "height": 0.0547710740265297, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-162-7", "text": "2.4 Foreign currency translation\n", "page_number": 162, "bounding_box": {"top_left_x": 0.1500302480338778, "top_left_y": 0.6020539152759948, "lower_right_x": 0.37265577737447064, "lower_right_y": 0.6127513906718015, "height": 0.010697475395806677, "width": 0.22262552934059285}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-162-8", "text": "(a) Functional and presentation currency\nItems included in the financial statements of each of the Group\u2019s entities are measured using the currency of\nthe primary economic environment in which the entity operates (\u201cthe functional currency\u201d). The\nconsolidated financial statements are presented in Euros, which is the Company\u2019s functional and\npresentation currency.\n", "page_number": 162, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.6191698759092854, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.691484809584938, "height": 0.07231493367565256, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-162-9", "text": "(b) Transactions and balances\n", "page_number": 162, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.7150192554557124, "lower_right_x": 0.3430127041742287, "lower_right_y": 0.727428326914848, "height": 0.012409071459135612, "width": 0.19358741681790684}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-162-10", "text": "Foreign currency transactions are translated into the functional currency using the exchange rates prevailing\nat the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such\ntransactions and from the translation at year-end exchange rates of monetary assets and liabilities\ndenominated in foreign currencies are recognised in the income statement.\n", "page_number": 162, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.732135216089003, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.787334189131365, "height": 0.05519897304236199, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-162-11", "text": "2.5 Intangible assets\n", "page_number": 162, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.8108686350021395, "lower_right_x": 0.29038112522686027, "lower_right_y": 0.8245614035087719, "height": 0.01369276850663248, "width": 0.14095583787053842}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-162-12", "text": "(a) Goodwill\nGoodwill represents the excess of the cost of an acquisition over the fair value of the Group\u2019s share of the\nnet identifiable assets of the acquired subsidiary at the date of acquisition. If the cost of acquisition is less\nthan the fair value of the net assets of the subsidiary acquired (also after re-assessment), the difference is\nrecognised directly in the income statement.\n", "page_number": 162, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.8284124946512623, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.8990158322635858, "height": 0.07060333761232351, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-162-13", "text": "F-23\n", "page_number": 162, "bounding_box": {"top_left_x": 0.48336358136721114, "top_left_y": 0.9238339751818571, "lower_right_x": 0.5130066545674531, "lower_right_y": 0.9341035515618314, "height": 0.010269576379974388, "width": 0.029643073200241954}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-163-0", "text": "Separately recognised goodwill is tested annually for impairment, or more frequently when there is an\nindication that the unit may be impaired, and carried at cost less accumulated impairment losses. Impairment\nlosses on goodwill are not reversed in subsequent periods. Gains and losses on the disposal of an entity\ninclude the carrying amount of goodwill relating to the entity sold.\n", "page_number": 163, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.06803594351732992, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.12665810868635002, "height": 0.05862216516902011, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-163-1", "text": "Goodwill is allocated to cash-generating units for the purpose of impairment testing. The allocation is made\nto those cash-generating units or groups of cash-generating units that are expected to benefit from the\nbusiness combination in which the goodwill arose.\n", "page_number": 163, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.1467693624304664, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.188275566966196, "height": 0.04150620453572959, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-163-2", "text": "(b) Patents\n", "page_number": 163, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.21181001283697048, "lower_right_x": 0.22262552934059285, "lower_right_y": 0.2255027813436029, "height": 0.013692768506632425, "width": 0.073200241984271}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-163-3", "text": "Acquired patents have a definite useful life and are carried at cost less accumulated amortisation and\nimpairment losses. Amortisation is calculated using the straight-line method to allocate the cost of patents\nover their estimated useful lives (generally 10 years unless a patent expires prior to that date). Amortisation\nbegins when an asset is available for use. However, in the years presented in these financial statements, no\namortisation on patents is recorded since the technology which the patents relate to is not yet available for\n", "page_number": 163, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.22892597347026103, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.30124090714591356, "height": 0.07231493367565253, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-163-4", "text": "use.\n", "page_number": 163, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.30509199828840394, "lower_right_x": 0.17846339987900786, "lower_right_y": 0.3115104835258879, "height": 0.006418485237483951, "width": 0.02903811252268601}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-163-5", "text": "(c) Computer software\n", "page_number": 163, "bounding_box": {"top_left_x": 0.1542649727767695, "top_left_y": 0.33504492939666236, "lower_right_x": 0.3000604960677556, "lower_right_y": 0.3491655969191271, "height": 0.014120667522464714, "width": 0.14579552329098608}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-163-6", "text": "Acquired computer software is capitalised on the basis of the costs incurred to acquire and bring to use the\nspecific software. These costs are amortised over their estimated useful lives (generally three years).\n", "page_number": 163, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.355584082156611, "lower_right_x": 0.8511796733212341, "lower_right_y": 0.3821138211382114, "height": 0.02652973898160038, "width": 0.7017543859649122}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-163-7", "text": "(d) Research and development\n", "page_number": 163, "bounding_box": {"top_left_x": 0.15063520871143377, "top_left_y": 0.40350877192982454, "lower_right_x": 0.3484573502722323, "lower_right_y": 0.417201540436457, "height": 0.01369276850663248, "width": 0.19782214156079853}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-163-8", "text": "Research expenditure is recognised as an expense in the period in which it is incurred. Costs incurred on\ndevelopment projects are recognised as intangible assets when it is probable that the project will be a success\nconsidering its commercial and technological feasibility, generally when filed for regulatory approval for\ncommercial production and when costs can be measured reliably. Other development expenditures are\nrecognised as an expense as incurred. Development costs previously recognised as an expense are not\nrecognised as an asset in a subsequent period. Development costs with a finite useful life that have been\ncapitalised are amortised from the commencement of the commercial production of the product on a straight-\nline basis over the period of its expected benefit.\n", "page_number": 163, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.4206247325631151, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.5340179717586649, "height": 0.11339323919554983, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-163-9", "text": "2.6 Property, plant and equipment\n", "page_number": 163, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.5575524176294394, "lower_right_x": 0.3871748336358137, "lower_right_y": 0.5712451861360719, "height": 0.01369276850663248, "width": 0.23774954627949182}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-163-10", "text": "Property, plant and equipment comprise the land and building in Leiden, leased under a finance lease\nagreement, machines and installations and other equipment. All property, plant and equipment is stated at\nhistorical cost less depreciation. Historical cost includes expenditures that are directly attributable to the\nacquisition of the items.\n", "page_number": 163, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.57466837826273, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.6320068463842533, "height": 0.05733846812152332, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-163-11", "text": "Subsequent costs are included in the asset\u2019s carrying amount or recognised as a separate asset, as\nappropriate, only when it is probable that future economic benefits associated with the item will flow to the\nGroup and the cost of the item can be measured reliably. All other repairs and maintenance charges are\nexpensed in the financial period in which these are incurred.\n", "page_number": 163, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.6534017971758665, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.7107402652973898, "height": 0.05733846812152321, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-163-12", "text": "Depreciation is calculated using the straight-line method to allocate the cost of the assets to their residual\n", "page_number": 163, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.732135216089003, "lower_right_x": 0.8493647912885662, "lower_right_y": 0.7458279845956355, "height": 0.01369276850663248, "width": 0.6999395039322444}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-163-13", "text": "values over their estimated useful lives. Land is not depreciated; other items are depreciated as follows:\n", "page_number": 163, "bounding_box": {"top_left_x": 0.1500302480338778, "top_left_y": 0.7462558836114677, "lower_right_x": 0.8112522686025408, "lower_right_y": 0.7599486521181001, "height": 0.01369276850663248, "width": 0.6612220205686631}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-163-14", "text": "Buildings\n", "page_number": 163, "bounding_box": {"top_left_x": 0.16878402903811252, "top_left_y": 0.764655541292255, "lower_right_x": 0.23714458560193588, "lower_right_y": 0.7770646127513907, "height": 0.012409071459135723, "width": 0.06836055656382337}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-163-15", "text": "20 years\n", "page_number": 163, "bounding_box": {"top_left_x": 0.43496672716273443, "top_left_y": 0.766367137355584, "lower_right_x": 0.48880822746521474, "lower_right_y": 0.7770646127513907, "height": 0.010697475395806677, "width": 0.053841500302480305}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 16, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-163-16", "text": "", "page_number": 163, "bounding_box": {"top_left_x": 0.1500302480338778, "top_left_y": 0.7702182284980744, "lower_right_x": 0.15849969751966123, "lower_right_y": 0.7732135216089003, "height": 0.002995293110825914, "width": 0.008469449485783431}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 17, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-163-17", "text": "Machines and installations\n", "page_number": 163, "bounding_box": {"top_left_x": 0.1693889897156685, "top_left_y": 0.7800599058622165, "lower_right_x": 0.34361766485178463, "lower_right_y": 0.7903294822421908, "height": 0.010269576379974277, "width": 0.17422867513611615}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 18, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-163-18", "text": "3-10 years\n", "page_number": 163, "bounding_box": {"top_left_x": 0.4204476709013914, "top_left_y": 0.7800599058622165, "lower_right_x": 0.48880822746521474, "lower_right_y": 0.7924689773213521, "height": 0.012409071459135612, "width": 0.06836055656382334}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 19, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-163-19", "text": "", "page_number": 163, "bounding_box": {"top_left_x": 0.1500302480338778, "top_left_y": 0.7839109970047069, "lower_right_x": 0.15849969751966123, "lower_right_y": 0.787334189131365, "height": 0.0034231921266580922, "width": 0.008469449485783431}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 20, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-163-20", "text": "3-5 years\n", "page_number": 163, "bounding_box": {"top_left_x": 0.4301270417422868, "top_left_y": 0.7928968763371844, "lower_right_x": 0.4882032667876588, "lower_right_y": 0.8070175438596491, "height": 0.014120667522464658, "width": 0.05807622504537202}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 21, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-163-21", "text": "Other equipment\n", "page_number": 163, "bounding_box": {"top_left_x": 0.16878402903811252, "top_left_y": 0.793752674368849, "lower_right_x": 0.28009679370840895, "lower_right_y": 0.8070175438596491, "height": 0.01326486949080008, "width": 0.11131276467029644}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 22, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-163-22", "text": "", "page_number": 163, "bounding_box": {"top_left_x": 0.15063520871143377, "top_left_y": 0.7976037655113393, "lower_right_x": 0.15849969751966123, "lower_right_y": 0.8001711596063329, "height": 0.0025673940949936247, "width": 0.00786448880822746}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 23, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-163-23", "text": "The assets\u2019 residual values and useful lives are reviewed, and adjusted if appropriate, at each balance sheet\ndate.\n", "page_number": 163, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.8245614035087719, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.8502353444587077, "height": 0.025673940949935803, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 24, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-163-24", "text": "An asset\u2019s carrying amount is written down immediately to its recoverable amount if the asset\u2019s carrying\namount is greater than its estimated recoverable amount (also refer to 2.7).\n", "page_number": 163, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.8759092854086435, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.9028669234060762, "height": 0.02695763799743267, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 25, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-163-25", "text": "F-24\n", "page_number": 163, "bounding_box": {"top_left_x": 0.48336358136721114, "top_left_y": 0.9238339751818571, "lower_right_x": 0.5130066545674531, "lower_right_y": 0.9341035515618314, "height": 0.010269576379974388, "width": 0.029643073200241954}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-164-0", "text": "Gains and losses on disposals are determined by comparing proceeds with carrying amount. These are\nincluded in the income statement.\n", "page_number": 164, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.08515190415062045, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.11210954214805306, "height": 0.026957637997432615, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-164-1", "text": "Finance leases\n", "page_number": 164, "bounding_box": {"top_left_x": 0.1500302480338778, "top_left_y": 0.1364997860504921, "lower_right_x": 0.24682395644283123, "lower_right_y": 0.14719726144629866, "height": 0.010697475395806566, "width": 0.09679370840895343}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-164-2", "text": "The Group leases certain property, plant and equipment. Leases of property, plant and equipment where the\nGroup has substantially all the risks and rewards of ownership are classified as finance leases. Finance leases\nare capitalised at the commencement of the lease at the lower of the fair value of the leased property and the\npresent value of the minimum lease payments.\n", "page_number": 164, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.15361574668378264, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.21095421480530593, "height": 0.057338468121523295, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-164-3", "text": "Each lease payment is allocated between the liability and finance charges so as to achieve a constant rate on\nthe finance balance outstanding. The corresponding rental obligations, net of finance charges, are included in\n\u201cfinance lease liabilities\u201d. The interest element of the finance cost is charged to the income statement over the\nlease period so as to produce a constant periodic rate of interest on the remaining balance of the liability for\neach period. The property, plant and equipment acquired under finance leases is depreciated over the shorter\nof the useful life of the asset or the lease term.\n", "page_number": 164, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.23234916559691912, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.314933675652546, "height": 0.08258451005562686, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-164-4", "text": "2.7 Impairment of non-financial assets\n", "page_number": 164, "bounding_box": {"top_left_x": 0.1500302480338778, "top_left_y": 0.3418913136499786, "lower_right_x": 0.4131881427707199, "lower_right_y": 0.35258878904578517, "height": 0.010697475395806566, "width": 0.26315789473684215}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-164-5", "text": "Goodwill and other assets not subject to amortisation are reviewed for impairment at least annually. Assets\nsubject to amortisation or depreciation are reviewed for impairment whenever events or changes in\ncircumstances indicate that the carrying amount may not be recoverable. An impairment loss is recognised\nfor the amount by which the asset\u2019s carrying amount exceeds its recoverable amount. The recoverable\namount is the higher of an asset\u2019s fair value less costs to sell and value-in-use (i.e. the present value of the\nfuture cash flows to be generated by an asset from its continuing use in the business). For the purpose of\nassessing impairment, assets are grouped at the lowest levels for which there are separately identifiable cash\nflows (cash-generating units). Non-financial assets other than goodwill that suffered impairment are\nreviewed for possible reversal of the impairment at each reporting date.\n", "page_number": 164, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.3590072742832692, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.4856653829696192, "height": 0.12665810868635002, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-164-6", "text": "2.8 Financial assets\n", "page_number": 164, "bounding_box": {"top_left_x": 0.1500302480338778, "top_left_y": 0.5096277278562259, "lower_right_x": 0.2825166364186328, "lower_right_y": 0.5190415062045357, "height": 0.00941377834830981, "width": 0.132486388384755}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-164-7", "text": "The Group has financial assets in the two categories \u201cloans and receivables\u201d and \u201cfinancial assets carried at\ncost\u201d. In the years presented in these financial statements, the Group did not purchase or hold any derivative\nfinancial assets.\n", "page_number": 164, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.5267436884895165, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.5648267008985879, "height": 0.038083012409071415, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-164-8", "text": "(a) Loans and receivables\n", "page_number": 164, "bounding_box": {"top_left_x": 0.15184513006654568, "top_left_y": 0.5883611467693625, "lower_right_x": 0.3194192377495463, "lower_right_y": 0.6024818142918271, "height": 0.014120667522464658, "width": 0.1675741076830006}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-164-9", "text": "Loans and receivables are non-derivative financial assets with fixed or determinable payments that are not\nquoted in an active market. They are included in \u201ccurrent assets\u201d, except for maturities greater than 12\nmonths after the balance sheet date, which are classified as \u201cnon-current assets\u201d. Loans and receivables are\ncarried at amortised costs using the effective interest method.\n", "page_number": 164, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.6089002995293111, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.6636713735558408, "height": 0.0547710740265297, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-164-10", "text": "(b) Financial assets carried at cost\n", "page_number": 164, "bounding_box": {"top_left_x": 0.1500302480338778, "top_left_y": 0.6854942233632862, "lower_right_x": 0.37749546279491836, "lower_right_y": 0.6983311938382541, "height": 0.012836970474967901, "width": 0.22746521476104056}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-164-11", "text": "Financial assets carried at cost (less accumulated impairment losses) are unquoted equity instruments that are\nnot carried at fair value because their fair value cannot be reliably measured. They are included in non-\ncurrent assets unless management intends to dispose of the investment within 12 months of the balance sheet\ndate. These financial assets are subsequently carried at cost.\n", "page_number": 164, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.7047496790757382, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.7599486521181001, "height": 0.05519897304236199, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-164-12", "text": "Regular purchases and sales of investments are recognised on trade-date; the date on which the Group\ncommits to purchase or sell the asset. Investments are initially recognised at fair value plus transaction costs.\nInvestments are derecognised when the rights to receive cash flows from the investments have expired or\nhave been transferred and the Group has transferred substantially all risks and rewards of ownership.\n", "page_number": 164, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.7834830979888746, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.8386820710312366, "height": 0.05519897304236199, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-164-13", "text": "The Group assesses at each balance sheet date whether there is objective evidence that a financial asset or a\ngroup of financial assets is impaired. If there is objective evidence that an impairment loss has been incurred\non an unquoted equity instrument that is not carried at fair value because its fair value cannot be reliably\nmeasured, the amount of the impairment loss is measured as the difference between the carrying amount of\n", "page_number": 164, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.8622165169020112, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.9174154899443732, "height": 0.05519897304236199, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-164-14", "text": "F-25\n", "page_number": 164, "bounding_box": {"top_left_x": 0.48336358136721114, "top_left_y": 0.9238339751818571, "lower_right_x": 0.5130066545674531, "lower_right_y": 0.9341035515618314, "height": 0.010269576379974388, "width": 0.029643073200241954}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-165-0", "text": "the financial asset and the present value of estimated future cash flows discounted at the current market rate\nof return for a similar financial asset.\n", "page_number": 165, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.06803594351732992, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.09542148053059478, "height": 0.027385537013264863, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-165-1", "text": "2.9 Inventories\n", "page_number": 165, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.11938382541720154, "lower_right_x": 0.25105868118572294, "lower_right_y": 0.13008130081300814, "height": 0.010697475395806608, "width": 0.10163339382940109}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-165-2", "text": "Inventories are stated at the lower of cost and net realisable value. Cost is determined using the first-in, first-\nout (FIFO) method. Net realisable value is the estimated selling price in the ordinary course of business, less\napplicable variable selling expenses.\n", "page_number": 165, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.1364997860504921, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.17800599058622166, "height": 0.04150620453572956, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-165-3", "text": "2.10 Trade receivables\n", "page_number": 165, "bounding_box": {"top_left_x": 0.1500302480338778, "top_left_y": 0.20154043645699615, "lower_right_x": 0.30490018148820325, "lower_right_y": 0.21223791185280275, "height": 0.010697475395806594, "width": 0.15486993345432545}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-165-4", "text": "Trade receivables are recognised initially at fair value and subsequently measured at amortised cost using the\neffective interest method, less provision for impairment. A provision for impairment of trade receivables is\nestablished when there is objective evidence that the Group will not be able to collect all amounts due\naccording to the original terms of receivables. Significant financial difficulties of the debtor, probability that\nthe debtor will enter bankruptcy or financial reorganisation, and default or delinquency in payments are\nconsidered indicators that the trade receivable is impaired. The amount of the provision is the difference\nbetween the asset\u2019s carrying amount and the present value of estimated future cash flows, discounted at the\neffective interest rate. The amount of the provision is recognised in the income statement within \u201cother\ncosts\u201d.\n", "page_number": 165, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.2186563970902867, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.34403080872913994, "height": 0.12537441163885324, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-165-5", "text": "2.11 Cash and cash equivalents\n", "page_number": 165, "bounding_box": {"top_left_x": 0.1500302480338778, "top_left_y": 0.36927685066324345, "lower_right_x": 0.3629764065335753, "lower_right_y": 0.38296961916987593, "height": 0.01369276850663248, "width": 0.21294615849969753}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-165-6", "text": "Cash and cash equivalents includes cash-in-hand, current accounts, deposits held at call with banks, other\nshort-term highly liquid investments with original maturities of three months or less, and bank overdrafts.\nBank overdrafts are shown separately within current liabilities on the balance sheet.\n", "page_number": 165, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.38339751818570816, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.4278990158322636, "height": 0.04450149764655542, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-165-7", "text": "2.12 Equity\n", "page_number": 165, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.4514334617030381, "lower_right_x": 0.23169993950393225, "lower_right_y": 0.464270432178006, "height": 0.012836970474967901, "width": 0.0822746521476104}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-165-8", "text": "Ordinary shares and preference shares are classified as equity.\n", "page_number": 165, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.46469833119383824, "lower_right_x": 0.5462794918330308, "lower_right_y": 0.48224219084296105, "height": 0.017543859649122806, "width": 0.39685420447670894}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-165-9", "text": "A financial instrument or its component parts are classified on initial recognition as a financial liability, a\nfinancial asset or an equity instrument in accordance with the substance of the contractual arrangement and\nthe definitions of a financial liability, a financial asset and an equity instrument. An equity instrument is\ndefined as any contract that evidences a residual interest in the assets of an entity after deducting all of its\nliabilities. Based on these principles, the Group\u2019s subordinated convertible loan is classified as equity.\n", "page_number": 165, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.5027813436029097, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.57466837826273, "height": 0.07188703465982027, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-165-10", "text": "Incremental costs directly attributable to the issue of new shares or options are shown in equity as a\ndeduction from the proceeds, net of tax.\n", "page_number": 165, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.5960633290543432, "lower_right_x": 0.8511796733212341, "lower_right_y": 0.6234488660676081, "height": 0.02738553701326485, "width": 0.7017543859649122}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-165-11", "text": "2.13 Deferred corporate income taxes\n", "page_number": 165, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.6465554129225503, "lower_right_x": 0.4059286146400484, "lower_right_y": 0.660676080445015, "height": 0.01412066752246477, "width": 0.2565033272837266}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-165-12", "text": "Deferred corporate income tax is recognised, using the liability method, on temporary differences arising\nbetween the tax bases of assets and liabilities and their carrying amounts in the consolidated financial\nstatements. Deferred corporate income tax is determined using tax rates (and laws) that have been enacted or\nsubstantially enacted by the balance sheet date and are expected to apply when the related deferred corporate\nincome tax asset is realised or the deferred corporate income tax liability is settled. Deferred corporate\nincome tax assets are recognised to the extent that it is probable that future taxable profit will be available\nagainst which the temporary differences can be utilised.\n", "page_number": 165, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.6636713735558408, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.7633718442447582, "height": 0.09970047068891741, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-165-13", "text": "Deferred corporate income tax is not accounted for if it arises from initial recognition of an asset or liability\nin a transaction other than a business combination that at the time of the transaction affects neither\naccounting nor taxable profit or loss.\n", "page_number": 165, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.7869062901155327, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.82798459563543, "height": 0.04107830551989733, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-165-14", "text": "2.14 Borrowings\n", "page_number": 165, "bounding_box": {"top_left_x": 0.1500302480338778, "top_left_y": 0.8519469405220368, "lower_right_x": 0.2631578947368421, "lower_right_y": 0.8626444159178434, "height": 0.010697475395806566, "width": 0.1131276467029643}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-165-15", "text": "Borrowings are recognised initially at fair value, net of transaction costs incurred. Borrowings are\nsubsequently stated at amortised cost; any difference between the proceeds (net of transaction costs) and the\nredemption value is recognised in the income statement over the period of the borrowings using the effective\n", "page_number": 165, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.8690629011553274, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.9101412066752247, "height": 0.04107830551989733, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 16, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-165-16", "text": "F-26\n", "page_number": 165, "bounding_box": {"top_left_x": 0.48336358136721114, "top_left_y": 0.9238339751818571, "lower_right_x": 0.5130066545674531, "lower_right_y": 0.9341035515618314, "height": 0.010269576379974388, "width": 0.029643073200241954}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-166-0", "text": "interest method.\n", "page_number": 166, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.06803594351732992, "lower_right_x": 0.2540834845735027, "lower_right_y": 0.08130081300813008, "height": 0.013264869490800163, "width": 0.10465819721718086}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-166-1", "text": "Borrowings are classified as \u201ccurrent liabilities\u201d unless the Group has an unconditional right to defer\nsettlement of the liability for at least 12 months after the balance sheet date (\u201cnon-current liabilities\u201d).\n", "page_number": 166, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.10569105691056911, "lower_right_x": 0.8511796733212341, "lower_right_y": 0.13307659392383397, "height": 0.027385537013264863, "width": 0.7017543859649122}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-166-2", "text": "2.15 Employee benefits\n", "page_number": 166, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.15361574668378264, "lower_right_x": 0.30973986690865096, "lower_right_y": 0.16773641420624733, "height": 0.014120667522464686, "width": 0.1603145795523291}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-166-3", "text": "(a) Pension obligations\nUntil 31 January 2006, the Group operated a collective defined benefit pension plan for nearly all\nemployees, funded through payments to an insurance company. This plan included an average pay part and a\ndefined contribution surplus salary part. The contract for the plan ended on 31 January 2006 and was not\nextended. As from 1 February 2006 onwards, the Group operates a defined contribution pension plan for all\nemployees (both a collective plan and a few individual plans).\n", "page_number": 166, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.17372700042789901, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.2601626016260163, "height": 0.08643560119811727, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-166-4", "text": "A defined contribution plan is a pension plan under which the Group pays fixed contributions into a separate\nentity. The Group has no legal or constructive obligations to pay further contributions once the contributions\nhave been paid. The contributions are recognised as employee benefit expense when they are due. Prepaid\ncontributions are recognised as an asset to the extent that a cash refund or a reduction in the future payments\nis available.\n", "page_number": 166, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.28369704749679076, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.3513050919982884, "height": 0.06760804450149765, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-166-5", "text": "A defined benefit plan is a pension plan that is not a defined contribution plan. Typically, defined benefit\nplans define an amount of pension benefit that an employee will receive on retirement, usually dependent on\none or more factors such as age, years of service and compensation. The liability recognised in the balance\nsheet in respect of defined benefit pension plans is the present value of the defined benefit obligation at the\nbalance sheet date less the fair value of plan assets, together with adjustments for unrecognised actuarial\ngains or losses and past service costs. The defined benefit obligation is calculated annually by an\nindependent actuary using the projected unit credit method. The present value of the defined benefit\nobligation is determined by discounting the estimated future cash outflows using a discount rate determined\non basis of corporate bonds, adjusted for the duration of the liability. Actuarial gains and losses arising from\nexperience adjustments and changes in actuarial assumptions in excess of the greater of 10% of the value of\nplan assets or 10% of the defined benefit obligation are charged or credited to the income statement over the\nemployees\u2019 expected average remaining working lives. Past-service costs related to changes to the pension\nplan are recognised immediately in the income statement, unless the changes to the pension plan are\nconditional on the employees remaining in service for a specified period of time (the \u201cvesting period\u201d). In\nthis case, the past-service costs are amortised on a straight-line basis over the vesting period.\n", "page_number": 166, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.3761232349165597, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.5887890457851946, "height": 0.21266581086863495, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-166-6", "text": "(b) Share-based compensation\n", "page_number": 166, "bounding_box": {"top_left_x": 0.1542649727767695, "top_left_y": 0.6123234916559692, "lower_right_x": 0.3514821536600121, "lower_right_y": 0.6247325631151048, "height": 0.012409071459135612, "width": 0.1972171808832426}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-166-7", "text": "The Company operates an equity-settled, share-based compensation plan. The costs of employee share\noption plans are measured by reference to the fair value of the options at the date at which the options are\ngranted using a Binomial option model.\n", "page_number": 166, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.6294394522892597, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.6709456568249893, "height": 0.04150620453572962, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-166-8", "text": "The costs of these options, which reflect the services rendered by employees in exchange for the grant of the\noptions, are recognised in the income statement, together with a corresponding increase in equity during the\nvesting period. The total amount to be expensed over the vesting period is determined by reference to the fair\nvalue of the options granted, excluding the impact of any non-market vesting conditions (for example,\nprofitability and sales growth targets).\n", "page_number": 166, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.6944801026957638, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.7633718442447582, "height": 0.06889174154899447, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-166-9", "text": "Estimates of forfeitures are included in assumptions about the number of options that are expected to become\nexercisable. At each balance sheet date, the Company revises its estimates of the number of options that are\nexpected to become exercisable. It recognises the impact of the revision of original estimates, if any, in the\nincome statement, with a corresponding adjustment to equity. The income statement charge or credit for a\nperiod represents the movement in cumulative expense recognised at the beginning and end of that period.\n", "page_number": 166, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.7869062901155327, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.8557980316645272, "height": 0.06889174154899447, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-166-10", "text": "The proceeds received net of any directly attributable transaction costs are credited to share capital (nominal\nvalue) and share premium when the options are exercised.\n", "page_number": 166, "bounding_box": {"top_left_x": 0.1500302480338778, "top_left_y": 0.8793324775353016, "lower_right_x": 0.8511796733212341, "lower_right_y": 0.9062901155327343, "height": 0.02695763799743267, "width": 0.7011494252873564}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-166-11", "text": "F-27\n", "page_number": 166, "bounding_box": {"top_left_x": 0.48336358136721114, "top_left_y": 0.9238339751818571, "lower_right_x": 0.5130066545674531, "lower_right_y": 0.9341035515618314, "height": 0.010269576379974388, "width": 0.029643073200241954}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-167-0", "text": "(c) Profit-sharing and bonus plans\n", "page_number": 167, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.10569105691056911, "lower_right_x": 0.3720508166969147, "lower_right_y": 0.1198117244330338, "height": 0.014120667522464686, "width": 0.22262552934059285}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-167-1", "text": "The Group recognises a liability and an expense for bonuses and profit-sharing plans if contractually obliged\nor if there is a past practice that has created a constructive obligation.\n", "page_number": 167, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.12280701754385964, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.15019255455712452, "height": 0.027385537013264877, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-167-2", "text": "2.16 Provisions\n", "page_number": 167, "bounding_box": {"top_left_x": 0.1500302480338778, "top_left_y": 0.17415489944373128, "lower_right_x": 0.2558983666061706, "lower_right_y": 0.18356867779204109, "height": 0.00941377834830981, "width": 0.10586811857229281}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-167-3", "text": "Provisions are recognised when; the Group has a present legal or constructive obligation as a result of past\nevents; it is probable that an outflow of resources will be required to settle the obligation; and the amount\ncan be reliably estimated. Provisions are not recognised for future operating losses.\n", "page_number": 167, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.19127086007702182, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.23234916559691912, "height": 0.0410783055198973, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-167-4", "text": "Provisions are measured at the present value of the expenditures expected to be required to settle the\nobligation using a pre-tax rate that reflects current market assessments of the time value of money and the\nrisks specific to the obligation. The increase in the provision due to passage of time is recognised as interest\nexpense.\n", "page_number": 167, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.25288831835686776, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.30979888746255885, "height": 0.05691056910569109, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-167-5", "text": "2.17 Revenue recognition\n", "page_number": 167, "bounding_box": {"top_left_x": 0.1500302480338778, "top_left_y": 0.33504492939666236, "lower_right_x": 0.32425892316999394, "lower_right_y": 0.345742404792469, "height": 0.010697475395806622, "width": 0.17422867513611615}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-167-6", "text": "Revenue comprises the fair value of the sale of goods and services, and is shown net of value-added tax,\nrebates and discounts and after eliminated sales within the Group. The Group\u2019s revenues primarily consist of\nsales of services, license and royalty revenues and subsidies (see 2.18). These revenues are recognised as\nfollows:\n", "page_number": 167, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.35216089002995293, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.40393667094565683, "height": 0.051775780915703895, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-167-7", "text": "(a) Service revenues\n", "page_number": 167, "bounding_box": {"top_left_x": 0.1500302480338778, "top_left_y": 0.43046640992725715, "lower_right_x": 0.2807017543859649, "lower_right_y": 0.441591784338896, "height": 0.011125374411638855, "width": 0.1306715063520871}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-167-8", "text": "Sales of services are recognised in the accounting period in which the services are rendered, by reference to\nthe stage of completion of the specific transaction when the outcome of a transaction can be estimated\nreliably. The stage of completion is assessed on the basis of the actual service provided as a proportion of the\ntotal services to be provided.\n", "page_number": 167, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.44801026957637996, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.503209242618742, "height": 0.05519897304236204, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-167-9", "text": "(b) License and royalty revenues\n", "page_number": 167, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.5267436884895165, "lower_right_x": 0.3629764065335753, "lower_right_y": 0.5391527599486521, "height": 0.012409071459135612, "width": 0.21355111917725347}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-167-10", "text": "License and royalty revenues include amounts earned from third parties with licenses and/or options to the\nGroup\u2019s intellectual property. License and royalty revenues are recognised when earned in accordance with\nthe substance and under the terms of the related agreements and when it is probable that the economic\nbenefits associated with the transaction will flow to the entity and the amount of the revenue can be\nmeasured reliably. In situations where the Group has continuing performance obligations, revenues related to\nlicense fee payments are deferred and the related revenue is recognised in the period of expected\nperformance.\n", "page_number": 167, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.543859649122807, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.6422764227642277, "height": 0.09841677364142065, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-167-11", "text": "Multiple element arrangements\n", "page_number": 167, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.6636713735558408, "lower_right_x": 0.352692075015124, "lower_right_y": 0.6777920410783055, "height": 0.014120667522464658, "width": 0.20326678765880216}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-167-12", "text": "In certain circumstances, it is necessary to apply the recognition criteria to the separately identifiable\ncomponents of a single transaction in order to reflect the substance of the transaction. Conversely, the\nrecognition criteria are applied to two or more transactions together when they are linked in such a way that\nthe commercial effect cannot be understood without reference to the series of transactions as a whole.\n", "page_number": 167, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.6807873341891314, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.7359863072314934, "height": 0.05519897304236199, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-167-13", "text": "The Group offers arrangements whereby a customer licenses the right to use the Group\u2019s intellectual\nproperty and purchases research and development services under one arrangement. When such multiple\nelement arrangements exist, an element is accounted for as a separable element if it has value to the customer\non a stand-alone basis and the fair value can be determined objectively and reliably.\n", "page_number": 167, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.7595207531022679, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.8181429182712879, "height": 0.05862216516902008, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-167-14", "text": "When license revenues and service revenues are identified as separable elements in a multiple element\ntransaction, the license revenue recognised is determined based on the fair value of the license in relation to\nthe fair value of the arrangement taken as a whole and is recognised in accordance with the accounting\npolicy for license and royalty revenues as discussed above. The revenue relating to the service element,\nwhich represents the fair value of the servicing arrangement in relation to the fair value of the arrangement,\n", "page_number": 167, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.8382541720154044, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.9101412066752247, "height": 0.07188703465982027, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-167-15", "text": "F-28\n", "page_number": 167, "bounding_box": {"top_left_x": 0.48336358136721114, "top_left_y": 0.9238339751818571, "lower_right_x": 0.5130066545674531, "lower_right_y": 0.9341035515618314, "height": 0.010269576379974388, "width": 0.029643073200241954}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-168-0", "text": "is recognised over the service period. The fair values of each element are determined based on the current\nmarket price of each of the elements when sold separately.\n", "page_number": 168, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.06803594351732992, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.09584937954642704, "height": 0.027813436029097124, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-168-1", "text": "2.18 Income from subsidies\n", "page_number": 168, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.11938382541720154, "lower_right_x": 0.338777979431337, "lower_right_y": 0.13008130081300814, "height": 0.010697475395806608, "width": 0.18935269207501512}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-168-2", "text": "The Group receives certain subsidies, which support the Group\u2019s research efforts in defined research and\ndevelopment projects. These subsidies generally provide for reimbursement of approved costs incurred as\ndefined in various grants. Subsidies are recognised at their fair value when there is a reasonable assurance\nthat the subsidy will be received and the Group will comply with all attached conditions.\n", "page_number": 168, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.1364997860504921, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.19169875909285408, "height": 0.05519897304236199, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-168-3", "text": "The Group includes income from subsidies under \u201cincome from subsidies\u201d in the income statement in order\nto enable comparison of its income statement with companies in the life sciences sector. Companies in the\nlife sciences sector generally present governmental subsidies as income, as these subsidies often are a\nsignificant source of income. Furthermore, research and development expenses would, generally, be incurred\nto the same amount if no governmental contributions would be granted.\n", "page_number": 168, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.21523320496362858, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.2858365425759521, "height": 0.07060333761232351, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-168-4", "text": "The WBSO (\u201cafdrachtvermindering speur- en ontwikkelingswerk\u201d) is a fiscal facility that provides subsidies\nto companies, knowledge centres and self-employed people who perform research and development\nactivities (as defined in the WBSO Act). Under this Act, a contribution is paid towards the labour costs of\nemployees directly involved in research and development. The contribution is in the form of a reduction of\npayroll taxes and social security contributions.\n", "page_number": 168, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.3076593923833975, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.37869062901155326, "height": 0.07103123662815575, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-168-5", "text": "Subsidies relating to labour costs (WBSO) are deferred and recognised in the income statement as negative\nlabour costs over the period necessary to match them with the labour costs that they are intended to\ncompensate.\n", "page_number": 168, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.40008557980316645, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.441591784338896, "height": 0.04150620453572956, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-168-6", "text": "2.19 Operating leases\n", "page_number": 168, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.46512623020967053, "lower_right_x": 0.294615849969752, "lower_right_y": 0.47881899871630296, "height": 0.013692768506632425, "width": 0.14519056261343014}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-168-7", "text": "Leases in which a significant portion of the risks and rewards of ownership are retained by the lessor are\nclassified as operating leases. Payments made under operating leases (net of any incentives received from the\nlessor) are charged to the income statement on a straight-line basis over the period of the lease.\n", "page_number": 168, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.48224219084296105, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.5237483953786907, "height": 0.04150620453572962, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-168-8", "text": "2.20 Dividend distribution\n", "page_number": 168, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.5472828412494651, "lower_right_x": 0.32849364791288566, "lower_right_y": 0.5579803166452717, "height": 0.010697475395806566, "width": 0.1790683605565638}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-168-9", "text": "Dividend distribution to the Company\u2019s Shareholders is recognised as a liability in the Group\u2019s financial\nstatements in the period in which the dividends are approved by the Company\u2019s Shareholders.\n", "page_number": 168, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.5643988018827557, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.5922122379118528, "height": 0.02781343602909714, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-168-10", "text": "3. Financial risk management\n", "page_number": 168, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.636285836542576, "lower_right_x": 0.40653357531760437, "lower_right_y": 0.6504065040650406, "height": 0.014120667522464658, "width": 0.2571082879612825}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-168-11", "text": "3.1 Financial risk factors\n", "page_number": 168, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.6747967479674797, "lower_right_x": 0.3206291591046582, "lower_right_y": 0.6846384253316218, "height": 0.009841677364142098, "width": 0.17120387174833637}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-168-12", "text": "The Group is exposed to a variety of financial risks: Market risk, credit risk, liquidity risk and cash flow and\nfair value interest rate risk. The Group\u2019s overall risk management program seeks to minimise potential\nadverse effects of these financial risk factors on the Group\u2019s financial performance.\n", "page_number": 168, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.6910569105691057, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.7359863072314934, "height": 0.04492939666238771, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-168-13", "text": "(a) Market risk\n", "page_number": 168, "bounding_box": {"top_left_x": 0.15063520871143377, "top_left_y": 0.7569533590072742, "lower_right_x": 0.2516636418632789, "lower_right_y": 0.7702182284980744, "height": 0.01326486949080019, "width": 0.10102843315184512}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-168-14", "text": "Foreign exchange risk arises from future commercial transactions and recognised assets and liabilities in\nforeign currencies. In the years presented, the Group had no significant outstanding receivables or payables\nin currencies other than euros. As of 31 December 2006, 12% of the outstanding payables and none of the\noutstanding receivables consist of currencies other than the Euro.\n", "page_number": 168, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.7732135216089003, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.8314077877620881, "height": 0.05819426615318779, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-168-15", "text": "The Group is not exposed to equity securities price risk, since it does not hold any such investments, or\ncommodity price risk.\n", "page_number": 168, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.8485237483953787, "lower_right_x": 0.8511796733212341, "lower_right_y": 0.8763371844244758, "height": 0.02781343602909714, "width": 0.7017543859649122}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 16, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-168-16", "text": "(b) Credit risk\n", "page_number": 168, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.8998716302952503, "lower_right_x": 0.24319419237749546, "lower_right_y": 0.9127086007702182, "height": 0.012836970474967901, "width": 0.0937689050211736}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 17, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-168-17", "text": "F-29\n", "page_number": 168, "bounding_box": {"top_left_x": 0.48336358136721114, "top_left_y": 0.9238339751818571, "lower_right_x": 0.5130066545674531, "lower_right_y": 0.9341035515618314, "height": 0.010269576379974388, "width": 0.029643073200241954}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-169-0", "text": "The five largest external partners generate approximately 56% of total revenues in 2006. The outstanding\nreceivables with these parties comprise of 57% of the total trade receivables at 31 December 2006.\nManagement does not believe that this results in major credit risks since all customers are companies of good\nreputations. The Group has policies in place to ensure that contracts are only signed with customers with an\nappropriate credit history.\n", "page_number": 169, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.06803594351732992, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.14035087719298245, "height": 0.07231493367565253, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-169-1", "text": "(c) Liquidity risk\n", "page_number": 169, "bounding_box": {"top_left_x": 0.15184513006654568, "top_left_y": 0.16131792896876337, "lower_right_x": 0.2613430127041742, "lower_right_y": 0.17458279845956354, "height": 0.013264869490800163, "width": 0.10949788263762852}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-169-2", "text": "Prudent liquidity risk management implies maintaining sufficient cash and marketable securities plus the\navailability of funding through an adequate amount of committed credit facilities. The Company raised \u20ac 20.0\nmillion cash (gross) in 2006 through its IPO and mainly invested these amounts in fixed-term deposits with\nfirst class financial institutions/ banks. As a result of the amount raised in the IPO, the Company has sufficient\nfunds for a period of at least 12 months. Due to the dynamic nature of the underlying businesses, the Group\naims to remain flexible in funding by keeping committed credit lines available.\n", "page_number": 169, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.1810012836970475, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.2635857937526744, "height": 0.08258451005562689, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-169-3", "text": "(d) Cash flow and fair value interest rate risk\nMost of the funds raised through the IPO have been invested in fixed-term deposits, with the amount\ndeposited decreasing over time in accordance with a fixed, pre-defined schedule. As a result, the Group\u2019s\nincome and operating cash flows are not significantly impacted by changes in market interest rates but the\nGroup does have a marginal fair-value risk.\n", "page_number": 169, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.28712023962344885, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.3594351732991014, "height": 0.07231493367565256, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-169-4", "text": "3.2 Estimation fair value of financial instruments\n", "page_number": 169, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.38296961916987593, "lower_right_x": 0.48336358136721114, "lower_right_y": 0.3936670945656825, "height": 0.010697475395806566, "width": 0.33393829401088926}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-169-5", "text": "The Group does not hold any financial instruments traded in active markets. Financial assets consist of loans\nand receivables and an unquoted equity investment, which is not carried at fair value because its fair value\ncannot be reliably measured.\n", "page_number": 169, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.40008557980316645, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.441591784338896, "height": 0.04150620453572956, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-169-6", "text": "4. Critical accounting estimates and judgements\n", "page_number": 169, "bounding_box": {"top_left_x": 0.1500302480338778, "top_left_y": 0.48224219084296105, "lower_right_x": 0.5638233514821537, "lower_right_y": 0.49893025246041933, "height": 0.016688061617458283, "width": 0.4137931034482759}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-169-7", "text": "Estimates and judgements are continually evaluated and are based on historical experience and other factors,\nincluding expectations of future events that are believed to be reasonable under the circumstances.\n", "page_number": 169, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.4993581514762516, "lower_right_x": 0.8469449485783425, "lower_right_y": 0.5267436884895165, "height": 0.02738553701326485, "width": 0.6975196612220206}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-169-8", "text": "The Group makes estimates and assumptions concerning the future. The resulting accounting estimates will,\nby definition, seldom equal the related actual results. The estimates and assumptions that have a significant\nrisk of causing a material adjustment to the carrying amounts of assets and liabilities within the next\nfinancial year as well as critical judgements in applying the Group\u2019s accounting policies are discussed\nbelow.\n", "page_number": 169, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.5477107402652974, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.6161745827984596, "height": 0.06846384253316218, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-169-9", "text": "(a) Impairment test of goodwill and patents\n", "page_number": 169, "bounding_box": {"top_left_x": 0.1500302480338778, "top_left_y": 0.6414206247325631, "lower_right_x": 0.4307320024198427, "lower_right_y": 0.6538296961916987, "height": 0.012409071459135612, "width": 0.2807017543859649}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-169-10", "text": "Goodwill and intangible assets not yet available for use are not amortised but are subject to an annual\nimpairment test or more frequent testing whenever events or changes in circumstances indicate that the\ncarrying amount may not be recoverable. For the purpose of the impairment testing, goodwill is allocated to\ncash-generating units. In the years presented, all goodwill recognised relates to the acquisition of Chienna\nB.V. in the year 2003 and is allocated to the Group\u2019s Products & Drug Delivery unit. The technology that the\npatents acquired as part of the acquisition of Chienna B.V. relates to, is not yet available for use. These\npatents were also allocated to the Group\u2019s Products & Drug Delivery unit and are tested for impairment as\npart of this cash-generating unit. The recoverable amount of the applicable cash-generating unit is\ndetermined based on value-in-use calculations by using the discounted cash flow model.\n", "page_number": 169, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.6602481814291827, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.787334189131365, "height": 0.12708600770218226, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-169-11", "text": "In performing impairment testing of goodwill and patents, management must make significant judgements\nand estimates to determine whether the cash flows generated by the cash-generating unit that the assets\nbelong to are less than the unit\u2019s carrying value. Determining cash flows requires the use of judgements and\nestimates that have been included in the Group\u2019s strategic plans and long-term forecasts. The data necessary\nfor performing the impairment tests are based on management estimates of future cash flows. The discount\nrates used are estimated pre-tax rates which reflect specific risks relating to the relevant segment.\n", "page_number": 169, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.8108686350021395, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.8934531450577664, "height": 0.08258451005562695, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-169-12", "text": "F-30\n", "page_number": 169, "bounding_box": {"top_left_x": 0.48336358136721114, "top_left_y": 0.9238339751818571, "lower_right_x": 0.5130066545674531, "lower_right_y": 0.9341035515618314, "height": 0.010269576379974388, "width": 0.029643073200241954}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-170-0", "text": "(b) Corporate income taxes\n", "page_number": 170, "bounding_box": {"top_left_x": 0.15063520871143377, "top_left_y": 0.06803594351732992, "lower_right_x": 0.3290986085904416, "lower_right_y": 0.0821566110397946, "height": 0.014120667522464686, "width": 0.17846339987900783}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-170-1", "text": "The Group, which has a history of recent tax losses, recognises deferred tax assets arising from unused tax\nlosses or tax credits only to the extent that the relevant fiscal unity has sufficient taxable temporary\ndifferences or there is convincing other evidence that sufficient taxable profit will be available against which\nthe unused tax losses or unused tax credits can be utilised by the fiscal unity. Management\u2019s judgement is\nthat sufficient convincing other evidence is not available and a deferred tax asset is therefore only recognised\nto the extent that a fiscal unity has sufficient taxable temporary differences.\n", "page_number": 170, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.08515190415062045, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.17115960633290545, "height": 0.086007702182285, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-170-2", "text": "(c) Pensions\n", "page_number": 170, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.19469405220367994, "lower_right_x": 0.2323049001814882, "lower_right_y": 0.2079589216944801, "height": 0.013264869490800163, "width": 0.08287961282516634}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-170-3", "text": "For the collective defined benefit pension plan that was operated by the Group until 31 January 2006,\nactuarial assumptions are made about demographic variables (such as mortality) and financial variables\n(such as future increases in salaries) for the calculation of the present value of the pension obligation and the\nnet cost. The discount rate is determined by reference to market rates of high-quality corporate bonds. Any\nchanges in these assumptions would have impacted the carrying amount of the Group\u2019s pension obligations.\nAdditional information on these assumptions is included in Note 15.\n", "page_number": 170, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.20838682071031236, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.29653401797175866, "height": 0.08814719726144629, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-170-4", "text": "(d) Share-based payments\n", "page_number": 170, "bounding_box": {"top_left_x": 0.15063520871143377, "top_left_y": 0.31792896876337184, "lower_right_x": 0.31881427707199034, "lower_right_y": 0.33204963628583656, "height": 0.014120667522464714, "width": 0.16817906836055657}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-170-5", "text": "Share options granted to employees are measured at the fair value of the equity instruments granted (indirect\nmethod of measurement). Fair value is determined through the use of an option-pricing model considering,\namong others, the following variables:\n", "page_number": 170, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.33504492939666236, "lower_right_x": 0.8511796733212341, "lower_right_y": 0.37869062901155326, "height": 0.0436456996148909, "width": 0.7017543859649122}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-170-6", "text": "a)   The exercise price of the option;\nb)   The expected life of the option;\nc)   The current value of the underlying shares;\nd)   The expected volatility of the share price, calculated considering the effect of dividends on stock price;\ne)   The dividends expected on the shares; and\nf)   The risk-free interest rate for the life of the option.\n", "page_number": 170, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.3970902866923406, "lower_right_x": 0.837265577737447, "lower_right_y": 0.48224219084296105, "height": 0.08515190415062046, "width": 0.6878402903811252}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-170-7", "text": "For the Company\u2019s share option plans, management\u2019s judgement is that the Binomial method is most\nappropriate for determining fair values as this method allows accounting for non-transferability, vesting\nconditions and early exercise. During 2006, options were granted at two different points in time; in the first\nquarter of the year related to the employees\u2019 2005 performance and on 31 December 2006 related to the\nemployees\u2019 2006 performance. At the time of granting the options related to the employee\u2019s 2005\nperformance as well as the conditional grant of options related to certain key management members\u2019 2006\nperformance, published share price information was not available and the Company therefore had to estimate\nthe fair value of its shares and the expected volatility of that value. At the time of the 31 December 2006\nunconditional option grants, published share price information was available, as the Company is publicly\nlisted from 4 October 2006 onwards. The expected volatility of the unconditional option grants on 31\nDecember 2006 is still based on the average historical volatility of the peers over a period that agrees with\nthe period of maturity, as the Company has only been listed for a relatively short period of time. All\nassumptions and estimates are further discussed in Note 12 to the consolidated financial statements.\n", "page_number": 170, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.4959349593495935, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.6812152332049636, "height": 0.1852802738553701, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-170-8", "text": "The result of the share option valuations and the related compensation expense is dependent on the model\nand input parameters used. Even though Management considers the fair values reasonable and defensible\nbased on the methodologies applied and the information available, others might derive at a different fair\nvalue for each of the Company\u2019s share option plans.\n", "page_number": 170, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.7047496790757382, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.7599486521181001, "height": 0.05519897304236199, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-170-9", "text": "(e) Capitalisation of development costs\n", "page_number": 170, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.7834830979888746, "lower_right_x": 0.4016938898971567, "lower_right_y": 0.7958921694480102, "height": 0.012409071459135612, "width": 0.25226860254083483}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-170-10", "text": "Costs incurred on development projects are recognised as intangible assets when it is probable that a project\nwill be a success considering its commercial and technological feasibility. Management\u2019s judgement is\nrequired in determining when the Group should start capitalising of development costs. Management\ndetermined that commercial and technological feasibility is, in general, probable when the Group files for\nregulatory approval for commercial production and costs can be measured reliably. At 31 December 2006,\nthe Group has not filed for regulatory approval for its proprietary drug delivery technology. Based on\nManagement\u2019s assessment of commercial and technological feasibility, no development costs have been\nrecognised as intangible assets in the consolidated financial statements.\n", "page_number": 170, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.7963200684638425, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.9135643988018828, "height": 0.11724433033804027, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-170-11", "text": "F-31\n", "page_number": 170, "bounding_box": {"top_left_x": 0.48336358136721114, "top_left_y": 0.9238339751818571, "lower_right_x": 0.5117967332123412, "lower_right_y": 0.9341035515618314, "height": 0.010269576379974388, "width": 0.028433151845130067}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-171-0", "text": "(f) Recent accounting announcements\n", "page_number": 171, "bounding_box": {"top_left_x": 0.1500302480338778, "top_left_y": 0.08600770218228498, "lower_right_x": 0.39201451905626133, "lower_right_y": 0.09927257167308515, "height": 0.013264869490800163, "width": 0.24198427102238354}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-171-1", "text": "The Group has adopted the following mandatory 2006 IFRS/ IFRIC updates:\n    -   IAS 19 Amendment, Actuarial Gains and Losses, Group Plans and Disclosures;\n    -   IAS 21 Amendment, Net Investment in a Foreign Operation;\n    -   IAS 39 Amendment, Cash Flow Hedge Accounting of Forecast Intragroup Transactions\n        IAS39p80;\n    -   IAS 39 Amendment, The Fair Value Option IAS39p9(b);\n    -   IAS 39 and IFRS 4 Amendment, Financial Guarantee Contracts IAS39p2(e);\n    -   IFRS 6, Exploration for and Evaluation of Mineral Resources;\n    -   IFRS 1 and IFRS 6 Amendment, IFRS 1 and IFRS 6 Amendment;\n    -   IFRIC 4, Determining whether an Arrangement Contains a Lease;\n    -   IFRIC 5, Rights to Interests Arising from Decommissioning, Restoration and Environmental\n        Rehabilitation Fund;\n    -   IFRIC 6, Liabilities Arising from Participating in a Specific Market \u2013 Waste Electrical and\n        Electronic Equipment Services.\n", "page_number": 171, "bounding_box": {"top_left_x": 0.15063520871143377, "top_left_y": 0.10569105691056911, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.33889602053915274, "height": 0.23320496362858362, "width": 0.7011494252873564}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-171-2", "text": "Adoption of these standards did not have an impact on the Group\u2019s financial statements.\n", "page_number": 171, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.36243046640992727, "lower_right_x": 0.7126436781609196, "lower_right_y": 0.37526743688489517, "height": 0.012836970474967901, "width": 0.5632183908045977}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-171-3", "text": "Early adoption of the below listed IFRS/ IFRIC updates is permitted:\n    -    IFRIC 7, Applying the Restatement Approach under IAS 29, Financial Reporting in\n         Hyperinflationary Economies;\n    -    IFRIC 8, Scope of IFRS 2;\n    -    IFRIC 9, Reassessment of Embedded Derivatives;\n    -    IFRIC 10, Interim Reporting and Impairment;\n    -    IAS 1 Amendment, Presentation of Financial Statements; Capital Disclosures;\n    -    IFRS 7, Financial Instruments: Disclosures;\n    -    IFRIC 11, IFRS 2 \u2013 Group and Treasury Share Transactions;\n    -    IFRS 8, Operating Segments;\n    -    IFRIC 12, Service Concession Arrangements.\n", "page_number": 171, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.39666238767650835, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.5853658536585366, "height": 0.1887034659820282, "width": 0.7023593466424682}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-171-4", "text": "The Group is currently investigating the impact of these standards and has therefore chosen not to early-\nadopt these standards. According to Management\u2019s preliminary assessment, the impact of adopting these\nstandards is minor.\n", "page_number": 171, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.6089002995293111, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.6469833119383825, "height": 0.038083012409071415, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-171-5", "text": "5. Segment information\n", "page_number": 171, "bounding_box": {"top_left_x": 0.1500302480338778, "top_left_y": 0.6739409499358151, "lower_right_x": 0.35329703569267995, "lower_right_y": 0.6910569105691057, "height": 0.017115960633290572, "width": 0.20326678765880216}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-171-6", "text": "Primary reporting format \u2013 business segments\nAt 31 December 2006, the Group is organised into two main business segments:\n", "page_number": 171, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.6979032948224219, "lower_right_x": 0.663036902601331, "lower_right_y": 0.7287120239623449, "height": 0.030808729139923052, "width": 0.5136116152450091}, "blob_type": "headline", "predictions": {}, "annotations": {"number_of_reportable_segments": ["two"]}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-171-7", "text": "(1) Providing development services for life sciences companies in the field of drug formulation (\u201cContract\n    Development unit\u201d); and\n(2) Development of a product portfolio based on the Group\u2019s proprietary drug delivery technology\n    (\u201cProducts & Drug Delivery unit\u201d).\n", "page_number": 171, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.7291399229781772, "lower_right_x": 0.8505747126436781, "lower_right_y": 0.7907573812580231, "height": 0.06161745827984588, "width": 0.7011494252873562}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-171-8", "text": "F-32\n", "page_number": 171, "bounding_box": {"top_left_x": 0.48336358136721114, "top_left_y": 0.9238339751818571, "lower_right_x": 0.5130066545674531, "lower_right_y": 0.9341035515618314, "height": 0.010269576379974388, "width": 0.029643073200241954}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-172-0", "text": "The segment results for the year ended 31 December 2006 are as follows:\n", "page_number": 172, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.08515190415062045, "lower_right_x": 0.6291591046581972, "lower_right_y": 0.09927257167308515, "height": 0.0141206675224647, "width": 0.47973381730187536}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-172-1", "text": "                                          Contract     Products &    Unallocated   Group\n                                       Development   Drug Delivery\nTotal gross segment revenues                 8,504            342            18     8,864\nInter-segment revenues                     (2,927)               -          (18)   (2,945)\nSubsidies                                        -            132              -      132\nRevenues                                     5,577            474              -    6,051\n\n\nOperating result                              635          (8,813)         (342)   (8,520)\nFinance costs \u2013 net                                                                 (145)\nResult before corporate income taxes                                               (8,665)\nCorporate income taxes                                                                   -\nResult for the year                                                                (8,665)\n", "page_number": 172, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.12280701754385964, "lower_right_x": 0.8614640048396854, "lower_right_y": 0.3346170303808301, "height": 0.21181001283697048, "width": 0.7120387174833636}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-172-2", "text": "Until 31 December 2005, all of the actual expenditures of the Company\u2019s supporting functions (such as the\nFinance Department, the Human Resources department, the IT department as well as the Executive Board)\nwere allocated to one of our two business segments Contract Development and Products & Drug Delivery.\nFrom 1 January 2006 onwards, only the budgeted expenditures for these supporting functions are allocated.\nIn case of variances to budget for these supporting functions, an \u201cunallocated\u201d result remains, which is\nshown in the column \u201cUnallocated\u201d. For 2006, we have witnessed a total overrun of \u20ac 342 for the supporting\ndepartments.\n", "page_number": 172, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.35301668806161746, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.45186136071887034, "height": 0.09884467265725289, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-172-3", "text": "Inter-segment transfers or transactions are entered into under normal commercial terms and conditions that\nwould also be available to unrelated third parties.\n", "page_number": 172, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.4582798459563543, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.4848095849379546, "height": 0.026529738981600326, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-172-4", "text": "The segment results for the year ended 31 December 2005 are as follows:\n", "page_number": 172, "bounding_box": {"top_left_x": 0.1500302480338778, "top_left_y": 0.5062045357295678, "lower_right_x": 0.6279491833030852, "lower_right_y": 0.5203252032520326, "height": 0.01412066752246477, "width": 0.4779189352692075}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-172-5", "text": "                                          Contract     Products &    Unallocated   Group\n                                       Development   Drug Delivery\nTotal gross segment revenues                 6,804            185             \u2013     6,989\nInter-segment revenues                       (366)               -            \u2013     (366)\nSubsidies                                        -            394             \u2013       394\nRevenues                                     6,438            579             \u2013     7,017\n\n\nOperating result                              718          (5,197)           35    (4,444)\nFinance costs \u2013 net                                                                 (118)\nResult before corporate income taxes                                               (4,562)\nCorporate income taxes                                                                353\nResult for the year                                                                (4,209)\n", "page_number": 172, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.543859649122807, "lower_right_x": 0.8614640048396854, "lower_right_y": 0.7560975609756098, "height": 0.21223791185280272, "width": 0.7120387174833636}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-172-6", "text": "The unallocated operating result of \u20ac 35 relates to one-off corporate matters, which are not allocated to one of\nthe business segments.\n", "page_number": 172, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.7903294822421908, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.8181429182712879, "height": 0.02781343602909714, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-172-7", "text": "F-33\n", "page_number": 172, "bounding_box": {"top_left_x": 0.48336358136721114, "top_left_y": 0.9238339751818571, "lower_right_x": 0.5130066545674531, "lower_right_y": 0.9341035515618314, "height": 0.010269576379974388, "width": 0.029643073200241954}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-173-0", "text": "Other segment items included in the income statement are as follows:\n", "page_number": 173, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.08515190415062045, "lower_right_x": 0.5946763460375075, "lower_right_y": 0.09927257167308515, "height": 0.0141206675224647, "width": 0.44525105868118564}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-173-1", "text": "                                   Contract     Products &    Unallocated   Group\n                                Development   Drug Delivery\nYear ended 31 December 2006\nDepreciation and amortisation          761             279            20    1,060\n\n\nYear ended 31 December 2005\nDepreciation and amortisation          633             230             \u2013      863\n", "page_number": 173, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.12280701754385964, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.2421908429610612, "height": 0.11938382541720155, "width": 0.7023593466424682}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-173-2", "text": "The segment assets and liabilities at 31 December 2006 and capital expenditure for the year then ended are as\nfollows:\n", "page_number": 173, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.2768506632434745, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.30380830124090713, "height": 0.026957637997432615, "width": 0.7023593466424682}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-173-3", "text": "follows:\n                                        Contract     Products &    Unallocated   Group\n                                     Development   Drug Delivery\nAssets                                     9,961          3,452         18,853   32,266\nLiabilities                                7,667         14,156       (10,699)   11,124\nCapital expenditure (Note 6 and 7)          582             111           505     1,198\n", "page_number": 173, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.3042362002567394, "lower_right_x": 0.8560193587416818, "lower_right_y": 0.3902439024390244, "height": 0.08600770218228498, "width": 0.7065940713853599}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-173-4", "text": "The segment assets and liabilities at 31 December 2005 and capital expenditure for the year then ended are as\nfollows:\n                                               Contract         Products &        Unallocated         Group\n                                            Development       Drug Delivery\nAssets                                             9,499              6,061              4,940        20,500\nLiabilities                                        7,722             11,373           (10,346)         8,749\nCapital expenditure (Note 6 and 7)                   559                271                552         1,382\n", "page_number": 173, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.41377834830979887, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.5271715875053488, "height": 0.11339323919554989, "width": 0.7023593466424682}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-173-5", "text": "Secondary reporting format \u2013 geographical segments\nThe Group\u2019s customers are mainly located in Europe and North America as shown below:\n", "page_number": 173, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.5507060333761232, "lower_right_x": 0.7247428917120388, "lower_right_y": 0.5806589644843817, "height": 0.029952931108258474, "width": 0.5753176043557169}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-173-6", "text": "Revenues          2006    2005\nEuropean Union    3,671   3,543\nNorth-America     1,844   2,222\nOther countries    536    1,252\n                  6,051   7,017\n", "page_number": 173, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.6020539152759948, "lower_right_x": 0.8620689655172413, "lower_right_y": 0.6876337184424476, "height": 0.08557980316645275, "width": 0.7126436781609194}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-173-7", "text": "Revenues are allocated based on the country in which the customer is located. Nearly all of the Group\u2019s\nassets and capital expenditure (as disclosed per business segment above) are located in the Netherlands.\n", "page_number": 173, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.7115960633290543, "lower_right_x": 0.8499697519661222, "lower_right_y": 0.7389816003423192, "height": 0.02738553701326485, "width": 0.7005444646098004}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-173-8", "text": "F-34\n", "page_number": 173, "bounding_box": {"top_left_x": 0.48336358136721114, "top_left_y": 0.9238339751818571, "lower_right_x": 0.5130066545674531, "lower_right_y": 0.9341035515618314, "height": 0.010269576379974388, "width": 0.029643073200241954}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-174-0", "text": "6. Intangible assets\n", "page_number": 174, "bounding_box": {"top_left_x": 0.1500302480338778, "top_left_y": 0.06803594351732992, "lower_right_x": 0.3145795523290986, "lower_right_y": 0.08515190415062045, "height": 0.01711596063329053, "width": 0.16454930429522083}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-174-1", "text": "                              Goodwill   Patents       Other    Total\n                                                   intangible\n                                                       assets\nAt 1 January 2005\nCost                              243     1,167           38    1,448\nAccumulated amortisation             -         -         (27)    (27)\nNet book amount                   243     1,167           11    1,421\n\n\nYear ended 31 December 2005\nOpening net book amount           243     1,167           11    1,421\nAdditions                            -         -         294     294\nAmortisation charge                  -         -         (10)    (10)\nClosing net book amount           243     1,167          295    1,705\nAt 31 December 2005\nCost                              243     1,167          332    1,742\nAccumulated amortisation             -         -        (37)     (37)\nNet book amount                   243     1,167          295    1,705\nYear ended 31 December 2006\nOpening net book amount           243     1,167          295    1,705\nAdditions                            -       50          122     172\nAmortisation charge                  -         -       (111)    (111)\nClosing net book amount           243     1,217          306    1,766\nAt 31 December 2006\nCost                              243     1,217          454    1,914\nAccumulated amortisation             -         -       (148)    (148)\nNet book amount                   243     1,217          306    1,766\n", "page_number": 174, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.10911424903722722, "lower_right_x": 0.8620689655172413, "lower_right_y": 0.5643988018827557, "height": 0.4552845528455285, "width": 0.7126436781609194}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-174-2", "text": "Other intangible assets consist of acquired software, which is amortised over its estimated useful lives.\n", "page_number": 174, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.5883611467693625, "lower_right_x": 0.8070175438596491, "lower_right_y": 0.6003423192126658, "height": 0.011981172443303323, "width": 0.6575922565033272}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-174-3", "text": "Patents\n", "page_number": 174, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.6225930680359435, "lower_right_x": 0.19782214156079855, "lower_right_y": 0.6328626444159179, "height": 0.010269576379974388, "width": 0.0483968542044767}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-174-4", "text": "In the years presented in these financial statements, no amortisation on patents is recorded since the\ntechnology, which the patents relate to, is not yet available for use. However, the Group estimates at the end\nof each annual reporting period the recoverable amount of these patents, irrespective of whether there is any\nindication that it may be impaired.\n", "page_number": 174, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.6397090286692341, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.6970474967907574, "height": 0.05733846812152332, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-174-5", "text": "Impairment test of goodwill and patents\n", "page_number": 174, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.7184424475823705, "lower_right_x": 0.40653357531760437, "lower_right_y": 0.7325631151048353, "height": 0.01412066752246477, "width": 0.2571082879612825}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-174-6", "text": "For the purpose of the impairment testing, goodwill and patents have been allocated to a cash-generating unit\nsince these assets do not generate cash inflows that are largely independent of those from other assets. In the\nyears presented, substantially all goodwill and patents recognised relate to the acquisition of Chienna B.V. in\n2003, and is allocated to the Group\u2019s Products & Drug Delivery unit (see Note 5 on segment information).\nThis business segment is treated as one cash-generating unit.\n", "page_number": 174, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.7355584082156611, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.8078733418913137, "height": 0.07231493367565256, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-174-7", "text": "The recoverable amount of this cash-generating unit is determined based on a value-in-use calculation (i.e.\nthe present value of the future cash flows expected to be derived from the Products & Drug Delivery unit\nover the remaining life of the patents). The calculation uses cash flow projections based on financial plans\nand existing and potential new customer contracts. No impairment loss has been recognised as a result of the\nimpairment testing of goodwill and patents. Key elements for assessing impairment include successful\ncompletion of the various (pre-) clinical stages of products currently under development, as well as existing\n", "page_number": 174, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.8288403936670946, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.9139922978177151, "height": 0.08515190415062046, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-174-8", "text": "F-35\n", "page_number": 174, "bounding_box": {"top_left_x": 0.48336358136721114, "top_left_y": 0.9238339751818571, "lower_right_x": 0.5130066545674531, "lower_right_y": 0.9341035515618314, "height": 0.010269576379974388, "width": 0.029643073200241954}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-175-0", "text": "customer contracts.\n", "page_number": 175, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.07145913564398802, "lower_right_x": 0.27586206896551724, "lower_right_y": 0.08130081300813008, "height": 0.009841677364142057, "width": 0.1264367816091954}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-175-1", "text": "For executing the impairment testing, Management considered the relevant current contracts with its\nlicensing partners, as well as ongoing discussions with potential parties to the extent these contracts provide\naccess to the PolyActive\u2122 technology the Group obtained when acquiring Chienna B.V.\n", "page_number": 175, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.10569105691056911, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.14719726144629866, "height": 0.04150620453572955, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-175-2", "text": "Management reviewed the contracted licensing revenues, the possibility of such revenues actually occurring\nand the timing thereof. The expected cash flow from this agreement has been discounted against a risk-\nadjusted discount rate of 35%. Management has also evaluated the likelihood of successfully completing one\nof the ongoing discussions regarding out-licensing of the PolyActive\u2122 technology based on the proposed\nterms and conditions. The envisaged cash flow is adjusted for probability of success and value of time.\nThe sum of both calculations results in a recoverable amount of the Products & Drug Delivery unit that\nsignificantly exceeds the unit\u2019s carrying value, so impairment of goodwill and patents is not considered\nnecessary.\n", "page_number": 175, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.1681643132220796, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.28754813863928114, "height": 0.11938382541720155, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-175-3", "text": "7. Property, plant and equipment\n", "page_number": 175, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.3076593923833975, "lower_right_x": 0.44041137326073804, "lower_right_y": 0.3243474540008558, "height": 0.016688061617458283, "width": 0.2909860859044162}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-175-4", "text": "                              Land    Buildings   Machines &          Other     Total\n                                                  installations   equipment\n\n\nAt 1 January 2005\nCost                          1,084      2,364          4,466        1,415     9,329\nAccumulated depreciation          -        (84)       (2,258)         (949)   (3,291)\nNet book amount               1,084      2,280          2,208          466     6,038\n\n\nYear ended 31 December 2005\nOpening net book amount       1,084      2,280          2,208          466     6,038\nAdditions                         -           -           814          274     1,088\nDepreciation charge               -      (118)          (523)         (212)    (853)\nClosing net book amount       1,084      2,162          2,499          528     6,273\nAt 31 December 2005\nCost                          1,084      2,364          5,280        1,689    10,417\nAccumulated depreciation          -      (202)        (2,781)       (1,161)   (4,144)\nNet book amount               1,084      2,162          2,499          528     6,273\nYear ended 31 December 2006\nOpening net book amount       1,084      2,162          2,499          528     6,273\nAdditions                         -           -           835          191     1,026\nDepreciation charge               -      (118)          (587)         (244)    (949)\nClosing net book amount       1,084      2,044          2,747          475     6,350\nAt 31 December 2006\nCost                          1,084      2,364          6,115        1,880    11,443\nAccumulated depreciation          -      (320)        (3,368)       (1,405)   (5,093)\nNet book amount               1,084      2,044          2,747          475     6,350\n", "page_number": 175, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.3247753530166881, "lower_right_x": 0.8608590441621294, "lower_right_y": 0.8078733418913137, "height": 0.4830979888746256, "width": 0.7114337568058076}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-175-5", "text": "The land and buildings as shown above relate to the main property utilised by the Company and are accounted\nfor as a finance lease. The land is not de-recognised from the balance sheet as the Group has a continuing\ninvolvement in the land. Accordingly, the amount received in relation to the land is considered to be financing\nand included within \u201cfinance lease liabilities\u201d on the balance sheet.\n", "page_number": 175, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.8314077877620881, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.8857509627727856, "height": 0.05434317501069752, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-175-6", "text": "F-36\n", "page_number": 175, "bounding_box": {"top_left_x": 0.48336358136721114, "top_left_y": 0.9238339751818571, "lower_right_x": 0.5130066545674531, "lower_right_y": 0.9341035515618314, "height": 0.010269576379974388, "width": 0.029643073200241954}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-176-0", "text": "Finance leases and securities\nProperty, plant and equipment includes the following amounts where the Group is a lessee under finance\nleases:\n", "page_number": 176, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.10569105691056911, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.1467693624304664, "height": 0.04107830551989729, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-176-1", "text": "                                  2006    2005\nCost capitalised finance leases   3,994   4,261\nAccumulated depreciation          (400)   (585)\nNet book amount                   3,594   3,676\n", "page_number": 176, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.15361574668378264, "lower_right_x": 0.8608590441621294, "lower_right_y": 0.22122379118528027, "height": 0.06760804450149763, "width": 0.7114337568058076}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-176-2", "text": "Finance lease liabilities are secured on the assets held under finance leases as the rights to the leased assets\nrevert to the lessor in the event of default. Bank overdrafts are secured on other property, plant and\nequipment of the subsidiary OctoPlus Development B.V. with book value at 31 December 2006 of \u20ac 2,192\n(2005: \u20ac 2,419) (Note 16).\n", "page_number": 176, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.2631578947368421, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.31835686777920413, "height": 0.05519897304236204, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-176-3", "text": "8. Financial assets carried at cost\n", "page_number": 176, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.3590072742832692, "lower_right_x": 0.4355716878402904, "lower_right_y": 0.3727000427899016, "height": 0.013692768506632425, "width": 0.28614640048396855}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-176-4", "text": "                        2006   2005\nBeginning of the year     16    16\nAdditions                  -      -\nEnd of the year           16    16\nNon-current portion     (16)   (16)\nCurrent portion            \u2013     \u2013\n", "page_number": 176, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.40008557980316645, "lower_right_x": 0.8608590441621294, "lower_right_y": 0.5019255455712451, "height": 0.10183996576807869, "width": 0.7114337568058076}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-176-5", "text": "Financial assets carried at cost relate to an investment in Zernike Investments Beheer B.V. As part of a sale\nand leaseback transaction for the land and building as included within property, plant and equipment, a\nGroup company became to hold all preference shares (90% of issued share capital) of Zernike Investment\nBeheer B.V. having its legal seat in Maassluis, the Netherlands. This Group company is entitled to a pre-\ndefined share of the profit of Zernike Investment Beheer B.V. However, the Group has no significant\ninfluence on Zernike Investment Beheer B.V.\u2019s business and operating policy.\n", "page_number": 176, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.5233204963628584, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.6093281985451433, "height": 0.08600770218228493, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-176-6", "text": "9. Cash, cash equivalents and deposits\n                                                         2006    2005\nCash at bank and in hand                                5,535     226\nBank deposits (< 3 months)                              3,000    9,500\nCash and cash equivalents                               8,535    9,726\nBank overdrafts                                        (1,482)   (496)\nNet cash and cash equivalents                           7,053    9,230\n\n\nShort-term deposits (between 3 months and 12 months)   11,500        -\nLong-term deposits (> 12 months)                        1,000        -\nTotal short-term and long-term deposits                12,500        -\n", "page_number": 176, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.6328626444159179, "lower_right_x": 0.8656987295825771, "lower_right_y": 0.8348309798887462, "height": 0.20196833547282833, "width": 0.7162734422262552}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-176-7", "text": "The effective interest rate on all bank deposits was approximately 2.9% in 2006, with the maturity on these\ndeposits varying between directly withdrawable and 13 months.\n", "page_number": 176, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.8519469405220368, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.8797603765511339, "height": 0.02781343602909714, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-176-8", "text": "F-37\n", "page_number": 176, "bounding_box": {"top_left_x": 0.48336358136721114, "top_left_y": 0.9238339751818571, "lower_right_x": 0.5130066545674531, "lower_right_y": 0.9341035515618314, "height": 0.010269576379974388, "width": 0.029643073200241954}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-177-0", "text": "10. Inventories\n", "page_number": 177, "bounding_box": {"top_left_x": 0.1500302480338778, "top_left_y": 0.10569105691056911, "lower_right_x": 0.2807017543859649, "lower_right_y": 0.11852802738553701, "height": 0.012836970474967901, "width": 0.1306715063520871}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-177-1", "text": "                          2006   2005\nInventory raw materials    498     15\n", "page_number": 177, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.1467693624304664, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.17672229353872487, "height": 0.029952931108258474, "width": 0.7023593466424682}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-177-2", "text": "Raw materials have increased significantly year-on-year as the Group started producing its own\npharmaceutical products, such as Locteron, from 2006 onwards. Significant amounts of high-value\ninventories are required for these productions.\n", "page_number": 177, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.19469405220367994, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.2362002567394095, "height": 0.04150620453572956, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-177-3", "text": "There has not been a reversal of any write-down of assets in the years 2005 or 2006.\n", "page_number": 177, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.259734702610184, "lower_right_x": 0.6920750151240169, "lower_right_y": 0.2729995721009842, "height": 0.01326486949080019, "width": 0.542649727767695}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-177-4", "text": "11. Trade and other receivables\n", "page_number": 177, "bounding_box": {"top_left_x": 0.1500302480338778, "top_left_y": 0.31450577663671375, "lower_right_x": 0.42528735632183906, "lower_right_y": 0.3252032520325203, "height": 0.010697475395806566, "width": 0.27525710828796124}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-177-5", "text": "                                                     2006    2005\nTrade receivables                                   1,181   1,387\nProvision for impairment of receivables              (42)    (42)\nTrade receivables \u2013 net                             1,139   1,345\n\n\n\nCorporate income taxes                                 6        -\nWage taxes                                            21        -\nVAT to be received                                   350     255\nSocial securities and other taxes                    377     255\n\n\n\n                                                    2006    2005\nPrepaid expenses                                     473     351\nAccrued income                                        42     484\nOther amounts to be received                         570     330\nOther receivables, prepayments and accrued income   1,085   1,165\n", "page_number": 177, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.3384681215233205, "lower_right_x": 0.8656987295825771, "lower_right_y": 0.6401369276850664, "height": 0.30166880616174585, "width": 0.7162734422262552}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-177-6", "text": "Accrued income includes \u20ac 88 (2005: \u20ac 113) related to subsidies.\n", "page_number": 177, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.6568249893025246, "lower_right_x": 0.5644283121597096, "lower_right_y": 0.670517757809157, "height": 0.013692768506632369, "width": 0.4150030248033877}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-177-7", "text": "The nominal value less impairment provision of trade and other receivables are assumed to approximate their\nfair values.\n", "page_number": 177, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.6910569105691057, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.7171587505348738, "height": 0.026101839965768092, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-177-8", "text": "Additions to and releases from the provision for impaired receivables are included in \u201cother costs\u201d in the\nincome statement. However, there was no movement in the provision for impairment of receivables in 2006.\n", "page_number": 177, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.7424047924689773, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.7702182284980744, "height": 0.02781343602909714, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-177-9", "text": "F-38\n", "page_number": 177, "bounding_box": {"top_left_x": 0.48336358136721114, "top_left_y": 0.9238339751818571, "lower_right_x": 0.5130066545674531, "lower_right_y": 0.9341035515618314, "height": 0.010269576379974388, "width": 0.029643073200241954}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-178-0", "text": "12. Shareholders\u2019 equity\n", "page_number": 178, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.08557980316645272, "lower_right_x": 0.3629764065335753, "lower_right_y": 0.10269576379974327, "height": 0.017115960633290545, "width": 0.21355111917725347}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-178-1", "text": "Share capital & share premium reserve\n                              Number of issued shares                 Share capital (\u20ac x 1,000)\n                           Ordinary     Class AP    Class BP     Ordinary   Class AP    Class     Total\n                             shares                                shares                 BP\nAt 1 January 2005            46,934            -             -        47           -        -       47\nNew shares issued                  -     53,752         14,863          -         54       15       69\nAt 31 December 2005          46,934      53,752         14,863        47          54       15      116\nNew shares issued up            290       2,177           609           -          2        1        3\nto 3 October 2006\nAt 3 October 2006            47,224      55,929         15,472        47          56       16      119\n\n\nShare conversion             71,401     (55,929)    (15,472)          72        (56)     (16)         -\nShares after                118,625            -             -       119           -        -      119\nconversion\nShare split              11,862,500            -             -     1,305           -        -     1,305\nNew shares issued         4,301,076            -             -       516           -        -      516\nAt 31 December 2006      16,163,576                                1,940           -        -     1,940\n", "page_number": 178, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.12623020967051776, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.41762943945228925, "height": 0.29139922978177146, "width": 0.7313974591651542}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-178-2", "text": "The number of outstanding shares per 31 December 2005 was 115,549, comprising of 46,934 Ordinary\nshares, 53,752 Class AP preferred shares and 14,863 Class BP preferred shares.\n", "page_number": 178, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.4411638853230638, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.4689773213521609, "height": 0.02781343602909714, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-178-3", "text": "As a result of the January 2005 investment agreement, additional shares were issued in June 2006 and a total\nof \u20ac 750 was raised. As a consequence, the number of Class AP preferred shares increased with 2,177 shares\nto 55,929 shares per 30 June 2006 and the number of Class BP preferred shares increased with 609 shares to\n15,472 shares per 30 June 2006. As a result of this transaction, share capital increased with \u20ac 3, share\npremium reserve increased with \u20ac 583 and the subordinated convertible loan increased with \u20ac 164.\n", "page_number": 178, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.4719726144629867, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.543859649122807, "height": 0.07188703465982033, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-178-4", "text": "Because of exercising options in 2006 in the period 1 January up to 3 October, the number of ordinary shares\nincreased with 290 shares to 47,224 per 3 October 2006, resulting in an increase of share capital with \u20ac 0 and\nan increase of share premium reserve with \u20ac 104.\n", "page_number": 178, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.5472828412494651, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.5887890457851946, "height": 0.04150620453572951, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-178-5", "text": "Immediately prior to OctoPlus\u2019 IPO on 4 October 2006, which is discussed in more detail below, a Deed of\nAmendment and Conversion was executed which had the following impact:\n", "page_number": 178, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.6123234916559692, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.6397090286692341, "height": 0.02738553701326485, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-178-6", "text": "An authorised capital of the Company of \u20ac 8,640, divided into 36,000,000 ordinary shares with a\nnominal value of \u20ac 0.12 per share and 36,000,000 preference shares with a nominal value of \u20ac 0.12\nper share.\nAll Ordinary (\u201cClass C\u201d) shares, all Class AP preferred shares and all Class BP preferred shares,\noutstanding immediately prior to the IPO were converted into the same number of ordinary shares,\nA split of each of these ordinary shares into 100 ordinary shares with a nominal value of \u20ac 0.01 per\nshare,\nAn increase in the nominal value of these ordinary shares to \u20ac 0.12 per share, resulting in an\nincrease of share capital with \u20ac 1,305 and a corresponding reduction in share premium reserve,\nThe creation of a new class of preference shares.\n", "page_number": 178, "bounding_box": {"top_left_x": 0.2075015124016939, "top_left_y": 0.6439880188275567, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.7993153615746684, "height": 0.15532734274711169, "width": 0.6442831215970962}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-178-7", "text": "-\n", "page_number": 178, "bounding_box": {"top_left_x": 0.17906836055656383, "top_left_y": 0.6499786050492083, "lower_right_x": 0.18632788868723532, "lower_right_y": 0.6538296961916987, "height": 0.0038510911424903815, "width": 0.007259528130671489}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-178-8", "text": "", "page_number": 178, "bounding_box": {"top_left_x": 0.18148820326678766, "top_left_y": 0.6953359007274283, "lower_right_x": 0.1881427707199032, "lower_right_y": 0.6983311938382541, "height": 0.002995293110825803, "width": 0.006654567453115545}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-178-9", "text": "", "page_number": 178, "bounding_box": {"top_left_x": 0.17846339987900786, "top_left_y": 0.7287120239623449, "lower_right_x": 0.18753781004234724, "lower_right_y": 0.732135216089003, "height": 0.0034231921266580922, "width": 0.009074410163339375}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-178-10", "text": "", "page_number": 178, "bounding_box": {"top_left_x": 0.17906836055656383, "top_left_y": 0.7595207531022679, "lower_right_x": 0.1881427707199032, "lower_right_y": 0.7633718442447582, "height": 0.0038510911424903815, "width": 0.009074410163339375}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-178-11", "text": "", "page_number": 178, "bounding_box": {"top_left_x": 0.17846339987900786, "top_left_y": 0.7916131792896877, "lower_right_x": 0.1881427707199032, "lower_right_y": 0.7963200684638425, "height": 0.004706889174154849, "width": 0.009679370840895346}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-178-12", "text": "As a result of this Deed, the total number of issued and outstanding ordinary shares immediately prior to the\nIPO was 11,862,500. With the IPO, the Company issued 4,301,076 new shares at a price of \u20ac 4.65 per share,\nraising a total of \u20ac 20.0 million (gross). As a result, the total number of issued and outstanding ordinary\nshares increased to 16,163,576 at 31 December 2006. No preference shares are issued and outstanding at 31\nDecember 2006.\n", "page_number": 178, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.8211382113821138, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.8900299529311082, "height": 0.06889174154899436, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-178-13", "text": "F-39\n", "page_number": 178, "bounding_box": {"top_left_x": 0.48336358136721114, "top_left_y": 0.9238339751818571, "lower_right_x": 0.5130066545674531, "lower_right_y": 0.9341035515618314, "height": 0.010269576379974388, "width": 0.029643073200241954}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-179-0", "text": "No shares are held as treasury shares at 31 December 2005 and 2006.\n", "page_number": 179, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.06803594351732992, "lower_right_x": 0.5922565033272837, "lower_right_y": 0.08172871202396234, "height": 0.013692768506632425, "width": 0.44283121597096187}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-179-1", "text": "Other reserves\n", "page_number": 179, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.10569105691056911, "lower_right_x": 0.24682395644283123, "lower_right_y": 0.11638853230637569, "height": 0.01069747539580658, "width": 0.09739866908650938}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-179-2", "text": "The costs of share options to employees and Executive Board are recognised in the income statement,\ntogether with a corresponding increase in equity during the vesting period, taking into account (deferral of)\ncorporate income taxes. The accumulated expense of share options recognised in the income statement is\nshown separately in the equity category \u201cother reserves\u201d in the \u201cconsolidated statement of changes in\nequity\u201d. Pursuant to the options being exercised, lapsed or forfeited, \u201cother reserves\u201d is reversed with a\ncorresponding entry to \u201cretained earnings\u201d.\nIn the years presented in these financial statements, the Company did not have any legal or other types of\nreserves.\n", "page_number": 179, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.12280701754385964, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.23577235772357724, "height": 0.1129653401797176, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-179-3", "text": "Share options\n", "page_number": 179, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.26144629867351304, "lower_right_x": 0.24198427102238354, "lower_right_y": 0.2738553701326487, "height": 0.012409071459135668, "width": 0.09255898366606169}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-179-4", "text": "The Company operates an equity-settled share based compensation plan. As per the stock option plan\napproved by the Shareholders and Board of Supervisory Directors on 1 September 2006, the option pool is\nmaximised at 7.5% of the issued and outstanding share capital. As of 31 December 2006, the option pool\ntherefore amounts to 1,212,268 options (7.5% of 16,163,576 issued and outstanding ordinary shares). Out of\nthis pool, the number of issued and outstanding stock options is 652,815 per 31 December 2006 (2005:\n331,400).\n", "page_number": 179, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.28027385537013266, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.3628583654257595, "height": 0.08258451005562684, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-179-5", "text": "The exercise price of the granted options is equal to or higher than the market price of the shares on the date of\nthe (conditional) grant. All options are subject to the employee completing a pre-defined number of years of\nservice (\u201cthe vesting period\u201d). Each instalment of the Company\u2019s graded vesting awards is treated as a\nseparate share option grant. Consequently, the vesting periods for the individual instalments of the Company\u2019s\ngraded vesting awards vary between 1 and 4 years for options granted after 1 December 2004 and between 0\nand 5 years for options granted before 1 December 2004. The options are exercisable from the grant date\nonwards, except for certain key management members whose options are only exercisable after the\nconditionally granted options become unconditional due to achieving pre-defined milestones. Employees that\nhave exercised options and leave the Company during the vesting period are generally obliged to repay part of\nthe proceeds (\u201cthe award\u201d) received.\n", "page_number": 179, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.386392811296534, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.5271715875053488, "height": 0.14077877620881474, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-179-6", "text": "The Group has no legal or constructive obligation to repurchase or settle the options in cash.\n", "page_number": 179, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.5507060333761232, "lower_right_x": 0.735632183908046, "lower_right_y": 0.5639709028669234, "height": 0.01326486949080019, "width": 0.5862068965517241}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-179-7", "text": "Movements in the number of share options outstanding and their related weighted average exercise prices are\nas follows:\n", "page_number": 179, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.5849379546427044, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.6123234916559692, "height": 0.02738553701326485, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-179-8", "text": "as follows:\n                         2006                      2005\n                  Average     Number of     Average     Number of\n                  exercise      options     exercise      options\n                 price in \u20ac                price in \u20ac\n                 per share                 per share\nAt 1 January          3.49      331,400         3.50      376,500\nGranted               2.95      385,115            -             -\nForfeited             3.32      (21,900)        3.58      (11,600)\nExercised             3.58      (33,500)           -             -\nLapsed                3.58       (8,300)        3.58      (33,500)\nAt 31 December        3.19      652,815         3.49      331,400\n", "page_number": 179, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.6127513906718015, "lower_right_x": 0.8608590441621294, "lower_right_y": 0.7971758664955071, "height": 0.18442447582370558, "width": 0.7114337568058076}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-179-9", "text": "F-40\n", "page_number": 179, "bounding_box": {"top_left_x": 0.48336358136721114, "top_left_y": 0.9238339751818571, "lower_right_x": 0.5130066545674531, "lower_right_y": 0.9341035515618314, "height": 0.010269576379974388, "width": 0.029643073200241954}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-180-0", "text": "Share options outstanding at the end of the year have the following expiry year and exercise prices:\n", "page_number": 180, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.06803594351732992, "lower_right_x": 0.778584392014519, "lower_right_y": 0.0821566110397946, "height": 0.014120667522464686, "width": 0.6291591046581971}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-180-1", "text": "Expiry year   Share options    Exercise price in \u20ac   Share options    Exercise price in \u20ac\n                                   per share                              per share\n                        2006                 2006              2005                 2005\n2005                                                          6,500                  3.58\n2006                  10,000                  3.58           40,700                  3.58\n2007                  40,500                  3.74           49,000                  3.71\n2008                       -                     -                -                     -\n2009                 222,200                  3.43          235,200                  3.43\n2010                  10,000                  2.70                -\n2011                 370,115                  2.99                -\n                     652,815                                331,400\n", "page_number": 180, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.10569105691056911, "lower_right_x": 0.8584392014519057, "lower_right_y": 0.28840393667094566, "height": 0.18271287976037653, "width": 0.7090139140955838}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-180-2", "text": "The 6,500 options with expiry year 2005 outstanding at 31 December 2005 relate to share options exercised in\n2005 for which the formal registration and share issuance did not take place until 2006. For further details on\nthe options with an expiry date in 2006 but still included as outstanding options at 31 December 2006,\nreference is made to Note 32.\n", "page_number": 180, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.3076593923833975, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.36157466837826274, "height": 0.05391527599486523, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-180-3", "text": "A total of 385,115 options were granted to OctoPlus employees in 2006 (2005: no options granted). 90,600\noptions were granted to OctoPlus employees in the first quarter of based on the employees\u2019 2005 performance.\nThe fair value of these 90,600 options granted, which needs to be recorded as an expense over the lifetime of\nthese options, was \u20ac 107, using the Binomial valuation model. The significant inputs into the model for the\noptions granted in 2006 were an exercise price of \u20ac 2.70 per share at the grant date, annual risk-free interest\nrates between 3.03% and 3.54%, volatility of 93% and no expected dividend yields. The historical volatility\nused is based on the average of the historical weekly volatility of the peers over a period that agrees with the\nperiod of maturity. Since the Company was not listed at the time of granting these 90,600 options, the share\nprice was not readily available at the valuation date of the share option. The share price used at the first\nquarter 2006 grant dates have been estimated by Management on basis of a valuation that was performed in\nconjunction with the venture capital round of January 2005. The respective estimated share price at the date of\nthis valuation was \u20ac 2.70 per share. New shares, as a result of the January 2005 investment agreement have\nalso been issued in 2006 for a price of \u20ac 2.70 per share. This valuation was not performed contemporaneously\nwith the option grants, but Management believes that the share price at the grant date approximates the share\nprice calculated at the valuation date.\n", "page_number": 180, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.386392811296534, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.5986307231493367, "height": 0.21223791185280272, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-180-4", "text": "Following assessment of certain key management members\u2019 achievement, 236,015 of the conditionally\ngranted options became unconditional pursuant to certain key management members achieving pre-defined\nmilestones. The exercise price of these options is \u20ac 2.70 per share, identical to the other options granted in the\nfirst quarter of the year 2006. Apart from these options being conditional to achieving the pre-defined\nmilestones, these options could only be granted following extension of the option pool to 7.5% of the issued\nand outstanding share capital, which extension was approved in the shareholders meeting of 1 September\n2006. A total of 58,500 options have been awarded to certain other employees of the Company related to their\n2006 performance. The exercise price of these options is \u20ac 4.55 per share, identical to the 2006 OctoPlus\nclosing share price.\n", "page_number": 180, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.6225930680359435, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.7488232777064613, "height": 0.1262302096705178, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-180-5", "text": "The fair value of these 294,515 options granted, which needs to be recorded as an expense over the lifetime of\nthese options, was \u20ac 368, using the Binomial valuation model. The significant inputs into the model for the\noptions related to the employees\u2019 2006 performance granted in 2006 were an exercise price of \u20ac 2.70 per share\nfor the conditional option grants and \u20ac 4.55 per share for the unconditional option grants respectively, an\nannual risk-free interest rate of 3.92%, volatility of 69% and no expected dividend yields. The historical\nvolatility used is based on the average of the historical weekly volatility of the peers over a period that agrees\nwith the period of maturity.\n", "page_number": 180, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.7697903294822422, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.8694908001711597, "height": 0.09970047068891741, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-180-6", "text": "Warrants\n", "page_number": 180, "bounding_box": {"top_left_x": 0.1500302480338778, "top_left_y": 0.8930252460419341, "lower_right_x": 0.20810647307924984, "lower_right_y": 0.9032948224219084, "height": 0.010269576379974277, "width": 0.05807622504537205}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-180-7", "text": "F-41\n", "page_number": 180, "bounding_box": {"top_left_x": 0.48336358136721114, "top_left_y": 0.9238339751818571, "lower_right_x": 0.5117967332123412, "lower_right_y": 0.9341035515618314, "height": 0.010269576379974388, "width": 0.028433151845130067}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-181-0", "text": "In 2003 and 2004 various parties (including employees and Management) guaranteed a loan made by a bank\nto the Group in a total amount of \u20ac 400 and provided loans to the Group totalling \u20ac 250. As part of the\nagreements, these parties had the option to receive an interest of 1.0% per month (based on the amount\nguaranteed or loan provided) or the lower interest of 0.5% per month and 140 warrants per \u20ac 100 per month.\nIn total, 3,920 warrants, with each warrant entitling the holder thereof the right to acquire 100 shares, have\nbeen granted as part of this arrangement (2003: 560 and 2004: 3,360). The warrants can be exercised until 30\nNovember 2008. The exercise price of these warrants was determined at \u20ac 5.50. No warrants have been\nexercised until 31 December 2006.\n", "page_number": 181, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.06803594351732992, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.18142918271287975, "height": 0.11339323919554983, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-181-1", "text": "13. Convertible subordinated loan\n", "page_number": 181, "bounding_box": {"top_left_x": 0.1500302480338778, "top_left_y": 0.2220795892169448, "lower_right_x": 0.44464609800362975, "lower_right_y": 0.23448866067608046, "height": 0.012409071459135668, "width": 0.294615849969752}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-181-2", "text": "Following the shareholders\u2019 agreement of 29 December 2004, on 19 January 2005, a group of venture capital\ninvestors participated in the Company for an amount of \u20ac 19,000 (\u20ac 18,250 in 2005 and \u20ac 750 in 2006). In\naddition to the preference shares issued (see note 12), \u20ac 3,985 was provided to the Group in 2005 and an\n", "page_number": 181, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.24261874197689345, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.28754813863928114, "height": 0.04492939666238768, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-181-3", "text": "additional \u20ac 164 in 2006.\nAt the time the subordinated convertible loan was outstanding, the Company did not have an obligation to\nredeem the loan or to pay interest/dividends, except when normal dividends are paid to the other Shareholders.\nThe loan issuer was only entitled to collect any sums pursuant to the loan agreement if and to the extent the\n(other) investors received any sums pursuant to their ownership of Class AP preferred shares in the Company.\nThe total amount of the subordinated convertible loan was therefore classified as equity in the 2005\nconsolidated financial statements.\nAs per the contract for this subordinated convertible loan, the Class BP preferred shares were converted into\nordinary shares and the loan was converted into share premium reserve at the time of the Company\u2019s IPO on 4\nOctober 2006.\n", "page_number": 181, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.28797603765511337, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.4313222079589217, "height": 0.1433461703038083, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-181-4", "text": "14. Deferred corporate income taxes\n", "page_number": 181, "bounding_box": {"top_left_x": 0.1500302480338778, "top_left_y": 0.47539580658964486, "lower_right_x": 0.4646098003629764, "lower_right_y": 0.4895164741121095, "height": 0.014120667522464658, "width": 0.3145795523290986}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-181-5", "text": "Deferred corporate income tax assets and liabilities are offset when there is a legally enforceable right to offset\ncurrent tax assets against current tax liabilities and when the deferred corporate income taxes relate to the\nsame fiscal authority.\n", "page_number": 181, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.4959349593495935, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.5451433461703038, "height": 0.049208386820710326, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-181-6", "text": "Deferred corporate income tax assets and liabilities are measured at the (substantially) enacted tax rates that\nare expected to apply to the period when the asset is realised or the liability is settled. For the Group\u2019s deferred\ncorporate tax assets and liabilities at 31 December 2006, this resulted in a corporate income tax rate of 25.5%\n(31 December 2005: 29.1%) used to calculate the deferred corporate income tax assets and liabilities for fiscal\nunity OctoPlus N.V. and Chienna B.V., both located in the Netherlands, and a corporate income tax rate\nvarying between 15% for losses up to $50,000, 25% for losses between $50,001 - $75,000, 34% for losses\nbetween $75,001 - $100,000 and 39% for all losses in excess of $100,000 for the US Company OctoPlus Inc.\n", "page_number": 181, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.5455712451861361, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.6401369276850664, "height": 0.09456568249893027, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-181-7", "text": "The movement on the recognised deferred corporate income tax liability is as follows:\n", "page_number": 181, "bounding_box": {"top_left_x": 0.15063520871143377, "top_left_y": 0.6636713735558408, "lower_right_x": 0.6957047791893527, "lower_right_y": 0.676936243046641, "height": 0.01326486949080019, "width": 0.5450695704779189}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-181-8", "text": "                                            2006   2005\nBeginning of the year                          -    353\nDeferred corporate income taxes (Note 24)      -   (353)\nEnd of the year                                -       -\n", "page_number": 181, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.6773641420624733, "lower_right_x": 0.8596491228070176, "lower_right_y": 0.748395378690629, "height": 0.07103123662815569, "width": 0.7102238354506957}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-181-9", "text": "Over the last few years, the Company has shown a net loss, with in general deferred corporate income tax\nassets, caused by these net losses, well exceeding any potential deferred corporate income tax liabilities. As a\nconsequence, the Company did not record any deferred corporate income tax assets or liabilities, with 2004\nyear-end balances as the only exception. In 2004, the new fiscal unity OctoPlus N.V. was created and the\ndeferred corporate income tax liability arising from the deferral of a gain on the sale of property in this fiscal\nunity was higher than the deferred corporate income tax asset arising from the 2004 net book loss in the\nfiscal unity.\n", "page_number": 181, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.7697903294822422, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.8694908001711597, "height": 0.09970047068891741, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-181-10", "text": "Temporary differences\n", "page_number": 181, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.8930252460419341, "lower_right_x": 0.29522081064730793, "lower_right_y": 0.905862216516902, "height": 0.012836970474967901, "width": 0.14579552329098608}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-181-11", "text": "F-42\n", "page_number": 181, "bounding_box": {"top_left_x": 0.48336358136721114, "top_left_y": 0.9238339751818571, "lower_right_x": 0.5130066545674531, "lower_right_y": 0.9341035515618314, "height": 0.010269576379974388, "width": 0.029643073200241954}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-182-0", "text": "In 2004, a fiscal reserve for re-investments was created for a \u20ac 1.6 million gain on the sale of the Company\u2019s\nmain property, as recorded in fiscal unity OctoPlus N.V. (which property was subsequently leased back\nthrough a finance lease). A substantial part of this fiscal reserve for re-investments is used in OctoPlus\nN.V.\u2019s 2005 corporate income tax filing and the remaining part will be used in OctoPlus N.V.\u2019s 2006\ncorporate income tax filing.\nTo date, none of the Group companies have witnessed any other significant temporary differences.\n", "page_number": 182, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.06803594351732992, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.157466837826273, "height": 0.08943089430894308, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-182-1", "text": "Permanent differences\n", "page_number": 182, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.18014548566538297, "lower_right_x": 0.29522081064730793, "lower_right_y": 0.19169875909285408, "height": 0.011553273427471117, "width": 0.14579552329098608}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-182-2", "text": "In the years 2005 and 2006, two significant permanent differences arose related to the January 2005\nfinancing round and the October 2006 IPO. For book purposes, these expenditures (amounting to \u20ac 4.2\nmillion in total) are directly offset with the proceeds within share premium reserve but for tax purposes,\nthese expenditures are deducted from taxable income, resulting in \u20ac 4.2 million of additional tax losses\ncarried forward.\n", "page_number": 182, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.19811724433033803, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.26572528883183566, "height": 0.06760804450149763, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-182-3", "text": "Corporate Income Tax 2007 Bill\n", "page_number": 182, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.290543431750107, "lower_right_x": 0.3629764065335753, "lower_right_y": 0.30380830124090713, "height": 0.013264869490800135, "width": 0.21355111917725347}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-182-4", "text": "As of 1 January 2007, the Corporate Income Tax 2007 Bill became effective. As from this date onwards, tax\nloss carry-forward in the Netherlands is subject to a time limitation of 9 years. The Corporate Income Tax\n2007 Bill has become effective retroactively, with a transitional provision for losses sustained in the years up\nto 2002. These losses may still be offset against future profits up to and including book years starting in 2011.\nThe total amounts of tax losses carried forward and corporate deferred tax assets as well as the amounts of\nrecognised and unrecognised corporate deferred taxes per fiscal unity are as follows:\n", "page_number": 182, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.3042362002567394, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.392811296534018, "height": 0.08857509627727855, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-182-5", "text": "                      Tax losses   Deferred tax   Recognised         Not\n                        carried           asset                recognised\n                       forward\nAt 31 December 2005\nOctoPlus N.V. 1           5,660          1,645          381        1,264\n               2\nChienna B.V.              4,911          1,429             -       1,429\nOctoPlus Inc                   -              -            -            -\n                        10,571           3,074          381        2,693\nAt 31 December 2006\nOctoPlus N.V. 1         12,874           3,283          381        2,902\n               2\nChienna B.V.              9,733          2,482             -       2,482\nOctoPlus Inc                127             31             -          31\n                        22,734           5,796          381        5,415\n", "page_number": 182, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.417201540436457, "lower_right_x": 0.8608590441621294, "lower_right_y": 0.6367137355584083, "height": 0.21951219512195125, "width": 0.7114337568058076}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-182-6", "text": "1\n The use of tax losses in future years may be restricted as a result of profit split rules for mergers and fiscal\nunities as stipulated in the Dutch corporate income tax act 1969.\n2\n  Chienna B.V. was acquired on 1 March 2003 and was included in the fiscal unity OctoPlus N.V. as of 1\nJanuary 2007.\n", "page_number": 182, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.6576807873341891, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.7188703465982028, "height": 0.061189559264013704, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-182-7", "text": "The tax losses carried forward per year are as follows:\n", "page_number": 182, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.7424047924689773, "lower_right_x": 0.49304295220810646, "lower_right_y": 0.756525459991442, "height": 0.01412066752246477, "width": 0.3436176648517846}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-182-8", "text": "Tax losses carried forward per year:   OctoPlus Inc   OctoPlus N.V.   Chienna B.V.\n2002 or earlier                                   -             23            930\n2003                                              -           2,545            716\n2004                                              -            604           1,165\n2005                                              -           3,603          2,095\n2006                                           127            6,099          4,827\n", "page_number": 182, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.7800599058622165, "lower_right_x": 0.837265577737447, "lower_right_y": 0.8797603765511339, "height": 0.09970047068891741, "width": 0.6878402903811252}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-182-9", "text": "F-43\n", "page_number": 182, "bounding_box": {"top_left_x": 0.48336358136721114, "top_left_y": 0.9238339751818571, "lower_right_x": 0.5130066545674531, "lower_right_y": 0.9341035515618314, "height": 0.010269576379974388, "width": 0.029643073200241954}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-183-0", "text": "Total tax losses carried forward   127   12,874   9,733\n", "page_number": 183, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.0646127513906718, "lower_right_x": 0.8445251058681186, "lower_right_y": 0.10569105691056911, "height": 0.041078305519897315, "width": 0.6950998185117967}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-183-1", "text": "F-44\n", "page_number": 183, "bounding_box": {"top_left_x": 0.48336358136721114, "top_left_y": 0.9238339751818571, "lower_right_x": 0.5130066545674531, "lower_right_y": 0.9341035515618314, "height": 0.010269576379974388, "width": 0.029643073200241954}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-184-0", "text": "15. Pension liabilities\n", "page_number": 184, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.08643560119811725, "lower_right_x": 0.3339382940108893, "lower_right_y": 0.09927257167308515, "height": 0.012836970474967901, "width": 0.18451300665456746}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-184-1", "text": "The amounts recognised in the balance sheet for the defined benefit plan per 31 December 2005 and 2006 are\ndetermined as follows:\n", "page_number": 184, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.12623020967051776, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.15062045357295678, "height": 0.02439024390243902, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-184-2", "text": "                                      2006   2005\nPresent value of funded obligations      -    924\nFair value of plan assets                -   (794)\n                                         -    130\nUnrecognised actuarial losses            -    (41)\nLiability in the balance sheet           -     89\n", "page_number": 184, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.15703893881044073, "lower_right_x": 0.8632788868723533, "lower_right_y": 0.2631578947368421, "height": 0.10611895592640136, "width": 0.7138535995160314}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-184-3", "text": "Until 31 January 2006, the Company operated a collective defined benefit plan. This plan was replaced on 1\nFebruary 2006 by a collective defined contribution plan. Under this new plan, the Group has no legal or\nconstructive obligations to pay further contributions if the fund does not hold sufficient assets to pay all\nemployees the benefits relating to employee service in the current and prior periods. No amounts have been\nrecognised in the balance sheet at year-end 2006 for the terminated defined benefit plan, as the only risk\nremaining for the Company after the termination date is the risk involving the transfer of pension benefits\nfrom the Company\u2019s pension plan to a third party pension plan at the end of employment with one of the\nGroup companies; which risk and its financial impact is perceived by the Company as not material.\n", "page_number": 184, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.28369704749679076, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.3970902866923406, "height": 0.11339323919554983, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-184-4", "text": "The amounts recognised in the income statement for the defined benefit plan are as follows:\n", "page_number": 184, "bounding_box": {"top_left_x": 0.15063520871143377, "top_left_y": 0.4206247325631151, "lower_right_x": 0.7307924984875983, "lower_right_y": 0.433461703038083, "height": 0.012836970474967901, "width": 0.5801572897761645}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-184-5", "text": "                                                                                             2006        2005\nCurrent service cost                                                                             5         62\nInterest cost                                                                                    4         45\nExpected return on plan assets                                                                 (4)        (40)\nOther costs                                                                                      8         73\nCurtailment                                                                                   (80)           -\nTotal expense, included in \u201cemployee benefits\u201d (Note 20)                                      (67)        140\n\n\nThe actual return on plan assets for the defined benefit plan in 2006 (1 January 2006 \u2013 31 January 2006) was \u20ac\n0 (2005: loss of \u20ac 6).\n", "page_number": 184, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.4548566538296962, "lower_right_x": 0.8656987295825771, "lower_right_y": 0.6264441591784339, "height": 0.17158750534873768, "width": 0.7162734422262552}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-184-6", "text": "The movement in the liability recognised in the balance sheet is as follows:\n", "page_number": 184, "bounding_box": {"top_left_x": 0.15063520871143377, "top_left_y": 0.6499786050492083, "lower_right_x": 0.6243194192377496, "lower_right_y": 0.6628155755241762, "height": 0.012836970474967901, "width": 0.4736842105263158}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-184-7", "text": "                                                             2006    2005\nBeginning of the year                                          89     131\nTotal expense charged to the income statement                  13     140\nContributions (incl. other costs paid)                       (22)    (182)\nCurtailment                                                  (80)        -\nEnd of the year                                                 -      89\n\n\nThe principal actuarial assumptions used were as follows:\n                                                             2006    2005\nDiscount rate                                               4.25%   5.00%\nExpected return on plan assets                              4.25%   5.00%\nRate of salary increases                                    2.50%   2.00%\nRate of pension benefit increases                           0.25%   1.00%\n", "page_number": 184, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.6632434745400085, "lower_right_x": 0.8656987295825771, "lower_right_y": 0.8960205391527599, "height": 0.23277706461275138, "width": 0.7162734422262552}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-184-8", "text": "F-45\n", "page_number": 184, "bounding_box": {"top_left_x": 0.48336358136721114, "top_left_y": 0.9238339751818571, "lower_right_x": 0.5130066545674531, "lower_right_y": 0.9341035515618314, "height": 0.010269576379974388, "width": 0.029643073200241954}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-185-0", "text": "Assumptions regarding future mortality experience have been set based on published statistics used by Dutch\ninsurance companies (\u201ccollectief '93\u201d).\n", "page_number": 185, "bounding_box": {"top_left_x": 0.1500302480338778, "top_left_y": 0.06803594351732992, "lower_right_x": 0.8499697519661222, "lower_right_y": 0.09584937954642704, "height": 0.027813436029097124, "width": 0.6999395039322445}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-185-1", "text": "16. Borrowings and finance lease liabilities\n", "page_number": 185, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.1364997860504921, "lower_right_x": 0.5178463399879008, "lower_right_y": 0.1527599486521181, "height": 0.016260162601625994, "width": 0.36842105263157887}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-185-2", "text": "                            2006    2005\n\n\nNon-current portion         3,592   3,649\nCurrent portion              164     142\nFinance lease liabilities   3,756   3,791\n", "page_number": 185, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.1775780915703894, "lower_right_x": 0.8596491228070176, "lower_right_y": 0.2601626016260163, "height": 0.08258451005562689, "width": 0.7102238354506957}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-185-3", "text": "The bank overdraft of \u20ac 1,482 (2005: \u20ac 496) relates to the facility with ABN Amro Bank N.V. (see for more\ndetails below).\n", "page_number": 185, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.28369704749679076, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.3115104835258879, "height": 0.02781343602909714, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-185-4", "text": "Finance lease liabilities\n                                                                  2006      2005\nFinance lease liabilities \u2013 minimum lease payments:\nNo later than 1 year                                               517       500\nBetween 1 and 5 years                                            1,711     1,693\nLater than 5 years                                               4,968     5,311\n                                                                 7,196     7,504\nFuture finance charges on finance leases                        (3,440)   (3,713)\nPresent value of finance lease liabilities                       3,756     3,791\n\n\nThe present value of finance lease liabilities is as follows:\nNo later than 1 year                                               164       142\nBetween 1 and 5 years                                              417       384\nLater than 5 years                                               3,175     3,265\n                                                                 3,756     3,791\n", "page_number": 185, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.33504492939666236, "lower_right_x": 0.8608590441621294, "lower_right_y": 0.599058622165169, "height": 0.26401369276850667, "width": 0.7114337568058076}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-185-5", "text": "Lease liabilities are effectively secured by the lessor as the rights to the leased asset revert to the lessor in the\nevent of default.\n", "page_number": 185, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.6225930680359435, "lower_right_x": 0.8511796733212341, "lower_right_y": 0.6469833119383825, "height": 0.024390243902439046, "width": 0.7017543859649122}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-185-6", "text": "Bank overdrafts\n", "page_number": 185, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.6726572528883183, "lower_right_x": 0.2540834845735027, "lower_right_y": 0.6846384253316218, "height": 0.011981172443303434, "width": 0.10465819721718086}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-185-7", "text": "The Company\u2019s subsidiary OctoPlus Development B.V. utilises a current account lending facility with ABN\nAmro Bank N.V. amounting to \u20ac 2.0 million for working capital and investment purposes. OctoPlus\nDevelopment B.V has provided the following securities.:\n", "page_number": 185, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.6910569105691057, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.732135216089003, "height": 0.04107830551989733, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-185-8", "text": "-   Pledge on equipment (excluding finance leases) (book value at 31 December 2006: \u20ac 2,192 and 31\n    December 2005: \u20ac 2,419);\n-   Pledge on inventories and receivables (book value at 31 December 2006: \u20ac 1,624 and 31 December\n    2005: \u20ac 1,360);\n-   Joint and several liability of OctoPlus N.V.;\n-   In addition, the financing agreement included a covenant which required the shareholders\u2019 equity\n    of OctoPlus Development B.V. to exceed 25% of its balance sheet total. No breaches of this\n    covenant have occurred during 2005 and 2006.\n", "page_number": 185, "bounding_box": {"top_left_x": 0.17846339987900786, "top_left_y": 0.7325631151048353, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.8592212237911853, "height": 0.12665810868634997, "width": 0.6733212341197823}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-185-9", "text": "The carrying amounts of short-term borrowings (bank overdrafts) approximate their fair values.\n", "page_number": 185, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.8827556696619597, "lower_right_x": 0.764670296430732, "lower_right_y": 0.8968763371844245, "height": 0.01412066752246477, "width": 0.6152450090744102}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-185-10", "text": "F-46\n", "page_number": 185, "bounding_box": {"top_left_x": 0.48336358136721114, "top_left_y": 0.9238339751818571, "lower_right_x": 0.5130066545674531, "lower_right_y": 0.9341035515618314, "height": 0.010269576379974388, "width": 0.029643073200241954}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-186-0", "text": "Effective interest rates and borrowing facilities\nThe effective interest rates at the balance sheet date were as follows:\n", "page_number": 186, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.06803594351732992, "lower_right_x": 0.5898366606170599, "lower_right_y": 0.09927257167308515, "height": 0.03123662815575523, "width": 0.440411373260738}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-186-1", "text": "                            2006   2005\nBank overdrafts             4.5%   4.5%\nFinance lease liabilities   9.1%   9.1%\n", "page_number": 186, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.12280701754385964, "lower_right_x": 0.8542044767090139, "lower_right_y": 0.17115960633290545, "height": 0.0483525887890458, "width": 0.704779189352692}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-186-2", "text": "The Group\u2019s only borrowing facility at 31 December 2005 and 2006 is the current account lending facility of\nOctoPlus Development B.V. amounting to \u20ac 2.0 million referred to above. The undrawn borrowing facility at\nthe balance sheet date was as follows:\n", "page_number": 186, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.19469405220367994, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.23277706461275138, "height": 0.03808301240907144, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-186-3", "text": "                                                   2006    2005\nUndrawn borrowing facility (at floating rate)       518    1,504\n\n\n17. Trade and other payables\n                                                   2006    2005\n\nTrade payables                                     2,468   1,491\n\n\nCurrent amounts due to related parties (Note 31)     12        -\nPayable to related parties                           12        -\n\n\nCorporate income taxes                                 -      2\nWage taxes and accrued social security costs        226     237\nSocial securities and other taxes                   226     239\n\n\n\nSubsidies received in advance (Note 18)             853     853\nDeferred income                                     448     147\nPrepayments by customers                            928     745\nAccrued expenses                                    925     831\nOther amounts to be paid                               -     67\nOther current liabilities                          3,154   2,643\nNon-current portion: Deferred income                 26        -\nOther current and non-current liabilities          3,180   2,643\n", "page_number": 186, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.259734702610184, "lower_right_x": 0.8656987295825771, "lower_right_y": 0.6949080017115961, "height": 0.43517329910141206, "width": 0.7162734422262552}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-186-4", "text": "Trade payables have increased significantly to \u20ac 2,468 (2005: \u20ac 1,491), mainly as a result of some large\nvendor invoices related to the Company\u2019s IPO of 4 October 2006 outstanding at year-end 2006. These\ninvoices have been reimbursed early 2007.\n", "page_number": 186, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.7115960633290543, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.7526743688489517, "height": 0.04107830551989733, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-186-5", "text": "18. Income from subsidies\n", "page_number": 186, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.7744972186563971, "lower_right_x": 0.37265577737447064, "lower_right_y": 0.787334189131365, "height": 0.012836970474967901, "width": 0.2232304900181488}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-186-6", "text": "OctoPlus Technologies B.V. started a development project in the year 2001 of which the expected cost\napproximated \u20ac 7,432. For this project, SenterNovem, the department of the Ministry of Economic Affairs\nresponsible for subsidies, has granted a technical development credit of 35% of the amounts spent between 30\nJanuary 2001 and 31 March 2005, which equals an amount of \u20ac 2,601. The partnership with SenterNovem for\nthis project has been terminated in 2005 and the Group will finance the remaining amounts internally.\n", "page_number": 186, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.8108686350021395, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.883183568677792, "height": 0.07231493367565256, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-186-7", "text": "Further conditions with regard to the          repayment of the technical development\n                                        F-47\n", "page_number": 186, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.9067180145485665, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.9345314505776636, "height": 0.02781343602909714, "width": 0.7023593466424682}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-187-0", "text": "credit have been stipulated by SenterNovem and are dependent of net turnover resulting from this\ndevelopment project. Based on the contract with SenterNovem, the following redemption conditions have\nbeen agreed:\n", "page_number": 187, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.06803594351732992, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.11125374411638853, "height": 0.04321780059905861, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-187-1", "text": "-   Annually before 27 February of the following calendar year, during the development period and\n    further from 2005 and during a maximum of 10 calendar years, an amount equal to 35% of the\n    royalty fees and entrance fees resulting or derived from the development project.\n-   Within four weeks after receiving the final decision concerning the magnitude of the grant: 35% of\n    the proceeds obtained by sale or otherwise of a null series, prototype, parts hereof or from other\n    assets that have been financed by this grant.\n-   Within four weeks after receiving the final decision concerning the magnitude of the grant: 35% of\n    the value of the assets financed with the grant and still can be used and are not used for the\n    production of rendering services resulting from the grant.\n", "page_number": 187, "bounding_box": {"top_left_x": 0.17846339987900786, "top_left_y": 0.1116816431322208, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.24989302524604193, "height": 0.1382113821138211, "width": 0.6733212341197823}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-187-2", "text": "The contract described above is the only subsidy contract of any OctoPlus legal entity with redemption\nconditions; i.e. a part of potential future revenues needs to be paid to SenterNovem. The total subsidy received\nhas been recognised as \u201cincome from subsidies\u201d since it is non-refundable. A liability for the royalty fees will\nonly be recognised when such payments become probable.\n", "page_number": 187, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.2734274711168164, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.3286264441591784, "height": 0.05519897304236199, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-187-3", "text": "In 2004, in collaboration with the Thorax Centre of Erasmus University (Rotterdam, the Netherlands),\nOctoPlus Technologies B.V. commenced a 3-year research project for a novel approach to treat myocardial\nregeneration. Total costs of this project approximate \u20ac 3,250. SenterNovem has granted a subsidy of \u20ac 2,000\nin order to relieve OctoPlus Technologies B.V.\u2019s and Erasmus University\u2019s burden in the costs. OctoPlus will\nfinance the costs that exceed the \u20ac 2,000 subsidy. An advance of 25% of the total subsidy (\u20ac 500) was\nreceived by OctoPlus in December 2004 and is recorded as \u201csubsidies received in advance\u201d under \u201cother\ncurrent liabilities\u201d on the balance sheet at 31 December 2005 and 31 December 2006 (Note 17).\n", "page_number": 187, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.35216089002995293, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.44843816859221225, "height": 0.09627727856225932, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-187-4", "text": "In 2004, OctoPlus Technologies B.V., in partnership with Utrecht University (Utrecht, the Netherlands),\ninitiated a study for a second-generation drug delivery technology. For this study, a total subsidy of \u20ac 1,413\nhas been granted of which \u20ac 897 is allocated to OctoPlus Technologies B.V. (being 70% of its estimated\nexpenditures) and \u20ac 516 is allocated to Utrecht University (being 60% of its estimated expenditures). The\nproject is expected to run over a period of 3 years. An advance of 25% of the total subsidy (\u20ac 353) was\nreceived by OctoPlus in December 2004 and is recorded as \u201csubsidies received in advance\u201d under \u201cother\ncurrent liabilities\u201d on the balance sheet at 31 December 2005 and 31 December 2006 (Note 17).\n", "page_number": 187, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.4719726144629867, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.5708172871202396, "height": 0.09884467265725289, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-187-5", "text": "In 2005, a development project was carried out in association with InnoCore Technologies B.V. The total\nestimated project costs amount to \u20ac 122 and OctoPlus Technologies B.V.\u2019s share of the total project costs was\n\u20ac 54. SenterNovem granted in total \u20ac 50 in subsidy to this project.\n", "page_number": 187, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.5917843388960206, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.6354300385109114, "height": 0.04364569961489084, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-187-6", "text": "19. Raw materials and auxiliaries and costs of contracted work and other\nexternal charges\n", "page_number": 187, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.675224646983312, "lower_right_x": 0.8511796733212341, "lower_right_y": 0.707744972186564, "height": 0.03252032520325199, "width": 0.7017543859649122}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-187-7", "text": "The costs included in raw materials and auxiliaries are the materials used in production runs for customers.\nCosts of contracted work and other external charges include costs related to clinical studies, toxicology studies\nand other purchased research and development costs.\n", "page_number": 187, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.7124518613607189, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.7535301668806161, "height": 0.04107830551989722, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-187-8", "text": "F-48\n", "page_number": 187, "bounding_box": {"top_left_x": 0.48336358136721114, "top_left_y": 0.9238339751818571, "lower_right_x": 0.5130066545674531, "lower_right_y": 0.9341035515618314, "height": 0.010269576379974388, "width": 0.029643073200241954}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-188-0", "text": "20. Employee benefits\n", "page_number": 188, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.06803594351732992, "lower_right_x": 0.338777979431337, "lower_right_y": 0.08515190415062045, "height": 0.01711596063329053, "width": 0.18935269207501512}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-188-1", "text": "                                                             2006    2005\nWages and salaries                                           5,517   3,994\nSocial security costs                                         399     462\nShare options granted to directors and employees (Note 12)     90     132\nPension costs \u2013 defined contribution plans                    201      30\nPension costs \u2013 defined benefit plans (Note 15)               (67)    140\n                                                             6,140   4,758\n\n\nNumber of employees at 31 December                            139     110\n", "page_number": 188, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.10911424903722722, "lower_right_x": 0.8608590441621294, "lower_right_y": 0.2635857937526744, "height": 0.15447154471544716, "width": 0.7114337568058076}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-188-2", "text": "The wages and salaries are net of WBSO subsidies of \u20ac 475 (2005: \u20ac 337).\n", "page_number": 188, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.28712023962344885, "lower_right_x": 0.6218995765275257, "lower_right_y": 0.3008130081300813, "height": 0.01369276850663248, "width": 0.4724742891712038}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-188-3", "text": "21. Other costs\n", "page_number": 188, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.3418913136499786, "lower_right_x": 0.2807017543859649, "lower_right_y": 0.35258878904578517, "height": 0.010697475395806566, "width": 0.13127646702964305}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-188-4", "text": "                            2006    2005\nHousing costs                669     540\nProduction costs             967     957\nOffice expenses              438     224\nSelling & Marketing costs    825     715\nGeneral expenses             658     538\nOther personnel costs       1,706   1,239\n                            5,263   4,213\n", "page_number": 188, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.3795464270432178, "lower_right_x": 0.8608590441621294, "lower_right_y": 0.5169020111253744, "height": 0.1373555840821566, "width": 0.7114337568058076}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-188-5", "text": "Other costs have increased mainly due to an increase in staff and activities of the Company.\n", "page_number": 188, "bounding_box": {"top_left_x": 0.1512401693889897, "top_left_y": 0.5575524176294394, "lower_right_x": 0.735632183908046, "lower_right_y": 0.5716730851519042, "height": 0.01412066752246477, "width": 0.5843920145190562}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-188-6", "text": "For leases where the Group is a lessee under operating leases, lease rentals amounting to \u20ac 255 (2005: \u20ac 233)\nare included in \u201cother costs\u201d in the income statement.\n", "page_number": 188, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.5952075310226786, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.6195977749251177, "height": 0.024390243902439046, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-188-7", "text": "The amount of inventories recognised as an expense in 2006 is \u20ac 675 (2005: \u20ac 564) and are included in\n\u201cproduction costs\u201d under \u201cother costs\u201d.\n", "page_number": 188, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.6435601198117245, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.6709456568249893, "height": 0.02738553701326485, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-188-8", "text": "22. Research and development costs\n", "page_number": 188, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.6944801026957638, "lower_right_x": 0.45977011494252873, "lower_right_y": 0.7086007702182285, "height": 0.01412066752246477, "width": 0.31034482758620685}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-188-9", "text": "The costs directly attributable to research and development recognised as costs in the income statement were\nas follows:\n", "page_number": 188, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.7184424475823705, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.7462558836114677, "height": 0.02781343602909714, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-188-10", "text": "                                                        2006    2005\nDirect research and non-capitalised development costs   6,526   3,378\n", "page_number": 188, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.766367137355584, "lower_right_x": 0.8566243194192378, "lower_right_y": 0.7976037655113393, "height": 0.03123662815575523, "width": 0.7071990320629159}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-188-11", "text": "The Group\u2019s total costs related to research and development including indirect costs are \u20ac 9.3 million (2006)\nand \u20ac 5.8 million (2005).\n", "page_number": 188, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.8177150192554558, "lower_right_x": 0.8511796733212341, "lower_right_y": 0.8455284552845529, "height": 0.02781343602909714, "width": 0.7017543859649122}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-188-12", "text": "F-49\n", "page_number": 188, "bounding_box": {"top_left_x": 0.48336358136721114, "top_left_y": 0.9238339751818571, "lower_right_x": 0.5130066545674531, "lower_right_y": 0.9341035515618314, "height": 0.010269576379974388, "width": 0.029643073200241954}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-189-0", "text": "23. Interest income and interest costs\n", "page_number": 189, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.06803594351732992, "lower_right_x": 0.4694494857834241, "lower_right_y": 0.0821566110397946, "height": 0.014120667522464686, "width": 0.3200241984271023}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-189-1", "text": "                                                2006    2005\n Interest income:\n - Bank deposits                                 246     287\n\n\n Interest costs:\n - Bank borrowings, overdrafts and other debt    (34)    (44)\n - Finance leases                               (357)   (361)\n                                                (391)   (405)\n Finance costs \u2013 net                            (145)   (118)\n\n\n\n24. Corporate income taxes\n                                                2006    2005\n Deferred corporate income taxes (Note 14)          -    353\n Tax income                                         -    353\n", "page_number": 189, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.09199828840393667, "lower_right_x": 0.8656987295825771, "lower_right_y": 0.3560119811724433, "height": 0.2640136927685066, "width": 0.7162734422262552}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-189-2", "text": "25. Earnings per share\n", "page_number": 189, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.38296961916987593, "lower_right_x": 0.3484573502722323, "lower_right_y": 0.3970902866923406, "height": 0.014120667522464658, "width": 0.19903206291591044}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-189-3", "text": "Basic\n", "page_number": 189, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.4206247325631151, "lower_right_x": 0.18874773139745918, "lower_right_y": 0.4313222079589217, "height": 0.010697475395806566, "width": 0.03932244404113733}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-189-4", "text": "Basic earnings per share is calculated by dividing the result attributable to equity holders of the Company by\nthe weighted average number of shares outstanding during the year.\n", "page_number": 189, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.43774069319640563, "lower_right_x": 0.8511796733212341, "lower_right_y": 0.46555412922550277, "height": 0.02781343602909714, "width": 0.7017543859649122}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-189-5", "text": "                                                            2006         2005\nResult attributable to equity holders of the Company      (8,665)      (4,209)\nWeighted average number of ordinary shares             12,757,468   11,197,700\nBasic earnings per share (\u20ac per share)                     (0.68)       (0.38)\n", "page_number": 189, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.4890885750962773, "lower_right_x": 0.852994555353902, "lower_right_y": 0.5566966195977749, "height": 0.06760804450149765, "width": 0.7035692679975801}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-189-6", "text": "For more details about conversion of all ordinary (\u201cClass C\u201d) shares, all non-convertible AP shares (\u201cClass\nAP preferred shares\u201d) and all BP shares (\u201cClass BP preferred shares\u201d), outstanding until the IPO, and\nconversion of these shares into the newly created ordinary shares, reference is made to note 12.\n", "page_number": 189, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.5780915703893881, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.6195977749251177, "height": 0.04150620453572962, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-189-7", "text": "Diluted\n", "page_number": 189, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.6431322207958922, "lower_right_x": 0.20326678765880218, "lower_right_y": 0.6534017971758665, "height": 0.010269576379974388, "width": 0.05384150030248033}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-189-8", "text": "For both years included in these financial statements, the share options and warrants are not included in the\ndiluted earnings per share calculation as the Group was loss-making. Consequently basic and diluted earning\nper share are the same.\n", "page_number": 189, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.6602481814291827, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.7013264869490801, "height": 0.04107830551989733, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-189-9", "text": "26. Dividends per share\n", "page_number": 189, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.7252888318356868, "lower_right_x": 0.352692075015124, "lower_right_y": 0.7394094993581515, "height": 0.014120667522464658, "width": 0.20326678765880216}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-189-10", "text": "The Company did not declare dividends for any of the years presented in these consolidated financial\nstatements.\n", "page_number": 189, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.7458279845956355, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.7702182284980744, "height": 0.024390243902438935, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-189-11", "text": "F-50\n", "page_number": 189, "bounding_box": {"top_left_x": 0.48336358136721114, "top_left_y": 0.9238339751818571, "lower_right_x": 0.5130066545674531, "lower_right_y": 0.9341035515618314, "height": 0.010269576379974388, "width": 0.029643073200241954}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-190-0", "text": "27. Cash flow statement\n", "page_number": 190, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.06803594351732992, "lower_right_x": 0.35753176043557167, "lower_right_y": 0.0821566110397946, "height": 0.014120667522464686, "width": 0.20810647307924982}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-190-1", "text": "In the consolidated cash flow statement, purchases of property, plant and equipment comprise:\n                                                                                          2006       2005\nAdditions according to Note 7                                                            1,026       1,088\nNon-cash transactions                                                                    (110)       (164)\nPurchases of property, plant and equipment                                                 916        924\n\n\nIn the cash flow statement, proceeds from issuance of shares comprise:\n                                                                                          2006       2005\nIssue of share capital                                                                  17,966      13,199\nConverted loan from Statutory Director (Note 31)                                                -    (161)\nProceeds from issuance of shares                                                        17,966      13,038\n", "page_number": 190, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.10911424903722722, "lower_right_x": 0.8656987295825771, "lower_right_y": 0.30124090714591356, "height": 0.19212665810868634, "width": 0.7162734422262552}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-190-2", "text": "28. Contingencies\n", "page_number": 190, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.3418913136499786, "lower_right_x": 0.3042952208106473, "lower_right_y": 0.35772357723577236, "height": 0.01583226358579376, "width": 0.15486993345432545}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-190-3", "text": "Contingent liabilities\n", "page_number": 190, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.3628583654257595, "lower_right_x": 0.28554143980641256, "lower_right_y": 0.3761232349165597, "height": 0.01326486949080019, "width": 0.1361161524500907}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-190-4", "text": "As a result of the acquisition of Chienna B.V. in 2003, the Group is obliged to make certain milestone\npayments up to 3 years after the acquisition date (1 March 2003) and has profit-sharing obligations during\nthe patents terms. Up to 31 December 2006, milestone payments amounting to \u20ac 30 have been made, with a\ncorresponding adjustment of goodwill. No profit-sharing payments have been made up to 31 December\n2006. If and when profit-sharing payments have to be made during the remainder of the patents terms is\nuncertain and dependent on the commercial success of the Chienna technology.\n", "page_number": 190, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.3795464270432178, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.46555412922550277, "height": 0.08600770218228498, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-190-5", "text": "Subsidies\n", "page_number": 190, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.4890885750962773, "lower_right_x": 0.21294615849969753, "lower_right_y": 0.4993581514762516, "height": 0.010269576379974332, "width": 0.06352087114337568}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-190-6", "text": "For the development project, which started in 2001 (expected cost approximates \u20ac 7,432), repayment of the\ntechnical development subsidy from SenterNovem is dependent on the net turnover resulting from this\ndevelopment project. Further details on these conditions are provided in Note 18.\n", "page_number": 190, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.5062045357295678, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.5477107402652974, "height": 0.04150620453572962, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-190-7", "text": "Royalties\n", "page_number": 190, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.5712451861360719, "lower_right_x": 0.21173623714458562, "lower_right_y": 0.5836542575952075, "height": 0.012409071459135612, "width": 0.062310949788263764}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-190-8", "text": "The Group is obliged to pay royalties to Utrecht University for revenues received based on the OctoDEX\u2122\ntechnology platform. Such royalties shall not exceed 2% of such revenues. Furthermore, Leiden University\nMedical Centre is entitled to certain royalty revenues. Depending on the cumulative revenues, the royalties\nvary from 30% for cumulative revenues below \u20ac 15 million to 12.5% once cumulative revenues have\nexceeded \u20ac 30 million.\n", "page_number": 190, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.5840821566110398, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.6563970902866924, "height": 0.07231493367565256, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-190-9", "text": "29. Commitments\n", "page_number": 190, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.7013264869490801, "lower_right_x": 0.30490018148820325, "lower_right_y": 0.7154471544715447, "height": 0.014120667522464658, "width": 0.1554748941318814}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-190-10", "text": "Capital commitments\nAt 31 December 2006 there were no capital expenditures contracted for but not yet incurred.\n", "page_number": 190, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.7424047924689773, "lower_right_x": 0.7344222625529341, "lower_right_y": 0.7723577235772358, "height": 0.029952931108258474, "width": 0.5849969751966122}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-190-11", "text": "Operating lease commitments\n", "page_number": 190, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.793752674368849, "lower_right_x": 0.338777979431337, "lower_right_y": 0.8078733418913137, "height": 0.014120667522464658, "width": 0.18935269207501512}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-190-12", "text": "The Group leases various equipment under operating lease agreements. The lease expenditure charged to the\nincome statement during the year is disclosed in Note 21.\n", "page_number": 190, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.8108686350021395, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.8386820710312366, "height": 0.02781343602909714, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-190-13", "text": "F-51\n", "page_number": 190, "bounding_box": {"top_left_x": 0.48336358136721114, "top_left_y": 0.9238339751818571, "lower_right_x": 0.5117967332123412, "lower_right_y": 0.9341035515618314, "height": 0.010269576379974388, "width": 0.028433151845130067}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-191-0", "text": "The future aggregate minimum lease payments under non-cancellable operating leases are as follows:\n", "page_number": 191, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.08857509627727857, "lower_right_x": 0.7979431336963098, "lower_right_y": 0.10183996576807873, "height": 0.013264869490800163, "width": 0.6485178463399879}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-191-1", "text": "                                              2006   2005\nNo later than 1 year                           251    165\nLater than 1 year and no later than 5 years    28     35\nLater than 5 years                             86     93\n                                               365    293\n", "page_number": 191, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.11938382541720154, "lower_right_x": 0.8608590441621294, "lower_right_y": 0.20196833547282841, "height": 0.08258451005562688, "width": 0.7114337568058076}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-191-2", "text": "Future finance lease commitments\n", "page_number": 191, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.22892597347026103, "lower_right_x": 0.37265577737447064, "lower_right_y": 0.2396234488660676, "height": 0.010697475395806566, "width": 0.2232304900181488}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-191-3", "text": "The future finance lease commitments, as mentioned below, relate to a finance lease contract signed by the\nCompany in 2006 for additional office, laboratory and production facilities. These facilities are currently\nbeing built on a location adjacent to the Company\u2019s headquarters and are expected to be ready at the end of\n2007.\n", "page_number": 191, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.24604193410355157, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.29781771501925547, "height": 0.051775780915703895, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-191-4", "text": "                                               2006    2005\nNo later than 1 year                             63       -\nLater than 1 year and no later than 5 years    3,007      -\nLater than 5 years                            11,966      -\n                                              15,036      -\n", "page_number": 191, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.32135216089002994, "lower_right_x": 0.8608590441621294, "lower_right_y": 0.4073598630723149, "height": 0.08600770218228498, "width": 0.7114337568058076}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-191-5", "text": "Other operating commitments\n", "page_number": 191, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.43089430894308944, "lower_right_x": 0.34361766485178463, "lower_right_y": 0.44373127941805734, "height": 0.012836970474967901, "width": 0.19419237749546278}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-191-6", "text": "The Group has made other commitments related to the two ongoing clinical studies at 31 December 2006\namounting to \u20ac 1,011 (2005: \u20ac 0), of which \u20ac 477 relate to conditional commitments.\n", "page_number": 191, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.4441591784338896, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.4758237056054771, "height": 0.03166452717158752, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-191-7", "text": "Bank guarantees\n", "page_number": 191, "bounding_box": {"top_left_x": 0.1500302480338778, "top_left_y": 0.4993581514762516, "lower_right_x": 0.2601330913490623, "lower_right_y": 0.5109114249037228, "height": 0.011553273427471145, "width": 0.11010284331518452}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-191-8", "text": "As of 31 December 2006, the Company has guarantees amounting to \u20ac 116 (2005: \u20ac 116).\n", "page_number": 191, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.5164741121095422, "lower_right_x": 0.7186932849364791, "lower_right_y": 0.5297389816003423, "height": 0.01326486949080008, "width": 0.5692679975801572}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-191-9", "text": "30. Business combinations\n", "page_number": 191, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.5541292255027813, "lower_right_x": 0.37749546279491836, "lower_right_y": 0.5682498930252461, "height": 0.01412066752246477, "width": 0.2280701754385965}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-191-10", "text": "There were no business combinations effected during the years ended 31 December 2005 and 2006.\n", "page_number": 191, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.57466837826273, "lower_right_x": 0.7743496672716274, "lower_right_y": 0.5887890457851946, "height": 0.014120667522464658, "width": 0.6249243799153055}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-191-11", "text": "31. Related-party transactions\n", "page_number": 191, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.6123234916559692, "lower_right_x": 0.3339382940108893, "lower_right_y": 0.6255883611467694, "height": 0.01326486949080019, "width": 0.18451300665456746}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-191-12", "text": "Some of our key management personnel are also a shareholder. Related-party transactions with key\nmanagement personnel are discussed in section b \u201ckey management personnel\u201d of this footnote.\n", "page_number": 191, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.6294394522892597, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.6572528883183568, "height": 0.02781343602909714, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-191-13", "text": "a) Shareholders\n", "page_number": 191, "bounding_box": {"top_left_x": 0.1500302480338778, "top_left_y": 0.6807873341891314, "lower_right_x": 0.2516636418632789, "lower_right_y": 0.691484809584938, "height": 0.010697475395806566, "width": 0.10163339382940109}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-191-14", "text": "Following the changes in Shareholders in January 2005, no individual party had a significant influence over\nthe Company and there were no related-party transactions with Shareholders therefore.\n", "page_number": 191, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.6979032948224219, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.725716730851519, "height": 0.02781343602909714, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-191-15", "text": "b) Key Management Personnel\n", "page_number": 191, "bounding_box": {"top_left_x": 0.1500302480338778, "top_left_y": 0.7458279845956355, "lower_right_x": 0.3484573502722323, "lower_right_y": 0.7599486521181001, "height": 0.014120667522464658, "width": 0.1984271022383545}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 16, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-191-16", "text": "For key management personnel, a distinction has been made between (1) Board of Supervisory Directors and\n(2) Executive Board and Other key management personnel; representing the other members of the Company\u2019s\n\u201cCorporate Management Team\u201d.\n", "page_number": 191, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.766367137355584, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.8078733418913137, "height": 0.04150620453572962, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 17, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-191-17", "text": "(1) Board of Supervisory Directors\nThe remuneration of the Board of Supervisory Directors amounts to \u20ac 30 (2005: \u20ac 15). The remuneration of\nthe individual members of the Supervisory Board is set out in the table below:\n", "page_number": 191, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.82798459563543, "lower_right_x": 0.8324258923169994, "lower_right_y": 0.8750534873769791, "height": 0.047068891741549046, "width": 0.6830006049606775}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 18, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-191-18", "text": "F-52\n", "page_number": 191, "bounding_box": {"top_left_x": 0.48336358136721114, "top_left_y": 0.9238339751818571, "lower_right_x": 0.5130066545674531, "lower_right_y": 0.9341035515618314, "height": 0.010269576379974388, "width": 0.029643073200241954}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-192-0", "text": "                             Base    Other   2006    2005\n                            salary           Total   Total\nH. Stellingsma (Chairman)      18        -     18      15\nR. Kuijten                      4        -      4        -\nP. Toon                         4        -      4        -\nPh. Smith                       4        -      4        -\n                               30        -     30      15\n", "page_number": 192, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.10226786478391099, "lower_right_x": 0.8608590441621294, "lower_right_y": 0.21566110397946084, "height": 0.11339323919554985, "width": 0.7114337568058076}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-192-1", "text": "After the IPO of 4 October 2006, the remuneration of the chairman of the Board of Supervisory Directors was\nincreased to reflect that the Company became publicly listed company. The other Board of Supervisory\nDirectors also received a remuneration from the date of the IPO onwards. Part of the remuneration of the\nBoard of Supervisory Directors (\u20ac 12, 2005: \u20ac 0) was not reimbursed per 31 December 2006 and is recorded\nunder \u201cpayable to related parties\u201d in the balance sheet.\n", "page_number": 192, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.24261874197689345, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.3115104835258879, "height": 0.06889174154899444, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-192-2", "text": "(2) Executive Board and Other key management personnel\nThe remuneration of Executive Board and Other key management personnel amounts to \u20ac 1,197 (2005: \u20ac\n761); with the details set out in the table below:\n", "page_number": 192, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.33504492939666236, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.3795464270432178, "height": 0.04450149764655542, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-192-3", "text": "                        Base    Bonus   Pensions   Other   2006    2005\n                       salary\nJ.J.M. Holthuis, CEO     197       53        20       21    291     258\nJ.C.H.L. Pauli, CFO      169       29        10        2    210     146\nOther key management     592       46        29       29    696     357\n                         958      128        59       52   1,197    761\n", "page_number": 192, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.39666238767650835, "lower_right_x": 0.8596491228070176, "lower_right_y": 0.49293966623876767, "height": 0.09627727856225932, "width": 0.7102238354506957}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-192-4", "text": "Note: Excluding social security charges and expenditures for share-based payments.\n", "page_number": 192, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.5164741121095422, "lower_right_x": 0.6823956442831216, "lower_right_y": 0.5305947796320069, "height": 0.014120667522464658, "width": 0.5329703569267997}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-192-5", "text": "Mr. Pauli was engaged on an 80% basis until 1 February 2006 and on a 100% basis afterwards. The group of\nkey management personnel was increased by one person on 1 September 2005 onwards and by a second\nperson on 2 January 2006 onwards and consisted of 6 employees as of 31 December 2006.\n", "page_number": 192, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.5541292255027813, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.5956354300385109, "height": 0.04150620453572962, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-192-6", "text": "The remuneration of Executive Board and Other key management personnel results in the following costs in\nthe income statement related to key management compensation:\n", "page_number": 192, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.6161745827984596, "lower_right_x": 0.8511796733212341, "lower_right_y": 0.6435601198117245, "height": 0.02738553701326485, "width": 0.7017543859649122}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-192-7", "text": "                                                  2006    2005\nSalaries and other short-term employee benefits   1,176    781\nPost-employment benefits                            59     62\nShare-based payments                                67     95\n                                                  1,302    938\n", "page_number": 192, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.6499786050492083, "lower_right_x": 0.8656987295825771, "lower_right_y": 0.7381258023106547, "height": 0.08814719726144638, "width": 0.7162734422262552}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-192-8", "text": "Loans from Executive Board members\n", "page_number": 192, "bounding_box": {"top_left_x": 0.15063520871143377, "top_left_y": 0.7560975609756098, "lower_right_x": 0.411373260738052, "lower_right_y": 0.7685066324347454, "height": 0.012409071459135612, "width": 0.26073805202661826}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-192-9", "text": "A loan of \u20ac 161 provided by Mr. Holthuis was converted into 59,800 preference shares with a share price of \u20ac\n2.69 as part of the private offering of the Company\u2019s securities in 2005 (see Note 12).\n", "page_number": 192, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.7766367137355584, "lower_right_x": 0.8511796733212341, "lower_right_y": 0.8040222507488233, "height": 0.02738553701326485, "width": 0.7017543859649122}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-192-10", "text": "Executive Board and Other key management personnel\u2019s interests in the Company\nThe Executive Board and Other key management personnel own shares and have share options and warrant\nrights in the Company as follows:\n", "page_number": 192, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.8245614035087719, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.8694908001711597, "height": 0.04492939666238771, "width": 0.7023593466424682}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-192-11", "text": "Shares\n", "page_number": 192, "bounding_box": {"top_left_x": 0.5704779189352692, "top_left_y": 0.8930252460419341, "lower_right_x": 0.6194797338173019, "lower_right_y": 0.9037227214377407, "height": 0.010697475395806566, "width": 0.0490018148820327}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-192-12", "text": "Options\n", "page_number": 192, "bounding_box": {"top_left_x": 0.6823956442831216, "top_left_y": 0.8930252460419341, "lower_right_x": 0.73502722323049, "lower_right_y": 0.9071459135643988, "height": 0.014120667522464658, "width": 0.05263157894736836}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-192-13", "text": "Warrants\n", "page_number": 192, "bounding_box": {"top_left_x": 0.7834240774349668, "top_left_y": 0.8930252460419341, "lower_right_x": 0.8511796733212341, "lower_right_y": 0.9037227214377407, "height": 0.010697475395806566, "width": 0.06775559588626734}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-192-14", "text": "F-53\n", "page_number": 192, "bounding_box": {"top_left_x": 0.48336358136721114, "top_left_y": 0.9238339751818571, "lower_right_x": 0.5130066545674531, "lower_right_y": 0.9341035515618314, "height": 0.010269576379974388, "width": 0.029643073200241954}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-193-0", "text": "                                Shares    Options   Warrants\nAt 31 December 2005\nJ.J.M. Holthuis, CEO          3,089,500    73,500          -\nJ.C.H.L. Pauli, CFO   1         37,900     57,100    126,000\nOther key management      2    122,600    133,600     56,000\n                              3,250,000   264,200    182,000\n\n\nAt 31 December 2006\nJ.J.M. Holthuis, CEO          3,091,900   150,370          -\nJ.C.H.L. Pauli, CFO             46,500    102,514    126,000\nOther key management 2          71,500    253,231          -\n                              3,209,900   506,115    126,000\n", "page_number": 193, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.06803594351732992, "lower_right_x": 0.8596491228070176, "lower_right_y": 0.2781343602909713, "height": 0.2100984167736414, "width": 0.7102238354506957}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-193-1", "text": "                                                                   3,209,900            506,115            126,000\n1\n  In 2003 and 2004, J.C.H.L. Pauli received a total of 1,260 warrants, with each warrant giving the right to acquire\n100 shares. For comparison purposes, the number of shares that can be acquired through exercising these warrants\nare shown in this table.\n2\n  In 2004, one of the Other key management members received 560 warrants, each giving the right to acquire 100\nshares. For comparison purposes, the number of shares that can be acquired through exercising these warrants are\nshown in this table. This Other key management member left the Company in the first quarter of 2006. The warrants\nowned by this person are therefore not included in the outstanding warrants at 31 December 2006. The shares owned\nby this person are also not included in the shares owned by Other key management at 31 December 2006. This\ncaused the shares owned by Other key management to decrease year-on-year but none of all key management has\nsold shares in the year 2005 or 2006.\n", "page_number": 193, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.2785622593068036, "lower_right_x": 0.8572292800967937, "lower_right_y": 0.43089430894308944, "height": 0.15233204963628583, "width": 0.7078039927404718}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-193-2", "text": "The shares owned by Mr. Holthuis at 31 December 2006 represent 19.1% of the total of issued and\noutstanding share capital at 31 December 2006 (2005: 26.7%).\n", "page_number": 193, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.4514334617030381, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.4809584937954643, "height": 0.029525032092426184, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-193-3", "text": "Share options\nJ.J.M. Holthuis holds share options in the Company as follows:\n", "page_number": 193, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.5027813436029097, "lower_right_x": 0.5511191772534785, "lower_right_y": 0.5340179717586649, "height": 0.03123662815575523, "width": 0.4016938898971566}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-193-4", "text": "                         2006                     2005\n                  Average     Number of    Average     Number of\n                  exercise      options    exercise      options\n                 price in \u20ac               price in \u20ac\n                 per share                per share\nAt 1 January          3.43       73,500        3.43       73,500\nGranted               2.70       76,870                        -\nForfeited                             -                        -\nExercised                             -                        -\nLapsed                                -                        -\nAt 31 December        3.05      150,370        3.43       73,500\n", "page_number": 193, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.5575524176294394, "lower_right_x": 0.8608590441621294, "lower_right_y": 0.7355584082156611, "height": 0.17800599058622169, "width": 0.7114337568058076}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-193-5", "text": "The outstanding share options held by Mr. Holthuis on 31 December 2006 expire as follows: 73,500 options\non 29 December 2009, 7,100 options on 31 March 2011 and 69,770 options on 31 December 2011.\n", "page_number": 193, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.7539580658964484, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.7830551989730423, "height": 0.029097133076593895, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-193-6", "text": "J.C.H.L. Pauli, CFO, holds share options in the Company as follows:\n", "page_number": 193, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.8040222507488233, "lower_right_x": 0.5856019358741682, "lower_right_y": 0.8181429182712879, "height": 0.014120667522464658, "width": 0.4361766485178463}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-193-7", "text": "2006\n", "page_number": 193, "bounding_box": {"top_left_x": 0.5559588626739262, "top_left_y": 0.8416773641420625, "lower_right_x": 0.5904416212946159, "lower_right_y": 0.8515190415062045, "height": 0.009841677364141987, "width": 0.03448275862068961}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-193-8", "text": "2005\n", "page_number": 193, "bounding_box": {"top_left_x": 0.7447065940713854, "top_left_y": 0.8416773641420625, "lower_right_x": 0.779189352692075, "lower_right_y": 0.8515190415062045, "height": 0.009841677364141987, "width": 0.03448275862068961}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-193-9", "text": "Average\n", "page_number": 193, "bounding_box": {"top_left_x": 0.5027223230490018, "top_left_y": 0.858793324775353, "lower_right_x": 0.5662431941923775, "lower_right_y": 0.8724860932819855, "height": 0.01369276850663248, "width": 0.06352087114337568}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-193-10", "text": "Number of\n", "page_number": 193, "bounding_box": {"top_left_x": 0.5801572897761645, "top_left_y": 0.858793324775353, "lower_right_x": 0.663036902601331, "lower_right_y": 0.8694908001711597, "height": 0.010697475395806677, "width": 0.08287961282516643}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-193-11", "text": "Number of\n", "page_number": 193, "bounding_box": {"top_left_x": 0.7737447065940714, "top_left_y": 0.858793324775353, "lower_right_x": 0.8602540834845736, "lower_right_y": 0.8694908001711597, "height": 0.010697475395806677, "width": 0.0865093768905022}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-193-12", "text": "Average\n", "page_number": 193, "bounding_box": {"top_left_x": 0.6944948578342408, "top_left_y": 0.8592212237911853, "lower_right_x": 0.7549909255898367, "lower_right_y": 0.8724860932819855, "height": 0.01326486949080019, "width": 0.060496067755595906}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-193-13", "text": "options\n", "page_number": 193, "bounding_box": {"top_left_x": 0.6055656382335148, "top_left_y": 0.8724860932819855, "lower_right_x": 0.6575922565033273, "lower_right_y": 0.8857509627727856, "height": 0.01326486949080019, "width": 0.052026618269812475}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-193-14", "text": "options\n", "page_number": 193, "bounding_box": {"top_left_x": 0.7985480943738656, "top_left_y": 0.8724860932819855, "lower_right_x": 0.8511796733212341, "lower_right_y": 0.8861788617886179, "height": 0.01369276850663248, "width": 0.052631578947368474}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-193-15", "text": "exercise\n", "page_number": 193, "bounding_box": {"top_left_x": 0.5075620084694494, "top_left_y": 0.8729139922978177, "lower_right_x": 0.5662431941923775, "lower_right_y": 0.8827556696619597, "height": 0.009841677364141987, "width": 0.05868118572292802}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 16, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-193-16", "text": "exercise\n", "page_number": 193, "bounding_box": {"top_left_x": 0.6963097398669087, "top_left_y": 0.8729139922978177, "lower_right_x": 0.7549909255898367, "lower_right_y": 0.883183568677792, "height": 0.010269576379974277, "width": 0.05868118572292802}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 17, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-193-17", "text": "price in\n", "page_number": 193, "bounding_box": {"top_left_x": 0.49788263762855417, "top_left_y": 0.8870346598202824, "lower_right_x": 0.5517241379310345, "lower_right_y": 0.9007274283269149, "height": 0.01369276850663248, "width": 0.053841500302480305}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 18, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-193-18", "text": "n\u20ac\n", "page_number": 193, "bounding_box": {"top_left_x": 0.5523290986085905, "top_left_y": 0.8870346598202824, "lower_right_x": 0.5656382335148216, "lower_right_y": 0.8968763371844245, "height": 0.009841677364142098, "width": 0.01330913490623109}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 19, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-193-19", "text": "price in\n", "page_number": 193, "bounding_box": {"top_left_x": 0.6866303690260133, "top_left_y": 0.8870346598202824, "lower_right_x": 0.7422867513611615, "lower_right_y": 0.9002995293110826, "height": 0.01326486949080019, "width": 0.05565638233514825}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 20, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-193-20", "text": "n\u20ac\n", "page_number": 193, "bounding_box": {"top_left_x": 0.7434966727162734, "top_left_y": 0.8870346598202824, "lower_right_x": 0.7549909255898367, "lower_right_y": 0.8968763371844245, "height": 0.009841677364142098, "width": 0.011494252873563315}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 21, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-193-21", "text": "per share\n", "page_number": 193, "bounding_box": {"top_left_x": 0.49788263762855417, "top_left_y": 0.9011553273427471, "lower_right_x": 0.5662431941923775, "lower_right_y": 0.9139922978177151, "height": 0.012836970474968012, "width": 0.06836055656382328}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 22, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-193-22", "text": "per share\n", "page_number": 193, "bounding_box": {"top_left_x": 0.6866303690260133, "top_left_y": 0.9011553273427471, "lower_right_x": 0.7549909255898367, "lower_right_y": 0.9139922978177151, "height": 0.012836970474968012, "width": 0.06836055656382345}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 23, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-193-23", "text": "F-54\n", "page_number": 193, "bounding_box": {"top_left_x": 0.48336358136721114, "top_left_y": 0.9238339751818571, "lower_right_x": 0.5130066545674531, "lower_right_y": 0.9345314505776636, "height": 0.010697475395806566, "width": 0.029643073200241954}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-194-0", "text": "At 1 January     3.48    57,100    3.48   57,100\nGranted          2.70    55,414                -\nForfeited                      -               -\nExercised        3.58    (7,500)               -\nLapsed           3.58    (2,500)               -\nAt 31 December   3.05   102,514    3.48   57,100\n", "page_number": 194, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.07145913564398802, "lower_right_x": 0.8608590441621294, "lower_right_y": 0.16944801026957637, "height": 0.09798887462558835, "width": 0.7114337568058076}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-194-1", "text": "The outstanding share options held by Mr. Pauli on 31 December 2006 expire as follows: 13,500 options on\n14 December 2009, 23,600 options on 29 December 2009, 7,200 options on 31 March 2011 and 48,214\noptions on 31 December 2011. The remaining 10,000 options have expired on 24 December 2006. Mr. Pauli\nhas notified the Company that he will exercise these options but the issuance of new shares has not taken\nplace until 2007. These share options have therefore been included as outstanding options at 31 December\n2006 (see note 32).\n", "page_number": 194, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.1878476679503637, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.27214377406931967, "height": 0.08429610611895597, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-194-2", "text": "Other key management personnel hold share options in the Company as follows:\n", "page_number": 194, "bounding_box": {"top_left_x": 0.1512401693889897, "top_left_y": 0.2939666238767651, "lower_right_x": 0.662431941923775, "lower_right_y": 0.3080872913992298, "height": 0.014120667522464714, "width": 0.5111917725347852}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-194-3", "text": "                                          2006                      2005\n                                   Average     Number of     Average     Number of\n                                   exercise      options     exercise      options\n                                  price in \u20ac                price in \u20ac\n                                  per share                 per share\nAt 1 January                           3.47      133,600         3.47      133,600\nGranted                                2.70      152,131                         -\nForfeited                              3.43      (13,000)                        -\nExercised                              3.58      (15,000)                        -\nLapsed                                                  -                        -\nChanges in Other key management                   (4,500)                        -\nAt 31 December                         3.01      253,231         3.47      133,600\n", "page_number": 194, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.33162173727000427, "lower_right_x": 0.8608590441621294, "lower_right_y": 0.5267436884895165, "height": 0.1951219512195122, "width": 0.7114337568058076}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-194-4", "text": "The 4,500 options (negative) included under \u201cchanges in Other key management\u201d above, relate to the balance\nof options added for a person becoming an \u201cOther key management\u201d member on 1 January 2006 and options\ndeducted for an \u201cOther key management\u201d member leaving the Company in the first quarter of 2006.\nThe outstanding share options held by Other key management personnel on 31 December 2006 expire as\nfollows: 14,000 options on 31 May 2007, 74,000 options on 14 December 2009, 13,100 options on 29\nDecember 2009, 10,000 options on 31 December 2010, 9,000 options on 31 January 2011, 15,100 options on\n31 March 2011 and 118,031 options on 31 December 2011.\n", "page_number": 194, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.543859649122807, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.6469833119383825, "height": 0.1031236628155755, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-194-5", "text": "Warrants\n", "page_number": 194, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.670517757809157, "lower_right_x": 0.2177858439201452, "lower_right_y": 0.6812152332049636, "height": 0.010697475395806566, "width": 0.06836055656382334}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-194-6", "text": "In addition to stock options, Mr. Pauli holds a total of 1,260 warrants (31 December 2005: 1,260) in the\nCompany, with each warrant giving the right to acquire 100 shares at an exercise price of \u20ac 5.50 per share. Mr.\nPauli guaranteed a loan made by a bank to the Group in a total amount of \u20ac 150 during the period 1 December\n2003 to 31 May 2004. This loan was repaid on 31 May 2004. As compensation for this guarantee, Mr. Pauli\nreceived an interest rate of 0.5% per month and a total of 1,260 warrants in the Company (see Note 12).\n", "page_number": 194, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.6876337184424476, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.7595207531022679, "height": 0.07188703465982027, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-194-7", "text": "One other former employee (and former Other key management member) also holds a total of 560 warrants\n(31 December 2005: 560) in the Company, with each warrant giving the right to acquire 100 shares at an\nexercise price of \u20ac 5.50 per share. This person guaranteed a loan made by a bank to the Group in a total amount\nof \u20ac 100 during the period 1 February 2004 to 31 May 2004. This loan was repaid on 31 May 2004. As\ncompensation for this guarantee, this person received an interest rate of 0.5% per month and a total of 560\nwarrants in the Company (see Note 12).\n", "page_number": 194, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.762943945228926, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.8476679503637141, "height": 0.08472400513478817, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-194-8", "text": "32. Events after the balance sheet date\n", "page_number": 194, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.8690629011553274, "lower_right_x": 0.4791288566243194, "lower_right_y": 0.883183568677792, "height": 0.014120667522464658, "width": 0.3297035692679976}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-194-9", "text": "Equity transactions\n", "page_number": 194, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.8904578519469405, "lower_right_x": 0.2752571082879613, "lower_right_y": 0.9037227214377407, "height": 0.01326486949080019, "width": 0.12583182093163944}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-194-10", "text": "In\n", "page_number": 194, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.9101412066752247, "lower_right_x": 0.1645493042952208, "lower_right_y": 0.920410783055199, "height": 0.010269576379974277, "width": 0.015124016938898949}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-194-11", "text": "2006,\n", "page_number": 194, "bounding_box": {"top_left_x": 0.1736237144585602, "top_left_y": 0.9101412066752247, "lower_right_x": 0.21234119782214156, "lower_right_y": 0.9208386820710313, "height": 0.010697475395806566, "width": 0.038717483363581356}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-194-12", "text": "10,000\n", "page_number": 194, "bounding_box": {"top_left_x": 0.2220205686630369, "top_left_y": 0.9101412066752247, "lower_right_x": 0.2661826981246219, "lower_right_y": 0.9208386820710313, "height": 0.010697475395806566, "width": 0.044162129461585015}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-194-13", "text": "share\n", "page_number": 194, "bounding_box": {"top_left_x": 0.2752571082879613, "top_left_y": 0.9101412066752247, "lower_right_x": 0.3145795523290986, "lower_right_y": 0.920410783055199, "height": 0.010269576379974277, "width": 0.03932244404113733}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-194-14", "text": "options\n", "page_number": 194, "bounding_box": {"top_left_x": 0.323653962492438, "top_left_y": 0.9101412066752247, "lower_right_x": 0.37265577737447064, "lower_right_y": 0.922122379118528, "height": 0.011981172443303323, "width": 0.049001814882032646}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-194-15", "text": "with\n", "page_number": 194, "bounding_box": {"top_left_x": 0.382335148215366, "top_left_y": 0.9101412066752247, "lower_right_x": 0.411373260738052, "lower_right_y": 0.920410783055199, "height": 0.010269576379974277, "width": 0.02903811252268601}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 16, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-194-16", "text": "exercise\n", "page_number": 194, "bounding_box": {"top_left_x": 0.5571687840290381, "top_left_y": 0.9101412066752247, "lower_right_x": 0.6098003629764065, "lower_right_y": 0.920410783055199, "height": 0.010269576379974277, "width": 0.05263157894736836}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 17, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-194-17", "text": "price\n", "page_number": 194, "bounding_box": {"top_left_x": 0.6188747731397459, "top_left_y": 0.9101412066752247, "lower_right_x": 0.6533575317604355, "lower_right_y": 0.9229781771501926, "height": 0.012836970474967901, "width": 0.03448275862068961}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 18, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-194-18", "text": "of\n", "page_number": 194, "bounding_box": {"top_left_x": 0.662431941923775, "top_left_y": 0.9101412066752247, "lower_right_x": 0.6830006049606776, "lower_right_y": 0.920410783055199, "height": 0.010269576379974277, "width": 0.020568663036902635}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 19, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-194-19", "text": "share\n", "page_number": 194, "bounding_box": {"top_left_x": 0.7737447065940714, "top_left_y": 0.9101412066752247, "lower_right_x": 0.8082274652147611, "lower_right_y": 0.920410783055199, "height": 0.010269576379974277, "width": 0.034482758620689724}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 20, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-194-20", "text": "\u20ac\n", "page_number": 194, "bounding_box": {"top_left_x": 0.6836055656382335, "top_left_y": 0.9105691056910569, "lower_right_x": 0.6963097398669087, "lower_right_y": 0.920410783055199, "height": 0.009841677364142098, "width": 0.012704174228675202}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 21, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-194-21", "text": "3.58\n", "page_number": 194, "bounding_box": {"top_left_x": 0.7029643073200242, "top_left_y": 0.9105691056910569, "lower_right_x": 0.73502722323049, "lower_right_y": 0.920410783055199, "height": 0.009841677364142098, "width": 0.03206291591046573}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 22, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-194-22", "text": "an\n", "page_number": 194, "bounding_box": {"top_left_x": 0.4204476709013914, "top_left_y": 0.9114249037227214, "lower_right_x": 0.43738656987295826, "lower_right_y": 0.920410783055199, "height": 0.00898587933247752, "width": 0.016938898971566863}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 23, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-194-23", "text": "8 per\n", "page_number": 194, "bounding_box": {"top_left_x": 0.735632183908046, "top_left_y": 0.9114249037227214, "lower_right_x": 0.764670296430732, "lower_right_y": 0.9225502781343603, "height": 0.011125374411638855, "width": 0.029038112522686066}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 24, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-194-24", "text": "were\n", "page_number": 194, "bounding_box": {"top_left_x": 0.8179068360556564, "top_left_y": 0.9114249037227214, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.9208386820710313, "height": 0.00941377834830981, "width": 0.033877797943133725}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 25, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-194-25", "text": "F-55\n", "page_number": 194, "bounding_box": {"top_left_x": 0.48336358136721114, "top_left_y": 0.9238339751818571, "lower_right_x": 0.5130066545674531, "lower_right_y": 0.9345314505776636, "height": 0.010697475395806566, "width": 0.029643073200241954}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-195-0", "text": "exercised. However, the formal registration of the share issuance did not take place until 2007. The related\n10,000 share options have therefore been included as outstanding options at 31 December 2006 (Note 12).\n", "page_number": 195, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.06803594351732992, "lower_right_x": 0.8517846339987901, "lower_right_y": 0.09584937954642704, "height": 0.027813436029097124, "width": 0.7023593466424682}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-195-1", "text": "F-56\n", "page_number": 195, "bounding_box": {"top_left_x": 0.48336358136721114, "top_left_y": 0.9238339751818571, "lower_right_x": 0.5130066545674531, "lower_right_y": 0.9341035515618314, "height": 0.010269576379974388, "width": 0.029643073200241954}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-196-0", "text": "OctoPlus International Holding B.V.\n", "page_number": 196, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.07830551989730423, "lower_right_x": 0.6672716273442226, "lower_right_y": 0.09927257167308515, "height": 0.020967051775780912, "width": 0.5178463399879008}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-196-1", "text": "Consolidated Financial Statements\n31 December 2005, 2004 and 2003\n", "page_number": 196, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.1433461703038083, "lower_right_x": 0.6436781609195402, "lower_right_y": 0.19169875909285408, "height": 0.048352588789045775, "width": 0.49425287356321834}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-196-2", "text": "F-57\n", "page_number": 196, "bounding_box": {"top_left_x": 0.48336358136721114, "top_left_y": 0.9238339751818571, "lower_right_x": 0.5130066545674531, "lower_right_y": 0.9323919554985024, "height": 0.008557980316645342, "width": 0.029643073200241954}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-197-0", "text": "Deloitte. oui Accumane\n\nKangalpark 143\n2321 WV Leiden\nP.0.80x 402\n2300 AK Leiden\nNetherlands\n\nTel: +31 (71) $352352\nFax: +31 (71) 5352370\n\nweww.deloitte.nl\nBeconnumber 200943\n\nDate From Our reference\n\n31 August 2006 3100101130-019\n\nSubject Your reference\n\nIndependent Auditor\u2019s Report\n\nIntroduction\n\nWe have audited the accompanying consolidated and Company-only balance sheets of Octoplus\nInternational Holding B.V., Leiden, as of 31 December 2003, 2004 and 2005, and the related\nstatements of income, changes in equity and cash flows and the notes thereon for the years then\nended. These financial statements are the responsibility of the company's management. Our\nresponsibility is to express an opinion on these financial statements based on our audit.\n\nScope\n\nWe conducted our audit in accordance with auditing standards generally accepted in the\nNetherlands. Those standards require that we plan and perform the audit to obtain reasonable\nassurance about whether the financial statements are free of material misstatement. An audit\nincludes examining, on a test basis, evidence supporting the amounts and disclosures in the\nfinancial statements. An audit also includes assessing the accounting principles used and\nsignificant estimates made by management, as well as evaluating the overall presentation of the\nfinancial statements. We believe that our audit provides a reasonable basis for our opinion.\n\nOpinion\n\nIn our opinion, the financial statements give a true and fair view of the financial position of the\ncompany as of 31 December 2003, 2004 and 2005 and the results of its operations and its cash\nflows for the years then ended in accordance with International Financial Reporting Standards,\nas published by the International Accounting Standards Board and adopted by the E.U.\n\nDeloitte Accountants B.V.\n\nyh\n\nJ. Verloop RA\n\n \n\nAllagreements with Deloitte are governed by the General Terms and Conditions of Deloitte, registered with Member of\nthe District Court of Rotterdam under deed number 84/2004, Deloitte Touche Tohmatsu\n\nDeloitte Accountants BL. is registered with the Trade Register of the Chamber of Commerce and Industry in\nRotterdam number 24362853,", "page_number": 197, "bounding_box": {"top_left_x": 0.22262552934059285, "top_left_y": 0.10911424903722722, "lower_right_x": 0.7918935269207501, "lower_right_y": 0.7154471544715447, "height": 0.6063329054343175, "width": 0.5692679975801572}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-197-1", "text": "", "page_number": 197, "bounding_box": {"top_left_x": 0.82335148215366, "top_left_y": 0.3607188703465982, "lower_right_x": 0.8275862068965517, "lower_right_y": 0.3893881044073599, "height": 0.02866923406076166, "width": 0.00423472474289166}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-197-2", "text": "", "page_number": 197, "bounding_box": {"top_left_x": 0.822746521476104, "top_left_y": 0.45742404792468977, "lower_right_x": 0.8275862068965517, "lower_right_y": 0.5173299101412067, "height": 0.05990586221651689, "width": 0.004839685420447659}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-197-3", "text": "F-58\n", "page_number": 197, "bounding_box": {"top_left_x": 0.48336358136721114, "top_left_y": 0.9238339751818571, "lower_right_x": 0.5130066545674531, "lower_right_y": 0.9341035515618314, "height": 0.010269576379974388, "width": 0.029643073200241954}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-198-0", "text": "Consolidated balance sheet\n", "page_number": 198, "bounding_box": {"top_left_x": 0.1500302480338778, "top_left_y": 0.08515190415062045, "lower_right_x": 0.42528735632183906, "lower_right_y": 0.10183996576807873, "height": 0.016688061617458283, "width": 0.27525710828796124}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-198-1", "text": "(In Euro x 1,000)\n", "page_number": 198, "bounding_box": {"top_left_x": 0.7834240774349668, "top_left_y": 0.08857509627727857, "lower_right_x": 0.8753781004234725, "lower_right_y": 0.10183996576807873, "height": 0.013264869490800163, "width": 0.09195402298850575}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-198-2", "text": "Consolidated balance sheet\n                                                                At 31 December\n                                                    Note    2005       2004      2003\nASSETS\nNon-current assets\nIntangible assets\nGoodwill                                              6       243      243         213\nPatents                                               6     1,167    1,167       1,167\nOther intangible assets                               6       295       11          21\n                                                            1,705    1,421       1,401\nProperty, plant and equipment\nLand and buildings                                    7     3,246    3,364           -\nMachines and installations                            7     2,499    2,208       1,619\nOther equipment                                       7       528      466         605\n                                                            6,273    6,038       2,224\nFinancial assets carried at cost                      8        16       16           -\nReceivables from related parties                     10         -        -         908\n                                                            7,994    7,475       4,533\nCurrent assets\nInventories                                           9        15       15          15\nTrade receivables                                    10     1,345    1,174         775\nReceivables from related parties                     10         -        3          95\nSocial security and other taxes                      10       255       49         176\nOther receivables, prepayments and accrued income    10     1,165      556         578\nCash and cash equivalents                            11     9,726       82          20\n                                                           12,506    1,879       1,659\nTotal assets                                               20,500    9,354       6,192\n\n\nEQUITY\nShareholders\u2019 equity                                 12     7,766   (1,356)      1,151\nConvertible subordinated loan                        13     3,985         -          -\nTotal group equity                                         11,751   (1,356)      1,151\n\nLIABILITIES\nNon-current liabilities\nDeferred corporate income tax liabilities            14         -      353          -\nPension liabilities                                  15        89      131        122\nBorrowings                                           16         -        -        554\nFinance lease liabilities                            16     3,649    3,670         80\nDebt to related parties                              17         -      161        161\nOther non-current liabilities                        17         -       30          -\n                                                            3,738    4,345        917\nCurrent liabilities\nCurrent portion of non-current liabilities           16       142      120         189\nBank overdrafts                                      16       496    1,758         777\nTrade payables                                       17     1,491    1,079         909\nDebt to related parties                              17         -        -         150\nSocial security and other taxes                      17       239      221          99\nOther current liabilities                            17     2,643    3,187       2,000\n                                                            5,011    6,365       4,124\nTotal liabilities                                           8,749   10,710       5,041\nTotal equity and liabilities                               20,500    9,354       6,192\n", "page_number": 198, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.10226786478391099, "lower_right_x": 0.8808227465214761, "lower_right_y": 0.8934531450577664, "height": 0.7911852802738554, "width": 0.7313974591651542}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-198-3", "text": "F-59\n", "page_number": 198, "bounding_box": {"top_left_x": 0.48336358136721114, "top_left_y": 0.9238339751818571, "lower_right_x": 0.5130066545674531, "lower_right_y": 0.9341035515618314, "height": 0.010269576379974388, "width": 0.029643073200241954}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-199-0", "text": "The notes on pages F-64 to F-104 are an integral part of these consolidated financial statements\n", "page_number": 199, "bounding_box": {"top_left_x": 0.14942528735632185, "top_left_y": 0.07145913564398802, "lower_right_x": 0.7549909255898367, "lower_right_y": 0.08515190415062045, "height": 0.013692768506632425, "width": 0.6055656382335148}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-199-1", "text": "F-60\n", "page_number": 199, "bounding_box": {"top_left_x": 0.48336358136721114, "top_left_y": 0.9238339751818571, "lower_right_x": 0.5130066545674531, "lower_right_y": 0.9341035515618314, "height": 0.010269576379974388, "width": 0.029643073200241954}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-200-0", "text": "Consolidated income statement\n", "page_number": 200, "bounding_box": {"top_left_x": 0.1161524500907441, "top_left_y": 0.12623020967051776, "lower_right_x": 0.42589231699939506, "lower_right_y": 0.1433461703038083, "height": 0.017115960633290545, "width": 0.30973986690865096}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-200-1", "text": "(In Euro x 1,000)\n", "page_number": 200, "bounding_box": {"top_left_x": 0.7332123411978222, "top_left_y": 0.12965340179717585, "lower_right_x": 0.8269812462189957, "lower_right_y": 0.1433461703038083, "height": 0.013692768506632452, "width": 0.09376890502117352}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-200-2", "text": "                                                             Year ending 31 December\n                                                     Note    2005       2004      2003\n\nService revenues                                             6,563     4,924     5,043\nRoyalty and license revenues                                    60        60         -\nIncome from subsidies                                 18       394       708       818\nOther income                                          18         -        26         -\nTotal revenues                                               7,017     5,718     5,861\n\nRaw materials and auxiliaries                          19      237        70        36\nCost of contracted work and other external charges     19    1,390       307       639\nEmployee benefits                                      20    4,758     3,597     3,450\nDepreciation and amortisation                         6,7      863       860       668\nOther costs                                            21    4,213     2,667     3,275\nTotal operating costs                                       11,461     7,501     8,068\n\nOperating loss                                              (4,444)   (1,783)   (2,207)\n\nInterest income                                       23        287        18        77\nInterest costs                                        23      (405)     (412)     (106)\nResult before corporate income taxes                        (4,562)   (2,177)   (2,236)\n\nCorporate income taxes                                24        353     (353)         -\nResult for the year                                         (4,209)   (2,530)   (2,236)\n", "page_number": 200, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.16730851519041506, "lower_right_x": 0.8251663641863279, "lower_right_y": 0.5134788189987163, "height": 0.3461703038083012, "width": 0.7096188747731398}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-200-3", "text": "Attributable to:\n", "page_number": 200, "bounding_box": {"top_left_x": 0.1161524500907441, "top_left_y": 0.5344458707744972, "lower_right_x": 0.22141560798548093, "lower_right_y": 0.5451433461703038, "height": 0.010697475395806566, "width": 0.10526315789473684}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-200-4", "text": "(4,209)   (2,530)   (2,236)\n", "page_number": 200, "bounding_box": {"top_left_x": 0.588021778584392, "top_left_y": 0.5507060333761232, "lower_right_x": 0.8154869933454325, "lower_right_y": 0.5609756097560976, "height": 0.010269576379974388, "width": 0.22746521476104054}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-200-5", "text": "Equity holders of the Company\n", "page_number": 200, "bounding_box": {"top_left_x": 0.1161524500907441, "top_left_y": 0.5507060333761232, "lower_right_x": 0.3139745916515426, "lower_right_y": 0.5614035087719298, "height": 0.010697475395806566, "width": 0.19782214156079853}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-200-6", "text": "Result per share for result attributable to the equity holders\nof the Company during the year (expressed in Euro per\nshare)\n\u2013 basic                                                          25   (37.59)   (53.91)   (47.64)\n\u2013 diluted                                                        25   (37.59)   (53.91)   (47.64)\n", "page_number": 200, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.5780915703893881, "lower_right_x": 0.8166969147005445, "lower_right_y": 0.6551133932391956, "height": 0.07702182284980752, "width": 0.7011494252873564}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-200-7", "text": "The notes on pages F-64 to F-104 are an integral part of these consolidated financial statements.\n", "page_number": 200, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.6773641420624733, "lower_right_x": 0.7108287961282517, "lower_right_y": 0.6910569105691057, "height": 0.013692768506632369, "width": 0.5952813067150635}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-200-8", "text": "F- 61\n", "page_number": 200, "bounding_box": {"top_left_x": 0.5075620084694494, "top_left_y": 0.9242618741976893, "lower_right_x": 0.5390199637023594, "lower_right_y": 0.9311082584510055, "height": 0.0068463842533161845, "width": 0.03145795523290995}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-201-0", "text": "Consolidated statement of changes in equity\n", "page_number": 201, "bounding_box": {"top_left_x": 0.1191772534785239, "top_left_y": 0.1467693624304664, "lower_right_x": 0.5468844525105868, "lower_right_y": 0.1643132220795892, "height": 0.017543859649122806, "width": 0.4277071990320629}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-201-1", "text": "(In Euro x 1,000)\n", "page_number": 201, "bounding_box": {"top_left_x": 0.73502722323049, "top_left_y": 0.15019255455712452, "lower_right_x": 0.8251663641863279, "lower_right_y": 0.1608900299529311, "height": 0.010697475395806594, "width": 0.09013914095583797}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-201-2", "text": "                                      Note           Attributable to equity holders of the Company\n\n                                               Share       Share      Other    Retained   Conver-      Total\n                                               capital   premium    reserves   earnings      tible    equity\n                                                          reserve                            loan\nBalance at 1 January 2003                          47      4,746           -   (1,411)          -     3,382\nIncome/(expense) recognised directly in\nequity                                               -          -          -         -          -          -\nResult for the year                                  -          -          -   (2,236)          -    (2,236)\nTotal recognised income for 2003                     -          -          -   (2,236)          -    (2,236)\n\nEmployees share option scheme:\n\u2013 value of employee services              12        -          -          5          -          -         5\n                                                    -          -          5          -          -         5\nBalance at 31 December 2003                        47      4,746          5    (3,647)          -     1,151\n\n\nBalance at 1 January 2004                          47      4,746          5    (3,647)          -     1,151\nIncome/(expense) recognised directly in\nequity                                               -          -          -         -          -          -\nResult for the year                                  -          -          -   (2,530)          -    (2,530)\nTotal recognised income for 2004                     -          -          -   (2,530)          -    (2,530)\n\nEmployees share option scheme:\n\u2013 value of employee services              12        -          -         23          -          -         23\n                                                    -          -         23          -          -         23\nBalance at 31 December 2004                        47      4,746         28    (6,177)          -    (1,356)\n\n\nBalance at 1 January 2005                          47      4,746         28    (6,177)          -    (1,356)\nIncome/(expense) recognised directly in\nequity                                               -          -          -         -          -          -\nResult for the year                                  -          -          -   (4,209)          -    (4,209)\nTotal recognised income for 2005                     -          -          -   (4,209)          -    (4,209)\n\nEmployee share option scheme:\n\u2013 value of employee services              12         -          -      132            -         -       132\n\nIssue of share capital                    12      69      13,130         -        -            -     13,199\nConvertible subordinated loan             13       -           -         -        -        3,985      3,985\n                                                  69      13,130       132        -        3,985     17,316\nBalance at 31 December 2005                      116      17,876       160 (10,386)        3,985     11,751\n", "page_number": 201, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.1951219512195122, "lower_right_x": 0.822141560798548, "lower_right_y": 0.8219940094137783, "height": 0.6268720581942662, "width": 0.7065940713853599}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-201-3", "text": "The notes on pages F-64 to F-104 are an integral part of these consolidated financial statements.\n", "page_number": 201, "bounding_box": {"top_left_x": 0.11736237144585603, "top_left_y": 0.8382541720154044, "lower_right_x": 0.7126436781609196, "lower_right_y": 0.8523748395378691, "height": 0.014120667522464658, "width": 0.5952813067150635}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-201-4", "text": "F- 62\n", "page_number": 201, "bounding_box": {"top_left_x": 0.5075620084694494, "top_left_y": 0.9242618741976893, "lower_right_x": 0.5408348457350273, "lower_right_y": 0.9311082584510055, "height": 0.0068463842533161845, "width": 0.03327283726557784}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-202-0", "text": "Consolidated cash flow statement\n", "page_number": 202, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.1433461703038083, "lower_right_x": 0.4440411373260738, "lower_right_y": 0.157466837826273, "height": 0.014120667522464686, "width": 0.32849364791288566}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-202-1", "text": "(In Euro x 1,000)\n", "page_number": 202, "bounding_box": {"top_left_x": 0.7320024198427102, "top_left_y": 0.1467693624304664, "lower_right_x": 0.8263762855414398, "lower_right_y": 0.157466837826273, "height": 0.010697475395806594, "width": 0.09437386569872963}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-202-2", "text": "                                                                                Year ending 31 December\n                                                                  Note         2005        2004       2003\n\nCash flows from operating activities\nResult before corporate income taxes                                         (4,562)        (2,177)   (2,236)\nAdjustments for:\n\u2013          Depreciation and amortisation                            6,7          863           860       668\n\u2013          Share-based payments                                      20          132             23         5\n\u2013          (Gain)/loss on sale of property, plant and equipment      27            -           (26)         -\n\u2013          Interest costs                                                        405           412       106\n\u2013          Interest income                                                     (287)           (18)      (77)\n\u2013          Change in pension provision                                          (42)              9        65\nChanges in working capital:\n\u2013          Trade receivables                                                   (171)         (399)       286\n\u2013          Receivables from related parties                                        3         1,000        16\n\u2013          Social securities and other taxes                                   (206)           127      (49)\n\u2013          Other receivables, prepayments and accrued income                   (609)            22       135\n\u2013          Trade payables                                                        412           170       610\n\u2013          Other liabilities and accruals                                      (556)         1,339       859\nCash generated from operations                                               (4,618)         1,342       388\nInterest received                                                                287            18        77\nInterest paid                                                                  (405)         (412)     (106)\nCorporate income taxes paid                                                        -             -         -\nNet cash used in/generated from operating activities                         (4,736)           948       359\n\nCash flows from investing activities\nAcquisition of subsidiaries, net of cash acquired                    30            -              -   (1,481)\nPurchases of property, plant and equipment                           27        (924)          (924)     (710)\nProceeds from sale of property, plant and equipment                  27            -             26         -\nPurchases of intangible assets                                        6        (294)           (30)      (27)\nPurchases of financial assets carried at cost                         8            -           (16)         -\nNet cash used in investing activities                                        (1,218)          (944)   (2,218)\n\nCash flows from financing activities\nProceeds from issuance of shares                                     12      13,038               -        -\nProceeds from issuance of convertible subordinated loan              13       3,985               -        -\nProceeds from and repayment of finance lease liabilities             27       (163)           (219)     (90)\nProceeds from borrowings                                                          -               -      150\nRepayments of borrowings                                                          -           (704)    (108)\nNet cash generated from/used in financing activities                         16,860           (923)     (48)\n\nCash, cash equivalents and bank overdrafts\nNet increase/(decrease) during the year                                       10,906          (919)   (1,907)\nBalance at beginning of the year                                             (1,676)          (757)     1,150\nBalance at end of the year                                           11        9,230        (1,676)     (757)\n\nThe notes on pages F-64 to F-104 are an integral part of these consolidated financial statements.\n", "page_number": 202, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.1810012836970475, "lower_right_x": 0.8245614035087719, "lower_right_y": 0.8716302952503209, "height": 0.6906290115532734, "width": 0.7090139140955838}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-202-3", "text": "F- 63\n", "page_number": 202, "bounding_box": {"top_left_x": 0.5075620084694494, "top_left_y": 0.9242618741976893, "lower_right_x": 0.5408348457350273, "lower_right_y": 0.9311082584510055, "height": 0.0068463842533161845, "width": 0.03327283726557784}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-203-0", "text": "Notes to the consolidated financial statements December 2005, 2004 and 2003\n", "page_number": 203, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.12623020967051776, "lower_right_x": 0.8711433756805808, "lower_right_y": 0.14377406931964057, "height": 0.017543859649122806, "width": 0.7555958862673926}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-203-1", "text": "1. General information\n", "page_number": 203, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.1810012836970475, "lower_right_x": 0.31276467029643074, "lower_right_y": 0.19341035515618313, "height": 0.01240907145913564, "width": 0.19721718088324258}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-203-2", "text": "OctoPlus International Holding B.V. (\"the Company\") and its subsidiaries (together \u201cthe Group\u201d) are engaged in providing\nservices for life sciences companies in the field of drug formulation. Furthermore, the Group develops a product portfolio\nbased on its proprietary drug delivery technology.\n", "page_number": 203, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.20154043645699615, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.24176294394522893, "height": 0.04022250748823278, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-203-3", "text": "The Company is a limited liability company incorporated and domiciled in the Netherlands. The address of its registered\noffice is Zernikedreef 12, 2333 CL Leiden, the Netherlands.\n", "page_number": 203, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.2631578947368421, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.28968763371844247, "height": 0.02652973898160038, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-203-4", "text": "These consolidated financial statements are subject to approval by the General Meeting of Shareholders.\n", "page_number": 203, "bounding_box": {"top_left_x": 0.11675741076830005, "top_left_y": 0.3110825845100556, "lower_right_x": 0.7676950998185118, "lower_right_y": 0.3252032520325203, "height": 0.014120667522464714, "width": 0.6509376890502118}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-203-5", "text": "2. Summary of significant accounting policies\n", "page_number": 203, "bounding_box": {"top_left_x": 0.1161524500907441, "top_left_y": 0.3453145057766367, "lower_right_x": 0.4984875983061101, "lower_right_y": 0.36243046640992727, "height": 0.017115960633290572, "width": 0.382335148215366}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-203-6", "text": "The principal accounting policies applied in the preparation of these consolidated financial statements are set out below.\nThese policies have been consistently applied to all the years presented, unless otherwise stated.\n", "page_number": 203, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.36585365853658536, "lower_right_x": 0.8838475499092558, "lower_right_y": 0.3936670945656825, "height": 0.02781343602909714, "width": 0.7683000604960677}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-203-7", "text": "2.1 Basis of preparation\n", "page_number": 203, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.417201540436457, "lower_right_x": 0.27586206896551724, "lower_right_y": 0.4278990158322636, "height": 0.010697475395806566, "width": 0.16031457955232908}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-203-8", "text": "The Group has adopted International Financial Reporting Standards (\"IFRS\"), including International Accounting\nStandards (\"IAS\") and interpretations issued by the International Accounting Standards Board (\"IASB\") as adopted by the\nEU (\"EU-IFRS\"), as its primary accounting basis for the consolidated financial statements as from 1 January 2005 (see\nNote 33 for the impact of adopting IFRS). For the Group, there are no differences between EU-IFRS and IFRS. The\nGroup\u2019s transition date to IFRS is 1 January 2003. The Group prepared its opening balance sheet on the basis of IFRS at\nthat date. With reference to the company-only income statement of the Company, use has been made of the exemption\npursuant to Section 402 of Book 2 of the Netherlands Civil Code.\n", "page_number": 203, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.43431750106974754, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.5297389816003423, "height": 0.09542148053059474, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-203-9", "text": "The consolidated financial statements have been prepared under the historical cost convention. Furthermore, the\nconsolidated financial statements are presented in euros and all values are rounded to the nearest thousand except when\notherwise indicated.\n", "page_number": 203, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.5507060333761232, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.5887890457851946, "height": 0.038083012409071415, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-203-10", "text": "The preparation of financial statements in conformity with IFRS requires the use of certain critical accounting estimates. It\nalso requires management to exercise its judgement in the process of applying the Group\u2019s accounting policies. The areas\ninvolving a higher degree of judgement or complexity or areas where assumptions and estimates are significant to the\nconsolidated financial statements are disclosed in Note 4.\n", "page_number": 203, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.6123234916559692, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.6675224646983312, "height": 0.05519897304236199, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-203-11", "text": "", "page_number": 203, "bounding_box": {"top_left_x": 0.11494252873563218, "top_left_y": 0.6889174154899443, "lower_right_x": 0.21657592256503327, "lower_right_y": 0.6940522036799316, "height": 0.005134788189987249, "width": 0.10163339382940109}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-203-12", "text": "2.2 Consolidation\n", "page_number": 203, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.6923406076166024, "lower_right_x": 0.23714458560193588, "lower_right_y": 0.7017543859649122, "height": 0.00941377834830981, "width": 0.12159709618874774}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-203-13", "text": "The Company is the holding company of a group of companies. The other consolidated group companies (\u201csubsidiaries\u201d)\n", "page_number": 203, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.7081728712023962, "lower_right_x": 0.8850574712643678, "lower_right_y": 0.7222935387248609, "height": 0.014120667522464658, "width": 0.7695099818511797}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-203-14", "text": "are:\n       -   OctoShare B.V., 100%, having its legal seat in Leiden, the Netherlands\n       -   OctoPlus Development B.V., 100%, having its legal seat in Leiden, the Netherlands\n       -   OctoPlus Technologies B.V., 100%, having its legal seat in Leiden, the Netherlands\n       -   OctoPlus Sciences B.V., 100%, having its legal seat in Leiden, the Netherlands\n       -   OctoShed B.V., 100%, having its legal seat in Leiden, the Netherlands\n       -   Chienna B.V., 100%, having its legal seat in Bilthoven, the Netherlands\n       -   OctoPlus Inc., 100%, having its legal seat in Delaware, United States of America\n", "page_number": 203, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.7252888318356868, "lower_right_x": 0.7017543859649122, "lower_right_y": 0.8318356867779204, "height": 0.1065468549422336, "width": 0.5862068965517241}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-203-15", "text": "Subsidiaries\n", "page_number": 203, "bounding_box": {"top_left_x": 0.11736237144585603, "top_left_y": 0.8485237483953787, "lower_right_x": 0.1984271022383545, "lower_right_y": 0.8600770218228498, "height": 0.011553273427471145, "width": 0.08106473079249847}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 16, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-203-16", "text": "F- 64\n", "page_number": 203, "bounding_box": {"top_left_x": 0.5075620084694494, "top_left_y": 0.9242618741976893, "lower_right_x": 0.5420447670901392, "lower_right_y": 0.9306803594351734, "height": 0.006418485237484006, "width": 0.034482758620689724}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-204-0", "text": "Subsidiaries are all entities over which the Group has the power to govern the financial and operating policies, generally\naccompanied by a shareholding of more than one half of the voting rights. The existence and effect of potential voting\nrights that are currently exercisable or convertible are considered when assessing whether the Group controls another\nentity. Subsidiaries are fully consolidated from the date on which control is transferred to the Group. They are de-\nconsolidated from the date that control ceases.\n", "page_number": 204, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.12623020967051776, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.1951219512195122, "height": 0.06889174154899444, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-204-1", "text": "The purchase method of accounting is used to account for the acquisition of subsidiaries by the Group. The cost of an\nacquisition is measured as the fair value of the assets given, equity instruments issued and liabilities incurred or assumed\nat the date of exchange, plus costs directly attributable to the acquisition. Identifiable assets acquired and liabilities and\ncontingent liabilities assumed in a business combination are measured initially at their fair values at the acquisition date,\nirrespective of the extent of any minority interest. The excess of the cost of acquisition over the fair value of the Group\u2019s\nshare of the identifiable net assets acquired is recorded as goodwill. If the cost of acquisition is less than the fair value of\nthe net assets of the subsidiary acquired (also after re-assessment), the difference is recognised directly in the income\nstatement.\n", "page_number": 204, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.2186563970902867, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.3252032520325203, "height": 0.10654685494223362, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-204-2", "text": "Inter-company transactions, balances and unrealised gains on transactions between group companies are eliminated.\nUnrealised losses between group companies are also eliminated, however, these are considered to be an impairment\nindicator of the asset transferred. Accounting policies of subsidiaries have been changed where necessary to ensure\nconsistency with the policies adopted by the Group.\n", "page_number": 204, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.34873769790329484, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.40393667094565683, "height": 0.05519897304236199, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-204-3", "text": "2.3 Segment reporting\n", "page_number": 204, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.4240479246897732, "lower_right_x": 0.2661826981246219, "lower_right_y": 0.4381685922122379, "height": 0.014120667522464714, "width": 0.15063520871143377}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-204-4", "text": "A business segment is a group of assets and operations engaged in providing products or services that are subject to risks and\nreturns that are different from those of other business segments. A geographical segment is engaged in providing products\nor services within a particular economic environment which are subject to risks and returns that are different from those of\nsegments operating in other economic environments.\n", "page_number": 204, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.44458707744972187, "lower_right_x": 0.8898971566848155, "lower_right_y": 0.49636285836542576, "height": 0.051775780915703895, "width": 0.7743496672716274}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-204-5", "text": "2.4 Foreign currency translation\n", "page_number": 204, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.5198973042362003, "lower_right_x": 0.3333333333333333, "lower_right_y": 0.5331621737270005, "height": 0.01326486949080019, "width": 0.21778584392014516}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-204-6", "text": "(a) Functional and presentation currency\n", "page_number": 204, "bounding_box": {"top_left_x": 0.1161524500907441, "top_left_y": 0.5370132648694907, "lower_right_x": 0.3762855414398064, "lower_right_y": 0.5502781343602909, "height": 0.01326486949080019, "width": 0.2601330913490623}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-204-7", "text": "Items included in the financial statements of each of the Group\u2019s entities are measured using the currency of the primary\neconomic environment in which the entity operates (\u201cthe functional currency\u201d). The consolidated financial statements are\npresented in euros, which is the Company\u2019s functional and presentation currency.\n", "page_number": 204, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.5507060333761232, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.5947796320068464, "height": 0.04407359863072313, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-204-8", "text": "(b) Transactions and balances\n", "page_number": 204, "bounding_box": {"top_left_x": 0.1161524500907441, "top_left_y": 0.6157466837826273, "lower_right_x": 0.30550514216575925, "lower_right_y": 0.629867351305092, "height": 0.014120667522464658, "width": 0.18935269207501515}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-204-9", "text": "Foreign currency transactions are translated into the functional currency using the exchange rates prevailing at the dates of\nthe transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the\ntranslation at year-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognised\nin the income statement.\n", "page_number": 204, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.6328626444159179, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.6859221223791185, "height": 0.05305947796320065, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-204-10", "text": "2.5 Intangible assets\n", "page_number": 204, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.7115960633290543, "lower_right_x": 0.2516636418632789, "lower_right_y": 0.7222935387248609, "height": 0.010697475395806566, "width": 0.13611615245009073}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-204-11", "text": "(a) Goodwill\n", "page_number": 204, "bounding_box": {"top_left_x": 0.11857229280096794, "top_left_y": 0.7287120239623449, "lower_right_x": 0.1984271022383545, "lower_right_y": 0.7394094993581515, "height": 0.010697475395806566, "width": 0.07985480943738656}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-204-12", "text": "Goodwill represents the excess of the cost of an acquisition over the fair value of the Group\u2019s share of the net identifiable\nassets of the acquired subsidiary at the date of acquisition. If the cost of acquisition is less than the fair value of the net\nassets of the subsidiary acquired (also after re-assessment), the difference is recognised directly in the income statement.\n", "page_number": 204, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.7424047924689773, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.7834830979888746, "height": 0.04107830551989733, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-204-13", "text": "Separately recognised goodwill is tested annually for impairment and carried at cost less accumulated impairment losses.\nImpairment losses on goodwill are not reversed. Gains and losses on the disposal of an entity include the carrying amount\nof goodwill relating to the entity sold.\n", "page_number": 204, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.8040222507488233, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.8446726572528883, "height": 0.04065040650406504, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-204-14", "text": "F- 65\n", "page_number": 204, "bounding_box": {"top_left_x": 0.5075620084694494, "top_left_y": 0.9242618741976893, "lower_right_x": 0.5420447670901392, "lower_right_y": 0.9311082584510055, "height": 0.0068463842533161845, "width": 0.034482758620689724}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-205-0", "text": "Goodwill is allocated to cash-generating units for the purpose of impairment testing. The allocation is made to those cash-\ngenerating units or groups of cash-generating units that are expected to benefit from the business combination in which the\ngoodwill arose.\n", "page_number": 205, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.12623020967051776, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.16645271715875054, "height": 0.04022250748823278, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-205-1", "text": "(b) Patents\n", "page_number": 205, "bounding_box": {"top_left_x": 0.11857229280096794, "top_left_y": 0.2255027813436029, "lower_right_x": 0.18330308529945555, "lower_right_y": 0.2362002567394095, "height": 0.010697475395806594, "width": 0.06473079249848761}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-205-2", "text": "Acquired patents have a definite useful life and are carried at cost less accumulated amortisation and impairment losses.\nAmortisation is calculated using the straight-line method to allocate the cost of patents over their estimated useful lives\n(generally 10 years unless a patent expires prior to that date). Amortisation begins when an asset is available for use.\nHowever, in the years presented in these financial statements, no amortisation on patents is recorded since the technology\nwhich the patents relate to is not yet available for use.\n", "page_number": 205, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.24261874197689345, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.3102267864783911, "height": 0.06760804450149763, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-205-3", "text": "(c) Computer software\n", "page_number": 205, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.33162173727000427, "lower_right_x": 0.26073805202661826, "lower_right_y": 0.34488660676080446, "height": 0.01326486949080019, "width": 0.14035087719298245}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-205-4", "text": "Acquired computer software is capitalised on the basis of the costs incurred to acquire and bring to use the specific\nsoftware. These costs are amortised over their estimated useful lives (generally three years).\n", "page_number": 205, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.3453145057766367, "lower_right_x": 0.8850574712643678, "lower_right_y": 0.3761232349165597, "height": 0.030808729139922997, "width": 0.7695099818511797}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-205-5", "text": "(d) Research and development\n", "page_number": 205, "bounding_box": {"top_left_x": 0.11736237144585603, "top_left_y": 0.39666238767650835, "lower_right_x": 0.30973986690865096, "lower_right_y": 0.41078305519897307, "height": 0.014120667522464714, "width": 0.19237749546279492}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-205-6", "text": "Research expenditure is recognised as an expense as incurred. Costs incurred on development projects are recognised as\nintangible assets when it is probable that the project will be a success considering its commercial and technological\nfeasibility, generally when filed for regulatory approval for commercial production and costs can be measured reliably.\nOther development expenditures are recognised as an expense as incurred. Development costs previously recognised as an\nexpense are not recognised as an asset in a subsequent period. Development costs with a finite useful life that have been\ncapitalised are amortised from the commencement of the commercial production of the product on a straight-line basis\nover the period of its expected benefit.\n", "page_number": 205, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.41377834830979887, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.5100556268720582, "height": 0.09627727856225932, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-205-7", "text": "2.6 Property, plant and equipment\n", "page_number": 205, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.5335900727428327, "lower_right_x": 0.3484573502722323, "lower_right_y": 0.5464270432178006, "height": 0.012836970474967901, "width": 0.23290986085904414}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-205-8", "text": "Property, plant and equipment comprise the land and building in Leiden, leased under a financial lease agreement, and\nmachinery and other equipment. All property, plant and equipment is stated at historical cost less depreciation. Historical\ncost includes expenditures that are directly attributable to the acquisition of the items.\n", "page_number": 205, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.5468549422336328, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.5917843388960206, "height": 0.04492939666238771, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-205-9", "text": "Subsequent costs are included in the asset\u2019s carrying amount or recognised as a separate asset, as appropriate, only when it\nis probable that future economic benefits associated with the item will flow to the Group and the cost of the item can be\nmeasured reliably. All other repairs and maintenance charges are expensed in the financial period in which these are\nincurred.\n", "page_number": 205, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.6123234916559692, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.6640992725716731, "height": 0.051775780915703895, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-205-10", "text": "Depreciation is calculated using the straight-line method to allocate the cost of the assets to their residual values over their\nestimated useful lives. Land is not depreciated; other items are depreciated as follows:\n", "page_number": 205, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.6910569105691057, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.7154471544715447, "height": 0.024390243902439046, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-205-11", "text": "Buildings\n", "page_number": 205, "bounding_box": {"top_left_x": 0.13490623109497882, "top_left_y": 0.7218656397090286, "lower_right_x": 0.20326678765880218, "lower_right_y": 0.7325631151048353, "height": 0.010697475395806677, "width": 0.06836055656382337}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-205-12", "text": "20 years\n", "page_number": 205, "bounding_box": {"top_left_x": 0.3914095583787054, "top_left_y": 0.7218656397090286, "lower_right_x": 0.4500907441016334, "lower_right_y": 0.7325631151048353, "height": 0.010697475395806677, "width": 0.05868118572292802}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-205-13", "text": "", "page_number": 205, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.725716730851519, "lower_right_x": 0.12885662431941924, "lower_right_y": 0.7287120239623449, "height": 0.002995293110825914, "width": 0.013309134906231104}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-205-14", "text": "Machinery and installations\n", "page_number": 205, "bounding_box": {"top_left_x": 0.13732607380520268, "top_left_y": 0.7355584082156611, "lower_right_x": 0.3145795523290986, "lower_right_y": 0.7475395806589645, "height": 0.011981172443303434, "width": 0.17725347852389595}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-205-15", "text": "3-10 years\n", "page_number": 205, "bounding_box": {"top_left_x": 0.382335148215366, "top_left_y": 0.7355584082156611, "lower_right_x": 0.4500907441016334, "lower_right_y": 0.7475395806589645, "height": 0.011981172443303434, "width": 0.0677555958862674}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 16, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-205-16", "text": "", "page_number": 205, "bounding_box": {"top_left_x": 0.11796733212341198, "top_left_y": 0.7389816003423192, "lower_right_x": 0.12885662431941924, "lower_right_y": 0.7415489944373128, "height": 0.0025673940949936247, "width": 0.01088929219600726}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 17, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-205-17", "text": "Other equipment\n", "page_number": 205, "bounding_box": {"top_left_x": 0.13914095583787053, "top_left_y": 0.7492511767222936, "lower_right_x": 0.24682395644283123, "lower_right_y": 0.7616602481814292, "height": 0.012409071459135612, "width": 0.1076830006049607}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 18, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-205-18", "text": "3-5 years\n", "page_number": 205, "bounding_box": {"top_left_x": 0.38656987295825773, "top_left_y": 0.7492511767222936, "lower_right_x": 0.4500907441016334, "lower_right_y": 0.7620881471972615, "height": 0.012836970474967901, "width": 0.06352087114337568}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 19, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-205-19", "text": "", "page_number": 205, "bounding_box": {"top_left_x": 0.11796733212341198, "top_left_y": 0.7526743688489517, "lower_right_x": 0.12885662431941924, "lower_right_y": 0.7552417629439452, "height": 0.0025673940949935137, "width": 0.01088929219600726}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 20, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-205-20", "text": "The assets\u2019 residual values and useful lives are reviewed, and adjusted if appropriate, at each balance sheet date.\n", "page_number": 205, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.7800599058622165, "lower_right_x": 0.8173018753781004, "lower_right_y": 0.7941805733846812, "height": 0.014120667522464658, "width": 0.7017543859649122}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 21, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-205-21", "text": "An asset\u2019s carrying amount is written down immediately to its recoverable amount if the asset\u2019s carrying amount is greater\nthan its estimated recoverable amount (also refer to 2.7).\n", "page_number": 205, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.8142918271287976, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.8412494651262302, "height": 0.02695763799743267, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 22, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-205-22", "text": "F- 66\n", "page_number": 205, "bounding_box": {"top_left_x": 0.5075620084694494, "top_left_y": 0.9238339751818571, "lower_right_x": 0.5408348457350273, "lower_right_y": 0.9311082584510055, "height": 0.007274283269148474, "width": 0.03327283726557784}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-206-0", "text": "Gains and losses on disposals are determined by comparing proceeds with carrying amount. These are included in the\nincome statement.\n", "page_number": 206, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.12623020967051776, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.15190415062045357, "height": 0.025673940949935803, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-206-1", "text": "Finance leases\n", "page_number": 206, "bounding_box": {"top_left_x": 0.11736237144585603, "top_left_y": 0.17415489944373128, "lower_right_x": 0.21234119782214156, "lower_right_y": 0.1857081728712024, "height": 0.011553273427471117, "width": 0.09497882637628553}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-206-2", "text": "The Group leases certain property, plant and equipment. Leases of property, plant and equipment where the Group has\nsubstantially all the risks and rewards of ownership are classified as finance leases. Finance leases are capitalised at the\ncommencement of the lease at the lower of the fair value of the leased property and the present value of the minimum lease\npayments.\n", "page_number": 206, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.19469405220367994, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.24646983311938384, "height": 0.051775780915703895, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-206-3", "text": "Each lease payment is allocated between the liability and finance charges so as to achieve a constant rate on the finance\nbalance outstanding. The corresponding rental obligations, net of finance charges, are included in \u201cfinance lease\nliabilities\u201d. The interest element of the finance cost is charged to the income statement over the lease period so as to produce\na constant periodic rate of interest on the remaining balance of the liability for each period. The property, plant and\nequipment acquired under finance leases is depreciated over the shorter of the useful life of the asset or the lease term.\n", "page_number": 206, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.27000427899015833, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.33889602053915274, "height": 0.06889174154899441, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-206-4", "text": "Borrowing costs\n", "page_number": 206, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.3590072742832692, "lower_right_x": 0.22262552934059285, "lower_right_y": 0.3727000427899016, "height": 0.013692768506632425, "width": 0.10707803992740471}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-206-5", "text": "Borrowing costs incurred for the construction of any qualifying asset are capitalised during the period of time that is\nrequired to complete and prepare the asset for its intended use. Other borrowing costs are expensed.\n", "page_number": 206, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.37312794180573383, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.40393667094565683, "height": 0.030808729139922997, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-206-6", "text": "2.7 Impairment of non-financial assets\n", "page_number": 206, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.4249037227214377, "lower_right_x": 0.37265577737447064, "lower_right_y": 0.4381685922122379, "height": 0.01326486949080019, "width": 0.2571082879612825}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-206-7", "text": "Goodwill and other assets not subject to amortisation are reviewed for impairment at least annually. Assets subject to\namortisation or depreciation are reviewed for impairment whenever events or changes in circumstances indicate that the\ncarrying amount may not be recoverable. An impairment loss is recognised for the amount by which the asset\u2019s carrying\namount exceeds its recoverable amount. The recoverable amount is the higher of an asset\u2019s fair value less costs to sell and\nvalue-in-use (i.e. the present value of the future cash flows to be generated by an asset from its continuing use in the\nbusiness). For the purpose of assessing impairment, assets are grouped at the lowest levels for which there are separately\nidentifiable cash flows (cash-generating units). Non-financial assets other than goodwill that suffered impairment are\nreviewed for possible reversal of the impairment at each reporting date.\n", "page_number": 206, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.44458707744972187, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.5532734274711169, "height": 0.10868635002139498, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-206-8", "text": "2.8 Financial assets\n", "page_number": 206, "bounding_box": {"top_left_x": 0.1161524500907441, "top_left_y": 0.57466837826273, "lower_right_x": 0.24682395644283123, "lower_right_y": 0.5853658536585366, "height": 0.010697475395806566, "width": 0.13067150635208713}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-206-9", "text": "The Group has financial assets in the two categories \u201cloans and receivables\u201d and \u201cfinancial assets carried at cost\u201d. In the\nyears presented in these financial statements, the Group did not purchase or hold any derivative financial assets.\n", "page_number": 206, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.5917843388960206, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.6191698759092854, "height": 0.02738553701326485, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-206-10", "text": "(a) Loans and receivables\n", "page_number": 206, "bounding_box": {"top_left_x": 0.11736237144585603, "top_left_y": 0.6405648267008985, "lower_right_x": 0.279491833030853, "lower_right_y": 0.6538296961916987, "height": 0.01326486949080019, "width": 0.16212946158499697}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-206-11", "text": "Loans and receivables are non-derivative financial assets with fixed or determinable payments that are not quoted in an\nactive market. They are included in \u201ccurrent assets\u201d, except for maturities greater than 12 months after the balance sheet\ndate, which are classified as \u201cnon-current assets\u201d. Loans and receivables are carried at amortised costs using the effective\ninterest method.\n", "page_number": 206, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.6568249893025246, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.7120239623448866, "height": 0.05519897304236199, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-206-12", "text": "(b) Financial assets carried at cost\n", "page_number": 206, "bounding_box": {"top_left_x": 0.11857229280096794, "top_left_y": 0.7355584082156611, "lower_right_x": 0.338777979431337, "lower_right_y": 0.7462558836114677, "height": 0.010697475395806566, "width": 0.22020568663036905}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-206-13", "text": "Financial assets carried at cost (less accumulated impairment losses) are unquoted equity instruments that are not carried at\nfair value because their fair value cannot be reliably measured. They are included in non-current assets unless management\nintends to dispose of the investment within 12 months of the balance sheet date. These financial assets are subsequently\ncarried at cost.\n", "page_number": 206, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.7526743688489517, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.8040222507488233, "height": 0.051347881899871606, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-206-14", "text": "Regular purchases and sales of investments are recognised on trade-date; the date on which the Group commits to\npurchase or sell the asset. Investments are initially recognised at fair value plus transaction costs. Investments are\n", "page_number": 206, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.82798459563543, "lower_right_x": 0.8850574712643678, "lower_right_y": 0.8553701326486949, "height": 0.02738553701326485, "width": 0.7695099818511797}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-206-15", "text": "F- 67\n", "page_number": 206, "bounding_box": {"top_left_x": 0.5075620084694494, "top_left_y": 0.9242618741976893, "lower_right_x": 0.5408348457350273, "lower_right_y": 0.9311082584510055, "height": 0.0068463842533161845, "width": 0.03327283726557784}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-207-0", "text": "derecognised when the rights to receive cash flows from the investments have expired or have been transferred and the\nGroup has transferred substantially all risks and rewards of ownership.\n", "page_number": 207, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.12623020967051776, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.1540436456996149, "height": 0.02781343602909714, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-207-1", "text": "The Group assesses at each balance sheet date whether there is objective evidence that a financial asset or a group of\nfinancial assets is impaired. If there is objective evidence that an impairment loss has been incurred on an unquoted equity\ninstrument that is not carried at fair value because its fair value cannot be reliably measured, the amount of the impairment\nloss is measured as the difference between the carrying amount of the financial asset and the present value of estimated\nfuture cash flows discounted at the current market rate of return for a similar financial asset.\n", "page_number": 207, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.17415489944373128, "lower_right_x": 0.8905021173623714, "lower_right_y": 0.24176294394522893, "height": 0.06760804450149765, "width": 0.7749546279491832}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-207-2", "text": "2.9 Inventories\n", "page_number": 207, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.3008130081300813, "lower_right_x": 0.2177858439201452, "lower_right_y": 0.3115104835258879, "height": 0.010697475395806566, "width": 0.10223835450695705}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-207-3", "text": "Inventories are stated at the lower of cost and net realisable value. Cost is determined using the first-in, first-out (FIFO)\nmethod. Net realisable value is the estimated selling price in the ordinary course of business, less applicable variable\nselling expenses.\n", "page_number": 207, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.31792896876337184, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.3590072742832692, "height": 0.04107830551989733, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-207-4", "text": "2.10 Trade receivables\n", "page_number": 207, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.3795464270432178, "lower_right_x": 0.26799758015728975, "lower_right_y": 0.3923833975181857, "height": 0.012836970474967901, "width": 0.1524500907441016}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-207-5", "text": "Trade receivables are recognised initially at fair value and subsequently measured at amortised cost using the effective\ninterest method, less provision for impairment. A provision for impairment of trade receivables is established when there\nis objective evidence that the Group will not be able to collect all amounts due according to the original terms of\nreceivables. Significant financial difficulties of the debtor, probability that the debtor will enter bankruptcy or financial\nreorganisation, and default or delinquency in payments are considered indicators that the trade receivable is impaired. The\namount of the provision is the difference between the asset\u2019s carrying amount and the present value of estimated future\ncash flows, discounted at the effective interest rate. The amount of the provision is recognised in the income statement\nwithin \u201cother costs\u201d.\n", "page_number": 207, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.39666238767650835, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.5062045357295678, "height": 0.10954214805305945, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-207-6", "text": "2.11 Cash and cash equivalents\n", "page_number": 207, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.5301668806161746, "lower_right_x": 0.323653962492438, "lower_right_y": 0.5430038510911425, "height": 0.012836970474967901, "width": 0.20810647307924984}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-207-7", "text": "Cash and cash equivalents includes cash-in-hand, current accounts, deposits held at call with banks, other short-term\nhighly liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown\nseparately within current liabilities on the balance sheet.\n", "page_number": 207, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.5434317501069748, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.5879332477535302, "height": 0.04450149764655542, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-207-8", "text": "2.12 Equity\n", "page_number": 207, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.6089002995293111, "lower_right_x": 0.1984271022383545, "lower_right_y": 0.6230209670517758, "height": 0.014120667522464658, "width": 0.08287961282516636}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-207-9", "text": "Ordinary shares and preference shares are classified as equity.\n", "page_number": 207, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.6260162601626016, "lower_right_x": 0.5075620084694494, "lower_right_y": 0.6401369276850664, "height": 0.01412066752246477, "width": 0.3920145190562613}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-207-10", "text": "A financial instrument or its component parts are classified on initial recognition as a financial liability, a financial asset or\nan equity instrument in accordance with the substance of the contractual arrangement and the definitions of a financial\nliability, a financial asset and an equity instrument. An equity instrument is defined as any contract that evidences a\nresidual interest in the assets of an entity after deducting all of its liabilities. Based on these principles, the Group\u2019s\nsubordinated convertible loan is classified as equity.\n", "page_number": 207, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.6602481814291827, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.7291399229781772, "height": 0.06889174154899447, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-207-11", "text": "Incremental costs directly attributable to the issue of new shares or options are shown in equity as a deduction from the\nproceeds, net of tax.\n", "page_number": 207, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.7526743688489517, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.7792041078305519, "height": 0.02652973898160027, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-207-12", "text": "2.13 Deferred corporate income taxes\n", "page_number": 207, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.8005990586221652, "lower_right_x": 0.36721113127646704, "lower_right_y": 0.8138639281129654, "height": 0.01326486949080019, "width": 0.2516636418632789}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-207-13", "text": "Deferred corporate income tax is recognised, using the liability method, on temporary differences arising between the tax\nbases of assets and liabilities and their carrying amounts in the consolidated financial statements. Deferred corporate\nincome tax is determined using tax rates (and laws) that have been enacted or substantially enacted by the balance sheet\ndate and are expected to apply when the related deferred corporate income tax asset is realised or the deferred corporate\n", "page_number": 207, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.8177150192554558, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.8729139922978177, "height": 0.05519897304236199, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-207-14", "text": "F- 68\n", "page_number": 207, "bounding_box": {"top_left_x": 0.5075620084694494, "top_left_y": 0.9242618741976893, "lower_right_x": 0.5408348457350273, "lower_right_y": 0.9311082584510055, "height": 0.0068463842533161845, "width": 0.03327283726557784}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-208-0", "text": "income tax liability is settled. Deferred corporate income tax assets are recognised to the extent that it is probable that\nfuture taxable profit will be available against which the temporary differences can be utilised.\n", "page_number": 208, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.12623020967051776, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.15361574668378264, "height": 0.027385537013264877, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-208-1", "text": "Deferred corporate income tax is not accounted for if it arises from initial recognition of an asset or liability in a\ntransaction other than a business combination that at the time of the transaction affects neither accounting nor taxable\nprofit or loss.\n", "page_number": 208, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.17415489944373128, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.21566110397946084, "height": 0.04150620453572956, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-208-2", "text": "2.14 Borrowings\n", "page_number": 208, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.23919554985023533, "lower_right_x": 0.22746521476104054, "lower_right_y": 0.2503209242618742, "height": 0.011125374411638855, "width": 0.1119177253478524}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-208-3", "text": "Borrowings are recognised initially at fair value, net of transaction costs incurred. Borrowings are subsequently stated at\namortised cost; any difference between the proceeds (net of transaction costs) and the redemption value is recognised in\nthe income statement over the period of the borrowings using the effective interest method.\n", "page_number": 208, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.2563115104835259, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.29653401797175866, "height": 0.04022250748823275, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-208-4", "text": "Borrowings are classified as \u201ccurrent liabilities\u201d unless the Group has an unconditional right to defer settlement of the\nliability for at least 12 months after the balance sheet date (\u201cnon-current liabilities\u201d).\n", "page_number": 208, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.31792896876337184, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.34488660676080446, "height": 0.026957637997432615, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-208-5", "text": "2.15 Employee benefits\n", "page_number": 208, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.36585365853658536, "lower_right_x": 0.27041742286751363, "lower_right_y": 0.37997432605905007, "height": 0.014120667522464714, "width": 0.15486993345432548}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-208-6", "text": "(a) Pension obligations\n", "page_number": 208, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.38339751818570816, "lower_right_x": 0.2655777374470659, "lower_right_y": 0.3970902866923406, "height": 0.013692768506632425, "width": 0.15003024803387777}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-208-7", "text": "The Group operates a collective defined benefit pension plan for nearly all employees funded through payments to an\ninsurance company. This plan includes an average pay part and a defined contribution surplus salary part. The Group also\noperates some individual defined contribution pension plans. A defined contribution plan is a pension plan under which\nthe Group pays fixed contributions into a separate entity. The Group has no legal or constructive obligations to pay further\ncontributions if the fund does not hold sufficient assets to pay all employees the benefits relating to employee service in\nthe current and prior periods. A defined benefit plan is a pension plan that is not a defined contribution plan. Typically,\ndefined benefit plans define an amount of pension benefit that an employee will receive on retirement, usually dependent\non one or more factors such as age, years of service and compensation.\n", "page_number": 208, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.40008557980316645, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.5100556268720582, "height": 0.10997004706889174, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-208-8", "text": "The liability recognised in the balance sheet in respect of defined benefit pension plans is the present value of the defined\nbenefit obligation at the balance sheet date less the fair value of plan assets, together with adjustments for unrecognised\nactuarial gains or losses and past service costs. The defined benefit obligation is calculated annually by an independent\nactuary using the projected unit credit method. The present value of the defined benefit obligation is determined by\ndiscounting the estimated future cash outflows using a discount rate determined on basis of corporate bonds, adjusted for\nthe duration of the liability.\n", "page_number": 208, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.5335900727428327, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.6140350877192983, "height": 0.08044501497646561, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-208-9", "text": "Actuarial gains and losses arising from experience adjustments and changes in actuarial assumptions in excess of the\ngreater of 10% of the value of plan assets or 10% of the defined benefit obligation are charged or credited to the income\nstatement over the employees\u2019 expected average remaining working lives.\n", "page_number": 208, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.636285836542576, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.6777920410783055, "height": 0.04150620453572951, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-208-10", "text": "Past-service costs related to changes to the pension plan are recognised immediately in the income statement, unless the\nchanges to the pension plan are conditional on the employees remaining in service for a specified period of time (the\n\u201cvesting period\u201d). In this case, the past-service costs are amortised on a straight-line basis over the vesting period.\n", "page_number": 208, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.7013264869490801, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.7394094993581515, "height": 0.038083012409071415, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-208-11", "text": "For defined contribution plans, the Group pays contributions to pension insurance plans on a contractual basis. The Group\nhas no further payment obligations once the contributions have been paid. The contributions are recognised as employee\nbenefit expense when they are due. Prepaid contributions are recognised as an asset to the extent that a cash refund or a\nreduction in the future payments is available.\n", "page_number": 208, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.762943945228926, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.8177150192554558, "height": 0.05477107402652981, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-208-12", "text": "(b) Share-based compensation\n", "page_number": 208, "bounding_box": {"top_left_x": 0.12038717483363581, "top_left_y": 0.8382541720154044, "lower_right_x": 0.3145795523290986, "lower_right_y": 0.8519469405220368, "height": 0.013692768506632369, "width": 0.1941923774954628}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-208-13", "text": "F- 69\n", "page_number": 208, "bounding_box": {"top_left_x": 0.5075620084694494, "top_left_y": 0.9238339751818571, "lower_right_x": 0.5408348457350273, "lower_right_y": 0.9311082584510055, "height": 0.007274283269148474, "width": 0.03327283726557784}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-209-0", "text": "The Company operates an equity-settled, share-based compensation plan. The costs of employee share option plans are\nmeasured by reference to the fair value of the options at the date at which the options are granted using a Binomial option\nmodel.\n", "page_number": 209, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.12623020967051776, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.1643132220795892, "height": 0.03808301240907144, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-209-1", "text": "The costs of these options, which reflect the services rendered by employees in exchange for the grant of the options, are\nrecognised in the income statement, together with a corresponding increase in equity during the vesting period. The total\namount to be expensed over the vesting period is determined by reference to the fair value of the options granted,\nexcluding the impact of any non-market vesting conditions (for example, profitability and sales growth targets).\n", "page_number": 209, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.19127086007702182, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.24304664099272572, "height": 0.051775780915703895, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-209-2", "text": "Estimates of forfeitures are included in assumptions about the number of options that are expected to become exercisable.\nAt each balance sheet date, the Company revises its estimates of the number of options that are expected to become\nexercisable. It recognises the impact of the revision of original estimates, if any, in the income statement, with a\ncorresponding adjustment to equity. The income statement charge or credit for a period represents the movement in\ncumulative expense recognised at the beginning and end of that period.\n", "page_number": 209, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.26658108686350024, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.3346170303808301, "height": 0.06803594351732989, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-209-3", "text": "The proceeds received net of any directly attributable transaction costs are credited to share capital (nominal value) and\nshare premium when the options are exercised.\n", "page_number": 209, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.355584082156611, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.38339751818570816, "height": 0.02781343602909714, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-209-4", "text": "(c) Profit-sharing and bonus plans\n", "page_number": 209, "bounding_box": {"top_left_x": 0.11736237144585603, "top_left_y": 0.40350877192982454, "lower_right_x": 0.33575317604355714, "lower_right_y": 0.41762943945228925, "height": 0.014120667522464714, "width": 0.2183908045977011}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-209-5", "text": "The Group recognises a liability and an expense for bonuses and profit-sharing plans if contractually obliged or if there is\na past practice that has created a constructive obligation.\n", "page_number": 209, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.4206247325631151, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.44843816859221225, "height": 0.02781343602909714, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-209-6", "text": "2.16 Provisions\n", "page_number": 209, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.4719726144629867, "lower_right_x": 0.22020568663036902, "lower_right_y": 0.4813863928112965, "height": 0.00941377834830981, "width": 0.10465819721718088}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-209-7", "text": "Provisions are recognised when: The Group has a present legal or constructive obligation as a result of past events; it is\nmore likely than not that an outflow of resources will be required to settle the obligation; and the amount can be reliably\nestimated. Provisions are not recognised for future operating losses.\n", "page_number": 209, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.4890885750962773, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.5293110825845101, "height": 0.040222507488232806, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-209-8", "text": "Provisions are measured at the present value of the expenditures expected to be required to settle the obligation using a\npre-tax rate that reflects current market assessments of the time value of money and the risks specific to the obligation.\nThe increase in the provision due to passage of time is recognised as interest expense.\n", "page_number": 209, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.5507060333761232, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.5917843388960206, "height": 0.04107830551989733, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-209-9", "text": "2.17 Revenue recognition\n", "page_number": 209, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.6123234916559692, "lower_right_x": 0.28554143980641256, "lower_right_y": 0.6260162601626016, "height": 0.013692768506632369, "width": 0.1699939503932244}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-209-10", "text": "Revenue comprises the fair value of the sale of goods and services, and is shown net of value-added tax, rebates and\ndiscounts and after eliminated sales within the Group. The Group\u2019s revenues primarily consist of sales of services, license\nand royalty revenues and subsidies (see 2.18). These revenues are recognised as follows:\n", "page_number": 209, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.6294394522892597, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.6709456568249893, "height": 0.04150620453572962, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-209-11", "text": "(a) Service revenues\n", "page_number": 209, "bounding_box": {"top_left_x": 0.11675741076830005, "top_left_y": 0.691484809584938, "lower_right_x": 0.24682395644283123, "lower_right_y": 0.7051775780915703, "height": 0.013692768506632369, "width": 0.1300665456745312}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-209-12", "text": "Sales of services are recognised in the accounting period in which the services are rendered, by reference to the stage of\ncompletion of the specific transaction when the outcome of a transaction can be estimated reliably. The stage of\ncompletion is assessed on the basis of the actual service provided as a proportion of the total services to be provided.\n", "page_number": 209, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.7115960633290543, "lower_right_x": 0.8898971566848155, "lower_right_y": 0.7496790757381258, "height": 0.038083012409071415, "width": 0.7743496672716274}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-209-13", "text": "(b) License and royalty revenues\n", "page_number": 209, "bounding_box": {"top_left_x": 0.1161524500907441, "top_left_y": 0.7732135216089003, "lower_right_x": 0.32425892316999394, "lower_right_y": 0.7864783910997005, "height": 0.01326486949080019, "width": 0.20810647307924984}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-209-14", "text": "License and royalty revenues include amounts earned from third parties with licenses and/or options to the Group\u2019s\nintellectual property. License and royalty revenues are recognised when earned in accordance with the substance and\nunder the terms of the related agreements and when it is probable that the economic benefits associated with the\ntransaction will flow to the entity and the amount of the revenue can be measured reliably. In situations where the Group\nhas continuing performance obligations, revenues related to license fee payments are deferred and the related revenue is\nrecognised in the period of expected performance.\n", "page_number": 209, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.7869062901155327, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.8724860932819855, "height": 0.08557980316645275, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-209-15", "text": "F- 70\n", "page_number": 209, "bounding_box": {"top_left_x": 0.5075620084694494, "top_left_y": 0.9242618741976893, "lower_right_x": 0.5408348457350273, "lower_right_y": 0.9311082584510055, "height": 0.0068463842533161845, "width": 0.03327283726557784}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-210-0", "text": "Multiple element arrangements\n", "page_number": 210, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.1433461703038083, "lower_right_x": 0.3139745916515426, "lower_right_y": 0.157466837826273, "height": 0.014120667522464686, "width": 0.19842710223835447}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-210-1", "text": "In certain circumstances, it is necessary to apply the recognition criteria to the separately identifiable components of a\nsingle transaction in order to reflect the substance of the transaction. Conversely, the recognition criteria are applied to two\nor more transactions together when they are linked in such a way that the commercial effect cannot be understood without\nreference to the series of transactions as a whole.\n", "page_number": 210, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.16046213093709885, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.21437740693196405, "height": 0.0539152759948652, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-210-2", "text": "The Group offers arrangements whereby a customer licenses the right to use the Group\u2019s intellectual property and\npurchases research and development services under one arrangement. When such multiple element arrangements exist, an\nelement is accounted for as a separable element if it has value to the customer on a stand-alone basis and the fair value can\nbe determined objectively and reliably.\n", "page_number": 210, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.23919554985023533, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.29311082584510056, "height": 0.05391527599486523, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-210-3", "text": "When license revenues and service revenues are identified as separable elements in a multiple element transaction, the\nlicense revenue recognised is determined based on the fair value of the license in relation to the fair value of the\narrangement taken as a whole and is recognised in accordance with the accounting policy for license and royalty revenues\nas discussed above. The revenue relating to the service element, which represents the fair value of the servicing\narrangement in relation to the fair value of the arrangement, is recognised over the service period. The fair values of each\nelement are determined based on the current market price of each of the elements when sold separately.\n", "page_number": 210, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.31450577663671375, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.3970902866923406, "height": 0.08258451005562684, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-210-4", "text": "2.18 Income from subsidies\n", "page_number": 210, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.4206247325631151, "lower_right_x": 0.3000604960677556, "lower_right_y": 0.42961061189559263, "height": 0.00898587933247752, "width": 0.18451300665456744}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-210-5", "text": "The Group receives certain subsidies, which support the Group\u2019s research efforts in defined research and development\nprojects. These subsidies generally provide for reimbursement of approved costs incurred as defined in various grants.\nSubsidies are recognised at their fair value when there is a reasonable assurance that the subsidy will be received and the\nGroup will comply with all attached conditions.\n", "page_number": 210, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.43431750106974754, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.4895164741121095, "height": 0.05519897304236199, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-210-6", "text": "The Group includes income from subsidies under \u201cincome from subsidies\u201d in the income statement in order to enable\ncomparison of its income statement with companies in the life sciences sector. Companies in the life sciences sector\ngenerally present governmental subsidies as income, as these subsidies often are a significant source of income.\nFurthermore, research and development expenses would, generally, be incurred to the same amount if no governmental\ncontributions would be granted.\n", "page_number": 210, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.513050919982884, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.5819426615318785, "height": 0.06889174154899447, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-210-7", "text": "The WBSO (\u201cafdrachtvermindering speur- en ontwikkelingswerk\u201d) is a fiscal facility that provides subsidies to\ncompanies, knowledge centres and self-employed people who perform research and development (as defined in the WBSO\nAct). Under this Act, a contribution is paid towards the labour costs of employees directly involved in research and\ndevelopment. The contribution is in the form of a reduction of payroll taxes and social security contributions.\n", "page_number": 210, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.6020539152759948, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.6572528883183568, "height": 0.05519897304236199, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-210-8", "text": "Subsidies relating to labour costs (WBSO) are deferred and recognised in the income statement as negative labour costs\nover the period necessary to match them with the labour costs that they are intended to compensate.\n", "page_number": 210, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.6773641420624733, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.7051775780915703, "height": 0.027813436029097027, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-210-9", "text": "2.19 Operating leases\n", "page_number": 210, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.7287120239623449, "lower_right_x": 0.2613430127041742, "lower_right_y": 0.7394094993581515, "height": 0.010697475395806566, "width": 0.14579552329098605}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-210-10", "text": "Leases in which substantially all the risks and rewards of ownership are retained by the lessor are classified as operating\nleases. Payments made under operating leases (net of any incentives received from the lessor) are charged to the income\nstatement on a straight-line basis over the period of the lease.\n", "page_number": 210, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.7458279845956355, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.7864783910997005, "height": 0.04065040650406504, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-210-11", "text": "2.20 Dividend distribution\n", "page_number": 210, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.8074454428754814, "lower_right_x": 0.29522081064730793, "lower_right_y": 0.8181429182712879, "height": 0.010697475395806566, "width": 0.17967332123411978}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-210-12", "text": "Dividend distribution to the Company\u2019s shareholders is recognised as a liability in the Group\u2019s financial statements in the\nperiod in which the dividends are approved by the Company\u2019s shareholders.\n", "page_number": 210, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.8245614035087719, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.8519469405220368, "height": 0.02738553701326485, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-210-13", "text": "F- 71\n", "page_number": 210, "bounding_box": {"top_left_x": 0.5075620084694494, "top_left_y": 0.9242618741976893, "lower_right_x": 0.5390199637023594, "lower_right_y": 0.9311082584510055, "height": 0.0068463842533161845, "width": 0.03145795523290995}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-211-0", "text": "3. Financial risk management\n", "page_number": 211, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.1433461703038083, "lower_right_x": 0.367816091954023, "lower_right_y": 0.1600342319212666, "height": 0.016688061617458283, "width": 0.25226860254083483}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-211-1", "text": "3.1 Financial risk factors\n", "page_number": 211, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.18356867779204109, "lower_right_x": 0.28554143980641256, "lower_right_y": 0.19341035515618313, "height": 0.009841677364142043, "width": 0.1699939503932244}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-211-2", "text": "3.1 Financial risk factors\nThe Group is exposed to a variety of financial risks: Market risk, credit risk, liquidity risk and cash flow and fair value\ninterest rate risk. The Group\u2019s overall risk management program seeks to minimise potential adverse effects of these\nfinancial risk factors on the Group\u2019s financial performance.\n", "page_number": 211, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.19383825417201542, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.2396234488660676, "height": 0.04578519469405218, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-211-3", "text": "(a) Market risk\n", "page_number": 211, "bounding_box": {"top_left_x": 0.1191772534785239, "top_left_y": 0.2631578947368421, "lower_right_x": 0.2177858439201452, "lower_right_y": 0.2738553701326487, "height": 0.010697475395806622, "width": 0.09860859044162129}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-211-4", "text": "Foreign exchange risk arises from future commercial transactions and recognised assets and liabilities in foreign\ncurrencies. In the years presented, the Group had no significant outstanding receivables or payables in currencies other\nthan euros.\n", "page_number": 211, "bounding_box": {"top_left_x": 0.1161524500907441, "top_left_y": 0.28027385537013266, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.31835686777920413, "height": 0.03808301240907147, "width": 0.7695099818511797}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-211-5", "text": "The Group is not exposed to equity securities price risk, since it does not hold any such investments, or commodity price\nrisk.\n", "page_number": 211, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.3384681215233205, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.3628583654257595, "height": 0.02439024390243899, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-211-6", "text": "(b) Credit risk\n", "page_number": 211, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.386392811296534, "lower_right_x": 0.20810647307924984, "lower_right_y": 0.40008557980316645, "height": 0.013692768506632425, "width": 0.0925589836660617}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-211-7", "text": "The five largest external partners generate approximately 55% of total revenues in 2005. The outstanding receivables with\nthese parties comprise of 55% of the total trade receivables at 31 December 2005. Management does not believe that this\nresults in major credit risks since all customers are companies of good reputations. The Group has policies in place to ensure\nthat contracts are only signed with customers with an appropriate credit history.\n", "page_number": 211, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.40350877192982454, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.4587077449721866, "height": 0.05519897304236204, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-211-8", "text": "(c) Liquidity risk\n", "page_number": 211, "bounding_box": {"top_left_x": 0.11857229280096794, "top_left_y": 0.48224219084296105, "lower_right_x": 0.22323049001814882, "lower_right_y": 0.49293966623876767, "height": 0.010697475395806622, "width": 0.10465819721718088}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-211-9", "text": "Prudent liquidity risk management implies maintaining sufficient cash and marketable securities plus the availability of\nfunding through an adequate amount of committed credit facilities. Due to the dynamic nature of the underlying businesses,\nthe Group aims to maintain flexibility in funding by keeping committed credit lines available. Management considers the\nexisting funding to provide sufficient time to create shareholder value before a next financing round is carried out.\n", "page_number": 211, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.4993581514762516, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.5532734274711169, "height": 0.05391527599486523, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-211-10", "text": "(d) Cash flow and fair value interest rate risk\n", "page_number": 211, "bounding_box": {"top_left_x": 0.11675741076830005, "top_left_y": 0.57466837826273, "lower_right_x": 0.4016938898971567, "lower_right_y": 0.5879332477535302, "height": 0.01326486949080019, "width": 0.28493647912885667}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-211-11", "text": "As the Group has no significant long-term interest-bearing assets or debts, the Group\u2019s income and operating cash flows\nare not significantly impacted by changes in market interest rates.\n", "page_number": 211, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.5883611467693625, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.6191698759092854, "height": 0.03080872913992294, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-211-12", "text": "3.2 Estimation fair value of financial instruments\n", "page_number": 211, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.6397090286692341, "lower_right_x": 0.4452510586811857, "lower_right_y": 0.6516902011125374, "height": 0.011981172443303323, "width": 0.32970356926799754}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-211-13", "text": "The Group does not hold any financial instruments traded in active markets. Financial assets consist of loans and\nreceivables and an unquoted equity investment, which is not carried at fair value because its fair value cannot be reliably\nmeasured.\n", "page_number": 211, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.6568249893025246, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.6970474967907574, "height": 0.04022250748823275, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-211-14", "text": "4. Critical accounting estimates and judgements\n", "page_number": 211, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.7389816003423192, "lower_right_x": 0.5220810647307925, "lower_right_y": 0.7522464698331194, "height": 0.01326486949080019, "width": 0.40653357531760437}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-211-15", "text": "4. Critical accounting estimates and judgements\nEstimates and judgements are continually evaluated and are based on historical experience and other factors, including\nexpectations of future events that are believed to be reasonable under the circumstances.\n", "page_number": 211, "bounding_box": {"top_left_x": 0.1161524500907441, "top_left_y": 0.7526743688489517, "lower_right_x": 0.8566243194192378, "lower_right_y": 0.7804878048780488, "height": 0.02781343602909714, "width": 0.7404718693284937}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 16, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-211-16", "text": "The Group makes estimates and assumptions concerning the future. The resulting accounting estimates will, by definition,\nseldom equal the related actual results. The estimates and assumptions that have a significant risk of causing a material\nadjustment to the carrying amounts of assets and liabilities within the next financial year as well as critical judgements in\napplying the Group\u2019s accounting policies are discussed below.\n", "page_number": 211, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.8040222507488233, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.8557980316645272, "height": 0.051775780915703895, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 17, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-211-17", "text": "F- 72\n", "page_number": 211, "bounding_box": {"top_left_x": 0.5075620084694494, "top_left_y": 0.9242618741976893, "lower_right_x": 0.5408348457350273, "lower_right_y": 0.9306803594351734, "height": 0.006418485237484006, "width": 0.03327283726557784}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-212-0", "text": "(a) Impairment test of goodwill and patents\n", "page_number": 212, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.12623020967051776, "lower_right_x": 0.38898971566848156, "lower_right_y": 0.14035087719298245, "height": 0.014120667522464686, "width": 0.2734422262552934}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-212-1", "text": "Goodwill and intangible assets not yet available for use are not amortised but are subject to an annual impairment test or\nmore frequent testing whenever events or changes in circumstances indicate that the carrying amount may be not be\nrecoverable. For the purpose of the impairment testing, goodwill is allocated to cash-generating units. In the years\npresented, all goodwill recognised relates to the acquisition of Chienna B.V. in the year 2003 and is allocated to the\nGroup\u2019s Drug delivery & products unit. The technology that the patents acquired as part of the acquisition of Chienna\nB.V. relates to, are not yet available for use. These patents were also allocated to the Group\u2019s Drug delivery & products\nunit and are tested for impairment as part of this cash-generating unit. The recoverable amount of the applicable cash-\ngenerating unit is determined based on value-in-use calculations by using the discounted cash flow model.\n", "page_number": 212, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.1433461703038083, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.25331621737270005, "height": 0.10997004706889174, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-212-2", "text": "In performing impairment testing of goodwill and patents, management must make significant judgements and estimates\nto determine whether the cash flows generated by the cash-generating unit the assets belong to are less than the unit\u2019s\ncarrying value (see Note 6). Determining cash flows requires the use of judgements and estimates that have been included\nin the Group\u2019s strategic plans and long-term forecasts. The data necessary for performing the impairment tests are based\non management estimates of future cash flows. The discount rates used are estimated pre-tax rates which reflect specific\nrisks relating to the relevant segment.\n", "page_number": 212, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.2768506632434745, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.3590072742832692, "height": 0.08215661103979466, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-212-3", "text": "(b) Corporate income taxes\n", "page_number": 212, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.3795464270432178, "lower_right_x": 0.28917120387174833, "lower_right_y": 0.3936670945656825, "height": 0.014120667522464714, "width": 0.17362371445856017}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-212-4", "text": "The Group, which has a history of recent tax losses, recognises deferred tax assets arising from unused tax losses or tax\ncredits only to the extent that the relevant fiscal unity has sufficient taxable temporary differences or there is convincing\nother evidence that sufficient taxable profit will be available against which the unused tax losses or unused tax credits can\nbe utilised by the fiscal unity. Management\u2019s judgement is that sufficient convincing other evidence is not available and a\ndeferred tax asset is therefore only recognised to the extent that a fiscal unity has sufficient taxable temporary differences.\n", "page_number": 212, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.39666238767650835, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.46555412922550277, "height": 0.06889174154899441, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-212-5", "text": "(c) Pensions\n", "page_number": 212, "bounding_box": {"top_left_x": 0.11857229280096794, "top_left_y": 0.4890885750962773, "lower_right_x": 0.1984271022383545, "lower_right_y": 0.49978605049208386, "height": 0.010697475395806566, "width": 0.07985480943738656}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-212-6", "text": "For the calculation of the present value of the pension obligation and the net cost, actuarial assumptions are made about\ndemographic variables (such as mortality) and financial variables (such as future increases in salaries). The discount rate is\ndetermined by reference to market rates of high-quality corporate bonds. Any changes in these assumptions will impact the\ncarrying amount of the Group\u2019s pension obligations. Additional information on these assumptions is included in Note 15.\n", "page_number": 212, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.5062045357295678, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.560119811724433, "height": 0.05391527599486523, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-212-7", "text": "(d) Share-based payments\n", "page_number": 212, "bounding_box": {"top_left_x": 0.11675741076830005, "top_left_y": 0.5815147625160462, "lower_right_x": 0.28009679370840895, "lower_right_y": 0.5947796320068464, "height": 0.01326486949080019, "width": 0.1633393829401089}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-212-8", "text": "Share options granted to employees are measured at the fair value of the equity instruments granted (indirect method of\nmeasurement). Fair value is determined through the use of an option-pricing model considering, among others, the\nfollowing variables:\n", "page_number": 212, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.5986307231493367, "lower_right_x": 0.8898971566848155, "lower_right_y": 0.6401369276850664, "height": 0.04150620453572962, "width": 0.7743496672716274}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-212-9", "text": "a)   The exercise price of the option;\nb)   The expected life of the option;\nc)   The current value of the underlying shares;\nd)   The expected volatility of the share price, calculated considering the effect of dividends on stock price;\ne)   The dividends expected on the shares; and\nf)   The risk-free interest rate for the life of the option.\n", "page_number": 212, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.6568249893025246, "lower_right_x": 0.7888687235329703, "lower_right_y": 0.7394094993581515, "height": 0.08258451005562684, "width": 0.6733212341197822}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-212-10", "text": "For the Company\u2019s share option plans, management\u2019s judgement is that the Binomial method is most appropriate for\ndetermining fair values as this method allows accounting for non-transferability, vesting conditions and early exercise.\nSince the Company is not listed, there is no published share price information. Consequently, the Company needs to\nestimate the fair value of its shares and the expected volatility of that value. These assumptions and estimates are further\ndiscussed in Note 12 to the consolidated financial statements.\n", "page_number": 212, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.7560975609756098, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.8211382113821138, "height": 0.06504065040650409, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-212-11", "text": "The result of the share option valuations and the related compensation expense is dependent on the model and input\nparameters used. Even though Management considers the fair values reasonable and defensible based on the\n", "page_number": 212, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.8451005562687206, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.8729139922978177, "height": 0.02781343602909714, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-212-12", "text": "F- 73\n", "page_number": 212, "bounding_box": {"top_left_x": 0.5075620084694494, "top_left_y": 0.9242618741976893, "lower_right_x": 0.5408348457350273, "lower_right_y": 0.9311082584510055, "height": 0.0068463842533161845, "width": 0.03327283726557784}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-213-0", "text": "methodologies applied and the information available, others might derive at a different fair value for each of the\nCompany\u2019s share option plans.\n", "page_number": 213, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.12623020967051776, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.1540436456996149, "height": 0.02781343602909714, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-213-1", "text": "(e) Capitalisation of development costs\n", "page_number": 213, "bounding_box": {"top_left_x": 0.11736237144585603, "top_left_y": 0.17415489944373128, "lower_right_x": 0.3623714458560194, "lower_right_y": 0.188275566966196, "height": 0.014120667522464714, "width": 0.24500907441016334}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-213-2", "text": "Costs incurred on development projects are recognised as intangible assets when it is probable that a project will be a\nsuccess considering its commercial and technological feasibility. Management\u2019s judgement is required in determining\nwhen the Group should start capitalising of development costs. Management determined that commercial and\ntechnological feasibility is, in general, probable when the Group files for regulatory approval for commercial production\nand costs can be measured reliably. At 31 December 2005, the Group has not filed for regulatory approval for its\nproprietary drug delivery technology. Based on Management\u2019s assessment of commercial and technological feasibility, no\ndevelopment costs have been recognised as intangible assets in the consolidated financial statements.\n", "page_number": 213, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.19469405220367994, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.28968763371844247, "height": 0.09499358151476253, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-213-3", "text": "5. Segment information\n", "page_number": 213, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.33504492939666236, "lower_right_x": 0.3145795523290986, "lower_right_y": 0.3491655969191271, "height": 0.014120667522464714, "width": 0.19903206291591047}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-213-4", "text": "Primary reporting format \u2013 business segments\nAt 31 December 2005, the Group is organised into two main business segments:\n(1) Providing development services for life sciences companies in the field of drug formulation (\u201cContract development\n    unit\u201d); and\n(2) Development of a product portfolio based on the Group\u2019s proprietary drug delivery technology (\u201cDrug delivery &\n    products unit\u201d).\n", "page_number": 213, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.355584082156611, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.44843816859221225, "height": 0.09285408643560122, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-213-5", "text": "The segment results for the year ending 31 December 2005 are as follows:\n", "page_number": 213, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.5233204963628584, "lower_right_x": 0.5904416212946159, "lower_right_y": 0.5340179717586649, "height": 0.010697475395806566, "width": 0.4748941318814277}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-213-6", "text": "                                        Contract   Drug delivery   Unallocated   Group\n                                     development   and products\nTotal gross segment revenues               6,804            185             \u2013     6,989\nInter-segment revenues                     (366)               -            \u2013     (366)\nSubsidies and other income                     -            394             \u2013       394\nRevenues                                   6,438            579             \u2013     7,017\n\n\nOperating result                            718          (5,197)           35    (4,444)\nFinance costs \u2013 net                                                               (118)\nResult before corporate income tax                                               (4,562)\nCorporate income taxes                                                              353\nResult for the year                                                              (4,209)\n", "page_number": 213, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.5575524176294394, "lower_right_x": 0.8082274652147611, "lower_right_y": 0.7633718442447582, "height": 0.20581942661531882, "width": 0.6926799758015729}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-213-7", "text": "The segment results for the year ending 31 December 2004 are as follows:\n", "page_number": 213, "bounding_box": {"top_left_x": 0.11736237144585603, "top_left_y": 0.7800599058622165, "lower_right_x": 0.5801572897761645, "lower_right_y": 0.7941805733846812, "height": 0.014120667522464658, "width": 0.4627949183303085}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-213-8", "text": "                                  Contract   Drug delivery and   Unallocated   Group\n                               development            products\nTotal gross segment revenues         5,418                359             \u2013    5,777\n\n\n\n\n                                   F- 74\n", "page_number": 213, "bounding_box": {"top_left_x": 0.11675741076830005, "top_left_y": 0.8177150192554558, "lower_right_x": 0.8905021173623714, "lower_right_y": 0.9311082584510055, "height": 0.11339323919554978, "width": 0.7737447065940714}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-214-0", "text": "Inter-segment revenues               (772)      (21)   \u2013    (793)\nSubsidies and other income             26       708    \u2013      734\nRevenues                             4,672    1,046    \u2013    5,718\n\n\nOperating result                      813    (2,596)   \u2013   (1,783)\nFinance costs - net                                         (394)\nResult before corporate income tax                         (2,177)\nCorporate income taxes                                      (353)\nResult for the year                                        (2,530)\n", "page_number": 214, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.12623020967051776, "lower_right_x": 0.9001814882032668, "lower_right_y": 0.2807017543859649, "height": 0.15447154471544713, "width": 0.7846339987900787}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-214-1", "text": "The segment results for the year ending 31 December 2003 are as follows:\n", "page_number": 214, "bounding_box": {"top_left_x": 0.11675741076830005, "top_left_y": 0.3042362002567394, "lower_right_x": 0.5807622504537205, "lower_right_y": 0.3162173727000428, "height": 0.011981172443303378, "width": 0.4640048396854205}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-214-2", "text": "                                        Contract   Drug delivery   Unallocated   Group\n                                     development   and products\nTotal gross segment revenues               5,123            276             \u2013     5,399\nInter-segment revenues                     (356)              \u2013             \u2013     (356)\nSubsidies and other income                     -            818             \u2013       818\nRevenues                                   4,767          1,094             \u2013     5,861\n\n\nOperating result                             17          (2,224)            \u2013    (2,207)\nFinance costs - net                                                                (29)\nResult before corporate income tax                                               (2,236)\nCorporate income taxes                                                                 -\nResult for the year                                                              (2,236)\n", "page_number": 214, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.3384681215233205, "lower_right_x": 0.8130671506352087, "lower_right_y": 0.5477107402652974, "height": 0.20924261874197692, "width": 0.6975196612220206}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-214-3", "text": "Unallocated costs represent corporate expenses. Inter-segment transfers or transactions are entered into under the normal\ncommercial terms and conditions that would also be available to unrelated third parties.\n", "page_number": 214, "bounding_box": {"top_left_x": 0.1161524500907441, "top_left_y": 0.5643988018827557, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.5905006418485238, "height": 0.026101839965768092, "width": 0.7695099818511797}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-214-4", "text": "Other segment items included in the income statement are as follows:\n", "page_number": 214, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.6123234916559692, "lower_right_x": 0.5511191772534785, "lower_right_y": 0.6247325631151048, "height": 0.012409071459135612, "width": 0.4355716878402903}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-214-5", "text": "                                   Contract   Drug delivery   Unallocated   Group\n                                development   and products\nYear ending 31 December 2005\nDepreciation and amortisation          633             230             \u2013      863\n\n\nYear ending 31 December 2004\nDepreciation and amortisation          644             216             \u2013      860\n\n\nYear ending 31 December 2003\nDepreciation and amortisation          492             176             \u2013      668\n", "page_number": 214, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.6465554129225503, "lower_right_x": 0.8033877797943134, "lower_right_y": 0.8142918271287976, "height": 0.1677364142062473, "width": 0.6878402903811253}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-214-6", "text": "The segment assets and liabilities at 31 December 2005 and capital expenditure for the year then ending are as follows:\n", "page_number": 214, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.8485237483953787, "lower_right_x": 0.8511796733212341, "lower_right_y": 0.8626444159178434, "height": 0.014120667522464658, "width": 0.735632183908046}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-214-7", "text": "F- 75\n", "page_number": 214, "bounding_box": {"top_left_x": 0.5075620084694494, "top_left_y": 0.9242618741976893, "lower_right_x": 0.5420447670901392, "lower_right_y": 0.9311082584510055, "height": 0.0068463842533161845, "width": 0.034482758620689724}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-215-0", "text": "                                        Contract   Drug delivery   Unallocated   Group\n                                     development   and products\nAssets                                     9,499          6,061          4,940   20,500\nLiabilities                                7,722         11,373       (10,346)    8,749\nCapital expenditure (Note 6 and 7)          559             271           552     1,382\n", "page_number": 215, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.12665810868635002, "lower_right_x": 0.8124621899576527, "lower_right_y": 0.20753102267864784, "height": 0.08087291399229782, "width": 0.6969147005444646}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-215-1", "text": "The segment assets and liabilities at 31 December 2004 and capital expenditure for the year then ending are as follows:\n                                               Contract        Drug delivery      Unallocated           Group\n                                            development        and products\nAssets                                              5,450              1,717             2,187           9,354\nLiabilities                                         4,169              5,571               970          10,710\nCapital expenditure (Note 6 and 7)                  1,147                124             3,423           4,694\n", "page_number": 215, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.22892597347026103, "lower_right_x": 0.8511796733212341, "lower_right_y": 0.32734274711168165, "height": 0.09841677364142062, "width": 0.735632183908046}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-215-2", "text": "The segment assets and liabilities at 31 December 2003 and capital expenditure for the year then ending are as follows:\n                                               Contract        Drug delivery      Unallocated           Group\n                                            development        and products\nAssets                                              3,094              1,167             1,931           6,192\nLiabilities                                         2,354              3,452             (765)           5,041\nCapital expenditure (Note 6 and 7)                    617              1,513                88           2,218\n", "page_number": 215, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.34873769790329484, "lower_right_x": 0.8511796733212341, "lower_right_y": 0.4462986735130509, "height": 0.09756097560975607, "width": 0.735632183908046}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-215-3", "text": "Secondary reporting format \u2013 geographical segments\nThe Group\u2019s customers are mainly located in Europe and North-America as shown below:\n", "page_number": 215, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.4685494223363286, "lower_right_x": 0.6787658802177858, "lower_right_y": 0.4993581514762516, "height": 0.030808729139922997, "width": 0.5632183908045977}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-215-4", "text": "Revenues          2005    2004    2003\nEuropean Union    3,543   4,141   4,362\nNorth-America     2,222   1,088    688\nOther countries   1,252    489     811\n                  7,017   5,718   5,861\n", "page_number": 215, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.5198973042362003, "lower_right_x": 0.8124621899576527, "lower_right_y": 0.6024818142918271, "height": 0.08258451005562684, "width": 0.6969147005444646}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-215-5", "text": "Revenues are allocated based on the country in which the customer is located. All of the Group\u2019s assets and capital\nexpenditure (as disclosed per business segment above) are located in the Netherlands.\n", "page_number": 215, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.6260162601626016, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.6534017971758665, "height": 0.02738553701326496, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-215-6", "text": "6. Intangible assets\n", "page_number": 215, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.6910569105691057, "lower_right_x": 0.2764670296430732, "lower_right_y": 0.707744972186564, "height": 0.016688061617458283, "width": 0.16091954022988503}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-215-7", "text": "                           Goodwill   Patents        Other    Total\n                                                intangibles\n\nAt 1 January 2003\nCost                              -         -           11      11\nAccumulated amortisation          -         -           (6)     (6)\nNet book amount                   -         -            5       5\n", "page_number": 215, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.732135216089003, "lower_right_x": 0.8124621899576527, "lower_right_y": 0.8284124946512623, "height": 0.09627727856225932, "width": 0.6969147005444646}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-215-8", "text": "Year ending 31 December 2003\n", "page_number": 215, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.8519469405220368, "lower_right_x": 0.32849364791288566, "lower_right_y": 0.8656397090286693, "height": 0.01369276850663248, "width": 0.2129461584996975}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-215-9", "text": "F- 76\n", "page_number": 215, "bounding_box": {"top_left_x": 0.5075620084694494, "top_left_y": 0.9242618741976893, "lower_right_x": 0.5408348457350273, "lower_right_y": 0.9306803594351734, "height": 0.006418485237484006, "width": 0.03327283726557784}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-216-0", "text": "Opening net book amount                          -         -            5       5\nAdditions                                        -         -           27      27\nAcquisition of subsidiary                     213     1,167              -   1,380\nAmortisation charge                              -         -         (11)     (11)\nClosing net book amount                       213     1,167            21    1,401\nAt 31 December 2003\nCost                                          213     1,167            38    1,418\nAccumulated amortisation                         -         -          (17)    (17)\nNet book amount                               213     1,167            21    1,401\n\n\nYear ending 31 December 2004\nOpening net book amount                       213     1,167            21    1,401\nAdditions (related to 2003 acquisition)        30          -             -     30\nAmortisation charge                              -         -          (10)    (10)\nClosing net book amount                       243     1,167            11    1,421\nAt 31 December 2004\nCost                                          243     1,167            38    1,448\nAccumulated amortisation                         -         -          (27)    (27)\nNet book amount                               243     1,167            11    1,421\n\n\n\n                                          Goodwill   Patents        Other    Total\n                                                               intangibles\nYear ending 31 December 2005\nOpening net book amount                       243     1,167            11    1,421\nAdditions                                        -         -          294     294\nAmortisation charge                              -         -          (10)    (10)\nClosing net book amount                       243     1,167           295    1,705\nAt 31 December 2005\nCost                                          243     1,167           332    1,742\nAccumulated amortisation                         -         -         (37)     (37)\nNet book amount                               243     1,167           295    1,705\n", "page_number": 216, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.12623020967051776, "lower_right_x": 0.809437386569873, "lower_right_y": 0.6880616174582799, "height": 0.5618314077877621, "width": 0.6938898971566848}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-216-1", "text": "Other intangibles consist of acquired software.\n", "page_number": 216, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.7047496790757382, "lower_right_x": 0.411373260738052, "lower_right_y": 0.7180145485665383, "height": 0.01326486949080019, "width": 0.2958257713248639}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-216-2", "text": "The items included under \u201cacquisition of subsidiary\u201d relate to the acquisition of Chienna B.V. at 1 March 2003.\n", "page_number": 216, "bounding_box": {"top_left_x": 0.11675741076830005, "top_left_y": 0.7184424475823705, "lower_right_x": 0.8112522686025408, "lower_right_y": 0.7351305091998288, "height": 0.016688061617458283, "width": 0.6944948578342408}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-216-3", "text": "Patents\n", "page_number": 216, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.7560975609756098, "lower_right_x": 0.1645493042952208, "lower_right_y": 0.7667950363714163, "height": 0.010697475395806566, "width": 0.04900181488203266}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-216-4", "text": "In the years presented in these financial statements, no amortisation on patents is recorded since the technology which the\npatents relate to are not yet available for use. However, the Group estimates at the end of each annual reporting period the\nrecoverable amount of these patents, irrespective of whether there is any indication that it may be impaired.\n", "page_number": 216, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.7732135216089003, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.8147197261446298, "height": 0.04150620453572951, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-216-5", "text": "Impairment test of goodwill and patents\n", "page_number": 216, "bounding_box": {"top_left_x": 0.11796733212341198, "top_left_y": 0.8348309798887462, "lower_right_x": 0.367816091954023, "lower_right_y": 0.848951647411211, "height": 0.01412066752246477, "width": 0.249848759830611}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-216-6", "text": "F- 77\n", "page_number": 216, "bounding_box": {"top_left_x": 0.5075620084694494, "top_left_y": 0.9242618741976893, "lower_right_x": 0.5408348457350273, "lower_right_y": 0.9311082584510055, "height": 0.0068463842533161845, "width": 0.03327283726557784}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-217-0", "text": "For the purpose of the impairment testing, goodwill and patents have been allocated to a cash-generating unit since these\nassets do not generate cash inflows that are largely independent of those from other assets. In the years presented, all\ngoodwill and patents recognised relate to the acquisition of Chienna B.V. in 2003 and are allocated to the Group\u2019s Drug\ndelivery & products unit (see Note 5 on segment information). This business segment is treated as one cash-generating\nunit.\n", "page_number": 217, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.12623020967051776, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.1951219512195122, "height": 0.06889174154899444, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-217-1", "text": "The recoverable amount of this cash-generating unit is determined based on a value-in-use calculation (i.e. the present\nvalue of the future cash flows expected to be derived from the Drug delivery & products unit). The calculation uses cash\nflow projections based on financial plans and existing and potential new customer contracts. No impairment loss has been\nrecognised as a result of the impairment testing of goodwill and patents.\n", "page_number": 217, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.2186563970902867, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.27214377406931967, "height": 0.05348737697903297, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-217-2", "text": "For executing the impairment testing, Management considered the relevant current contracts with its licensing partners, as\nwell as ongoing discussions with potential parties to the extent these contracts provide access to the PolyActive\u2122\ntechnology the Group obtained when acquiring Chienna B.V.\n", "page_number": 217, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.2939666238767651, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.3346170303808301, "height": 0.04065040650406504, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-217-3", "text": "Management reviewed the contracted licensing revenues, the possibility of such revenues actually occurring and the\ntiming thereof. The expected cash flow from this agreement has been discounted against a risk-adjusted discount rate of\n35%. Management has also evaluated the likelihood of successfully completing one of the ongoing discussions regarding\nout-licensing of the PolyActive\u2122 technology based on the proposed terms and conditions. The envisaged cash flow is\nadjusted for probability of success and value of time.\n", "page_number": 217, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.355584082156611, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.4244758237056055, "height": 0.06889174154899447, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-217-4", "text": "The sum of both calculations results in a recoverable amount of the Drug delivery & products unit that significantly\nexceeds the unit\u2019s carrying value, so impairment of goodwill and patents is not considered to be necessary.\n", "page_number": 217, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.44801026957637996, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.472400513478819, "height": 0.024390243902439046, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-217-5", "text": "7. Property, plant and equipment\n", "page_number": 217, "bounding_box": {"top_left_x": 0.1161524500907441, "top_left_y": 0.4959349593495935, "lower_right_x": 0.4016938898971567, "lower_right_y": 0.5100556268720582, "height": 0.014120667522464714, "width": 0.2855414398064126}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-217-6", "text": "                               Land   Buildings   Machines &          Other     Total\n                                                  installations   equipment\nAt 1 January 2003\nCost                              -           -         2,948          927     3,875\nAccumulated depreciation          -           -       (1,311)         (494)   (1,805)\nNet book amount                   -           -         1,637          433     2,070\n\n\n\nYear ending 31 December 2003\nOpening net book amount           -           -         1,637          433     2,070\nAdditions                         -           -           428          282       710\nAcquisition of subsidiary         -           -               -        101       101\nDisposals                         -           -               -           -         -\nDepreciation charge               -           -         (446)         (211)    (657)\nClosing net book amount           -           -         1,619          605     2,224\nAt 31 December 2003\nCost                              -           -         3,376        1,310     4,686\nAccumulated depreciation          -           -       (1,757)         (705)   (2,462)\nNet book amount                   -           -         1,619          605     2,224\n", "page_number": 217, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.5335900727428327, "lower_right_x": 0.8124621899576527, "lower_right_y": 0.8557980316645272, "height": 0.3222079589216945, "width": 0.6969147005444646}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-217-7", "text": "F- 78\n", "page_number": 217, "bounding_box": {"top_left_x": 0.5075620084694494, "top_left_y": 0.9242618741976893, "lower_right_x": 0.5408348457350273, "lower_right_y": 0.9311082584510055, "height": 0.0068463842533161845, "width": 0.03327283726557784}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-218-0", "text": "Year ending 31 December 2004\nOpening net book amount            -       -    1,619       605     2,224\nAdditions                      1,084   2,364    1,111       105     4,664\nDisposals                          -       -         -         -         -\nDepreciation charge                -    (84)    (522)     (244)     (850)\nClosing net book amount        1,084   2,280    2,208       466     6,038\nAt 31 December 2004\nCost                           1,084   2,364    4,466     1,415     9,329\nAccumulated depreciation           -    (84)   (2,258)    (949)    (3,291)\nNet book amount                1,084   2,280    2,208       466     6,038\n\n\nYear ending 31 December 2005\nOpening net book amount        1,084   2,280    2,208       466     6,038\nAdditions                          -       -      814       274     1,088\nDisposals                          -       -         -         -         -\nDepreciation charge                -   (118)    (523)     (212)     (853)\nClosing net book amount        1,084   2,162    2,499       528     6,273\nAt 31 December 2005\nCost                           1,084   2,364    5,280     1,689    10,417\nAccumulated depreciation           -   (202)   (2,781)   (1,161)   (4,144)\nNet book amount                1,084   2,162    2,499       528     6,273\n", "page_number": 218, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.12623020967051776, "lower_right_x": 0.8130671506352087, "lower_right_y": 0.4895164741121095, "height": 0.36328626444159173, "width": 0.6975196612220206}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-218-1", "text": "The items included under \u201cacquisition of subsidiary\u201d relate to the acquisition of Chienna B.V. at 1 March 2003.\n", "page_number": 218, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.513050919982884, "lower_right_x": 0.8112522686025408, "lower_right_y": 0.5267436884895165, "height": 0.01369276850663248, "width": 0.6957047791893527}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-218-2", "text": "In 2004 an item of property, plant and equipment in the category \u201cmachines & installations\u201d was sold for Euro 26. The\nhistorical cost of the item was Euro 21 and it was fully depreciated at the time of sale. Accordingly both \u201ccost\u201d and\n\u201caccumulated depreciation\u201d at 31 December 2004 are reduced by Euro 21.\n", "page_number": 218, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.5472828412494651, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.5883611467693625, "height": 0.04107830551989733, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-218-3", "text": "Acquisition of the assets and liabilities of OctoShed B.V. in 2004\nAt 31 December 2003, OctoShed B.V., a 100% subsidiary of Holthuis-Bernaerts Holding B.V., was the direct parent of\nOctoPlus International Holding B.V.\n", "page_number": 218, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.6101839965768079, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.6538296961916987, "height": 0.04364569961489084, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-218-4", "text": "In 2004, it was decided that the Company should acquire the building as well as the other assets and liabilities of OctoShed\nB.V. On 15 April 2004, OctoShed B.V. sold its shares in OctoPlus International Holding B.V. to Holthuis-Bernaerts\nHolding B.V. On the same date, a subsidiary of the Company, OctoShare B.V. acquired the OctoShed B.V. shares held by\nHolthuis-Bernaerts Holding B.V. Consequently, OctoShed B.V. became a new group company.\n", "page_number": 218, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.6773641420624733, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.7325631151048353, "height": 0.05519897304236199, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-218-5", "text": "This transaction is not considered a business combination but an acquisition of individual assets and liabilities. In the\nGroup\u2019s accounts, the cost of the acquisition of assets and liabilities of OctoShed B.V. is allocated between the individual\nidentifiable assets and liabilities based on their relative fair values at the date of acquisition, obtained through an\nindependent third party valuation. This resulted in Euro 1,084 being allocated to the land, Euro 2,364 being allocated to the\nbuilding and Euro 1,007 being allocated to other equipment (clean rooms).\n", "page_number": 218, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.7526743688489517, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.8215661103979461, "height": 0.06889174154899447, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-218-6", "text": "Shortly after the acquisition of the assets and liabilities of OctoShed B.V., on 28 May 2004, the Company entered into a sale\nand leaseback transaction with two external parties named Zernike Investments Beheer B.V. (\u201cZernike\u201d) and Fortress\n", "page_number": 218, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.8416773641420625, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.8694908001711597, "height": 0.02781343602909714, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-218-7", "text": "F- 79\n", "page_number": 218, "bounding_box": {"top_left_x": 0.5075620084694494, "top_left_y": 0.9242618741976893, "lower_right_x": 0.5408348457350273, "lower_right_y": 0.9311082584510055, "height": 0.0068463842533161845, "width": 0.03327283726557784}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-219-0", "text": "Participations B.V. (\u201cFortress\u201d) for both the permanent ground lease of the land and the building, whereby a distinction was\nmade between the sale of the Zernikedreef building and the land it is built on (Zernike) and the sales of the land next to the\nZernikedreef building (Fortress). However, Zernike and Fortress are two subsidiaries of the same company. From OctoPlus\u2019\nperspective, the entire sale and leaseback agreement is therefore entered into with one external party. The selling price for\nthe building and the land in this transaction was equal to the selling price in the prior transaction with OctoShed B.V.\n", "page_number": 219, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.12623020967051776, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.1951219512195122, "height": 0.06889174154899444, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-219-1", "text": "The lease of the building is accounted for as a finance lease. Furthermore, as a result of the Group\u2019s continuing involvement\nin the land, the land is not derecognised from the balance sheet. Accordingly, the amount received in relation to the land is\nconsidered to be financing and included within \u201cfinance lease liabilities\u201d on the balance sheet.\n", "page_number": 219, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.2186563970902867, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.2584510055626872, "height": 0.03979460847240049, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-219-2", "text": "Finance leases and securities\nProperty, plant and equipment includes the following amounts where the Group is a lessee under finance leases:\n                                                                            2005         2004         2003\nCost \u2013 capitalised finance leases                                          4,261         4,097          357\nAccumulated depreciation                                                    (585)        (358)        (200)\nNet book amount                                                            3,676         3,739          157\n", "page_number": 219, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.28027385537013266, "lower_right_x": 0.8173018753781004, "lower_right_y": 0.37997432605905007, "height": 0.09970047068891741, "width": 0.7017543859649122}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-219-3", "text": "Finance lease liabilities are secured on the assets held under finance leases as the rights to the leased assets revert to the\nlessor in the event of default. Bank overdrafts are secured on other property, plant and equipment with book value at 31\nDecember 2005 of Euro 2,419 (2004: Euro 2,366 and 2003: Euro 2,097) (Note 16).\n", "page_number": 219, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.40350877192982454, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.44330338040222506, "height": 0.03979460847240052, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-219-4", "text": "8. Financial assets carried at cost\n", "page_number": 219, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.48224219084296105, "lower_right_x": 0.396854204476709, "lower_right_y": 0.49550706033376124, "height": 0.01326486949080019, "width": 0.28130671506352084}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-219-5", "text": "                        2005   2004   2003\nBeginning of the year    16      \u2013      \u2013\nAdditions                  -     16     \u2013\nEnd of the year          16      16     \u2013\nNon-current portion     (16)   (16)     \u2013\nCurrent portion            \u2013     \u2013      \u2013\n", "page_number": 219, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.5198973042362003, "lower_right_x": 0.8130671506352087, "lower_right_y": 0.62002567394095, "height": 0.1001283697047497, "width": 0.6975196612220206}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-219-6", "text": "Financial assets carried at cost relate to the investment in Zernike Investments Beheer B.V. Following the acquisition of\nOctoShed B.V. and the subsequent disposal of the property (see Note 7), a Group company became to hold all preference\nshares (90% of issued share capital) of Zernike Investment Beheer B.V. having its legal seat in Maassluis, the Netherlands.\nThis Group company is entitled to a pre-defined share of the profit of Zernike Investment Beheer B.V. However, the\nGroup has no significant influence on Zernike Investment Beheer B.V.\u2019s business and operating policy.\n", "page_number": 219, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.6431322207958922, "lower_right_x": 0.8898971566848155, "lower_right_y": 0.7120239623448866, "height": 0.06889174154899447, "width": 0.7743496672716274}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-219-7", "text": "9. Inventories\n", "page_number": 219, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.7359863072314934, "lower_right_x": 0.2323049001814882, "lower_right_y": 0.7496790757381258, "height": 0.013692768506632369, "width": 0.11675741076830005}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-219-8", "text": "                                  2005    2004    2003\nRaw materials                       15      15      15\n\n\n10. Trade and other receivables\n                                   2005    2004   2003\nTrade receivables                 1,387   1,216    834\n", "page_number": 219, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.7595207531022679, "lower_right_x": 0.8033877797943134, "lower_right_y": 0.8613607188703466, "height": 0.10183996576807874, "width": 0.6878402903811253}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-219-9", "text": "F- 80\n", "page_number": 219, "bounding_box": {"top_left_x": 0.5075620084694494, "top_left_y": 0.9242618741976893, "lower_right_x": 0.5408348457350273, "lower_right_y": 0.9306803594351734, "height": 0.006418485237484006, "width": 0.03327283726557784}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-220-0", "text": "Provision for impairment of receivables              (42)    (42)    (59)\nTrade receivables \u2013 net                             1,345   1,174    775\n\n\n\nReceivables from related parties (Note 31)              -      3    1,003\nNon-current portion:                                    -       -   (908)\nCurrent receivables from related parties                -      3      95\n\n\n\nCorporate income taxes                                  -      6     123\nVAT to be received                                   255      43        -\nPrepaid social security costs                           -       -     53\nSocial security and other taxes                      255      49     176\n\n\n\n                                                    2005    2004    2003\nPrepaid expenses                                     351     181      34\nAccrued income                                       484     319     401\nOther amounts to be received                         330      56     143\nOther receivables, prepayments and accrued income   1,165    556     578\n", "page_number": 220, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.12623020967051776, "lower_right_x": 0.8130671506352087, "lower_right_y": 0.47411210954214805, "height": 0.3478818998716303, "width": 0.6975196612220206}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-220-1", "text": "Accrued income includes Euro 113 (2004: Euro 218 and 2003: Euro 183) related to subsidies.\n", "page_number": 220, "bounding_box": {"top_left_x": 0.1161524500907441, "top_left_y": 0.4925117672229354, "lower_right_x": 0.7011494252873564, "lower_right_y": 0.5066324347454001, "height": 0.014120667522464714, "width": 0.5849969751966122}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-220-2", "text": "The nominal value less impairment provision of trade and other receivables are assumed to approximate their fair values.\n", "page_number": 220, "bounding_box": {"top_left_x": 0.11736237144585603, "top_left_y": 0.5267436884895165, "lower_right_x": 0.8711433756805808, "lower_right_y": 0.5408643560119811, "height": 0.014120667522464658, "width": 0.7537810042347247}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-220-3", "text": "Additions to and releases from the provision for impaired receivables are included in \u201cother costs\u201d in the income\nstatement. However, there was no movement in the provision for impairment of receivables during 2005.\n", "page_number": 220, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.5643988018827557, "lower_right_x": 0.8844525105868118, "lower_right_y": 0.5892169448010269, "height": 0.024818142918271224, "width": 0.7689050211736237}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-220-4", "text": "11. Cash and cash equivalents\n", "page_number": 220, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.6123234916559692, "lower_right_x": 0.37084089534180276, "lower_right_y": 0.6260162601626016, "height": 0.013692768506632369, "width": 0.2552934059286146}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-220-5", "text": "                           2005    2004   2003\nCash at bank and in hand    226      82     20\nShort-term bank deposits   9,500      -      -\n                           9,726     82     20\n", "page_number": 220, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.6328626444159179, "lower_right_x": 0.8124621899576527, "lower_right_y": 0.6974753958065897, "height": 0.0646127513906718, "width": 0.6969147005444646}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-220-6", "text": "The effective interest rate on short-term bank deposits was 2.1% in 2005; these deposits have an average maturity of 30\ndays.\n", "page_number": 220, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.7218656397090286, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.7462558836114677, "height": 0.024390243902439046, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-220-7", "text": "Cash, cash equivalents and bank overdrafts include the following for the purposes of the cash flow statement:\n                                                                            2005          2004          2003\nCash and cash equivalents                                                  9,726            82            20\nBank overdrafts                                                            (496)       (1,758)          (777)\nNet cash and cash equivalents                                              9,230       (1,676)          (757)\n12. Shareholders\u2019 equity\n", "page_number": 220, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.7697903294822422, "lower_right_x": 0.8124621899576527, "lower_right_y": 0.8724860932819855, "height": 0.10269576379974321, "width": 0.6969147005444646}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-220-8", "text": "F- 81\n", "page_number": 220, "bounding_box": {"top_left_x": 0.5075620084694494, "top_left_y": 0.9242618741976893, "lower_right_x": 0.5390199637023594, "lower_right_y": 0.9306803594351734, "height": 0.006418485237484006, "width": 0.03145795523290995}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-221-0", "text": "Share capital\n", "page_number": 221, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.1433461703038083, "lower_right_x": 0.20326678765880218, "lower_right_y": 0.157466837826273, "height": 0.014120667522464686, "width": 0.08771929824561404}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-221-1", "text": "                         Number of issued shares            Share capital (Euro x 1,000)\n                      Ordinary   Class AP    Class BP   Ordinary     Class     Class       Total\n                        shares                            shares       AP        BP\nAt 1 January 2003      46,934           \u2013          \u2013         47         \u2013          \u2013         47\nNew shares issued           \u2013           \u2013          \u2013          \u2013         \u2013          \u2013          \u2013\nAt 31 December 2003    46,934           \u2013          \u2013         47         \u2013          \u2013         47\nNew shares issued           \u2013           \u2013          \u2013          \u2013         \u2013          \u2013          \u2013\nAt 31 December 2004    46,934           \u2013          \u2013         47         \u2013          \u2013         47\nNew shares issued           \u2013      53,752     14,863          \u2013        54         15         69\nAt 31 December 2005    46,934      53,752     14,863         47        54         15        116\n", "page_number": 221, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.16046213093709885, "lower_right_x": 0.8275862068965517, "lower_right_y": 0.329482242190843, "height": 0.16902011125374414, "width": 0.7120387174833636}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-221-2", "text": "The total authorised number of ordinary (\u201cclass C\u201d) shares is 234,760 shares (2004 and 2003: 234,760 shares) with a par\nvalue of Euro 1.00 per share (2004 and 2003: Euro 1.00 per share). All issued ordinary shares are fully paid.\n\n\nThe non-convertible AP shares (\u201cclass A preference shares\u201d) and the BP shares (\u201cclass B preference shares\u201d) were issued\non 19 January 2005 and have a par value of Euro 1.00 per share. The class BP shares were granted on the condition that\nthe holder provided the Group with a subordinated loan of Euro 268.13 multiplied by the number of Class BP preference\nshares received (total of Euro 3,985). The contribution paid in excess of the nominal value of the Class AP preference\nshares is recorded as share premium. All issued preference shares are fully paid.\n", "page_number": 221, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.35216089002995293, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.4689773213521609, "height": 0.11681643132220798, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-221-3", "text": "The AP shares are non-redeemable and have the same voting and dividend entitlements as the ordinary class C shares. The\nBP shares are non-redeemable and have the same voting entitlements as the ordinary class C shares. Out of the profits\nearned in the past financial year, first, if possible, an amount shall be paid to the holders of BP shares at a rate of one per\ncent (1%) of the nominal value of those shares. Any remaining profit is added to each of the profit reserves AP and C in\nproportion to the total nominal values of the issued classes of shares AP and C. In addition to these rights, the holders of\nthe class AP and BP shares are entitled to be repaid their initial investments in the Company before any proceeds from a\nsale of the Company are allocated between the shareholders. Furthermore, the class AP and BP shareholders are prioritised\nover holders of ordinary shares in the event of liquidation of the Company.\n", "page_number": 221, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.4925117672229354, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.6024818142918271, "height": 0.10997004706889174, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-221-4", "text": "No shares are held as treasury shares at 31 December 2003, 2004 and 2005.\n", "page_number": 221, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.6225930680359435, "lower_right_x": 0.588626739261948, "lower_right_y": 0.6358579375267437, "height": 0.01326486949080019, "width": 0.4730792498487598}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-221-5", "text": "Share premium\n", "page_number": 221, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.6568249893025246, "lower_right_x": 0.2159709618874773, "lower_right_y": 0.670517757809157, "height": 0.013692768506632369, "width": 0.10042347247428916}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-221-6", "text": "The total addition to share premium in 2005 amounts to Euro 13.1 million. The share premium paid by the Class AP\nshareholders amounts to Euro 14.4 million (Euro 268.13 multiplied with 53,752 Class AP shares). This amount is reduced\nby Euro 1.2 million of expenses related to the issuance of the preference shares and Euro 0.1 million related to capital tax\non issuance of share capital.\n", "page_number": 221, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.6739409499358151, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.7282841249465126, "height": 0.05434317501069752, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-221-7", "text": "Other reserves\n", "page_number": 221, "bounding_box": {"top_left_x": 0.1161524500907441, "top_left_y": 0.7526743688489517, "lower_right_x": 0.21294615849969753, "lower_right_y": 0.7633718442447582, "height": 0.010697475395806566, "width": 0.09679370840895343}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-221-8", "text": "The costs of share options to employees and Management are recognised in the income statement, together with a\ncorresponding increase in equity during the vesting period, taking into account (deferral of) corporate income taxes. The\naccumulated expense of share options recognised in the income statement is shown separately in the equity category\n\u201cother reserves\u201d in the \u201cconsolidated statement of changes in equity\u201d. In the years presented in these financial statements,\nthe Company did not have any legal or other types of reserves.\n", "page_number": 221, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.7697903294822422, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.8373983739837398, "height": 0.0676080445014976, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-221-9", "text": "Share options\n", "page_number": 221, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.858793324775353, "lower_right_x": 0.20810647307924984, "lower_right_y": 0.8720581942661532, "height": 0.01326486949080019, "width": 0.0925589836660617}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-221-10", "text": "F- 82\n", "page_number": 221, "bounding_box": {"top_left_x": 0.5075620084694494, "top_left_y": 0.9242618741976893, "lower_right_x": 0.5408348457350273, "lower_right_y": 0.9311082584510055, "height": 0.0068463842533161845, "width": 0.03327283726557784}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-222-0", "text": "As part of the shareholders agreement dated 29 December 2004 between the Company and its shareholders, it was agreed to\nreserve 4,283 ordinary shares for the Company\u2019s stock option plan. Under this plan, 3,314 stock options are outstanding at\n31 December 2005 (31 December 2004: 3,765 and 31 December 2003: 1,756).\n", "page_number": 222, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.12623020967051776, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.16773641420624733, "height": 0.04150620453572956, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-222-1", "text": "The exercise price of the granted options is higher than the market price of the shares on the date of the grant. Options are\nconditional on the employee completing a pre-defined number of years service (\u201cthe vesting period\u201d). Each instalment of\nthe Company\u2019s graded vesting awards is treated as a separate share option grant. Consequently, the vesting periods for the\nindividual instalments of the Company\u2019s graded vesting awards vary between 1 and 4 years for options granted after 1\nDecember 2004 and between 0 and 5 years for options granted before 1 December 2004. The options are exercisable from\nthe grant date, but employees that have exercised options and leave the Company during the vesting period are obliged to\nsell the shares which they are entitled to. Furthermore, the proceeds (\u201cthe award\u201d) that the employees receive will have to be\npartially repaid to the Company if the date of leaving is within the vesting periods.\n", "page_number": 222, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.19127086007702182, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.29995721009841675, "height": 0.10868635002139493, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-222-2", "text": "The Group has no legal or constructive obligation to repurchase or settle the options in cash.\n", "page_number": 222, "bounding_box": {"top_left_x": 0.11675741076830005, "top_left_y": 0.32135216089002994, "lower_right_x": 0.6866303690260133, "lower_right_y": 0.3346170303808301, "height": 0.01326486949080019, "width": 0.5698729582577132}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-222-3", "text": "Movements in the number of share options outstanding and their related weighted average exercise prices are as follows:\n", "page_number": 222, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.355584082156611, "lower_right_x": 0.8608590441621294, "lower_right_y": 0.36970474967907574, "height": 0.014120667522464714, "width": 0.7453115547489413}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-222-4", "text": "                        2005                    2004                    2003\n                 Average     Number of   Average     Number of   Average     Number of\n                  exercise     options    exercise     options    exercise     options\n                  price in                price in                price in\n                 Euro per                Euro per                Euro per\n                    share                   share                   share\nAt 1 January       350.06        3,765     358.00        1,756     358.00        1,295\nGranted                 -            -     347.70        2,562     358.00          486\nForfeited          358.00        (116)     358.00        (273)     358.00         (25)\nExercised               -            -          -            -          -            -\nLapsed             358.00        (335)     358.00        (280)          -            -\nAt 31 December     348.98        3,314     350.06        3,765     358.00        1,756\n", "page_number": 222, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.3727000427899016, "lower_right_x": 0.8082274652147611, "lower_right_y": 0.5618314077877621, "height": 0.18913136499786048, "width": 0.6926799758015729}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-222-5", "text": "Share options outstanding at the end of the year have the following expiry year and exercise prices:\n", "page_number": 222, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.5780915703893881, "lower_right_x": 0.7277676950998185, "lower_right_y": 0.5922122379118528, "height": 0.01412066752246477, "width": 0.6122202056866304}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-222-6", "text": "Expiry year   Exercise price in Euro           Share options\n                    per share\n                                       2005              2004   2003\n2004                 358.00                -                -    620\n2005                 358.00               65              491    590\n2006                 358.00              407              432    546\n2007                 371.41              490              490      -\n2008                   -                   -                -      -\n2009                 342.50            2,352            2,352      -\n                                       3,314            3,765   1,756\n", "page_number": 222, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.6157466837826273, "lower_right_x": 0.8082274652147611, "lower_right_y": 0.7766367137355584, "height": 0.1608900299529311, "width": 0.6926799758015729}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-222-7", "text": "For further details on the options with an expiry date in 2005 but still included as outstanding options at 31 December 2005,\nreference is made to Note 32.\n", "page_number": 222, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.7971758664955071, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.8202824133504493, "height": 0.023106546854942178, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-222-8", "text": "No options were granted during 2005. The fair value of options granted during 2004 determined using the Binomial\nvaluation model was Euro 320 (2003: Euro 85). The significant inputs into the model for the options granted in 2004 were\n", "page_number": 222, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.8451005562687206, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.8763371844244758, "height": 0.03123662815575523, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-222-9", "text": "F- 83\n", "page_number": 222, "bounding_box": {"top_left_x": 0.5075620084694494, "top_left_y": 0.9242618741976893, "lower_right_x": 0.5408348457350273, "lower_right_y": 0.9311082584510055, "height": 0.0068463842533161845, "width": 0.03327283726557784}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-223-0", "text": "share prices in the range Euro 269.13 \u2013 284.14 (2003: Euro 285.39 \u2013 299.16) at the grant dates, annual risk-free interest rates\nbetween 2.92% and 3.15% (2003: 3.09% and 3.21%), volatility between 87% and 94% (2003: between 95% and 106%) and no\nexpected dividend yields. The historical volatility used is based on the average of the historical weekly volatility of the peers\nover a period that agrees with the period of maturity. The exercise prices and option lives are disclosed above.\n", "page_number": 223, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.12965340179717585, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.19127086007702182, "height": 0.061617458279845966, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-223-1", "text": "Since the Company is not listed, the share price is not readily available at the valuation date of the share option. The share\nprices used at the grant dates in 2003 and 2004 have been estimated by Management on basis of two valuations that were\nperformed in conjunction with two venture capital rounds. The respective estimated share prices at the dates of these valuations\nwere Euro 314.17 per share in December 2001 and Euro 269.13 per share in December 2004. These valuations were not\nperformed contemporaneously with the option grants, but Management believes that the share price at the grant date is\nappropriately estimated by assuming the share price of the Company decreased linearly between December 2001 and\nDecember 2004.\n", "page_number": 223, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.21181001283697048, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.31835686777920413, "height": 0.10654685494223365, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-223-2", "text": "Warrants\nIn 2003 and 2004 various parties (including employees and Management) guaranteed a loan made by a bank to the Group\nin a total amount of Euro 400 and provided loans to the Group totalling Euro 250. As part of the agreements, these parties\nhad the option to receive an interest of 1.0% per month (based on the amount guaranteed or loan provided) or the lower\ninterest of 0.5% per month and 140 warrants per Euro 100 per month.\n", "page_number": 223, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.34146341463414637, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.41762943945228925, "height": 0.07616602481814289, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-223-3", "text": "In total 3,920 warrants have been granted as part of this arrangement (2003: 560 and 2004: 3,360). The warrants can be\nexercised between 1 June 2004 and 30 November 2008. The exercise price of these warrants was determined at Euro\n550.00. No warrants have been exercised until 31 December 2005.\n", "page_number": 223, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.43774069319640563, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.4818142918271288, "height": 0.04407359863072319, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-223-4", "text": "13. Convertible subordinated loan\n", "page_number": 223, "bounding_box": {"top_left_x": 0.11675741076830005, "top_left_y": 0.5164741121095422, "lower_right_x": 0.40653357531760437, "lower_right_y": 0.5297389816003423, "height": 0.01326486949080008, "width": 0.2897761645493043}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-223-5", "text": "Following the shareholders\u2019 agreement on 29 December 2004, on 19 January 2005, a group of venture capital investors\nparticipated in the Company for an amount of Euro 18,250. In addition to the preference shares issued (see note 12), Euro\n3,985 was provided to the Group as a subordinated convertible loan. The Company does not have an obligation to redeem\nthe loan or to pay interest/dividends, except when normal dividends are paid to the other shareholders. The loan issuer is\nonly entitled to collect any sums pursuant to the loan agreement if and to the extent the (other) investors receive any sums\npursuant to their ownership of Class AP shares in the Company. The total amount of the subordinated convertible loan is\ntherefore classified as equity in the consolidated financial statements.\n", "page_number": 223, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.5370132648694907, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.6332905434317501, "height": 0.09627727856225932, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-223-6", "text": "14. Deferred corporate income taxes\n", "page_number": 223, "bounding_box": {"top_left_x": 0.11675741076830005, "top_left_y": 0.6739409499358151, "lower_right_x": 0.42105263157894735, "lower_right_y": 0.6880616174582799, "height": 0.01412066752246477, "width": 0.3042952208106473}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-223-7", "text": "Deferred corporate income tax assets and liabilities are offset when there is a legally enforceable right to offset current tax\nassets against current tax liabilities and when the deferred corporate income taxes relate to the same fiscal authority. The\noffset amounts are as follows:\n", "page_number": 223, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.6944801026957638, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.7325631151048353, "height": 0.038083012409071526, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-223-8", "text": "                                                      2005   2004   2003\nDeferred corporate income tax assets:\n\u2013 Deferred tax assets to be recovered after 1 year       -      -      -\n\u2013 Deferred tax assets to be recovered within 1 year      -      -      -\n", "page_number": 223, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.7560975609756098, "lower_right_x": 0.8130671506352087, "lower_right_y": 0.8249893025246042, "height": 0.06889174154899447, "width": 0.6975196612220206}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-223-9", "text": "Deferred corporate income tax liabilities:\n", "page_number": 223, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.8451005562687206, "lower_right_x": 0.37749546279491836, "lower_right_y": 0.8557980316645272, "height": 0.010697475395806566, "width": 0.2619479733817302}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-223-10", "text": "F- 84\n", "page_number": 223, "bounding_box": {"top_left_x": 0.5075620084694494, "top_left_y": 0.9238339751818571, "lower_right_x": 0.5420447670901392, "lower_right_y": 0.9311082584510055, "height": 0.007274283269148474, "width": 0.034482758620689724}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-224-0", "text": "\u2013 Deferred tax liabilities to be recovered after 1 year                               -    353      -\n\u2013 Deferred tax liabilities to be recovered within 1 year                              -      -      -\n                                                                                      -    353      -\nNet deferred tax balance at the end of the year                                       -    353      -\n\n\nThe movement on the recognised deferred corporate income tax liability is as follows:\n                                                                             2005         2004   2003\nBeginning of the year                                                          353           -      -\nIncome statement charge/(credit) (Note 24)                                   (353)         353      -\nEnd of the year                                                                   -        353      -\n", "page_number": 224, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.12623020967051776, "lower_right_x": 0.8124621899576527, "lower_right_y": 0.30466409927257165, "height": 0.1784338896020539, "width": 0.6969147005444646}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-224-1", "text": "Deferred corporate income tax assets and liabilities are measured at the (substantially) enacted tax rates that are expected\nto apply to the period when the asset is realised or the liability is settled. For the Group\u2019s deferred corporate tax assets and\nliabilities, realisation is not expected before 2007 and therefore a corporate tax rate of 29.1% is used to calculate the\ndeferred corporate tax assets and liabilities at 31 December 2005 (31 December 2004: 30.0% and 31 December 2003:\n34.5%).\n", "page_number": 224, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.32135216089002994, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.3893881044073599, "height": 0.06803594351732994, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-224-2", "text": "The movement in deferred corporate tax assets and liabilities during the year, without taking into consideration the\noffsetting of balances within the same tax jurisdiction, is as follows:\n", "page_number": 224, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.4103551561831408, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.4381685922122379, "height": 0.02781343602909714, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-224-3", "text": "Deferred corporate tax liabilities:            Deferral of    Other   Total\n                                              gains on sale\n                                                    of PPE\nAt 1 January 2003                                         -       -       -\nCharged /(credited) to the income statement               -       -       -\nAt 31 December 2003                                       -       -       -\nCharged/(credited) to the income statement             481       14    495\nAt 31 December 2004                                    481       14    495\nCharged /(credited) to the income statement           (15)        7     (8)\nAt 31 December 2005                                    466       21    487\n", "page_number": 224, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.4591356439880188, "lower_right_x": 0.7834240774349668, "lower_right_y": 0.6230209670517758, "height": 0.16388532306375697, "width": 0.6678765880217786}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-224-4", "text": "The deferral of gains on sale of property, plant and equipment (\u201cherinvesteringsreserve\u201d) relates to the taxable profit in the\nfiscal unity OctoPlus International Holding B.V. from the sale of a building in 2004. This building was subsequently leased\nback by the Group (see Note 7).\n", "page_number": 224, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.6465554129225503, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.686777920410783, "height": 0.04022250748823275, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-224-5", "text": "Deferred corporate tax assets:               Tax losses   Other   Total\n                                               carried\n                                              forward\nAt 1 January 2003                                     -       -       -\nCredited/(charged) to the income statement            -       -       -\nAt 31 December 2003                                   -       -       -\nCredited/(charged) to the income statement          83       59    142\nAt 31 December 2004                                 83       59    142\nCredited/(charged) to the income statement         298       47    345\n", "page_number": 224, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.7081728712023962, "lower_right_x": 0.7834240774349668, "lower_right_y": 0.8557980316645272, "height": 0.14762516046213092, "width": 0.6678765880217786}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-224-6", "text": "F- 85\n", "page_number": 224, "bounding_box": {"top_left_x": 0.5075620084694494, "top_left_y": 0.9242618741976893, "lower_right_x": 0.5420447670901392, "lower_right_y": 0.9302524604193411, "height": 0.005990586221651717, "width": 0.034482758620689724}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-225-0", "text": "At 31 December 2005   381   106   487\n", "page_number": 225, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.12323491655969192, "lower_right_x": 0.7840290381125227, "lower_right_y": 0.14035087719298245, "height": 0.01711596063329053, "width": 0.6684815486993345}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-225-1", "text": "Deferred corporate income tax assets are recognised for tax loss carry-forwards to the extent that the realisation of the\nrelated tax benefit through the future taxable profits is probable. Currently, there is no expiry date in Dutch tax law related\nto tax loss carry-forwards. The total amounts of tax losses carried forward and corporate deferred tax assets as well as the\namounts of recognised and unrecognised corporate deferred taxes per fiscal unity are as follows:\n", "page_number": 225, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.16388532306375694, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.21780059905862217, "height": 0.05391527599486523, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-225-2", "text": "                                        Tax losses   Deferred tax   Recognised         Not\n                                          carried           asset                recognised\n                                         forward\nAt 31 December 2003\nOctoPlus International Holding B.V. 1           5              2             -           2\n                   2\nOctoShare B.V.                              2,563            884             -         884\n               3\nChienna B.V.                                1,646            558             -         568\n                                            4,214          1,454             -       1,454\nAt 31 December 2004\nOctoPlus International Holding B.V.           277             83           83             -\nOctoShare B.V.                              2,971            891             -         891\nChienna B.V.                                2,900            870             -         870\n                                            6,148          1,844           83        1,761\nAt 31 December 2005\nOctoPlus International Holding B.V.         2,689            781          298          483\nOctoShare B.V.                              2,971            864             -         864\nChienna B.V.                                4,911          1,429             -       1,429\n                                          10,571           3,074          298        2,776\n", "page_number": 225, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.23919554985023533, "lower_right_x": 0.8130671506352087, "lower_right_y": 0.5425759520753102, "height": 0.30338040222507484, "width": 0.6975196612220206}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-225-3", "text": "1\n At 1 March 2004 the fiscal unity OctoShare B.V. was merged with OctoPlus International Holding B.V., forming the fiscal\nunity OctoPlus International Holding B.V. OctoShed B.V. entered the fiscal unity on 16 April 2004 and since this date the\nCompany constitutes a fiscal unity with all of its subsidiaries except for Chienna B.V.\n2\n    Deferred tax losses prior to 1 March 2004\n3\n    Chienna B.V. was acquired on 1 March 2003\n", "page_number": 225, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.5643988018827557, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.6397090286692341, "height": 0.07531022678647836, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-225-4", "text": "15. Pension liabilities\n", "page_number": 225, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.6773641420624733, "lower_right_x": 0.29522081064730793, "lower_right_y": 0.691484809584938, "height": 0.014120667522464658, "width": 0.17967332123411978}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-225-5", "text": "The amounts recognised in the balance sheet for the defined benefit plan are determined as follows:\n", "page_number": 225, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.6979032948224219, "lower_right_x": 0.7307924984875983, "lower_right_y": 0.7120239623448866, "height": 0.01412066752246477, "width": 0.6152450090744102}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-225-6", "text": "                                      2005    2004    2003\nPresent value of funded obligations    924     712     526\nFair value of plan assets             (794)   (566)   (386)\n                                       130     146     140\nUnrecognised actuarial losses          (41)    (15)    (18)\nLiability in the balance sheet          89     131     122\n", "page_number": 225, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.7184424475823705, "lower_right_x": 0.8124621899576527, "lower_right_y": 0.8194266153187848, "height": 0.10098416773641428, "width": 0.6969147005444646}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-225-7", "text": "The amounts recognised in the income statement for the defined benefit plan are as follows:\n", "page_number": 225, "bounding_box": {"top_left_x": 0.11736237144585603, "top_left_y": 0.8382541720154044, "lower_right_x": 0.6817906836055656, "lower_right_y": 0.8523748395378691, "height": 0.014120667522464658, "width": 0.5644283121597096}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-225-8", "text": "F- 86\n", "page_number": 225, "bounding_box": {"top_left_x": 0.5075620084694494, "top_left_y": 0.9242618741976893, "lower_right_x": 0.5408348457350273, "lower_right_y": 0.9311082584510055, "height": 0.0068463842533161845, "width": 0.03327283726557784}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-226-0", "text": "                                                           2005   2004   2003\nCurrent service cost                                         62     83     70\nInterest cost                                                45     39     30\nExpected return on plan assets                             (40)   (31)   (23)\nOther costs                                                  73     80     75\nTotal expense, included in \u201cemployee benefits\u201d (Note 20)   140    171    152\n", "page_number": 226, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.12623020967051776, "lower_right_x": 0.8124621899576527, "lower_right_y": 0.23234916559691912, "height": 0.10611895592640136, "width": 0.6969147005444646}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-226-1", "text": "The actual return on plan assets in 2005 was a loss of Euro 6 (2004: gain of Euro 2 and 2003: loss of Euro 14).\n", "page_number": 226, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.24946512623020967, "lower_right_x": 0.7985480943738656, "lower_right_y": 0.2631578947368421, "height": 0.013692768506632425, "width": 0.6830006049606775}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-226-2", "text": "The movement in the liability recognised in the balance sheet is as follows:\n                                                                                2005     2004    2003\nBeginning of the year                                                            131      122      57\nTotal expense charged to the income statement                                    140      171     152\nContributions (incl. other costs paid)                                          (182)   (162)    (87)\nEnd of the year                                                                   89      131     122\n\n\nThe principal actuarial assumptions used were as follows:\n                                                                                2005     2004    2003\nDiscount rate                                                                  5.00%    5.50%   5.75%\nExpected return on plan assets                                                 5.00%    5.50%   5.75%\nRate of salary increases                                                       2.00%    2.00%   2.00%\nRate of pension benefit increases                                              1.00%    1.50%   1.75%\n", "page_number": 226, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.31792896876337184, "lower_right_x": 0.8124621899576527, "lower_right_y": 0.5408643560119811, "height": 0.22293538724860928, "width": 0.6969147005444646}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-226-3", "text": "Assumptions regarding future mortality experience have been set based on published statistics used by Dutch insurance\ncompanies (\u201ccollectief '93\u201d).\n", "page_number": 226, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.5643988018827557, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.5900727428326915, "height": 0.025673940949935803, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-226-4", "text": "16. Borrowings and finance lease liabilities\n", "page_number": 226, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.6294394522892597, "lower_right_x": 0.47368421052631576, "lower_right_y": 0.6435601198117245, "height": 0.01412066752246477, "width": 0.3581367211131276}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-226-5", "text": "                            2005    2004    2003\n\n\nNon-current portion             -       -   554\nCurrent portion                 -       -   109\nBorrowings                      -       -   663\n\n\nNon-current portion         3,649   3,670     80\nCurrent portion              142     120      80\nFinance lease liabilities   3,791   3,790   160\n", "page_number": 226, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.6670945656824989, "lower_right_x": 0.8130671506352087, "lower_right_y": 0.819854514334617, "height": 0.15275994865211806, "width": 0.6975196612220206}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-226-6", "text": "F- 87\n", "page_number": 226, "bounding_box": {"top_left_x": 0.5075620084694494, "top_left_y": 0.9242618741976893, "lower_right_x": 0.5408348457350273, "lower_right_y": 0.9302524604193411, "height": 0.005990586221651717, "width": 0.03327283726557784}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-227-0", "text": "ABN Amro Bank N.V., current account (see Note 11)   496   1,758     -\nING Bank N.V., current account (see Note 11)          -       -   777\nBank overdrafts                                     496   1,758   777\n", "page_number": 227, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.12623020967051776, "lower_right_x": 0.8082274652147611, "lower_right_y": 0.17458279845956354, "height": 0.048352588789045775, "width": 0.6926799758015729}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-227-1", "text": "Borrowings\n", "page_number": 227, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.1985451433461703, "lower_right_x": 0.19298245614035087, "lower_right_y": 0.21138211382113822, "height": 0.01283697047496793, "width": 0.07743496672716273}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-227-2", "text": "The amount included under borrowings at 31 December 2003 is a Euro loan issued by ING Bank N.V. This loan was\nguaranteed by the Dutch government for 90% of the nominal amount. The duration was 12 years and the interest was\nfixed. As from April 2003 the interest was fixed at 4.8%. The redemption was Euro 28 per quarter, starting at 1 October\n2001. The total remaining loan balance was early redeemed in 2004.\n", "page_number": 227, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.21181001283697048, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.27000427899015833, "height": 0.058194266153187846, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-227-3", "text": "Finance lease liabilities\n", "page_number": 227, "bounding_box": {"top_left_x": 0.11796733212341198, "top_left_y": 0.290543431750107, "lower_right_x": 0.26799758015728975, "lower_right_y": 0.30124090714591356, "height": 0.010697475395806566, "width": 0.15003024803387777}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-227-4", "text": "                                                                  2005      2004    2003\nFinance lease liabilities \u2013 minimum lease payments:\nNo later than 1 year                                               500       467      81\nBetween 1 and 5 years                                            1,693     1,632      88\nLater than 5 years                                               5,311     5,615       -\n                                                                 7,504     7,714    169\nFuture finance charges on finance leases                        (3,713)   (3.924)    (9)\nPresent value of finance lease liabilities                       3,791     3,790    160\n\n\nThe present value of finance lease liabilities is as follows:\nNo later than 1 year                                               142       120      80\nBetween 1 and 5 years                                              384       322      80\nLater than 5 years                                               3,265     3,348       -\n                                                                 3,791     3,790    160\n", "page_number": 227, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.3076593923833975, "lower_right_x": 0.8124621899576527, "lower_right_y": 0.5477107402652974, "height": 0.2400513478818999, "width": 0.6969147005444646}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-227-5", "text": "Lease liabilities are effectively secured by the lessor as the rights to the leased asset revert to the lessor in the event of\ndefault.\n", "page_number": 227, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.5712451861360719, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.5956354300385109, "height": 0.024390243902439046, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-227-6", "text": "Bank overdrafts\n", "page_number": 227, "bounding_box": {"top_left_x": 0.11736237144585603, "top_left_y": 0.62002567394095, "lower_right_x": 0.21960072595281308, "lower_right_y": 0.6332905434317501, "height": 0.01326486949080008, "width": 0.10223835450695705}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-227-7", "text": "The Company\u2019s subsidiary OctoPlus Development B.V., utilises a current account lending facility with ABN Amro Bank\nN.V. amounting to Euro 2.0 million for working capital and investment purposes. The following securities have been\nprovided by OctoPlus Development B.V.:\n", "page_number": 227, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.6397090286692341, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.6777920410783055, "height": 0.038083012409071415, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-227-8", "text": "-   Pledge on equipment (book value at 31 December 2005: Euro 2,419 and 31 December 2004: Euro 2,366);\n-   Pledge on inventories and receivables (book value at 31 December 2005: Euro 1,360 and 31 December 2004:\n    Euro 1,158);\n-   Joint and several liability of OctoPlus International Holding B.V.;\n-   In addition, the financing agreement included a covenant which required the shareholders\u2019 equity of OctoPlus\n    Development B.V. to exceed 25% of its balance sheet total. No breaches of this covenant have occurred during\n    2003, 2004 and 2005.\n", "page_number": 227, "bounding_box": {"top_left_x": 0.14458560193587416, "top_left_y": 0.6842105263157895, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.7907573812580231, "height": 0.1065468549422336, "width": 0.7410768300060495}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-227-9", "text": "The carrying amounts of short-term borrowings (bank overdrafts) approximate their fair values.\n", "page_number": 227, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.8108686350021395, "lower_right_x": 0.7150635208711433, "lower_right_y": 0.8249893025246042, "height": 0.01412066752246477, "width": 0.5995160314579552}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-227-10", "text": "Effective interest rates and borrowing facilities\n", "page_number": 227, "bounding_box": {"top_left_x": 0.11857229280096794, "top_left_y": 0.8451005562687206, "lower_right_x": 0.4150030248033878, "lower_right_y": 0.8592212237911853, "height": 0.014120667522464658, "width": 0.29643073200241987}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-227-11", "text": "F- 88\n", "page_number": 227, "bounding_box": {"top_left_x": 0.5075620084694494, "top_left_y": 0.9242618741976893, "lower_right_x": 0.5408348457350273, "lower_right_y": 0.9311082584510055, "height": 0.0068463842533161845, "width": 0.03327283726557784}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-228-0", "text": "The effective interest rates at the balance sheet date were as follows:\n", "page_number": 228, "bounding_box": {"top_left_x": 0.11675741076830005, "top_left_y": 0.12623020967051776, "lower_right_x": 0.5468844525105868, "lower_right_y": 0.13692768506632436, "height": 0.010697475395806594, "width": 0.4301270417422868}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-228-1", "text": "                            2005   2004   2003\nBank overdrafts             4.5%   4.5%   3.1%\nFinance lease liabilities   9.1%   8.9%   5.7%\n", "page_number": 228, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.16046213093709885, "lower_right_x": 0.8033877797943134, "lower_right_y": 0.20881471972614463, "height": 0.048352588789045775, "width": 0.6878402903811253}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-228-2", "text": "At 31 December 2003, the Group utilised a current account lending facility with ING Bank N.V. amounting to Euro 831.\nThe Group\u2019s only borrowing facility at 31 December 2004 and 2005 is the current account lending facility of OctoPlus\nDevelopment B.V. amounting to Euro 2.0 million referred to above. The undrawn borrowing facility at the balance sheet\ndate was as follows:\n", "page_number": 228, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.23234916559691912, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.28412494651262304, "height": 0.05177578091570392, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-228-3", "text": "                                                2005    2004   2003\nUndrawn borrowing facility (at floating rate)   1,504   242      54\n", "page_number": 228, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.3076593923833975, "lower_right_x": 0.8033877797943134, "lower_right_y": 0.3384681215233205, "height": 0.030808729139922997, "width": 0.6878402903811253}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-228-4", "text": "F- 89\n", "page_number": 228, "bounding_box": {"top_left_x": 0.5075620084694494, "top_left_y": 0.9242618741976893, "lower_right_x": 0.5408348457350273, "lower_right_y": 0.9311082584510055, "height": 0.0068463842533161845, "width": 0.03327283726557784}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-229-0", "text": "17. Trade and other payables\n", "page_number": 229, "bounding_box": {"top_left_x": 0.11796733212341198, "top_left_y": 0.12623020967051776, "lower_right_x": 0.3623714458560194, "lower_right_y": 0.14291827128797605, "height": 0.016688061617458283, "width": 0.2444041137326074}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-229-1", "text": "                                                       2005    2004    2003\n\nTrade payables                                         1,491   1,079    909\n\n\nNon-current amounts due to related parties (Note 31)       -    161     161\nCurrent amounts due to related parties (Note 31)           -       -    150\nDebt to related parties                                    -    161     311\n\n\nCorporate income taxes                                    2        -       -\nWage taxes                                              204     194      78\nAccrued social security costs                            33      27      21\nSocial security and other taxes                         239     221      99\n\n\n\nSubsidies received in advance (Note 18)                 853     821        -\nDeferred income                                         147     766     551\nPrepayments by customers                                745     844     320\nAccrued expenses                                        831     641     592\nOther amounts to be paid                                 67     145     537\n                                                       2,643   3,217   2,000\nNon-current portion: Deferred income                       -    (30)       -\nOther current liabilities                              2,643   3,187   2,000\n", "page_number": 229, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.1433461703038083, "lower_right_x": 0.8130671506352087, "lower_right_y": 0.5237483953786907, "height": 0.38040222507488236, "width": 0.6975196612220206}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-229-2", "text": "18. Income from subsidies and other income\n", "page_number": 229, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.5643988018827557, "lower_right_x": 0.4839685420447671, "lower_right_y": 0.5785194694052204, "height": 0.014120667522464658, "width": 0.3684210526315789}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-229-3", "text": "Income from subsidies\n", "page_number": 229, "bounding_box": {"top_left_x": 0.11736237144585603, "top_left_y": 0.5986307231493367, "lower_right_x": 0.25650332728372655, "lower_right_y": 0.6127513906718015, "height": 0.01412066752246477, "width": 0.1391409558378705}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-229-4", "text": "OctoPlus Technologies B.V. started a development project in the year 2001 of which the expected cost approximate Euro\n7,432. For this project, SenterNovem, the department of the Ministry of Economic Affairs responsible for subsidies, has\ngranted a technical development credit of 35% of the amounts spent between 30 January 2001 and 31 March 2005, which\nequals an amount of Euro 2,601. The partnership with SenterNovem for this project has been terminated in 2005 and the\nGroup will finance the remaining amounts internally.\n", "page_number": 229, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.6191698759092854, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.6880616174582799, "height": 0.06889174154899447, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-229-5", "text": "Further conditions with regard to the repayment of the technical development credit have been stipulated by SenterNovem\nand are dependent of net turnover resulting from this development project. Based on the contract with SenterNovem, the\nfollowing redemption conditions have been agreed:\n", "page_number": 229, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.7081728712023962, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.7496790757381258, "height": 0.04150620453572951, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-229-6", "text": "-   Annually before 27 February of the following calendar year, during the development period and further from 2005\n    and during a maximum of 10 calendar years, an amount equal to 35% of the royalty fees and entrance fees\n    resulting or derived from the development project.\n-   Within four weeks after receiving the final decision concerning the magnitude of the grant: 35% of the proceeds\n    obtained by sale or otherwise of a null series, prototype, parts hereof or from other assets that have been financed\n    by this grant.\n", "page_number": 229, "bounding_box": {"top_left_x": 0.14458560193587416, "top_left_y": 0.7526743688489517, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.8386820710312366, "height": 0.08600770218228493, "width": 0.7410768300060495}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-229-7", "text": "F- 90\n", "page_number": 229, "bounding_box": {"top_left_x": 0.5075620084694494, "top_left_y": 0.9238339751818571, "lower_right_x": 0.5408348457350273, "lower_right_y": 0.9311082584510055, "height": 0.007274283269148474, "width": 0.03327283726557784}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-230-0", "text": "-   Within four weeks after receiving the final decision concerning the magnitude of the grant: 35% of the value of the\n    assets financed with the grant and still can be used and are not used for the production of rendering services\n    resulting from the grant.\n", "page_number": 230, "bounding_box": {"top_left_x": 0.14458560193587416, "top_left_y": 0.12623020967051776, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.16773641420624733, "height": 0.04150620453572956, "width": 0.7410768300060495}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-230-1", "text": "The contract described above is the only subsidy contract of any OctoPlus legal entity with redemption conditions; i.e. a part\nof potential future revenues needs to be paid to SenterNovem. The total subsidy received has been recognised as \u201cincome\nfrom subsidies\u201d since it is non-refundable. A liability for the royalty fees will only be recognised when such payments\nbecome probable.\n", "page_number": 230, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.19127086007702182, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.24304664099272572, "height": 0.051775780915703895, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-230-2", "text": "In 2002 a development project was commenced in association with Diatos S.A. (France). OctoPlus Technologies\u2019 share of\nthe estimated costs amounts to Euro 1,925. SenterNovem has granted Euro 1,155 subsidy for this project. The Group will\nfinance the remainder.\n", "page_number": 230, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.26658108686350024, "lower_right_x": 0.8898971566848155, "lower_right_y": 0.3042362002567394, "height": 0.03765511339323918, "width": 0.7743496672716274}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-230-3", "text": "In 2003 a development project was initiated in association with CytImmune Sciences Inc. (USA). OctoPlus Technologies\u2019\nshare of the estimated cost amounts to Euro 2,007. SenterNovem has granted Euro 1,204 subsidy to this project. The Group\nfinances the remainder of these costs. On 22 December 2004 OctoPlus and CytImmune Sciences Inc. agreed to terminate\ntheir collaboration in this project.\n", "page_number": 230, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.3281985451433462, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.38339751818570816, "height": 0.05519897304236199, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-230-4", "text": "In 2004 in collaboration with the Thorax Centre of Erasmus University (Rotterdam, the Netherlands) OctoPlus\nTechnologies B.V. commenced a 3-year research project for a novel approach to treat myocardial regeneration. Total costs\nof this project approximate Euro 3,250. SenterNovem has granted a subsidy of Euro 2,000 in order to relieve OctoPlus\nTechnologies B.V.\u2019s and Erasmus University\u2019s burden in the costs. OctoPlus will finance the costs that exceed the Euro\n2,000 subsidy. An advance of 25% of the total subsidy (Euro 500) was received by OctoPlus in December 2004 and is\nrecorded as \u201csubsidies received in advance\u201d under \u201cother current liabilities\u201d on the balance sheet at 31 December 2004 and\n31 December 2005 (Note 17).\n", "page_number": 230, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.40350877192982454, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.49978605049208386, "height": 0.09627727856225932, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-230-5", "text": "In 2004, OctoPlus Technologies B.V., in partnership with Utrecht University (Utrecht, the Netherlands), initiated a study for\na second-generation drug delivery technology. For this study, a total subsidy of Euro 1,413 has been granted of which Euro\n897 is allocated to OctoPlus Technologies B.V. (being 70% of its estimated expenditures) and Euro 516 is allocated to\nUtrecht University (being 60% of its estimated expenditures). The project is expected to run over a period of 3 years. An\nadvance of 25% of the total subsidy (Euro 353) was received by OctoPlus in December 2004 and is recorded as \u201csubsidies\nreceived in advance\u201d under \u201cother current liabilities\u201d on the balance sheet at 31 December 2004 and 31 December 2005\n(Note 17).\n", "page_number": 230, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.5233204963628584, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.6187419768934531, "height": 0.09542148053059474, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-230-6", "text": "In 2005, a development project was carried out in association with InnoCore Technologies B.V. The total estimated project\ncosts amount to Euro 122 and OctoPlus Technologies B.V.\u2019s share of the total project costs was Euro 54. SenterNovem\ngranted in total Euro 50 in subsidy to this project.\n", "page_number": 230, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.6397090286692341, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.6812152332049636, "height": 0.04150620453572951, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-230-7", "text": "Other income\n", "page_number": 230, "bounding_box": {"top_left_x": 0.1161524500907441, "top_left_y": 0.7047496790757382, "lower_right_x": 0.20326678765880218, "lower_right_y": 0.714163457424048, "height": 0.00941377834830981, "width": 0.08711433756805809}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-230-8", "text": "Other income of Euro 26 in 2004 relates to a gain on sale of property, plant and equipment. No items were recorded as other\nincome in 2003 and 2005.\n", "page_number": 230, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.7218656397090286, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.7449721865639709, "height": 0.02310654685494229, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-230-9", "text": "19. Raw materials and auxiliaries and costs of contracted work\nThe costs included in raw materials and auxiliaries are the materials used in production for customers. Costs of contracted\nwork and other external charges include costs related to clinical studies, toxicology studies and other purchased research and\ndevelopment costs.\n", "page_number": 230, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.7869062901155327, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.8480958493795464, "height": 0.061189559264013704, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-230-10", "text": "F- 91\n", "page_number": 230, "bounding_box": {"top_left_x": 0.5075620084694494, "top_left_y": 0.9242618741976893, "lower_right_x": 0.5390199637023594, "lower_right_y": 0.9311082584510055, "height": 0.0068463842533161845, "width": 0.03145795523290995}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-231-0", "text": "20. Employee benefits\n", "page_number": 231, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.12623020967051776, "lower_right_x": 0.3000604960677556, "lower_right_y": 0.14291827128797605, "height": 0.016688061617458283, "width": 0.18451300665456744}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-231-1", "text": "                                                             2005    2004    2003\nWages and salaries                                           3,994   3,063   2,938\nSocial security costs                                         462     318     349\nShare options granted to directors and employees (Note 12)    132      23       5\nPension costs \u2013 defined contribution plans                     30      22       6\nPension costs \u2013 defined benefit plans (Note 15)               140     171     152\n                                                             4,758   3,597   3,450\n\n\nNumber of employees at 31 December                            110      93      91\n", "page_number": 231, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.1433461703038083, "lower_right_x": 0.8130671506352087, "lower_right_y": 0.31792896876337184, "height": 0.17458279845956354, "width": 0.6975196612220206}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-231-2", "text": "The wages and salaries are net of WBSO subsidies of Euro 337 (2004: Euro 312 and 2003: Euro 320).\n", "page_number": 231, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.3384681215233205, "lower_right_x": 0.7489413188142771, "lower_right_y": 0.35258878904578517, "height": 0.014120667522464658, "width": 0.6333938294010889}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-231-3", "text": "21. Other costs\n", "page_number": 231, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.3898160034231921, "lower_right_x": 0.24682395644283123, "lower_right_y": 0.40350877192982454, "height": 0.013692768506632425, "width": 0.13127646702964307}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-231-4", "text": "                            2005    2004    2003\nHousing costs                540     485     785\nProduction costs             957     663     758\nOffice expenses              224     153     189\nSelling & Marketing costs    715     550     358\nGeneral expenses             538     385     683\nOther personnel costs       1,239    431     502\n                            4,213   2,667   3,275\n", "page_number": 231, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.4274711168164313, "lower_right_x": 0.8124621899576527, "lower_right_y": 0.5614035087719298, "height": 0.1339323919554985, "width": 0.6969147005444646}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-231-5", "text": "In general, other costs have increased due to an increase in staff and activities of the Company. This is shown in particular\nin other personnel costs in 2005 by an increase of costs related to temporary employees, recruiting and training of\npersonnel.\n", "page_number": 231, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.6020539152759948, "lower_right_x": 0.8898971566848155, "lower_right_y": 0.6435601198117245, "height": 0.04150620453572962, "width": 0.7743496672716274}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-231-6", "text": "Housing costs in 2003 were significantly higher than in 2004 and 2005 as the company owning the building (OctoShed\nB.V.) was not part of the Group. The resulting operating lease charges are included under housing costs. Following the\nsale and leaseback transaction in 2004, as described under note 7, the Group entered into a finance lease agreement and the\nmonthly rental charges for the building are recorded under depreciation and amortisation and interest charges from then\nonwards.\n", "page_number": 231, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.6636713735558408, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.7325631151048353, "height": 0.06889174154899447, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-231-7", "text": "For leases where the Group is a lessee under operating leases, lease rentals amounting to Euro 233 (2004: Euro 109 and\n2003: Euro 22) are included in \u201cother costs\u201d in the 2005 income statement.\n", "page_number": 231, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.7560975609756098, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.7804878048780488, "height": 0.024390243902439046, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-231-8", "text": "22. Research and development costs\n", "page_number": 231, "bounding_box": {"top_left_x": 0.1161524500907441, "top_left_y": 0.8211382113821138, "lower_right_x": 0.4204476709013914, "lower_right_y": 0.8348309798887462, "height": 0.013692768506632369, "width": 0.3042952208106473}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-231-9", "text": "The costs directly attributable to research and development (as required disclosed under the Group\u2019s accounting policies)\nrecognised as costs in the income statement were as follows:\n", "page_number": 231, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.8451005562687206, "lower_right_x": 0.8838475499092558, "lower_right_y": 0.8729139922978177, "height": 0.02781343602909714, "width": 0.7683000604960677}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-231-10", "text": "F- 92\n", "page_number": 231, "bounding_box": {"top_left_x": 0.5075620084694494, "top_left_y": 0.9242618741976893, "lower_right_x": 0.5408348457350273, "lower_right_y": 0.9311082584510055, "height": 0.0068463842533161845, "width": 0.03327283726557784}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-232-0", "text": "                                                        2005    2004    2003\nDirect research and non-capitalised development costs   3,378   2,261   1,945\n", "page_number": 232, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.1433461703038083, "lower_right_x": 0.8033877797943134, "lower_right_y": 0.17458279845956354, "height": 0.03123662815575523, "width": 0.6878402903811253}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-232-1", "text": "The Group\u2019s total costs related to research and development including indirect costs are Euro 5.8 million (2005), Euro 3.7\nmillion (2004) and Euro 3.3 million (2003).\n", "page_number": 232, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.19811724433033803, "lower_right_x": 0.882637628554144, "lower_right_y": 0.22250748823277705, "height": 0.02439024390243902, "width": 0.7670901391409558}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-232-2", "text": "23. Interest income and interest costs\n                                                2005    2004    2003\n Interest income:\n - Bank deposits                                 287        -       -\n - Current accounts                                 -     18      77\n                                                 287      18      77\n Interest expense:\n - Bank borrowings, overdrafts and other debt    (44)   (200)    (94)\n - Finance leases                               (361)   (212)    (12)\n                                                (405)   (412)   (106)\n Finance costs \u2013 net                            (118)   (394)    (29)\n\n\n\n24. Corporate income taxes\n                                                2005    2004    2003\n Current corporate income taxes                     -       -       -\n Deferred corporate income taxes (Note 14)       353    (353)       -\n Tax (charge)/income                             353    (353)       -\n", "page_number": 232, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.2631578947368421, "lower_right_x": 0.8130671506352087, "lower_right_y": 0.5785194694052204, "height": 0.3153615746683783, "width": 0.6975196612220206}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-232-3", "text": "The tax on the Group\u2019s profit before tax differs from the theoretical amount that would arise using the statutory corporate\nincome tax rate in the Netherlands of 31.5% (2004 and 2003: 34.5%) to profits of the consolidated companies as follows:\n", "page_number": 232, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.6020539152759948, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.629867351305092, "height": 0.02781343602909714, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-232-4", "text": "                                                                2005      2004      2003\nResult before corporate income tax                            (4,562)   (2,177)   (2,236)\nTax calculated at domestic tax rates applicable to profits     1,437       751       771\nIncome not subject to tax                                           -         -         -\nExpenses not deductible for tax purposes                            -         -         -\nDeferred tax liability on fiscal reserve for re-investments      481     (481)          -\nUtilisation of previously unrecognised tax losses                   -         -         -\nDeferred income tax assets not recognised (tax losses)        (1,565)    (623)     (771)\nTax (charge)/income                                              353     (353)          -\n", "page_number": 232, "bounding_box": {"top_left_x": 0.12522686025408347, "top_left_y": 0.6499786050492083, "lower_right_x": 0.8124621899576527, "lower_right_y": 0.8031664527171587, "height": 0.15318784766795035, "width": 0.6872353297035693}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-232-5", "text": "F- 93\n", "page_number": 232, "bounding_box": {"top_left_x": 0.5075620084694494, "top_left_y": 0.9242618741976893, "lower_right_x": 0.5408348457350273, "lower_right_y": 0.9311082584510055, "height": 0.0068463842533161845, "width": 0.03327283726557784}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-233-0", "text": "25. Earnings per share\n", "page_number": 233, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.12623020967051776, "lower_right_x": 0.30973986690865096, "lower_right_y": 0.14291827128797605, "height": 0.016688061617458283, "width": 0.1941923774954628}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-233-1", "text": "Basic\n", "page_number": 233, "bounding_box": {"top_left_x": 0.11736237144585603, "top_left_y": 0.1668806161745828, "lower_right_x": 0.15486993345432548, "lower_right_y": 0.17586649550706032, "height": 0.00898587933247752, "width": 0.037507562008469456}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-233-2", "text": "Basic earnings per share is calculated by dividing the profit attributable to equity holders of the Company by the weighted\naverage number of shares outstanding during the year.\n", "page_number": 233, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.1810012836970475, "lower_right_x": 0.8850574712643678, "lower_right_y": 0.20881471972614463, "height": 0.02781343602909714, "width": 0.7695099818511797}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-233-3", "text": "The class AP and BP shares issued in 2005 are non-convertible preference shares with a par value of Euro 1.00 per share\n(i.e. the same par value as the existing class C ordinary shares). The holders of these shares do not have right to fixed\npreference dividends. However, out of the profits earned in the past financial year, first, if possible, an amount shall be\npaid to the holders of BP shares at a rate of one per cent (1%) of the nominal value of those shares. In addition the holders\nof the BP shares will receive interest on the subordinated convertible loan if and to the extent dividends are paid to the\nholders of class AP shares. Therefore the total amounts received by the holders of class BP shares become identical to the\ndividend percentage received by the class AP shareholders.\n", "page_number": 233, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.23234916559691912, "lower_right_x": 0.8850574712643678, "lower_right_y": 0.3423192126658109, "height": 0.10997004706889177, "width": 0.7695099818511797}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-233-4", "text": "Class AP and BP shares have been included in the weighted average number of shares from 19 January 2005 (see Note 12).\n", "page_number": 233, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.36243046640992727, "lower_right_x": 0.8802177858439202, "lower_right_y": 0.3748395378690629, "height": 0.012409071459135612, "width": 0.764670296430732}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-233-5", "text": "                                                         2005      2004      2003\nResult attributable to equity holders of the Company   (4,209)   (2,530)   (2,236)\n\n\nWeighted average number of ordinary class C shares      46,934   46,934    46,934\nWeighted average number of class AP shares              50,954         -         -\nWeighted average number of class BP shares              14,089         -         -\n                                                       111,977   46,934    46,934\n\n\nBasic earnings per share (Euro per share)              (37.59)   (53.91)   (47.64)\n", "page_number": 233, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.39666238767650835, "lower_right_x": 0.8124621899576527, "lower_right_y": 0.5498502353444588, "height": 0.1531878476679504, "width": 0.6969147005444646}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-233-6", "text": "Diluted\n", "page_number": 233, "bounding_box": {"top_left_x": 0.1161524500907441, "top_left_y": 0.5712451861360719, "lower_right_x": 0.1675741076830006, "lower_right_y": 0.5815147625160462, "height": 0.010269576379974277, "width": 0.0514216575922565}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-233-7", "text": "Diluted\nDiluted earnings per share is calculated by adjusting the weighted average number of ordinary shares outstanding to assume\nconversion of all dilutive potential ordinary shares. The convertible subordinated debt does not represent potential ordinary\nshares since the holder is not entitled to ordinary shares in addition to the class BP shares issued in 2005 (Note 12). The\nCompany has therefore two categories of dilutive potential ordinary shares: Share options and warrants.\n", "page_number": 233, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.5819426615318785, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.6435601198117245, "height": 0.061617458279845994, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-233-8", "text": "For all years included in these financial statements, the share options and warrants are not included in the diluted earnings\nper share calculation as the Group was loss-making and the share options and warrants were \u201cout-of-the-money\u201d for all\nthree years (i.e. the exercise prices are higher than the estimated average price of the ordinary shares). Consequently basic\nand diluted earning per share are the same.\n", "page_number": 233, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.6636713735558408, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.7188703465982028, "height": 0.05519897304236199, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-233-9", "text": "26. Dividends per share\n", "page_number": 233, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.7595207531022679, "lower_right_x": 0.3194192377495463, "lower_right_y": 0.772785622593068, "height": 0.01326486949080019, "width": 0.20387174833635813}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-233-10", "text": "The Company did not declare dividends for any of the years presented in these consolidated financial statements.\n", "page_number": 233, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.7800599058622165, "lower_right_x": 0.8130671506352087, "lower_right_y": 0.7907573812580231, "height": 0.010697475395806566, "width": 0.6975196612220206}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-233-11", "text": "F- 94\n", "page_number": 233, "bounding_box": {"top_left_x": 0.5075620084694494, "top_left_y": 0.9242618741976893, "lower_right_x": 0.5420447670901392, "lower_right_y": 0.9306803594351734, "height": 0.006418485237484006, "width": 0.034482758620689724}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-234-0", "text": "27. Cash flow statement\n", "page_number": 234, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.12623020967051776, "lower_right_x": 0.3194192377495463, "lower_right_y": 0.14035087719298245, "height": 0.014120667522464686, "width": 0.20387174833635813}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-234-1", "text": "In the cash flow statement, purchases of property, plant and equipment comprise:\n", "page_number": 234, "bounding_box": {"top_left_x": 0.1161524500907441, "top_left_y": 0.16388532306375694, "lower_right_x": 0.6194797338173019, "lower_right_y": 0.17800599058622166, "height": 0.014120667522464714, "width": 0.5033272837265579}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-234-2", "text": "                                             2005      2004    2003\nAdditions according to Note 7                1,088    4,664    710\nOf which finance leases (non-cash)           (164)   (3,740)      -\nPurchases of property, plant and equipment    924       924    710\n", "page_number": 234, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.181857081728712, "lower_right_x": 0.8124621899576527, "lower_right_y": 0.2503209242618742, "height": 0.06846384253316218, "width": 0.6969147005444646}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-234-3", "text": "In the cash flow statement, proceeds from sale of property, plant and equipment comprise:\n                                                                            2005            2004   2003\nNet book amount (Note 7)                                                        -              -      -\nGain on sale of property, plant and equipment                                   -             26      -\nProceeds from sale of property, plant and equipment                             -             26      -\n\n\nIn the cash flow statement, proceeds from issuance of shares comprise:\n                                                                            2005            2004   2003\nIssue of share capital                                                    13,199               -      -\nConverted loan from Statutory Director (Note 31)                           (161)               -      -\nProceeds from issuance of shares                                          13,038               -      -\n", "page_number": 234, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.2507488232777065, "lower_right_x": 0.8124621899576527, "lower_right_y": 0.45785194694052206, "height": 0.20710312366281558, "width": 0.6969147005444646}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-234-4", "text": "28. Contingencies\n", "page_number": 234, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.4993581514762516, "lower_right_x": 0.26497277676951, "lower_right_y": 0.5134788189987163, "height": 0.014120667522464658, "width": 0.14942528735632182}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-234-5", "text": "Contingent consideration\n", "page_number": 234, "bounding_box": {"top_left_x": 0.1191772534785239, "top_left_y": 0.5198973042362003, "lower_right_x": 0.2807017543859649, "lower_right_y": 0.5305947796320069, "height": 0.010697475395806566, "width": 0.161524500907441}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-234-6", "text": "As a result of the acquisition of Chienna B.V. in 2003, the Group is obliged to make certain milestone payments up to 3\nyears after the acquisition date (1 March 2003) and has profit-sharing obligations during the patents terms. Up to 31\nDecember 2005, milestone payments amounting to Euro 30 have been made. This resulted in a corresponding adjustment\nof goodwill in 2004. No profit-sharing payments have been made up to 31 December 2005. If and when profit-sharing\npayments have to be made during the remainder of the patents terms is uncertain and dependent on the commercial success\nof the Chienna technology.\n", "page_number": 234, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.5370132648694907, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.6187419768934531, "height": 0.08172871202396237, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-234-7", "text": "Subsidies\n", "page_number": 234, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.6397090286692341, "lower_right_x": 0.17906836055656383, "lower_right_y": 0.6504065040650406, "height": 0.010697475395806566, "width": 0.06352087114337569}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-234-8", "text": "For the development project which started in 2001 (expected cost approximates Euro 7,432), repayment of the technical\ndevelopment subsidy from SenterNovem is dependent on the net turnover resulting from this development project. Further\ndetails on these conditions are provided in Note 18.\n", "page_number": 234, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.6568249893025246, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.6983311938382541, "height": 0.04150620453572951, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-234-9", "text": "Royalties\n", "page_number": 234, "bounding_box": {"top_left_x": 0.1161524500907441, "top_left_y": 0.7201540436456996, "lower_right_x": 0.17906836055656383, "lower_right_y": 0.7325631151048353, "height": 0.012409071459135723, "width": 0.06291591046581974}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-234-10", "text": "The Group is obliged to pay royalties to Utrecht University for revenues received based on the OctoDEX\u2122 technology\nplatform. Such royalties shall not exceed 2% of such revenues. Furthermore, Leiden University Medical Centre is entitled to\ncertain royalty revenues. Depending on the cumulative revenues, the royalties vary from 30% for cumulative revenues less\nEuro 15 million to 12.5% once cumulative revenues have exceeded Euro 30 million.\n", "page_number": 234, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.7389816003423192, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.7903294822421908, "height": 0.051347881899871606, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-234-11", "text": "F- 95\n", "page_number": 234, "bounding_box": {"top_left_x": 0.5075620084694494, "top_left_y": 0.9242618741976893, "lower_right_x": 0.5420447670901392, "lower_right_y": 0.9311082584510055, "height": 0.0068463842533161845, "width": 0.034482758620689724}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-235-0", "text": "29. Commitments\n", "page_number": 235, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.12623020967051776, "lower_right_x": 0.2655777374470659, "lower_right_y": 0.14035087719298245, "height": 0.014120667522464686, "width": 0.15003024803387777}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-235-1", "text": "Capital commitments\nAt the balance sheet dates 31 December 2003, 2004 and 2005 there are no capital expenditures contracted for but not yet\nincurred.\n", "page_number": 235, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.1647411210954215, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.20539152759948653, "height": 0.04065040650406504, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-235-2", "text": "Operating lease commitments\nThe Group leases various plant and machinery under operating lease agreements. The lease expenditure charged to the\nincome statement during the year is disclosed in Note 7.\n", "page_number": 235, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.21523320496362858, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.25673940949935814, "height": 0.04150620453572956, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-235-3", "text": "The future aggregate minimum lease payments under non-cancellable operating leases are as follows:\n", "page_number": 235, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.28027385537013266, "lower_right_x": 0.7483363581367211, "lower_right_y": 0.2939666238767651, "height": 0.013692768506632425, "width": 0.6327888687235329}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-235-4", "text": "                                              2005   2004   2003\nNo later than 1 year                          165     209   509\nLater than 1 year and no later than 5 years     35    72      57\nLater than 5 years                              93    100      -\n                                              293     381   566\n", "page_number": 235, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.3110825845100556, "lower_right_x": 0.8124621899576527, "lower_right_y": 0.3902439024390244, "height": 0.0791613179289688, "width": 0.6969147005444646}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-235-5", "text": "30. Business combinations\n", "page_number": 235, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.43774069319640563, "lower_right_x": 0.338777979431337, "lower_right_y": 0.44843816859221225, "height": 0.010697475395806622, "width": 0.22323049001814882}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-235-6", "text": "There were no business combinations effected during the years ending 31 December 2004 and 2005. For the business\ncombination effected in 2003, please refer to Note 33 on \u201cadoption of IFRS\u201d.\n", "page_number": 235, "bounding_box": {"top_left_x": 0.11675741076830005, "top_left_y": 0.4582798459563543, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.4843816859221224, "height": 0.026101839965768092, "width": 0.7689050211736237}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-235-7", "text": "31. Related-party transactions\n", "page_number": 235, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.5233204963628584, "lower_right_x": 0.37265577737447064, "lower_right_y": 0.5391527599486521, "height": 0.015832263585793704, "width": 0.2571082879612825}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-235-8", "text": "a) Shareholders\n", "page_number": 235, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.5609756097560976, "lower_right_x": 0.21718088324258925, "lower_right_y": 0.5738125802310655, "height": 0.012836970474967901, "width": 0.1016333938294011}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-235-9", "text": "At 31 December 2003, OctoShed B.V. was the direct parent of the Company (holder of 68% of the shares) and Holthuis-\nBernaerts Holding B.V. the ultimate controlling party (holder of 100% of the shares in OctoShed B.V.). On 15 April 2004,\nOctoShed B.V. sold its shares in OctoPlus International Holding B.V. to Holthuis-Bernaerts Holding B.V.\n", "page_number": 235, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.5780915703893881, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.6195977749251177, "height": 0.04150620453572962, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-235-10", "text": "Following the changes in shareholders in 2005, no individual party controls the Company. However, Holthuis-Bernaerts\nHolding B.V. has significant influence over the Company (27% of the voting rights). For further details on the changes in\nshareholders in 2005, reference is made to Note 12 and 13.\n", "page_number": 235, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.6397090286692341, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.6812152332049636, "height": 0.04150620453572951, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-235-11", "text": "The following transactions were carried out with the shareholders:\n", "page_number": 235, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.7047496790757382, "lower_right_x": 0.5275257108287962, "lower_right_y": 0.7154471544715447, "height": 0.010697475395806566, "width": 0.411978221415608}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-235-12", "text": "Transactions                                     2005   2004   2003\nSale of services, royalty and license revenues     60     60      -\nPurchases of goods and services                     -   140    481\n", "page_number": 235, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.7389816003423192, "lower_right_x": 0.8033877797943134, "lower_right_y": 0.787334189131365, "height": 0.0483525887890458, "width": 0.6878402903811253}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-235-13", "text": "The \u201cpurchases of goods and services\u201d relate to rental of office space from the direct parent of the Company, OctoShed\nB.V., until 15 April 2004. At this date the Company purchased the building from OctoShed B.V. For further details on this\ntransaction, reference is made to Note 7.\n", "page_number": 235, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.8074454428754814, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.8476679503637141, "height": 0.04022250748823275, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-235-14", "text": "F- 96\n", "page_number": 235, "bounding_box": {"top_left_x": 0.5075620084694494, "top_left_y": 0.9242618741976893, "lower_right_x": 0.5408348457350273, "lower_right_y": 0.9311082584510055, "height": 0.0068463842533161845, "width": 0.03327283726557784}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-236-0", "text": "Services are negotiated with related parties on an arm\u2019s length basis.\n", "page_number": 236, "bounding_box": {"top_left_x": 0.11736237144585603, "top_left_y": 0.12623020967051776, "lower_right_x": 0.543254688445251, "lower_right_y": 0.14035087719298245, "height": 0.014120667522464686, "width": 0.425892316999395}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-236-1", "text": "Receivables                                       2005   2004   2003\nLoan to OctoShed B.V.                                -      -   908\nCurrent account OctoShed B.V.                        -      -     94\nCurrent account Holthuis-Bernaerts Holding B.V.      -     3      1\n", "page_number": 236, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.16046213093709885, "lower_right_x": 0.8033877797943134, "lower_right_y": 0.22593068035943517, "height": 0.06546854942233632, "width": 0.6878402903811253}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-236-2", "text": "As a part of the restructuring of the group in 2004, OctoShed B.V. has become a new group company (Note 7). Accordingly,\nthe loan included in the balance sheet at 31 December 2003 has become an intra-group loan, which was eliminated upon\nconsolidation.\n", "page_number": 236, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.24946512623020967, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.28712023962344885, "height": 0.03765511339323918, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-236-3", "text": "Loans from shareholders\n", "page_number": 236, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.3110825845100556, "lower_right_x": 0.28433151845130067, "lower_right_y": 0.3217800599058622, "height": 0.010697475395806622, "width": 0.16878402903811252}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-236-4", "text": "2005\n", "page_number": 236, "bounding_box": {"top_left_x": 0.6188747731397459, "top_left_y": 0.3110825845100556, "lower_right_x": 0.6563823351482153, "lower_right_y": 0.3217800599058622, "height": 0.010697475395806622, "width": 0.037507562008469386}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-236-5", "text": "2004\n", "page_number": 236, "bounding_box": {"top_left_x": 0.6969147005444646, "top_left_y": 0.3110825845100556, "lower_right_x": 0.7301875378100423, "lower_right_y": 0.3217800599058622, "height": 0.010697475395806622, "width": 0.033272837265577726}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-236-6", "text": "2003\n", "page_number": 236, "bounding_box": {"top_left_x": 0.7689050211736237, "top_left_y": 0.3110825845100556, "lower_right_x": 0.8033877797943134, "lower_right_y": 0.3217800599058622, "height": 0.010697475395806622, "width": 0.034482758620689724}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-236-7", "text": "7X Life Science Fund B.V. (Note 17)\n", "page_number": 236, "bounding_box": {"top_left_x": 0.11675741076830005, "top_left_y": 0.3281985451433462, "lower_right_x": 0.35329703569267995, "lower_right_y": 0.3418913136499786, "height": 0.013692768506632425, "width": 0.2365396249243799}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-236-8", "text": "150\n", "page_number": 236, "bounding_box": {"top_left_x": 0.779794313369631, "top_left_y": 0.3281985451433462, "lower_right_x": 0.8033877797943134, "lower_right_y": 0.33889602053915274, "height": 0.010697475395806566, "width": 0.023593466424682408}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-236-9", "text": "", "page_number": 236, "bounding_box": {"top_left_x": 0.6497277676950998, "top_left_y": 0.3329054343175011, "lower_right_x": 0.6563823351482153, "lower_right_y": 0.337612323491656, "height": 0.004706889174154905, "width": 0.006654567453115545}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-236-10", "text": "", "page_number": 236, "bounding_box": {"top_left_x": 0.720508166969147, "top_left_y": 0.3329054343175011, "lower_right_x": 0.7295825771324864, "lower_right_y": 0.337612323491656, "height": 0.004706889174154905, "width": 0.00907441016333943}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-236-11", "text": "7X Life Sciences Fund granted the Company a loan that was redeemable per 30 November 2004 and carried 5% interest per\nannum. The loan was fully redeemed in 2004. As additional compensation for this loan, 7X Life Science Fund B.V. received\n1,260 warrants in the Company (see Note 12).\n", "page_number": 236, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.36243046640992727, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.40393667094565683, "height": 0.04150620453572956, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-236-12", "text": "b) Supervisory Directors and Statutory Directors\n", "page_number": 236, "bounding_box": {"top_left_x": 0.11796733212341198, "top_left_y": 0.4240479246897732, "lower_right_x": 0.41984271022383546, "lower_right_y": 0.4381685922122379, "height": 0.014120667522464714, "width": 0.3018753781004235}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-236-13", "text": "The remuneration of the Supervisory Directors amounts to Euro 15 (2004: Euro 40 and 2003: \u20ac 39). The remuneration of\nthe individual members of the Supervisory Board is set out in the table below:\n", "page_number": 236, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.44458707744972187, "lower_right_x": 0.8638838475499092, "lower_right_y": 0.4689773213521609, "height": 0.024390243902439046, "width": 0.7483363581367211}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-236-14", "text": "                             Base    Other   2005    2004    2003\n                            salary           Total   Total   Total\nH. Stellingsma (Chairman)      15        -     15      11      11\nR. Kuijten                       -       -       -       -       -\nP. Toon                          -       -       -       -       -\nPh. Smith                        -       -       -       -       -\nFormer members                   -       -       -     29      28\n                               15        -     15      40      39\n", "page_number": 236, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.4890885750962773, "lower_right_x": 0.8124621899576527, "lower_right_y": 0.6170303808301241, "height": 0.12794180573384678, "width": 0.6969147005444646}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-236-15", "text": "Mr. Stellingsma guaranteed a loan made by a bank to the Group in a total amount of Euro 150 from 1 December 2003 to 31\nMay 2004. This guarantee terminated on 31 May 2004. As compensation for this guarantee, Mr. Stellingsma received an\ninterest rate of 1.0% per month.\n", "page_number": 236, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.6431322207958922, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.6812152332049636, "height": 0.038083012409071415, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 16, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-236-16", "text": "The remuneration of Statutory Directors amounts to Euro 263 (2004: Euro 199 and 2003: Euro 180). The remuneration of\nthe individual members of the Board of Management is set out in the table below:\n", "page_number": 236, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.7047496790757382, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.7325631151048353, "height": 0.02781343602909714, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 17, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-236-17", "text": "                        Base    Bonus   Pensions   Other   2005   2004   2003\n                       salary\nJ.J.M. Holthuis, CEO     175       41        20       22   258    199    180\nJ.C.H.L. Pauli, CFO      125       11        10        -   146    122      63\n                         300       52        30       22   404    321    243\n", "page_number": 236, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.7458279845956355, "lower_right_x": 0.8124621899576527, "lower_right_y": 0.8249893025246042, "height": 0.07916131792896874, "width": 0.6969147005444646}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 18, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-236-18", "text": "Mr. Pauli was appointed to Statutory Director on 22 December 2004. The remuneration of Mr. Pauli in 2003 and 2004 was\ntherefore not received in the position of Statutory Director of the Company.\n", "page_number": 236, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.8485237483953787, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.8750534873769791, "height": 0.02652973898160038, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 19, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-236-19", "text": "F- 97\n", "page_number": 236, "bounding_box": {"top_left_x": 0.5075620084694494, "top_left_y": 0.9238339751818571, "lower_right_x": 0.5408348457350273, "lower_right_y": 0.9311082584510055, "height": 0.007274283269148474, "width": 0.03327283726557784}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-237-0", "text": "The remuneration of Statutory Directors results in the following costs in the income statement related to key management\ncompensation:\n", "page_number": 237, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.1433461703038083, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.17115960633290545, "height": 0.02781343602909714, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-237-1", "text": "                                                  2005   2004   2003\nSalaries and other short-term employee benefits   443    321    264\nPost-employment benefits                            30     20     5\nShare-based payments                                56     4      1\n                                                  529    345    270\n\n\n\nLoans from Statutory Directors                    2005   2004   2003\nJ.J.M. Holthuis, Chief Executive Officer             -   161    161\n", "page_number": 237, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.1750106974753958, "lower_right_x": 0.8130671506352087, "lower_right_y": 0.3281985451433462, "height": 0.15318784766795038, "width": 0.6975196612220206}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-237-2", "text": "The loan provided by Mr. Holthuis was converted into 598 preference shares with a share price of Euro 269.13 as part of the\nprivate offering of the Company\u2019s securities in 2005 (see Note 12 and below).\n", "page_number": 237, "bounding_box": {"top_left_x": 0.1161524500907441, "top_left_y": 0.34873769790329484, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.376551133932392, "height": 0.02781343602909714, "width": 0.7695099818511797}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-237-3", "text": "Statutory Directors\u2019 interests in the Company\n", "page_number": 237, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.40008557980316645, "lower_right_x": 0.4204476709013914, "lower_right_y": 0.41420624732563116, "height": 0.014120667522464714, "width": 0.30490018148820325}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-237-4", "text": "e Statutory Directors\u2019 own shares and have share options and warrant rights in the Company as follows:\n", "page_number": 237, "bounding_box": {"top_left_x": 0.1397459165154265, "top_left_y": 0.417201540436457, "lower_right_x": 0.7743496672716274, "lower_right_y": 0.42961061189559263, "height": 0.012409071459135612, "width": 0.6346037507562008}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-237-5", "text": "", "page_number": 237, "bounding_box": {"top_left_x": 0.11675741076830005, "top_left_y": 0.41805733846812154, "lower_right_x": 0.132486388384755, "lower_right_y": 0.4206247325631151, "height": 0.002567394094993569, "width": 0.015728977616454934}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-237-6", "text": "he\n", "page_number": 237, "bounding_box": {"top_left_x": 0.13309134906231096, "top_left_y": 0.4184852374839538, "lower_right_x": 0.13914095583787053, "lower_right_y": 0.4274711168164313, "height": 0.00898587933247752, "width": 0.006049606775559574}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-237-7", "text": "                       Shares   Options   Warrants\nAt 31 December 2003\nJ.J.M. Holthuis, CEO   30,172         -          -\nJ.C.H.L. Pauli, CFO         -      200         210\n                       30,172      200         210\n\n\nAt 31 December 2004\nJ.J.M. Holthuis, CEO   30,172      735           -\nJ.C.H.L. Pauli, CFO         -      571       1,260\n                       30,172     1,306      1,260\n\n\nAt 31 December 2005\nJ.J.M. Holthuis, CEO   30,895      735           -\nJ.C.H.L. Pauli, CFO      379       571       1,260\n                       31,274     1,306      1,260\n", "page_number": 237, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.4514334617030381, "lower_right_x": 0.8130671506352087, "lower_right_y": 0.7086007702182285, "height": 0.25716730851519043, "width": 0.6975196612220206}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-237-8", "text": "Shares\n", "page_number": 237, "bounding_box": {"top_left_x": 0.1161524500907441, "top_left_y": 0.732135216089003, "lower_right_x": 0.1645493042952208, "lower_right_y": 0.7428326914848096, "height": 0.010697475395806566, "width": 0.0483968542044767}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-237-9", "text": "Mr. Holthuis holds 30,895 shares in the Company through Holthuis-Bernaerts Holding B.V. (100% owned by Mr. Holthuis)\nand Mr. Pauli holds 379 shares in the Company at 31 December 2005 (2004 and 2003: 0 shares).\n", "page_number": 237, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.7492511767222936, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.7770646127513907, "height": 0.02781343602909714, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-237-10", "text": "Share options\n", "page_number": 237, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.7971758664955071, "lower_right_x": 0.20810647307924984, "lower_right_y": 0.8112965340179717, "height": 0.014120667522464658, "width": 0.0925589836660617}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-237-11", "text": "J.J.M. Holthuis, CEO, holds 735 share options (31 December 2004: 735 and 31 December 2003: 0 share options) in the\nCompany at an exercise price of Euro 342.50. These options expire on 29 December 2009.\n", "page_number": 237, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.8142918271287976, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.8421052631578947, "height": 0.02781343602909714, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-237-12", "text": "F- 98\n", "page_number": 237, "bounding_box": {"top_left_x": 0.5075620084694494, "top_left_y": 0.9242618741976893, "lower_right_x": 0.5408348457350273, "lower_right_y": 0.9311082584510055, "height": 0.0068463842533161845, "width": 0.03327283726557784}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-238-0", "text": "J.C.H.L. Pauli, CFO, holds share options in the Company as follows:\n", "page_number": 238, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.12623020967051776, "lower_right_x": 0.5408348457350273, "lower_right_y": 0.14035087719298245, "height": 0.014120667522464686, "width": 0.4252873563218391}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-238-1", "text": "                        2005                    2004                    2003\n                 Average     Number of   Average     Number of   Average     Number of\n                  exercise     options    exercise     options    exercise     options\n                  price in                price in                price in\n                 Euro per                Euro per                Euro per\n                    share                   share                   share\nAt 1 January       347.93          571     358.00          200     358.00          200\nGranted                              -     342.50          371                       -\nForfeited                            -                       -                       -\nExercised                            -                       -                       -\nLapsed                               -                       -                       -\nAt 31 December                     571     347.93          571     358.00          200\n", "page_number": 238, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.16046213093709885, "lower_right_x": 0.8082274652147611, "lower_right_y": 0.34873769790329484, "height": 0.188275566966196, "width": 0.6926799758015729}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-238-2", "text": "The outstanding share options held by Mr. Pauli expire as follows: 75 options on 31 January 2006, 125 options on 24\nDecember 2006 and 371 options 29 December 2009. On 31 January 2006 Mr. Pauli exercised 75 share options with an\nexercise price of Euro 358.00 per share (Note 32).\n", "page_number": 238, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.36927685066324345, "lower_right_x": 0.8850574712643678, "lower_right_y": 0.40949935815147626, "height": 0.040222507488232806, "width": 0.7695099818511797}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-238-3", "text": "Warrants\n", "page_number": 238, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.43089430894308944, "lower_right_x": 0.1839080459770115, "lower_right_y": 0.441591784338896, "height": 0.010697475395806566, "width": 0.06836055656382335}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-238-4", "text": "In addition to stock options, Mr. Pauli holds a total of 1,260 warrants (31 December 2004: 1,260 and 31 December 2003: 210)\nin the Company at an exercise price of Euro 550. Mr. Pauli guaranteed a loan made by a bank to the Group in a total amount\nof Euro 150 during the period 1 December 2003 to 31 May 2004. This loan was repaid on 31 May 2004. As compensation\nfor this guarantee, Mr. Pauli received an interest rate of 0.5% per month and a total of 1,260 warrants in the Company (see\nNote 12).\n", "page_number": 238, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.44801026957637996, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.5169020111253744, "height": 0.06889174154899441, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-238-5", "text": "32. Events after the balance sheet date\n", "page_number": 238, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.5545571245186136, "lower_right_x": 0.44041137326073804, "lower_right_y": 0.5682498930252461, "height": 0.01369276850663248, "width": 0.3248638838475499}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-238-6", "text": "Equity transactions\n", "page_number": 238, "bounding_box": {"top_left_x": 0.11796733212341198, "top_left_y": 0.5780915703893881, "lower_right_x": 0.24198427102238354, "lower_right_y": 0.5887890457851946, "height": 0.010697475395806566, "width": 0.12401693889897156}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-238-7", "text": "In 2005, 65 share options with an exercise price of Euro 358.00 per share were exercised. However, the formal registration of\nthe share issuance did not take place until 1 March 2006. The related 65 share options have therefore been included as\noutstanding options at 31 December 2005 (Note 12).\n", "page_number": 238, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.5952075310226786, "lower_right_x": 0.8898971566848155, "lower_right_y": 0.6332905434317501, "height": 0.038083012409071415, "width": 0.7743496672716274}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-238-8", "text": "In addition, 225 share options with an exercise price of Euro 358.00 per share were exercised on 31 January 2006. However,\nthe formal registration of the share issuance has not yet taken place.\n", "page_number": 238, "bounding_box": {"top_left_x": 0.1161524500907441, "top_left_y": 0.6568249893025246, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.6846384253316218, "height": 0.02781343602909714, "width": 0.7695099818511797}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-238-9", "text": "33. Adoption of IFRS\n", "page_number": 238, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.7218656397090286, "lower_right_x": 0.3000604960677556, "lower_right_y": 0.7376979032948224, "height": 0.015832263585793815, "width": 0.18451300665456744}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-238-10", "text": "The Group has adopted International Financial Reporting Standards (\"IFRS\"), including International Accounting Standards\n(\"IAS\") and interpretations issued by the International Accounting Standards Board (\"IASB\") as adopted by the EU (\"EU-\nIFRS\"), as its primary accounting basis for the consolidated financial statements as from 1 January 2005. For the Group,\nthere are no differences between EU-IFRS and IFRS since the carve-out sections are not applicable to the Group.\n", "page_number": 238, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.7424047924689773, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.7976037655113393, "height": 0.05519897304236199, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-238-11", "text": "Until 2004, the Group prepared its consolidated financial statements in accordance with Generally Accepted Accounting\nPrinciples in the Netherlands (\"Dutch GAAP\"). Since the Group has decided to provide comparative figures for 2003 and\n2004, the transition date to IFRS is 1 January 2003. The Group converted the 2003 and 2004 financial information in the\nconsolidated financial statements to IFRS for comparison purposes.\n", "page_number": 238, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.8177150192554558, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.8729139922978177, "height": 0.05519897304236199, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-238-12", "text": "F- 99\n", "page_number": 238, "bounding_box": {"top_left_x": 0.5075620084694494, "top_left_y": 0.9238339751818571, "lower_right_x": 0.5408348457350273, "lower_right_y": 0.9311082584510055, "height": 0.007274283269148474, "width": 0.03327283726557784}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-239-0", "text": "Transition to IFRS: IFRS 1 exemptions and exceptions\n", "page_number": 239, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.1433461703038083, "lower_right_x": 0.4543254688445251, "lower_right_y": 0.157466837826273, "height": 0.014120667522464686, "width": 0.338777979431337}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-239-1", "text": "IFRS 1, First-time Adoption of International Financial Reporting Standards requires the Group to determine its accounting\npolicies according to IFRS and apply these retrospectively to determine its consolidated opening balance sheet under IFRS\nat the date of transition (1 January 2003). However, IFRS 1 allows a number of optional exemptions as well as requires the\napplication of a number of mandatory exceptions to this general principle. The exemptions and exceptions are set out below,\nincluding a short description of the choices made by the Group.\n", "page_number": 239, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.16046213093709885, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.2293538724860933, "height": 0.06889174154899444, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-239-2", "text": "Employee benefits (IAS 19)\n", "page_number": 239, "bounding_box": {"top_left_x": 0.11796733212341198, "top_left_y": 0.25288831835686776, "lower_right_x": 0.28554143980641256, "lower_right_y": 0.26572528883183566, "height": 0.012836970474967901, "width": 0.16757410768300057}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-239-3", "text": "The Group elected the exemption not to retrospectively recalculate the pension liabilities under IAS 19 Employee Benefits.\nAccordingly all cumulative actuarial gains and losses in relation to the employee benefit plan were recognised directly in\nequity at 1 January 2003.\n", "page_number": 239, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.26615318784766795, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.3102267864783911, "height": 0.04407359863072313, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-239-4", "text": "Share-based payments (IFRS 2)\n", "page_number": 239, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.33162173727000427, "lower_right_x": 0.31276467029643074, "lower_right_y": 0.3453145057766367, "height": 0.013692768506632425, "width": 0.19721718088324258}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-239-5", "text": "In accordance with IFRS 1, the Group has only expensed share options that are granted after 7 November 2002 and vested\nafter 1 January 2005. For other options granted, only additional disclosures have been provided.\n", "page_number": 239, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.345742404792469, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.3761232349165597, "height": 0.030380830124090707, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-239-6", "text": "Other IFRS 1\n", "page_number": 239, "bounding_box": {"top_left_x": 0.1161524500907441, "top_left_y": 0.3975181857081729, "lower_right_x": 0.19721718088324258, "lower_right_y": 0.4073598630723149, "height": 0.009841677364142043, "width": 0.08106473079249849}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-239-7", "text": "1 exemptions and exceptions\n", "page_number": 239, "bounding_box": {"top_left_x": 0.19782214156079855, "top_left_y": 0.3975181857081729, "lower_right_x": 0.37265577737447064, "lower_right_y": 0.41078305519897307, "height": 0.01326486949080019, "width": 0.1748336358136721}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-239-8", "text": "The following exemptions in IFRS 1 regarding retrospectively application of the Group\u2019s accounting policies under IFRS,\n", "page_number": 239, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.41377834830979887, "lower_right_x": 0.8850574712643678, "lower_right_y": 0.4330338040222507, "height": 0.019255455712451852, "width": 0.7695099818511797}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-239-9", "text": "were not applied by or are not applicable to the Group:\n-   Business combinations (IFRS 3);\n-   Fair value or revaluation as deemed cost (IAS 16);\n-   Cumulative translation differences (IAS 21);\n-   Compound financial instruments (IAS 32/39);\n-   Transition dates for subsidiaries, associates and joint ventures (IAS 28/31);\n-   Designation of previously recognised financial instruments (IAS 32/39);\n-   Insurance contracts (IFRS 4);\n-   Comparatives for financial instruments (IAS 32 and IAS 39);\n-   Changes in existing decommissioning, restoration and similar liabilities included in the cost of property, plant and\n    equipment (IFRIC 1);\n-   Arrangements containing leases (IFRIC 4);\n-   Fair value measurement of \u201cno active market\u201d financial assets and financial liabilities (IAS 32/39); and\n-   Exploration and evaluation assets (IFRS 6).\n", "page_number": 239, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.433461703038083, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.6640992725716731, "height": 0.2306375695335901, "width": 0.7701149425287356}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-239-10", "text": "IFRS 1 prohibits retrospective application of some aspects of other IFRS standards relating to:\n-   Derecognition of financial assets and financial liabilities (IAS 32/39);\n-   Hedge accounting (IAS 32/39);\n-   Estimates (IAS 8) ; and\n-   Assets classified as held for sale and discontinued operations (IFRS 5).\n", "page_number": 239, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.685066324347454, "lower_right_x": 0.6963097398669087, "lower_right_y": 0.7680787334189131, "height": 0.08301240907145913, "width": 0.5807622504537205}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-239-11", "text": "In accordance with the IFRS 1 provision regarding estimates, which is the only of the four mandatory exceptions applicable\nto the Group, estimates under IFRS at the date of transition to IFRS (1 January 2003) are consistent with estimates made for\nthe same date under Dutch GAAP. Both existing estimates under Dutch GAAP and new estimates under IFRS reflect\nconditions that existed at the date of transition to IFRS and do not reflect any subsequent new information.\n", "page_number": 239, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.7903294822421908, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.8446726572528883, "height": 0.05434317501069752, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-239-12", "text": "F- 100\n", "page_number": 239, "bounding_box": {"top_left_x": 0.5075620084694494, "top_left_y": 0.9242618741976893, "lower_right_x": 0.5480943738656987, "lower_right_y": 0.9311082584510055, "height": 0.0068463842533161845, "width": 0.04053236539624927}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-240-0", "text": "Key Impact on 2003 and 2004 financial information\nReconciliation of the result for 2004 and 2003 reported in the Dutch GAAP consolidated financial statements to the result\nfor the year under IFRS:\n", "page_number": 240, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.12665810868635002, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.17115960633290545, "height": 0.04450149764655542, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-240-1", "text": "                                                                2004      2003\nResult for the year (before changes in accounting policies)   (1,083)   (1,421)\nBusiness combinations                                             146        60\nIntangible assets                                               (188)      (67)\nRevenue recognition                                             (165)     (131)\nEmployee benefits                                                (24)         -\nLeases                                                              -       (1)\nShare-based payments                                             (23)       (5)\nCorporate income taxes                                        (1,193)     (671)\nResult for the year (after changes in accounting policies)    (2,530)   (2,236)\n", "page_number": 240, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.1775780915703894, "lower_right_x": 0.7658802177858439, "lower_right_y": 0.3252032520325203, "height": 0.14762516046213092, "width": 0.6503327283726558}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-240-2", "text": "Reconciliation of the Group\u2019s shareholders\u2019 equity as reported in the consolidated financial statements under Dutch GAAP\nto its shareholders\u2019 equity under IFRS at 1 January 2003 and 31 December 2003 and 2004:\n", "page_number": 240, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.3418913136499786, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.36970474967907574, "height": 0.02781343602909714, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-240-3", "text": "                                                 31 Dec. 2004 31 Dec. 2003    1 Jan. 2003\nEquity (before changes in accounting policies)          1,243        2,326          3,747\nBusiness combinations                                     159            60               -\nIntangible assets                                       (582)        (394)           (327)\nRevenue recognition                                       (42)         123             254\nEmployee benefits                                         (75)         (51)           (51)\nLeases (incl. sale and leaseback transaction)           (509)           (3)             (2)\nCorporate income taxes                                (1,550)        (910)           (239)\nEquity (after changes in accounting policies)         (1,356)        1,151          3,382\n", "page_number": 240, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.3761232349165597, "lower_right_x": 0.7658802177858439, "lower_right_y": 0.5091998288403937, "height": 0.13307659392383403, "width": 0.6503327283726558}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-240-4", "text": "Presentation\n", "page_number": 240, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.5267436884895165, "lower_right_x": 0.19782214156079855, "lower_right_y": 0.5370132648694907, "height": 0.010269576379974277, "width": 0.08227465214761041}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-240-5", "text": "In general, adoption of IFRS did not result in significant changes to the presentation of the Consolidated balance sheet,\nIncome statement, Cash flow statement or the Consolidated statement of changes in equity.\n", "page_number": 240, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.543859649122807, "lower_right_x": 0.8850574712643678, "lower_right_y": 0.5708172871202396, "height": 0.02695763799743256, "width": 0.7695099818511797}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-240-6", "text": "However, the presentation and classification of accrued service revenue has changed under IFRS compared to Dutch GAAP.\nThe revenue from services included in the line item \u201cChange in Work in Progress\u201d in the Dutch GAAP financial statements\nhas been reclassified to \u201cService revenues\u201d in the IFRS financial statements. Furthermore, the work in progress balance\nregarding the rendering of services, as presented under Dutch GAAP, is effectively a receivable (accrued revenues) from the\ncustomers and not inventory. Therefore, the work in progress balance in the IFRS balance sheet is presented under accrued\nrevenues (within \u201cother receivables, prepayments and accrued income\u201d) or deferred revenues (within \u201cother current\nliabilities\u201d) in the IFRS financial statements and not under \u201cInventory\u201d.\n", "page_number": 240, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.5917843388960206, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.6876337184424476, "height": 0.09584937954642703, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-240-7", "text": "Business combinations\n", "page_number": 240, "bounding_box": {"top_left_x": 0.1161524500907441, "top_left_y": 0.7115960633290543, "lower_right_x": 0.25650332728372655, "lower_right_y": 0.7218656397090286, "height": 0.010269576379974277, "width": 0.14035087719298245}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-240-8", "text": "The business combination effected in 2003 (Chienna B.V.) has been accounted for in accordance with IFRS 3, Business\nCombinations. Based on IFRS 3, the acquirer shall, at the acquisition date, allocate the cost of a business combination by\nrecognising the acquiree\u2019s identifiable assets, liabilities and contingent liabilities that satisfy the recognition criteria at their\nfair values at that date. The purchase price allocation performed on basis of IFRS 3 resulted in an additional amount of Euro\n167 being allocated to patents (in process research and development). Consequently, the amount of patents is Euro 167\nhigher and the amount of goodwill Euro 167 lower, at the acquisition date 1 March 2003, under IFRS compared to Dutch\nGAAP.\n", "page_number": 240, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.7287120239623449, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.8215661103979461, "height": 0.09285408643560122, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-240-9", "text": "Under Dutch GAAP, the acquisition of OctoShed B.V. in 2004 was accounted for as a business combination. Under IFRS,\nthe acquisition does not represent a business combination based on the criteria in IFRS 3 (see Note 7). The cost of the\n", "page_number": 240, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.8451005562687206, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.8729139922978177, "height": 0.02781343602909714, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-240-10", "text": "F- 101\n", "page_number": 240, "bounding_box": {"top_left_x": 0.5075620084694494, "top_left_y": 0.9242618741976893, "lower_right_x": 0.5462794918330308, "lower_right_y": 0.9311082584510055, "height": 0.0068463842533161845, "width": 0.038717483363581384}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-241-0", "text": "acquisition is allocated between the individual identifiable assets and liabilities based on their relative fair values at the date\nof acquisition and no goodwill is recorded. The goodwill initially recognised (Euro 165) and the goodwill amortisation\nrecorded in 2004 (Euro 23) under Dutch GAAP are therefore reversed under IFRS.\n", "page_number": 241, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.12623020967051776, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.16773641420624733, "height": 0.04150620453572956, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-241-1", "text": "Under Dutch GAAP, acquired goodwill is capitalised and amortised. IFRS 3 requires goodwill not to be amortised, but to be\nsubject to impairment testing annually, or more frequently if events or changes in circumstances indicate that the asset might\nbe impaired. As a result, the goodwill amortisation recorded under Dutch GAAP amounting to Euro 122 in 2004 and Euro\n60 in 2003 has been reversed under IFRS.\n", "page_number": 241, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.19127086007702182, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.24176294394522893, "height": 0.05049208386820711, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-241-2", "text": "The Group conducted an impairment test of the goodwill at 31 December 2003, 31 December 2004 and 31 December 2005\nin accordance with IAS 36, Impairment of Assets. No impairments were identified.\n", "page_number": 241, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.26658108686350024, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.29311082584510056, "height": 0.026529738981600326, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-241-3", "text": "Intangible assets\nUnder IFRS, the expenses incurred to register patents, even though paid to an external party, are not considered the separate\nacquisition of a patent. The registration costs for patents are part of the expenditures for the research and development\nproject they relate to. Therefore, registration costs for patents must be expensed as incurred as long as the research and\ndevelopment project does not yet meet the criteria for capitalisation. Consequently, the book values of patents amounting to\nEuro 575 at 31 December 2004, Euro 379 at 31 December 2003 and Euro 304 at 1 January 2003 have been reversed.\n", "page_number": 241, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.31450577663671375, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.40051347881899874, "height": 0.08600770218228498, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-241-4", "text": "The expenses for formation of a company or issuance of shares cannot be distinguished from the cost of developing the\nbusiness as a whole. Therefore, such items do not qualify as intangible assets as defined in IAS 38 and should not be\ncapitalised. This resulted in an IFRS adjustment amounting to Euro 7 at 31 December 2004, Euro 15 at 31 December 2003\nand Euro 23 at 1 January 2003.\n", "page_number": 241, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.4206247325631151, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.4758237056054771, "height": 0.05519897304236199, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-241-5", "text": "Revenue recognition\n", "page_number": 241, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.4993581514762516, "lower_right_x": 0.24621899576527526, "lower_right_y": 0.5100556268720582, "height": 0.010697475395806566, "width": 0.13067150635208713}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-241-6", "text": "Under Dutch GAAP, revenues from the sales of certain services were recognised based on the percentage of completion\nwith zero profit method. Under IFRS, revenues on all services are recognised based on the percentage of completion\nmethod. As a result, accrued income at 31 December 2004 was increased by Euro 48, at 31 December 2003 by Euro 123\nand at 1 January 2003 by Euro 254 compared to Dutch GAAP. Consequently, revenues for 2004 under IFRS are reduced by\nEuro 75 and revenues for 2003 by Euro 131 compared to Dutch GAAP.\n", "page_number": 241, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.5164741121095422, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.5845100556268721, "height": 0.06803594351732989, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-241-7", "text": "Furthermore, under Dutch GAAP, an up-front payment for an option to use the Group\u2019s technology was recognised as\nrevenue immediately. In line with the Group\u2019s IFRS policies when there are future support requirements or deliverables,\nrevenue is recognised using a proportional performance basis over the term of the option period. Consequently, revenue\namounting to Euro 90 recognised in 2004 under Dutch GAAP was deferred under IFRS and recognised over the option\nperiod (Euro 60 in 2005 and Euro 30 in 2006). This results in Euro 90 higher deferred revenues in the balance sheet at 31\nDecember 2004 and Euro 30 higher deferred revenue in the balance sheet at 31 December 2005.\n", "page_number": 241, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.6054771074026529, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.6876337184424476, "height": 0.08215661103979466, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-241-8", "text": "Employee benefits\n", "page_number": 241, "bounding_box": {"top_left_x": 0.1161524500907441, "top_left_y": 0.7115960633290543, "lower_right_x": 0.23109497882637628, "lower_right_y": 0.7222935387248609, "height": 0.010697475395806566, "width": 0.11494252873563218}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-241-9", "text": "In accordance with IAS 19, the Group recognises the unfunded part of defined benefit obligations with respect to pensions\nand post-employment benefits. At the transition date 1 January 2003, the difference between the unfunded part of the IFRS\nemployee benefit obligations and the pension provisions under Dutch GAAP was Euro 51, and is charged directly to equity\nin the IFRS opening balance. Furthermore, the pension provision at 31 December 2003 is increased by Euro 51 and the\npension provision at 31 December 2004 is increased by Euro 75 compared to Dutch GAAP.\n", "page_number": 241, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.7287120239623449, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.7963200684638425, "height": 0.0676080445014976, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-241-10", "text": "Under IFRS, the 2004 pension charge including interest expenses is Euro 24 higher than under Dutch GAAP. In 2003, the\npension charge under IFRS is unchanged compared to Dutch GAAP.\n", "page_number": 241, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.8177150192554558, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.8446726572528883, "height": 0.02695763799743256, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-241-11", "text": "F- 102\n", "page_number": 241, "bounding_box": {"top_left_x": 0.5075620084694494, "top_left_y": 0.9242618741976893, "lower_right_x": 0.5517241379310345, "lower_right_y": 0.9311082584510055, "height": 0.0068463842533161845, "width": 0.04416212946158504}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-242-0", "text": "Share-based payments\n", "page_number": 242, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.12623020967051776, "lower_right_x": 0.25529340592861466, "lower_right_y": 0.14035087719298245, "height": 0.014120667522464686, "width": 0.1397459165154265}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-242-1", "text": "Under Dutch GAAP, the Group did not record any charges for employee share options since all of the options granted to\nemployees were issued at an exercise price equal to the price of the Company\u2019s shares on the date of grant (the options were\ngranted \"at the money\") or a higher exercise price.\n", "page_number": 242, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.1433461703038083, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.18485237483953787, "height": 0.04150620453572956, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-242-2", "text": "In accordance with IFRS 2, Share-based Payment, the Group recognises compensation charges in its income statement for\nall employee share options using \u201cthe fair value method\u201d. The compensation charges are recognised over the vesting period\nof the options, based upon the fair values of the options granted to the employees, with a corresponding increase in\nshareholders' equity. This resulted in an additional expense of Euro 23 in 2004 and Euro 5 in 2003 compared to Dutch\nGAAP. However, this has no impact on total equity since the recognition of an expense results in a corresponding increase\ndirectly in equity.\n", "page_number": 242, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.20838682071031236, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.28968763371844247, "height": 0.08130081300813011, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-242-3", "text": "Leases (incl. sale and leaseback transaction)\n", "page_number": 242, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.3110825845100556, "lower_right_x": 0.39201451905626133, "lower_right_y": 0.32349165596919127, "height": 0.012409071459135668, "width": 0.2764670296430732}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-242-4", "text": "Under IFRS, the acquisition of OctoShed B.V. in 2004 does not represent a business combination based on the criteria in\nIFRS 3. The cost of the acquisition is allocated between the individual identifiable assets and liabilities based on their\nrelative fair values at the date of acquisition and no goodwill is recorded. The goodwill initially recognised under Dutch\nGAAP is therefore reversed. In addition, the book values of the building and other items of property, plant and equipment\nare lowered to the allocated cost that was actually paid for the acquisition of OctoShed B.V. These IFRS adjustments\nresulted in Euro 507 lower equity at 31 December 2004.\n", "page_number": 242, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.32391955498502356, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.41078305519897307, "height": 0.08686350021394951, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-242-5", "text": "The related impact on the income statement for 2004 is presented in the line \u201cbusiness combinations\u201d in the reconciliation of\nthe result for 2004 (Euro 47 lower costs compared to Dutch GAAP, of which reversal of the amortisation of goodwill\namounts to Euro 23).\n", "page_number": 242, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.43089430894308944, "lower_right_x": 0.8905021173623714, "lower_right_y": 0.472400513478819, "height": 0.04150620453572956, "width": 0.7749546279491832}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-242-6", "text": "In addition some of the Group\u2019s lease contracts have been reclassified from operational leases to finance leases, which did\nnot result in any significant impact on equity or the result for the years presented.\n", "page_number": 242, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.4959349593495935, "lower_right_x": 0.8850574712643678, "lower_right_y": 0.5220367993153616, "height": 0.026101839965768148, "width": 0.7695099818511797}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-242-7", "text": "", "page_number": 242, "bounding_box": {"top_left_x": 0.11917725347852388, "top_left_y": 0.5417201540436457, "lower_right_x": 0.16091954022988506, "lower_right_y": 0.5459991442019684, "height": 0.004278990158322671, "width": 0.04174228675136117}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-242-8", "text": "Taxation\n", "page_number": 242, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.5459991442019684, "lower_right_x": 0.17422867513611615, "lower_right_y": 0.5545571245186136, "height": 0.00855798031664523, "width": 0.058681185722928006}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-242-9", "text": "Under Dutch GAAP, the Group recognised deferred corporate income tax assets amounting to Euro 1,640 at 31 December\n2004, Euro 910 at 31 December 2003 and Euro 246 at 1 January 2003.\n", "page_number": 242, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.5609756097560976, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.5879332477535302, "height": 0.02695763799743256, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-242-10", "text": "Under IFRS, the existence of unused tax losses is strong evidence that future taxable profit may not be available. Therefore,\nwhen an entity has a history of recent losses, the entity recognises a deferred tax asset arising from unused tax losses or tax\ncredits only to the extent that the entity has sufficient taxable temporary differences or there is convincing other evidence\nthat sufficient taxable profit will be available against which the unused tax losses or unused tax credits can be utilised by the\nentity. Management has concluded that sufficient \u201cconvincing other evidence\u201d is not available and has therefore only\nrecognised deferred tax assets to the extent that the fiscal unities have taxable temporary differences.\n", "page_number": 242, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.6089002995293111, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.691484809584938, "height": 0.08258451005562684, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-242-11", "text": "As described in the paragraph above regarding leases, the acquisition of Octoshed B.V. does not qualify as a business\ncombination. Since the acquisition does not affect accounting or taxable profit either, no deferred tax liability is accounted\nfor under IFRS. However, the subsequent sale and leaseback transaction did result in a taxable gain. The tax effect on this\ngain was deferred by creating a fiscal provision (\u201cherinvesteringsreserve\u201d). The deferred tax liability from this transaction is\nvalued against 30% at 31 December 2004 (since it will be settled after 2007) and not discounted. Therefore, a deferred tax\nliability of Euro 481 was recognised, which was partly offset with the deferred tax asset from tax losses carried forward in\nthe same fiscal unity. This resulted in a net deferred tax liability of Euro 353 recognised in the IFRS balance sheet at 31\nDecember 2004, and a tax expense in the IFRS income statement for 2004 of Euro 353 (2003: Euro 0).\n", "page_number": 242, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.7150192554557124, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.8249893025246042, "height": 0.1099700470688918, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-242-12", "text": "F- 103\n", "page_number": 242, "bounding_box": {"top_left_x": 0.5075620084694494, "top_left_y": 0.9242618741976893, "lower_right_x": 0.5517241379310345, "lower_right_y": 0.9311082584510055, "height": 0.0068463842533161845, "width": 0.04416212946158504}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-243-0", "text": "The remaining deferred corporate income tax assets recognised under Dutch GAAP, for which the Group does not have\ntaxable temporary differences available, have been reversed in the IFRS financial statements. The related impact on the\nincome statement for 2004 is a reversal of deferred tax income amounting to Euro 1,193 (2003: Euro 671).\n", "page_number": 243, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.12623020967051776, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.16773641420624733, "height": 0.04150620453572956, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-243-1", "text": "In addition, the IFRS conversion has resulted in temporary differences between the carrying amount of assets and liabilities\nand their tax bases. However, this did not result in a tax effect on the IFRS opening equity at 1 January 2003 since the\nGroup only recognises deferred tax assets to the extent that the fiscal unities have taxable temporary differences available to\nnet these with. This was not the case at 1 January 2003.\n", "page_number": 243, "bounding_box": {"top_left_x": 0.11554748941318814, "top_left_y": 0.19127086007702182, "lower_right_x": 0.8856624319419237, "lower_right_y": 0.24304664099272572, "height": 0.051775780915703895, "width": 0.7701149425287356}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-243-2", "text": "F- 104\n", "page_number": 243, "bounding_box": {"top_left_x": 0.5075620084694494, "top_left_y": 0.9238339751818571, "lower_right_x": 0.5511191772534785, "lower_right_y": 0.9311082584510055, "height": 0.007274283269148474, "width": 0.04355716878402904}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-244-0", "text": "ISSUER\n", "page_number": 244, "bounding_box": {"top_left_x": 0.4688445251058681, "top_left_y": 0.12665810868635002, "lower_right_x": 0.5323653962492438, "lower_right_y": 0.13735558408215662, "height": 0.010697475395806594, "width": 0.06352087114337573}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-244-1", "text": " OctoPlus N.V.\nBusiness Address\nZernikedreef 12\n2333 CL Leiden\nThe Netherlands\n", "page_number": 244, "bounding_box": {"top_left_x": 0.44162129461585, "top_left_y": 0.1527599486521181, "lower_right_x": 0.5614035087719298, "lower_right_y": 0.22165169020111253, "height": 0.06889174154899444, "width": 0.11978221415607981}, "blob_type": "paragraph", "predictions": {}, "annotations": {"issuer_name": ["OctoPlus N.V."]}}, {"blob_number_in_page": 2, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-244-2", "text": "LEGAL ADVISORS TO THE ISSUER\n", "page_number": 244, "bounding_box": {"top_left_x": 0.3623714458560194, "top_left_y": 0.23919554985023533, "lower_right_x": 0.6388384754990926, "lower_right_y": 0.24989302524604193, "height": 0.010697475395806594, "width": 0.2764670296430732}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-244-3", "text": "   As to United States law   As to Netherlands law\nHughes Hubbard & Reed LLP    Loyens & Loeff N.V.\n   One Battery Park Plaza         Weena 690\n    New York, NY 10004        3012 CN Rotterdam\n  United States of America     The Netherlands\n", "page_number": 244, "bounding_box": {"top_left_x": 0.18330308529945555, "top_left_y": 0.26658108686350024, "lower_right_x": 0.735632183908046, "lower_right_y": 0.33204963628583656, "height": 0.06546854942233632, "width": 0.5523290986085905}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-244-4", "text": "JOINT GLOBAL COORDINATORS, JOINT BOOKRUNNERS AND UNDERWRITERS\n", "page_number": 244, "bounding_box": {"top_left_x": 0.18330308529945555, "top_left_y": 0.34873769790329484, "lower_right_x": 0.8179068360556564, "lower_right_y": 0.36243046640992727, "height": 0.013692768506632425, "width": 0.6346037507562008}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-244-5", "text": "Cowen International Limited", "page_number": 244, "bounding_box": {"top_left_x": 0.18753781004234724, "top_left_y": 0.3748395378690629, "lower_right_x": 0.3992740471869328, "lower_right_y": 0.3851091142490372, "height": 0.010269576379974332, "width": 0.2117362371445856}, "blob_type": "headline", "predictions": {}, "annotations": {"investment_bank": ["Cowen International Limited"]}}, {"blob_number_in_page": 6, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-244-6", "text": "Kempen & Co N.V.\n", "page_number": 244, "bounding_box": {"top_left_x": 0.589231699939504, "top_left_y": 0.3748395378690629, "lower_right_x": 0.73502722323049, "lower_right_y": 0.3898160034231921, "height": 0.014976465554129237, "width": 0.145795523290986}, "blob_type": "headline", "predictions": {}, "annotations": {"investment_bank": ["Kempen & Co N.V."]}}, {"blob_number_in_page": 7, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-244-7", "text": "Cowen International Limited\n     1 Snowden Street\n         11th Floor\n    London EC2A 2DQ\n     United Kingdom\n", "page_number": 244, "bounding_box": {"top_left_x": 0.1881427707199032, "top_left_y": 0.3855370132648695, "lower_right_x": 0.3992740471869328, "lower_right_y": 0.4450149764655541, "height": 0.0594779632006846, "width": 0.21113127646702962}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-244-8", "text": "Beethovenstraat 300\n", "page_number": 244, "bounding_box": {"top_left_x": 0.5928614640048396, "top_left_y": 0.3902439024390244, "lower_right_x": 0.7307924984875983, "lower_right_y": 0.4022250748823278, "height": 0.011981172443303378, "width": 0.13793103448275867}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-244-9", "text": " Beethovenstraat 300\n1077 WZ Amsterdam\n", "page_number": 244, "bounding_box": {"top_left_x": 0.5898366606170599, "top_left_y": 0.40393667094565683, "lower_right_x": 0.735632183908046, "lower_right_y": 0.4154899443731279, "height": 0.011553273427471089, "width": 0.1457955232909861}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-244-10", "text": "The Netherlands\n", "page_number": 244, "bounding_box": {"top_left_x": 0.6049606775559588, "top_left_y": 0.41805733846812154, "lower_right_x": 0.7162734422262553, "lower_right_y": 0.4300385109114249, "height": 0.011981172443303378, "width": 0.1113127646702965}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-244-11", "text": "CO-MANAGER AND UNDERWRITER\n", "page_number": 244, "bounding_box": {"top_left_x": 0.35753176043557167, "top_left_y": 0.4617030380830124, "lower_right_x": 0.647912885662432, "lower_right_y": 0.472400513478819, "height": 0.010697475395806622, "width": 0.2903811252268603}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-244-12", "text": "    SNS Securities N.V.\nNieuwezijds Voorburgwal 162\n    1012 SJ Amsterdam\n      The Netherlands\n", "page_number": 244, "bounding_box": {"top_left_x": 0.4010889292196007, "top_left_y": 0.4890885750962773, "lower_right_x": 0.6049606775559588, "lower_right_y": 0.5408643560119811, "height": 0.05177578091570384, "width": 0.20387174833635813}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-244-13", "text": "LEGAL ADVISORS TO THE UNDERWRITERS\n", "page_number": 244, "bounding_box": {"top_left_x": 0.323653962492438, "top_left_y": 0.5575524176294394, "lower_right_x": 0.677555958862674, "lower_right_y": 0.5682498930252461, "height": 0.010697475395806677, "width": 0.35390199637023595}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-244-14", "text": "As to United States law    As to Netherlands law\n     Ashurst LLP          Houthoff Buruma N.V.\n  Broadwalk House               Weena 355\n    5 Appold Street         3013 AL Rotterdam\n London EC2A 2HA             The Netherlands\n   United Kingdom\n", "page_number": 244, "bounding_box": {"top_left_x": 0.21355111917725347, "top_left_y": 0.5849379546427044, "lower_right_x": 0.7447065940713854, "lower_right_y": 0.6670945656824989, "height": 0.08215661103979455, "width": 0.531155474894132}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-244-15", "text": "LISTING AND PAYING AGENT\n", "page_number": 244, "bounding_box": {"top_left_x": 0.37689050211736236, "top_left_y": 0.6824989302524604, "lower_right_x": 0.6212946158499697, "lower_right_y": 0.6949080017115961, "height": 0.012409071459135612, "width": 0.24440411373260734}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 16, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-244-16", "text": "   Listing Agent\nKempen & Co N.V.\nBeethovenstraat 300\n1077 WZ Amsterdam\n  The Netherlands\n", "page_number": 244, "bounding_box": {"top_left_x": 0.2220205686630369, "top_left_y": 0.711168164313222, "lower_right_x": 0.36721113127646704, "lower_right_y": 0.7770646127513907, "height": 0.06589644843816866, "width": 0.14519056261343014}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 17, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-244-17", "text": "Paying Agent\n", "page_number": 244, "bounding_box": {"top_left_x": 0.6140350877192983, "top_left_y": 0.7115960633290543, "lower_right_x": 0.7065940713853599, "lower_right_y": 0.7222935387248609, "height": 0.010697475395806566, "width": 0.09255898366606163}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 18, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-244-18", "text": "Fortis Bank (Nederland) N.V.\n", "page_number": 244, "bounding_box": {"top_left_x": 0.5571687840290381, "top_left_y": 0.7252888318356868, "lower_right_x": 0.764670296430732, "lower_right_y": 0.7359863072314934, "height": 0.010697475395806566, "width": 0.2075015124016939}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 19, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-244-19", "text": "Rokin 55\n", "page_number": 244, "bounding_box": {"top_left_x": 0.6285541439806412, "top_left_y": 0.7394094993581515, "lower_right_x": 0.6920750151240169, "lower_right_y": 0.7492511767222936, "height": 0.009841677364142098, "width": 0.06352087114337568}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 20, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-244-20", "text": "1012 KK Amsterdam\n", "page_number": 244, "bounding_box": {"top_left_x": 0.5898366606170599, "top_left_y": 0.7526743688489517, "lower_right_x": 0.7320024198427102, "lower_right_y": 0.7633718442447582, "height": 0.010697475395806566, "width": 0.14216575922565033}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 21, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-244-21", "text": "The Netherlands\n", "page_number": 244, "bounding_box": {"top_left_x": 0.604355716878403, "top_left_y": 0.766367137355584, "lower_right_x": 0.7162734422262553, "lower_right_y": 0.7770646127513907, "height": 0.010697475395806677, "width": 0.11191772534785238}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 22, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-244-22", "text": "INDEPENDENT AUDITORS\n", "page_number": 244, "bounding_box": {"top_left_x": 0.3914095583787054, "top_left_y": 0.793752674368849, "lower_right_x": 0.604355716878403, "lower_right_y": 0.8044501497646556, "height": 0.010697475395806566, "width": 0.21294615849969756}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 23, "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "blob_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb-244-23", "text": "Deloitte Accountants B.V.\n     Kanaalpark 143\n     2321 JV Leiden\n    The Netherlands\n", "page_number": 244, "bounding_box": {"top_left_x": 0.4101633393829401, "top_left_y": 0.8189987163029525, "lower_right_x": 0.5916515426497277, "lower_right_y": 0.8729139922978177, "height": 0.05391527599486523, "width": 0.18148820326678766}, "blob_type": "paragraph", "predictions": {}, "annotations": {"external_auditor": ["Deloitte Accountants B.V."]}}], "document_id": "deba113b48e63ba66e3605d0c78e83e736dd8d75d20498850338be34d6ea61cb", "pages_in_documents": 245}